PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ping, DS; Boekhoudt, G; Boss, JM				Ping, DS; Boekhoudt, G; Boss, JM			trans-retinoic acid blocks platelet-derived growth factor-BB-induced expression of the murine monocyte chemoattractant-1 gene by blocking the assembly of a promoter proximal Sp1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; OSTEOBLASTIC MC3T3-E1 CELLS; MESSENGER-RNA EXPRESSION; BARE-LYMPHOCYTE-SYNDROME; CLASS-II GENES; PROTEIN-1 GENE; ALLERGIC INFLAMMATION; CHEMOTACTIC PROTEIN-1; HISTONE ACETYLATION	Proper regulation of the CC chemokine MCP-1 (monocyte chemoattractant protein-1) is important for normal inflammatory responses. MCP-1 is regulated by a wide variety of agents, including platelet-derived growth factor-BB (PDGF-BB) and tumor necrosis factor-alpha (TNF). Using both in vivo and in vitro assays, the elements required for expression between these two cytokines were compared. In vivo genomic footprinting showed that PDGF-BB induction occurred through the occupancy of the proximal regulatory region, and unlike TNF induction, no changes in the NF-kappa B binding, distal regulatory region occurred. Treatment of cells with trans-retinoic acid, an inhibitor of PDGF-BB activity, resulted in a 50% reduction in PDGF-BB-mediated induction and a concomitant block in the assembly of the proximal regulatory region. trans-Retinoic acid had minimal effect on TNF induction or promoter occupancy. An inhibitor of histone deacetylation was found to stimulate expression of MCP-1 in a manner that correlated with increased accessibility to the proximal regulatory region, These results show that the mechanisms of PDGF-BB and TNF activation of MCP-1 are distinct, although they both require the proximal regulatory region Sp1 binding site. The results also suggest that part of the mechanism used by both of these cytokines involves a process that regulates transcription factor access to the regulatory regions.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Boss, JM (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, 1510 Clifton Rd,Rm 3131, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA074271] Funding Source: NIH RePORTER; NCI NIH HHS [CA74271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bogdanov VY, 1998, J BIOL CHEM, V273, P24932, DOI 10.1074/jbc.273.38.24932; BRACH MA, 1992, MOL PHARMACOL, V42, P63; Brown Z, 1996, J LEUKOCYTE BIOL, V59, P75, DOI 10.1002/jlb.59.1.75; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLOTTA F, 1994, AM J PATHOL, V144, P975; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Faller DV, 1997, J CELL PHYSIOL, V172, P240, DOI 10.1002/(SICI)1097-4652(199708)172:2<240::AID-JCP11>3.3.CO;2-T; FRAZIERJESSEN MR, 1995, J IMMUNOL, V154, P1838; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; Gibran NS, 1997, J SURG RES, V70, P1, DOI 10.1006/jsre.1997.5017; Glabinski AR, 1996, J IMMUNOL, V156, P4363; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HASEGAWA SL, 1993, J IMMUNOL, V150, P1781; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P1243, DOI 10.1093/nar/19.6.1243; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Izumi S, 1997, EUR J IMMUNOL, V27, P816, DOI 10.1002/eji.1830270404; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lloyd CM, 1997, J LEUKOCYTE BIOL, V62, P676, DOI 10.1002/jlb.62.5.676; LouisPlence P, 1997, J IMMUNOL, V159, P3899; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1994, CURRENT PROTOCOLS MO; Ping DS, 1999, J IMMUNOL, V162, P727; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P11; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shyy JYJ, 1995, J BIOMECH, V28, P1451, DOI 10.1016/0021-9290(95)00093-3; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sozzani S, 1997, J LEUKOCYTE BIOL, V62, P30, DOI 10.1002/jlb.62.1.30; SUN Y, 1993, GENE, V131, P301, DOI 10.1016/0378-1119(93)90311-P; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Valente AJ, 1998, J IMMUNOL, V161, P3719; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Volejnikova S, 1997, AM J PATHOL, V150, P1711; Weiss L, 1997, J INFECT DIS, V176, P1621, DOI 10.1086/517341; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	61	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31909	31916		10.1074/jbc.274.45.31909	http://dx.doi.org/10.1074/jbc.274.45.31909			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542218	hybrid			2022-12-25	WOS:000083532100026
J	Aplin, AE; Short, SM; Juliano, RL				Aplin, AE; Short, SM; Juliano, RL			Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; FOCAL ADHESION KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; C-SRC; EXPRESSION; D1; RAS; PHOSPHORYLATION	Integrin cooperation with growth factor receptors to enable permissive signaling to the mitogen-activated protein (MAP) kinase pathway has important implications for cell proliferation, differentiation, and survival. Here we have sought to determine whether anchorage regulation of the MAP kinase pathway is specific to the alpha chain subunit of the integrins employed during adhesion. Human umbilical vein endothelial cells (HUVECs) anchored via endogenous alpha(2), alpha(3), or alpha(5) integrin subunits or NIH3T3 fibroblast cells lines anchored via ectopically expressed human integrin alpha(2) or alpha(5) subunits displayed comparable MAP kinase activation upon growth factor stimulation, regardless of the integrin alpha chain employed. In contrast, when either cell type was maintained in suspension, growth factor treatment inefficiently activated the MAP kinase pathway, The integrin-mediated enhancement of MAP kinase activation by growth factor correlated with the tyrosine phosphorylation of focal adhesion kinase but was independent of Shc. These data indicate that integrin modulation of the MAP kinase pathway is supported by a variety of integrin complexes and imply that other pathways may be required for the previously reported alpha chain-specific effects on cell cycle regulation and cell differentiation.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [GM 26165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aplin AE, 1999, J CELL SCI, V112, P695; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; TARONE G, 1993, DEVELOPMENT, V117, P1369; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	34	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31223	31228		10.1074/jbc.274.44.31223	http://dx.doi.org/10.1074/jbc.274.44.31223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531317	Green Published, hybrid			2022-12-25	WOS:000083379400021
J	Barbosa-Tessmann, IP; Chen, C; Zhong, C; Schuster, SM; Nick, HS; Kilberg, MS				Barbosa-Tessmann, IP; Chen, C; Zhong, C; Schuster, SM; Nick, HS; Kilberg, MS			Activation of the unfolded protein response pathway induces human asparagine synthetase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GLUCOSE; ELEMENT; CELLS; IDENTIFICATION; INDUCTION; CHOP	The gene for the amino acid biosynthetic activity asparagine synthetase (AS) is induced by both amino acid and glucose deprivation of cells. The data reported here document that the human AS gene is induced following activation of the Unfolded Response Pathway (UPR), also known as the Endoplasmic Reticulum Stress Response (ERSR) in mammals. Increased AS transcription occurs in response to glucose deprivation, tunicamycin, or azetidine-2-carboxylate, all known to activate the UPR/ERSR pathway. Previously identified ERSR target genes contain multiple copies of a single highly conserved cis-element. In contrast, the human AS gene does not contain the ERSR element, as it has been described for other responsive genes. Instead, AS induction requires an Spl-like sequence, a sequence previously shown to be associated with amino acid control of transcription, and possibly, a third region containing no consensus sequences for known transcription factors. Oligonucleotides covering each of these regions form DNA-protein complexes in vitro, and for some the amount of these complexes is greater when nuclear extracts from glucose-starved cells are tested. These results document that a wider range of metabolic activities are activated by the UPR/ERSR pathway than previously recognized and that genomic elements other than those already described can serve to enhance transcription of specific target genes.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Box 100245, Gainesville, FL 32610 USA.		Barbosa-Tessmann, Ione Parra/H-3856-2012	Barbosa-Tessmann, Ione Parra/0000-0001-9860-378X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUSSOLATI O, 1995, EXP CELL RES, V220, P283, DOI 10.1006/excr.1995.1317; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; KERRIGAN LA, 1994, CURRENT PROTOCOLS MO; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; PATTERSO.MK, 1970, CANCER RES, V30, P1064; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	27	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31139	31144		10.1074/jbc.274.44.31139	http://dx.doi.org/10.1074/jbc.274.44.31139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531303	hybrid			2022-12-25	WOS:000083379400007
J	English, JM; Pearson, G; Hockenberry, T; Shivakumar, L; White, MA; Cobb, MH				English, JM; Pearson, G; Hockenberry, T; Shivakumar, L; White, MA; Cobb, MH			Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS TRANSFORMATION; EXPRESSION; EFFECTORS; SCAFFOLD; CASCADE	The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-l in cells, which suggests that ERK5 might mediate Raf-independent signaling by Bas. We found that Raf-1 does contribute to Ras activation of ERK5 but in a manner that does not; correlate with Raf-l catalytic activity. A clue to the mechanism of action of Raf-1 on ERK5 comes from the observation that endogenous Raf-l binds to endogenous ERK5, suggesting the involvement of regulatory protein-protein interactions. This interaction is specific because Raf-l binds only to ERK5 and not ERK2 or SAPK. Finally, we demonstrate the ERK5/MEK5 pathway is required for Raf-dependent cellular transformation and that a constitutively active form of MEK5, MEK5DD, synergizes with Raf to transform NIH 3T3 cells. These observations suggest that ERK5 plays a large role in Raf-l-mediated signal transduction.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Schering Plough Corp, Res Inst, Dept Biol Res Oncol, Kenilworth, NJ 07033 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Merck & Company; Schering Plough Corporation	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA71443, T32-CA66187] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443, T32CA066187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOI KY, 1994, CELL, V78, P499; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	19	106	108	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31588	31592		10.1074/jbc.274.44.31588	http://dx.doi.org/10.1074/jbc.274.44.31588			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531364	hybrid			2022-12-25	WOS:000083379400068
J	Jacob, RF; Cenedella, RJ; Mason, RP				Jacob, RF; Cenedella, RJ; Mason, RP			Direct evidence for immiscible cholesterol domains in human ocular lens fiber cell plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE MEMBRANE; SPHINGOMYELIN; BILAYERS; PROTEIN; LIPIDS; PHOSPHATIDYLCHOLINE; CHROMATOGRAPHY; PHOSPHOLIPIDS	The molecular structure of human ocular lens fiber cell plasma membranes was examined directly using small angle x-ray diffraction approaches. A distinct biochemical feature of these membranes is their high relative levels of free cholesterol; the mole ratio of cholesterol to phospholipid (C/P) measured in these membranes ranges from 1 to 4. The organization of cholesterol in this membrane system is not well understood however. In this study, the structure of plasma membrane samples isolated from nuclear (3.3 C/P) and cortical (2.4 C/P) regions of human lenses was evaluated with x-ray diffraction approaches. Meridional diffraction patterns obtained from the oriented membrane samples demonstrated the presence of an immiscible cholesterol domain with a unit cell periodicity of 34.0 Angstrom consistent with a cholesterol monohydrate bilayer, The dimensions of the sterol-rich domains remained constant over a broad range of temperatures (5-20 degrees C) and relative humidity levels (31-97%). In contrast, dimensions of the surrounding sterol-poor phase were significantly affected by experimental conditions. Similar structural features were observed in membranes reconstituted from fiber cell plasma membrane lipid extracts. The results of this study indicate that the lens fiber cell plasma membrane is a complex structure consisting of separate sterol-rich and -poor domains. Maintenance of these separate domains may be required for the normal function of lens fiber cell plasma membrane and may interfere with the cataractogenic aggregation of soluble lens proteins at the membrane surface.	Med Coll Penn & Hahnemann Univ, Sch Med, Cardiovasc & Pulm Res Inst, Membrane Biophys Lab,Neurosci Grad Program, Pittsburgh, PA 15212 USA; Kirksville Coll Osteopath Med, Dept Biochem, Kirksville, MO 63501 USA	Drexel University	Mason, RP (corresponding author), Allegheny Gen Hosp, 320 East North Ave,2-ST, Pittsburgh, PA 15212 USA.				NEI NIH HHS [EY02568] Funding Source: Medline; NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSNETT S, 1995, INVEST OPHTH VIS SCI, V36, P1793; BITTMAN R, 1993, CHOLESTEROL MEMBRANE, P46; BLOEMENDAL H, 1972, Cell Differentiation, V1, P91, DOI 10.1016/0045-6039(72)90032-2; Borchman D, 1996, EXP EYE RES, V62, P191, DOI 10.1006/exer.1996.0023; BROEKHUYSE RM, 1974, EXP EYE RES, V19, P297, DOI 10.1016/0014-4835(74)90148-1; BROEKHUYSE RM, 1976, EXP EYE RES, V22, P653, DOI 10.1016/0014-4835(76)90010-5; BROEKHUYSE RM, 1977, LIPID METABOLISM MAM, V2, P145; Byrdwell WC, 1997, OPHTHALMIC RES, V29, P191; BYRDWELL WC, 1994, INVEST OPHTH VIS SCI, V35, P4333; CALHOUN WI, 1979, BIOCHEMISTRY-US, V18, P1717, DOI 10.1021/bi00576a013; CENEDELLA RJ, 1979, EXP EYE RES, V28, P673, DOI 10.1016/0014-4835(79)90068-X; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; CENEDELLA RJ, 1982, LIPIDS, V17, P443, DOI 10.1007/BF02535224; CHANDRASEKHER G, 1995, EXP EYE RES, V60, P707, DOI 10.1016/S0014-4835(05)80012-0; CRAVEN BM, 1976, NATURE, V260, P727, DOI 10.1038/260727a0; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; EMMELOT P, 1977, MAMMALIAN CELL MEMBR, V2, P1; ENGELMAN DM, 1972, J BIOL CHEM, V247, P3694; FLESCHNER CR, 1991, J LIPID RES, V32, P45; GERSON RJ, 1990, EXP EYE RES, V50, P65, DOI 10.1016/0014-4835(90)90012-J; HARRIS JS, 1995, BIOCHEMISTRY-US, V34, P3851, DOI 10.1021/bi00011a043; Houslay MD, 1982, DYNAMICS BIOL MEMBRA, P71; KIRBY TJ, 1962, ARCH OPHTHALMOL-CHIC, V68, P486; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LAUGHLIN RC, 1962, J AM MED ASS, V182; LEES MB, 1972, ANAL BIOCHEM, V47, P184, DOI 10.1016/0003-2697(72)90291-6; LI LK, 1985, J LIPID RES, V26, P600; LI LK, 1987, BIOCHIM BIOPHYS ACTA, V917, P112, DOI 10.1016/0005-2760(87)90291-8; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2020, DOI 10.1021/bi00122a018; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; POLLET S, 1978, J LIPID RES, V19, P916; Rafferty N. S., 1985, OCULAR LENS STRUCTUR, P1; RICE PA, 1989, P NATL ACAD SCI USA, V86, P6445, DOI 10.1073/pnas.86.17.6445; RUOCCO MJ, 1984, BIOPHYS J, V46, P695, DOI 10.1016/S0006-3495(84)84068-0; RUSSELL P, 1981, EXP EYE RES, V32, P511, DOI 10.1016/S0014-4835(81)80030-9; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1237, P127, DOI 10.1016/0005-2736(95)00096-L; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SUBRAMANIAM S, 1987, J PHYS CHEM-US, V91, P1715, DOI 10.1021/j100291a010; Tang DX, 1998, EXP EYE RES, V66, P559, DOI 10.1006/exer.1997.0467; Tulenko TN, 1998, J LIPID RES, V39, P947; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; ZELENKA PS, 1984, CURR EYE RES, V3, P1337, DOI 10.3109/02713688409007421	45	80	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31613	31618		10.1074/jbc.274.44.31613	http://dx.doi.org/10.1074/jbc.274.44.31613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531368	hybrid			2022-12-25	WOS:000083379400072
J	Pastorino, JG; Tafani, M; Rothman, RJ; Marcineviciute, A; Hoek, JB; Farber, JL				Pastorino, JG; Tafani, M; Rothman, RJ; Marcineviciute, A; Hoek, JB; Farber, JL			Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CYTOCHROME-C; CELL-DEATH; CYCLOSPORINE-A; CERAMIDE; APOPTOSIS; HEPATOCYTES; RELEASE; INDUCTION; STIMULATION	The overexpression of Bax kills cells by a mechanism that depends on induction of the mitochondrial permeability transition (MPT) (Pastorino, J. G., Chen, S.-T., Tafani, M., Snyder, J. W., and Farber, J. L. (1998) J. Biol Chem. 273, 7770-7775). In the present study, purified, recombinant Bax opened the mitochondrial permeability transition pore (PTP). Depending on its concentration, Bax had two distinct effects. Al a concentration of 125 nM, Bax caused the release of the intermembranous proteins cytochrome c and adenylate kinase and the release from the matrix of sequestered calcein, effects prevented by the inhibitor of the PTP cyclosporin A (CSA), AL this concentration of Bax, there was no detectable mitochondrial swelling or depolarization. These effects of low Bax concentrations are interpreted as the consequence of transient, non-synchronous activation of the PTP followed by a prompt recovery of mitochondrial integrity, By contrast, Bax concentrations between 250 nM and 1 mu M caused a sustained opening of the PTP with consequent persistent mitochondrial swelling and deenergization (the MPT). CSA prevented the RIFT induced by fax, Increasing concentrations of calcium caused a greater proportion of the mitochondrial to undergo the MPT in the presence of Bax. Importantly, two known mediators of apoptosis, ceramide and GD3 ganglioside, potentiated the induction by Bax of the MPT, The data imply that Bax mediates the opening of the mitochondrial PTP with the resultant release of cytochrome c from the intermembranous space.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA	Jefferson University	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 208,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	John.Farber@mail.tju.edu	Tafani, Marco/U-7230-2019; Tafani, Marco/C-3275-2017	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X; Hoek, Jan/0000-0001-7127-4218	NIDDK NIH HHS [DK38305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CRISS WE, 1970, J BIOL CHEM, V245, P6352; CRISS WE, 1970, CANCER RES, V30, P370; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Hassouna I, 1996, NEUROSCI LETT, V204, P85, DOI 10.1016/0304-3940(96)12323-5; HOEK JB, 1980, J BIOL CHEM, V255, P1458; Hoek JB, 1997, MOL CELL BIOCHEM, V174, P173, DOI 10.1023/A:1006831703155; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	34	252	260	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31734	31739		10.1074/jbc.274.44.31734	http://dx.doi.org/10.1074/jbc.274.44.31734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531385	hybrid			2022-12-25	WOS:000083379400089
J	Yokouchi, M; Kondo, T; Houghton, A; Bartkiewicz, M; Horne, WC; Zhang, H; Yoshimura, A; Baron, R				Yokouchi, M; Kondo, T; Houghton, A; Bartkiewicz, M; Horne, WC; Zhang, H; Yoshimura, A; Baron, R			Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE KINASE; EGF RECEPTOR; P53-ASSOCIATED PROTEIN; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; PROTOONCOGENE; PRODUCT; STIMULATION; ACTIVATION	c-Cbl plays a negative regulatory role in tyrosine kinase signaling by an as yet undefined mechanism. We demonstrate here, using the yeast two-hybrid system and an in vitro binding assay, that the c-Cbl RING finger domain interacts with UbcH7, a ubiquitin-conjugating enzyme (E2). UbcH7 interacted with the wild-type c-Cbl RING finger domain but not with a RING finger domain that lacks the amino acids that are deleted in 70Z-Cbl, an oncogenic mutant of c-Cbl. The in vitro interaction was enhanced by sequences on both the N- and C-terminal sides of the RING finger. In vivo and in vitro experiments revealed that c-Cbl and UbcH7 synergistically promote the ligand-induced ubiquitination of the epidermal growth factor receptor (EGFR), In contrast, 70Z-Cbl markedly reduced the ligand-induced, UbcH7-mediated ubiquitination of the EGFR. MG132, a proteasome inhibitor, significantly prolonged the ligand-induced phosphorylation of both the EGFR and c-Cbl, Thus, c-Cbl plays an essential role in the ligand-induced ubiquitination of the EGFR by a mechanism that involves an interaction of the RING finger domain with UbcH7. This mechanism participates in the down-regulation of tyrosine kinase receptors and loss of this function, as occurs in the naturally occurring 70Z-Cbl isoform, probably contributes to oncogenic transformation.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Yale University; Yale University; Yale University; Kurume University	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.	roland.baron@yale.edu	Kondo, Takeshi/G-2103-2012; Yoshimura, Akihiko/K-5515-2013	Kondo, Takeshi/0000-0001-7455-5824; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42927] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu G, 1999, MOL CELL BIOL, V19, P724; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Leevers SJ, 1999, NAT CELL BIOL, V1, pE10, DOI 10.1038/8969; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	46	282	287	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31707	31712		10.1074/jbc.274.44.31707	http://dx.doi.org/10.1074/jbc.274.44.31707			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531381	hybrid			2022-12-25	WOS:000083379400085
J	Kundra, R; Kornfeld, S				Kundra, R; Kornfeld, S			Asparagine-linked oligosaccharides protect Lamp-1 and Lamp-2 from intracellular proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HAMSTER OVARY CELLS; MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; LATE ENDOSOMES; RAB9; GLYCOSYLATION; COMPARTMENTS; TRAFFICKING; BIOGENESIS	Lysosomes contain several integral membrane proteins (termed Lamps and Limps) that are extensively glycosylated with asparagine-linked oligosaccharides. It has been postulated that these glycans protect the underlying polypeptides from the proteolytic environment of the lysosome. Previous attempts to test this hypothesis have been inconclusive because they utilized approaches that prevent initial glycosylation and thereby impair protein folding. We have used endoglycosidase H to remove the Asn-linked glycans from fully folded lysosomal membrane proteins in living cells. Deglycosylation of Lamp-1 and Lamp-8 resulted in their rapid degradation, whereas Limp-a was relatively stable in the lysosome in the absence of high mannose Asn-linked oligosaccharides. Depletion of Lamp-1 and Lamp-2 had no measurable effect on endosomal/lysosomal pH, osmotic stability, or density, and cell viability was maintained. Transport of endocytosed material to dense lysosomes was delayed in endoglycosidase H treated cells, but the rate of degradation of internalized bovine serum albumin was unchanged. These data provide direct evidence that Asn-linked oligosaccharides protect a subset of lysosomal membrane proteins from proteolytic digestion in intact cells.	Washington Univ, Sch Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline; NHLBI NIH HHS [T32HL07088] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKASAKI K, 1994, J BIOCHEM, V116, P670; Andrejewski N, 1999, J BIOL CHEM, V274, P12692, DOI 10.1074/jbc.274.18.12692; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P326; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Bright NA, 1997, J CELL SCI, V110, P2027; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; GOTTLIEB C, 1974, P NATL ACAD SCI USA, V71, P1078, DOI 10.1073/pnas.71.4.1078; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; HUTERER S, 1974, CAN J BIOCHEM CELL B, V52, P507, DOI 10.1139/o74-075; JADOT M, 1992, J BIOL CHEM, V267, P11069; Jadot M, 1997, EUR J BIOCHEM, V249, P862, DOI 10.1111/j.1432-1033.1997.t01-1-00862.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Ohashi M, 1999, J CELL SCI, V112, P1125; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; RUDD PM, 1995, BBA-PROTEIN STRUCT M, V1248, P1, DOI 10.1016/0167-4838(94)00230-E; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; STOCHAJ U, 1992, BIOCHIM BIOPHYS ACTA, V1122, P327, DOI 10.1016/0167-4838(92)90413-8; Tjelle TE, 1996, J CELL SCI, V109, P2905; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBERKEL PHC, 1995, BIOCHEM J, V312, P107, DOI 10.1042/bj3120107; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114	41	138	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31039	31046		10.1074/jbc.274.43.31039	http://dx.doi.org/10.1074/jbc.274.43.31039			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521503	hybrid			2022-12-25	WOS:000083276700099
J	Revington, M; McLachlin, DT; Shaw, GS; Dunn, SD				Revington, M; McLachlin, DT; Shaw, GS; Dunn, SD			The dimerization domain of the b subunit of the Escherichia coli F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-SYNTHASE; DELTA-SUBUNIT; 2ND STALK; BACKBONE DYNAMICS; F-0 PARTS; F1; RELAXATION; F1-ATPASE; MUTATION; INTERACT	In this study a series of N- and/or C-terminal truncations of the cytoplasmic domain of the b subunit of the Escherichia coli F1F0 ATP synthase were tested for their ability to form dimers using sedimentation equilibrium ultracentrifugation. The deletion of residues between positions 53 and. 122 resulted in a strongly decreased tendency to form dimers, whereas all the polypeptides that included that sequence exhibited high levels of dimer formation, b dimers existed in a reversible monomer-dimer equilibrium and when mixed with other b truncations formed heterodimers efficiently, provided both constructs included the 53-122 sequence. Sedimentation velocity and N-15 NMR relaxation measurements indicated that the dimerization region is highly extended in solution, consistent with an elongated second stalk structure, A cysteine introduced at position 105 was found to readily form intersubunit disulfides, whereas other single cysteines at positions 103-110 failed to form disulfides either with the identical mutant or when mixed with the other 103-110 cysteine mutants, These studies establish that the b subunit dimer depends on interactions that occur between residues in the 53-122 sequence and that the two subunits are oriented in a highly specific manner at the dimer interface.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@julian.uwo.ca	Dunn, Stanley/D-3418-2013; Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fillingame RH, 1998, ACTA PHYSIOL SCAND, V163, P163; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; REYNAUD J, 1963, BIOCHIM BIOPHYS ACTA, V77, P521, DOI 10.1016/0006-3002(63)90535-3; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; SVEDBERG T, 1940, ULTRACENTRIFUGE, P406; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; WEAST RC, 1970, CRC HDB CHEM PHYSICS, pD176; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	29	50	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31094	31101		10.1074/jbc.274.43.31094	http://dx.doi.org/10.1074/jbc.274.43.31094			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521510	hybrid			2022-12-25	WOS:000083276700106
J	Schlodder, E; Witt, HT				Schlodder, E; Witt, HT			Stoichiometry of proton release from the catalytic center in photosynthetic water oxidation - Reexamination by a glass electrode study at pH 5.5-7.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; SPLITTING ENZYME-SYSTEM; CYANOBACTERIUM-SYNECHOCOCCUS SP; NANOSECOND REDUCTION KINETICS; PHOTOSYSTEM-II PARTICLES; OPTICAL CHARACTERIZATION; MANGANESE COMPLEX; POSSIBLE STATES; SINGLE FLASHES; S-0 STATE	The catalytic center (CC) of water oxidation in photosystem II passes through four stepwise increased oxidized states (S-0-S-4) before O-2 evolution takes place from 2H(2)O in the S-4 --> S-0 transition. The pattern of the release of the four protons from the CC cannot be followed directly in the medium, because proton release from unknown amino acid residues also takes place. However, pH-independent net charge oscillations of 0:0:1:1 in S-0:S-1:S-2:S-3 have been considered as an intrinsic indicator for the H+ release from the CC. The net charges have been proposed to be created as the charge difference between electron abstraction and H+ release from the CC. Then the H+ release from the CC is 1:0:1:2 for the S-0 --> S-1 --> S-2 --> S-3 --> S-0 transition. Strong support for this conclusion is given in this work with the analysis of the pH-dependent pattern of H+ release in the medium measured directly by a glass electrode between pH 5.5 and 7.2. Improved and crystallizable photosystem II core complexes from the cyanobacterium Synechococcus elongatus were used as material. The pattern can be explained by protons released from the CC with a stoichiometry of 1:0:1:2 and protons from an amino acid group (pK approximate to 5.7) that is deprotonated and reprotonated through electrostatic interaction with the oscillating net charges 0:0:1:1 in S-0:S-1:S-2:S-3. Possible water derivatives that circulate through the S states have been named.	Tech Univ Berlin, Max Volmer Inst Biophys & Phys Chem, D-10623 Berlin, Germany	Technical University of Berlin	Witt, HT (corresponding author), Tech Univ Berlin, Max Volmer Inst Biophys & Phys Chem, Str 17 Juni 135, D-10623 Berlin, Germany.	witt@phosis1.chem.tu-berlin.de	Schlodder, Eberhard/AAP-6766-2021					Ahlbrink R, 1998, BIOCHEMISTRY-US, V37, P1131, DOI 10.1021/bi9719152; Ahrling KA, 1997, BIOCHEMISTRY-US, V36, P13148, DOI 10.1021/bi971815w; BLANKENSHIP RE, 1975, FEBS LETT, V51, P287, DOI 10.1016/0014-5793(75)80909-4; BOGERSHAUSEN O, 1995, BBA-BIOENERGETICS, V1230, P177, DOI 10.1016/0005-2728(95)00057-P; BOUGES B, 1971, BIOCHIM BIOPHYS ACTA, V234, P103, DOI 10.1016/0005-2728(71)90135-6; BRETTEL K, 1984, BIOCHIM BIOPHYS ACTA, V766, P403, DOI 10.1016/0005-2728(84)90256-1; BRUDVIG G, 1987, PROGR PHOTOSYNTHETIC, V1, P491; DAU H, 1998, PHOTOSYNTHESIS MECH, V2, P1927; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P1, DOI 10.1016/0005-2728(84)90073-2; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; DISMUKES GC, 1986, PHOTOCHEM PHOTOBIOL, V43, P99, DOI 10.1111/j.1751-1097.1986.tb05598.x; DORING R, 1969, Z NATURFORSCH B, V24, P132; FORSTER V, 1985, PHOTOCHEM PHOTOBIOL, V41, P183, DOI 10.1111/j.1751-1097.1985.tb03469.x; FOWLER CF, 1977, BIOCHIM BIOPHYS ACTA, V462, P414, DOI 10.1016/0005-2728(77)90139-6; GERKEN S, 1988, FEBS LETT, V237, P69, DOI 10.1016/0014-5793(88)80174-1; Haumann M, 1997, FEBS LETT, V410, P243, DOI 10.1016/S0014-5793(97)00596-6; HAUMANN M, 1994, BIOCHEMISTRY-US, V33, P864, DOI 10.1021/bi00170a003; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P165; Hillier W, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1307; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; Iuzzolino L, 1998, BIOCHEMISTRY-US, V37, P17112, DOI 10.1021/bi9817360; JAHNS P, 1991, BIOCHIM BIOPHYS ACTA, V1057, P313, DOI 10.1016/S0005-2728(05)80142-2; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; KLEIN MP, 1993, PHOTOSYNTH RES, V38, P265, DOI 10.1007/BF00046751; KLIMOV VV, 1977, FEBS LETT, V82, P183, DOI 10.1016/0014-5793(77)80580-2; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRETSCHMANN H, 1988, BIOCHIM BIOPHYS ACTA, V932, P358, DOI 10.1016/0005-2728(88)90171-5; KRETSCHMANN H, 1993, BIOCHIM BIOPHYS ACTA, V1144, P331, DOI 10.1016/0005-2728(93)90118-Y; Kretschmann H, 1996, BBA-BIOENERGETICS, V1274, P1, DOI 10.1016/0005-2728(95)00150-6; KRETSCHMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P208, DOI 10.1016/S0005-2728(05)80205-1; KUSUNOKI M, 1993, PHOTOSYNTH RES, V38, P331, DOI 10.1007/BF00046758; Messinger J, 1997, J AM CHEM SOC, V119, P11349, DOI 10.1021/ja972696a; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MEYER B, 1989, BIOCHIM BIOPHYS ACTA, V974, P36, DOI 10.1016/S0005-2728(89)80163-X; RAPPAPORT F, 1991, BIOCHEMISTRY-US, V30, P10004, DOI 10.1021/bi00105a027; SAPHON S, 1977, Z NATURFORSCH C, V32, P617; SAYGIN O, 1985, PHOTOBIOCH PHOTOBIOP, V10, P71; SAYGIN O, 1984, FEBS LETT, V176, P83, DOI 10.1016/0014-5793(84)80916-3; SAYGIN O, 1987, BIOCHIM BIOPHYS ACTA, V893, P452, DOI 10.1016/0005-2728(87)90097-1; SAYGIN O, 1985, FEBS LETT, V187, P224, DOI 10.1016/0014-5793(85)81246-1; STIEHL HH, 1969, Z NATURFORSCH PT B, VB 24, P1588; TIMASHEFF SN, 1990, PROTEIN STRUCTURE PR, P331; TOMMOS C, 1999, IN PRESS BIOCH BIOPH; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; Zouni A, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P925	46	126	129	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30387	30392		10.1074/jbc.274.43.30387	http://dx.doi.org/10.1074/jbc.274.43.30387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521415	hybrid			2022-12-25	WOS:000083276700011
J	Jacobsen, BM; Skalnik, DG				Jacobsen, BM; Skalnik, DG			YY1 binds five cis-elements and trans-activates the myeloid cell-restricted gp91(phox) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CUT HOMEODOMAIN PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; TRANSCRIPTION FACTOR YY1; IFN-GAMMA INDUCTION; RNA-POLYMERASE-II; C-MYC PROMOTER; DNA-BINDING; GENE-EXPRESSION; ADENOVIRUS E1A	Four transcriptional activating cis-elements within the gp91(phox) promoter bind a protein complex of similar mobility and binding specificity, denoted BID (binding increased during differentiation). The intensity of BID complexes increases upon myeloid cell differentiation, coincident with induction of gp91(phox) expression, and BID competes with the transcriptional repressor CDP for binding to each of these promoter elements. To determine the identity of BID, an expression Library was ligand screened with the BID-binding site that surrounds the -145-base pair (bp) region of the gp91(phox) promoter. One recovered factor that exhibits the expected binding specificity is YY1, a ubiquitous multifunctional transcription factor. BID complexes that form with the four binding sites within the gp91(phox) promoter are disrupted by YY1 antiserum, and a fifth YY1-binding site was detected in the -412-bp promoter region. Overexpression of YY1 in transient co-transfection assays trans-activates a minimal promoter containing two copies of the -145-bp binding site from the gp91(phox) promoter. Neither the level of YY1 protein nor DNA binding activity increases during myeloid cell differentiation, These studies identify a target gene of YY1 function in mature myeloid cells, and demonstrate that YY1 function can be controlled during myeloid development by the modulation of a competing DNA-binding factor.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Canc Res Bldg,1044 W Walnut St,Rm 472, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu		Jacobsen, Britta/0000-0001-8234-1690	NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; Eklund EA, 1997, J BIOL CHEM, V272, P9344; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; Gilly M, 1996, GENE, V179, P237, DOI 10.1016/S0378-1119(96)00366-6; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; HUMMELL DS, 1993, J IMMUNOL, V151, P3131; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P5672; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Last TJ, 1998, GENE, V221, P267, DOI 10.1016/S0378-1119(98)00415-6; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Lien LL, 1997, MOL CELL BIOL, V17, P2279, DOI 10.1128/MCB.17.4.2279; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Mailly F, 1996, MOL CELL BIOL, V16, P5346; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; TUCKER KA, 1987, BLOOD, V70, P372; VALARCHE I, 1993, DEVELOPMENT, V119, P881; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Xie JP, 1998, J CELL BIOCHEM, V70, P489, DOI 10.1002/(SICI)1097-4644(19980915)70:4<489::AID-JCB6>3.0.CO;2-F; YamitHezi A, 1997, GENE, V185, P99, DOI 10.1016/S0378-1119(96)00636-1	61	28	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29984	29993		10.1074/jbc.274.42.29984	http://dx.doi.org/10.1074/jbc.274.42.29984			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514482	hybrid			2022-12-25	WOS:000083176400061
J	Kurashima, K; D'Souza, S; Szaszi, K; Ramjeesingh, R; Orlowski, J; Grinstein, S				Kurashima, K; D'Souza, S; Szaszi, K; Ramjeesingh, R; Orlowski, J; Grinstein, S			The apical Na+/H+ exchanger isoform NHE3 is regulated by the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CAMP-MEDIATED INHIBITION; CYTOPLASMIC DOMAIN; ATP DEPENDENCE; CELLS; MEMBRANE; IDENTIFICATION; PHOSPHORYLATION; SENSITIVITY; E3KARP	The epithelial isoform of the Na+/H+ exchanger, NHE3, associates with at least two related regulatory factors called NHERF1/EBP50 and NHERF2/TKA-1/ E3KARP. These factors in addition interact with the cytoskeletal protein ezrin, which in turn binds to actin. The possible linkage of NHE3 with the cytoskeleton prompted us to test the effect of actin-modifying agents on NHE3 activity. Cytochalasins B and D and latrunculin B, which interfere with actin polymerization, induced a profound inhibition of NHE3 activity. The effect was isoform-specific inasmuch as the "housekeeping" exchanger NHE1 was virtually unaffected. Cytoskeletal disorganization was associated with a subcellular redistribution of NHE3, which accumulated at sites where actin aggregated, suggesting a physical interaction of exchangers with the cytoskeleton. An interaction was further suggested by the co-sedimentation of a detergent-insoluble fraction of NHE3 with the actin cytoskeleton. Inhibition of transport was not due to diminution in the number of transporters at the plasmalemma. Functional analyses of NHE1/NHE3 chimeras revealed that the cytoplasmic domain of NHE3 conferred sensitivity to cytochalasin B. Progressive carboxyl-terminal and internal deletions of the cytoplasmic region of NHE3 indicated that the region between residues 650 and 684 is critical for this response. This region overlaps with the domain reported to interact with NHERF and also contains a putative ezrin-binding site; hence, it likely plays a role in interactions with the cytoskeleton.	Hosp Sick Children, Res Inst, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University	Grinstein, S (corresponding author), Hosp Sick Children, Res Inst, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Szaszi, Katalin/J-7522-2012; Ramjeesingh, Ravi/AAB-3374-2022	Szaszi, Katalin/0000-0002-2490-8422; Orlowski, John/0000-0001-7371-175X; Ramjeesingh, Ravi/0000-0001-5584-3505				Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CANTIELLO HF, 1995, AM J PHYSIOL-RENAL, V269, pF637, DOI 10.1152/ajprenal.1995.269.5.F637; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Hallows KR, 1996, J CELL PHYSIOL, V167, P60, DOI 10.1002/(SICI)1097-4652(199604)167:1<60::AID-JCP7>3.0.CO;2-A; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; Mauerer UR, 1998, J GEN PHYSIOL, V111, P161, DOI 10.1085/jgp.111.1.161; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Noel J, 1996, J CELL SCI, V109, P929; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	39	110	111	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29843	29849		10.1074/jbc.274.42.29843	http://dx.doi.org/10.1074/jbc.274.42.29843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514464	hybrid			2022-12-25	WOS:000083176400043
J	Sakai, T; Furuyama, T; Ohoka, Y; Miyazaki, N; Fujioka, S; Sugimoto, H; Amasaki, M; Hattori, S; Matsuya, T; Inagaki, S				Sakai, T; Furuyama, T; Ohoka, Y; Miyazaki, N; Fujioka, S; Sugimoto, H; Amasaki, M; Hattori, S; Matsuya, T; Inagaki, S			Mouse semaphorin H induces PC12 cell neurite outgrowth activating Ras-mitogen-activated protein kinase signaling pathway via Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; DEPENDENT ACTIVATION; PHORBOL ESTER; GROWTH; RECEPTOR; FAMILY; PHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; TRANSMEMBRANE	We recently showed that mouse semaphorin H (MSH), a secreted semaphorin molecule, acts as a chemorepulsive factor on sensory neurites. In this study,we found for the first time that MSH induces neurite outgrowth in PC12 cells in a dose-dependent manner. Comparison of Ras-mitogen-activated protein kinase (MAPK) signaling pathways between MSH and nerve growth factor (NGF) revealed that these pathways are crucial for MSH action as well as NCF. K-252a, an inhibitor of tyrosine autophosphorylation of tyrosine kinase receptors (Trks), did not inhibit the action of MSH, suggesting that MSH action occurs via a different receptor than NGF. L- and N-types of voltage-dependent Ca2+ channel blockers, diltiazem and omega-conotoxin, inhibited MSH-induced neurite outgrowth and MAPK phosphorylation in a Ca2+-dependent manner. A transient elevation in intracellular Ca2+ level was observed upon MSH stimulation. These findings suggest that extracellular Ca2+ influx, followed by activation of the Ras-MAPK: signaling pathway, is required for MSH induced PC12 cell neurite outgrowth.	Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Oral & Maxillofacial Surg 1, Suita, Osaka 5650871, Japan; Natl Inst Longev Sci, Dept Mol Genet Res, Ohbu 4745822, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 1878502, Japan	Osaka University; Osaka University; National Center for Neurology & Psychiatry - Japan	Inagaki, S (corresponding author), Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Yamadaoka 1-7, Suita, Osaka 5650871, Japan.			Furuyama, Tatsuo/0000-0001-7349-103X				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso M, 1998, EUR J CELL BIOL, V76, P93, DOI 10.1016/S0171-9335(98)80021-6; Bentley David, 1994, Current Opinion in Neurobiology, V4, P43, DOI 10.1016/0959-4388(94)90030-2; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Douglas DN, 1999, BBA-MOL CELL RES, V1448, P439, DOI 10.1016/S0167-4889(98)00161-X; DYER D, 1992, MOL BRAIN RES, V14, P302, DOI 10.1016/0169-328X(92)90097-U; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FUKUDA M, 1995, ONCOGENE, V11, P239; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; IVINS JK, 1991, J NEUROSCI, V11, P1597; Jackson TR, 1996, J CELL SCI, V109, P289; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAHLE P, 1994, J NEUROCHEM, V62, P479; Kobayashi H, 1997, J NEUROSCI, V17, P8339; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Miyazaki N, 1999, NEUROSCI RES, V33, P269, DOI 10.1016/S0168-0102(99)00015-2; Miyazaki N, 1999, NEUROSCIENCE, V93, P401, DOI 10.1016/S0306-4522(99)00134-7; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5	38	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29666	29671		10.1074/jbc.274.42.29666	http://dx.doi.org/10.1074/jbc.274.42.29666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514436	hybrid			2022-12-25	WOS:000083176400015
J	Chaudhary, PM; Jasmin, A; Eby, MT; Hood, L				Chaudhary, PM; Jasmin, A; Eby, MT; Hood, L			Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins	ONCOGENE			English	Article						vFLIP; NF-kappa B; TNFR; apoptosis; HHV8	NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; KAPOSIS-SARCOMA; HERPESVIRUS HUMAN-HERPESVIRUS-8; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; CD95 FAS/APO-1; KINASE-ALPHA; TNF; ACTIVATION	Death Effector Domains (DEDs) have been known to mediate the recruitment of Caspase 8 and its homologs to the aggregated death-inducing signaling complex (DISC), consisting of the death domain (DD)-containing receptors and various signaling proteins. In addition, several viruses were recently shown to encode proteins with DEDs (also called FLICE inhibitory proteins or vFLIPs) which have the ability of blocking cell death induced by DD-containing receptors. We provide evidence that vFLIPs can also modulate the NF-kappa B pathway and physically interact with several signaling proteins, such as the TRAFs, RIP, NIK and the IKKs, Modulation of the NF-kappa B pathway may play a role in the natural history of infection by these viruses.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Chaudhary, Preet/E-1970-2018					Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Birthistle K, 1997, J INFECTION, V34, P21, DOI 10.1016/S0163-4453(97)80005-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brooks LA, 1997, J PATHOL, V182, P262, DOI 10.1002/(SICI)1096-9896(199707)182:3<262::AID-PATH836>3.0.CO;2-Q; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gallo R C, 1998, J Natl Cancer Inst Monogr, P55; Gilmore TD, 1996, ONCOGENE, V13, P1367; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karp JE, 1996, HEMATOL ONCOL CLIN N, V10, P1031, DOI 10.1016/S0889-8588(05)70383-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miles SA, 1996, HEMATOL ONCOL CLIN N, V10, P1011, DOI 10.1016/S0889-8588(05)70381-6; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	59	241	246	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5738	5746		10.1038/sj.onc.1202976	http://dx.doi.org/10.1038/sj.onc.1202976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523854				2022-12-25	WOS:000083095100002
J	Li, SY; Labrecque, S; Gauzzi, MC; Cuddihy, AR; Wong, AHT; Pellegrini, S; Matlashewski, GJ; Koromilas, AE				Li, SY; Labrecque, S; Gauzzi, MC; Cuddihy, AR; Wong, AHT; Pellegrini, S; Matlashewski, GJ; Koromilas, AE			The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha	ONCOGENE			English	Article						interferon; human papilloma virus; cell signaling; oncoproteins; protein phosphorylation; DNA-binding	ANOGENITAL HUMAN PAPILLOMAVIRUS; TYROSINE KINASE; GENE-EXPRESSION; IFN-GAMMA; TRANSCRIPTIONAL ACTIVATION; BETA RECEPTOR; PROTEIN; BINDING; SUBUNIT; CELLS	We have examined the effects of human papilloma virus (HPV) E6 proteins on interferon (IFN) signaling. Here we show that expression of the 'malignant' HPV-18 E6 in human HT1080 cells results in inhibition of Jak-STAT activation in response to IFN-alpha but not IFN-gamma. This inhibitory effect is not shared by the 'benign' HPV-11 E6, The DNA-binding and transactivation capacities of the transcription factor ISGF3 are diminished in cells expressing HPV-18 E6 after IFN-alpha treatment as a result of decreased tyrosine phosphorylation of Tyk2, STAT2 and STAT1. However, HPV-18 E6 does not affect the induction of tyrosine phosphorylation and DNA-binding of STAT1 by IFN-gamma. In addition, HPV E6 proteins physically interact,vith Tyk2, This interaction takes place preferably with HPV-18 E6 and to a lesser extent with HPV-11 E6. The E6/Tyk2 interaction requires the JH(6)-JH(7) domains of Tyk2, which are important for Tyk2 binding to the cytoplasmic portion of IFN-alpha receptor 1 (IFNAR1). These findings demonstrate an inhibitory role of HPV-18 E6 in the IFN-alpha-induced Jak-STAT pathway, which may be explained, at least in part, by the ability of E6 to interact with and impair Tyk2 activation.	McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; McGill Univ, Inst Parasitol, Montreal, PQ, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada; Inst Pasteur, INSERM, U276, F-75724 Paris 15, France	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Koromilas, AE (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine St, Montreal, PQ H3T 1E2, Canada.		Pellegrini, Sandra -/G-5546-2015; Gauzzi, Maria Cristina/N-7038-2017; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Gauzzi, Maria Cristina/0000-0002-2996-5231; Pellegrini, Sandra/0000-0001-5837-7589; Cuddihy, Andrew/0000-0002-9898-0443				BLUYSSEN HAR, 1996, CYTOKINE GROWTH F R, V1, P11; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; FUERST TR, 1986, P NATL ACAD SCI USA, V86, P2365; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAY R, 1994, ATCC CELL LINES HYBR, P70; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; LABRECQUE S, 1995, ONCOGENE, V11, P387; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; ROCKLEY PF, 1995, PHARMACOL THERAPEUT, V65, P265, DOI 10.1016/0163-7258(94)00063-9; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Routes JM, 1996, J IMMUNOL, V156, P1055; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAH KV, 1996, FIELDS VIROLOGY, P2077; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STELLATO G, 1992, SEX TRANSM DIS, V19, P124, DOI 10.1097/00007435-199205000-00002; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TROFATTER KF, 1991, DERMATOL CLIN, V9, P343; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VILCEK J, 1996, FIELDS VIROLOGY, P375; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	49	205	220	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5727	5737		10.1038/sj.onc.1202960	http://dx.doi.org/10.1038/sj.onc.1202960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523853	Bronze			2022-12-25	WOS:000083095100001
J	Bardelli, A; Longati, P; Williams, TA; Benvenuti, S; Comoglio, PM				Bardelli, A; Longati, P; Williams, TA; Benvenuti, S; Comoglio, PM			A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; TYROSINE KINASE; ANTENNAPEDIA HOMEOBOX; FACTOR/SCATTER FACTOR; CELL-TRANSFORMATION; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; EPITHELIAL-CELLS; PROTOONCOGENE; MORPHOGENESIS	Interaction of the hepatocyte growth factor (HGF) with its receptor, the Met tyrosine kinase, results in invasive growth, a genetic program essential to embryonic development and implicated in tumor metastasis. Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356)). We report that peptides derived from the Met receptor tail, but not from the activation loop, bind the receptor and inhibit the kinase activity in vitro. Cell delivery of the tail receptor peptide impairs HGF-dependent Met phosphorylation and downstream signaling. In normal and transformed epithelial cells, the tail receptor peptide inhibits HGF-mediated invasive growth, as measured by cell migration, invasiveness, and branched morphogenesis. The Met tail peptide inhibits the closely related Ron receptor but does not significantly affect the epidermal growth factor, platelet-derived growth factor, or vascular endothelial growth factor receptor activities. These experiments show that carboxyl-terminal sequences impair the catalytic properties of the Met receptor, thus suggesting that in the resting state the nonphosphorylated tail acts as an intramolecular modulator. Furthermore, they provide a strategy to selectively target the MET proto-oncogene by using small, cell-permeable, peptide derivatives.	Univ Turin, Sch Med, Inst Canc Res Treatment, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Bardelli, A (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 424 N Bond St, Baltimore, MD 21231 USA.		Williams, Tracy/K-5604-2013; BARDELLI, Alberto/J-9721-2018	Williams, Tracy Ann/0000-0002-2388-6444; Comoglio, Paolo/0000-0002-7056-5328; Benvenuti, Silvia/0000-0002-3041-4429; BARDELLI, Alberto/0000-0003-1647-5070				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; FOURNIER E, 1995, ONCOGENE, V11, P921; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; LONGATI P, 1994, ONCOGENE, V9, P49; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moley JF, 1997, ANNU REV MED, V48, P409; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEREZ F, 1992, J CELL SCI, V102, P717; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZHU H, 1994, J BIOL CHEM, V269, P29943	53	53	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29274	29281		10.1074/jbc.274.41.29274	http://dx.doi.org/10.1074/jbc.274.41.29274			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506185	hybrid			2022-12-25	WOS:000083017800064
J	Bouckaert, J; Hamelryck, TW; Wyns, L; Loris, R				Bouckaert, J; Hamelryck, TW; Wyns, L; Loris, R			The crystal structures of Man(alpha 1-3)Man(alpha 1-0)Me and Man(alpha 1-6)Man(alpha 1-0)Me in complex with concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PISUM-SATIVUM LECTIN; ASPARAGINE-LINKED GLYCOPEPTIDES; ERYTHRINA-CORALLODENDRON LECTIN; LENS-CULINARIS LECTIN; CARBOHYDRATE INTERACTIONS; ANGSTROM RESOLUTION; A INTERACTIONS; X-RAY; BINDING; PROTEIN	The crystal structures of concanavalin A in complex with Man(alpha 1-6)Man(alpha 1-O)Me and Man(alpha 1-3)Man(alpha 1-O)Me were determined at resolutions of 2.0 and 2.8 Angstrom respectively. In both structures, the O-1-linked mannose binds in the conserved monosaccharide-binding site. The O-3-linked mannose of Man(alpha 1-3)Man(alpha 1-O)Me binds in the hydrophobic subsite formed by Tyr-12, Tyr-100, and Leu-99. The shielding of a hydrophobic surface is consistent with the associated large heat capacity change. The O-6-linked mannose of Man(alpha 1-6)Man(alpha 1-)Me binds in the same subsite formed by Tyr-12 and Asp-16 as the reducing mannose of the highly specific trimannose Man(alpha 1-3)[Man(alpha 1-6)]Man(alpha 1-O)Me. However, it is much less tightly bound. Its O-2 hydroxyl makes no hydrogen bond with the conserved water 1. Water 1 is present in all the sugar-containing concanavalin A structures and increases the complementarity between the protein-binding surface and the sugar, but is not necessarily a hydrogen-bonding partner. A water analysis of the carbohydrate-binding site revealed a conserved water molecule replacing O-4 on the alpha 1-3-linked arm of the trimannose. No such water is found for the reducing or O-6-linked mannose. Our data indicate that the central mannose of Man(alpha 1-3)[Man(alpha 1-6)]Man(alpha 1-O)Me primarily functions as a hinge between the two outer subsites.	Free Univ Brussels VIB, Ultrastruct Lab, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Bouckaert, J (corresponding author), Free Univ Brussels VIB, Ultrastruct Lab, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	bouckaej@vub.ac.be	Loris, Remy/GPG-0894-2022; Hamelryck, Thomas/A-3923-2012	Bouckaert, Julie/0000-0001-8112-1442; Hamelryck, Thomas/0000-0003-2917-3602; Loris, Remy/0000-0002-8862-3338				BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1288; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1294; Bradbrook GM, 1998, J CHEM SOC FARADAY T, V94, P1603, DOI 10.1039/a800429c; BREWER CF, 1996, CHEMTRACTS BIOCH MOL, V6, P165; Brewin NJ, 1997, TRENDS PLANT SCI, V2, P92, DOI 10.1016/S1360-1385(96)10058-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; Deacon A, 1997, J CHEM SOC FARADAY T, V93, P4305, DOI 10.1039/a704140c; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; GUPTA D, 1997, GLYCOSCIENCES, P333; Hamelryck TW, 1999, J MOL BIOL, V286, P1161, DOI 10.1006/jmbi.1998.2534; Hamodrakas SJ, 1997, J STRUCT BIOL, V118, P23, DOI 10.1006/jsbi.1996.3837; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; Imberty A, 1997, CURR OPIN STRUC BIOL, V7, P617, DOI 10.1016/S0959-440X(97)80069-3; Kanellopoulos PN, 1996, J STRUCT BIOL, V116, P345, DOI 10.1006/jsbi.1996.0052; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Loris R, 1996, J BIOL CHEM, V271, P30614, DOI 10.1074/jbc.271.48.30614; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MANDAL DK, 1993, BIOCHEMISTRY-US, V32, P5116, DOI 10.1021/bi00070a020; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; Moothoo DN, 1999, GLYCOBIOLOGY, V9, P539, DOI 10.1093/glycob/9.6.539; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; Moreno E, 1997, BIOCHEMISTRY-US, V36, P4429, DOI 10.1021/bi962231h; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Schwarz FP, 1996, BIOCHEM J, V316, P123, DOI 10.1042/bj3160123; Sharon N., 1989, LECTINS, P26; Singha NC, 1996, BIOSCIENCE REP, V16, P1, DOI 10.1007/BF01200996; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; VANDRIESSCHE E, 1982, LECTINS BIOL BIOCH C, V2, P729; vanEijsden RR, 1995, PLANT MOL BIOL, V29, P431, DOI 10.1007/BF00020975; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907	50	48	49	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29188	29195		10.1074/jbc.274.41.29188	http://dx.doi.org/10.1074/jbc.274.41.29188			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506175	hybrid			2022-12-25	WOS:000083017800054
J	Ohmura, K; Kohno, N; Kobayashi, Y; Yamagata, R; Sato, S; Kashiwabara, S; Baba, T				Ohmura, K; Kohno, N; Kobayashi, Y; Yamagata, R; Sato, S; Kashiwabara, S; Baba, T			A homologue of pancreatic trypsin is localized in the acrosome of mammalian sperm and is released during acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA; SEQUENCE; FERTILIZATION; PENETRATION; EXPRESSION; PROTEINS; GENE	We have identified cDNA and genomic clones encoding a homologue of pancreatic trypsin, termed TESP4, as a candidate protein involved in the sperm penetration of the egg zona pellucida in mouse. The deduced amino acid sequence indicates that TESP4 is 90% identical to pancreatic trypsin. Analysis of Northern blotting and reverse transcriptase-polymerase chain reaction reveals that the mouse TESP4 gene is ubiquitously expressed in all tissues tested, including the pancreas and testis, and the transcript is present in the haploid stages of male germ cells. Moreover, immunochemical analysis of mouse cauda epididymal sperm using an affinity-purified antibody against bovine pancreatic trypsinogen shows that TESP4 is localized only in the sperm acrosome and is released during the acrosome reaction induced by calcium ionophore A23187. These findings may open a new point of view regarding the molecular mechanisms of the sperm/egg interactions, including the sperm penetration of the egg zona pellucida.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan; Natl Inst Adv Interdisciplinary Res, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST)	Baba, T (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City, Tsukuba, Ibaraki 3058572, Japan.							BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BABA T, 1994, J BIOL CHEM, V269, P10133; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Eddy E. M., 1994, P29; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER LR, 1982, J REPROD FERTIL, V65, P185, DOI 10.1530/jrf.0.0650185; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KLEMM U, 1991, HUM GENET, V87, P635; Kohno N, 1998, BIOCHEM BIOPH RES CO, V245, P658, DOI 10.1006/bbrc.1998.8501; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAMOTO H, 1973, BIOL REPROD, V9, P533, DOI 10.1093/biolreprod/9.5.533; Roach JC, 1997, J MOL EVOL, V45, P640, DOI 10.1007/PL00006268; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Stambaugh R., 1969, Biology of Reproduction, V1, P223, DOI 10.1095/biolreprod1.3.223; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Yamagata K, 1998, ZYGOTE, V6, P311, DOI 10.1017/S0967199498000264; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; YAMAGATA K, 1999, IN PRESS DEV GENET; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; YOUNG CL, 1978, ATLAS PROTEIN SEQ S3, V5, P73; ZANEVELD LJD, 1971, P INT RES C PROTEINA, P236	26	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29426	29432		10.1074/jbc.274.41.29426	http://dx.doi.org/10.1074/jbc.274.41.29426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506205	hybrid			2022-12-25	WOS:000083017800084
J	Park, JS; Wang, M; Park, SJ; Lee, SH				Park, JS; Wang, M; Park, SJ; Lee, SH			Zinc finger of replication protein A, a non-DNA binding element, regulates its DNA binding activity through redox	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-ALPHA-PRIMASE; T4 GENE-32 PROTEIN; GLUCOCORTICOID RECEPTOR; RAD52 PROTEIN; DAMAGE-RECOGNITION; FUNCTIONAL DOMAINS; 70-KDA SUBUNIT; CELLS	Eukaryotic replication protein A (RPA) is a single-stranded DNA-binding protein with multiple functions in DNA replication, repair, and genetic recombination. RPA contains an evolutionarily conserved 4-cysteine-type zinc finger motif (X3CX2-4CX12-15CX2C) that has a potential role in regulation of DNA replication and repair (Dong, J., Park, J-S., and Lee, S-H. (1999) Biochem. J. 337, 311-317 and Lin, Y,-L., Shivji, M. K. K., Chen, C., Kolodner, R., Wood, R. D., and Dutta, A. (1998) J. Biol. Chem. 273, 1453-1461), even though the zinc finger itself is not essential for its DNA binding activity (Kim, D. K, Stigger, E., and Lee, S.-H. (1996) J. Biol. Chem. 271, 15124-15129). Here, we show that RPA single-stranded DNA (ssDNA) binding activity is regulated by reduction-oxidation (redox) through its zinc finger domain. RPA-ssDNA interaction was stimulated 10-fold by the reducing agent, dithiothreitol (DTT), whereas treatment of RPA with oxidizing agent, diazene dicarboxylic acid bis[N,N-dimethylamide] (diamide), significantly reduced this interaction. The effect of diamide was re versed by the addition of excess DTT, suggesting that RPA ssDNA binding activity is regulated by redox. Redox regulation of RPA-ssDNA interaction was more effective in the presence of 0.2 M NaCl or higher. Cellular redox factor, thioredoxin, was able to replace DTT in stimulation of RPA DNA binding activity, suggesting that redox protein may be involved in RPA modulation in vivo. In contrast to wild-type RPA, zinc finger mutant (cysteine to alanine mutation at amino acid 486) did not require DTT for its ssDNA binding activity and is not affected by redox. Together, these results suggest a novel function for a putative zinc finger in the regulation of RPA DNA binding activity through cellular redox.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Canc, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Lee, SH (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	slee@iupui.edu			NIGMS NIH HHS [GM52358] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Casadevall M, 1998, J INORG BIOCHEM, V71, P147, DOI 10.1016/S0162-0134(98)10046-6; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; Dong JW, 1999, BIOCHEM J, V337, P311, DOI 10.1042/0264-6021:3370311; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EAGLE PA, 1992, VIROLOGY, V187, P777, DOI 10.1016/0042-6822(92)90479-9; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; GIEDROC DP, 1992, BIOCHEMISTRY-US, V31, P765, DOI 10.1021/bi00118a018; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; QIU HW, 1994, J BIOL CHEM, V269, P2773; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Wang Y, 1998, RADIAT RES, V149, P284, DOI 10.2307/3579962; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu XS, 1996, MOL CELL BIOL, V16, P1035; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	54	68	69	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29075	29080		10.1074/jbc.274.41.29075	http://dx.doi.org/10.1074/jbc.274.41.29075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506160	hybrid			2022-12-25	WOS:000083017800039
J	Serpe, M; Joshi, A; Kosman, DJ				Serpe, M; Joshi, A; Kosman, DJ			Structure-function analysis of the protein-binding domains of Mac1p, a copper-dependent transcriptional activator of copper uptake in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IRON UPTAKE; YEAST; IDENTIFICATION; TRANSPORT; EXPRESSION; REPRESSION; SEQUENCES; TFIIB; GENES	The Mac1 protein in Saccharomyces cerevisiae is essential for the expression of yeast high affinity copper uptake. A positive transcription factor, Mac1p binds via its N-terminal domain to GCTC elements in the promoters of CTR1 and FRE1, encoding a copper permease and metal reductase, respectively. Mac1p-dependent transcriptional. activation is negatively regulated by copper. We have mapped the domains in Mac1p responsible for its nuclear localization and for the protein-protein interactions that underlie its transcriptional activity. Immunofluorescence studies indicate that Mac1p contains two nuclear localization signals, one each in the N- and C-terminal halves of the protein. Yeast one-hybrid analysis demonstrates that the copper-dependent transcriptional activity in Mac1p resides primarily in a cysteine-rich element encompassing residues 264-279. Two-hybrid analysis indicates that a copper-independent Mac1p-Mac1p interaction linked to DNA binding is due primarily to a predicted helix in the C-terminal region of the protein encompassing residues 388-406. Point mutations within this putative helix abrogate the Mac1-Mac1 interaction in vivo and formation of a ternary (Mac1p)(2).DNA complex in vitro. When produced in normal abundance, Mac1pI396D and Mac1pF400D helix mutants do not support transcriptional activation in vivo consistent with an essential Mac1p dimerization in transcriptional activation. Lastly, the one- and two-hybrid data indicate that an intramolecular interaction between the DNA-binding and transactivation domains negatively modulates Mac1p activity.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@acsu.buffalo.edu	Serpe, Michael/T-4176-2019	Serpe, Michael/0000-0002-0161-1087; Joshi, Atul/0000-0002-6709-0851; Serpe, Mihaela/0000-0002-9205-8589	NIGMS NIH HHS [GM46787] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BARTEL PL, 1993, BIOTECHNIQUES, V14, P92; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; DAMERON CT, 1993, BIOCHEMISTRY-US, V32, P7294, DOI 10.1021/bi00079a028; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIX DR, 1994, J BIOL CHEM, V269, P26092; DOBI A, 1995, J BIOL CHEM, V270, P10171, DOI 10.1074/jbc.270.17.10171; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Miller JH., 1972, EXPT MOL GENETICS; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Shirley RL, 1998, J CELL SCI, V111, P3129; SIKORSKI RS, 1989, GENETICS, V122, P19; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; Turner RB, 1998, NAT STRUCT BIOL, V5, P551, DOI 10.1038/805; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	35	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29211	29219		10.1074/jbc.274.41.29211	http://dx.doi.org/10.1074/jbc.274.41.29211			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506178	hybrid			2022-12-25	WOS:000083017800057
J	Didier, C; Emonet-Piccardi, N; Beani, JC; Cadet, J; Richard, MJ				Didier, C; Emonet-Piccardi, N; Beani, JC; Cadet, J; Richard, MJ			L-arginine increases UVA cytotoxicity in irradiated human keratinocyte cell line: potential role of nitric oxide	FASEB JOURNAL			English	Article						DNA damage; NO; metalloenzymes; SNAP	HUMAN SKIN FIBROBLASTS; ADP-RIBOSE SYNTHETASE; HYDROGEN-PEROXIDE; DNA-DAMAGE; PEROXYNITRITE; SUPEROXIDE; APOPTOSIS; INJURY; POLY(ADP-RIBOSE); TOXICITY	Human fibroblasts and keratinocytes possess nitric oxide synthases (NOS), which metabolize L-arginine (L-Arg) for producing nitric oxide (NO.), This report delineates the relations between NO. and UVA in the human keratinocyte cell line HaCaT. NOS activity was stimulated by exposure of cells to L-Arg just after irradiation. L-Arg (5 mM) supply led to an increase in UVA (25.3 J/cm(2)) cytotoxicity (% of viability 18 +/- 3%) whereas neither L-Arg itself nor UVA irradiation induced cell death at the doses used in this study. Cells were also treated either with L-thiocitrulline (L-Thio), an irreversible inhibitor of NOS, or with exogenous superoxide dismutase (SOD) and catalase, L-Thio and SOD prevented L-Arg-mediated deleterious effects in irradiated cells, whereas catalase was ineffective. Intracellular antioxidant enzyme activities were also determined. UVA/L-Arg stress altered catalase (66% decrease) and glutathione peroxidase (83% decrease). DNA damage was evaluated using the 'comet assay' and quantified using the 'tail moment'. UVA alone was genotoxic (mean tail moment: 25.43 +/- 1.23, P < 0.001 compared control cells), The addition of L-Arg potentiated DNA damage (mean tail moment: 41.05+/-3.9) whereas L-Thio prevented them (mean tail moment 9.86 +/- 0.98). We attempted to assess the effect of poly(ADP-ribose) polymerase (PARP) inhibition on cell death. Using the PARP inhibitor 3-aminobenzamide, we established that PARP determines both cell lysis and DNA damage induced by UVA and/or L-Arg, Our findings demonstrated that L-Arg was able to increase UVA-mediated deleterious effects in keratinocytes (both DNA damage age and cytotoxicity) and that the ratio NO./O-2(.-) plays a key role in these processes.	Univ Grenoble 1, LCR7 8, LBSO, F-38043 Grenoble 03, France; CEA, Serv Chim Inorgan & Biol, Dept Rech Fondamentale Mat Condensee, F-38054 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Richard, MJ (corresponding author), CHU Albert Michallon, Lab Biochim C, LBSO, F-38043 Grenoble 03, France.		DIDIER, Christine O/P-2785-2014; Cadet, Jean/M-2971-2018	DIDIER, Christine O/0000-0003-3979-0743; Cadet, Jean/0000-0003-2594-9485				ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Baudouin JE, 1996, J INVEST DERMATOL, V106, P428, DOI 10.1111/1523-1747.ep12343523; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEERS RF, 1952, J BIOL CHEM, V195, P133; BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bruch-Gerharz D, 1998, J INVEST DERMATOL, V110, P1, DOI 10.1046/j.1523-1747.1998.00084.x; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Emonet-Piccardi N, 1998, FREE RADICAL RES, V29, P307, DOI 10.1080/10715769800300341; Filep JG, 1997, BIOCHEM J, V321, P897, DOI 10.1042/bj3210897; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; INADA C, 1995, LIFE SCI, V56, P1467, DOI 10.1016/0024-3205(95)00109-J; Ioannidis I, 1996, BIOCHEM J, V318, P789, DOI 10.1042/bj3180789; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kim Y M, 1995, Adv Pharmacol, V34, P277; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; LECCIA MT, 1993, PHOTOCHEM PHOTOBIOL, V58, P548, DOI 10.1111/j.1751-1097.1993.tb04930.x; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MEBMER UK, 1996, FEBS LETT, V384, P162; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; PARAT MO, 1995, FREE RADICAL RES, V23, P339, DOI 10.3109/10715769509065255; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VILLIOTOU V, 1995, ANTICANCER RES, V15, P931; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Wang RJ, 1996, J INVEST DERMATOL, V106, P419, DOI 10.1111/1523-1747.ep12343428; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	33	21	22	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1817	1824		10.1096/fasebj.13.13.1817	http://dx.doi.org/10.1096/fasebj.13.13.1817			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506585				2022-12-25	WOS:000083063400017
J	Reuven, NB; Arad, G; Maor-Shoshani, A; Livneh, Z				Reuven, NB; Arad, G; Maor-Shoshani, A; Livneh, Z			The mutagenesis protein UmuC is a DNA polymerase activated by UmuD ', RecA, and SSB and is specialized for translesion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET-LIGHT MUTAGENESIS; SINGLE-STRANDED VECTOR; ESCHERICHIA-COLI; UV MUTAGENESIS; BACTERIOPHAGE-LAMBDA; ABASIC SITE; MECHANISM; REPAIR; BYPASS; INVOLVEMENT	Replication of DNA lesions leads to the formation of mutations. In Escherichia coli this process is regulated by the SOS stress response, and requires the mutagenesis proteins UmuC and UmuD', Analysis of translesion replication using a recently reconstituted in vitro system (Reuven, N. B., Tomer, G., and Livneh, Z. (1998) Mol. Cell 2, 191-199) revealed that lesion bypass occurred with a UmuC fusion protein, UmuD', RecA, and SSB in the absence of added DNA polymerase, Further analysis revealed that UmuC was a DNA polymerase (E. coli DNA polymerase V), with a weak polymerizing activity. Upon addition of UmuD', RecA, and SSB, the UmuC DNA polymerase was greatly activated, and replicated a synthetic abasic site with great efficiency (45% bypass in 6 min), 10-100-fold higher than E. coli DNA polymerases I, II, or III holoenzyme, Analysis of bypass products revealed insertion of primarily dAMP (69%), and to a lesser degree dGMP (31%) opposite the abasic site. The UmuC104, mutant protein was defective both in lesion bypass and in DNA synthesis. These results indicate that UmuC is a UmuD'-, RecA-, and SSB-activated DNA polymerase, which is specialized for lesion bypass. UmuC is a member of a new family of DNA polymerases which are specialized for lesion bypass, and include the yeast RAD30 and the human XP-V genes, encoding DNA polymerase eta.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bclivneh@weizmann.weizmann.ac.il	Reuven, Nina/AAM-8711-2020	Reuven, Nina/0000-0003-1569-3818				BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARZILAI R, 1973, J MOL BIOL, V74, P739, DOI 10.1016/0022-2836(73)90062-4; BRIDGES BA, 1976, MOL GEN GENET, V144, P53, DOI 10.1007/BF00277304; BRIDGES BA, 1990, MUTAGENESIS, V5, P35, DOI 10.1093/mutage/5.1.35; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; BROTCORNELANNOYE A, 1985, MOL GEN GENET, V199, P64, DOI 10.1007/BF00327511; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; COX MM, 1981, J BIOL CHEM, V256, P4676; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; KOCH WH, 1992, MOL GEN GENET, V233, P443, DOI 10.1007/BF00265442; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; STEINBORN G, 1978, MOL GEN GENET, V165, P87, DOI 10.1007/BF00270380; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X	29	289	293	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31763	31766		10.1074/jbc.274.45.31763	http://dx.doi.org/10.1074/jbc.274.45.31763			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542196	hybrid			2022-12-25	WOS:000083532100004
J	Alberdi, E; Aymerich, MS; Becerra, SP				Alberdi, E; Aymerich, MS; Becerra, SP			Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons - Evidence for a PEDF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME COMPLEX RECEPTOR; AMYLOID-BETA PEPTIDE; NEUROTROPHIC ACTIVITY; NONINHIBITORY SERPIN; NEURITE OUTGROWTH; HEPATOMA-CELLS; NERVOUS-SYSTEM; BOVINE EYES; PROTEIN; GENE	Pigment epithelium-derived factor (PEDF);has neuronal differentiation and survival;activity on retinoblastoma and cerebellar granule (CG) cells. Here, we investigated the presence of PEDF receptors on retinoblastoma Y-79 and CG cells. PEDF radiolabeled with I-125 remained biologically active and was used for radioligand binding analysis. The binding was saturable and specific to a single class of receptors on both cells and with similar affinities (K-d = 1.7-3.6 nM, B-max = 10.5-2.7 x 10(5) sites/Y-79 cell; and K-d = 3.2 nM, B-max = 1.1 x 10(3) sites/CG cell). A polyclonal antiserum to PEDF, previously shown to block the PEDF neurotrophic activity, prevented the I-125-PEDF binding. We designed two peptides from a region previously shown to confer the neurotrophic property to human PEDF, synthetic peptides 34-mer (positions 44-77) and 44-mer (positions 78-121). Only peptide 44-mer competed for the binding to Y-79 cell receptors (EC50 = 5 nM) and exhibited neuronal differentiating activity. PEDF affinity column chromatography of membrane proteins from both cell types revealed a PEDF-binding protein of similar to 80 kDa. These results are the first demonstration of at PEDF-binding protein with characteristics of a PEDF receptor and suggest that the region comprising amino acid positions 78-121 of PEDF might be involved in ligand-receptor interactions.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Becerra, SP (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Rm 308,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.		Alberdi, Elena/D-6383-2017; Alberdi, Elena/AAH-1757-2019; Aymerich, M. S./H-2873-2017	Alberdi, Elena/0000-0002-8000-142X; Alberdi, Elena/0000-0002-8000-142X; Aymerich, M. S./0000-0001-9750-1538				Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.3.CO;2-H; BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Becerra SP, 1999, RETINAL DEGENERATIVE DISEASES AND EXPERIMENTAL THERAPY, P519, DOI 10.1007/978-0-585-33172-0_49; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BU GJ, 1994, J BIOL CHEM, V269, P18521; DeCoster MA, 1999, J NEUROSCI RES, V56, P604; Festoff BW, 1996, J NEUROBIOL, V30, P255, DOI 10.1002/(SICI)1097-4695(199606)30:2<255::AID-NEU7>3.0.CO;2-4; GOLFATH R, 1996, MOL VIS, V2, P5; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Houenou LJ, 1999, J COMP NEUROL, V412, P506; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; Kohji T, 1998, NEUROSCI LETT, V243, P133, DOI 10.1016/S0304-3940(98)00109-8; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Lotery AJ, 1996, HUM MOL GENET, V5, P705, DOI 10.1093/hmg/5.5.705; Narita M, 1997, J NEUROCHEM, V68, P587; Ortego J, 1996, INVEST OPHTH VIS SCI, V37, P2759; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; Perez-Mediavilla LA, 1998, BBA-GENE STRUCT EXPR, V1398, P203, DOI 10.1016/S0167-4781(98)00055-4; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; Shirozu M, 1996, GENOMICS, V37, P273, DOI 10.1006/geno.1996.0560; SMIRNOVA IV, 1994, SEMIN THROMB HEMOST, V20, P426, DOI 10.1055/s-2007-1001931; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Taniwaki T, 1997, J NEUROCHEM, V68, P26; TOMBRANTINK J, 1994, GENOMICS, V19, P266, DOI 10.1006/geno.1994.1057; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; WAGNER SL, 1991, J NEUROCHEM, V56, P234, DOI 10.1111/j.1471-4159.1991.tb02586.x; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060	44	115	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31605	31612		10.1074/jbc.274.44.31605	http://dx.doi.org/10.1074/jbc.274.44.31605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531367	hybrid			2022-12-25	WOS:000083379400071
J	Schaeffer, ML; Khoo, KH; Besra, GS; Chatterjee, D; Brennan, PJ; Belisle, JT; Inamine, JM				Schaeffer, ML; Khoo, KH; Besra, GS; Chatterjee, D; Brennan, PJ; Belisle, JT; Inamine, JM			The pimB gene of Mycobacterium tuberculosis encodes a mannosyltransferase involved in lipoarabinomannan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; ANCHOR; GLYCOSYLTRANSFERASES; GLYCOPROTEIN; MACROPHAGES; ETHAMBUTOL; DEFINITION; LIPOMANNAN; SEQUENCE; STRAINS	The biosynthesis of lipoarabinomannan (LAM), a key mycobacterial lipoglycan that has been implicated in numerous immunoregulatory functions, was examined utilizing D-mannosamine (ManN) as a tool to identify mannosyltransferase genes involved in LAM synthesis, Cell-free reactions utilizing cellular membranes of mycobacteria as the enzyme source indicated that ManN inhibited the synthesis of phosphatidylinositol mannosides, early precursors to LAM, A selection strategy was devised to screen a Mycobacterium tuberculosis genomic library in Mycobacterium smegmatis for clones conferring conditional resistance to ManN, with the rationale that overexpression of the gene(s) encoding a target of ManN would impart a ManN-resistant phenotype under these conditions. This strategy led to the identification of pimB, whose deduced amino acid sequence shows similarity to mannosyltransferases and other glycosyltransferases. Partially purified recombinant PimB protein from Escherichia coli or membranes from M. smegmatis overexpressing the pimB gene were used in cell-free assays to show that PimB catalyzes the formation of triacylphosphatidylinositol dimannoside from GDP-mannose and triacylphosphatidylinositol monomannoside.	Colorado State Univ, Dept Microbiol, Mycobacteriol Res Labs, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Newcastle Univ, Sch Med, Sch Microbiol Immunol & Virol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Colorado State University; Academia Sinica - Taiwan; Newcastle University - UK	Inamine, JM (corresponding author), Colorado State Univ, Dept Microbiol, Mycobacteriol Res Labs, Ft Collins, CO 80523 USA.	jinamine@cvmbs.colostate.edu	Belisle, John T/B-8944-2017; Khoo, Kay-Hooi/E-1989-2019	Belisle, John T/0000-0002-2539-2798; Khoo, Kay-Hooi/0000-0003-2906-406X; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035220, R01AI037139, R21AI037139, U19AI038087] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35220, AI-37139, AI-38087] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BALLOU CE, 1972, METHOD ENZYMOL, V28, P493; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chopra I, 1998, TUBERCLE LUNG DIS, V78, P89, DOI 10.1016/S0962-8479(98)80001-4; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; HOROWITZ MI, 1991, ARCH BIOCHEM BIOPHYS, V288, P317, DOI 10.1016/0003-9861(91)90201-S; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KAPLAN G, 1987, J IMMUNOL, V138, P3028; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; PANGBORN MC, 1966, J LIPID RES, V7, P627; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SALMAN M, 1999, BIOCHIM BIOPHYS ACTA, V146, P437; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233	40	100	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31625	31631		10.1074/jbc.274.44.31625	http://dx.doi.org/10.1074/jbc.274.44.31625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531370	hybrid			2022-12-25	WOS:000083379400074
J	Stradal, TB; Gimona, M				Stradal, TB; Gimona, M			Ca2+-dependent association of S100A6 (Calcyclin) with the plasma membrane and the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SMOOTH-MUSCLE CELLS; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; ANNEXIN-XI; EXPRESSION; IDENTIFICATION; GENE; FIBROBLASTS; CALPONIN	Expression of S100A6 (Calcyclin), a member of the S100 family and of Zn2+-binding proteins is elevated in a number of malignant tumors. In vitro the protein associates with several actin-binding proteins and annexins in a Ca2+-dependent manner. We have now studied the subcellular localization of S100A6 using a new, specific monoclonal antibody. Immunofluorescence microscopy of unfixed, ultrathin, frozen sections demonstrated a dual localization of S100A6 at the nuclear envelope and the plasma membrane of porcine smooth muscle only in the presence of Ca2+. The same localization was found by immunofluorescence and immunogold electron microscopy as well as by confocal laser scanning microscopy with cultured, fixed, human CaKi-2 and porcine ST interphase cells. Upon cell division, however, S100A6 was found exclusively in the cytoplasm. Cell fractionation studies showed that S100A6 was present in the microsomal fraction in the presence of Ca2+ and was released from this fraction by the addition of EGTA/EDTA but not by Triton X-100. The data demonstrate that S100A6 is localized both at the plasma membrane and the nuclear envelope in vivo and suggest a Ca2+-dependent interaction with annexins or other components of the nuclear envelope.	Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria	Austrian Academy of Sciences	Gimona, M (corresponding author), Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, Billrothstr 11, A-5020 Salzburg, Austria.			Stradal, Theresia/0000-0002-0352-9474				Barwise JL, 1996, J CELL SCI, V109, P247; BAZAN HEP, 1992, EXP EYE RES, V55, P173, DOI 10.1016/0014-4835(92)90105-2; BRINCK U, 1995, J DERMATOL SCI, V10, P181, DOI 10.1016/0923-1811(95)00402-E; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CALABRETTA B, 1985, P NATL ACAD SCI USA, V82, P4463, DOI 10.1073/pnas.82.13.4463; Carafoli E, 1997, CELL CALCIUM, V22, P313, DOI 10.1016/S0143-4160(97)90016-6; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Garbuglia M, 1998, CELL CALCIUM, V24, P177, DOI 10.1016/S0143-4160(98)90127-0; GHEZZO F, 1989, DNA-J MOLEC CELL BIO, V8, P171, DOI 10.1089/dna.1.1989.8.171; GILCHRIST JSC, 1994, MOL CELL BIOCHEM, V135, P79, DOI 10.1007/BF00925963; Gimona M, 1997, J CELL SCI, V110, P611; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; Golitsina NL, 1996, BIOCHEM BIOPH RES CO, V220, P360, DOI 10.1006/bbrc.1996.0410; GUO XJ, 1990, CELL GROWTH DIFFER, V1, P333; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; KIHLMARK M, 1988, CELL BIOL LAB MANUAL, P152; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kordowska J, 1998, EUR J BIOCHEM, V253, P57, DOI 10.1046/j.1432-1327.1998.2530057.x; KUZNICKI J, 1989, BIOCHEM J, V263, P951; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; Lesniak W, 1996, BIOCHEM BIOPH RES CO, V220, P269, DOI 10.1006/bbrc.1996.0394; Mandinova A, 1998, J CELL SCI, V111, P2043; MANI RS, 1995, J BIOL CHEM, V270, P6658, DOI 10.1074/jbc.270.12.6658; MARKS A, 1990, BIOESSAYS, V12, P381, DOI 10.1002/bies.950120806; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; TONINI GP, 1995, EUR J CANCER, V31A, P499, DOI 10.1016/0959-8049(95)00043-I; VOLTZ A, 1993, GENOMICS, V18, P92; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WILLS FL, 1994, PROTEIN SCI, V3, P2311, DOI 10.1002/pro.5560031216; Yamashita N, 1999, J COMP NEUROL, V404, P235; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V	39	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31593	31596		10.1074/jbc.274.44.31593	http://dx.doi.org/10.1074/jbc.274.44.31593			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531365	hybrid			2022-12-25	WOS:000083379400069
J	White, KA; Lin, SH; Cotter, RJ; Raetz, CRH				White, KA; Lin, SH; Cotter, RJ; Raetz, CRH			A Haemophilus influenzae gene that encodes a membrane bound 3-deoxy-D-manno-octulosonic acid (Kdo) kinase - Possible involvement of Kdo phosphorylation in bacterial virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; LIPID-A; LIPOPOLYSACCHARIDE BIOSYNTHESIS; BORDETELLA-PERTUSSIS; CHEMICAL-STRUCTURE; IDENTIFICATION; ENDOTOXIN; STRAIN; TRANSFERASE	The lipopolysaccharide of Haemophilus influenzae contains a single 3-deoxy-D-manno-octulosonic acid (Kdo) residue derivatized with either a phosphate or an ethanolamine pyrophosphate moiety at the 4-OH position. In previous studies, we identified a kinase unique to H. influenzae extracts that phosphorylates Kdo-lipid IVA, a key precursor of lipopolysaccharide in this organism. We have now identified the gene encoding the Kdo kinase by using an expression cloning approach. A cosmid library containing random DNA fragments from H. influenzae strain Rd was constructed in Escherichia coli. Extracts of 472 colonies containing individual hybrid cosmids were assayed for Kdo kinase activity. A single hybrid cosmid directing expression of the kinase was found. The kinase gene was identified by activity assays, sub-cloning, and DNA sequencing. When the putative kinase gene was expressed in E. coli behind a T7 promoter, massive overproduction of kinase activity was achieved (similar to 8000-fold higher than in H. influenzae membranes). The catalytic properties and the product generated by the overexpressed kinase, assayed with Kdo-lipid IV,as the substrate, were the same as observed with H. influenzae membranes. Unexpectedly, the kinase gene was identical to a previously characterized open reading frame (orfZ), which had been shown to be important for establishing bacteremia in an infant rat model (Hood, D. W., Deadman, M. E., Alien, T., Masoud, H., Martin, A., Brisson, J. R., Fleischmann, R., Venter, J, C., Richards, J. C., and Moxon, E. R. (1996) Mol. Microbiol. 22, 951-965). However, based solely on the genome sequence of H. influenzae Rd, no biochemical function had been assigned to the product of orfZ, which we now designate kdkA ("Kdo kinase A"). Although Kdo phosphorylation may be critical for bacterial virulence of H. influenzae, it does not appear to be required for growth.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spect Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, GM-54882] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCK K, 1994, EUR J BIOCHEM, V225, P1029, DOI 10.1111/j.1432-1033.1994.1029b.x; BRADE H, 1985, J BACTERIOL, V161, P795, DOI 10.1128/JB.161.2.795-798.1985; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; Carballo PMS, 1999, EUR J BIOCHEM, V261, P500, DOI 10.1046/j.1432-1327.1999.00299.x; CHABY R, 1975, EUR J BIOCHEM, V59, P277, DOI 10.1111/j.1432-1033.1975.tb02452.x; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Dotson GD, 1998, J BACTERIOL, V180, P330, DOI 10.1128/JB.180.2.330-337.1998; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; HIGH NJ, 1993, MOL MICROBIOL, V9, P1275, DOI 10.1111/j.1365-2958.1993.tb01257.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; JAROSIK GP, 1994, INFECT IMMUN, V62, P4861, DOI 10.1128/IAI.62.11.4861-4867.1994; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KLEIN JO, 1997, PEDIATR INFECT DIS J, V16, P5; KUMADA H, 1993, FEMS MICROBIOL LETT, V108, P75; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MOXON ER, 1992, J INFECT DIS S1, V165, P77; MOXON ER, 1991, REV INFECT DIS    S6, V13, P518; Murphy TF, 1997, ANN NY ACAD SCI, V830, P353, DOI 10.1111/j.1749-6632.1997.tb51907.x; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; QURESHI N, 1988, J BIOL CHEM, V263, P11971; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; ZAMZE SE, 1987, BIOCHEM J, V245, P583, DOI 10.1042/bj2450583; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; [No title captured]	54	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31391	31400		10.1074/jbc.274.44.31391	http://dx.doi.org/10.1074/jbc.274.44.31391			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531340	hybrid			2022-12-25	WOS:000083379400044
J	Kapila, YL; Wang, SH; Johnson, PW				Kapila, YL; Wang, SH; Johnson, PW			Mutations in the heparin binding domain of fibronectin in cooperation with the V region induce decreases in pp125(FAK) levels plus proteoglycan-mediated apoptosis via caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PERIODONTAL-LIGAMENT CELLS; MAMMARY EPITHELIAL-CELLS; HUMAN ENDOTHELIAL-CELLS; FN-C/H-V; INTEGRIN ALPHA-4-BETA-1; SYNTHETIC PEPTIDE; SYNOVIAL-FLUID; EXTRACELLULAR-MATRIX; SUPPRESSES APOPTOSIS	Intact fibronectin (FN) protects cells from apoptosis. When FN is fragmented, specific domains induce proteinase expression in fibroblasts. However, it is not known whether specific domains of FN can also regulate apoptosis. We exposed fibroblasts to four recombinant FN fragments and then assayed for apoptosis using criteria of cellular shape change, condensed nuclear morphology, and DNA fragmentation. The fragments extended from the RGD-containing repeat III10 to III15; they included (V+) or excluded (V-) the alternatively spliced V region and contained either a mutated (H-) or an unmutated (H+) heparin binding domain. Only the V+H- fragment triggered decreases in pp125(FAK) levels and apoptosis, which was rescued by intact FN and inhibitors of caspase-1 and caspase-3, This apoptotic mechanism was mediated by a chondroitin sulfate proteoglycan, since treating cells with chondroitin sulfate or chondroitinase reversed the apoptotic cell shape changes. The alpha 4 integrin receptor may also be involved, since using a blocking antibody to alpha 4 alone induced apoptotic cell shape changes, whereas co-treatment with this antibody plus V+H+ reversed these effects. These results demonstrate that the V and heparin binding domains of FN modulate pp125(FAK) levels and regulate apoptosis through a chondroitin sulfate proteoglycan- and possibly alpha 4 integrin-mediated pathway, which triggers a caspase cascade.	Univ Calif San Francisco, Dept Stomatol, Sch Dent, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kapila, YL (corresponding author), Univ Calif San Francisco, Dept Stomatol, Sch Dent, HSW 604,Box 0512, San Francisco, CA 94143 USA.		Kapila, Yvonne/AAG-5418-2021		NIDCR NIH HHS [K15 DE00344] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000344] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOBERBARKALOW FJ, 1991, J BIOL CHEM, V266, P7812; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARSONS S, 1985, ARTHRITIS RHEUM, V28, P601, DOI 10.1002/art.1780280602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Crouch DH, 1996, ONCOGENE, V12, P2689; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Goh KL, 1997, DEVELOPMENT, V124, P4309; Goruppi S, 1996, ONCOGENE, V12, P471; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Ilic D, 1998, J CELL BIOL, V143, P547; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; Kapila YL, 1996, MATRIX BIOL, V15, P251, DOI 10.1016/S0945-053X(96)90116-X; Kapila YL, 1998, J PERIODONTOL, V69, P1008, DOI 10.1902/jop.1998.69.9.1008; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; SORSA T, 1992, INFECT IMMUN, V60, P4491, DOI 10.1128/IAI.60.11.4491-4495.1992; TALONPOIKA J, 1993, SCAND J DENT RES, V101, P375; TALONPOIKA J, 1993, MOL BIOL CELL, V5, P439; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VERFAILLIE CM, 1994, BLOOD, V84, P1802; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WILKE MS, 1993, J INVEST DERMATOL, V101, P43, DOI 10.1111/1523-1747.ep12358823; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; XIE DL, 1992, J RHEUMATOL, V19, P1448; XIE DL, 1994, ARCH BIOCHEM BIOPHYS, V311, P205, DOI 10.1006/abbi.1994.1228; Yoshikawa H, 1996, J IMMUNOL, V156, P1832; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	45	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30906	30913		10.1074/jbc.274.43.30906	http://dx.doi.org/10.1074/jbc.274.43.30906			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521484	hybrid			2022-12-25	WOS:000083276700080
J	Solis-Herruzo, JA; Rippe, RA; Schrum, LW; de la Torre, P; Garcia, I; Jeffrey, JJ; Munoz-Yague, T; Brenner, DA				Solis-Herruzo, JA; Rippe, RA; Schrum, LW; de la Torre, P; Garcia, I; Jeffrey, JJ; Munoz-Yague, T; Brenner, DA			Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN COLLAGENASE-3 GENE; ACUTE-PHASE RESPONSE; INTERSTITIAL COLLAGENASE; C-JUN; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; OKADAIC ACID; DIFFERENTIAL EXPRESSION; 5'-FLANKING REGION	The role of IL-6 in collagen production and tissue remodeling is controversial. In Rat-1 fibroblasts, we measured the effect of IL-6 on matrix metalloproteinase-13 (MMP-13), c-jun, junB, and c-fos gene expression, binding of activator protein 1 (AP1) to DNA, amount of AP1 proteins, immunoreactive MMP-13 and TIMP-1 proteins, and Jun N-terminal kinase activity. We show that IL-6 increased MMP-13-mRNA and MMP-13 protein. These effects were exerted by acting on the AP1-binding site of the MMP-13 promoter, as shown by transfecting cells with reporter plasmids containing mutations in this element. Mobility shift assays demonstrated that IL-6 induced the DNA binding activity of AP1. This effect was accompanied by a marked increase in c-Jun, JunB, and c-Fos mRNA, as well as in c-Jun protein and its phosphorylated form. The latter is not due to increased Jun N-terminal kinase activity but to a decreased serine/threonine phosphatase activity. We conclude that IL-6 increases interstitial MMP-13 gene expression at the promoter level. This effect seems to be mediated by the induction of c-jun, junB, and c-fos gene expression, by the binding of AP1 to DNA, by increasing phosphorylated c-Jun, and by the inhibition of serine/threonine phosphatase activity. These effects of IL-6 might contribute to remodeling connective tissue.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Hosp Univ 12 Octubre, Dept Med Gastroenterol, Madrid 28041, Spain; Albany Med Coll, Dept Med, Div Hematol, Albany, NY 12208 USA	University of North Carolina; University of North Carolina Chapel Hill; Hospital Universitario 12 de Octubre; Albany Medical College	Solis-Herruzo, JA (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.	jasolis@h12o.es	García-Ruiz, Inmaculada/G-8204-2015	García-Ruiz, Inmaculada/0000-0003-4185-8524; Brenner, David/0000-0003-2573-525X	NIDDK NIH HHS [DK 47361] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; Barber MD, 1999, CLIN SCI, V96, P83, DOI 10.1042/CS19980185; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BELKA C, 1995, LEUKEMIA, V9, P288; Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1995, ONCOGENE, V10, P985; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CURRAN T, 1987, ONCOGENE, V2, P79; DAFFADA AAI, 1994, BBA-MOL CELL RES, V1222, P234, DOI 10.1016/0167-4889(94)90174-0; DEVIERE J, 1992, GASTROENTEROLOGY, V103, P1296, DOI 10.1016/0016-5085(92)91519-A; DIBATTISTA JA, 1995, J RHEUMATOL, V22, P123; Diez Ruiz A., 1993, Alcohol and Alcoholism, V28, P319; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNCAN MR, 1991, J INVEST DERMATOL, V97, P686, DOI 10.1111/1523-1747.ep12483971; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EMONARD H, 1992, MATRIX, V12, P471, DOI 10.1016/S0934-8832(11)80091-0; EMONARD H, 1990, CELL MOL BIOL, V36, P131; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GAIRE M, 1994, J BIOL CHEM, V269, P2032; Grumbles RM, 1997, J CELL BIOCHEM, V67, P92; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HENSCHLER R, 1991, FEBS LETT, V283, P47, DOI 10.1016/0014-5793(91)80550-M; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano T, 1998, Int Rev Immunol, V16, P249; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Jenab S, 1997, ENDOCRINOLOGY, V138, P2740, DOI 10.1210/en.138.7.2740; KAKUMU S, 1991, AM J GASTROENTEROL, V86, P1804; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOCH KS, 1992, BIOCHEM BIOPH RES CO, V183, P184, DOI 10.1016/0006-291X(92)91626-2; Kojima H, 1996, ONCOGENE, V12, P547; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOTZ M, 1991, J BIOL CHEM, V266, P2017; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PETERSEN M, 1995, PHOTOCHEM PHOTOBIOL, V62, P444, DOI 10.1111/j.1751-1097.1995.tb02366.x; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SATO T, 1990, BIOCHEM BIOPH RES CO, V170, P824, DOI 10.1016/0006-291X(90)92165-V; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SEKIYAMA KD, 1994, CLIN EXP IMMUNOL, V98, P71; SHINGU M, 1993, CLIN EXP IMMUNOL, V94, P145; Silacci P, 1998, J BIOL CHEM, V273, P13625, DOI 10.1074/jbc.273.22.13625; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Solis-Herruzo JA, 1998, CELL SIGNAL, V10, P173, DOI 10.1016/S0898-6568(97)00036-3; SUN YQ, 1992, J CLIN IMMUNOL, V12, P197, DOI 10.1007/BF00918089; Sweeting J, 1989, Gastroenterology, V97, P1056; TAGA T, 1992, HDB BASIC CLIN RES, P144; Tardif G, 1997, BIOCHEM J, V323, P13, DOI 10.1042/bj3230013; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; THIELE DL, 1989, HEPATOLOGY, V9, P497, DOI 10.1002/hep.1840090325; VINCENTI MP, 1988, BIOCHEM J, V331, P341; WANG Y, 1995, GENE, V162, P285, DOI 10.1016/0378-1119(95)00295-H; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WLASCHEK M, 1993, J INVEST DERMATOL, V101, P164, DOI 10.1111/1523-1747.ep12363644	82	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30919	30926		10.1074/jbc.274.43.30919	http://dx.doi.org/10.1074/jbc.274.43.30919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521486	hybrid, Green Published			2022-12-25	WOS:000083276700082
J	Yusta, B; Somwar, R; Wang, F; Munroe, D; Grinstein, S; Klip, A; Drucker, DJ				Yusta, B; Somwar, R; Wang, F; Munroe, D; Grinstein, S; Klip, A; Drucker, DJ			Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADENYLYL-CYCLASE; GENE-EXPRESSION; ACTIVATION; CELLS; GLUCOSE; TRANSDUCTION; HEPATOCYTES; INCREASE; CLONING	Glucagon-like peptide-2 (GLP-2) promotes the expansion of the intestinal epithelium through stimulation of the GLP-2 receptor, a recently identified member of the glucagon-secretin G protein-coupled receptor superfamily. Although activation of G protein-coupled receptors may lead to stimulation of cell growth, the mechanisms transducing the GLP-2 signal to mitogenic proliferation remain unknown. We now report studies of GLP-2R signaling in baby hamster kidney (BHK) cells expressing a transfected rat GLP-2 receptor (BHK-GLP-2R cells). GLP-2, but not glucagon or GLP-1, increased the levels of cAMP and activated both cAMP-response element- and AP-l-dependent transcriptional activity in a dose-dependent manner. The activation of AP-l-luciferase activity was protein kinase A (PKA) -dependent and markedly diminished in the presence of a dominant negative inhibitor of PKA. Although GLP-2 stimulated the expression of c-fos, c-jun, junB, and zif268, and transiently increased p70 S6 kinase in quiescent BHK-GLP-2R cells, GLP-2 also inhibited extracellular signal-regulated kinase 1/2 and reduced serum-stimulated Elk-1 activity. Furthermore, no rise in intracellular calcium was observed following GLP-2 exposure in BHK-GLP-2R cells. Although GLP-2 stimulated both cAMP accumulation and cell proliferation, 8-bromo-cyclic AMP alone did not promote, cell proliferation. These findings suggest that the GLP-2R may be coupled to activation of mitogenic signaling in heterologous cell types independent of PKA via as yet unidentified downstream mediators of GLP-2 action in vivo.	Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hosp Sick Children, Dept Cell Biol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hosp Sick Children, Dept Physiol, Toronto, ON M5G 2C4, Canada; Allelix Biopharmaceut Inc, Mississauga, ON L4V 1P1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Dept Med, 101 Coll St,CCRW3-838, Toronto, ON M5G 2C4, Canada.		Drucker, Daniel J/A-4092-2010					Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Brubaker PL, 1997, ENDOCRINOLOGY, V138, P4837, DOI 10.1210/en.138.11.4837; Cheeseman CI, 1996, AM J PHYSIOL-GASTR L, V271, pG477, DOI 10.1152/ajpgi.1996.271.3.G477; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; Drucker DJ, 1999, TRENDS ENDOCRIN MET, V10, P153, DOI 10.1016/S1043-2760(98)00136-2; Drucker DJ, 1999, AM J PHYSIOL-GASTR L, V276, pG79, DOI 10.1152/ajpgi.1999.276.1.G79; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; GALANG CK, 1994, ONCOGENE, V9, P2913; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hansen LH, 1998, AM J PHYSIOL-CELL PH, V274, pC1552, DOI 10.1152/ajpcell.1998.274.6.C1552; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jin TR, 1996, MOL CELL BIOL, V16, P19; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; ORSKOV C, 1987, SCAND J CLIN LAB INV, V47, P165; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Scott RB, 1998, AM J PHYSIOL-GASTR L, V275, pG911, DOI 10.1152/ajpgi.1998.275.5.G911; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; TANG EKY, 1992, BIOCHEM J, V283, P341, DOI 10.1042/bj2830341; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; Wojdemann M, 1998, SCAND J GASTROENTERO, V33, P828; Xiao QA, 1999, GASTROENTEROLOGY, V117, P99, DOI 10.1016/S0016-5085(99)70555-X; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685	45	87	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30459	30467		10.1074/jbc.274.43.30459	http://dx.doi.org/10.1074/jbc.274.43.30459			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521425	hybrid			2022-12-25	WOS:000083276700021
J	Li, R				Li, R			Stimulation of DNA replication in Saccharomyces cerevisiae by a glutamine- and proline-rich transcriptional activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP1; COMPLEX; PROTEIN; RECOGNITION; INTERACTS; PROMOTER; ELEMENTS; ORIGINS; CELLS	Glutamine-rich Sp1 and proline-rich CTF1, two extensively studied mammalian transcription factors, bind to origins of replication in DNA tumor viruses and stimulate viral DNA replication in mammalian cells. Here it is shown that, when tethered to a plasmid-borne cellular origin of replication, the activation domains of both proteins can enhance origin function in Saccharomyces cerevisiae, Hydrophobic patches in Spl and CTF1 that mediate transcriptional activation in higher eukaryotes are also important for activation of replication in yeast. However, only the activation domain of CTF1 can enhance initiation of replication from a chromosomally embedded origin. This correlates with the ability of CTF1 to alter the local chromatin structure around the chromosomal origin of replication. The CTF1-induced chromatin remodeling occurs at multiple stages of the cell cycle. These findings strongly suggest a high degree of conservation in the mechanisms used by various types of transcription factors to stimulate viral and cellular DNA replication in eukaryotes.	Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEPAMPHILIS ML, 1993, TRENDS CELL BIOL, V3, P1161; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HEINTZ N H, 1992, Current Opinion in Cell Biology, V4, P459, DOI 10.1016/0955-0674(92)90012-2; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30310	30314		10.1074/jbc.274.42.30310	http://dx.doi.org/10.1074/jbc.274.42.30310			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514526	hybrid			2022-12-25	WOS:000083176400105
J	Shimomura, I; Bashmakov, Y; Horton, JD				Shimomura, I; Bashmakov, Y; Horton, JD			Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; BOUND TRANSCRIPTION FACTOR; STEAROYL-COA DESATURASE; LEUCINE ZIPPER PROTEIN; TRANSGENIC MICE; BINDING PROTEINS; ADIPOSE-TISSUE; CHOLESTEROL-SYNTHESIS; CULTURED-CELLS; ACID SYNTHESIS	Hepatic steatosis is common in non-insulin-dependent diabetes and can be associated with fibrosis and cirrhosis in a subset of individuals. Increased rates of fatty acid synthesis have been reported in livers from rodent models of diabetes and may contribute to the development of steatosis. Sterol regulatory element-binding proteins (SREBPs) are a family of regulated transcription factors that stimulate lipid synthesis in liver. In the current studies, we measured the content of SREBPs in livers from two mouse models of diabetes, obese ob/ob mice and transgenic aP2-SREBP-1c436 (aP2-SREBP-1c) mice that overexpress nuclear SREBP-1c only in adipose tissue. The aP2-SREBP-1c mice exhibit a syndrome that resembles congenital generalized lipodystrophy in humans. Both lines of mice develop hyperinsulinemia, hyperglycemia, and hepatic steatosis. Nuclear SREBP-1c protein levels were significantly elevated in livers from ob/ob and aP2-SREBP-1c mice compared with wild-type mice. Increased nuclear SREBP-1c protein was associated with elevated mRNA levels for known SREBP target genes involved in fatty acid biosynthesis, which led to significantly higher rates of hepatic fatty acid synthesis in vivo. These studies suggest that increased levels of nuclear SREBP-1c contribute to the elevated rates of hepatic fatty acid synthesis that leads to steatosis in diabetic mice.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horton, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75235 USA.		Adiels, Martin/C-9278-2011	Bashmakov, Yuriy/0000-0002-2265-3817	NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; MARTIN RJ, 1974, LIFE SCI, V14, P1447, DOI 10.1016/0024-3205(74)90155-6; MEMON RA, 1994, HORM METAB RES, V26, P85, DOI 10.1055/s-2007-1000778; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VANSTEENBERGEN W, 1995, INT J OBESITY, V19, pS27; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	31	552	571	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30028	30032		10.1074/jbc.274.42.30028	http://dx.doi.org/10.1074/jbc.274.42.30028			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514488	hybrid			2022-12-25	WOS:000083176400067
J	Ye, X; Mehlen, P; Rabizadeh, S; VanArsdale, T; Zhang, HY; Shin, H; Wang, JJL; Leo, E; Zapata, J; Hauser, CA; Reed, JC; Bredesen, DE				Ye, X; Mehlen, P; Rabizadeh, S; VanArsdale, T; Zhang, HY; Shin, H; Wang, JJL; Leo, E; Zapata, J; Hauser, CA; Reed, JC; Bredesen, DE			TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; INDUCED CELL-DEATH; TERMINAL KINASE; BINDING-SITES; P75 RECEPTOR; TNF; ACTIVATION	The common neurotrophin receptor, p75(NTR), has been shown to signal in the absence of Trk tyrosine kinase receptors, including induction of neural apoptosis and activation of NF-kappa B. However, the mechanisms by which p75NTR initiates these intracellular signal transduction pathways are unknown. Here we report interactions between p75(NTR) and the six members of TRAF (tumor necrosis factor receptor-associated factors) family proteins. The binding of different TRAF proteins to p75(NTR) was mapped to distinct regions in p75NTR. Furthermore, TRAF4 interacted with dimeric p75(NTR), whereas TRAF2 interacted preferentially with monomeric p75(NTR). TRAF2-p75(NTR), TRAF4-p75(NTR), and TRAF6-p75(NTR) interactions modulated p75(NTR)-induced cell death and NF-kappa B activation with contrasting effects. Coexpression of TRAF2 with p75NTR enhanced cell death, whereas coexpression of TRAF6 was cytoprotective. Furthermore, overexpression of TRAF4 abrogated the ability of dimerization to prevent the induction of apoptosis normally mediated by monomeric p75NTR. TRAF4 also inhibited the NF-KB response, whereas TRAF2 and TRAF6 enhanced p75NTR-induced NF-kappa B activation. These results demonstrate that TRAF family proteins interact with p75(NTR) and differentially modulate its NF-kappa B activation and cell death induction.	Burnham Inst, Program Aging & Canc, La Jolla, CA 92037 USA; Burnham Inst, Program Apoptosis & Cell Death, La Jolla, CA 92037 USA; Burnham Inst, Program Gene Regulat, La Jolla, CA 92037 USA; Univ Lyon 1, CNRS, UMR 5534, Ctr Mol & Cellular Genet, F-69622 Villeurbanne, France; Univ Calif Los Angeles, Interdepartmental Program Neurosci, Los Angeles, CA 90024 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of California System; University of California Los Angeles; University of California System; University of California San Diego	Bredesen, DE (corresponding author), Buck Ctr Res Aging, POB 638, Novato, CA 94948 USA.		Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035155, R01NS033376] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NINDS NIH HHS [NS33376, NS35155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Frade JM, 1996, NATURE, V383, P166; GALANG CK, 1994, ONCOGENE, V9, P2913; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Krajewska M, 1998, AM J PATHOL, V152, P1549; Krajewski S, 1997, J IMMUNOL, V159, P5841; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Masson R, 1998, MECH DEVELOP, V71, P187, DOI 10.1016/S0925-4773(97)00192-5; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderZee CEEM, 1996, SCIENCE, V274, P1729, DOI 10.1126/science.274.5293.1729; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Ye X., UNPUB; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yeo TT, 1997, J NEUROSCI, V17, P7594; Yoon SO, 1998, J NEUROSCI, V18, P3273	52	154	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30202	30208		10.1074/jbc.274.42.30202	http://dx.doi.org/10.1074/jbc.274.42.30202			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514511	hybrid			2022-12-25	WOS:000083176400090
J	Akagi, T; Motegi, M; Tamura, A; Suzuki, R; Hosokawa, Y; Suzuki, H; Ota, H; Nakamura, S; Morishima, Y; Taniwaki, M; Seto, M				Akagi, T; Motegi, M; Tamura, A; Suzuki, R; Hosokawa, Y; Suzuki, H; Ota, H; Nakamura, S; Morishima, Y; Taniwaki, M; Seto, M			A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue	ONCOGENE			English	Article						translocation; 18q21; MALT lymphoma; MALT1; extranodal lymphoma	T(11-18)(Q21-Q21); TRANSLOCATION; CLONING; CD22; AMPLIFICATION; EXPRESSION; MOLECULE; VECTOR; YEAST	The t(11;18) (q21;q21) translocation is a characteristic chromosomal aberration in low-grade B-cell lymphoma of mucose-associated lymphoid tissue (MALT) type. We previously identified a YAC clone y789F3, which includes the breakpoint at 18q21 in a MALT lymphoma patient. BAC and PAC contigs were constructed on the YAC, and BAC 193f9 was found to encompass the breakpoint region. In the present study, we further narrowed down the breakpoint region at 18q21 in five MALT lymphoma patients by means of FISH and Southern blot analyses using the plasmid contig constructed from BAC 193f9, The breakpoints at 18q21 in three of the five MALT lymphoma patients were found to be clustered approximately within the 20 kb region. By using exon amplification and cDNA library screening, we identified a novel cDNA spanning the breakpoint region that exhibited aberrant mRNA signals in four of the five MALT lymphoma patients. The nucleotide sequence predicted an 813 amino acid protein that shows significant sequence similarity to the CD22 beta and laminin 5 alpha 3b subunit, We refer to the gene encoding this transcript as MALT1 (Mucosa-Associated Lymphoid Tissue lymphoma translocation gene 1). The alteration of MALT1 by translocation strongly suggests that this gene plays an important role in the pathogenesis of MALT lymphoma.	Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6020841, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Kyoto Prefectural University of Medicine; Shinshu University; Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Nakamura, Shigeo/I-1571-2012	Suzuki, Ritsuro/0000-0002-5974-7614				Akagi T, 1999, GENE CHROMOSOME CANC, V24, P315; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GRIFFIN CA, 1992, GENE CHROMOSOME CANC, V4, P153, DOI 10.1002/gcc.2870040209; HARRIS NL, 1994, BLOOD, V84, P1361; HORSMAN D, 1992, GENE CHROMOSOME CANC, V4, P183, DOI 10.1002/gcc.2870040213; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LEROUX D, 1993, GENE CHROMOSOME CANC, V7, P54, DOI 10.1002/gcc.2870070109; LEVINE EG, 1989, BLOOD, V74, P1796; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEHLS M, 1994, ONCOGENE, V9, P2169; Ott G, 1997, CANCER RES, V57, P3944; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 1989, MOL CLONING; SARKAR FH, 1993, DNA CELL BIOL, V12, P611, DOI 10.1089/dna.1993.12.611; SETO M, 1992, ONCOGENE, V7, P1401; Silverman Gary A., 1995, V54, P65; Stoffel A, 1999, GENE CHROMOSOME CANC, V24, P156; TANIWAKI M, 1995, BLOOD, V86, P1481, DOI 10.1182/blood.V86.4.1481.bloodjournal8641481; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO K, 1993, ONCOGENE, V8, P2617	26	275	281	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5785	5794		10.1038/sj.onc.1203018	http://dx.doi.org/10.1038/sj.onc.1203018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523859				2022-12-25	WOS:000083095100007
J	Lerm, M; Schmidt, G; Goehring, UR; Schirmer, J; Aktories, K				Lerm, M; Schmidt, G; Goehring, UR; Schirmer, J; Aktories, K			Identification of the region of Rho involved in substrate recognition by Escherichia coli cytotoxic necrotizing factor 1 (CNF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BOTULINUM ADP-RIBOSYLTRANSFERASE; BINDING PROTEIN-RHO; GENE-PRODUCT; DERMONECROTIC TOXIN; BORDETELLA; GTPASES; CELLS; RAS; EFFECTOR	The Escherichia coli cytotoxic necrotizing factor 1 (CNF1) and the Bordetella dermonecrotic toxin (DNT) activate Rho GTPases by deamidation of Gln(63) of RhoA (Gln(61) of Cdc42 and Rac). In addition, both toxins possess in vitro transglutaminase activity in the presence of primary amines. Here we characterized the region of Rho essential for substrate recognition by the toxins using Rho/Ras chimeras as protein substrates, The chimeric protein Ras55Rho was deamidated or transglutaminated by CNF1. Rat pheochromocytoma PC12 cells microinjected with Ras55Rho developed formation of neurite-like structures after treatment with the CNF1 holotoxin indicating activation of the Ha-Ras chimera and Ras-like effects in intact cells. The Ras59Rho78Ras chimera protein contained the minimal Rho sequence allowing deamidation or transglutamination by CNF1. A peptide covering mainly the switch II region and consisting of amino acid residues Asp(59) through Asp(78) Of RhoA was substrate for CNF1. Changes of amino acid residues Arg(68) Or Leu(72) of RhoA into the corresponding residues of Ras (R68ARhoA and L72QRhoA) inhibited deamidation and transglutamination of the mutants by CNF1. In contrast to CNF1, DNT did not modify Rho/Ras chimeras or the switch II peptide (Asp59 through Asp78). Glucosylation of RhoA at Thr(37) blocked deamidation by DNT but not by CNF. The data indicate that CNF1 recognizes Rho GTPases exclusively in the switch II region, whereas the substrate recognition by DNT is characterized by additional structural requirements.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Herman Herder Str 5, D-79104 Freiburg, Germany.		Aktories, Klaus/CAJ-5682-2022; Lerm, Maria/AAA-1780-2020; Lerm, Maria/AAM-8705-2020	Aktories, Klaus/0000-0002-5397-0436; Lerm, Maria/0000-0002-5092-9892; 				AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1998, NATURWISSENSCHAFTEN, V85, P253, DOI 10.1007/s001140050495; SCHMIDT G, 1999, N-S ARCH PHARMACOL, V359, pR60; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699	35	57	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28999	29004		10.1074/jbc.274.41.28999	http://dx.doi.org/10.1074/jbc.274.41.28999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506148	hybrid			2022-12-25	WOS:000083017800027
J	Xu, T; Vasilyeva, E; Forgac, M				Xu, T; Vasilyeva, E; Forgac, M			Subunit interactions in the clathrin-coated vesicle vacuolar (H+)-ATPase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; H+-ATPASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CHROMAFFIN GRANULES; 40-KDA SUBUNIT; CROSS-LINKING; ALPHA-SUBUNIT; CDNA SEQUENCE; IN-VITRO	The vacuolar (H+)-ATPases (or V-ATPases) are structurally related to the F1F0 ATP synthases of mitochondria, chloroplasts and bacteria, being composed of a peripheral (V-1) and an integral (V-0) domain. To further investigate the arrangement of subunits in the V-ATPase complex, covalent cross-linking has been carried out on the V-ATPase from clathrin-coated vesicles using three different cross-linking reagents. Crosslinked products were identified by molecular weight and by Western blot analysis using polyclonal antibodies raised against individual V-ATPase subunits, In the intact V1V0 complex, evidence for cross-linking of subunits C and E, D and F, as well as E and G by disuccinimidyl glutarate was obtained, while in the free V-1 domain, cross-linking of subunits H and E was also observed. Subunits C and E as well as D and E could be cross-linked by 1-ethyl-3-(dimethylaminopropyl)carbodiimide, while subunits a and E could be cross-linked by 4-(N-maleimido)benzophenone. It was further demonstrated that it is possible to treat the V-ATPase with potassium iodide and MgATP in such a way that while subunits A, B, and H are nearly quantitatively removed, significant amounts of subunits C, D, E, and F remain attached to the membrane, suggesting that one or more of these latter subunits are in contact with the V-0 domain. In addition, treatment of the V-ATPase with cystine, which modifies Cys-254 of the catalytic A subunit, results in dissociation of subunit H, suggesting communication between the catalytic nucleotide binding site and subunit H. Finally, the stoichiometry of subunits F, G, and H were determined by quantitative amino acid analysis. Based on these and previous observations, a new structural model of the V-ATPase from clathrin-coated vesicles is proposed.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; AGGLER R, 1993, J BIOL CHEM, V268, P20831; AGGLER R, 1996, J BIOL CHEM, V271, P13888; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRY OH, 1951, J BIOL CHEM, V193, P265; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; LIU Q, 1994, J BIOL CHEM, V269, P31592; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEK F, 1994, J BIOL CHEM, V269, P24102; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	50	118	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28909	28915		10.1074/jbc.274.41.28909	http://dx.doi.org/10.1074/jbc.274.41.28909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506135	hybrid			2022-12-25	WOS:000083017800014
J	Wang, XZ; Jolicoeur, EM; Conte, N; Chaffanet, M; Zhang, YH; Mozziconacci, MJ; Feiner, H; Birnbaum, D; Pebusque, MJ; Ron, D				Wang, XZ; Jolicoeur, EM; Conte, N; Chaffanet, M; Zhang, YH; Mozziconacci, MJ; Feiner, H; Birnbaum, D; Pebusque, MJ; Ron, D			gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line	ONCOGENE			English	Article						signal transduction; EGF receptor; tyrosine kinase; tenascin; CHOP	PAIR-RULE GENE; WERNER-SYNDROME; GROWTH-FACTOR; REGION	gamma-heregulin is a recently described novel isoform of the heregulin/neuregulin class of EGF-like ligands that bind to and activate receptors of the ErbB family, Deregulated signaling through the heregulin-ErbB pathway is thought to be implicated in the development of a subset of human breast cancers. gamma-heregulin has been found to be expressed in the culture supernatant of MDA-MB-175, a breast carcinoma cell line. gamma-heregulin is characterized by the presence of a large N-terminal peptide extension that is not found in other heregulin isoforms, Here we report that this unique N-terminal extension of gamma-heregulin is identical to the N-terminus of DOC4, a product of a recent ly identified CHOP-dependent stress-induced gene, Human DOC4 and the heregulin-encoding genes map to different chromosomes and the MDA-MB-175 cell line contains a chromosomal translocation that leads to the fusion of DOC4 and HGL, on chromosomes 11 and 8, respectively. Thus, gamma-heregulin is a product of a mutant fusion gene and not a bona fide normal isoform, We speculate that the mutation may be selected for by virtue of its ability to activate ErbB signaling through the production of an autocrine ligand.	NYU, Med Ctr, Kaplan Canc Ctr, Dept Med,Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Dept Cell Biol,Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, Dept Pathol,Skirball Inst Biomol Med, New York, NY 10016 USA; Inst J Paoli I Calmettes, Lab Cylogenet, F-13009 Marseille, France; Inst Cancerol & Immunol Marseille, Marseille, France	New York University; New York University; New York University; UNICANCER; Institut Paoli-Calmette (IPC)	Ron, D (corresponding author), NYU, Med Ctr, Kaplan Canc Ctr, Dept Med,Skirball Inst Biomol Med, 550 1St Ave, New York, NY 10016 USA.		CHAFFANET, Max/AAU-5743-2020	CHAFFANET, Max/0000-0002-2344-1488; Ron, David/0000-0002-3014-5636; Conte, Nathalie/0000-0002-1010-3121	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chaffanet M, 1996, CYTOGENET CELL GENET, V72, P63, DOI 10.1159/000134164; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; LEE J, 1993, GENOMICS, V16, P790, DOI 10.1006/geno.1993.1272; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619	11	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5718	5721		10.1038/sj.onc.1202950	http://dx.doi.org/10.1038/sj.onc.1202950			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523851				2022-12-25	WOS:000083016500013
J	Yoshii, S; Tanaka, M; Otsuki, Y; Wang, DY; Guo, RJ; Zhu, Y; Takeda, R; Hanai, H; Kaneko, E; Sugimura, H				Yoshii, S; Tanaka, M; Otsuki, Y; Wang, DY; Guo, RJ; Zhu, Y; Takeda, R; Hanai, H; Kaneko, E; Sugimura, H			alpha PIX nucleotide exchange factor is activated by interaction with phosphatidylinositol 3-kinase	ONCOGENE			English	Article						PAK; PDGF; EphB2; Nck; phosphoinositide	XENOPUS-LAEVIS DEVELOPMENT; FOCAL ADHESION KINASE; ADAPTER PROTEIN NCK; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; MEMBRANE LOCALIZATION; CELL MOTILITY; SH3 DOMAIN; RECEPTOR; PHOSPHORYLATION	p21-activated kinase (PAK) is a common effector protein of the small GTPases Cdc42 and Rac, leading to the activation of downstream mitogen activated protein kinases, PAK also mediates polarized cytoskeletal changes induced by these GTPases, The recently identified PAK-interacting exchange factor (PIN) acts as a guanine nucleotide exchange factor on Rac, and colocalizes with PAK in a focal complex, but little is known about the associated signaling cascades, including upstream activators of PIX. In this study, we show that one of the isoforms of PIX, alpha PIX, is activated by signaling cascades from the platelet-derived growth factor (PDGF) receptor and EphB2 receptor, and from integrin-induced signaling through phosphatidylinositol 3-kinase (PW-kinase). alpha PIX is activated ba forming a complex with these receptors either ria association with PAK and Nck, or direct association with the p85 regulatory subunit of PU-kinase. Synthetic phosphoinositide and membrane targeted PW-kinase augmented the alpha PIX activity in vivo. In Xenopus, aggregates of mesodermal cells derived from embryos microinjected with alpha PIX significantly increased the peripheral spreading on fibronectin substrate in response to PDGF through PI3-kinase. These results indicate that alpha PIX is activated by PI3-kinase, and is involved in the receptor mediated signaling leading to the activation of the kinase activity of PAK, and the migration of mesodermal cells on extracellular matrix.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.		Wang, Dong-Yu/C-6307-2019	Wang, Dong-Yu/0000-0002-5434-287X; Otsuki, Yoshiro/0000-0002-0568-3811				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; JONES SD, 1993, DEV GENET, V14, P185, DOI 10.1002/dvg.1020140305; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KELLER R, 1992, DEV DYNAM, V195, P162, DOI 10.1002/aja.1001950303; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Tanaka M, 1998, ONCOGENE, V17, P1509, DOI 10.1038/sj.onc.1202068; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YANO H, 1993, J BIOL CHEM, V268, P25846; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	46	89	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5680	5690		10.1038/sj.onc.1202936	http://dx.doi.org/10.1038/sj.onc.1202936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523848				2022-12-25	WOS:000083016500009
J	Dong, WJ; Xing, J; Villain, M; Hellinger, M; Robinson, JM; Chandra, R; Solaro, RJ; Umeda, PK; Cheung, HC				Dong, WJ; Xing, J; Villain, M; Hellinger, M; Robinson, JM; Chandra, R; Solaro, RJ; Umeda, PK; Cheung, HC			Conformation of the regulatory domain of cardiac muscle troponin C in its complex with cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM-BINDING; ORIENTATION FACTOR; ENERGY-TRANSFER; MODEL; FLUORESCENCE; CONTRACTION; TRANSITION; RESOLUTION	Calcium activation of fast striated muscle results from. an opening of the regulatory N-terminal domain of fast skeletal troponin C (fsTnC), and a substantial exposure of a hydrophobic patch, essential for Ca2+-dependent interaction with fast skeletal troponin I (fsTnI). This interaction is obligatory to relieve the inhibition of strong, force-generating actin-myosin interactions, We have determined intersite distances in the N-terminal domain of cardiac TnC (cTnC) by fluorescence resonance energy transfer measurements and found negligible increases in these distances when the single regulatory site is saturated with Ca2+. However, in the presence of bound cardiac TnI (cTnI), activator Ca2+ induces significant increases in the distances and a substantial opening of the N-domain, This open conformation within the cTnc.cTnI complex has properties favorable for the Ca2+-induced interaction with an additional segment of cTnI. Thus, the binding of cTnI to cTnC is a prerequisite to achieve a Ca2+-induced open N-domain similar to that previously observed in fsTnC with no bound fsTnI, This role of cardiac TnI has not been previously recognized. Our results also indicate that structural information derived from a single protein may not be sufficient for inference of a structure/function relationship.	Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cheung, HC (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, 520 CH-19, Birmingham, AL 35294 USA.	hccheung@uab.edu	Dong, Wenji/A-8579-2011		NHLBI NIH HHS [HL63377, HL52508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063377, R01HL052508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; Dong WJ, 1997, J BIOL CHEM, V272, P19229, DOI 10.1074/jbc.272.31.19229; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6745, DOI 10.1021/bi962226d; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; Gong Z, 1998, BIOPHYS J, V74, pA51; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; She MD, 1998, J MOL BIOL, V281, P445, DOI 10.1006/jmbi.1998.1933; She MD, 1998, EUR J BIOCHEM, V252, P600, DOI 10.1046/j.1432-1327.1998.2520600.x; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027	28	89	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31382	31390		10.1074/jbc.274.44.31382	http://dx.doi.org/10.1074/jbc.274.44.31382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531339	hybrid			2022-12-25	WOS:000083379400043
J	Lee, CH; Wei, LN				Lee, CH; Wei, LN			Characterization of receptor-interacting protein 140 in retinoid receptor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASE; NEURONAL DIFFERENTIATION; ORPHAN RECEPTORS; CO-REPRESSOR; ACTIVATION; BINDING; LIGAND	Receptor-interacting protein 140 (RIP140) contains multiple receptor interaction domains and interacts with retinoic acid receptors in a ligand-dependent manner. Nine LXXLL receptor-interacting motifs are organized into two clusters within this molecule, each differentially interacting with retinoic acid receptor (RAR) and retinoid X receptor (RXR). RAR interacts with the 5' cluster, whereas RXR interacts with both clusters. Additionally, a third ligand-dependent receptor-interacting domain is assigned to the very C terminus of this molecule, which contains no LXXLL motif. In mammalian cells, receptor heterodimerization is required for efficient interaction of RAR/RXR with RIP140. Furthermore, the heterodimeric, holoreceptors cooperatively interact with RIP140, which requires the activation function 2 domains of both receptors, By using different retinoic acid reporter systems, it is demonstrates that RIP140 strongly suppresses retinoic acid induction of reporter activities, but coactivator SRC-1 enhances it. Furthermore, an intrinsic repressive activity of RIP140 is demonstrated in a GAL4 fusion system. Unlike receptor corepressor, which interacts with antagonist-bound RAR/RXRs, RIP140 does not interact with antagonist-occupied RAR/RXR dimers, These data suggest that RIP140 represents a third coregulator category that is able to suppress the activation of certain agonist-bound hormone receptors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal C, 1996, J BIOL CHEM, V271, P12209, DOI 10.1074/jbc.271.21.12209; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Botling J, 1997, J BIOL CHEM, V272, P9443; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chinpaisal C, 1998, J BIOL CHEM, V273, P18077, DOI 10.1074/jbc.273.29.18077; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lee CH, 1999, BIOCHEMISTRY-US, V38, P8820, DOI 10.1021/bi9903547; Lee CH, 1998, J BIOL CHEM, V273, P25209, DOI 10.1074/jbc.273.39.25209; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; YAO M, 1995, J NEUROSCI RES, V41, P792, DOI 10.1002/jnr.490410610; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	41	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31320	31326		10.1074/jbc.274.44.31320	http://dx.doi.org/10.1074/jbc.274.44.31320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531331	hybrid			2022-12-25	WOS:000083379400035
J	Bourne, Y; Grassi, J; Bougis, PE; Marchot, P				Bourne, Y; Grassi, J; Bougis, PE; Marchot, P			Conformational flexibility of the acetylcholinesterase tetramer suggested by X-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRIC-EEL ACETYLCHOLINESTERASE; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; FASCICULIN; COMPLEX; TORPEDO; CHOLINESTERASES; ELECTROPHORUS; PROTEINS; FORMS	Acetylcholinesterase, a polymorphic enzyme, appears to form amphiphilic and nonamphiphilic tetramers from a single splice variant; this suggests discrete tetrameric arrangements where the amphipathic carboxyl-terminal sequences can be either buried or exposed. Two distinct, but related crystal structures of the soluble, trypsin-released tetramer of acetylcholinesterase from Electrophorus electricus were solved at 4.5 and 4.2 A resolution by molecular replacement. Resolution at these levels is sufficient to provide substantial information on the relative orientations of the subunits within the tetramer. The two structures, which show canonical homodimers of subunits assembled through four-helix bundles, reveal discrete geometries in the assembly of the dimers to form: (a) a loose, pseudo-square planar tetramer with antiparallel alignment of the two four-helix bundles and a large space in the center where the carboxyl-terminal sequences may be buried or (b) a compact, square nonplanar tetramer that may expose all four sequences on a single side. Comparison of these two structures points to significant conformational flexibility of the tetramer about the four-helix bundle axis and along the dimer-dimer interface. Hence, in solution, several conformational states of a flexible tetrameric arrangement of acetylcholinesterase catalytic subunits may exist to accommodate discrete carboxyl-terminal sequences of variable dimensions and amphipathicity.	Inst Biol & Microbiol Struct, CNRS, Unite Architecture & Fonct Macromol Biol 9039, F-13402 Marseille 20, France; CEA, Serv Pharmacol & Immunol, Dept Rech Med, F-91191 Gif Sur Yvette, France; Univ Mediterraneee, CNRS, Unite Mixte Rech 6560, Inst Federatif Jean Roche, F-13916 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Marchot, P (corresponding author), Inst Biol & Microbiol Struct, CNRS, Unite Architecture & Fonct Macromol Biol 9039, F-13402 Marseille 20, France.	marchot.p@jean-roche.univ-mrs.fr	MARCHOT, Pascale/AAC-4752-2022; Bourne, Yves/AAC-4635-2022; BOUGIS, Pierre E/I-2111-2013	MARCHOT, Pascale/0000-0003-0630-0541; Bourne, Yves/0000-0003-3850-0548; 				ANGLISTER L, 1978, J MOL BIOL, V125, P293, DOI 10.1016/0022-2836(78)90404-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERMAN HA, 1985, BIOCHEMISTRY-US, V24, P7140, DOI 10.1021/bi00346a018; Blong RM, 1997, BIOCHEM J, V327, P747, DOI 10.1042/bj3270747; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTAUD J, 1975, BRAIN RES, V88, P127, DOI 10.1016/0006-8993(75)90959-2; CARTAUD J, 1978, J CELL BIOL, V77, P315, DOI 10.1083/jcb.77.2.315; CHOTHIA C, 1975, J MOL BIOL, V97, P55, DOI 10.1016/S0022-2836(75)80021-0; CYGLER M, 1993, PROTEIN SCI, V2, P366; DUDAI Y, 1974, BIOCHEM BIOPH RES CO, V59, P117, DOI 10.1016/S0006-291X(74)80182-8; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; GENTRY MK, 1995, J NEUROCHEM, V64, P842; Giles K, 1997, PROTEIN ENG, V10, P677, DOI 10.1093/protein/10.6.677; GRASSI J, 1988, ANAL BIOCHEM, V168, P436, DOI 10.1016/0003-2697(88)90341-7; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; LEE SL, 1982, J BIOL CHEM, V257, P2292; LEUZINGER W, 1968, P NATL ACAD SCI USA, V59, P620, DOI 10.1073/pnas.59.2.620; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RALSTON JS, 1985, J BIOL CHEM, V260, P4312; Raves ML, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P351; REMY MH, 1995, EUR J BIOCHEM, V231, P651, DOI 10.1111/j.1432-1033.1995.tb20744.x; RIEGER F, 1973, EUR J BIOCHEM, V34, P539, DOI 10.1111/j.1432-1033.1973.tb02792.x; ROSENBERRY TL, 1974, BIOCHEMISTRY-US, V13, P3068, DOI 10.1021/bi00712a012; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHRAG JD, 1988, J BIOL CHEM, V263, P9795; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SUSSMAN JL, 1988, J MOL BIOL, V203, P821, DOI 10.1016/0022-2836(88)90213-6; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1974, MOL PHARMACOL, V10, P78	45	139	142	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30370	30376		10.1074/jbc.274.43.30370	http://dx.doi.org/10.1074/jbc.274.43.30370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521413	Green Published, hybrid			2022-12-25	WOS:000083276700009
J	Brinkman, BMN; Telliez, JB; Schievella, AR; Lin, LL; Goldfeld, AE				Brinkman, BMN; Telliez, JB; Schievella, AR; Lin, LL; Goldfeld, AE			Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2-and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; SIGNAL-TRANSDUCTION; 55-KDA RECEPTOR; MICE DEFICIENT; CELL-DEATH; INFECTION; MONOCYTOGENES; ANTIBODIES; RESISTANT; PATHWAYS	Engagement of the tumor necrosis factor-alpha (TNF-alpha) receptors by the TNF-alpha ligand results in the rapid induction of TNF-alpha gene expression. The study presented here shows that autoregulation of TNF-alpha gene transcription by selective signaling through tumor necrosis factor receptor 1 (TNFR1) requires p38 mitogen-activated protein (MAP) kinase activity and the binding of the transcription factors ATF-2 and Jun to the TNF-alpha cAMP-response element (CRE) promoter element. Consistent with these findings, TNFR1 engagement results in increased p38 MAP kinase activity and p38-dependent phosphorylation of ATF-2. Furthermore, overexpression of MADD ((M) under bar AP kinase-(a) under bar ctivating (d) under bar eath (d) under bar omain protein), an adapter protein that binds to the death domain of TNFR1 and activates MAP kinase cascades, results in CRE-dependent induction of TNF-alpha gene expression. Thus, the TNF-alpha CRE site is the target of TNFR1 stimulation and mediates the autoregulation of TNF-alpha gene transcription.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Genet Inst, Small Molecule Drug Discovery Grp, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Goldfeld, AE (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.		Brinkman, Brigitta/C-1100-2009; Goldfeld, Anne/AAF-1818-2019		NATIONAL CANCER INSTITUTE [R29CA058735] Funding Source: NIH RePORTER; NCI NIH HHS [CA58735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal B.B., 1995, HUMAN CYTOKINES THEI; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Boehm JC, 1996, J MED CHEM, V39, P3929, DOI 10.1021/jm960415o; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARINO MW, 1997, P NATL ACAD SCI USA, V94, P8098; Nashleanas M, 1998, J IMMUNOL, V160, P5506; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; TSAI EY, 1996, MOL CELL BIOL, V16, P458; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WONG GHW, 1992, J IMMUNOL, V149, P3350; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763	33	82	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30882	30886		10.1074/jbc.274.43.30882	http://dx.doi.org/10.1074/jbc.274.43.30882			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521481	hybrid			2022-12-25	WOS:000083276700077
J	Fu, CA; Shen, M; Huang, BCB; Lasaga, J; Payan, DG; Luo, Y				Fu, CA; Shen, M; Huang, BCB; Lasaga, J; Payan, DG; Luo, Y			TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; SH2/SH3 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; TNF RECEPTOR-1; SAPK/JNK; STRESS; NCK; INFLAMMATION; DROSOPHILA; P38	Germinal center kinases (GCKs) compose a subgroup of the Ste20 family of kinases. Here we describe the cloning and characterization of a novel GCK family kinase, Traf2- and Nck-interacting kinase (TNIK) that interacts with both Traf2 and Nck. TNIK encodes a polypeptide of 1360 amino acids with eight spliced isoforms. It has 90% amino acid identity to the Nck-interacting kinase in both the N-terminal kinase domain and the C-terminal germinal center kinase homology region. The homology drops to 53% in the intermediate region. TNIK specifically activates the c-Jun N-terminal kinase pathway when transfected into Phoenix-A cells (derivatives of 293 cells), similar to many GCKs. However, in contrast to other GCKs, this activation is mediated solely by the GCK homology region of TNIK. In addition, in Phoenix-A, NIH-3T3, and Hela cells, overexpression of wild type TNIK, but not the kinase mutant form of TNIK, results in the disruption of F-actin structure and the inhibition of cell spreading. Furthermore, TNIK can phosphorylate Gelsolin in vitro. This is the first time that a GCK family kinase is shown to be potentially involved in the regulation of cytoskeleton.	Rigel Inc, S San Francisco, CA 94080 USA		Luo, Y (corresponding author), Rigel Inc, 240 E Grand Ave, S San Francisco, CA 94080 USA.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; COLIGAN JE, 1999, CURR PROTOCOLS IMM S, V31; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	25	136	146	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30729	30737		10.1074/jbc.274.43.30729	http://dx.doi.org/10.1074/jbc.274.43.30729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521462	hybrid			2022-12-25	WOS:000083276700058
J	Igishi, T; Fukuhara, S; Patel, V; Katz, BZ; Yamada, KR; Gutkind, JS				Igishi, T; Fukuhara, S; Patel, V; Katz, BZ; Yamada, KR; Gutkind, JS			Divergent signaling pathways link focal adhesion kinase to mitogen-activated protein kinase cascades - Evidence for a role of paxillin in c-Jun NH2-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; V-CRK; TRANSDUCTION PATHWAY; SUBSTRATE P130(CAS); CELL-SURVIVAL; SRC	Stimulation of a number of cell surface receptors, including integrins and Cf protein-coupled receptors, results in the activation of a non-receptor tyrosine kinase known as focal adhesion kinase (FAK), In turn, this kinase is believed to play a critical role in signaling to intracellular kinase cascades controlling gene expression such as extracellular signal-regulated kinases (ERKs), by a yet poorly defined mechanism, Furthermore, whether this tyrosine kinase also mediates the activation of other mitogen-activated protein kinase family members, such as c-Jun NH2-terminal kinases (JNKs), is still unclear. We show here that the activation of FAK by anchoring to the cell membrane is itself sufficient to stimulate potently both ERK and JNK. These effects were found to be phosphatidylinositol 5-kinase-independent, as FAK effectively stimulated Akt, and wortmannin suppressed Akt but not ERK or JNK: activation. As previously reported by others, activation of ERK correlated with the ability of FAK to induce tyrosine phosphorylation of Shc. Surprisingly, however, stimulation of JNK was not dependent on the kinase activity of FAK or on the ability to induce tyrosine phosphorylation of FAK substrates. Instead, we provide evidence that FAK may stimulate JNK through a novel pathway involving the recruitment of paxillin to the plasma membrane and the subsequent activation of a biochemical route dependent on small GTP-binding proteins of the Rho family.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Rm 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023025, ZIAES023025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	61	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30738	30746		10.1074/jbc.274.43.30738	http://dx.doi.org/10.1074/jbc.274.43.30738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521463	hybrid			2022-12-25	WOS:000083276700059
J	Jones, N; Master, Z; Jones, J; Bouchard, D; Gunji, Y; Sasaki, H; Daly, R; Alitalo, K; Dumont, DJ				Jones, N; Master, Z; Jones, J; Bouchard, D; Gunji, Y; Sasaki, H; Daly, R; Alitalo, K; Dumont, DJ			Identification of Tek/Tie2 binding partners - Binding to a multifunctional docking site mediates cell survival and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING MOLECULES; ENDOTHELIAL-CELLS; TIE2 RECEPTOR; BETA-RECEPTOR; SH2 DOMAINS; PROTEIN; ANGIOGENESIS; ANGIOPOIETIN-1	The Tek/Tie2 receptor tyrosine kinase plays a pivotal role in vascular and hematopoietic development. To study the signal transduction pathways that are mediated by this receptor, we have used the yeast two-hybrid system to identify signaling molecules that associate with the phosphorylated Tek receptor. Using this approach, we demonstrate that five molecules, Grb2, Grb7, Grb14, Shp2, and the p85 subunit of phosphatidylinositol 3-kinase can interact with Tek in a phosphotyrosine-dependent manner through their SH2 domains. Mapping of the binding sites of these molecules on Tek. reveals the presence of a multisubstrate docking site in the carboxyl tail of Tek (Tyr(1100)). Mutation of this site abrogates binding of Grb2 and Grb7 to Tek in vivo, and this site is required for tyrosine phosphorylation of Grb7 and p85 in vivo. Furthermore, stimulation of Tek-expressing cells with Angiopoietin-1 results in phosphorylation of both Tek and p85 and in activation of endothelial cell migration and survival pathways that are dependent in part on phosphatidylinositol 3-kinase. Taken together, these results demonstrate that Angiopoietin-1-induced signaling from the Tek receptor is mediated by a multifunctional docking site that is responsible for activation of both cell migration and cell survival pathways.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Amgen Inst, Toronto, ON M5G 2G1, Canada; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Helsinki; National Cancer Center - Japan; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Dumont, DJ (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, 2075 Bayview Ave,Res Bldg,S-227, Toronto, ON M4N 3M5, Canada.	ddumont@srcl.sunnybrook.utoronto.ca	Alitalo, Kari K/J-5013-2014; Daly, Roger J/C-8179-2009	Alitalo, Kari K/0000-0002-7331-0902; Master, Zubin/0000-0002-3462-4546; Daly, Roger/0000-0002-5739-8027				Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; HUANG LW, 1995, ONCOGENE, V11, P2097; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Keegan K, 1996, ONCOGENE, V12, P1537; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	171	184	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30896	30905		10.1074/jbc.274.43.30896	http://dx.doi.org/10.1074/jbc.274.43.30896			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521483	hybrid			2022-12-25	WOS:000083276700079
J	Trinel, PA; Plancke, Y; Gerold, P; Jouault, T; Delplace, F; Schwarz, RT; Strecker, G; Poulain, D				Trinel, PA; Plancke, Y; Gerold, P; Jouault, T; Delplace, F; Schwarz, RT; Strecker, G; Poulain, D			The Candida albicans phospholipomannan is a family of glycolipids presenting phosphoinositolmannosides with long linear chains of beta-1,2-linked mannose residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; MYCOBACTERIUM-TUBERCULOSIS; OLIGOMANNOSIDIC EPITOPES; MONOCLONAL-ANTIBODY; SEROTYPE-A; CELL-WALL; NIH B-792; STRUCTURAL-ANALYSIS; MURINE MACROPHAGES; PARASITIC PROTOZOA	In a series of studies, we have shown that Candida albicans synthesizes a glycolipid, phospholipomannan (PLM), which reacted with antibodies specific for beta-1,2-oligomannosides and was biosynthetically labeled by [H-3]mannose, [H-3]palmitic acid, and [P-32]phosphorus. NMR studies evidenced linear chains of beta-1,2-oligomannose as the albicans cell wall and to bind to and stimulate macrophage cells. In this study, we show by thin layer chromatography scanning of metabolically radiolabeled extracts that the C. albicans PLM corresponds to a family of mannose and inositol co-labeled glycolipids. We describe the purification process of the molecule and the release of its glycan fraction through alkaline hydrolysis. Analysis of this glycan fraction by radiolabeling and methylation-methanolysis confirmed the presence of inositol and of 1,2-linked mannose units. NMR studies evidenced linear chains of beta-1,2-oligomannose as the major PLM components. Mass spectrometry analysis revealed that these chains were present in phosphoinositolmannosides with degrees of polymerization varying from 8 to 18 sugar residues. The PLM appears as a new type of eukaryotic inositol-tagged glycolipid in relationship to both the absence of glucosamine and the organization of its glycan chains. This first structural evidence for the presence of beta-1,2-oligomannosides in a glycoconjugate other than the C. albicans phosphopeptidomannan may have some pathophysiological relevance to the adhesive, protective epitope, and signaling properties thus far established for these residues.	Ctr Hosp Univ, Fac Med, Lab Mycol Fondamentale & Appl, INSERM,Equipe Mixte 9915, F-59045 Lille, France; Univ Lille 1, Chim Biol Lab, F-59655 Villeneuve Dascq, France; Univ Lille 1, CNRS, Unite Mixte 111, F-59655 Villeneuve Dascq, France; Univ Marburg, Zentrum Hyg & Med Mikrobiol, D-35037 Marburg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Philipps University Marburg	Poulain, D (corresponding author), Ctr Hosp Univ, Fac Med, Lab Mycol Fondamentale & Appl, INSERM,Equipe Mixte 9915, Pl Verdun, F-59045 Lille, France.		Jouault, Thierry/I-1071-2018; Poulain, Daniel/C-8683-2014; Jouault, Thierry/J-7437-2012; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Poulain, Daniel/0000-0002-0729-5468				BARNES PF, 1992, J IMMUNOL, V149, P541; CaesarTonThat TC, 1997, INFECT IMMUN, V65, P5354, DOI 10.1128/IAI.65.12.5354-5357.1997; CANTELLI C, 1995, MICROBIOL-SGM, V141, P2693, DOI 10.1099/13500872-141-10-2693; CASSONE A, 1988, J MED MICROBIOL, V27, P233, DOI 10.1099/00222615-27-4-233; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DeBernardis F, 1997, INFECT IMMUN, V65, P3399, DOI 10.1128/IAI.65.8.3399-3405.1997; FAILLE C, 1990, INFECT IMMUN, V58, P3537, DOI 10.1128/IAI.58.11.3537-3544.1990; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; Fradin C, 1996, J LEUKOCYTE BIOL, V60, P81, DOI 10.1002/jlb.60.1.81; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; HERNANDO FL, 1993, J MED VET MYCOL, V31, P219; HOPWOOD V, 1986, INFECT IMMUN, V54, P222, DOI 10.1128/IAI.54.1.222-227.1986; IBRAHIM AS, 1995, INFECT IMMUN, V63, P1993, DOI 10.1128/IAI.63.5.1993-1998.1995; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; JOUAULT T, 1994, IMMUNOLOGY, V83, P268; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KOBAYASHI H, 1991, BIOCHEM BIOPH RES CO, V175, P1003, DOI 10.1016/0006-291X(91)91664-X; KOBAYASHI H, 1994, INFECT IMMUN, V62, P615, DOI 10.1128/IAI.62.2.615-622.1994; Leberer E, 1997, CURR BIOL, V7, P539, DOI 10.1016/S0960-9822(06)00252-1; LI RK, 1993, J BIOL CHEM, V268, P18293; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; OKAWA Y, 1994, FEBS LETT, V45, P167; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P327, DOI 10.1016/S0732-8893(97)00240-X; POULAIN D, 1993, INFECT IMMUN, V61, P1164, DOI 10.1128/IAI.61.3.1164-1166.1993; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; Schofield L, 1996, IMMUNOL CELL BIOL, V74, P555, DOI 10.1038/icb.1996.89; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; Soll DR, 1997, MICROBIOL-UK, V143, P279, DOI 10.1099/00221287-143-2-279; TOJO M, 1988, CLIN CHEM, V34, P539; TRINEL PA, 1992, INFECT IMMUN, V60, P3845, DOI 10.1128/IAI.60.9.3845-3851.1992; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1996, MICROBIOL-UK, V142, P2263, DOI 10.1099/13500872-142-8-2263; Yoshida A, 1997, INFECT IMMUN, V65, P1953, DOI 10.1128/IAI.65.5.1953-1955.1997	39	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30520	30526		10.1074/jbc.274.43.30520	http://dx.doi.org/10.1074/jbc.274.43.30520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521433	hybrid			2022-12-25	WOS:000083276700029
J	Waldhoer, M; Wise, A; Milligan, G; Freissmuth, M; Nanoff, C				Waldhoer, M; Wise, A; Milligan, G; Freissmuth, M; Nanoff, C			Kinetics of ternary complex formation with fusion proteins composed of the A(1)-adenosine receptor and G protein alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(1) ADENOSINE RECEPTORS; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; BOVINE BRAIN; ADRENERGIC-RECEPTORS; ADENYLYL-CYCLASE; PERTUSSIS-TOXIN; AGONIST; BINDING; ACTIVATION	High affinity agonist binding to G protein-coupled receptors depends on the formation of a ternary complex between agonist, receptor, and G protein. This process is too slow to be accounted for by a simple diffusion-controlled mechanism. We have tested if the interaction between activated receptor and G; protein is rate-limiting by fusing the coding sequence of the human A1-adenosine receptor to that of G alpha(i.1) (A1/G alpha(i-1)) and of G alpha(o) (A(1)/G alpha(o)). Fusion proteins of the expected molecular mass were detected following transfection of HEK293 cells. Ternary complex formation was monitored by determining the kinetics for binding of the high affinity agonist (-)-N-6-3[I-125] (iodo-4-hydroxyphenylisopropyl)adenosine; these were similar in the wild-type receptor and the fusion proteins over the temperature range of 10 to 30 degrees C. Agonist dissociation may be limited by the stability of the ternary complex. This assumption was tested by creating fusion proteins in which the Cys(351) of G alpha(i-1) was replaced with glycine (A(1)/G alpha(i-1)C351G) or isoleucine (A(1)/G alpha(i-1)C351I) to lower the affinity of the receptor for the G protein. In these mutated fusion proteins, the dissociation rate of the ternary complex was accelerated; in contrast, the rate of the forward reaction was not affected. We therefore conclude that (i) receptor activation per se rather than its interaction with the G; protein is rate-limiting in ternary complex formation; (ii) the stability of the ternary complex is determined by the dissociation rate of the Gr protein. These features provide for a kinetic proofreading mechanism that sustains the fidelity of receptor-G protein coupling.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Glaxo Wellcome Res & Dev Ltd, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Vienna; GlaxoSmithKline; University of Glasgow	Freissmuth, M (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	freissmuth@univie.ac.at	Milligan, Graeme/F-9426-2011; Waldhoer, Maria/HDO-0619-2022	Milligan, Graeme/0000-0002-6946-3519; Waldhoer, Maria/0000-0003-3534-1959; nanoff, christian/0000-0002-8857-2470; Freissmuth, Michael/0000-0001-9398-1765				Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; CASADO V, 1993, J PHARMACOL EXP THER, V266, P1463; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Felber S, 1996, BIOPHYS J, V71, P3051, DOI 10.1016/S0006-3495(96)79499-7; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; FREUND S, 1994, N-S ARCH PHARMACOL, V350, P49; GANTZOS RD, 1988, BIOCHEM PHARMACOL, V37, P2815, DOI 10.1016/0006-2952(88)90045-7; Gao ZH, 1999, BIOCHEM J, V338, P729, DOI 10.1042/0264-6021:3380729; GEORGOUSSI Z, 1993, MOL PHARMACOL, V44, P62; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Holler C, 1999, CELL MOL LIFE SCI, V55, P257, DOI 10.1007/s000180050288; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Kenakin T, 1996, PHARMACOL REV, V48, P413; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LINDEN J, 1984, MOL PHARMACOL, V26, P414; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NAKATA H, 1990, J BIOL CHEM, V265, P671; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; NANOFF C, 1995, MOL PHARMACOL, V48, P806; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NEUHIG RR, 1988, BIOCHEMISTRY-US, V27, P2374; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SELZER E, 1993, P NATL ACAD SCI USA, V90, P1609, DOI 10.1073/pnas.90.4.1609; THOMSEN WJ, 1989, BIOCHEMISTRY-US, V28, P8778, DOI 10.1021/bi00448a015; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f	48	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30571	30579		10.1074/jbc.274.43.30571	http://dx.doi.org/10.1074/jbc.274.43.30571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521440	hybrid			2022-12-25	WOS:000083276700036
J	Muchowski, PJ; Hays, LG; Yates, JR; Clark, JI				Muchowski, PJ; Hays, LG; Yates, JR; Clark, JI			ATP and the core "alpha-crystallin" domain of the small heat-shock protein alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; INDUCED CONFORMATIONAL-CHANGES; LIMITED PROTEOLYTIC SITES; MOLECULAR CHAPERONE; A-CRYSTALLIN; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; MISSENSE MUTATION; LENS CRYSTALLINS; BINDING DOMAINS	Electrospray ionization mass spectrometry (ESI-LC/MS) of tryptic digests of human alpha B-crystallin in the presence and absence of ATP identified four residues located within the core "alpha-crystallin" domain, Lys(82), Lys(103), Arg(116), and Arg(123) that were shielded from the action of trypsin in the presence of ATP. In control experiments, chymotrypsin was used in place of trypsin. The chymotryptic fragments of human alpha B-crystallin produced in the presence and absence of ATP were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), Seven chymotryptic cleavage sites, Trp(60), Phe(61), Phe(75), Phe(84), Phe(113), Phe(118), and Tyr(122), located near or within the core alpha-crystallin domain, were shielded from the action of chymotrypsin in the presence of ATP. Chemically similar analogs of ATP were less protective than ATP against proteolysis by trypsin or chymotrypsin. ATP had no effect on the enzymatic: activity of trypsin and the K-m for trypsin was 0.031 mM in the presence of ATP and 0.029 mM in the absence of ATP. The results demonstrated an ATP-de; pendent structural modification in the Gore alpha-crystallin domain conserved in nearly all identified small heat-shock proteins that act as molecular chaperones.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Clark, JI (corresponding author), Univ Washington, Dept Biol Struct, Box 357420, Seattle, WA 98195 USA.				NEI NIH HHS [T 32 EY07031, EY0452, R01 EY004542] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007031, R01EY004542] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BANEYX F, 1992, J BIOL CHEM, V267, P11637; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Branden C., 1999, INTRO PROTEIN STRUCT; Briand L, 1999, FEBS LETT, V442, P43, DOI 10.1016/S0014-5793(98)01611-1; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHAO KL, 1990, J BIOL CHEM, V265, P1067; Collada C, 1997, PLANT PHYSIOL, V115, P71, DOI 10.1104/pp.115.1.71; Creighton T. E., 1993, PROTEINS STRUCTURE M; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hubbard SJ, 1998, PROTEIN ENG, V11, P349, DOI 10.1093/protein/11.5.349; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kantorow M, 1998, INT J BIOL MACROMOL, V22, P307, DOI 10.1016/S0141-8130(98)00028-2; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liao JH, 1998, BIOCHEM BIOPH RES CO, V244, P131, DOI 10.1006/bbrc.1998.8226; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; NADEAU K, 1993, J BIOL CHEM, V268, P1479; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RAO PV, 1994, J BIOL CHEM, V269, P13266; Rawat U, 1998, J BIOL CHEM, V273, P9415, DOI 10.1074/jbc.273.16.9415; REDDY MC, 1992, BIOCHEM BIOPH RES CO, V189, P1578, DOI 10.1016/0006-291X(92)90256-K; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; RIEDEL A, 1959, Z PHYSIOL CHEM, V316, P61; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SHEVCHENKO A, 1996, ANAL CHEM, V68, P3202; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; VOORTER CEM, 1989, FEBS LETT, V259, P50; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	73	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30190	30195		10.1074/jbc.274.42.30190	http://dx.doi.org/10.1074/jbc.274.42.30190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514509	hybrid			2022-12-25	WOS:000083176400088
J	Fujimoto, J; Sawamoto, K; Okabe, M; Takagi, Y; Tezuka, T; Yoshikawa, S; Ryo, H; Okano, H; Yamamoto, T				Fujimoto, J; Sawamoto, K; Okabe, M; Takagi, Y; Tezuka, T; Yoshikawa, S; Ryo, H; Okano, H; Yamamoto, T			Cloning and characterization of Dfak56, a homolog of focal adhesion kinase, in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; PS INTEGRINS; PP125(FAK); PHOSPHORYLATION; ACTIVATION; RECEPTOR; PAXILLIN; IDENTIFICATION	The focal adhesion kinase (FAK) protein-tyrosine kinase plays important roles in cell adhesion in vertebrates. Using polymerase chain reaction-based cloning strategy, we cloned a Drosophila gene that is homologous to the vertebrate FAK family of protein-tyrosine kinases. me designated this gene Dfak56 and characterized its gene product. The overall protein structure and deduced amino acid sequence of Dfak56 show significant similarity to those of FAK and PYK2. Dfak56 has in vitro autophosphorylation activity at tyrosine residues. Expression of the Dfak56 mRNA and the protein was observed in the central nervous system and the muscle-epidermis attachment site in the embryo, where Drosophila position-specific integrins are localized The results suggest that like FAK in vertebrates, Dfak56 functions downstream of integrins. Dfak56 was tyrosine-phosphorylated upon integrin-dependent attachment of the cell to the extracellular matrix. We conclude that the Dfak56 tyrosine kinase is involved in integrin-mediated cell adhesion signaling and thus is a functional homolog of vertebrate FAK.	Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan; Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Neurosci,Div Neuroanat, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Radiat Biol & Med Genet, Osaka 5650871, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Hirohashi Cell Configurat Project, Tsukuba, Ibaraki 3002635, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Mol Neurobiol, Tsukuba, Ibaraki 3050006, Japan	University of Tokyo; Osaka University; Japan Science & Technology Agency (JST); Osaka University; Japan Science & Technology Agency (JST); University of Tsukuba	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Okano, Hideyuki/I-7584-2019	Sawamoto, Kazunobu/0000-0003-1984-5129				AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brower DL, 1995, IMMUNOL CELL BIOL, V73, P558, DOI 10.1038/icb.1995.89; BUNCH TA, 1992, DEVELOPMENT, V116, P239; Bunch TA, 1998, DEVELOPMENT, V125, P1679; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FESSLER LI, 1994, METHOD ENZYMOL, V245, P271; FURUTA Y, 1995, ONCOGENE, V11, P1989; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Haimovich B, 1996, J BIOL CHEM, V271, P16332, DOI 10.1074/jbc.271.27.16332; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hoang B, 1998, J NEUROSCI, V18, P7847; ILLC D, 1995, NATURE, V377, P539; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; Prout M, 1997, GENETICS, V146, P275; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.3.CO;2-D; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Takagi Y, 1998, NEUROSCI LETT, V244, P149, DOI 10.1016/S0304-3940(98)00145-1; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Tippmer S, 1996, EUR J BIOCHEM, V236, P953, DOI 10.1111/j.1432-1033.1996.00953.x; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; UI K, 1994, IN VITRO CELL DEV-AN, V30A, P209; WEHRLI M, 1993, MECH DEVELOP, V43, P21, DOI 10.1016/0925-4773(93)90020-X; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	45	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29196	29201		10.1074/jbc.274.41.29196	http://dx.doi.org/10.1074/jbc.274.41.29196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506176	hybrid			2022-12-25	WOS:000083017800055
J	Kardassis, D; Papakosta, P; Pardali, K; Moustakas, A				Kardassis, D; Papakosta, P; Pardali, K; Moustakas, A			c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Spl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA; CELL-GROWTH; BINDING PROTEIN; P53-INDEPENDENT PATHWAY; FUNCTIONAL INTERACTIONS; SYNERGISTIC ACTIVATION; FAMILY PROTEINS; SMAD PROTEINS; PC12 CELLS	The cell cycle inhibitor protein p21(WAF1/Cip1) (p21) is a critical downstream effector in p53-dependent mechanisms of growth control and p53-independent pathways of terminal differentiation. We have recently reported that the transforming growth factor-p pathway-specific Smad3 and Smad4 proteins transactivate the human p21 promoter via a short proximal region, which contains multiple binding sites for the ubiquitous transcription factor Spl. In the present study we show that the Sp1-occupied promoter region mediates transactivation of the p21 promoter by c-Jun and the related proteins JunB, JunD, and ATF-2. By using gel electrophoretic mobility shift assays we show that this region does not contain a binding site for c-Jun. In accordance with the DNA binding data, c-Jun was unable to transactivate the p21 promoter when overexpressed in the Sp1-deficient Drosophila-derived SL2 cells. Coexpression of c-Jun and Sp1 in these cells resulted in a strong synergistic transactivation of this promoter. In addition, a chimeric promoter consisting of six tandem high affinity Sp1-binding sites fused with the CAT gene was transactivated by overexpressed c-Jun in HepG2 cells. The above data propose functional cooperation between c-Jun and Sp1. Physical interactions between the two factors were demonstrated in vitro by using GST-Sp1 hybrid proteins expressed in bacteria and in vitro transcribed-translated c-Sun. The region of c-Jun mediating interaction with Sp1 was mapped within the basic region leucine zipper domain. In vivo, functional interactions between c-Jun and Sp1 were demonstrated using a GAL4-based transactivation assay. Overexpressed c-Jun transactivated a chimeric promoter consisting of five tandem GAL1-binding sites only when coexpressed with GAL4-(Sp1-(83-778) fusion proteins in HepG2 cells. By utilizing the same assay, we found that the glutamine-rich segment of the B domain of Sp1 (Bc, amino acids 424-542) was sufficient: for c-Jun-induced transactivation of the p21 promoter. In conclusion, our data support a mechanism of superactivation of Sp1 by c-Jun, which is based on physical and functional interactions between these two transcription factors on the human p21 and possibly other Sp1-dependent promoters.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Heraklion, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Heraklion, Crete, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Heraklion, Crete, Greece.			Pardali, Katerina/0000-0002-4360-730X				AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Bannister AJ, 1995, ONCOGENE, V11, P2509; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hunt KK, 1998, CANCER RES, V58, P5656; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; JIANG HP, 1994, ONCOGENE, V9, P3397; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LI L, 1990, J BIOL CHEM, V265, P1556; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MICHIELI P, 1994, CANCER RES, V54, P3391; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yan GZ, 1997, J NEUROSCI, V17, P6122; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	68	177	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29572	29581		10.1074/jbc.274.41.29572	http://dx.doi.org/10.1074/jbc.274.41.29572			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506225				2022-12-25	WOS:000083017800104
J	O'Reilly, MS; Wiederschain, D; Stetler-Stevenson, WG; Folkman, J; Moses, MA				O'Reilly, MS; Wiederschain, D; Stetler-Stevenson, WG; Folkman, J; Moses, MA			Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN ADHESION MOLECULE; LEWIS-LUNG-CARCINOMA; GROWTH-FACTOR; ANGIOGENESIS INHIBITOR; ENDOTHELIAL-CELLS; IDENTIFICATION; COLLAGENASE; IV; PLASMINOGEN; ECTODOMAIN	We have previously reported the identification of the endogenous angiogenesis inhibitor angiostatin, a specific inhibitor of endothelial cell proliferation in vitro and angiogenesis in vivo. In our original studies, we demonstrated that a Lewis lung carcinoma (LLC-LM) primary tumor could suppress the growth of its metastases by generating angiostatin. Angiostatin, a 38-kDa internal fragment of plasminogen, was purified from the serum and urine of mice bearing LLC-LM, and its discovery provides the first proven mechanism for concomitant resistance (O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A, Moses, BZ A, Lane, W. S., Cao, Y., Sage, E. II., and Folkman, J. (1999 Cell 79, 315-328). Subsequently, we have shown that systemic administration of angiostatin can regress a wide variety of malignant tumors in vivo. However, at the time of our initial discovery of angiostatin, the source of the protein was unclear. We hypothesized that the tumor or stromal cells might produce an enzyme that could cleave plasminogen sequestered by the primary tumor into angiostatin. Alternatively, we speculated that the tumor cells might express angiostatin. By Northern analysis, however, we have found no evidence that the tumor cells express angiostatin or other fragments of plasminogen (data not shown). me now report that gelatinase A (matrix metalloproteinase-2), produced directly by the LLC-LM cells, is responsible for the production of angiostatin, which suppresses the growth of metastases in our original model.	Childrens Hosp, Dept Surg, Surg Res Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Moses, MA (corresponding author), Childrens Hosp, Dept Surg, Surg Res Lab, Boston, MA 02115 USA.		Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC009164] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Couet J, 1996, J BIOL CHEM, V271, P4545; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gately S, 1996, CANCER RES, V56, P4887; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NELSON J, 1995, CANCER RES, V55, P3772; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0	29	208	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29568	29571		10.1074/jbc.274.41.29568	http://dx.doi.org/10.1074/jbc.274.41.29568			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506224	hybrid			2022-12-25	WOS:000083017800103
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy	FASEB JOURNAL			English	Article						multidrug transporter; protein folding; proteasome inhibitor; endoplasmic reticulum	TRANSMEMBRANE CONDUCTANCE REGULATOR; HIV-1 PROTEASE INHIBITORS; CYSTIC-FIBROSIS; ENDOPLASMIC-RETICULUM; CONFORMATIONAL MATURATION; FUNCTIONAL CONSEQUENCES; CHEMICAL CHAPERONES; QUALITY-CONTROL; IN-VITRO; MUTANTS	The human multidrug resistance P-glycoprotein (P-gp) contributes to the phenomenon of multidrug resistance during cancer and AIDS chemotherapy. A potential novel strategy to circumvent the effects of P-gp during chemotherapy is to prevent maturation of P-gp during biosynthesis so that the transporter does not reach the cell surface. Here we report that immature, core-glycosylated P-gp that is prevented from reaching the cell surface by processing mutations or by proteasome inhibitors such as lactacystin or MG-132 exhibited no detectable drug-stimulated ATPase activity. Disulfide cross-linking analysis also showed that the immature P-gp did not exhibit ATP-induced conformational changes as found in the mature enzyme. In addition, the immature P-gp was more sensitive to trypsin than the mature enzyme. These results suggest that P-gp is unlikely to be functional immediately after synthesis. These differences in the structural and enzymatic properties of the mature and core-glycosylated, immature P-g-p could potentially be used during chemotherapy, and should result in the search for compounds that can specifically inhibit the maturation of P-gp.-Loo, T. W., Clarke, D. M. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Room 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; BIEDLER JL, 1970, CANCER RES, V30, P1174; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHAN HS, 1996, EUR J CANCER, V6, P1051; Charuk JHM, 1998, AM J PHYSIOL-RENAL, V274, pF1127, DOI 10.1152/ajprenal.1998.274.6.F1127; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fisher GA, 1996, EUR J CANCER, V32A, P1082, DOI 10.1016/0959-8049(96)00111-6; Goldstein LJ, 1996, EUR J CANCER, V32A, P1039, DOI 10.1016/0959-8049(96)00100-1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schuetz EG, 1996, P NATL ACAD SCI USA, V93, P4001, DOI 10.1073/pnas.93.9.4001; SHEN DW, 1986, J BIOL CHEM, V261, P7762; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P207; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	51	75	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1724	1732		10.1096/fasebj.13.13.1724	http://dx.doi.org/10.1096/fasebj.13.13.1724			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506575				2022-12-25	WOS:000083063400007
J	Xu, XZ; Liao, J; Creek, KE; Pirisi, L				Xu, XZ; Liao, J; Creek, KE; Pirisi, L			Human keratinocytes and tumor-derived cell lines express alternatively spliced forms of transforming growth factor-alpha mRNA, encoding precursors lacking carboxyl-terminal valine residues	ONCOGENE			English	Article						TGF-alpha variant; splicing; CHO cells	HUMAN PAPILLOMAVIRUS TYPE-16; TGF-ALPHA; FACTOR RECEPTOR; MESSENGER-RNAS; SEQUENCES; DNA; TRANSFECTION; ASSOCIATION; INDUCTION; CARCINOMA	The human transforming growth factor-alpha (TGF-alpha) gene is thought to contain five introns and six exons, encoding a transmembrane precursor (proTGF-alpha) from which the mature polypeptide is released by proteolytic cleavage, We identified a novel 32-nucleotide exon (exon alpha) within intron 5 and an alternative splice acceptor site in exon 6, splitting exon 6 into two segments: 6A and 6B, Therefore, in addition to wild type (wt) proTGF-alpha mRNA, which skips exon alpha, two novel proTGF-alpha variants are produced: Variant I (VaI), skipping exons alpha and 6A, and Variant II (VaII) which includes exon a and skips exon 6A, The only significant difference between variant and wt proTGF-alpha proteins is that the two wt carboxyl-terminal valines are replaced in the variants by five or four other amino acids, respectively, Both variant TGF-alpha mRNAs were readily detected in human keratinocytes and tumor-derived cell lines. Their protein products were cleaved as efficiently as wt TGF-alpha in response to the calcium ionophore A23187, However, both variants (but not wt) reduced serum requirements for proliferation in CHO cells. In addition, VaII-expressing CHO cells (not VaI or wt) formed foci in monolayer cultures, These results suggest that variant TGF-alpha precursors induce autonomous growth.	Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Childrens Canc Res Lab, Dept Pediat, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [CA 62094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1985, CANCER CELL, V3, P79; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DIPAOLO JA, 1990, VIROLOGY, V177, P777, DOI 10.1016/0042-6822(90)90548-6; EZZAT S, 1995, J CLIN ENDOCR METAB, V80, P534, DOI 10.1210/jc.80.2.534; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Knebelmann B, 1998, CANCER RES, V58, P226; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LEE DC, 1995, PHARMACOL REV, V47, P51; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PFEFFER S, 1985, NATURE, V313, P184, DOI 10.1038/313184a0; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; QIAN JF, 1993, AM J HUM GENET, V53, P168; Seki S, 1997, VIRCHOWS ARCH, V430, P29, DOI 10.1007/BF01008013; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	29	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5554	5562		10.1038/sj.onc.1203091	http://dx.doi.org/10.1038/sj.onc.1203091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523832				2022-12-25	WOS:000082894700008
J	Dutta, B; Huang, W; Molero, M; Kekuda, R; Leibach, FH; Devoe, LD; Ganapathy, V; Prasad, PD				Dutta, B; Huang, W; Molero, M; Kekuda, R; Leibach, FH; Devoe, LD; Ganapathy, V; Prasad, PD			Cloning of the human thiamine transporter, a member of the folate transporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION TRANSPORTER; BORDER MEMBRANE-VESICLES; RENAL BRUSH-BORDER; FUNCTIONAL EXPRESSION; HUMAN PLACENTA; INTESTINE; PROTEIN; SYSTEM	We have isolated a cDNA from human placenta, which, when expressed heterologously in mammalian cells, mediates the transport of the water-soluble vitamin thiamine. The cDNA codes for a protein of 497 amino acids containing 12 putative transmembrane domains, Northern blot analysis indicates that this transporter is widely expressed in human tissues. When expressed in HeLa cells, the cDNA induces the transport of thiamine (K-i = 2.5 +/- 0.6 mu M) in a Na+-independent manner, The cDNA-mediated transport of thiamine is stimulated by an outwardly directed H+ gradient. Substrate specificity assays indicate that the transporter is specific to thiamine, Even though thiamine is an organic cation, the cDNA-induced thiamine transport is not inhibited by other organic cations. Similarly, thiamine is not a substrate for the known members of mammalian organic cation transporter family. The thiamine transporter gene, located on human chromosome 1q24, consists of 6 exons and is most likely the gene defective in the metabolic disorder, thiamine-responsive megaloblastic anemia. At the level of amino acid sequence, the thiamine transporter is most closely related to the reduced-folate transporter and thus represents member of the folate transporter family.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Prasad, PD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	pprasad@mail.mcg.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33347] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BETTENDORFF L, 1994, J BIOL CHEM, V269, P14379; CASIROLA D, 1990, J MEMBRANE BIOL, V118, P11, DOI 10.1007/BF01872201; CHEN CP, 1978, J NUTR SCI VITAMINOL, V24, P351, DOI 10.3177/jnsv.24.351; DANCIS J, 1988, AM J OBSTET GYNECOL, V159, P1435, DOI 10.1016/0002-9378(88)90570-4; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; Grassl SM, 1998, BBA-BIOMEMBRANES, V1371, P213, DOI 10.1016/S0005-2736(98)00019-4; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HOYUMPA AM, 1975, GASTROENTEROLOGY, V68, P1218; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; KOMAI T, 1974, J NUTR SCI VITAMINOL, V20, P179, DOI 10.3177/jnsv.20.179; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laforenza U, 1997, AM J CLIN NUTR, V66, P320, DOI 10.1093/ajcn/66.2.320; Laforenza U, 1998, J MEMBRANE BIOL, V161, P151, DOI 10.1007/s002329900322; MIYAMOTO Y, 1988, AM J PHYSIOL, V255, pG85, DOI 10.1152/ajpgi.1988.255.1.G85; Neufeld EJ, 1997, AM J HUM GENET, V61, P1335, DOI 10.1086/301642; *NUTR FDN INC, 1989, NUTR REV PRES KNOWL; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; OTT RJ, 1991, AM J PHYSIOL, V261, pF443, DOI 10.1152/ajprenal.1991.261.3.F443; Pan BF, 1999, TOXICOL SCI, V47, P181, DOI 10.1093/toxsci/47.2.181; Prasad PD, 1999, ARCH BIOCHEM BIOPHYS, V366, P95, DOI 10.1006/abbi.1999.1213; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRASAD PD, 1992, J BIOL CHEM, V267, P23632; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; SCHENKER S, 1990, J LAB CLIN MED, V116, P106; SETH P, 1999, FASEB J, V13; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; ZEMPLENI J, 1992, INT J VITAM NUTR RES, V62, P165	37	150	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31925	31929		10.1074/jbc.274.45.31925	http://dx.doi.org/10.1074/jbc.274.45.31925			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542220	hybrid			2022-12-25	WOS:000083532100028
J	Schottelius, AJG; Mayo, MW; Sartor, RB; Badwin, AS				Schottelius, AJG; Mayo, MW; Sartor, RB; Badwin, AS			Interleukin-10 signaling blocks inhibitor of kappa B kinase activity and nuclear factor kappa B DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; CYTOKINE PRODUCTION; REGULATORY REGION; HUMAN MONOCYTES; IN-VIVO; ACTIVATION; ALPHA; IL-10	The transcription factor nuclear factor kappa B (NF-kappa B) coordinates the activation of numerous genes in response to pathogens and proinflammatory cytokines and is, therefore, pivotal in the development of acute and chronic inflammatory diseases. In its inactive state, NF-kappa B is constitutively present in the cytoplasm as a p50-p65 heterodimer bound to its inhibitory protein I kappa B, Proinflammatory cytokines, such as tumor necrosis factor (TNF), activate NF-kappa B by stimulating the activity of the I kappa B kinases (IKKs) which phosphorylate I kappa B alpha on serine residues 32 and 36, targeting it for rapid degradation by the 26 S proteasome, This enables the release and nuclear translocation of the NF-kappa B complex and activation of gene transcription. Interleukin-10 (IL-10) is a pleiotropic cytokine that controls inflammatory processes by suppressing the production of proinflammatory cytokines which are known to be transcriptionally controlled by NF-kappa B. Conflicting data exists on the effects of IL-10 on TNF- and LPS-induced NF-kappa B activity in human monocytes and the molecular mechanisms involved have not been elucidated. In this study, we show that IL-10 functions to block NF-kappa B activity at two levels: 1) through the suppression of IKK activity and 2) through the inhibition of NF-kappa B DNA binding activity. This is the first evidence of an anti-inflammatory protein inhibiting IKK activity and demonstrates that IKK is a logical target for blocking inflammatory diseases.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastronintestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Badwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047700] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NIDDK NIH HHS [R01 DK 47700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; BECKER H, 1995, CLIN EXP IMMUNOL, V99, P325; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burkhardt H, 1997, RHEUMATOL INT, V17, P85, DOI 10.1007/s002960050014; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Clarke CJP, 1998, EUR J IMMUNOL, V28, P1719, DOI 10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO;2-Q; DE WMR, 1991, J EXP MED, V174, P1209; DELPRETE G, 1993, J IMMUNOL, V150, P353; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dokter WHA, 1996, LEUKEMIA, V10, P1308; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; Herfarth HH, 1998, GASTROENTEROLOGY, V115, P856, DOI 10.1016/S0016-5085(98)70257-4; Herfarth HH, 1996, GUT, V39, P836, DOI 10.1136/gut.39.6.836; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Mori N, 1997, EUR J HAEMATOL, V59, P162; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; Poe JC, 1997, J IMMUNOL, V159, P846; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Romano MF, 1996, J IMMUNOL, V156, P2119; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1917, DOI 10.1016/0016-5085(95)90158-2; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WANG P, 1994, J IMMUNOL, V153, P811; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	423	446	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31868	31874		10.1074/jbc.274.45.31868	http://dx.doi.org/10.1074/jbc.274.45.31868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542212	hybrid, Green Published			2022-12-25	WOS:000083532100020
J	Widlund, HR; Kuduvalli, PN; Bengtsson, M; Cao, H; Tullius, TD; Kubista, M				Widlund, HR; Kuduvalli, PN; Bengtsson, M; Cao, H; Tullius, TD; Kubista, M			Nucleosome structural features and intrinsic properties of the TATAAACGCC repeat sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; POSITIONING SEQUENCES; CRYSTAL-STRUCTURE; TRIPLET REPEATS; DNA FLEXIBILITY; HELICAL REPEAT; BASE-PAIRS; CHROMATIN; MOBILITY; COMPLEX	Nucleosomes, the fundamental building blocks of chromatin, play an architectural role in ensuring the integrity of the genome and act as a regulator of transcription. Intrinsic properties of the underlying DNA sequence, such as flexibility and intrinsic bending, direct the formation of nucleosomes, We have earlier identified genomic nucleosome-positioning sequences with increased in vitro ability for nucleosome formation. One group of sequences bearing a 10-base pair consensus repeat sequence of TATAAACGCC had the highest reported nucleosome affinity from genomic material. Here, we report the intrinsic physical properties of this sequence and the structural details of the nucleosome it forms, as analyzed by footprinting techniques, The minor groove is buried toward the histone octamer at the AA steps and facing outwards at the CC steps. By cyclization kinetics, the overall helical repeat of the free DNA sequence was found to be 10.5 base pairs/turn. Our experiments also showed that this sequence is highly flexible, having a J-factor 25-fold higher than that of random sequence DNA, In addition, the data suggest that twist flexibility is an important determinant for translational nucleosome positioning, particularly over the dyad region.	Chalmers Univ Technol, Lundberg Inst, Dept Biochem & Biophys, SE-41390 Gothenburg, Sweden; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Boston Univ, Dept Chem, Boston, MA 02215 USA	Chalmers University of Technology; Howard Hughes Medical Institute; Johns Hopkins University; Boston University	Kubista, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Dana 630,44 Binney St, Boston, MA 02115 USA.	Mikael.Kubista@molbiotech.chalmers.se	Kubista, Mikael/A-5689-2008; Tullius, Thomas D./A-9685-2008	Kubista, Mikael/0000-0002-2940-352X; Tullius, Thomas D./0000-0003-4425-796X; Widlund, Hans/0000-0002-7506-2447	NIGMS NIH HHS [GM41930, R01 GM041930-10, R01 GM041930] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041930] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BOLSHOY A, 1995, NAT STRUCT BIOL, V2, P446, DOI 10.1038/nsb0695-446; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; de Souza ON, 1998, BIOPOLYMERS, V46, P403; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DLAKIC M, 1995, J BIOL CHEM, V270, P29945; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; El Hassan MA, 1998, J MOL BIOL, V282, P331, DOI 10.1006/jmbi.1998.1994; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hunter CA, 1997, J MOL BIOL, V265, P603, DOI 10.1006/jmbi.1996.0755; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KUDUVALLI PN, 1995, BIOCHEMISTRY-US, V34, P3899, DOI 10.1021/bi00012a005; Lowary PT, 1997, P NATL ACAD SCI USA, V94, P1183, DOI 10.1073/pnas.94.4.1183; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; RHODES D, 1979, NUCLEIC ACIDS RES, V6, P1805, DOI 10.1093/nar/6.5.1805; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; Widlund HR, 1997, J MOL BIOL, V267, P807, DOI 10.1006/jmbi.1997.0916; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1	33	70	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31847	31852		10.1074/jbc.274.45.31847	http://dx.doi.org/10.1074/jbc.274.45.31847			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542209	hybrid			2022-12-25	WOS:000083532100017
J	Ghafourifar, P; Schenk, U; Klein, SD; Richter, C				Ghafourifar, P; Schenk, U; Klein, SD; Richter, C			Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria - Evidence for intramitochondrial peroxynitrite formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; LIPID-PEROXIDATION; MEDIATED APOPTOSIS; HL-60 CELLS; SUPEROXIDE; CALCIUM; DYSFUNCTION; NEUROTOXICITY; CALMODULIN; ACTIVATION	Nitric oxide (NO) is synthesized by members of the NO synthase (NOS) family. Recently the existence of a mitochondrial NOS (mtNOS), its Ca2+ dependence, and its relevance for mitochondrial bioenergetics was reported (Ghafourifar, P., and Richter, C. (1997) FEBS Lett. 418, 291-296; Giulivi, C., Poderoso, J. J., and Boveris, A. (1998) J. Biol. Chem. 273, 11038-11043). Here we report on the possible involvement of mtNOS in apoptosis. We show that uptake of Ca2+ by mitochondria triggers mtNOS activity and causes the release of cytochrome c from isolated mitochondria in a Bcl-2-sensitive manner. mtNOS-induced cytochrome c release was paralleled by increased lipid peroxidation. The release of cytochrome c as well as increase in lipid peroxidation were prevented by NOS inhibitors, a superoxide dismutase mimic, and a peroxynitrite scavenger. We show that mtNOS-induced cytochrome c release is not mediated via the mitochondrial permeability transition pore because the release was aggravated by cyclosporin A and abolished by blockade of mitochondrial calcium uptake by ruthenium red. We conclude that, upon Ca2+-induced mtNOS activation, peroxynitrite is formed within mitochondria, which causes the release of cytochrome c from isolated mitochondria, and we propose a mechanism by which elevated Ca2+ levels induce apoptosis.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Ghafourifar, P (corresponding author), Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland.		Klein, Sabine D./T-2854-2019	Klein, Sabine D./0000-0001-6843-1454				Almeida A, 1998, BRAIN RES, V790, P209, DOI 10.1016/S0006-8993(98)00064-X; Baek JH, 1997, INT J CANCER, V73, P725, DOI 10.1002/(SICI)1097-0215(19971127)73:5<725::AID-IJC19>3.3.CO;2-T; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DARLEYUSMAR V, 1994, MITOCHONDRIA DNA PRO, P1; Dolinska M, 1998, NEUROCHEM INT, V33, P233, DOI 10.1016/S0197-0186(98)00020-5; Estevez AG, 1998, J NEUROSCI, V18, P923; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; GHAFOURIFAR P, 1999, SYMBIOSIS EUKARYOTIS, V7, P503; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HATASE O, 1985, BIOCHEM BIOPH RES CO, V132, P63, DOI 10.1016/0006-291X(85)90988-X; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; ITANO T, 1986, BIOCHEM INT, V13, P787; Keller JN, 1998, J NEUROSCI, V18, P687; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Klein SD, 1997, ARCH BIOCHEM BIOPHYS, V348, P313, DOI 10.1006/abbi.1997.0437; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; LE WD, 1995, BRAIN RES, V686, P49, DOI 10.1016/0006-8993(95)00450-5; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Lin KT, 1998, AM J PHYSIOL-CELL PH, V274, pC855, DOI 10.1152/ajpcell.1998.274.4.C855; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Messmer UK, 1996, FEBS LETT, V384, P162; MONCADA S, 1991, PHARMACOL REV, V43, P109; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REMBOLD H, 1972, EUR J BIOCHEM, V28, P586, DOI 10.1111/j.1432-1033.1972.tb01947.x; Richter C, 1999, METHOD ENZYMOL, V301, P381; RICHTER C, 1990, BIOCHEM PHARMACOL, V40, P779, DOI 10.1016/0006-2952(90)90315-C; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Williamson J R, 1979, Methods Enzymol, V55, P200	41	283	294	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31185	31188		10.1074/jbc.274.44.31185	http://dx.doi.org/10.1074/jbc.274.44.31185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531311	hybrid			2022-12-25	WOS:000083379400015
J	Shistik, E; Keren-Raifman, T; Idelson, GH; Blumenstein, Y; Dascal, N; Ivanina, T				Shistik, E; Keren-Raifman, T; Idelson, GH; Blumenstein, Y; Dascal, N; Ivanina, T			The N terminus of the cardiac L-type Ca2+ channel alpha(1C) subunit - The initial segment is ubiquitous and crucial for protein kinase C modulation, but is not directly phosphorylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED CALCIUM CHANNELS; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; CURRENTS; NEURONS; ENHANCEMENT; REQUIREMENT; DIVERSITY; MYOCYTES	The first 46 amino acids (aa) of the N terminus of the rabbit heart (RH) L-type cardiac Ca2+ channel alpha(1C) subunit are crucial for the stimulating action of protein kinase C (PKC) and also hinder channel gating (Shistik, E,, Ivanina, T,, Blumenstein, Y., and Dascal, N, (1998) J, Biol Chem, 273, 17901-17909); The mechanism of PKC action and the location of the PKC target site are not known. Moreover, uncertainties in the genomic sequence of the N-terminal region of alpha(1C) leave open the question of the presence of RH-type N terminus in L-type channels in mammalian tissues. Here, we demonstrate the presence of alpha(1C) protein containing an RH-type initial N-terminal segment in rat heart and brain by using a newly prepared polyclonal antibody. Using deletion mutants of alpha(1C) expressed in Xenopus oocytes, we further narrowed down the part of the N terminus crucial for both inhibitory gating and for PKC effect to the first 20 amino acid residues, and we identify the first 5 aa as an important determinant of PKC action and of N-terminal effect on gating, The absence of serines and threonines in the first 5 aa and the absence of phosphorylation by PKC of a glutathione S-transferase-fusion protein containing the initial segment suggest that the effect of PKC does not arise through a direct phosphorylation of this segment. We propose that PKC acts by attenuating the inhibitory action of the N terminus via phosphorylation of a remote site, in the channel or in an auxiliary protein, that interacts with the initial segment of the N terminus.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel; Alomone Labs Ltd, IL-91042 Jerusalem, Israel	Tel Aviv University; Sackler Faculty of Medicine	Ivanina, T (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.	dascaln@post.tau.ac.il	Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146				Asai T, 1996, AM J PHYSIOL-HEART C, V270, pH620, DOI 10.1152/ajpheart.1996.270.2.H620; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOURINET E, 1992, PFLUG ARCH EUR J PHY, V421, P247, DOI 10.1007/BF00374834; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Brereton HM, 1997, CELL CALCIUM, V22, P39, DOI 10.1016/S0143-4160(97)90088-9; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; De Waard M, 1996, Ion Channels, V4, P41; DOERNER D, 1988, J NEUROSCI, V8, P4069; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; FFRENCHMULLEN JMH, 1995, J NEUROSCI, V15, P903; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; HALL KE, 1995, J NEUROSCI, V15, P6069; HERMAN MD, 1993, J PHYSIOL-LONDON, V462, P645, DOI 10.1113/jphysiol.1993.sp019574; Hsu KS, 1996, AM J PHYSIOL-CELL PH, V271, pC1269, DOI 10.1152/ajpcell.1996.271.4.C1269; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; Khan I, 1998, BIOCHEM MOL BIOL INT, V45, P895; KLEPPISCH T, 1992, BRAIN RES, V591, P283, DOI 10.1016/0006-8993(92)91709-N; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; McHugh D, 1997, J PHYSIOL-LONDON, V500, P311, DOI 10.1113/jphysiol.1997.sp022022; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; TAKAGI T, 1991, ADV ELECTROPHORESIS, V4, P391; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Yang Y, 1999, BIOPHYS J, V76, pA341; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592	45	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31145	31149		10.1074/jbc.274.44.31145	http://dx.doi.org/10.1074/jbc.274.44.31145			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531304	hybrid			2022-12-25	WOS:000083379400008
J	Suen, TC; Goss, PE				Suen, TC; Goss, PE			Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 bi-directional promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC BREAST-CANCER; EARLY EMBRYONIC LETHALITY; SUPPRESSOR GENE BRCA1; RNA-POLYMERASE-II; CELL-CYCLE; OVARIAN-CANCER; NUCLEAR PHOSPHOPROTEIN; MAMMALIAN-CELLS; FAMILIAL BREAST; MEIOTIC CELLS	BRCA1 is the first tumor suppressor gene linked to hereditary breast and ovarian cancers. Its involvement in sporadic breast cancer, however, remains nuclear. Recent studies showed that a loss or lowered expression of BRCA1 is not uncommon in nonfamilial breast cancers, In addition, there have been eases of inherited BRCA1-linked breast cancer with as yet unidentified mutation. Misregulation of BRCA1 at the transcription level is a possible mechanism for loss of BRCA1 expression. To understand transcriptional regulation of the BRCA1 gene, we cloned and examined the BRCA1 promoter, by both functional reporter gene analyses and protein-DNA complex formation electrophorectic mobility shift assays, A bi-directional promoter could be located within a 229-base pair (bp) intergenic region between BRCA1 and its neighboring gene, NBR2. Deletion analyses further delineated a minimal 56-bp EcoRI-HaeIII fragment, which could drive transcription in the NBR2 gene direction 2-4-fold higher than in the BRCA1 direction in all cell lines tested. Furthermore, transcriptional activity in the BRCA1 direction was undetectable in the muscle cell line C2C12, whereas activity in the NBR2 direction was maintained. These results were consistent with the expression pattern of the respective genes. A specific protein-DNA complex was detected when nuclear extracts from HeLa cells and Caco2, a colon cell line, were incubated with the 56-bp minimal promoter. This protein binding activity was further localized to an 18-bp fragment and might involve a tissue-specific factor, because binding was not detected in the C2C12 cell line. The correlation of the detection of this protein-DNA complex only in those cell lines that expressed the chloramphenicol acetyltransferase reporter gene in the BRCA1 direction suggests a significant positive role of this complex in the transcription of the BRCA1 gene.	Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Toronto, ON M5G 2M9, Canada; Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Canadian Blood Serv, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Goss, PE (corresponding author), Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Rm 5-303,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	pegoss@interlog.com						Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bienstock RJ, 1996, CANCER RES, V56, P2539; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; BROWN JA, 1996, NEUROSURG FOCUS, V1, P2; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YM, 1996, CANCER RES, V56, P3168; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobrovic A, 1997, CANCER RES, V57, P3347; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rao VN, 1996, ONCOGENE, V12, P523; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	58	30	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31297	31304		10.1074/jbc.274.44.31297	http://dx.doi.org/10.1074/jbc.274.44.31297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531328	hybrid			2022-12-25	WOS:000083379400032
J	Craxton, A; Jiang, AM; Kurosaki, T; Clark, EA				Craxton, A; Jiang, AM; Kurosaki, T; Clark, EA			Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Aht	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; LYN-DEFICIENT MICE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-2; SIGNALING PATHWAYS; CA2+ MOBILIZATION; P85 SUBUNIT; PHOSPHORYLATION	Activation of Akt by multiple stimuli including B cell antigen receptor (BCR) engagement requires phosphatidylinositol 3-kinase and regulates processes including cell survival, proliferation, and metabolism. BCR crosslinking activates three families of non-receptor protein tyrosine kinases (PTKs) and these are transducers of signaling events including phospholipase C and mitogen-activated protein kinase activation; however, the relative roles of PTKs in ECR-mediated Akt activation are unknown. We examined Akt activation in Lyn-, Syk- and Btk-deficient DT40 cells and B cells from Lyn(-/-) mice. BCR-mediated Akt activation required Syk and was partially dependent upon Btk. Increased BCR-induced Akt phosphorylation was observed in Lyn-deficient DT40 cells and Lyn(-/-) mice compared with wildtype cells suggesting that Lyn may negatively regulate Akt function. BCR-induced tyrosine phosphorylation of the phosphatidylinositol 3-kinase catalytic subunit was abolished in Syk-deficient cells consistent with a receptor-proximal role for Syk in BCR-mediated phosphatidylinositol 3-kinase activation; in contrast, it was maintained in Btk-deficient cells, suggesting Btk functions downstream of phosphatidylinositol 3-kinase. Calcium depletion did not influence BCR-induced Akt phosphorylation/activation, showing that neither Syk. nor Btk mediates its effects via changes in calcium levels. Thus, BCR-mediated Akt stimulation is regulated by multiple non-receptor PTK families which regulate Akt both proximal and distal to phosphatidylinositol 3-kinase activation.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 570, Japan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kansai Medical University	Craxton, A (corresponding author), Univ Washington, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.		Clark, Edward/K-3462-2012; Jones, Jeffrey A/E-9827-2013; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Clark, Edward A/0000-0001-8061-5475	NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI44250] Funding Source: Medline; NIGMS NIH HHS [GM37905] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037905] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAN WV, 1997, IMMUNITY, V7, P69; CHEN CLH, 1982, J IMMUNOL, V129, P2580; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; Lu YL, 1998, J IMMUNOL, V161, P5404; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	45	127	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30644	30650		10.1074/jbc.274.43.30644	http://dx.doi.org/10.1074/jbc.274.43.30644			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521450	hybrid			2022-12-25	WOS:000083276700046
J	Dupressoir, A; Barbot, W; Loireau, RP; Heidmann, T				Dupressoir, A; Barbot, W; Loireau, RP; Heidmann, T			Characterization of a mammalian gene related to the yeast CCR4 general transcription factor and revealed by transposon insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REGULATORY COMPLEX; MOUSE-LIVER; EXPRESSION; PROMOTER; PROTEIN; FAMILY; IDENTIFICATION; RETROTRANSPOSONS; SUPPRESSION	Murine intracisternal A-particles (IAPs) are reiterated retrovirus-like transposable elements that can act as insertional mutagens, Accordingly, we previously identified a chimeric transcript initiated at an IAP promoter and extending through a 3'-located open reading frame with significant similarity to the C-terminal domain of the yeast CCR4 general transcription factor. In this report, we characterize the corresponding murine gene, mCCR4, and its human homologue, thus providing the first description of CCR4-like factors in mammals, cDNA cloning revealed two mCCR4 mRNAs of 2.7 and 3.1 kilobases, differing by their transcription start sites within the native mCCR4 gene promoter, and encoding a putative 430-amino acid protein. The mCCR4 gene contains three exons and two introns spanning almost 27 kilobases. The IAP insertion, detected only in some laboratory mouse strains, is recent and lies within the first intron, The 5'-region of the gene has features of housekeeping gene promoters. It lacks a TATA box but contains a CpG island and Spl sites. This region discloses strong promoter activity in transient transfection assays and also stimulates transcription in the reverse orientation, a feature common to other CpG island-containing promoters, Transcripts were detected in all the organs tested, although at a variable level, and displayed no strain-dependent differences relative to the IAP insertion, suggesting the existence of mechanisms preserving mCCR4 transcription from the usually deleterious effects of intronic transposition, The strong amino acid conservation between the human, murine, and the previously identified Xenopus CCR4-like proteins, is consistent with an important and conserved role for this protein in vertebrates.	Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dupressoir, Anne/M-5280-2018	Dupressoir, Anne/0000-0002-3464-8513				Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Dupressoir A, 1995, BBA-GENE STRUCT EXPR, V1264, P397, DOI 10.1016/0167-4781(95)00181-6; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; Gwynn B, 1998, MOL CELL BIOL, V18, P6474, DOI 10.1128/MCB.18.11.6474; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LIAO WC, 1994, NUCLEIC ACIDS RES, V22, P4044, DOI 10.1093/nar/22.20.4044; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MALVAR T, 1992, GENETICS, V132, P951; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Puech A, 1997, J BIOL CHEM, V272, P5995, DOI 10.1074/jbc.272.9.5995; Qvist H, 1998, BIOL CHEM, V379, P75; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SCHILD D, 1995, GENETICS, V140, P115; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vasicek TJ, 1997, GENETICS, V147, P777; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; XIAO GH, 1995, ONCOGENE, V11, P81; ZACHAR Z, 1985, GENETICS, V111, P495; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	38	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31068	31075		10.1074/jbc.274.43.31068	http://dx.doi.org/10.1074/jbc.274.43.31068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521507	hybrid			2022-12-25	WOS:000083276700103
J	Jaspers, I; Samet, JM; Reed, W				Jaspers, I; Samet, JM; Reed, W			Arsenite exposure of cultured airway epithelial cells activates kappa B-dependent interleukin-8 gene expression in the absence of nuclear factor-kappa B nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-A; INFLAMMATORY CYTOKINES; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; TYROSINE KINASE; FACTOR-ALPHA; NF-KB; STRESS; INDUCTION	Airway epithelial cells respond to certain environmental stresses by mounting a proinflammatory response, which is characterized by enhanced synthesis and release of the neutrophil chemotactic and activating factor interleukin-8 (IL-8). IL-8 expression is regulated at the transcriptional level in part by the transcription factor nuclear factor (NF)-kappa B, We compared intracellular signaling mediating IL-8 gene expression in bronchial epithelial cells cultured in vitro and exposed to two inducers of cellular stress, sodium arsenite (As-III), and vanadyl sulfate (V-IV). Unstimulated bronchial epithelial cells expressed IL-8, and exposure to both metal compounds significantly enhanced IL-8 expression. Overexpression of a dominant negative inhibitor of NF-kappa B depressed both basal and metal-induced IL-8 expression. Low levels of nuclear NF-kappa B were constitutively present in unstimulated cultures. These levels were augmented by exposure to V-IV, but not As-III. Accordingly, V-IV induced I kappa B alpha breakdown and NF-kappa B nuclear translocation, whereas AsIII did not. However, both As-III and VN enhanced kappa B-dependent transcription. In addition, As-III activation of an IL-8 promoter-reporter construct was partially kappa B-dependent. These data suggested that AsIII enhanced IL-8 gene transcription independently of I kappa B alpha breakdown and nuclear translocation of NF-kappa B in part by enhancing transcription mediated by low levels of constitutive nuclear NF-kappa B.	Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; US EPA, Natl Hlth & Environm Effects Res Lab, Human Studies Div, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; United States Environmental Protection Agency	Reed, W (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, CB 7310,104 Mason Farm Rd, Chapel Hill, NC 27599 USA.		Jaspers, Ilona/AAZ-5035-2020					ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904, DOI 10.1164/ajrccm.153.3.8630571; BECKER SE, 1999, IN PRESS AM J RESP C; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; DEVLIN RB, 1994, AM J PHYSIOL, V266, P612; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Holz O, 1999, AM J RESP CRIT CARE, V159, P776, DOI 10.1164/ajrccm.159.3.9806098; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; KUNSCH C, 1994, J IMMUNOL, V153, P153; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Quay JL, 1998, AM J RESP CELL MOL, V19, P98, DOI 10.1165/ajrcmb.19.1.3132; Rashtchian A, 1992, PCR Methods Appl, V2, P124; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; REDDEL RR, 1988, CANCER RES, V48, P1904; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Richman-Eisenstat JB, 1993, AM J PHYSIOL, V264, P413; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shapiro L, 1997, EXP CELL RES, V231, P354, DOI 10.1006/excr.1997.3476; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Thomas LH, 1998, J IMMUNOL, V161, P1007; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Wu GD, 1997, J BIOL CHEM, V272, P2396; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	62	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31025	31033		10.1074/jbc.274.43.31025	http://dx.doi.org/10.1074/jbc.274.43.31025			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521501	hybrid			2022-12-25	WOS:000083276700097
J	Ning, YM; Robins, DM				Ning, YM; Robins, DM			AML3/CBF alpha 1 is required for androgen-specific activation of the enhancer of the mouse sex-limited protein (Slp) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; TRANSCRIPTIONAL REGULATION; OSTEOBLAST DIFFERENTIATION; GLUCOCORTICOID RECEPTORS; NONRECEPTOR FACTORS; DEPENDENT ENHANCER; RESPONSE ELEMENT; DOMAIN PROTEINS; FUSION PROTEIN; NERVOUS-SYSTEM	A complex 120-base pair enhancer, derived from the mouse sex-limited protein (Slp) gene, is activated solely by the androgen receptor (AR) in specific tissues, although it contains a hormone response element recognized by several steroid receptors. The generation of this transcriptional specificity has been ascribed to the interactions of the receptor with tissue-specific nonreceptor factors bound to accessory sites within the enhancer. Protein-DNA interaction assays revealed two factors binding the 5' part of the enhancer that differ widely in abundance between cells showing AR-specific activation of the Sip element compared with those that also permit activation by glucocorticoid receptor (GR). The factor designated B formed a complex centered on the sequence TGTGGT, a core motif recognized by members of the AML/CBF alpha transcription factor family. This complex was competed by a high affinity binding site specific for AML/CBF alpha and was specifically supershifted by an antibody to AML3/CBF alpha 1, placing factor B within the AML3/CBF alpha 1 subclass. Interestingly, this factor was shown to bind to a second site in the 3' part of the enhancer, positioned between the two critical AR binding sites. Transfection studies revealed that AML1-ETO, a dominant-negative AML/CBF alpha construct, abrogated AR induction of the enhancer, but not of simple hormone response elements. Furthermore, overexpression of AML3/CBF alpha 1 could rescue the AML1-ETO repression. Finally, glutathione S-transferase-AML/CBF alpha fusion proteins demonstrated direct interaction between AML/ CBF alpha and steroid receptors. Although this interaction was equivalent between AML1/CBF alpha 2 and AR or GR, AML3/CBF alpha 1 showed stronger interaction with AR than with GR. These data demonstrate that AML3/CBF alpha 1 is functionally required for hormonal induction of the Sip enhancer and that direct, preferential protein-protein interactions may contribute to AR-specific activation. These results demonstrate an intriguing role of AML3/ CBF alpha 1 in steroid- as well as tissue-specific activation of target genes.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Robins, DM (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.	drobins@umich.edu		Robins, Diane M./0000-0001-6727-6309	NIDDK NIH HHS [F32DK09764] Funding Source: Medline; NIGMS NIH HHS [GM31546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLEUTJENS CB, 1999, ENDOCRINOLOGY, V138, P5293; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frank R, 1995, ONCOGENE, V11, P2667; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HEMENWAY C, 1987, P NATL ACAD SCI USA, V84, P4816, DOI 10.1073/pnas.84.14.4816; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nelson SA, 1997, MOL CELL ENDOCRINOL, V133, P89, DOI 10.1016/S0303-7207(97)00150-0; NING YM, 1995, J STEROID BIOCHEM, V52, P187, DOI 10.1016/0960-0760(94)00162-F; NING YM, 1993, J BIOL CHEM, V268, P6073; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; ROBINS DM, 1994, J STEROID BIOCHEM, V49, P251, DOI 10.1016/0960-0760(94)90265-8; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; Scarlett CO, 1997, DNA CELL BIOL, V16, P45, DOI 10.1089/dna.1997.16.45; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Thackray VG, 1998, J STEROID BIOCHEM, V66, P171, DOI 10.1016/S0960-0760(98)00044-2; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	58	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30624	30630		10.1074/jbc.274.43.30624	http://dx.doi.org/10.1074/jbc.274.43.30624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521447	hybrid			2022-12-25	WOS:000083276700043
J	Ferrari, SL; Behar, V; Chorev, M; Rosenblatt, M; Bisello, A				Ferrari, SL; Behar, V; Chorev, M; Rosenblatt, M; Bisello, A			Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2 - Real-time monitoring by fluorescence microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PTH/PTHRP RECEPTOR; OSTEOBLAST-LIKE CELLS; COUPLED RECEPTOR; MEDIATED INTERNALIZATION; BIMOLECULAR INTERACTIONS; CROSS-LINKING; DESENSITIZATION; PEPTIDE; MECHANISMS; TRAFFICKING	Endocytosis and intracellular trafficking of the human parathyroid hormone receptor subtype 1 (hPTH1-Rc) and its ligands was monitored independently by real-time fluorescence microscopy in stably transfected HEK-293 cells. Complexes of fluorescence-labeled parathyroid hormone (PTH)-(1-34) agonist bound to the hPTH1-Rc internalized rapidly at 37 degrees C via clathrin-coated vesicles, whereas fluorescent PTH-(7-34) antagonist-hPTH1Rc complexes did not. A functional C terminus epitope-tagged receptor (C-Tag-hPTH1-Rc) was immunolocalized to the cell membrane and, to a lesser extent, the cytoplasm, PTH and PTH-related protein agonists stimulated C-Tag-hPTH1-Rc internalization. Relocalization to the cell membrane occurred 1 h after removal of the ligand. Endocytosis of fluorescent PTH agonist-hPTH1-Rc complexes was blocked by the protein kinase C (PKC) inhibitor staurosporine but not by the specific protein kinase A inhibitor N-(2-(methylamino)ethyl)-5-isoquinoline-sulfonamide. Fluorescent PTH antagonist-hPTH1-Rc complexes were rapidly internalized after PKC activation by phorbol 12-myristate 13-acetate or thrombin, but not after stimulation of the cAMP/protein kinase A pathway by forskolin. In cells co-expressing the hPTH1-Rc and a green fluorescent protein-beta-arrestin2 fusion protein (beta-Arr2-GFP), PTH agonists stimulated beta-Arr2-GFP mobilization to the cell membrane. Subsequently, fluorescent PTH-(1-34)hPTH1Rc complexes and beta-Arr2-GFP co-localized intracellularly. In conclusion, agonist-activated hPTHI-Rc internalization involves beta-arrestin mobilization and targeting to clathrin-coated vesicles. Our results also indicate that receptor occupancy, rather than receptor-mediated signaling, is necessary, although not sufficient, for endocytosis of the hPTH1-Rc, Activation of PKC, however, is absolutely required.	Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab HIM 944, Harvard Thorndike & Charles A Dana Res Labs, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Bisello, A (corresponding author), Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab HIM 944, Harvard Thorndike & Charles A Dana Res Labs, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	abisello@caregroup.harvard.edu	Ferrari, Serge/ABD-2730-2020	Ferrari, Serge/0000-0002-1372-4417	NIDDK NIH HHS [R01-DK47940] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047940] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADAMS AE, 1995, BIOCHEMISTRY-US, V34, P10553, DOI 10.1021/bi00033a030; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; CIVITELLI R, 1989, ENDOCRINOLOGY, V125, P1204, DOI 10.1210/endo-125-3-1204; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fitzpatrick Lorraine A., 1996, P339; FUKAYAMA S, 1992, ENDOCRINOLOGY, V131, P1757, DOI 10.1210/en.131.4.1757; Fukayama S, 1997, CELL SIGNAL, V9, P469, DOI 10.1016/S0898-6568(97)00044-2; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Huang ZM, 1999, ENDOCRINOLOGY, V140, P1294, DOI 10.1210/en.140.3.1294; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; NAKAMOTO C, 1995, BIOCHEMISTRY-US, V34, P10546, DOI 10.1021/bi00033a029; PERNALETE N, 1990, ENDOCRINOLOGY, V126, P407, DOI 10.1210/endo-126-1-407; Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756-3282(96)00008-7; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; Qian F, 1998, BIOCHEMISTRY-US, V37, P6240, DOI 10.1021/bi9726281; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Roettger BF, 1997, MOL PHARMACOL, V51, P357; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; ROUBINI E, 1992, BIOCHEMISTRY-US, V31, P4026, DOI 10.1021/bi00131a018; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SILVE CM, 1982, J CELL BIOL, V94, P379, DOI 10.1083/jcb.94.2.379; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; TEITELBAUM AP, 1986, ENDOCRINOLOGY, V118, P595, DOI 10.1210/endo-118-2-595; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	46	132	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29968	29975		10.1074/jbc.274.42.29968	http://dx.doi.org/10.1074/jbc.274.42.29968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514480	hybrid			2022-12-25	WOS:000083176400059
J	Maegawa, H; Hasegawa, M; Sugai, S; Obata, T; Ugi, S; Morino, K; Egawa, K; Fujita, T; Sakamoto, T; Nishio, Y; Kojima, H; Haneda, M; Yasuda, H; Kikkawa, R; Kashiwagi, A				Maegawa, H; Hasegawa, M; Sugai, S; Obata, T; Ugi, S; Morino, K; Egawa, K; Fujita, T; Sakamoto, T; Nishio, Y; Kojima, H; Haneda, M; Yasuda, H; Kikkawa, R; Kashiwagi, A			Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; RAT ADIPOSE-CELLS; RECEPTOR SUBSTRATE-1; MAP KINASE; SYP; ACTIVATION; SHPTP2; PHOSPHORYLATION	To elucidate the roles of SHP-2 genic (Tg) mice expressing a dominant negative mutant lacking protein tyrosine phosphatase domain (Delta PTP). On examining two lines of Tg mice identified by Southern blot, the transgene product Tvas expressed in skeletal muscle, liver, and adipose tissues, and insulin-induced association of insulin receptor substrate 1 with endogenous SHP-2 was inhibited, confirming that Delta PTP has a dominant negative property. The intraperitoneal glucose loading test demonstrated an increase in blood glucose levels in Tg mice. Plasma insulin levels in Tg mice after 4 h fasting were 3 times greater with comparable blood glucose levels. To estimate insulin sensitivity by a constant glucose, insulin, and somatostatin infusion, steady state blood glucose levels were higher, suggesting the presence of insulin resistance. Furthermore, we observed the impairment of insulin-stimulated glucose uptake in muscle and adipocytes in the presence of physiological concentrations of insulin. Moreover, tyrosine phosphorylation of insulin receptor substrate-1 and stimulation of phosphatidylinositol 3-kinase and Akt kinase activities by insulin were attenuated in muscle and liver. These results indicate that the inhibition of endogenous SHP-2 function by the overexpression of a dominant negative mutant may lead to impaired insulin sensitivity of glucose metabolism, and thus SHP-2 may function to modulate insulin signaling in target tissues.	Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan; Ono Pharmaceut, Fukui Inst Safety Res, Fukui 913, Japan	Shiga University of Medical Science; Ono Pharmaceutical Co Ltd	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med 3, Otsu, Shiga 5202192, Japan.		MORINO, KATSUTARO/I-3207-2019	MORINO, KATSUTARO/0000-0003-2420-3817; Maegawa, Hiroshi/0000-0002-4611-8149				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MAEGAWA H, 1986, AM J PHYSIOL, V251, pE616, DOI 10.1152/ajpendo.1986.251.5.E616; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Obata T, 1998, J BIOCHEM-TOKYO, V123, P813; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	49	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30236	30243		10.1074/jbc.274.42.30236	http://dx.doi.org/10.1074/jbc.274.42.30236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514516	hybrid			2022-12-25	WOS:000083176400095
J	Choi, KS; Eom, YW; Kang, Y; Ha, MJ; Rhee, H; Yoon, JW; Kim, SJ				Choi, KS; Eom, YW; Kang, Y; Ha, MJ; Rhee, H; Yoon, JW; Kim, SJ			Cdc2 and Cdk2 kinase activated by transforming growth factor-beta 1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; BETA-INDUCED APOPTOSIS; TGF-BETA; EPITHELIAL-CELLS; GENE-PRODUCT; C-MYC; DIFFERENTIAL REGULATION; TRANSGENIC MICE; INHIBITS GROWTH; MAMMALIAN-CELLS	The signaling pathway leading to TGF-beta 1-induced apoptosis was investigated using a TGF-beta 1-sensitive hepatoma cell line, FaO. Cell cycle analysis demonstrated that the accumulation of apoptotic cells was pre ceded by a progressive decrease of the cell, population in the G(1) phase concomitant with a slight increase of the cell population in the G(2)/M phase in response to TGB-beta 1. TGF-beta 1 induced a transient increase in the expression of Cdc2, cyclin A, cyclin B, and cyclin D1 at an early phase of apoptosis. During TGF-beta 1-induced apoptosis, the transient increase in cyclin-dependent kinase (Cdk) activities coincides with a dramatic increase in the hyperphosphorylated forms of RE. Treatment with roscovitine or olomoucine, inhibitors of Cdc2 and Cdk2, blocked TGF-beta 1-induced apoptosis by inhibiting RE phosphorylation. Overexpression of Bcl-2 or adenovirus E1B 19K suppressed TGF-beta 1-induced apoptosis by blocking the induction of Cdc2 mRNA and the subsequent activation of Cdc2 kinase, whereas activation of Cdk2 was not affected, suggesting that Cdc2 plays a more critical role in TGF-beta 1-induced apoptosis. in conclusion, we present the evidence that Cdc2 and Cdk2 kinase activity transiently induced by TGF-beta 1 phosphorylates RE as a physiological target in FaO cells and that RE hyperphosphorylation may trigger abrupt cell cycle progression, leading to irreversible cell death.	Ajou Univ, Sch Med, Inst Med Sci, Lab Endocrinol,Paldal Gu, Suwon 442749, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Lab Med Genet,Paldal Gu, Suwon 442749, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Univ Calgary, Fac Med,Julia McFarlane Diabet Res Ctr, Dept Microbiol & Infect Dis, Lab Viral & Immunopathogeneis Diabet, Calgary, AB T2N 4N1, Canada	Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Calgary	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Lab Endocrinol,Paldal Gu, 5 Wonchon Dong, Suwon 442749, South Korea.	kschoi@madang.ajou.ac.kr	Eom, Young/AAW-4659-2021	Choi, Kyeong Sook/0000-0003-2331-0856				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BenBassat H, 1997, CANCER RES, V57, P3741; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Buske C, 1997, LEUKEMIA, V11, P386, DOI 10.1038/sj.leu.2400586; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DeLuca A, 1997, J CELL BIOCHEM, V64, P579; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V253, P609, DOI 10.1006/bbrc.1998.9825; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fan GS, 1996, ONCOGENE, V12, P1909; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRANA X, 1995, ONCOGENE, V11, P211; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hsing AY, 1996, CANCER RES, V56, P5146; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAWRENCE DA, 1995, KIDNEY INT, V47, pS19; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Lim IK, 1997, INT J CANCER, V72, P351, DOI 10.1002/(SICI)1097-0215(19970717)72:2<351::AID-IJC25>3.0.CO;2-H; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN JK, 1992, CANCER RES, V52, P385; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEMON SA, 1995, J IMMUNOL, V155, P4644; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Palumbo GA, 1997, CANCER RES, V57, P2434; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SELVAM S, 1994, TRENDS LIFE SCI, V9, P1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shi LF, 1996, J IMMUNOL, V157, P2381; SHIMIZU T, 1995, CANCER RES, V55, P228; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Yao SL, 1996, CANCER RES, V56, P4551; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	76	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31775	31783		10.1074/jbc.274.45.31775	http://dx.doi.org/10.1074/jbc.274.45.31775			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542199	hybrid			2022-12-25	WOS:000083532100007
J	Weng, BY; Thompson, WC; Kim, HJ; Levine, RL; Moss, J				Weng, BY; Thompson, WC; Kim, HJ; Levine, RL; Moss, J			Modification of the ADP-ribosyltransferase and NAD glycohydrolase activities of a mammalian transferase (ADP-ribosyltransferase 5) by auto-ADP-ribosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; LYMPHOCYTE ALLOANTIGEN RT6.1; SKELETAL-MUSCLE CELLS; CYTOTOXIC T-CELLS; MOLECULAR CHARACTERIZATION; BACTERIAL TOXINS; NITRIC-OXIDE; EXPRESSION; SURFACE; PROTEIN	Mono-ADP-ribosylation, a post-translational modification in which the ADP-ribose moiety of NAD is transferred to an acceptor protein, is catalyzed by a family of amino acid-specific ADP-ribosyltransferases. ADP-ribosyltransferase 5 (ARTS), a murine transferase originally isolated from Yac-1 lymphoma cells, differed in properties from previously identified eukaryotic transferases in that it exhibited significant NAD glycohydrolase (NADase) activity. To investigate the mechanism of regulation of transferase and NADase activities, ARTS was synthesized as a FLAG fusion protein in Escherichia coli, Agmatine was used as the ADP-ribose acceptor to quantify transferase activity. ARTS was found to be primarily an NADase at 10 mu M NAD, whereas at higher NAD concentrations (1 mM), after some delay, transferase activity increased, whereas NADase activity fell. This change in catalytic activity was correlated with auto-ADP-ribosylation and occurred in a time- and NAD concentration-dependent manner. Based on the change in mobility of auto-ADP-ribosylated ARTS by SDS-poly acrylamide gel electrophoresis, the modification appeared to be stoichiometric and resulted in the addition of at least two ADP-ribose moieties, Auto-ADP-ribosylated ARTE isolated after incubation with NAD was primarily a transferase. These findings suggest that auto-ADP-ribosylation of ARTS was stoichiometric, resulted in at least two modifications and converted ARTS from an NADase to a transferase, and could be one mechanism for regulating enzyme activity.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Weng, BY (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,10 Ctr Dr,MSC 1434,Rm 5N307, Bethesda, MD 20892 USA.		Levine, Rodney L/D-9885-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000622] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; Donnelly LE, 1996, BIOCHEM J, V315, P635, DOI 10.1042/bj3150635; Han MK, 1996, BIOCHEM J, V318, P903, DOI 10.1042/bj3180903; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; KHARADIA SV, 1992, EXP CELL RES, V201, P33, DOI 10.1016/0014-4827(92)90345-9; KIM UH, 1993, ARCH BIOCHEM BIOPHYS, V305, P147, DOI 10.1006/abbi.1993.1404; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; LIEBERMAN I, 1957, J BIOL CHEM, V225, P883; Maehama T, 1996, FEBS LETT, V388, P189, DOI 10.1016/0014-5793(96)00568-6; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; Moss J, 1997, J BIOL CHEM, V272, P4342, DOI 10.1074/jbc.272.7.4342; Nemoto E, 1996, J IMMUNOL, V156, P85; OHNO T, 1995, ANAL BIOCHEM, V231, P115, DOI 10.1006/abio.1995.1510; Okamoto S, 1998, J IMMUNOL, V160, P4190; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; Okazaki IJ, 1996, BLOOD, V88, P915; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PEKALA PH, 1980, MOL CELL BIOCHEM, V31, P49, DOI 10.1007/BF00817890; PROCHAZKA M, 1991, IMMUNOGENETICS, V33, P152, DOI 10.1007/BF00210829; Rigby MR, 1996, J IMMUNOL, V156, P4259; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; UI M, 1990, ADP RIBOSYLATING TOX, P45; Wang J, 1996, J IMMUNOL, V156, P2819; WANG J, 1994, J IMMUNOL, V153, P4048; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493; Yu YJ, 1997, DNA CELL BIOL, V16, P235, DOI 10.1089/dna.1997.16.235; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1994, MOL CELL BIOCHEM, V138, P107, DOI 10.1007/BF00928450; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	39	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31797	31803		10.1074/jbc.274.45.31797	http://dx.doi.org/10.1074/jbc.274.45.31797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542202	hybrid			2022-12-25	WOS:000083532100010
J	Yan, Y; Mumby, MC				Yan, Y; Mumby, MC			Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein - PP2A regulates the activities of G(1) cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; INHIBITOR OKADAIC ACID; SV40 LARGE-T; CELL-CYCLE; GENE-PRODUCT; TUMOR-SUPPRESSOR; GROWTH-FACTOR; CALYCULIN-A; G1 ARREST; H1 KINASE	The function of the retinoblastoma protein (pRB) in controlling the G(1) to S transition is regulated by phosphorylation and dephosphorylation on serine and threonine residues. While the roles of cyclin-dependent kinases in phosphorylating and inactivating pRB have been characterized in detail, the roles of protein phosphatases in regulating the G(1)/S transition are not as well understood. We used cell-permeable inhibitors of protein phosphatases 1 and 2A to assess the contributions of these phosphatases in regulating cyclin-dependent kinase activity and pRB phosphorylation, Treating asynchronously growing Balb/c 3T3 cells with PP2A-selective concentrations of either okadaic acid or calyculin A caused a time- and dose-dependent decrease in PRE phosphorylation, Okadaic acid and calyculin A had no effect on pRB phosphatase activity even though PP2A was completely inhibited. The decrease in pRB phosphorylation correlated with inhibitor-induced suppression of G(1) cyclin dependent kinases including CDK2, CDK4, and CDK6. The inhibitors also caused decreases in the levels of cyclin D2 and cyclin E, and induction of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1). The decrease in cyclin dependent kinase activities were not dependent on induction of cyclin-dependent kinase inhibitors since CDK inhibition still occurred in the presence of actinomycin D or cycloheximide. In contrast, selective inhibition of protein phosphatase 1 with tautomycin inhibited pRB phosphatase activity and maintained pRB in a highly phosphorylated state. The results show that protein phosphatase 1 and protein phosphatase 2A, or SA-like phosphatases, play distinct roles in regulating PRE function. Protein phosphatase 1 is associated with the direct dephosphorylation of pRB while protein phosphatase ZA is involved in pathways regulating G(1) cyclin-dependent kinase activity.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mumby, MC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	marc.mumby@email.swmed.edu			NHLBI NIH HHS [HL31107] Funding Source: Medline; NIGMS NIH HHS [GM49505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049505] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Iavarone A, 1997, NATURE, V387, P417; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; KIM TA, 1993, P NATL ACAD SCI USA, V90, P5460, DOI 10.1073/pnas.90.12.5460; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LEE TH, 1995, SEMIN CANCER BIOL, V6, P203, DOI 10.1006/scbi.1995.0027; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDRE DD, 1992, J CELL SCI, V101, P79; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; YOU JS, 1995, J CELL PHYSIOL, V164, P424, DOI 10.1002/jcp.1041640223; Zeng YX, 1996, ONCOGENE, V12, P1557	59	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31917	31924		10.1074/jbc.274.45.31917	http://dx.doi.org/10.1074/jbc.274.45.31917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542219	hybrid			2022-12-25	WOS:000083532100027
J	Roig, J; Traugh, JA				Roig, J; Traugh, JA			p21-activated protein kinase gamma-PAK is activated by ionizing radiation and other DNA-damaging agents - Similarities and differences to alpha-PAK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; TYROSINE KINASE; CELL-CYCLE; STRESS; CDC42; CLEAVAGE; FAMILY; ACTIN; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; AUTOPHOSPHORYLATION	The p21-activated protein kinase gamma-PAK is activated 2-5-fold in response to ionizing radiation (IR) in 3T3-L1 fibroblasts and U937 leukemia cells. gamma-PAK is activated in a dose- and time-dependent manner. Doses from 1 to 100 Gy result in significant stimulation of activity at 30 min, whereas maximal stimulation is observed at 120 min after irradiation. UV (80 J/m(2)) and the DNA-damaging drugs cytosine beta-D-arabinofuranoside (AraC) and cis-platinum(II)diammine dichloride (cisplatin) also induce gamma-PAK activation. The activation of gamma-PAK in response to IR or AraC is dependent on tyrosine kinase and phosphoinositide 3-kinase activity, as demonstrated by use of the inhibitors genistein and wortmannin; in contrast activation of gamma-PAK by cisplatin and UV is not affected significantly by these inhibitors, suggesting that gamma-PAK can be activated by more than one pathway in response to different types of DNA damage. In contrast to gamma-PAK, alpha-PAK and JNK are activated only by cisplatin and UV in 3T3-L1 cells, suggesting differential regulation of the protein kinases. This is the first time that members of the Ste20/PAK family of protein kinases have been shown to be involved in the cellular response to IR and other DNA-damaging agents.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu	Roig, Joan/E-2836-2017	Roig, Joan/0000-0002-3872-4712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Faure S, 1999, J BIOL CHEM, V274, P3573, DOI 10.1074/jbc.274.6.3573; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Huang ZD, 1999, FASEB J, V13, pA1578; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KUFE DW, 1984, MOL PHARMACOL, V26, P128; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Roig J, 1999, FASEB J, V13, pA1579; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Tuazon PT, 1999, FASEB J, V13, pA1490; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Woloschak GE, 1997, STRESS-INDUCIBLE PROCESSES IN HIGHER EUKARYOTIC CELLS, P185; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	38	51	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31119	31122		10.1074/jbc.274.44.31119	http://dx.doi.org/10.1074/jbc.274.44.31119			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531298	hybrid			2022-12-25	WOS:000083379400002
J	Feng, ZW; Porter, AG				Feng, ZW; Porter, AG			NF-kappa B/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL DIFFERENTIATION; B-ALPHA; BCL-2; APOPTOSIS; TRANSCRIPTION; GROWTH; ACTIVATION; EXPRESSION; MICE	The expression, cellular localization, and activation of the NF-kappa B/Rel transcription factors are altered during neuronal differentiation, but the significance is unclear. Here we investigate the requirement for NF-kappa B/Rel proteins in neuronal differentiation. SH-SY5Y neuroblastoma cells were induced to differentiate with retinoic acid (RA) or 12-O-tetradecanoylphorbol 13-acetate (TPA), and differentiation was demonstrated by morphological criteria and the enhanced expression of Bcl-2. NF-kappa B was transiently activated after the addition of the differentiation inducers before the morphological signs of differentiation and the enhanced Bcl-2 synthesis. The onset of NF-kappa B activation coincided with a significant reduction in the amount of only one of four NF-kappa B-inhibitory proteins examined (I-kappa B beta). In contrast, NF-kappa B activation and the reduction in I-kappa B beta failed to occur in SH-SY5Y cells transformed with I-kappa B alpha M, a dominant-negative inhibitor of NF-kappa B/Rel proteins. These I-kappa B alpha M-expressing cells failed to differentiate into neuronal cell types when treated with RA or TPA, and the increased Bcl-2 synthesis was blocked. Therefore, NF-kappa B/Rel proteins are require(d) for neuronal differentiation of SH-SY5Y neuroblastoma cells.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Porter, AG (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal V. R., 1997, CURR BIOL, V7, P94; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bernier PJ, 1998, J NEUROSCI, V18, P2486; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; Esslinger CW, 1997, J IMMUNOL, V158, P5075; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; HANADA M, 1993, CANCER RES, V53, P4978; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; KORNER M, 1994, J NEUROCHEM, V62, P1716; KURATA S, 1993, FEBS LETT, V321, P201, DOI 10.1016/0014-5793(93)80108-7; LASORELLA A, 1995, CANCER RES, V55, P4711; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Ochoa-Garay J, 1998, J IMMUNOL, V160, P3835; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SHEPPARD AM, 1995, J BIOL CHEM, V270, P3710, DOI 10.1074/jbc.270.8.3710; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; Snapper CM, 1996, J IMMUNOL, V156, P183; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	27	64	69	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30341	30344		10.1074/jbc.274.43.30341	http://dx.doi.org/10.1074/jbc.274.43.30341			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521406	hybrid			2022-12-25	WOS:000083276700002
J	Ji, CH; Chen, Y; McCarthy, TL; Centrella, M				Ji, CH; Chen, Y; McCarthy, TL; Centrella, M			Cloning the promoter for transforming growth factor-beta type III receptor - Basal and conditional expression in fetal rat osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; ENRICHED CELL-CULTURES; TRANSCRIPTION FACTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; NUCLEOTIDE-SEQUENCE; COLLAGEN-SYNTHESIS; ENDOTHELIAL-CELLS; I EXPRESSION; CPG ISLANDS; BINDING	Transforming growth factor-p binds to three high affinity cell surface molecules that directly or indirectly regulate its biological effects. The type III receptor (TRIII) is a proteoglycan that lacks significant intracellular signaling or enzymatic motifs but may facilitate transforming growth factor-p binding to other receptors, stabilize multimeric receptor complexes, or segregate growth factor from activating receptors, Because various agents or events that regulate osteoblast function rapidly modulate TRIII expression, we cloned the 5' region of the rat TRIII gene to assess possible control elements. DNA fragments from this region directed high reporter gene expression in osteoblasts. Sequencing showed no consensus TATA or CCAAT boxes, whereas several nuclear factors binding sequences within the 3' region of the promoter co-mapped with multiple transcription initiation sites, DNase I footprints, gel mobility shift analysis, or loss of activity by deletion or mutation. An upstream enhancer was evident 5' proximal to nucleotide -979, and a silencer region occurred between nucleotides -2014 and -2194. Glucocorticoid sensitivity mapped between nucleotides -687 and -253, whereas bone morphogenetic protein 2 sensitivity co-mapped within the silencer region. Thus, the TRIII promoter contains cooperative basal elements and dispersed growth factor- and hormone-sensitive regulatory regions that can control TRIII expression by osteoblasts.	Yale Univ, Sch Med, Dept Surg, Plast Surg Sect, New Haven, CT 06520 USA	Yale University	Centrella, M (corresponding author), Yale Univ, Sch Med, Dept Surg, Plast Surg Sect, 333 Cedar St,POB 208041, New Haven, CT 06520 USA.	michael.centrella@yale.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK47421] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Austen M, 1997, CURR TOP MICROBIOL, V224, P123; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35; Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097-4644(19971215)67:4<528::AID-JCB10>3.3.CO;2-5; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Centrella M, 1996, J BIOL CHEM, V271, P18616, DOI 10.1074/jbc.271.31.18616; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; COCHET C, 1988, J BIOL CHEM, V263, P5707; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; Miao K, 1999, ARCH BIOCHEM BIOPHYS, V361, P7, DOI 10.1006/abbi.1998.0977; NAKAYAMA H, 1994, EXP CELL RES, V211, P301, DOI 10.1006/excr.1994.1091; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Shin JH, 1997, J BIOL CHEM, V272, P23498, DOI 10.1074/jbc.272.38.23498; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; Turner BC, 1998, CANCER RES, V58, P5466; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	48	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30487	30494		10.1074/jbc.274.43.30487	http://dx.doi.org/10.1074/jbc.274.43.30487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521429	hybrid			2022-12-25	WOS:000083276700025
J	Lindahl, B; Westling, C; Gimenez-Gallego, G; Lindahl, U; Salmivirta, M				Lindahl, B; Westling, C; Gimenez-Gallego, G; Lindahl, U; Salmivirta, M			Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; BASIC FGF; PEPTIDES; PROTEOGLYCANS; AGGREGATION; INHIBITION; PERLECAN; PLAQUES; AMYLIN	Heparan sulfate found in the cerebral plaques of Alzheimer's disease binds to beta-amyloid (A beta) fibrils. This interaction has been proposed to enhance fibril deposition and mediate A beta-induced glia activation and neurotoxicity. On the other hand, heparan sulfate augments signaling of fibroblast growth factor-2 (FGF-2), a neuroprotective factor that antagonizes the neurotoxic effects of A beta. We defined structures in heparan sulfate from human cerebral cortex that bind A beta fibrils. The minimal binding site is found in N-sulfated hexasaccharide domains and contains critical 2-O-sulfated iduronic acid residues. By contrast, binding of A beta monomers requires, in addition, 6-O-sulfate groups on glucosamine residues. The binding specificity of fibrillar A beta is shared by FGF-2, and we here show that cerebral heparan sulfate domains selected for binding to A beta-(1-40) fibrils bind also to FGF-2. These data suggest that neurotoxic and neuroprotective signals may converge by competing for the same binding sites on the heparan sulfate chain.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Ctr Invest Biol, E-28006 Madrid, Spain	Uppsala University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Salmivirta, M (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.							BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; KATO T, 1991, NEUROSCI LETT, V122, P33, DOI 10.1016/0304-3940(91)90186-W; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; Morita H, 1995, VIRCHOWS ARCH, V427, P395; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	30	58	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30631	30635		10.1074/jbc.274.43.30631	http://dx.doi.org/10.1074/jbc.274.43.30631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521448	hybrid, Green Published			2022-12-25	WOS:000083276700044
J	Loisel, TP; Ansanay, H; Adam, L; Marullo, S; Seifert, R; Lagace, M; Bouvier, M				Loisel, TP; Ansanay, H; Adam, L; Marullo, S; Seifert, R; Lagace, M; Bouvier, M			Activation of the beta(2)-adrenergic receptor-G alpha(s) complex leads to rapid depalmitoylation and inhibition of repalmitoylation of both the receptor and G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PALMITOYLATION SITE; PROTEIN ALPHA-SUBUNITS; BETA-2-ADRENERGIC RECEPTOR; FUSION PROTEIN; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; DOWN-REGULATION; SF9 CELLS; ACETYLCHOLINE-RECEPTORS; INDUCED INTERNALIZATION	Palmitoylation is unique among lipid modifications in that it is reversible. In recent years, dynamic palmitoylation of G protein alpha subunits and of their cognate receptors has attracted considerable attention. However, very little is known concerning the acylation/deacylation cycle of the proteins in relation to their activity status. In particular, the relative contribution of the activation and desensitization of the signaling unit to the regulation of the receptors and G proteins palmitoylation state is unknown. To address this issue, we took advantage of the fact that a fusion protein composed of the stimulatory alpha subunit of trimeric G protein (G alpha(s)) covalently attached to the beta(2)-adrenergic receptor (beta(2)AR) as a carboxyl-terminal extension (beta(2)AR-G alpha(s)) can be stimulated by agonists but does not undergo rapid inactivation, desensitization, or internalization. When expressed in Sf9 cells, both the receptor and the G alpha(s) moieties of the fusion protein were found to be palmitoylated via thioester linkage. Stimulation with the beta-adrenergic agonist isoproterenol led to a rapid depalmitoylation of both the beta(2)AR and G alpha(s) and inhibited repalmitoylation. The extent of depalmitoylation induced by a series of agonists was correlated (0.99) with activity. However, forskolin-stimulated cAMP production did not affect the palmitoylation state of beta(2)AR-G alpha(s), indicating that the agonist-promoted depalmitoylation is linked to conformational changes and not to second messenger generation. Given that, upon activation, the fusion protein mimics the activated receptor-G protein complex but cannot undergo desensitization, the data demonstrate that early steps in the activation process lead to the depalmitoylation of both receptor and G protein and that repalmitoylation requires later events that cannot be accommodated by the activated fusion protein.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Inst Cochin Genet Mol, CNRS, URA 1534, Dept Pharmacol Cellulaire & Mol, Paris, France; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; Stanford University	Bouvier, M (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	bouvier@bcm.umontreal.ca	Bouvier, Michel/H-2758-2014; Seifert, Roland/G-3189-2013; Marullo, Stefano/C-6142-2008	Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973				BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bertin B, 1997, RECEPTOR CHANNEL, V5, P41; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Bertin B, 1997, INT J CANCER, V71, P1029; Bohm SK, 1997, BIOCHEM J, V322, P1; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; LEGOCKI RP, 1981, ANAL BIOCHEM, V111, P385, DOI 10.1016/0003-2697(81)90577-7; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; Milligan G, 1998, TRENDS ENDOCRIN MET, V9, P13, DOI 10.1016/S1043-2760(98)00004-6; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OMARY MB, 1981, J BIOL CHEM, V256, P2888; OMARY MB, 1981, J BIOL CHEM, V256, P4715; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1999, EUR J BIOCHEM, V260, P661, DOI 10.1046/j.1432-1327.1999.00161.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; SEIFERT R, 1999, IN PRESS TRENDS PHAR; SVOBODA P, 1994, EUR J BIOCHEM, V224, P455, DOI 10.1111/j.1432-1033.1994.00455.x; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VANDEWESTERLO E, 1995, BIOCHEM J, V310, P559, DOI 10.1042/bj3100559; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	57	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31014	31019		10.1074/jbc.274.43.31014	http://dx.doi.org/10.1074/jbc.274.43.31014			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521499	hybrid			2022-12-25	WOS:000083276700095
J	Milla, ME; Leesnitzer, MA; Moss, ML; Clay, WC; Carter, HL; Miller, AB; Su, JL; Lambert, MH; Willard, DH; Sheeley, DM; Kost, TA; Burkhart, W; Moyer, M; Blackburn, RK; Pahel, GL; Mitchell, JL; Hoffmann, R; Becherer, JD				Milla, ME; Leesnitzer, MA; Moss, ML; Clay, WC; Carter, HL; Miller, AB; Su, JL; Lambert, MH; Willard, DH; Sheeley, DM; Kost, TA; Burkhart, W; Moyer, M; Blackburn, RK; Pahel, GL; Mitchell, JL; Hoffmann, R; Becherer, JD			Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CATALYTIC DOMAIN; CYTOPLASMIC DOMAIN; CYSTEINE SWITCH; METALLOPROTEINASE; PRECURSOR; CLEAVAGE; FURIN; STROMELYSIN-1; LOCALIZATION	The tumor necrosis factor-alpha-converting enzyme (TACE) is a membrane-anchored zinc metalloprotease involved in precursor tumor necrosis factor-alpha secretion. We designed a series of constructs containing full-length human TACE and several truncate forms for overexpression in insect cells. Here, we demonstrate that full-length TACE is expressed in insect cells inefficiently: only minor amounts of this enzyme are converted from an inactive precursor to the mature, functional form. Removal of the cytoplasmic and transmembrane domains resulted in the efficient secretion of mature, active TACE. Further removal of the cysteine-rich domain located between the catalytic and transmembrane domains resulted in the secretion of mature catalytic domain in association with the precursor (pro) domain. This complex was inactive and function was only restored after dissociation of the complex by dilution or treatment with 4-aminophenylmercuric acetate. Therefore, the pro domain of TACE is an inhibitor of the catalytic domain, and the cysteine-rich domain appears to play a role in the release of the pro domain. Insect cells failed to secrete a deletion mutant encoding the catalytic domain but lacking the inhibitory pro domain. This truncate was inactive and extensively degraded intracellularly, suggesting that the pro domain is required for the secretion of functional TACE.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Glaxo Wellcome Res & Dev Ltd, Div Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Div Chem, Res Triangle Pk, NC 27709 USA	University of Pennsylvania; University of Pennsylvania; GlaxoSmithKline; GlaxoSmithKline	Milla, ME (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	mmilla@mail.med.upenn.edu						BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; Clarke HRG, 1998, PROTEIN EXPRES PURIF, V13, P104, DOI 10.1006/prep.1998.0861; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FENOUILLET E, 1995, J GEN VIROL, V76, P1509, DOI 10.1099/0022-1317-76-6-1509; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, P102; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Moss ML, 1999, PROG INFLAM RES, P187; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Tang P, 1996, BIOCHEMISTRY-US, V35, P8216, DOI 10.1021/bi952182t; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang L, 1998, BIOCHEMISTRY-US, V37, P3165, DOI 10.1021/bi972741r; Wetmore DR, 1996, BIOCHEMISTRY-US, V35, P6549, DOI 10.1021/bi9530752; YAMSHCHIKOV GV, 1995, VIROLOGY, V214, P50, DOI 10.1006/viro.1995.9955	32	139	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30563	30570		10.1074/jbc.274.43.30563	http://dx.doi.org/10.1074/jbc.274.43.30563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521439	hybrid			2022-12-25	WOS:000083276700035
J	Pethe, V; Shekhar, PVM				Pethe, V; Shekhar, PVM			Estrogen inducibility of c-Ha-ras transcription in breast cancer cells - Identification of functional estrogen-responsive transcriptional regulatory elements in exon 1/intron 1 of the c-Ha-ras gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA ONCOGENE; MOUSE MAMMARY-TUMOR; 5' FLANKING REGION; NUCLEOTIDE-SEQUENCE; ELEVATED EXPRESSION; SYNERGISTIC ACTION; MAMMALIAN-CELLS; POINT MUTATION; MCF-7 CELLS; CARCINOGENESIS	Although mutation of ras gene is rare in human breast cancer, overexpression of normal c-Ha-ras gene is frequently observed. Using a mouse mammary metastasis model consisting of genetically related mammary tumor sublines with variant metastatic potential, we have previously (i) demonstrated a direct correlation between c-Ha-ras mRNA and protein levels and metastatic potential and (ii) identified a novel hormone-responsive transcriptional regulatory element in intron 1 of the mouse c-Ha-ras gene that contains the consensus half-site of a glucocorticoid response element and flanking consensus half-sites for estrogen response element. Here, we have examined the functionality of intron 1 sequence in context of upstream sequences by using transient transfection assays with plasmids expressing chloramphenicol acetyltransferase. Intron 1 sequence and sequences similar to intron 1 element located in exon 1 function as transcriptional regulatory elements that confer hormonal inducibility to chloramphenicol acetyltransferase gene expression both independently and in context of 5'-flanking sequences, Measurement of c-Ha-ras transcription rates and protein expression by nuclear run-on and metabolic labeling assays showed a 5-12-fold enhancement, respectively, following treatment with 17 beta-estradiol that was blunted by ICI 182,780 in the nonmetastatic variant, In contrast, constitutive overexpression of c-Ha-ras transcripts and protein in the metastatic subline was unaffected by estrogen and ICI 182,780. Gel shift assays demonstrated specific interaction of c-Ha-ras exon 1 sequence with nuclear proteins of human breast cancer MCF-7 cells with formation of two complexes, one of which contains estrogen receptor, Our data demonstrate a direct (i) interaction of c-Ha-ras sequence with estrogen receptor and (ii) stimulatory effect of estrogen on c-Ha-ras gene transcription and suggest that alteration in transcriptional regulation of c-Ha-ras gene by estrogen may play an important role in progression of breast cancer.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; Wayne State University	Shekhar, PVM (corresponding author), Karmanos Canc Inst, Breast Canc Program, 110 E Warren Ave, Detroit, MI 48201 USA.	shekharm@kci.wayne.edu		Shekhar, Malathy/0000-0003-2721-7202	NCI NIH HHS [CA60881, R29 CA060881-06, CA22453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060881, P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, INT J CANCER, P22; ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DAMANTE G, 1987, P NATL ACAD SCI USA, V84, P774, DOI 10.1073/pnas.84.3.774; DEBIASI F, 1989, INT J CANCER, V43, P431, DOI 10.1002/ijc.2910430315; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; GALAND P, 1971, J ENDOCRINOL, V49, P243, DOI 10.1677/joe.0.0490243; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, CURRENT PROTOCOLS MO, pCH4; ISONISHI S, 1991, CANCER RES, V51, P5903; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KYPRIANOU N, 1991, CANCER RES, V51, P162; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MUELLER GC, 1958, RECENT PROG HORM RES, V14, P95; NEADES R, 1991, MOL CARCINOGEN, V4, P369, DOI 10.1002/mc.2940040508; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; PELLING JC, 1986, CARCINOGENESIS, V7, P1599, DOI 10.1093/carcin/7.9.1599; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; SCREPANTI I, 1991, INT J CANCER, V47, P445, DOI 10.1002/ijc.2910470323; SHEKHAR PVM, 1994, INVAS METAST, V14, P27; SHEKHAR PVM, 1995, CANC MOL BIOL, V2, P529; SKLAR MD, 1988, CANCER RES, V48, P793; SOMMERS CL, 1990, CANCER RES, V50, P67; SPANDIDOS DA, 1984, ANTICANCER RES, V4, P269; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUKUMAR S, 1989, CURR TOP MICROBIOL, V148, P93; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA T, 1986, CANCER RES, V46, P437; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; THOR A, 1986, LAB INVEST, V55, P603; VANROY F, 1990, INT J CANCER, V46, P522, DOI 10.1002/ijc.2910460332; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191; WORLAND PJ, 1989, CANCER RES, V49, P51; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	56	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30969	30978		10.1074/jbc.274.43.30969	http://dx.doi.org/10.1074/jbc.274.43.30969			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521493	hybrid			2022-12-25	WOS:000083276700089
J	Thompson, PR; Schwartzenhauer, J; Hughes, DW; Berghuis, AM; Wright, GD				Thompson, PR; Schwartzenhauer, J; Hughes, DW; Berghuis, AM; Wright, GD			The COOH terminus of aminoglycoside phosphotransferase (3 ')-IIIa is critical for antibiotic recognition and resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-PHOSPHOTRANSFERASE TYPE IIIA; PROTEIN-KINASE; NUCLEIC-ACIDS; FORCE-FIELD; SPECTROSCOPY; ENZYMES	The aminoglycoside phosphotransferases (APHs) are widely distributed among pathogenic bacteria and are employed to covalently modify, and thereby detoxify, the clinically relevant aminoglycoside antibiotics. The crystal structure for one of these aminoglycoside kinases, APH(3')-IIIa, has been determined in complex with ADP and analysis of the electrostatic surface potential indicates that there is a large anionic depression present adjacent to the terminal phosphate group of the nucleotide, This region also includes a conserved COOH-terminal alpha-helix that contains the COOH-terminal residue phe(264). We report here mutagenesis and computer modeling studies aimed at examining the mode of aminoglycoside binding to APH(3')-IIIa. Specifically, seven site mutants were studied, five from the COOH-terminal helix (Asp(261), Glu(262), and Phe(264)), and two additional residues that line the wall of the anionic depression (Tyr(55) and Arg(211)). Using a molecular modeling approach, six ternary complexes of APH(3')-IIIa;ATP with the antibiotics, kanamycin, amikacin, butirosin, and ribostamycin were independently constructed and these agree well with the mutagenesis data. The results obtained show that the COOH-terminal carboxylate of Phe(264) is critical for proper function of the enzyme. Furthermore, these studies demonstrate that there exists multiple binding modes for the aminoglycosides, which provides a molecular basis for the broad substrate- and regiospecificity observed for this enzyme.	McMaster Univ, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Wright, GD (corresponding author), McMaster Univ, Antimicrobial Res Ctr, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Berghuis, Albert M/A-6495-2008; Wright, G/ABB-7666-2021	Berghuis, Albert/0000-0002-2663-025X; Wright, Gerard/0000-0002-9129-7131				BOTTO RE, 1983, J AM CHEM SOC, V105, P1021, DOI 10.1021/ja00342a062; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cox JR, 1997, BIOCHEMISTRY-US, V36, P2353, DOI 10.1021/bi9626822; Cox JR, 1996, J AM CHEM SOC, V118, P1295, DOI 10.1021/ja952994c; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; Daigle DM, 1997, J BIOL CHEM, V272, P24755, DOI 10.1074/jbc.272.40.24755; Daigle DM, 1999, CHEM BIOL, V6, P11, DOI 10.1016/S1074-5521(99)80016-7; DiGiammarino EL, 1998, BIOCHEMISTRY-US, V37, P3638, DOI 10.1021/bi972778b; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; HART TN, 1992, PROTEINS, V13, P206, DOI 10.1002/prot.340130304; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McKay GA, 1996, ANTIMICROB AGENTS CH, V40, P2648, DOI 10.1128/AAC.40.11.2648; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MERRIT EA, 1994, ACTA CRYSTALLOGR D, V40, P869; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Thompson PR, 1996, CHEM BIOL, V3, P747, DOI 10.1016/S1074-5521(96)90251-3; Thompson PR, 1996, BIOCHEMISTRY-US, V35, P8686, DOI 10.1021/bi960389w; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WRIGHT GD, 1999, RESOLVING ANTIBIOTIC, P27; Wright Gerard D., 1999, Frontiers in Bioscience, V4, pD9, DOI 10.2741/Wright	26	32	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30697	30706		10.1074/jbc.274.43.30697	http://dx.doi.org/10.1074/jbc.274.43.30697			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521458	hybrid			2022-12-25	WOS:000083276700054
J	Vyas, DR; McCarthy, JJ; Tsika, RW				Vyas, DR; McCarthy, JJ; Tsika, RW			Nuclear protein binding at the beta-myosin heavy chain A/T-rich element is enriched following increased skeletal muscle activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CARDIAC-MUSCLE; IN-VIVO; MEF2 BINDING; E-BOX; ENHANCER; PROMOTER	In adult mouse skeletal muscle, beta-myosin heavy chain (beta MyHC) gene expression is primarily restricted to slow-type I fibers but can be induced in fast-type II fibers by mechanical overload (MOV). Our previous transgenic analyses have delimited an 89-base pair (bp) MOV-responsive region (-293 to -205), and shown that mutation of the MCAT and C-rich elements within this region did not abolish beta MyHC transgene induction by MOV. In this study we describe an AIT-rich element (beta A/T-rich; -269 5'-GGAGATATTTTT-3'-258) located within this 89-bp region that, only under MOV conditions, revealed enriched binding as characterized by electrophoretic mobility shift assays and dimethyl sulfate and diethyl pyrocarbonate interference footprinting, Direct, competition, and supershift electrophoretic mobility shift assays revealed highly enriched specific binding activity at the beta A/T-rich element that was antigenically distinct from GATA-4, MEF2A-D, SRF, and Oct-1, nuclear proteins that were previously shown to bind A/T-rich elements. In vitro translated GATA-4, MEF2C, SRF, and Oct-1 bound to consensus GATA, MEF2, SRE, and Oct-1 elements, respectively, but not to the beta A/T-rich element. Two-dimensional UV cross-linking of the bromodeoxyuridine-substituted beta A/T-rich element with mechanically overloaded plantaris (MOV-P) nuclear extract detected two proteins (44 and 48 kDa). Our results indicate that the beta A/T-rich element may function in vivo as a beta MyHC MOV-inducible element during hypertrophy of adult skeletal muscle by binding two distinct proteins identified only in MOV-P nuclear extract.	Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Tsika, RW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Sch Vet Med, 1600 E Rollins Ave,W112 Vet Med Bldg, Columbia, MO 65211 USA.	tsikar@missouri.edu			NIAMS NIH HHS [R01 AR41464] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041464] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AcakpoSatchivi LJR, 1997, J CELL BIOL, V139, P1219, DOI 10.1083/jcb.139.5.1219; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Bonnefoy E, 1999, MOL CELL BIOL, V19, P2803; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG KC, 1993, J CELL SCI, V106, P331; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; Ferrari S, 1997, CELL GROWTH DIFFER, V8, P23; Fickett JW, 1996, MOL CELL BIOL, V16, P437; GASTAIGER M, 1995, NATURE, V373, P360; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; Hasegawa K, 1997, CIRCULATION, V96, P3943; HAUSCHKA SD, 1994, MYOLOGY, P3; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LIU ML, 1994, J BIOL CHEM, V269, P28514; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McCarthy JJ, 1999, J BIOL CHEM, V274, P14270, DOI 10.1074/jbc.274.20.14270; McCarthy JJ, 1997, AM J PHYSIOL-REG I, V272, pR1552, DOI 10.1152/ajpregu.1997.272.5.R1552; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Montgomery MO, 1997, GENE, V187, P159, DOI 10.1016/S0378-1119(96)00738-X; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1999, HEART DEV, P291; REISER PJ, 1985, J BIOL CHEM, V260, P9077; RINDT H, 1993, J BIOL CHEM, V268, P5332; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Salminen M, 1996, MOL CELL BIOL, V16, P76; Sartorius CA, 1998, J CELL BIOL, V141, P943, DOI 10.1083/jcb.141.4.943; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsika GL, 1996, AM J PHYSIOL-CELL PH, V271, pC690, DOI 10.1152/ajpcell.1996.271.2.C690; VANDELOISE C, 1995, FRANCAIS MODERN, V63, P85; VANDENBURGH HH, 1993, J CELL PHYSIOL, V155, P63, DOI 10.1002/jcp.1041550109; WANG RX, 1994, J MOL CELL CARDIOL, V26, P1155, DOI 10.1006/jmcc.1994.1134; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Weiss A, 1999, P NATL ACAD SCI USA, V96, P2958, DOI 10.1073/pnas.96.6.2958; Yu YT, 1996, J BIOL CHEM, V271, P24675	60	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30832	30842		10.1074/jbc.274.43.30832	http://dx.doi.org/10.1074/jbc.274.43.30832			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521475	hybrid			2022-12-25	WOS:000083276700071
J	Agadir, A; Chen, GQ; Bost, F; Li, Y; Mercola, D; Zhang, XK				Agadir, A; Chen, GQ; Bost, F; Li, Y; Mercola, D; Zhang, XK			Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; P21(WAF1/CIP1) EXPRESSION; SIGNAL-TRANSDUCTION; TUMOR PROMOTION; THYROID-HORMONE; LEUKEMIA-CELLS; AP-1; INHIBITION	Phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and all-trans-retinoic acid (trans-RA) are potent regulators of growth of cancer cells. In this study, we investigated the effect of TPA and trans-RA alone or their combination on proliferation of human breast cancer ZR75-1 and T47D and lung cancer H460 and H292 cell lines. trans-RA caused various degrees of growth inhibition of these cell lines. However, TPA showed inhibition of proliferation of H460 and H292 cells and induction of ZR75-1 cell growth. Although trans-RA did not significantly regulate the growth inhibitory effect of TPA, it completely prevented its growth stimulating function. The divergent effects of TPA were associated with specific disruption of cell cycle events, an induction of G(0)/G(1) arrest in H460 and H292 cells and inhibition of G(0)/G(1) arrest with increase of S phase in ZR75-1 cells. Induction of G(0)/G(1) arrest was accompanied by induction of p21(WAF1) and ERK activity, whereas inhibition of G(0)/G(1) arrest was associated with enhanced activity of JNK and AP-1 but not ERK. trans-RA did not affect TPA-induced p21(WAF1) expression. However, it inhibited TPA-induced AP-1 activity in ZR75-1 cells and the constitutive AP-1 activity in H460 and H292 cells, Thus, trans-RA modulates TPA activity through its interaction through TPA-induced JNK/AP-1 pathway but not TPA-induced ERK/p21(WAF1) pathway.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute	Zhang, XK (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013; BOST, Frederic/AAN-4691-2020	mercola, dan/0000-0002-0281-9840; BOST, Frederic/0000-0003-4509-4701	NATIONAL CANCER INSTITUTE [R01CA060988] Funding Source: NIH RePORTER; NCI NIH HHS [CA60988, CA51933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agadir A, 1997, CANCER RES, V57, P3444; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARITA Y, 1992, CANCER RES, V52, P4514; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; COLLINS SJ, 1987, BLOOD, V70, P1233; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Gudas Lorraine J., 1994, P443; HARPER JW, 1993, CELL, V75, P805; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hong Waun Ki, 1994, P597; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; HUNER T, 1992, CELL, V70, P375; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIKAWA U, 1989, ANNU REV BIOCHEM, V58, P31; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; Li JJ, 1996, CANCER RES, V56, P483; LIN M, 1996, J BIOL CHEM, V271, P31723; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OBRIAN CA, 1989, CANCER RES, V49, P3215; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SCITA G, 1994, CARCINOGENESIS, V15, P1043, DOI 10.1093/carcin/15.5.1043; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; YAMADA K, 1984, BIOCH BIOL INT, V34, P827; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG W, 1995, CANCER RES, V55, P668; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29779	29785		10.1074/jbc.274.42.29779	http://dx.doi.org/10.1074/jbc.274.42.29779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514454	hybrid			2022-12-25	WOS:000083176400033
J	Croce, R; Weiss, S; Bassi, R				Croce, R; Weiss, S; Bassi, R			Carotenoid-binding sites of the major light-harvesting complex II of higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; ENERGY-TRANSFER; CHLOROPHYLL-A; ANTENNA COMPLEX; SPECTRAL FORMS; IN-VITRO; PROTEIN; RECONSTITUTION; ABSORPTION; SUBUNIT	Recombinant light-harvesting complex II (LHCII) proteins with modified carotenoid composition have been obtained by in vitro reconstitution of the Lhcb1, protein overexpressed in bacteria. The monomeric protein possesses three xanthophyll-binding sites. The L1 and L2 sites, localized by electron crystallography in the helix A/helix B cross, have the highest affinity for lutein, but also bind violaxanthin and zeaxanthin with lower affinity. The latter xanthophyll causes disruption of excitation energy transfer. The occupancy of at Yeast one of these sites, probably L1, is essential for protein folding. Neoxanthin is bound to a distinct site (N1) that iis highly selective for this species and whose occupancy is not essential for protein folding. Whereas xanthophylls in the L1 and L2 sites interact mainly with chlorophyll a, neoxanthin shows strong interaction with chlorophyll b, inducing the hyperchromic effect of the 652 nm absorption band. This observation explains the recent results of energy transfer from carotenoids to chlorophyll b obtained by femtosecond absorption spectroscopy. Whereas xanthophylls in the L1 and L2 sites are active in photoprotection through chlorophyll-triplet quenching, neoxanthin seems to act mainly in O-1*(2) scavenging.	Univ Verona, Fac Sci Matemat Fisiche Nat Biotecnol Vegetali, Dipartimento Sci & Technol, I-37134 Verona, Italy	University of Verona	Croce, R (corresponding author), Univ Verona, Fac Sci Matemat Fisiche Nat Biotecnol Vegetali, Dipartimento Sci & Technol, Strada Grazie, I-37134 Verona, Italy.	croce@mpi-muelheim.mpg.de	Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; Croce, Roberta/HGU-9554-2022; Croce, Roberta/ABG-3595-2021	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; bassi, roberto/0000-0002-4140-8446				ANDERSSON PO, 1991, PHOTOCHEM PHOTOBIOL, V54, P353, DOI 10.1111/j.1751-1097.1991.tb02027.x; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1991, J PHOTOCHEM PHOTOBIO, V6, P381; BASSI R, 1999, IN PRESS P NATL ACAD; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; Carbonera D., 1992, REND LINCEI-SCI FIS, V3, P361; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; CRIMI M, 1999, IN PRESS BIOCHEMISTR; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P421; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; Desamero RZB, 1998, J PHYS CHEM B, V102, P8151, DOI 10.1021/jp980911j; DUNSMUIR P, 1985, NUCLEIC ACIDS RES, V13, P2503, DOI 10.1093/nar/13.7.2503; EADS DD, 1989, J PHYS CHEM-US, V93, P8271, DOI 10.1021/j100363a001; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; HUDSON BS, 1972, CHEM PHYS LETT, V14, P299, DOI 10.1016/0009-2614(72)80119-2; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; JENNINGS RC, 1993, BIOCHEMISTRY-US, V32, P3203, DOI 10.1021/bi00064a002; Koyama Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P243, DOI 10.1111/j.1751-1097.1996.tb03021.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MATSUOKA M, 1987, NUCLEIC ACIDS RES, V15, P6302, DOI 10.1093/nar/15.15.6302; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Peterman EJG, 1997, BIOCHEMISTRY-US, V36, P12208, DOI 10.1021/bi9711689; Peterman EJG, 1995, BIOPHYS J, V69, P2670, DOI 10.1016/S0006-3495(95)80138-4; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REMELLI R, 1999, IN PRESS J BIOL CHEM, V274; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; van der Vos R, 1991, APPL MAGN RESON, V2, P179, DOI 10.1007/BF03166035; VANDERVOS R, 1994, BBA-BIOENERGETICS, V1188, P243, DOI 10.1016/0005-2728(94)90042-6; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727	44	209	217	0	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29613	29623		10.1074/jbc.274.42.29613	http://dx.doi.org/10.1074/jbc.274.42.29613			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514429	hybrid			2022-12-25	WOS:000083176400008
J	Grober, J; Zaghini, I; Fujii, H; Jones, SA; Kliewer, SA; Willson, TM; Ono, T; Besnard, P				Grober, J; Zaghini, I; Fujii, H; Jones, SA; Kliewer, SA; Willson, TM; Ono, T; Besnard, P			Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene - Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ACTIVITY; RAT; EXPRESSION; ABSORPTION; CLONING; RABBIT; LIVER; CHOLESTEROL; INTESTINE; ILEUM	Intestinal bile acid-binding protein (I-BABP) iis a cytosolic protein that binds bile acids (BAs) with a high affinity. In the small intestine, its expression is restricted to the ileum where it is involved in the enterohepatic circulation of BAs, Using the human enterocyte-like Caco-2 cell line, we have recently shown that BAs increased I-BABP gene expression. To determine whether this regulation occurs in vivo, the effect of BA depletion or supplementation was studied in mice, A dramatic drop in I-BABP mRNA levels was observed in mice treated with the BA-binding resin cholestyramine, whereas an increase was found in animals fed with taurocholic acid. BAs are physiological ligands for the nuclear farnesoid X receptor (FXR), Both FXR and I-BABP are co-expressed along the small intestine and in Caco-2 cells. To determine the role of FXR in the regulation of I-BABP expression, the promoter of the human I-BABP gene was cloned. In Caco-2 cells, cotransfection of FXR and RXR alpha is required to obtain the full transactivation of the I-BABP promoter by BAs, Deletion and mutation analyses demonstrate that the FXR/RXR alpha heterodimer activates transcription through an inverted repeat bile acid responsive element located in position -160/-148 of the human I-BABP promoter. In conclusion, we show that FXR is a physiological BA sensor that is likely to play an essential role in BA homeostasis through the regulation of genes involved in their enterohepatic circulation.	ENSBANA, EP 1777 CNRS, CESG, F-21000 Dijon, France; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA	Institut Agro; AgroSup Dijon; Universite de Bourgogne; Niigata University; GlaxoSmithKline; GlaxoSmithKline	Besnard, P (corresponding author), ENSBANA, EP 1777 CNRS, CESG, 1 Esplanade Erasme, F-21000 Dijon, France.		feinstein, doug/M-9414-2019					Aldini R, 1996, GASTROENTEROLOGY, V110, P459, DOI 10.1053/gast.1996.v110.pm8566593; Amelsberg A, 1996, GASTROENTEROLOGY, V110, P1098, DOI 10.1053/gast.1996.v110.pm8612999; Arrese M, 1998, HEPATOLOGY, V28, P1081, DOI 10.1002/hep.510280424; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coppola CP, 1998, GASTROENTEROLOGY, V115, P1172, DOI 10.1016/S0016-5085(98)70088-5; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJII H, 1993, BIOCHEM BIOPH RES CO, V190, P175, DOI 10.1006/bbrc.1993.1027; FUJITA M, 1995, EUR J BIOCHEM, V233, P406, DOI 10.1111/j.1432-1033.1995.406_2.x; GORDON JI, 1983, J BIOL CHEM, V258, P3356; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4749; SHIAU YF, 1985, AM J PHYSIOL, V248, pG608, DOI 10.1152/ajpgi.1985.248.6.G608; Stengelin S, 1996, EUR J BIOCHEM, V239, P887, DOI 10.1111/j.1432-1033.1996.0887u.x; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	26	290	305	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29749	29754		10.1074/jbc.274.42.29749	http://dx.doi.org/10.1074/jbc.274.42.29749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514450	hybrid			2022-12-25	WOS:000083176400029
J	Healy, AM; Peters-Golden, M; Yao, JP; Brock, TG				Healy, AM; Peters-Golden, M; Yao, JP; Brock, TG			Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN ALVEOLAR MACROPHAGES; BASOPHILIC LEUKEMIA-CELLS; GREEN FLUORESCENT PROTEIN; HUMAN NEUTROPHILS; ACTIVATING PROTEIN; HUMAN-LEUKOCYTES; EXPRESSION; TRANSLOCATION; CLONING	5-Lipoxygenase catalyzes the synthesis of leukotrienes from arachidonic acid. This enzyme can reside either in the cytoplasm or the nucleus; its subcellular distribution is influenced by extracellular factors, and its nuclear import correlates with changes in leukotriene synthetic capacity. To identify sequences responsible for the nuclear import of B-lipoxygenase, we transfected NIH 3T3 cells and RAW 264.7 macrophages with expression vectors encoding various 5-lipoxygenase constructs fused to green fluorescent protein. Overexpression of wild type 5-lipoxygenase with or without fusion to green fluorescent protein resulted in a predominantly intranuclear pattern of fluorescence, similar to the distribution of native 5-lipoxygenase in primary alveolar macrophages. Within the 5-lipoxygenase protein is a sequence (Arg(638)-Lys(655)) that closely resembles a bipartite nuclear localization signal. Studies using deletion mutants indicated that this region was necessary for nuclear import of 5-lipoxygenase. Analysis of mutants containing specific amino acid substitutions within this sequence confirmed that it was this sequence that was necessary for nuclear import of 5-Lipoxygenase and that a specific arginine residue was critical for this function. As nuclear import of 5-lipoxygenase may regulate leukotriene production, natural or induced mutations in this bipartite nuclear localization sequence may also be important in affecting leukotriene synthesis.	Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, 6301 MSRB 3, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043574] Funding Source: NIH RePORTER; NCI NIH HHS [CA695568] Funding Source: Medline; NHLBI NIH HHS [R01 HL47391] Funding Source: Medline; NIAID NIH HHS [R29 AI43574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 1996, J IMMUNOL, V156, P2522; Brock TG, 1999, J IMMUNOL, V162, P1669; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; COFFEY MJ, 1994, AM J RESP CELL MOL, V11, P153, DOI 10.1165/ajrcmb.11.2.8049076; Covin RB, 1998, AM J PHYSIOL-LUNG C, V275, pL303, DOI 10.1152/ajplung.1998.275.2.L303; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kitzler JW, 1996, PROSTAG LEUKOTR ESS, V55, P269, DOI 10.1016/S0952-3278(96)90008-3; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; OCHI K, 1983, J BIOL CHEM, V258, P5754; PETERSEN MM, 1992, IMMUNOLOGY, V75, P275; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; PUERINGER RJ, 1992, J APPL PHYSIOL, V73, P781, DOI 10.1152/jappl.1992.73.2.781; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; STANKOVA J, 1995, BLOOD, V85, P3719, DOI 10.1182/blood.V85.12.3719.bloodjournal85123719; STEINHILBER D, 1993, BIOCHIM BIOPHYS ACTA, V1178, P1, DOI 10.1016/0167-4889(93)90104-W; SUZUKI K, 1993, AM J RESP CELL MOL, V8, P500, DOI 10.1165/ajrcmb/8.5.500; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29812	29818		10.1074/jbc.274.42.29812	http://dx.doi.org/10.1074/jbc.274.42.29812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514459	hybrid			2022-12-25	WOS:000083176400038
J	Ikebe, R; Reardon, S; Mitsui, T; Ikebe, M				Ikebe, R; Reardon, S; Mitsui, T; Ikebe, M			Role of the N-terminal region of the regulatory light chain in the dephosphorylation of myosin by myosin light chain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; PROTEIN KINASE-C; PURIFICATION; SITES; IDENTIFICATION; CONFORMATION; PROTEOLYSIS; MEROMYOSIN; SEQUENCE	Myosin regulatory light chain (RLC) is phosphorylated at various sites at its N-terminal region, and heterotrimeric myosin light chain phosphatase (MLCP) has phosphorylates myosin in vivo. Specificity of MLCP toward the various phosphorylation sites of RLC was studied, as well as the role of the N-terminal region of RLC in the dephosphorylation of myosin by MLCP. MLCP dephosphorylated phosphoserine 19, phosphothreonine 18, and phosphothreonine 9 efficiently with almost identical rates, whereas it failed to dephosphorylate phosphorylated serine 1/serine 2. Deletion of the N-terminal seven amino acid residues of RLC markedly decreased the dephosphorylation rate of phosphoserine 19 of RLC incorporated in the myosin molecule, whereas this deletion did not significantly affect the dephosphorylation rate of isolated RLC. On the other hand, deletion of only four N-terminal amino acid residues showed no effect on dephosphorylation of phosphoserine 19 of incorporated RLC, The inhibition of dephosphorylation by deletion of the seven N-terminal residues was also found with the catalytic subunit of MLCP. Phosphorylation at serine 1/serine 2 and threonine 9 did not influence the dephosphorylation rate of serine 19 and threonine 18 by MLCP. These results suggest that the N-terminal region of RLC plays an important role in substrate recognition of MLCP.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.		Mitsui, Toshiaki/N-9773-2017	Mitsui, Toshiaki/0000-0002-9165-8830	NHLBI NIH HHS [HL41776, HL61426, HL60381] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776, R01HL061426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLESSI D, 1992, EUR J BIOCHEM, V210, P1023; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; GONG MC, 1992, J BIOL CHEM, V267, P21492; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1982, J BIOCHEM-TOKYO, V91, P1809, DOI 10.1093/oxfordjournals.jbchem.a133874; IKEBE M, 1988, J BIOL CHEM, V263, P10698; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMISOYAMA H, 1993, BIOCHEMISTRY-US, V30, P9539; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MITSUI T, 1992, J BIOL CHEM, V267, P16727; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PATO MD, 1985, J BIOL CHEM, V260, P2359; PATO MD, 1983, J BIOL CHEM, V258, P7047; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; PERSECHINI A, 1984, BIOCHEMISTRY-US, V23, P4144, DOI 10.1021/bi00313a021; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; WALSH MP, 1983, METHOD ENZYMOL, V99, P279	38	16	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30122	30126		10.1074/jbc.274.42.30122	http://dx.doi.org/10.1074/jbc.274.42.30122			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514500	hybrid			2022-12-25	WOS:000083176400079
J	Kroll, SL; Paulding, WR; Schnell, PO; Barton, MC; Conaway, JW; Conaway, RC; Czyzyk-Krzeska, MF				Kroll, SL; Paulding, WR; Schnell, PO; Barton, MC; Conaway, JW; Conaway, RC; Czyzyk-Krzeska, MF			von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TUMOR-SUPPRESSOR PROTEIN; FACTOR MESSENGER-RNA; GENE-PRODUCT; TERMINATION SITES; DNA-SEQUENCE; FACTOR-SIII; ELONGIN-C; DISEASE; IDENTIFICATION	Rat pheochromocytoma (PC12) cells were stably transfected with either wild type or mutated human von Hippel-Lindau tumor suppressor protein (hpVHL). These proteins have opposing effects on regulating expression of the gene encoding tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis. Whereas wild type hpVHL represses levels of TH mRNA and protein 5-fold, a truncated pVHL mutant, pVHL(1-115), induces accumulation of TH mRNA and protein 3-fold. hpVHL-induced inhibition of TH gene expression does not involve either a decrease in TH mRNA stability or repression of TH promoter activity. However, repression results from inhibition of RNA elongation at a downstream region of the TH gene. This elongation pause is accompanied by hpVHL sequestration in the nuclear extracts of elongins B and C, regulatory components of the transcription elongation heterotrimer SIII (elongin A/B/C). Hypoxia, a physiological stimulus for TH gene expression, alleviates the elongation block. A truncated pVHL mutant, pVHL(1-115), stimulates TH gene expression by increasing the efficiency of TH transcript elongation. This is the first report showing pVHL-dependent regulation of specific transcript elongation in vivo, as well as dominant negative activity of pVHL mutants in pheochromocytoma cells.	Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center	Czyzyk-Krzeska, MF (corresponding author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, POB 670576, Cincinnati, OH 45267 USA.	Maria.Czyzykkrzeska@uc.edu		Barton, Michelle/0000-0002-4042-1374; Conaway, Joan/0000-0002-2786-0663	NHLBI NIH HHS [HL51078, HL58687, T32 HL07571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007571, R29HL051078, R01HL058687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Atuk NO, 1998, J CLIN ENDOCR METAB, V83, P117, DOI 10.1210/jc.83.1.117; BAEK KH, 1986, P NATL ACAD SCI USA, V83, P7623, DOI 10.1073/pnas.83.20.7623; Blakenship C, 1999, ONCOGENE, V18, P1529; Bouloux PMG, 1995, CLIN ENDOCRINOL, V43, P657, DOI 10.1111/j.1365-2265.1995.tb00531.x; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; FELDMAN JM, 1979, J CLIN ENDOCR METAB, V49, P445, DOI 10.1210/jcem-49-3-445; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Isobe K, 1998, EUR J ENDOCRINOL, V138, P383, DOI 10.1530/eje.0.1380383; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Kenady Daniel E., 1997, Current Opinion in Oncology, V9, P61; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maher ER, 1996, J MED GENET, V33, P328, DOI 10.1136/jmg.33.4.328; Moreland RJ, 1998, J BIOL CHEM, V273, P26610, DOI 10.1074/jbc.273.41.26610; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; Richards FM, 1998, J INTERN MED, V243, P527; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Takagi Y, 1997, J BIOL CHEM, V272, P27444, DOI 10.1074/jbc.272.43.27444	38	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30109	30114		10.1074/jbc.274.42.30109	http://dx.doi.org/10.1074/jbc.274.42.30109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514498	hybrid			2022-12-25	WOS:000083176400077
J	Nalca, A; Qiu, SGF; El-Guendy, N; Krishnan, S; Rangnekar, VM				Nalca, A; Qiu, SGF; El-Guendy, N; Krishnan, S; Rangnekar, VM			Oncogenic Ras sensitizes cells to apoptosis by Par-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ZIPPER PROTEIN PAR-4; MAMMALIAN-CELL; KINASE-C; ACTIVATION; EXPRESSION; RESISTANCE; SIGNAL; PHOSPHORYLATION; TRANSFORMATION	Certain mutations in the mammalian ras gene are oncogenic and are often detected in human cancers. Oncogenic Bas induces the transcription activity of NF-KB that confers cell survival. Oncogenic Ras also down-modulates the expression of Par-4, a transcriptional repressor protein, that is essential but not sufficient on its own to induce apoptosis, Were we show that reintroduction of Par-4 by transient transfection leads to apoptosis in cells expressing oncogenic Ras but not in those that lack oncogenic Ras expression. Par-4 abrogates oncogenic Ras-inducible NF-KB transcription activity but does not interfere with cytoplasmic activation, or the DNA binding activity, of NF-KB. Because abrogation of NF-KB transcription activity is sufficient to cause apoptosis in cells expressing oncogenic Was, our findings identify Par-4 as a novel example of a pro-apoptotic protein that selectively inhibits oncogenic Ras-dependent NF-kappa B function at the transcription level and suggest a mechanism by which Par-4 expression may selectively induce apoptosis in oncogenic Ras-expressing cells.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Combs Res Bldg,Rm 303,800 Rose St, Lexington, KY 40536 USA.		Nalca, Aysegul/L-8149-2019	Nalca, Aysegul/0000-0001-8581-7535; El-Guendy, Nadia/0000-0002-0770-3740	NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; BOS JL, 1989, CANCER RES, V49, P4682; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FILMUS J, 1992, ONCOGENE, V7, P521; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GALANG CK, 1994, ONCOGENE, V9, P2913; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; ISONISHI S, 1991, CANCER RES, V51, P5903; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; PARK M, 1998, ONCOGENES, P205; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	40	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29976	29983		10.1074/jbc.274.42.29976	http://dx.doi.org/10.1074/jbc.274.42.29976			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514481	hybrid			2022-12-25	WOS:000083176400060
J	Petrotchenko, EV; Doerflein, ME; Kakuta, Y; Pedersen, LC; Negishi, M				Petrotchenko, EV; Doerflein, ME; Kakuta, Y; Pedersen, LC; Negishi, M			Substrate gating confers steroid specificity to estrogen sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATASE ACTIVITY; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; SULFURYL TRANSFER; MECHANISM	Estrogen sulfotransferase (EST) exhibits a high substrate specificity and catalytic efficiency toward estro; gens such as estradiol (E2) but insignificant ability to sulfate hydroxysteroids such as dehydroepiandrosterone (DHEA). To provide the structural basis for this estrogen specificity, we mutated amino acid residues that constitute the substrate-binding site of EST. Among these mutants, only Tyr-81 decreased E2 and increased DHEA sulfotransferase activities. Substitution for Tyr-81 by smaller hydrophobic residues increased K-m(E2) for E2 activity, whereas the K-cat(E2) remained relatively constant. The Y81L mutant exhibited the same DHEA activity as wild-type hydroxysteroid sulfotransferase, for which K-m(DHEA) remained relatively constant, and k(cat(DHEA)) was markedly increased. The side chain of Tyr-81 is directed at the A-ring of the E2 molecule in the substrate-binding pocket of EST, constituting a steric gate with Phe-142 sandwiching E2 from the opposite side. The present mutagenesis study indicates that the 3b-hydroxyl group of the DHEA molecule is excluded from the catalytic site of EST through steric hindrance of Tyr-81 with the C-19 methyl group of DHEA. Thus, this stricture-like gating caused by steric hindrance appears to be a structural principle for conferring estrogen specificity to EST.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA.		Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928				Ahmed S, 1999, BIOCHEM BIOPH RES CO, V254, P811, DOI 10.1006/bbrc.1998.9934; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Dajani R, 1998, MOL PHARMACOL, V54, P942, DOI 10.1124/mol.54.6.942; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; EVANS TRJ, 1994, BRIT J CANCER, V69, P555, DOI 10.1038/bjc.1994.101; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDBERG R, 1989, NATURE, V338, P632; Negishi M, 1996, FASEB J, V10, P683, DOI 10.1096/fasebj.10.7.8635685; Selcer KW, 1996, J STEROID BIOCHEM, V59, P83, DOI 10.1016/S0960-0760(96)00089-1; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; Utsumi T, 1999, CANCER RES, V59, P377; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888	24	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30019	30022		10.1074/jbc.274.42.30019	http://dx.doi.org/10.1074/jbc.274.42.30019			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514486	hybrid			2022-12-25	WOS:000083176400065
J	Uddin, S; Majchrzak, B; Woodson, J; Arunkumar, P; Alsayed, Y; Pine, R; Young, PR; Fish, EN; Platanias, LC				Uddin, S; Majchrzak, B; Woodson, J; Arunkumar, P; Alsayed, Y; Pine, R; Young, PR; Fish, EN; Platanias, LC			Activation of the p38 mitogen-activated protein kinase by type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TYROSINE PHOSPHORYLATION; VAV PROTOONCOGENE PRODUCT; MAP KINASE; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; ALPHA; PATHWAYS; INTERLEUKIN-1; APOPTOSIS; DISTINCT	The p38 mitogen-activated protein (Map) kinase plays a critical role in the generation of signals in response to stress stimuli, but its role in interferon (IFN) signaling and its potential regulatory role in the activation of Jak-signal transducer and activator of transcription (Stat) pathway are not known. In the present study, we provide evidence that the p38 Map kinase is rapidly phosphorylated and activated during treatment of cells with Type I interferons (IFN alpha and IFN beta). Furthermore, the Type I IFN-dependent activation of p38 regulates induction of the catalytic domains of MapKap kinase-2 and MapKap kinase-3, strongly suggesting the existence of an IFN alpha signaling cascade activated downstream of the p38 kinase. The engagement of this pathway in interferon signaling plays a critical role in interferon-dependent transcriptional regulation, as evidenced by the fact that inhibition of p38 activation results in abrogation of interferon-dependent gene transcription via interferon-stimulated response elements. Interestingly, inhibition of the kinase activity of the p38 blocks IFN alpha-induced gene transcription without inhibiting DNA binding or tyrosine phosphorylation of Stat proteins, suggesting that the p38 pathway acts in cooperation with the Stat pathway. Thus, the p38 kinase signaling cascade is activated by the Type I interferon receptor and plays a critical role in interferon signaling and interferon-dependent transcriptional regulation.	Univ Illinois, Dept Mol Biol, Div Cardiovasc Dis, Hematol Oncol Sect, Chicago, IL 60607 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; Publ Hlth Res Inst, New York, NY 10016 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; GlaxoSmithKline	Platanias, LC (corresponding author), Univ Illinois, Dept Mol Biol, Div Cardiovasc Dis, Hematol Oncol Sect, MBRB,MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.			Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA73381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRUMER JL, 1997, J BIOL CHEM, V272, P20490; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; WEN Z, 1995, CELL, V28, P241; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	34	197	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30127	30131		10.1074/jbc.274.42.30127	http://dx.doi.org/10.1074/jbc.274.42.30127			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514501	hybrid			2022-12-25	WOS:000083176400080
J	van Geest, M; Lolkema, JS				van Geest, M; Lolkema, JS			Transmembrane segment (TMS) VIII of the Na+/citrate transporter CitS requires downstream TMS IX for insertion in the Escherichia coli membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; IN-VITRO TRANSLATION; DEPENDENT CITRATE CARRIER; ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; KLEBSIELLA-PNEUMONIAE; TOPOLOGY; PURIFICATION; BIOGENESIS; SEQUENCES	The amino acid sequence of the sodium ion-dependent citrate transporter CitS of IL pneumoniae contains 12 hydrophobic stretches that could form membrane-spanning segments. A previous analysis of the membrane topology in Escherichia coli using the PhoA gene fusion technique indicated that only nine of these hydrophobic segments span the membrane, while three segments, Vb, VIII and IX were predicted to have a periplasmic location (Van Geest, IM., and Lolkema, J. S. (1996) J. Biol. Chem. 271, 25582-25589), A topology study of C-terminally truncated CitS molecules in dog pancreas microsomes revealed that the protein traverses the endoplasmic reticulum membrane 11 times. In agreement with the PhoA fusion data, segment Vb was predicted to have a periplasmic location, but, in contrast, segments VIII and IX were found to be membrane-spanning (Van Geest, M., Nilsson, I., von Heijne, G., and Lolkema, J, S, (1999) J. Biol, Chem. 274, 2816-2823), In the present study, using site-directed Cys labeling, the topology of segments VIII and IX in the fall-length CitS protein was determined in the E. coli membrane, Engineered cysteine residues in the loop between the two segments were accessible to a membrane-impermeable thiol reagent exclusively from the cytoplasmic side of the membrane, demonstrating that transmembrane segments (TMSs) VIII and M are both membrane-spanning. It follows that the folding of CitS in the E. cold and endoplasmic reticulum membrane is the same. Cysteine accessibility studies of CitS-PhoA fusion molecules dem; onstrated that in the E. coli membrane segment VIII is exported to the periplasm in the absence of the C-terminal CitS sequences, thus explaining why the PhoA fusions do not correctly predict the topology. An engineered cysteine residue downstream of TMS VIII moved from a periplasmic to a cytoplasmic location when the fusion protein containing TMSs I-VIII was extended with segment IX, Thus, downstream segment M is both essential and sufficient for the insertion of segment VIII of CitS in the E. coli membrane.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.							ANDERSSON H, 1993, J BIOL CHEM, V268, P21389; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DRIESSEN AJM, 1996, HDB BIOL PHYS, V2, P759; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; POS KM, 1994, FEBS LETT, V347, P37, DOI 10.1016/0014-5793(94)00502-8; Sambrook J., 2002, MOL CLONING LAB MANU; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582	27	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29705	29711		10.1074/jbc.274.42.29705	http://dx.doi.org/10.1074/jbc.274.42.29705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514443	Green Published, hybrid			2022-12-25	WOS:000083176400022
J	Wu, C; Ghosh, S				Wu, C; Ghosh, S			beta-TrCP mediates the signal-induced ubiquitination of I kappa B beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE COMPLEX; ACTIVATION; ALPHA; DEGRADATION; IDENTIFICATION; COMPONENT; PROTEIN; PATHWAY	We have examined the role of beta-TrCP (beta-transducin repeat-containing protein) in the ubiquitination and degradation of I kappa B beta, one of the two major I kappa B isoforms in mammalian cells. We demonstrate that beta-TrCP interacts specifically with I kappa B beta, and such interaction is dependent on prior phosphorylation of I kappa B beta on serines 19 and 23. Interaction with beta-TrCP is also necessary for ubiquitination of I kappa B beta upon stimulation of cells, and deletion of the F-box in beta-TrCP abolishes its ability to ubiquitinate I kappa B beta. Therefore, these results indicate that beta-TrCP plays a critical role in the activation of NF-kappa B by assembling the ubiquitin ligase complex for both phosphorylated I kappa B alpha and I kappa B beta.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA.			Ghosh, Sankar/0000-0002-3227-0588	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Weil R, 1997, J BIOL CHEM, V272, P9942; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	24	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29591	29594		10.1074/jbc.274.42.29591	http://dx.doi.org/10.1074/jbc.274.42.29591			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514424	hybrid			2022-12-25	WOS:000083176400003
J	Kitareewan, S; Spinella, MJ; Allopenna, J; Reczek, PR; Dmitrovsky, E				Kitareewan, S; Spinella, MJ; Allopenna, J; Reczek, PR; Dmitrovsky, E			4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR gamma independent pathway	ONCOGENE			English	Article						retinoic acid; retinoid receptors; teratocarcinomas; 4HPR	HUMAN BREAST-CARCINOMA; RECEPTOR-GAMMA; PROMYELOCYTIC LEUKEMIA; ACID RECEPTORS; F9 CELLS; 4-HYDROXYPHENYL RETINAMIDE; HUMAN TERATOCARCINOMAS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; NUCLEAR RECEPTOR	Retinoids signal biological effects through retinoic acid receptors (RAR) and retinoid X receptors (RXR) and their co-regulators. We previously reported that all-trans retinoic acid (RA) triggers terminal differentiation in the human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1), through an RAR gamma dependent pathway. RAR gamma repression in NT2/D1-R1 cells accounts for RA resistance in this line. This report finds RAR gamma repression is due to selective repression of RAR gamma but not RAR beta transcription in NT2/D1-R1 cells. The repression is neither due to mutations in RAR gamma nor its promoter containing the RA response element. Prior work was confirmed and extended by demonstrating that an RAR gamma selective agonist preferentially signals differentiation of NT2/D1 cells, while RAR alpha/beta, RAR beta, RXR agonists and an RAR pan-antagonist do not even when NT2/D1 cells are treated with these retinoids at 10 mu M dosages. None of these examined retinoids induced differentiation of the RA resistant NT2/D1-R1 cells. In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RAR gamma was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells. 4HPR-induced apoptosis was unaffected by co-treatment of both cell lines with equimolar RAR antagonist. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) assays of total RNA from 4HPR-treated NT2/D1 and NT2/D1-R1 cells did not reveal RAR gamma induction. Since 4HPR signals in RA-resistant NT2/D1-R1 cells having an RAR; transcriptional block, these results indicate that 4HPR triggers apoptosis but not differentiation through an RAR gamma independent pathway. Taken together, these findings implicate a therapeutic role for 4HPR mediated apoptosis in germ cell tumors even when a maturation block is present.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Dept Med, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Buffalo, NY 14213 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb	Kitareewan, S (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [K01 CA75154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Bosl George J., 1997, P1397; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; Clifford JL, 1999, CANCER RES, V59, P14; De Palo G, 1997, TUMORI, V83, P884, DOI 10.1177/030089169708300603; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DOWLATSHAHI K, 1989, CANCER LETT, V47, P187, DOI 10.1016/0304-3835(89)90089-X; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; FONTANA JA, 1986, CANCER RES, V46, P2468; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; Kastner P, 1997, DEVELOPMENT, V124, P313; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kazmi SMI, 1996, CANCER RES, V56, P1056; KURIE JM, 1993, DIFFERENTIATION, V54, P123; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; MOASSER MM, 1995, CANCER, V76, P680, DOI 10.1002/1097-0142(19950815)76:4<680::AID-CNCR2820760423>3.0.CO;2-9; Monzon RI, 1997, MOL PHARMACOL, V51, P377; MOON RC, 1992, ANTICANCER RES, V12, P1147; MOON RC, 1979, CANCER RES, V39, P1339; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Park DJ, 1998, BIOTECHNIQUES, V24, P558, DOI 10.2144/98244bm07; PETKOVICH M, 1987, NATURE, V330, P44; POLLARD M, 1991, CANCER LETT, V59, P159, DOI 10.1016/0304-3835(91)90181-G; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Subbarayan V, 1997, MECH DEVELOP, V66, P131, DOI 10.1016/S0925-4773(97)00098-1; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452	50	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5747	5755		10.1038/sj.onc.1202981	http://dx.doi.org/10.1038/sj.onc.1202981			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523855				2022-12-25	WOS:000083095100003
J	Clemetson, JM; Polgar, J; Magnenat, E; Wells, TNC; Clemetson, KJ				Clemetson, JM; Polgar, J; Magnenat, E; Wells, TNC; Clemetson, KJ			The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to Fc alpha R and the natural killer receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); GAMMA-CHAIN; AGGREGATION; ADHESION; ACTIVATION; EXPRESSION; CONVULXIN; CHEMOKINE; CLONING	We have cloned the platelet collagen receptor glycoprotein (GP) VI from a human bone marrow cDNA library using rapid amplification of cDNA ends with platelet mRNA to complete the 5' end sequence. GPVI was isolated from platelets using affinity chromatography on the snake C-type lectin, convulxin, as a critical step. Internal peptide sequences were obtained, and degenerate primers were designed to amplify a fragment of the GPVI cDNA, which was then used as a probe to screen the library. Purified GPVI, as well as Fab fragments of polyclonal antibodies made against the receptor, inhibited collagen-induced platelet aggregation. The GPVI receptor cDNA has an open reading frame of 1017 base pairs coding for a protein of 339 amino acids including a putative 23-amino acid signal sequence and a 19-amino acid transmembrane domain between residues 247 and 265, GPVI belongs to the immunoglobulin superfamily, and its sequence is closely related to Fc alpha R and to the natural killer receptors, Its extracellular chain has two Ig-C2-like domains formed by disulfide bridges. An arginine residue is found in position 3 of the transmembrane portion, which should permit association with Fc gamma and its immunoreceptor tyrosine based activation motif via a salt bridge. With 51 amino acids, the cytoplasmic tail is relatively long and shows little homology to the C-terminal part of the other family members. The ability of the cloned GPVI cDNA to code for a functional platelet collagen receptor was demonstrated in the megakaryocytic cell line Dami, Dami cells transfected with GPVI cDNA mobilized intracellular Ca2+ in response to collagen, unlike the nontransfected or mock transfected Dami cells, which do not respond to collagen.	Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Serono Pharmaceut Res Inst SA, CH-1228 Geneva, Switzerland	University of Bern	Clemetson, KJ (corresponding author), Univ Bern, Theodor Kocher Inst, Freiestr 1, CH-3012 Bern, Switzerland.			Wells, Timothy/0000-0001-9796-847X				APTE AN, 1993, BIOTECHNIQUES, V15, P890; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1989, BLOOD, V74, P182; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1993, THROMB RES, V72, P367, DOI 10.1016/0049-3848(93)90148-H; Moshfegh K, 1999, LANCET, V353, P351, DOI 10.1016/S0140-6736(98)06448-4; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; POWER CA, 1995, CYTOKINE, V7, P479, DOI 10.1006/cyto.1995.0065; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Santoso S, 1999, BLOOD, V93, P2449, DOI 10.1182/blood.V93.8.2449.408k34_2449_2453; Strouse RJ, 1996, THROMB RES, V82, P485, DOI 10.1016/0049-3848(96)00099-0; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; WICKI AN, 1992, METHOD ENZYMOL, V215, P276; ZUTTER MM, 1995, BLOOD, V86, P3006	23	341	363	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29019	29024		10.1074/jbc.274.41.29019	http://dx.doi.org/10.1074/jbc.274.41.29019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506151	hybrid			2022-12-25	WOS:000083017800030
J	Kwon, YS; Kang, CW				Kwon, YS; Kang, CW			Bipartite modular structure of intrinsic, RNA hairpin-independent termination signal for phage RNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; T7-RNA POLYMERASE; TRANSCRIPTION; BACTERIOPHAGE-T7; DNA; PROTEIN	The phage SP6 RNA and T7 RNA polymerases, which are closely related to each other, intrinsically stop at two signals in the Escherichia coli rrnB terminator t1 through different mechanisms. The downstream signal functioned without an RNA secondary structure formation, in which the signal was still active when separated from the upstream, hairpin-forming signal, and IMP incorporation enhanced its efficiency. The sequence from -15 to -1 was essential for the downstream, hairpin-independent termination (at -1), The results of SP6 transcription with heteroduplex templates and ribonucleotide analogs suggested that the downstream signal consists of two functionally different modules. The effects of iodo-CMP or IMP incorporation into RNA on termination efficiency mere not sensitive to incorporation at -9 and upstream, but they were reactive to incorporation at -6 and -2, as reflected by strong iodo-rC:dG and weak rI:dC base pairing. Thus, the downstream module (from -8 similar to -6 to -1) appears to facilitate the release of RNA. Mismatches in the templates at -6 to +1 allowed for efficient termination, unlike those upstream of the sequence. The upstream module (from -15 to;-8 similar to -7) functions as a duplex. Pausing of the SP6 elongation complex at the termination site was detected when RNA release was suppressed by the incorporation of 5-bromo-UMP, and it was dependent on the upstream module, Results of single-round SP6 transcriptions using 3'-deoxynucleotides and immobilized templates indicated that RNA was not released from the elongation complexes halted at the termination site on the template variants carrying mutations in the upstream or downstream module, whereas such complexes on the wild type template were dissociated. Thus, halting or simple pausing was not sufficient for termination even when the downstream module was intact. The upstream module appears to mediate such conformation change necessary for termination.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kang, CW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong, Taejon 305701, South Korea.	ckang@sorak.kaist.ac.kr	Kang, Changwon/C-1938-2011	Kang, Changwon/0000-0002-0867-6385				AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CHRISTIANSEN J, 1988, NUCLEIC ACIDS RES, V16, P7457, DOI 10.1093/nar/16.15.7457; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Fu DJ, 1998, NAT BIOTECHNOL, V16, P381, DOI 10.1038/nbt0498-381; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Hartvig L, 1996, EMBO J, V15, P4767, DOI 10.1002/j.1460-2075.1996.tb00854.x; He B, 1998, J BIOL CHEM, V273, P18802, DOI 10.1074/jbc.273.30.18802; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; Jeong W, 1997, BIOCHEM MOL BIOL INT, V42, P711, DOI 10.1080/15216549700203131; Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MONFORTE JA, 1990, BIOCHEMISTRY-US, V29, P7882, DOI 10.1021/bi00486a015; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TYAGARAJAN K, 1991, BIOCHEMISTRY-US, V30, P10920, DOI 10.1021/bi00109a016; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702	24	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29149	29155		10.1074/jbc.274.41.29149	http://dx.doi.org/10.1074/jbc.274.41.29149			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506170	hybrid			2022-12-25	WOS:000083017800049
J	Shan, XC; Wange, RL				Shan, XC; Wange, RL			Itk/Emt/Tsk activation in response to CD3 cross-linking in Jurkat T cells requires ZAP-70 and Lat and is independent of membrane recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PLECKSTRIN HOMOLOGY DOMAINS; TEC FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; ITK; PHOSPHORYLATION; INTERLEUKIN-2; TCR; ASSOCIATION	The Tec family tyrosine kinase, Itk has been implicated in T cell antigen receptor (TCR) signaling, yet little is known about Itk regulation. Here, we investigate the role of the tyrosine kinase ZAP-70 in regulating Itk. Whereas Itk was activated in Jurkat T cells in response to CD3 cross-linking, Itk activation was defective in the ZAP-70-deficient P116 Jurkat T cell line. Itk responsiveness to TCR engagement was restored in Pile cells stably transfected with ZAP-70 cDNA, ZAP-70 itself could not directly phosphorylate the Itk kinase domain, indicating an indirect regulation of Itk activity. No role was found for ZAP-70 in regulating Itk recruitment to the plasma membrane, an event that has been suggested to be rate-limiting for the activation of Tec family kinases. Indeed, Itk was found to be constitutively targeted to the membrane fraction in both Jurkat and P116 cells. Lat, a prominent in vivo substrate of ZAP-70 that mediates assembly of multimolecular signaling complexes at the plasma membrane of T cells was also found to be required for TCR-stimulated Itk activation. Itk could not be activated by CD3 cross-linking in a Lat-negative cell line, unless Lat expression was restored. Lat and Itk were observed to co-associate in response to CD3 crosslinking in Jurkat T cells, but not in pile T cells. The Lat-Itk association correlated with Lat tyrosine phosphorylation, which was deficient in the P116 T cells. These data suggest that ZAP-70 and Lat play important, probably sequential, roles in regulating the activation of Itk following TCR engagement.	NIA, Biol Chem Lab, Gerontol Res Ctr, IRP,NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Biol Chem Lab, Gerontol Res Ctr, IRP,NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.			Wange, Ronald/0000-0001-9593-3572	NATIONAL INSTITUTE ON AGING [Z01AG000509] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CONLEY ME, 1995, CLIN IMMUNOL IMMUNOP, V76, pS192, DOI 10.1016/S0090-1229(95)90198-1; Eischen CM, 1997, J IMMUNOL, V159, P1135; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gibson S, 1996, J IMMUNOL, V156, P2716; GIBSON S, 1993, BLOOD, V82, P1561; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Lu YL, 1998, J IMMUNOL, V161, P5404; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rudd CE, 1998, CURR BIOL, V8, pR805, DOI 10.1016/S0960-9822(07)00505-2; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tanaka N, 1997, EUR J IMMUNOL, V27, P834; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Watts JD, 1996, FEBS LETT, V398, P217, DOI 10.1016/S0014-5793(96)01241-0; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	56	80	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29323	29330		10.1074/jbc.274.41.29323	http://dx.doi.org/10.1074/jbc.274.41.29323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506192	hybrid			2022-12-25	WOS:000083017800071
J	Allen, JW; Knoblach, SM; Faden, AI				Allen, JW; Knoblach, SM; Faden, AI			Combined mechanical trauma and metabolic impairment in vitro induces NMDA receptor-dependent neuronal cell death and caspase-3-dependent apoptosis	FASEB JOURNAL			English	Article						neuronal injury; ischemia; caspases; 3-nitropropionic acid	BRAIN INJURY; 3-NITROPROPIONIC ACID; CEREBRAL-ISCHEMIA; CASPASE-3-LIKE PROTEASE; IN-VITRO; MODEL; ACTIVATION; CULTURES; RAT; INHIBITION	Neuronal necrosis and apoptosis occur after traumatic brain injury (TBI) in animals and contribute to subsequent neurological deficits. In contrast, relatively little apoptosis is found after mechanical injury in vitro, Because in vivo trauma models and clinical head injury have associated cerebral ischemia and/or metabolic impairment, we transiently impaired cellular metabolism after mechanical trauma of neuronal-glial cultures by combining 5-nitropropionic acid treatment with concurrent glucose deprivation, This produced greater neuronal cell death than mechanical trauma alone. Such injury was attenuated by the NMDA receptor antagonist dizocilpine (MK801), In addition, this injury significantly increased the number of apoptotic cells over that accruing from mechanical injury alone. This apoptotic cell. death was accompanied by DNA fragmentation, attenuated by cycloheximide, and associated with an increase in caspase-3-like but not caspase-1-like activity, Cell death was reduced by the pan-caspase inhibitor BAF or the caspase-3 selective inhibitor z-DEVD-fmk, whereas the caspase-1 selective inhibitor z-YVAD-fmk had no effect; z-DEVD-fmk also reduced the number of apoptotic cells after combined injury. Moreover, cotreatment with MK801 and BAF resulted in greater neuroprotection than either drug alone. Thus, in vitro trauma with concurrent metabolic inhibition parallels in vivo TBI, showing both NMDA-sensitive necrosis and caspase-3-dependent apoptosis.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHS [R49 CCR306634-07] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arden S. R., 1997, Society for Neuroscience Abstracts, V23, P2294; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CIESLA Z, 1974, MOL GEN GENET, V135, P339, DOI 10.1007/BF00271148; Clark R. S. B., 1998, Society for Neuroscience Abstracts, V24, P251; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HASSEL B, 1995, J NEUROCHEM, V65, P1184; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MIRSA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1998, J NEUROCHEM, V71, P186; Pang Z, 1997, J NEUROSCI, V17, P3064; PATEL MN, 1993, NEUROTOXICOLOGY, V14, P35; RINK A, 1995, AM J PATHOL, V147, P1575; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIEGEL JH, 1995, TRAUMATIC BRAIN INJU, P85; Sonnewald U, 1996, NEUROCHEM RES, V21, P987, DOI 10.1007/BF02532408; Varming T, 1996, J NEUROSCI RES, V44, P40, DOI 10.1002/(SICI)1097-4547(19960401)44:1<40::AID-JNR5>3.0.CO;2-I; VERITY MA, 1991, MOL CHEM NEUROPATHOL, V15, P217; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	40	53	53	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1875	1882		10.1096/fasebj.13.13.1875	http://dx.doi.org/10.1096/fasebj.13.13.1875			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506592				2022-12-25	WOS:000083063400024
J	Crottet, P; Peitsch, MC; Servis, C; Corthesy, B				Crottet, P; Peitsch, MC; Servis, C; Corthesy, B			Covalent homodimers of murine secretory component induced by epitope substitution unravel the capacity of the polymeric Ig receptor to dimerize noncovalently in the absence of IgA ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL IMMUNOGLOBULIN-A; MANNOSE 6-PHOSPHATE RECEPTOR; WHEAT-GERM-AGGLUTININ; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; VIBRIO-CHOLERAE; BINDING-SITE; SIALIC-ACID; ANTIBODIES; PROTECTS	Recombinant secretory immunoglobulin A containing a bacterial epitope in domain I of the secretory component (SC) moiety can serve as a mucosal delivery vehicle triggering both mucosal and systemic responses (Corthesy, B., Kaufmann, M., Phalipon, A., Peitsch, M., Neutra, M. R., and Kraehenbuhl, J.-P. (1996) J. Biol. Chem. 271, 33670-33677), To load recombinant secretory IgA with multiple B and T epitopes and extend its biological functions, we selected, based on molecular modeling, five surface-exposed sites in domains II and III of murine SC, Loops predicted to be exposed at the surface of SC domains were replaced with the DYKDDDDK octapeptide (FLAG), Another two mutants were obtained with the FLAG inserted in between domains II and III or at the carboxyl terminus of SC. As shown by mass spectrometry, internal substitution of the FLAG into four of the mutants induced the formation of disulfide-linked homodimers, Three of the dimers and two of the monomers from SC mutants could be affinity-purified using an antibody to the FLAG, mapping them as candidates for insertion. FLAG-induced dimerization also occurred with the polymeric immunoglobulin receptor (pIgR) and might reflect the so-far nondemonstrated capacity of the receptor to oligomerize, By co-expressing in COS-7 cells and epithelial Caco-2 cells two pIgR constructs tagged at the carboxyl terminus with hexahistidine or FLAG, we provide the strongest evidence reported to date that the pIgR dimerizes noncovalently in the plasma membrane in the absence of polymeric IgA ligand, The implication of this finding is discussed in terms of IgA transport and specific antibody response at mucosal surfaces.	CHU Vaudois, Div Immunol & Allergie, CH-1011 Lausanne, Switzerland; Inst Suisse Rech Expt Canc, CH-1066 Epalinges, Switzerland; Glaxo Welcome Expt Res, CH-1228 Plan Les Ouates, Switzerland; Univ Lausanne, Inst Biochim, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne	Corthesy, B (corresponding author), CHU Vaudois, Div Immunol & Allergie, BH18-701,Rue Bugnon, CH-1011 Lausanne, Switzerland.		Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1993, J IMMUNOL, V151, P1346; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BAKOS MA, 1991, J IMMUNOL, V146, P162; BEALE D, 1988, INT J BIOCHEM, V20, P873, DOI 10.1016/0020-711X(88)90077-8; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BLANCHARD TG, 1995, INFECT IMMUN, V63, P1394, DOI 10.1128/IAI.63.4.1394-1399.1995; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; CLEVELAND MG, 1991, J IMMUNOL, V147, P181; Corthesy B, 1996, J BIOL CHEM, V271, P33670, DOI 10.1074/jbc.271.52.33670; Cottet S, 1997, EUR J BIOCHEM, V246, P23, DOI 10.1111/j.1432-1033.1997.00023.x; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; EIFFERT H, 1991, BIOL CHEM H-S, V372, P119, DOI 10.1515/bchm3.1991.372.1.119; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hendrickson BA, 1996, J IMMUNOL, V157, P750; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; Luton F, 1998, MOL BIOL CELL, V9, P1787, DOI 10.1091/mbc.9.7.1787; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; Morissey J. H., 1981, ANAL BIOCHEM, V117, P307; Mortz E, 1996, J MASS SPECTROM, V31, P1109, DOI 10.1002/(SICI)1096-9888(199610)31:10<1109::AID-JMS400>3.0.CO;2-9; PARR EL, 1995, J IMMUNOL METHODS, V180, P147, DOI 10.1016/0022-1759(94)00310-S; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singer KL, 1998, MOL BIOL CELL, V9, P901, DOI 10.1091/mbc.9.4.901; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SOLARI R, 1985, J BIOL CHEM, V260, P1141; SONG WX, 1995, J IMMUNOL, V155, P715; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; WELTZIN R, 1994, ANTIMICROB AGENTS CH, V38, P2785, DOI 10.1128/AAC.38.12.2785; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0	54	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31445	31455		10.1074/jbc.274.44.31445	http://dx.doi.org/10.1074/jbc.274.44.31445			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531346	hybrid			2022-12-25	WOS:000083379400050
J	Hawkins, M; Hu, MZ; Yu, JH; Eder, H; Vuguin, P; She, L; Barzilai, N; Leiser, M; Backer, JM; Rossetti, L				Hawkins, M; Hu, MZ; Yu, JH; Eder, H; Vuguin, P; She, L; Barzilai, N; Leiser, M; Backer, JM; Rossetti, L			Discordant effects of glucosamine on insulin-stimulated glucose metabolism and phosphatidylinositol 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE ACTIVITY; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; IN-VIVO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; PHOSPHOINOSITIDE 3-KINASE; HEXOSAMINE BIOSYNTHESIS; GLUT-4 TRANSLOCATION; INHIBITOR WORTMANNIN; DIABETIC RATS	The impact of increased GlcN availability on insulin-stimulated p85/p110 phosphatidylinositol 3-kinase (PI3K) activity in skeletal muscle was examined in relation to GlcN-induced defects in peripheral insulin action. Primed continuous GlcN infusion (750 mu mol/kg bolus; 30 mu mol/kg min) in conscious rats limited both maximal stimulation of muscle PI3K by acute insulin (1) (1 unit/kg) bolus (I + GlcN = 1.9-fold versus saline = 3.3-fold above fasting levels; p < 0.01) and chronic activation of PI3K following 3-h euglycemic, hyperinsulinemic (18 milliunits/kg min) clamp studies (I + GlcN = 1,2-fold versus saline = 2,6-fold stimulation;p < 0.01). To determine the time course of GlcN-induced defects in insulin-stimulated PI3K activity and peripheral insulin action, GlcN was administered for 30, 60, 90, or 120 min during 2-h euglycemic, hyperinsulinemic clamp studies. Activation of muscle PI3K by insulin was attenuated following only 30 min of GlcN infusion (GlcN 30 min = 1.5-fold versus saline = 2.5-fold stimulation; p < 0.05). In contrast, the first impairment in insulin-mediated glucose uptake (Rd) developed following 110 min of GlcN infusion (110 min = 39.9 +/- 1.8 versus 30 min = 42.8 +/- 1.4 mg/kg.min, p < 0.05), However, the ability of insulin to stimulate phosphatidylinositol 3,4,5-trisphosphate production and to activate glycogen synthase in skeletal muscle was preserved following up to 180 min of GlcN infusion. Thus, increased GlcN availability induced (a) profound and early inhibition of proximal insulin signaling at the level of PI3K and (b) delayed effects on insulin-mediated glucose uptake, yet, (c) complete sparing of insulin-mediated glycogen synthase activation, The pattern and time sequence of GlcN-induced defects suggest that the etiology of peripheral insulin resistance may be distinct from the rapid and marked impairment in insulin signaling.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu		vuguin, patricia/0000-0002-4982-0400	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048321, R29DK045024, P60DK020541, P30DK020541, R01DK045024, R37DK048321] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48321, DK20541, DK 45024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1991, ANAL BIOCHEM, V197, P113, DOI 10.1016/0003-2697(91)90365-Z; BACKER JM, 1993, J BIOL CHEM, V268, P8204; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; CHANG PY, 1994, J BIOL CHEM, V269, P16034; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Crook ED, 1996, DIABETES, V45, P322, DOI 10.2337/diabetes.45.3.322; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; DONG DLY, 1994, J BIOL CHEM, V269, P19321; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Frevert EU, 1998, DIABETES, V47, pA36; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; HEYDRICK SJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE604, DOI 10.1152/ajpendo.1995.268.4.E604; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; OKADA T, 1994, J BIOL CHEM, V269, P3568; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P122; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1993, AM J PHYSIOL, V265, pE761, DOI 10.1152/ajpendo.1993.265.5.E761; ROSSETTI L, 1989, J CLIN INVEST, V84, P892, DOI 10.1172/JCI114250; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Snow DM, 1998, INT REV CYTOL, V181, P43, DOI 10.1016/S0074-7696(08)60416-7; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wojtaszewski JFP, 1997, DIABETES, V46, P1775, DOI 10.2337/diabetes.46.11.1775	51	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31312	31319		10.1074/jbc.274.44.31312	http://dx.doi.org/10.1074/jbc.274.44.31312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531330	hybrid			2022-12-25	WOS:000083379400034
J	Krych-Goldberg, M; Hauhart, RE; Subramanian, VB; Yurcisin, BM; Crimmins, DL; Hourcade, DE; Atkinson, JP				Krych-Goldberg, M; Hauhart, RE; Subramanian, VB; Yurcisin, BM; Crimmins, DL; Hourcade, DE; Atkinson, JP			Decay accelerating activity of complement receptor type 1 (CD35) - Two active sites are required for dissociating C5 convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT CONSENSUS REPEATS; C3B C4B RECEPTOR; C3B/C4B RECEPTOR; HUMAN-ERYTHROCYTE; CR3 CD11B/CD18; CR-1 CD35; FACTOR-H; IDENTIFICATION; MUTAGENESIS; EXPRESSION	The goal of this study was to identify the site(s) in CRI that mediate the dissociation of the C3 and C5 convertases. To that end, truncated derivatives of CR1 whose extracellular part is composed of 30 tandem repealing modules, termed complement control protein repeats (CCPs), were generated. Site 1 (CCPs 1-3) alone mediated the decay acceleration of the classical and alternative pathway C3 convertases, Site 2 (CCPs 8-10 or the nearly identical CCPs 15-17) had one-fifth the activity of site 1. In contrast, for the C5 convertase, site 1 had only 0.5% of the decay accelerating activity, while site 2 had no detectable activity. Efficient C5 decay accelerating activity was detected in recombinants that carried both site 1 and site 2, The activity was reduced if the intervening repeats between site 1 and site 2 were deleted. The results indicate that, for the C5 convertases, decay accelerating activity is mediated primarily by site 1. A properly spaced site 2 has an important auxiliary role, which may involve its C3b binding capacity. Moreover, using homologous substitution mutagenesis, residues important in site 1 for dissociating activity were identified. Based on these results, we generated proteins one-fourth the size of CR1 but with enhanced decay accelerating activity for the C3 convertases.	Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Atkinson, JP (corresponding author), Washington Univ, Sch Med, Dept Med, Div Rheumatol, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.			Atkinson, John/0000-0002-2514-3441	NIAID NIH HHS [R01 AI41592] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BRODBECK WG, 1998, MOL IMMUNOL, V35, P426; CERVONI F, 1993, J IMMUNOL, V151, P939; COOPER NR, 1991, IMMUNOL TODAY, V12, P327, DOI 10.1016/0167-5699(91)90010-Q; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; EHLENBERGER AG, 1977, J EXP MED, V145, P357, DOI 10.1084/jem.145.2.357; FALLMAN M, 1993, J IMMUNOL, V151, P330; FEARON DT, 1980, J EXP MED, V152, P20, DOI 10.1084/jem.152.1.20; FISCHER E, 1986, CELL IMMUNOL, V97, P297, DOI 10.1016/0008-8749(86)90400-4; HEBERT LA, 1987, KIDNEY INT, V31, P870; HOGG N, 1984, EUR J IMMUNOL, V14, P236, DOI 10.1002/eji.1830140307; HONG KS, 1991, J IMMUNOL, V146, P1868; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; Hourcade DE, 1999, IMMUNOPHARMACOLOGY, V42, P167, DOI 10.1016/S0162-3109(99)00005-3; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KINOSHITA T, 1987, J IMMUNOL, V138, P2994; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; Krych M., 1997, Journal of Allergy and Clinical Immunology, V99, pS373; Krych M, 1998, MOL IMMUNOL, V35, P403, DOI 10.1016/S0161-5890(98)90822-7; KRYCH M, 1994, J BIOL CHEM, V269, P13273; KRYCH M, 1996, MOL IMMUNOL, V33, P33; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; MORGAN BP, 1999, COMPLEMENT REGULATOR, P250; NELSON RA, 1953, SCIENCE, V118, P733, DOI 10.1126/science.118.3077.733; NICKELLS MW, 1994, J IMMUNOL, V152, P676; NICKELLS MW, 1990, J IMMUNOL, V144, P4262; OSHEA JJ, 1985, J IMMUNOL, V135, P1325; PANGBURN MK, 1986, J IMMUNOL, V136, P2216; Pruitt SK, 1997, TRANSPLANTATION, V63, P900, DOI 10.1097/00007890-199703270-00017; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; TEDDER TF, 1983, J IMMUNOL, V130, P1668; THIEBLEMONT N, 1993, CLIN EXP IMMUNOL, V92, P106; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILSON JG, 1983, J IMMUNOL, V131, P684; WONG WW, 1991, J IMMUNOL, V146, P656	47	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31160	31168		10.1074/jbc.274.44.31160	http://dx.doi.org/10.1074/jbc.274.44.31160			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531307	hybrid			2022-12-25	WOS:000083379400011
J	Maroun, CR; Moscatello, DK; Naujokas, MA; Holgado-Madruga, M; Wong, AJ; Park, M				Maroun, CR; Moscatello, DK; Naujokas, MA; Holgado-Madruga, M; Wong, AJ; Park, M			A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; LINKED AGAMMAGLOBULINEMIA XLA; C-MET RECEPTOR; PLASMA-MEMBRANE; HIGH-AFFINITY; PHOSPHOINOSITIDE BINDING; SIGNALING MOLECULES; BILAYER-MEMBRANES	Stimulation of the hepatocyte growth factor receptor tyrosine kinase, Met, induces the inherent morphogenic program of epithelial cells. The multisubstrate binding protein Gab1 (Grb2-associated binder-1) is the major phosphorylated protein in epithelial cells following activation of Met. Gab1 contains a pleckstrin homology domain and multiple tyrosine residues that act to couple Met with multiple signaling proteins. Met receptor mutants that are impaired in their association with Gab1 fail to induce a morphogenic program in epithelial cells, which is rescued by overexpression of Gab1. The Gab1 pleckstrin homology domain binds to, phosphatidylinositol 3,4,5-trisphosphate and contains conserved residues, shown from studies of other pleckstrin homology domains to be crucial for phospholipid binding. Mutation of conserved phospholipid binding residues tryptophan 26 and arginine 29, generates Gab1 proteins with decreased phosphatidylinositol 3,4,5-trisphosphate binding, decreased localization at sites of cell-cell contact, and reduced ability to rescue Met-dependent morphogenesis. We conclude that the ability of the Gab1 pleckstrin homology domain to bind phosphatidylinositol 3,4,5-trisphosphate is critical for subcellular localization of Gab1 and for efficient morphogenesis downstream from the Met receptor.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Med, Montreal, PQ H31 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Oncol, Montreal, PQ H31 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Biochem, Montreal, PQ H31 1A1, Canada; Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Kimmel Canc Inst, Dept Pharmacol, Philadelphia, PA 19107 USA	McGill University; McGill University; McGill University; Jefferson University; Jefferson University	Park, M (corresponding author), Royal Victoria Hosp, Mol Oncol Grp, 687 Pine Ave W,Rm H5-10, Montreal, PQ H3A 1A1, Canada.	morag@lan1.molonc.mcgill.ca			NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS 34514] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BELLACOSA A, 1993, ONCOGENE, V8, P745; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Faletto D L, 1993, EXS, V65, P107; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Mattsson PT, 1996, BIOESSAYS, V18, P825, DOI 10.1002/bies.950181009; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SORIANO JV, 1995, J CELL SCI, V108, P413; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YANG XM, 1995, LAB INVEST, V73, P483; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	77	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31719	31726		10.1074/jbc.274.44.31719	http://dx.doi.org/10.1074/jbc.274.44.31719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531383	hybrid			2022-12-25	WOS:000083379400087
J	Wettreich, A; Sebollela, A; Carvalho, MA; Azevedo, SP; Borojevic, R; Ferreira, ST; Coelho-Sampaio, T				Wettreich, A; Sebollela, A; Carvalho, MA; Azevedo, SP; Borojevic, R; Ferreira, ST; Coelho-Sampaio, T			Acidic pH modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARIN-LIKE MOLECULES; HIGH-AFFINITY RECEPTOR; BASIC FIBROBLAST; EXTRACELLULAR-MATRIX; INTERFERON-GAMMA; BINDING DOMAIN; GM-CSF; SULFATE; CELLS	Granulocyte-macrophage colony-stimulating factor (GM-CSF) controls growth and differentiation of hematopoietic cells. Previous reports have indicated that the mitogenic activity of GM-CSF may be modulated by the glycosidic moiety of proteoglycans associated with the membrane of stromal cells. In this work, we have performed in vitro studies of the interaction between GM-CSF and glycosaminoglycans. The addition of heparin promoted a marked blue shift in the fluorescence emission spectrum of GM-CSF as well as a 30-fold increase in the intensity of light scattering, which indicates formation of large molecular weight complexes between the two molecules. Interestingly, heparin-induced changes in the spectral properties of GM-CSF were only observed at acidic pH. The dependence on acidic pH, together with a strict dependence on glycosaminoglycan sulfation and the fact that high ionic strength destabilized the interaction, indicates that the association between GM-CSF and glycosaminoglycans is mediated by electrostatic interactions. These interactions probably involve sulfate groups in the glycosaminoglycans and positively charged histidine residues in GM-CSF. We propose that negatively charged glycolipids present on the plasma membrane of the hematopoietic and/or the stromal cell could promote an acidic microenvironment capable of triggering interaction between GM-CSF and membrane-bound proteoglycans in vivo.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Histol & Embriol, Hosp Univ Clementino Fraga Filho, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, PABCAM, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Coelho-Sampaio, T (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.		Carvalho, Marcelo/T-2014-2019; Borojevic, Radovan/V-8500-2019; Sebollela, Adriano/O-4385-2014; Ferreira, Sergio/AAZ-1576-2020; Carvalho, Marcelo A/J-7144-2012	Borojevic, Radovan/0000-0002-2393-7280; Sebollela, Adriano/0000-0002-7444-9156; Ferreira, Sergio/0000-0001-7160-9866; Carvalho, Marcelo A/0000-0002-7053-0053				ALLEN TD, 1990, COLONY STIMULATING F; AlvarezSilva M, 1996, J LEUKOCYTE BIOL, V59, P435, DOI 10.1002/jlb.59.3.435; ALVAREZSILVA M, 1993, J CELL SCI, V104, P477; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BOHLEN P, 1985, FEBS LETT, V185, P177, DOI 10.1016/0014-5793(85)80765-1; BREMER EG, 1982, BIOCHEM BIOPH RES CO, V106, P711, DOI 10.1016/0006-291X(82)91769-7; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; Cantor C.R., 1980, BIOPHYSICAL CHEM 2, P838; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DECRISTAN G, 1990, J CELL PHYSIOL, V144, P505; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; GALLAGHER JT, 1988, EXPT HAEMATOLOGY TOD, P36; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; Gupta P, 1996, BLOOD, V87, P3229, DOI 10.1182/blood.V87.8.3229.bloodjournal8783229; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEHNINGER AL, 1968, P NATL ACAD SCI USA, V60, P1069, DOI 10.1073/pnas.60.4.1069; LI LY, 1994, GROWTH FACTORS, V11, P1, DOI 10.3109/08977199409015046; Lipscombe RJ, 1998, J LEUKOCYTE BIOL, V63, P342, DOI 10.1002/jlb.63.3.342; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; METCALF D, 1986, BLOOD, V67, P257; Meuillet E, 1996, GLIA, V17, P206, DOI 10.1002/(SICI)1098-1136(199607)17:3<206::AID-GLIA3>3.0.CO;2-Z; Modrowski D, 1998, J CELL PHYSIOL, V177, P187, DOI 10.1002/(SICI)1097-4652(199810)177:1<187::AID-JCP19>3.0.CO;2-A; MUTHER H, 1994, GROWTH FACTORS, V10, P17, DOI 10.3109/08977199409019600; NAGASAWA K, 1980, METHODS CARBOHYDR CH, V8, P287; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NARHI LO, 1991, J PROTEIN CHEM, V10, P359, DOI 10.1007/BF01025250; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PINEDALUCENA A, 1994, EUR J BIOCHEM, V222, P425, DOI 10.1111/j.1432-1033.1994.tb18881.x; Rietveld AWM, 1998, BIOCHEMISTRY-US, V37, P933, DOI 10.1021/bi9721593; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; Rourke AM, 1996, BIOCHEMISTRY-US, V35, P11913, DOI 10.1021/bi960491t; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; Valente-Mesquita VL, 1998, BIOPHYS J, V75, P471, DOI 10.1016/S0006-3495(98)77535-6; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; WANG HM, 1991, BIOCHEM J, V278, P689, DOI 10.1042/bj2780689; WINGFIELD P, 1988, EUR J BIOCHEM, V173, P65, DOI 10.1111/j.1432-1033.1988.tb13967.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	51	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31468	31475		10.1074/jbc.274.44.31468	http://dx.doi.org/10.1074/jbc.274.44.31468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531349	hybrid			2022-12-25	WOS:000083379400053
J	Ding, M; Shi, XL; Dong, ZG; Chen, F; Lu, YJ; Castranova, V; Vallyathan, V				Ding, M; Shi, XL; Dong, ZG; Chen, F; Lu, YJ; Castranova, V; Vallyathan, V			Freshly fractured crystalline silica induces activator protein-1 activation through ERKs and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FREE-RADICALS; INDUCED TRANSFORMATION; AP-1 TRANSACTIVATION; POTENTIAL ROLE; KINASE KINASE; GROWTH-FACTOR; LUNG INJURY; JB6 CELLS; C-JUN	The transcription factor activator protein-1 (AP-1) reportedly plays an important role in the induction of neoplastic transformation and multiple genes involved in cell proliferation, differentiation, and inflammation. To investigate the mechanisms of silica-induced carcinogenesis, AP-1-luciferase reporter transgenic mice were used as an in vivo model, whereas the JB6 mouse epidermal cell line and a rat lung epithelial cell line were employed as in vitro models to study the effects of silica at the molecular level. Freshly fractured silica caused an 8-fold increase in AP-1 activity in JB6 cells and a 2.5-fold increase in rat lung epithelial cells. The induction of AP-1 activity in cultured cell lines was time- and dose-dependent. Intratracheal administration of silica was also able to induce AP-1 transactivation in transgenic mice. AP-1 activation was first observed at 2 days after silica administration and reached its maximum at 3 days post-exposure of the mice to silica. The signal transduction pathways for AP-1 activation were also investigated using these cell lines. The results demonstrate that freshly fractured silica stimulates mitogen-activated protein kinase (MAPK) family members, as determined by the phosphorylation of p38 MAPK and extracellular signal-regulated protein kinases (ERKs). Inhibition of ERKs with PD98059 or of p38 with SB203580 significantly inhibited silica-induced AP-1 activation. These findings demonstrate for the first time that freshly fractured silica induces AP-1 activation, which may be mediated through p38 MAPK and ERK pathways. Unraveling the complex mechanisms associated with these events may provide insights into the initiation and progression of silica-induced carcinogenesis.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of Minnesota System	Vallyathan, V (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Shi, Xianglin/B-8588-2012					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V68, P1; Barthelman M, 1998, CANCER RES, V58, P711; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Chen F, 1998, ANN CLIN LAB SCI, V28, P1; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAIGHEAD JE, 1980, JAMA-J AM MED ASSOC, V244, P1939, DOI 10.1001/jama.244.17.1939; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DALAL NS, 1990, J TOXICOL ENV HEALTH, V29, P307, DOI 10.1080/15287399009531393; DALAL NS, 1990, FREE RADICAL RES COM, V9, P259, DOI 10.3109/10715769009145684; DANIEL LN, 1993, FREE RADICAL BIO MED, V14, P463, DOI 10.1016/0891-5849(93)90103-2; Daniel LN, 1995, SCAND J WORK ENV HEA, V21, P22; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding M, 1999, CANCER RES, V59, P1884; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; *INT AG RES CANC, 1987, IARC MON EV CARC RIS, V42, P1; JOHNSON NF, 1987, AM J IND MED, V11, P93, DOI 10.1002/ajim.4700110110; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MUHLE H, 1989, AM J IND MED, V15, P343, DOI 10.1002/ajim.4700150309; Muhle H, 1995, SCAND J WORK ENV HEA, V21, P27; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; REISER KM, 1979, TOXICOLOGY, V13, P51, DOI 10.1016/S0300-483X(79)80010-4; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHI XG, 1988, J TOXICOL ENV HEALTH, V25, P237, DOI 10.1080/15287398809531205; SHI XL, 1994, ENVIRON HEALTH PERSP, V102, P149, DOI 10.2307/3432231; Shi XL, 1998, J TOXICOL ENV HEAL B, V1, P181, DOI 10.1080/10937409809524551; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; VALLYATHAN V, 1995, AM J RESP CRIT CARE, V152, P1003, DOI 10.1164/ajrccm.152.3.7663775; VALLYATHAN V, 1988, AM REV RESPIR DIS, V138, P1213, DOI 10.1164/ajrccm/138.5.1213; WEHNER AP, 1986, ENVIRON RES, V40, P499, DOI 10.1016/S0013-9351(86)80125-6; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; ZISKIND M, 1976, AM REV RESPIR DIS, V113, P643	49	86	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30611	30616		10.1074/jbc.274.43.30611	http://dx.doi.org/10.1074/jbc.274.43.30611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521445	hybrid			2022-12-25	WOS:000083276700041
J	Carr-Schmid, A; Durko, N; Cavallius, J; Merrick, WC; Kinzy, TG				Carr-Schmid, A; Durko, N; Cavallius, J; Merrick, WC; Kinzy, TG			Mutations in a GTP-binding motif of eukaryotic elongation factor 1A reduce both translational fidelity and the requirement for nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TU; SACCHAROMYCES-CEREVISIAE; FACTOR 1-ALPHA; GUANINE-NUCLEOTIDE; AMINO-ACID; AMINOGLYCOSIDE ANTIBIOTICS; PHENOTYPIC SUPPRESSION; GUANOSINE DIPHOSPHATE; ESCHERICHIA-COLI; MUTANTS	A series of mutations in the highly conserved N(153)KMD(156)GTP-binding motif of the Saccharomyces cerevisiae translation elongation factor 1A (eEF1A) affect the GTP-dependent functions of the protein and increase misincorporation of amino acids in vitro. Two critical regulatory processes of translation elongation, guanine nucleotide exchange and translational fidelity, were analyzed in strains with the N153T, D156N, and N153T/D156E mutations. These strains are omnipotent suppressors of nonsense mutations, indicating reduced A site fidelity, which correlates with changes either in total translation rates in vivo or in GTPase activity in vitro, All three mutant proteins also show an increase in the K-m for GTP. An in vivo system lacking the guanine nucleotide exchange factor eukaryotic elongation factor 1B alpha (eEF1B alpha) and supported for growth by excess eEF1A was used to show the two mutations with the highest K-m for GTP restore most but not all growth defects found in these eEF1Ba deficient-strains to near wild type. An increase in K-m alone, however, is not sufficient for suppression and may indicate eEF1B alpha performs additional functions. Additionally, eEF1A mutations that suppress the requirement for guanine nucleotide exchange may not effectively perform all the functions of eEF1A in vivo.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Case Western Reserve University	Kinzy, TG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.			Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57483, R01 GM057483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Carr-Schmid A, 1999, MOL CELL BIOL, V19, P5257; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; Cavallius J, 1998, J BIOL CHEM, V273, P28752, DOI 10.1074/jbc.273.44.28752; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Dinman JD, 1997, RNA, V3, P870; DONG HJ, 1995, J MOL BIOL, V248, P551, DOI 10.1006/jmbi.1995.0242; Edmonds BT, 1998, J BIOL CHEM, V273, P10288, DOI 10.1074/jbc.273.17.10288; Farabaugh PJ, 1998, RNA, V4, P38; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HIRAGA K, 1993, FEBS LETT, V316, P165, DOI 10.1016/0014-5793(93)81208-H; HWANG YW, 1987, J BIOL CHEM, V262, P13081; HWANG YW, 1989, J BIOL CHEM, V264, P8304; HWANG YW, 1992, J BIOL CHEM, V267, P22198; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINZY TG, 1995, GENETICS, V141, P481; KURLAND CG, 1990, RIBOSOME, P513; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MORIKAWA K, 1978, J MOL BIOL, V125, P325, DOI 10.1016/0022-2836(78)90406-0; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; SANDBAKEN MG, 1988, GENETICS, V120, P923; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; Sherman F., 1986, METHODS YEAST GENETI; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; STOFFEL M, 1993, HUM MOL GENET, V2, P1, DOI 10.1093/hmg/2.1.1; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1993, FEBS LETT, V330, P334, DOI 10.1016/0014-5793(93)80899-6; YAMADA M, 1989, J BIOL CHEM, V264, P19192	31	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30297	30302		10.1074/jbc.274.42.30297	http://dx.doi.org/10.1074/jbc.274.42.30297			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514524	hybrid			2022-12-25	WOS:000083176400103
J	Davare, MA; Dong, F; Rubin, CS; Hell, JW				Davare, MA; Dong, F; Rubin, CS; Hell, JW			The A-kinase anchor protein MAP2B and cAMP-dependent protein kinase are associated with class C L-type calcium channels in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; 2 SIZE FORMS; DIFFERENTIAL SUBCELLULAR-LOCALIZATION; DIFFERENT COOH-TERMINI; HIPPOCAMPAL-NEURONS; REGULATORY SUBUNIT; CA2+ CHANNELS; CATALYTIC SUBUNIT; ALPHA-1 SUBUNIT; RAT-BRAIN	Phosphorylation by cAMP-dependent protein kinase (PKA) increases the activity of class C L-type Ca2+ channels which are clustered at postsynaptic sites and are important regulators of neuronal functions. We investigated a possible mechanism that could ensure rapid and efficient phosphorylation of these channels by PKA upon stimulation of cAMP-mediated signaling pathways. A kinase anchor proteins (AKAPs) bind to the regulatory R subunits of PRA and target the holoenzyme to defined subcellular compartments and substrates. Class C channels isolated from rat brain extracts by immunoprecipitation contain an endogenous kinase that phosphorylates kemptide, a classic PRA substrate peptide, and also the main phosphorylation site for PRA in the pore-forming ru, subunit of the class C channel complex, serine 1928. The kinase activity is inhibited by the PHA inhibitory peptide PKI(5-24) and stimulated by cAMP. Physical association of the catalytic C subunit of PHA with the immunoisolated class C channel complex was confirmed by immunoblotting, A direct protein overlay binding assay performed with P-32-labeled RII beta revealed a prominent AKAP with an M-r of 280,000 in class C channel complexes. The protein was identified by immunoblotting as the microtubule-associated protein MAP2B, a well established AKAP. Class C channels did not contain tubulin and MAP2B association was not disrupted by dilution or addition of nocodazole, two treatments that cause dissociation of microtubules, In vitro experiments show that MAP2B can directly bind to the cu, subunit of the class C channel. Our findings indicate that PKA is an integral part of neuronal class C L-type Ca2+ channels and suggest that the AKAP MAP2B may mediate this interaction. Neither PKA nor MAP2B were detected in immunoprecipitates of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-type glutamate receptors or class B N-type Ca2+ channels. Accordingly, MAP2B docked at class C Ca2+ channels may be important for recruiting PHA to postsynaptic sites.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	University of Wisconsin System; University of Wisconsin Madison; Yeshiva University; Albert Einstein College of Medicine	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, 3770 MSC,1300 Univ Ave, Madison, WI 53706 USA.		Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22792] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BOLSHAKOV VY, 1994, SCIENCE, V264, P148; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CACERES A, 1984, J NEUROSCI, V4, P394; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Christie BR, 1997, J NEUROPHYSIOL, V77, P1651, DOI 10.1152/jn.1997.77.3.1651; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; GROSS RA, 1990, J PHYSIOL-LONDON, V429, P483, DOI 10.1113/jphysiol.1990.sp018268; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WEI XY, 1994, J BIOL CHEM, V269, P1635; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; YANG S, 1995, BIOCHEMISTRY-US, P6267	53	114	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30280	30287		10.1074/jbc.274.42.30280	http://dx.doi.org/10.1074/jbc.274.42.30280			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514522	hybrid			2022-12-25	WOS:000083176400101
J	Lindley, TE; Scheiderer, CL; Walsh, PJ; Wood, CM; Bergman, HL; Bergman, AL; Laurent, P; Wilson, P; Anderson, PM				Lindley, TE; Scheiderer, CL; Walsh, PJ; Wood, CM; Bergman, HL; Bergman, AL; Laurent, P; Wilson, P; Anderson, PM			Muscle as the primary site of urea cycle enzyme activity in an alkaline lake-adapted tilapia, Oreochromis alcalicus grahami	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; AIR-BREATHING TELEOST; ACETYL-L-GLUTAMATE; HETEROPNEUSTES-FOSSILIS; SQUALUS-ACANTHIAS; MESSENGER-RNA; SUBCELLULAR-LOCALIZATION; MICROPTERUS-SALMOIDES; BATRACHOIDID FISHES; MAGADI TILAPIA	The tilapia fish Oreochromis alcalicus grahami from Kenya has adapted to living in waters at pH 10.5 by excreting the end product of nitrogen metabolism as urea rather than as ammonia directly across the gills as occurs in most fish, The level of activity in liver of the first enzyme in the urea cycle pathway, carbamoyl-phosphate synthetase III (CPSase III), is too low to account for the observed high rates of urea excretion. We report here the surprising finding that CPSase III and all other urea cycle enzyme activities are present in muscle of this species at levels more than sufficient to account for the rate of urea excretion; in addition, the basic kinetic properties of the CPSase III appear to be different hom those of other known type III CPSases. The sequence of the CPSase III cDNA is reported as well as the finding that glutamine synthetase activity is present in liver but not in muscle. This unusual form of adaptation may have occurred because of the apparent impossibility of packaging the needed amount of urea cycle enzymes in liver.	Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; Univ Wyoming, Dept Zool & Physiol, Laramie, WY 82071 USA	University of Minnesota System; University of Minnesota Duluth; University of Miami; McMaster University; University of Wyoming	Anderson, PM (corresponding author), Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA.	panderso@d.umn.edu	Wood, Chris M/C-3021-2009	Wood, Chris M/0000-0002-9542-2219				Anderson PA, 1995, AAOS INSTR COURS LEC, V44, P57; ANDERSON PM, 1981, J BIOL CHEM, V256, P2228; ANDERSON PM, 1995, J EXP BIOL, V198, P755; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; Campbell J.W., 1991, Biochemistry and Molecular Biology of Fishes, V1, P43; CASEY CA, 1983, J BIOL CHEM, V258, P8723; CHAKRAVORTY J, 1989, BIOCHEM INT, V19, P519; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; DKHAR J, 1991, BIOCHEM INT, V25, P1061; Felskie AK, 1998, COMP BIOCHEM PHYS B, V119, P355, DOI 10.1016/S0305-0491(97)00361-1; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; Julsrud EA, 1998, ARCH BIOCHEM BIOPHYS, V350, P55, DOI 10.1006/abbi.1997.0511; Kong HY, 1998, ARCH BIOCHEM BIOPHYS, V350, P157, DOI 10.1006/abbi.1997.0522; Korte JJ, 1997, J BIOL CHEM, V272, P6270, DOI 10.1074/jbc.272.10.6270; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; RAIJMAN L, 1976, ARCH BIOCHEM BIOPHYS, V175, P270, DOI 10.1016/0003-9861(76)90508-7; RANDALL DJ, 1989, NATURE, V337, P165, DOI 10.1038/337165a0; RUBIO V, 1983, EUR J BIOCHEM, V134, P337, DOI 10.1111/j.1432-1033.1983.tb07572.x; Saha N, 1997, COMP BIOCHEM PHYS B, V116, P57, DOI 10.1016/S0305-0491(96)00193-9; SAHA N, 1987, J EXP ZOOL, V241, P137, DOI 10.1002/jez.1402410117; SHANKAR RA, 1985, ARCH BIOCHEM BIOPHYS, V239, P248, DOI 10.1016/0003-9861(85)90833-1; Walsh PJ, 1997, ANNU REV PHYSIOL, V59, P299, DOI 10.1146/annurev.physiol.59.1.299; Wood Chris M., 1993, P379; WOOD CM, 1994, J EXP BIOL, V189, P13; WOOD CM, 1989, RESP PHYSIOL, V77, P1, DOI 10.1016/0034-5687(89)90025-X; XIONG XF, 1989, ARCH BIOCHEM BIOPHYS, V270, P198, DOI 10.1016/0003-9861(89)90021-0	26	59	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29858	29861		10.1074/jbc.274.42.29858	http://dx.doi.org/10.1074/jbc.274.42.29858			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514466	hybrid			2022-12-25	WOS:000083176400045
J	Schinke, T; Karsenty, G				Schinke, T; Karsenty, G			Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSGENIC MICE; CYCLIC-AMP; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; SOMATOSTATIN GENE; IN-VIVO; PROTEINS; BONE; DIFFERENTIATION	To elucidate the mechanisms of osteoblast-specific gene expression we are studying the regulation of osteocalcin, the most osteoblast-specific gene. Previous studies of OG2, one of the two mouse osteocalcin genes, identified two osteoblast-specific cia-acting elements, OSE1 and OSE2, the latter being the binding site of Cbfa1, the only osteoblast-specific transcription factor known to date. Here we show that OSE1. is a cis-acting element as important as OSE2 for the osteoblast-specific expression of OG2 in cell culture and transgenic mice. We also show that OSE1 is present in the promoter of several osteoblast-specific genes including Cbfa1 itself. These biological features demonstrate the importance of OSE1 and led us to further characterize this site and the factor binding to it, provisionally termed Osf1, We first defined the core OSE1 sequence, 5'-TTACATCA-3', which is necessary and sufficient for Osf1 binding do DNA. This sequence has no strong homology to any known transcription factor-binding sites. As a first step in identifying Osf1, we performed an analytical purification of this protein using nuclear extracts from two different osteoblastic cell lines, We purified Osf1 to homogeneity through a five-step procedure including a renaturation experiment and found that its apparent molecular mass is 40 kDa, In conclusion, this study indicates the existence of multiple osteoblast-specific cia-acting elements of equal importance in controlling OG2 promoter activity and provides the first biochemical characterization of Osf1, a novel osteoblast-specific transcription factor.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43655] Funding Source: Medline; NIDCR NIH HHS [R01 DE11290] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARNOTT D, 1993, CLIN CHEM, V39, P2005; Aubin Jane E., 1996, P51; Ausubel FM, 1995, CURRENT PROTOCOL MOL; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; Chen JK, 1996, J BONE MINER RES, V11, P654; Clemens TL, 1997, J BONE MINER RES, V12, P1570, DOI 10.1359/jbmr.1997.12.10.1570; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Gorski JP, 1998, CURR OPIN CELL BIOL, V10, P586, DOI 10.1016/S0955-0674(98)80033-1; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KLEEREKOPER M, 1998, METABOLIC BONE DIS, P387; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONTECINO M, 1994, BIOCHEMISTRY-US, V33, P348, DOI 10.1021/bi00167a045; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; POLIARD A, 1993, J CELL SCI, V106, P503; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Rowe D.W., 1998, METABOLIC BONE DIS C, V3, P651, DOI [10.1016/B978-012068700-8/50024-4, DOI 10.1016/B978-012068700-8/50024-4]; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	46	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30182	30189		10.1074/jbc.274.42.30182	http://dx.doi.org/10.1074/jbc.274.42.30182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514508	hybrid			2022-12-25	WOS:000083176400087
J	Hoeflich, KP; Yeh, WC; Yao, ZB; Mak, TW; Woodgett, JR				Hoeflich, KP; Yeh, WC; Yao, ZB; Mak, TW; Woodgett, JR			Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1)	ONCOGENE			English	Article						SAPK/JNK; protein kinase; protein phosphorylation; dominant negative; signal transduction; apoptosis; tumor necrosis factor	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GERMINAL CENTER KINASE; C-JUN; CELL-DEATH; NH2-TERMINAL KINASE; TERMINAL KINASE; MEK KINASE-1; FAMILY; PHOSPHORYLATION	Tumor necrosis factor-alpha (TNF), a major inflammatory cytokine, generates a wide variety of cellular responses via key cytoplasmic adaptor molecules named TNF receptor-associated factors (TRAFs). We report that TRAF2, TRAF5 and TRAF6 associate with apoptosis signal-regulating kinase 1 (ASK1), and a catalytically-inactive ASK1 mutant blocks stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) activation by these TRAFs, A truncated derivative of TRAF2, which inhibits SAPK activation by TNF, blocks TNF-induced ASK1 activation. Furthermore, protection from TNF-induced cell death conferred by an ASK1 mutant is dependent upon TRAF2. Hence, ASK1 is a common mediator of TRAF-regulated SAPK and apoptosis signaling, and the TRAF2-ASK1 connection completes the signaling cascade from TNF to SAPK/JNK activation.	Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Boulder, CO 80301 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Woodgett, JR (corresponding author), Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ADLER V, 1992, J BIOL CHEM, V267, P17001; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gruss HJ, 1996, INT J CLIN LAB RES, V26, P143, DOI 10.1007/BF02592977; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kiefer F, 1997, BIOCHEM SOC T, V25, P491, DOI 10.1042/bst0250491; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; YAN MH, 1994, NATURE, V372, P798; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	46	92	99	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5814	5820		10.1038/sj.onc.1202975	http://dx.doi.org/10.1038/sj.onc.1202975			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523862				2022-12-25	WOS:000083095100010
J	Blander, G; Kipnis, J; Leal, JFM; Yu, CE; Schellenberg, GD; Oren, M				Blander, G; Kipnis, J; Leal, JFM; Yu, CE; Schellenberg, GD; Oren, M			Physical and functional interaction between p53 and the Werner's syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; DNA HELICASE ACTIVITY; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; SPONTANEOUS IMMORTALIZATION; TUMOR SUPPRESSION; CELL SENESCENCE; MUTANT P53; FIBROBLASTS; EXPRESSION	Werner's syndrome is a human autosomal recessive disorder leading to premature aging. The mutations responsible for this disorder have recently been localized to a gene (WRN) encoding a protein that possesses DNA helicase and exonuclease activities. Patients carrying WRN gene mutations exhibit an elevated rate of cancer, accompanied by increased genomic instability. The latter features are also characteristic of the loss of function of p53, a tumor suppressor that is very frequently inactivated in human cancer. Moreover, changes in the activity of p53 have been implicated in the onset of cellular replicative senescence. We report here that the WRN protein can form a specific physical interaction with p53. This interaction involves the carboxyl-terminal part of WRN and the extreme carboxyl terminus of p53, a region that plays an important role in regulating the functional state of p53. A small fraction of WRN can be found in complex with endogenous p53 in nontransfected cells. Overexpression of WRN leads to augmented p53-dependent transcriptional activity and induction of p21(Waf1) protein expression. These findings support the existence of a cross-talk between WRN and p53, which may be important for maintaining genomic integrity and for preventing the accumulation of aberrations that can give rise to premature senescence and cancer.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Weizmann Institute of Science; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	lioren@wiccmail.weizmann.ac.il	Kipnis, Jonathan/AGG-9735-2022; Leal, Juan F Martinez/N-6328-2013	Kipnis, Jonathan/0000-0002-3714-517X; Leal, Juan F Martinez/0000-0002-7538-0875; Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R01 CA40099] Funding Source: Medline; NIA NIH HHS [AG120192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; BLOM T, 1992, EUR J IMMUNOL, V22, P2025, DOI 10.1002/eji.1830220811; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Martin GM, 1997, MOL MED, V3, P356, DOI 10.1007/BF03401682; Matuoka K, 1998, BBA-MOL CELL RES, V1401, P211, DOI 10.1016/S0167-4889(97)00133-X; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITSUDOMI T, 1992, ONCOGENE, V7, P171; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith JR, 1997, AGING-CLIN EXP RES, V9, P437; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	67	140	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29463	29469		10.1074/jbc.274.41.29463	http://dx.doi.org/10.1074/jbc.274.41.29463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506209	hybrid			2022-12-25	WOS:000083017800088
J	Ravid, T; Avner, R; Polak-Charcon, S; Faust, JR; Roitelman, J				Ravid, T; Avner, R; Polak-Charcon, S; Faust, JR; Roitelman, J			Impaired regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation in lovastatin-resistant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; LOW-DENSITY-LIPOPROTEIN; MEVALONATE-DERIVED PRODUCT; LEUCINE ZIPPER PROTEIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; MEMBRANE DOMAIN; RAT-LIVER; COMPETITIVE INHIBITOR	L-90 cells were selected to grow in the presence of serum lipoproteins and 90 mu M lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR). L-90 cells massively accumulate HMGR, a result of > 10-fold amplification of the gene and 40-fold rise in mRNA, and also overexpress other enzymes of the mevalonate pathway. Western blot and promoter-luciferase analyses indicate that transcriptional regulation of sterol-responsive genes by 25-hydroxycholesterol or mevalonate is normal. Yet, none of these genes is regulated by lipoproteins, a result of severe impairment in the low density lipoprotein receptor pathway. Moreover, L-90 cells do not accelerate the degradation of HMGR or transfected HMGal chimera in response to 25-hydroxycholesterol or mevalonate. This aberrant phenotype persists when cells are grown without lovastatin for up to 37 days. The inability to regulate HMGR degradation is not due to its overproduction since in LP-90 cells, which were selected for lovastatin resistance in lipoprotein-deficient serum, HMGR is overexpressed, yet its turnover is regulated normally. Also, the rapid degradation of transfected cu subunit of T cell receptor is markedly retarded in L-90 cells. These results show that in addition to gene amplification and overexpression of cholesterogenic enzymes, statin resistance can follow loss of regulated HMGR degradation.	Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Pathol, IL-52621 Tel Hashomer, Israel; Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tufts University	Roitelman, J (corresponding author), Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel.				NIDDK NIH HHS [P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BISHOP RW, 1992, J LIPID RES, V33, P549; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHOI JW, 1995, BIOCHEM J, V307, P233, DOI 10.1042/bj3070233; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; ENDO A, 1992, J LIPID RES, V33, P1569; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GAYEN AK, 1995, ARCH BIOCHEM BIOPHYS, V322, P475, DOI 10.1006/abbi.1995.1491; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; Hampton R, 1996, TRENDS BIOCHEM SCI, V21, P140, DOI 10.1016/S0968-0004(96)80168-X; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HASUMI K, 1987, EUR J BIOCHEM, V164, P547, DOI 10.1111/j.1432-1033.1987.tb11161.x; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LAM WL, 1992, J BIOL CHEM, V267, P5829; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1995, SOMAT CELL MOLEC GEN, V21, P189, DOI 10.1007/BF02254770; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; RYAN J, 1981, J BIOL CHEM, V256, P6762; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SINENSKY M, 1985, FEBS LETT, V186, P219, DOI 10.1016/0014-5793(85)80712-2; SINENSKY M, 1983, J BIOL CHEM, V258, P8547; SIPERSTEIN MD, 1966, J BIOL CHEM, V241, P602; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; YU H, 1997, J BIOL CHEM, V272, P2080	64	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29341	29351		10.1074/jbc.274.41.29341	http://dx.doi.org/10.1074/jbc.274.41.29341			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506194	hybrid			2022-12-25	WOS:000083017800073
J	Snapp, EL; Landfear, SM				Snapp, EL; Landfear, SM			Characterization of a targeting motif for a flagellar membrane protein in Leishmania enriettii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; GLUCOSE TRANSPORTERS; GENE; EXPRESSION; MOTILITY; POCKET; DOMAIN; LOCALIZATION; EVOLUTION; ISOFORMS	The surface membranes of eukaryotic flagella and cilia are contiguous with the plasma membrane. Despite the absence of obvious physical structures that could form a barrier between the two membrane domains, the lipid and protein compositions of flagella and cilia are distinct from the rest of the cell surface membrane. We have exploited a flagellar glucose transporter from the parasitic protozoan Leishmania enriettii as a model system to characterize the first targeting motif for a flagellar membrane protein in any eukaryotic organism. In this study, we demonstrate that the flagellar membrane-targeting motif is recognized by several species of Leishmania. Previously, we demonstrated that the 130 amino acid NH2-terminal cytoplasmic domain of isoform 1 glucose transporter was sufficient to target a nonflagellar integral membrane protein into the flagellar membrane. We have now determined that an essential flagellar targeting signal is located between amino acids 20 and 35 of the NH2-terminal domain. We have further analyzed the role of specific amino acids in this region by alanine replacement mutagenesis and determined that single amino acid substitutions did not abrogate targeting to the flagellar membrane. However, individual mutations located within a cluster of five contiguous amino acids, RTGTT, conferred differences in the degree of targeting to the flagellar membrane and the flagellar pocket, implying a role for these residues in the mechanism of flagellar trafficking.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Landfear, SM (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Snapp, Erik Lee/H-7152-2019	Snapp, Erik Lee/0000-0001-9482-2272; Landfear, Scott/0000-0002-1643-6664	NIAID NIH HHS [AI01162, AI25920] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BLOODGOOD RA, 1992, BIOL CELL, V76, P291, DOI 10.1016/0248-4900(92)90431-Y; CAIRNS BR, 1989, P NATL ACAD SCI USA, V85, P2130; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Colbert HA, 1997, J NEUROSCI, V17, P8259; Cosson J, 1996, CELL BIOL INT, V20, P83, DOI 10.1006/cbir.1996.0012; Croan DG, 1997, MOL BIOCHEM PARASIT, V89, P149, DOI 10.1016/S0166-6851(97)00111-4; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; ENGMAN DM, 1989, J BIOL CHEM, V264, P18627; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KANESHIRO ES, 1989, CILIARY FLAGELLAR ME, P241; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; Lindemann CB, 1997, INT REV CYTOL, V173, P1; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; Shinohara H, 1998, EUR J NEUROSCI, V10, P699, DOI 10.1046/j.1460-9568.1998.00088.x; Snapp EL, 1997, J CELL BIOL, V139, P1775, DOI 10.1083/jcb.139.7.1775; STACK SP, 1990, MOL CELL BIOL, V10, P6785, DOI 10.1128/MCB.10.12.6785; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WU YM, 1994, BIOCHEM J, V304, P833, DOI 10.1042/bj3040833	36	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29543	29548		10.1074/jbc.274.41.29543	http://dx.doi.org/10.1074/jbc.274.41.29543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506220	hybrid			2022-12-25	WOS:000083017800099
J	Brown, CY; Mize, GJ; Pineda, M; George, DL; Morris, DR				Brown, CY; Mize, GJ; Pineda, M; George, DL; Morris, DR			Role of two upstream open reading frames in the translational control of oncogene mdm2	ONCOGENE			English	Article						translation; oncogene; polysomes; messenger RNA; neoplasms	WILD-TYPE P53; DECARBOXYLASE MESSENGER-RNA; SOFT-TISSUE SARCOMAS; HUMAN TUMOR-CELLS; ENHANCED TRANSLATION; PROTEIN; AMPLIFICATION; GENE; OVEREXPRESSION; SUPPRESSION	Overexpression of oncoprotein MDM2 has been found in a significant number of human soft tissue tumors. In a subset of these tumors, overexpression is a result of enhanced translation of mdm2 mRNA, There are two transcripts from the mdm2 gene that differ only in their 5' leaders: a long form (L-mdm2) and a short form (S-mdm2) that arise from the use of different promoters. L-mdm2 mRNA contains two upstream open reading frames (uORFs) and this mRNA was loaded with ribosomes inefficiently in comparison with S-mdm2, The 5' leader of L-mdm2 was sufficient to transfer translational repression to a reporter gene and the two uORFs acted synergistically to achieve full suppression. In contrast, the 5' leader of S-mdm2 allowed efficient translation of an attached reporter gene in the tumor cells. These results are consistent with a model in which overexpression of MDM2 in certain tumors results from a change in mRNA structure due to a switch in promoter usage.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Washington; University of Washington Seattle; University of Pennsylvania	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011		NCI NIH HHS [CA66741, CA39053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066741, R01CA039053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BUTZ K, 1995, ONCOGENE, V10, P927; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CORDONCARDO C, 1994, CANCER RES, V54, P794; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JUVEN T, 1993, ONCOGENE, V8, P341; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS DR, 1997, MRNA METABOLISM POST, P165; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ruan H, 1997, MRNA FORMATION FUNCT, P305, DOI 10.1016/B978-012587545-5/50017-; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	33	94	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5631	5637		10.1038/sj.onc.1202949	http://dx.doi.org/10.1038/sj.onc.1202949			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523842				2022-12-25	WOS:000083016500003
J	Hede, SE; Amstrup, J; Christoffersen, BC; Novak, I				Hede, SE; Amstrup, J; Christoffersen, BC; Novak, I			Purinoceptors evoke different electrophysiological responses in pancreatic ducts - P2Y inhibits K+ conductance, and P2X stimulates cation conductance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SUBMANDIBULAR-GLAND; PAROTID ACINAR-CELLS; EXTRACELLULAR-ATP; INTRACELLULAR CALCIUM; NUCLEOTIDE RECEPTOR; MEMBRANE VOLTAGE; EPITHELIAL-CELLS; FUNCTIONAL EXPRESSION; PURINERGIC RECEPTORS; TRANSPORT-SYSTEMS	In epithelia, extracellular nucleotides are often associated with regulation of ion transporters, especially Cl- channels. In this study, we investigated which purinoceptors are present in native pancreatic ducts and how they regulate ion transport. We applied whole-cell patch-clamp recordings, intracellular Ca2+ and pH measurements, and reverse transcription-polymerase chain reaction (RT-PCR) analysis. The data show two types of purinoceptors and cellular responses. UTP and ATP produced large Ca2+ transients, a decrease in intracellular pH, 8-10-mV depolarization of the membrane voltage, and a decrease in the whole-cell conductance. The membrane effects were due to closure of K+ channels, as confirmed by dependence on extracellular K+. UTP/ATP effects could be associated with P2Y(2) purinoceptors, and RT-PCR revealed mRNAs for P2Y(2) and P2Y(4) receptors. On the other hand, 2',3'-O-4-benzoylbenzoyl-ATP induced Ca2+ influx and similar to 20-mV depolarization of the membrane voltage with a concomitant increase in the whole-cell conductance. These effects were depend ent on extracellular Na+, not Cl-, indicating opening of cation channels associated with P2X(7) purinoceptors. RT-PCR showed mRNAs for P2X(7) and P2X(4) receptors. In microperfused ducts, luminal (but not basolateral) ATP caused large depolarizations of membrane voltages recorded with microelectrodes, consistent with luminal localization of P2X(7) receptors. Thus, P2Y(2) (and possibly P2Y(4)) purinoceptors inhibit K+ channels and may not support secretion in native duets. P2X(7) (and possibly P2X(4)) receptors are associated with cation channels and may contribute to regulation of secretion.	Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	University of Copenhagen	Novak, I (corresponding author), Univ Copenhagen, August Krogh Inst, Univ Pk 13, DK-2100 Copenhagen O, Denmark.	inovak@aki.ku.dk	Novak, Ivana/M-2791-2014	Novak, Ivana/0000-0002-8917-8010				Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; Amsallem H, 1996, AM J PHYSIOL-CELL PH, V271, pC1546, DOI 10.1152/ajpcell.1996.271.5.C1546; BLEICH M, 1990, PFLUG ARCH EUR J PHY, V415, P449, DOI 10.1007/BF00373623; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; Cheung CY, 1998, BIOL SIGNAL RECEPT, V7, P321; Christoffersen BC, 1998, PFLUG ARCH EUR J PHY, V436, P33, DOI 10.1007/s004240050601; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Filippov AK, 1998, J NEUROSCI, V18, P5170, DOI 10.1523/JNEUROSCI.18-14-05170.1998; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; GRAY MA, 1990, J MEMBRANE BIOL, V115, P203, DOI 10.1007/BF01868636; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GROMADA J, 1995, PFLUG ARCH EUR J PHY, V429, P578, DOI 10.1007/BF00704164; HUG H, 1994, PFLUG ARCH EUR J PHY, V426, P412, DOI 10.1007/BF00388304; Hug MJ, 1996, PFLUG ARCH EUR J PHY, V432, P278, DOI 10.1007/s004240050134; HURLEY TW, 1993, AM J PHYSIOL, V265, pC1472, DOI 10.1152/ajpcell.1993.265.6.C1472; Inoue CN, 1997, AM J PHYSIOL-CELL PH, V272, pC1862, DOI 10.1152/ajpcell.1997.272.6.C1862; JORGENSEN TD, 1995, BIOCHEM J, V312, P457, DOI 10.1042/bj3120457; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V269, pF355, DOI 10.1152/ajprenal.1995.269.3.F355; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V268, pF211, DOI 10.1152/ajprenal.1995.268.2.F211; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Marcus DC, 1997, AM J PHYSIOL-CELL PH, V273, pC2022, DOI 10.1152/ajpcell.1997.273.6.C2022; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Metioui M, 1996, J CELL PHYSIOL, V168, P462, DOI 10.1002/(SICI)1097-4652(199608)168:2<462::AID-JCP25>3.0.CO;2-3; Montserrat C, 1996, FEBS LETT, V393, P264, DOI 10.1016/0014-5793(96)00900-3; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG104, DOI 10.1152/ajpgi.1998.275.1.G104; NOVAK I, 1993, PFLUG ARCH EUR J PHY, V425, P272, DOI 10.1007/BF00374178; NOVAK I, 1988, PFLUG ARCH EUR J PHY, V411, P58, DOI 10.1007/BF00581647; NOVAK I, 1991, PFLUG ARCH EUR J PHY, V419, P76, DOI 10.1007/BF00373750; NOVAK I, 1988, PFLUG ARCH EUR J PHY, V411, P546, DOI 10.1007/BF00582376; Novak I, 1998, GASTROENTEROLOGY, V115, P714, DOI 10.1016/S0016-5085(98)70151-9; Novak I, 1997, COMP BIOCHEM PHYS A, V118, P409, DOI 10.1016/S0300-9629(96)00331-3; NOVAK I, 1995, CELL PHYSIOL BIOCHEM, V5, P344, DOI 10.1159/000154770; NOVAK I, 1993, PFLUEGERS ARCH EUR J, V422, pR71; NOVAK I, 1988, PH HOMEOSTATIS MECHA, P447; OGDEN DC, 1994, MICROELECTRODE TECHN, P63; PAHL C, 1993, PFLUG ARCH EUR J PHY, V424, P315, DOI 10.1007/BF00384358; Park MK, 1997, AM J PHYSIOL-CELL PH, V272, pC1388, DOI 10.1152/ajpcell.1997.272.4.C1388; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Ralevic V, 1998, PHARMACOL REV, V50, P413; SASAKI T, 1990, FEBS LETT, V264, P130, DOI 10.1016/0014-5793(90)80782-E; SOLTOFF SP, 1990, J GEN PHYSIOL, V95, P319, DOI 10.1085/jgp.95.2.319; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; VINCENT P, 1992, J PHYSIOL-LONDON, V449, P313, DOI 10.1113/jphysiol.1992.sp019088; Wang CZ, 1996, BIOCHEM BIOPH RES CO, V220, P196, DOI 10.1006/bbrc.1996.0380; WARTH R, 1993, CELL PHYSIOL BIOCHEM, V3, P2, DOI 10.1159/000154663; Wu WL, 1998, BIOCHEM BIOPH RES CO, V248, P728, DOI 10.1006/bbrc.1998.9051; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956	61	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31784	31791		10.1074/jbc.274.45.31784	http://dx.doi.org/10.1074/jbc.274.45.31784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542200	hybrid			2022-12-25	WOS:000083532100008
J	Segrest, JP; Jones, MK; Klon, AE; Sheldahl, CJ; Hellinger, M; De Loof, H; Harvey, SC				Segrest, JP; Jones, MK; Klon, AE; Sheldahl, CJ; Hellinger, M; De Loof, H; Harvey, SC			A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEINS; AMPHIPATHIC HELIX; CONFORMATION; PEPTIDES; DOMAINS	Apolipoprotein A-I (apoA-I) is the principal protein of high density lipoprotein particles (HDL). ApoA-I contains a globular N-terminal domain (residues 1-43) and a lipid-binding C-terminal domain (residues 44-243), Here we propose a detailed model for the smallest discoidal HDL, consisting of two apoA-I molecules wrapped beltwise around a small patch of bilayer containing 160 lipid molecules. The C-terminal domain of each monomer is ringlike, a curved, planar amphipathic alpha helix with an average of 3.67 residues per turn, and with the hydrophobic surface curved toward the lipids. We have explored all possible geometries for forming the dimer of stacked rings, subject to the hypothesis that the optimal geometry will maximize intermolecular salt bridge interactions. The resulting model is an antiparallel arrangement with an alignment matching that of the (nonplanar) crystal structure of lipid-free apoA-I.	Univ Alabama, Med Ctr, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Med Ctr, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; Univ Alabama, Med Ctr, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Segrest, JP (corresponding author), Univ Alabama, Med Ctr, Dept Med, Birmingham, AL 35294 USA.		De Loof, Hans WY/B-8504-2008; De Loof, Hans/K-5774-2019	De Loof, Hans WY/0000-0003-4488-551X; De Loof, Hans/0000-0003-4488-551X	NHLBI NIH HHS [P01 HL-34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson D, 1980, Ann N Y Acad Sci, V348, P284, DOI 10.1111/j.1749-6632.1980.tb21308.x; BLUNDELL T, 1983, NATURE, V306, P281, DOI 10.1038/306281a0; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; FITCH WM, 1977, GENETICS, V86, P623; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONES MK, 1992, J LIPID RES, V33, P287; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; TALL AR, 1977, J BIOL CHEM, V252, P4701; WALD JH, 1990, J BIOL CHEM, V265, P20044; WLODAWER A, 1979, FEBS LETT, V104, P231, DOI 10.1016/0014-5793(79)80821-2; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042	24	298	321	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31755	31758		10.1074/jbc.274.45.31755	http://dx.doi.org/10.1074/jbc.274.45.31755			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542194	hybrid			2022-12-25	WOS:000083532100002
J	Mathisen, PM; Johnson, JM; Kawczak, JA; Tuohy, VK				Mathisen, PM; Johnson, JM; Kawczak, JA; Tuohy, VK			Visinin-like protein (VILIP) is a neuron-specific calcium-dependent double-stranded RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; KINASE; LOCALIZATION; DOMAIN; IDENTIFICATION; RECOGNITION; INTERFERON; RECOVERIN; MEMBRANE; SEQUENCE	Double-stranded RNA-binding proteins function in regulating the stability, translation, and localization of specific mRNAs. In this study, we have demonstrated that the neuron-specific, calcium-binding protein, visinin-like protein (VILIP) contains one double-stranded RNA-binding domain, a protein motif conserved among many double-stranded RNA-binding proteins. We showed that VILIP can specifically bind double-stranded RNA, and this interaction specifically requires the presence of calcium. Mobility shift studies indicated that VILIP binds double-stranded RNA as a single protein-RNA complex with an apparent equilibrium dissociation constant of 9.0 x 10(-6) M. To our knowledge, VILIP is the first double-stranded RNA-binding protein shown to be calcium-dependent. Furthermore, VILIP specifically binds the 3'-untranslated region of the neurotrophin receptor, trkB, an mRNA localized to hippocampal dendrites in an activity-dependent manner. Given that VILIP is also expressed in the hippocampus, these data suggest that VILIP may employ a novel, calcium-dependent mechanism to regulate its binding to important localized mRNAs in the central nervous system.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Mathisen, PM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, NB-30,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36054] Funding Source: Medline; CSR NIH HHS [RG2768] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CSR NIH HHS		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Boekhoff I, 1997, EUR J CELL BIOL, V72, P151; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAREY J, 1991, METHOD ENZYMOL, V208, P103; COX JA, 1994, J BIOL CHEM, V269, P32807; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794; Gao FB, 1998, BIOESSAYS, V20, P70, DOI 10.1002/(SICI)1521-1878(199801)20:1<70::AID-BIES10>3.0.CO;2-5; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Harada K, 1996, NATURE, V380, P175, DOI 10.1038/380175a0; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Johnson WC, 1997, BBA-PROTEIN STRUCT M, V1342, P164, DOI 10.1016/S0167-4838(97)00091-5; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; Laird-Offringa IA, 1998, NAT STRUCT BIOL, V5, P665, DOI 10.1038/1356; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Lenz SE, 1996, BIOCHEM BIOPH RES CO, V225, P1078, DOI 10.1006/bbrc.1996.1298; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NADURI S, 1998, EMBO J, V17, P5458; PATEL RC, 1992, J BIOL CHEM, V267, P7671; SAITOH S, 1995, NEUROSCI RES, V23, P383, DOI 10.1016/0168-0102(95)00968-Y; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEITZ TA, 1997, RNA WORLD, P219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	34	25	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31571	31576		10.1074/jbc.274.44.31571	http://dx.doi.org/10.1074/jbc.274.44.31571			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531361	hybrid			2022-12-25	WOS:000083379400065
J	Kim, T; Kim, TY; Song, YH; Min, IM; Yim, J; Kim, TK				Kim, T; Kim, TY; Song, YH; Min, IM; Yim, J; Kim, TK			Activation of interferon regulatory factor 3 in response to DNA-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-1; BOX-BINDING-PROTEIN; GENE-EXPRESSION; NUCLEAR TRANSLOCATION; BETA ENHANCEOSOME; VIRUS-INFECTION; MDR1 GENE; IN-VITRO; P53; INDUCTION	Genotoxic stress triggers signal transduction pathways that mediate either the protection or apoptosis of affected cells. The interferon regulatory factors (IRFs) are involved in a wide range of host defense mechanisms against environmental stresses. Treatment with DNA-damaging agents, including doxorubicin and UV radiation, caused phosphorylation of the IRF3 transcription factor. Phosphorylation of IRF3 induced its interaction with the transcriptional co-activator cAMP-response element binding protein-binding protein. Furthermore, genotoxic stress-induced phosphorylation of IRF3 resulted in its movement from the cytoplasm to the nucleus, where it activated transcription from its binding site. These observations suggest that IRF3 plays a role in the defensive responses induced by genotoxic stress.	Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA	Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea.		Min, Irene/AAQ-4186-2021	Min, Irene/0000-0002-1057-4804				Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bauerle PA, 1996, CELL, V87, P13; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARLOW H, 1988, ANTIBODIES LAB MANNU; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ohga T, 1996, CANCER RES, V56, P4224; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WOLFFE AP, 1992, NEW BIOL, V4, P290; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	45	81	84	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30686	30689		10.1074/jbc.274.43.30686	http://dx.doi.org/10.1074/jbc.274.43.30686			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521456	hybrid			2022-12-25	WOS:000083276700052
J	Rubinfeld, H; Hanoch, T; Seger, R				Rubinfeld, H; Hanoch, T; Seger, R			Identification of a cytoplasmic-retention sequence in ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; NUCLEAR EXPORT SIGNAL; MAP KINASE; PC12 CELLS; CASCADE; TRANSLOCATION; LOCALIZATION	A key step in the signaling mechanism of the mitogen-activated protein kinase/extracellular signal-responsive kinase (ERK) cascade is its translocation into the nucleus where it regulates transcription and other nuclear processes. In an attempt to characterize the subcellular localization of ERK2, we fused it to the S'-end of the gene expressing green fluorescent protein (GFP), resulting in a GFP-ERK2 protein. The expression of this construct in ;CHO cells resulted in a nuclear localization of the GFP-ERK2 protein. However, coexpression of the GFP-ERK2 with its upstream activator, MEK1, resulted in a cytosolic retention of the GFP-ERK2, which was the result of its association with MEK1, and was reversed upon stimulation. We then examined the role of the C-terminal region of ERK2 in its subcellular localization. Substitution of residues 312-319 of GFP-ERK2 to alanine residues prevented the cytosolic retention of ERK2 as well as its association with MEK1, without affecting its activity. Most important for the cytosolic retention are three acidic amino acids at positions 316, 319, and 320 of ERK2. Substitution of residues 321-327 to alanines impaired the nuclear translocation of ERK2 upon mitogenic stimulation. Thus, we conclude that residues 312-320 of ERK2 are responsible for its cytosolic retention, and residues 321-327 play a role in the mechanism of ERK2 nuclear translocation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.							Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	22	114	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30349	30352		10.1074/jbc.274.43.30349	http://dx.doi.org/10.1074/jbc.274.43.30349			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521408	hybrid			2022-12-25	WOS:000083276700004
J	Galbiati, F; Volonte, D; Engelman, JA; Scherer, PE; Lisanti, MP				Galbiati, F; Volonte, D; Engelman, JA; Scherer, PE; Lisanti, MP			Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts - Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; HUMAN BREAST-CANCER; ROUS-SARCOMA VIRUS; MUSCULAR-DYSTROPHY; INTEGRAL COMPONENT; TRANSPORT VESICLES; MEMBRANE DOMAINS; PLASMA-MEMBRANE; SMOOTH-MUSCLE; GENE FAMILY	Caveolin-8 is the principal structural protein of caveolae membrane domains in striated muscle cells. Caveolin-3 mRNA and protein expression are dramatically induced during the differentiation of C2C12 skeletal myoblasts, coincident with myoblast fusion. In these myotubes, caveolin-3 localizes to the sarcolemma (muscle cell plasma membrane), where it associates with the dystrophin-glycoprotein complex. However, it remains unknown what role caveolin-3 plays in myoblast differentiation and myotube formation. Here, we employ an antisense approach to derive stable C2C12 myoblasts that fail to express the caveolin-3 protein. We show that C2C12 cells harboring caveolin-3 antisense undergo differentiation and express normal amounts of four muscle-specific marker proteins. However, C2C12 cells harboring caveolin-3 antisense fail to undergo myoblast fusion and, therefore, do not form myotubes, Interestingly, treatment with specific p38 mitogen-activated protein kinase inhibitors blocks both myotube formation and caveolin-3 expression, but does not affect the expression of other muscle-specific proteins. In addition, we find that three human rhabdomyosarcoma cell lines do not express caveolin-3 and fail to undergo myoblast fusion, Taken together, these results support the idea that caveolin-3 expression is required fear myoblast fusion and myotube formation, and suggest that p38 is an upstream regulator of caveolin-3 expression.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382				BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BONILLA E, 1981, AM J PATHOL, V104, P167; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	34	117	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30315	30321		10.1074/jbc.274.42.30315	http://dx.doi.org/10.1074/jbc.274.42.30315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514527	hybrid			2022-12-25	WOS:000083176400106
J	Murakami, M; Kambe, T; Shimbara, S; Yamamoto, S; Kuwata, H; Kudo, I				Murakami, M; Kambe, T; Shimbara, S; Yamamoto, S; Kuwata, H; Kudo, I			Functional association of type IIA secretory phospholipase A, with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; A(2) TYPE-II; MAST-CELLS; SUBCELLULAR-LOCALIZATION; PROSTAGLANDIN SYNTHESIS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ENDOTHELIAL-CELLS	An emerging body of evidence suggests that type IIA secretory phospholipase A(2) (sPLA(2)-IIA) participates in the amplification of the stimulus-induced cyclooxygenase (COX)-2-dependent delayed prostaglandin (PG)-biosynthetic response in several cell types. However, the biological importance of the ability of sPLA(2)-IIA to bind to heparan sulfate proteoglycan (HSPG) on cell surfaces has remained controversial. Here we show that glypican, a glycosylphosphatidylinositol (GPI)-anchored HSPG, acts as a physical and functional adaptor for sPLA(2)-IIA. sPLA(2)-IIA-dependent PGE(2) generation by interleukin-1-stimulated cells was markedly attenuated by treatment of the cells with heparin, heparinase or GPI-specific phospholipase C, which solubilized the cell surface-associated sPLA(2)-IIA. Overexpression of glypican-1 increased the association of sPLA(2)-IIA with the cell membrane, and glypican-1 was coimmunoprecipitated by the antibody against sPLA(2)-IIA Glypican-1 overexpression led to marked augmentation of sPLA(2)-IIA-mediated arachidonic acid release, PGE(2) generation, and COX-2 induction in interleukin-1-stimulated cells, particularly when the sPLA(2)-IIA expression level was suboptimal. Immunofluorescent microscopic analyses of cytokine-stimulated cells revealed that sPLA(2)-IIA was present in the caveolae, a microdomain in which GPI-anchored proteins reside, and also appeared in the perinuclear area in proximity to COX-2. We therefore propose that a GPI-anchored HSPG glypican facilitates the trafficking of sPLA(2)-IIA into particular subcellular compartments, and arachidonic acid thus released from the compartments may link efficiently to the downstream COX-2-mediated PG biosynthesis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.	kudo@pharm.showa-u.ac.jp	Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777				AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Fayard JM, 1998, J CELL SCI, V111, P985; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; Koumanov KS, 1998, BIOCHEM J, V336, P625, DOI 10.1042/bj3360625; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; MURAKAMI M, 1999, IN PRESS J BIOL CHEM, V274; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Oishi T, 1996, FEBS LETT, V394, P55, DOI 10.1016/0014-5793(96)00929-5; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Polgar J, 1997, BIOCHEM J, V327, P259, DOI 10.1042/bj3270259; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SAWADA H, 1999, IN PRESS EUR J BIOCH; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Surette ME, 1998, BIOCHEM J, V330, P915; Tada K, 1998, J IMMUNOL, V161, P5008; Takasaki J, 1998, FEBS LETT, V440, P377, DOI 10.1016/S0014-5793(98)01490-2; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	76	153	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29927	29936		10.1074/jbc.274.42.29927	http://dx.doi.org/10.1074/jbc.274.42.29927			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514475	hybrid			2022-12-25	WOS:000083176400054
J	Sacristan, MP; de Diego, JG; Bonilla, M; Martin-Zanca, D				Sacristan, MP; de Diego, JG; Bonilla, M; Martin-Zanca, D			Molecular cloning and characterization of the 5 ' region of the mouse trkA proto-oncogene	ONCOGENE			English	Article						trkA; proto-oncogene; promoter; NGF receptor; CpG island; IRR	RECEPTOR-RELATED RECEPTOR; NERVE GROWTH-FACTOR; IN-SITU HYBRIDIZATION; TYROSINE KINASE; EXPRESSION; CELLS; GENE; NEURONS; NEUROTROPHINS; TRANSCRIPTION	The trkA proto-oncogene encodes a high-affinity NGF receptor that is essential for the survival, differentiation and maintenance of many neural and non-neural cell types. Altered expression of the trkA gene or trkA receptor malfunction have been implicated in neurodegeneration, tumor progression and oncogenesis. We have cloned and characterized the 5' region of the mouse trkA gene and have identified its promoter, trkA promoter sequences are GC-rich, lack genuine TATA or CAAT boxes, and are contained within a CpG island which extends over the entire first coding exon, The mouse trkA transcription start site is located 70/71 bp upstream to the AUG translation initiation codon, Sequence analysis showed that the gene encoding the insulin receptor-related receptor, IRR, is located just 1.6 kbp upstream to the trkA gene and is transcribed in the opposite direction, We have used trkA-CAT transcriptional fusions to study trkA promoter function in transient transfection experiments. RNase protection assays and CAT protein ELISA analyses showed that a 150 bp long DNA segment, immediately upstream to the start site, is sufficient to direct accurate transcription in trkA-expressing cells, Dissection of this fragment allowed us to identify a 13 bp cis-regulatory element essential for both promoter activity and cell-type specific expression, Deletion of this 13 bp segment as well as modification of its sequence by site-directed mutagenesis led to a dramatic decline in promoter activity, Gel mobility shift assays carried out with double-stranded oligonucleotides containing the 13 bp element revealed several specific DIVA-protein complexes when nuclear extracts from trkA-expressing cells were used. Supershift experiments showed that the Sp1 transcription factor was a component of one of these complexes, Our results identify a minimal trkA gene promoter, located very close to the transcription start site, and define a 13 bp enhancer within this promoter sequence.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Salamanca	Martin-Zanca, D (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Avda Campo Charro S-N, Salamanca 37007, Spain.		Sacristan, Maria/Y-4923-2019; Sacristán, María P/A-9587-2016	Sacristan, Maria/0000-0003-2314-8430; Sacristán, María P/0000-0003-2314-8430				AUSUBEL FM, 1995, CURR PROTO MOL BIOL; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boissiere F, 1997, EXP NEUROL, V145, P245, DOI 10.1006/exnr.1997.6443; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; Fagan AM, 1996, J NEUROSCI, V16, P6208; Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.0.CO;2-1; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; Mayerhofer A, 1996, ENDOCRINOLOGY, V137, P5662, DOI 10.1210/en.137.12.5662; Miralles F, 1998, J ENDOCRINOL, V156, P431, DOI 10.1677/joe.0.1560431; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Parks CL, 1996, J BIOL CHEM, V271, P4417; REINHARDT RR, 1994, J NEUROSCI, V14, P4674; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Tsuji N, 1996, MOL BRAIN RES, V41, P250, DOI 10.1016/0169-328X(96)00102-7; Valent A, 1997, EUR J HUM GENET, V5, P102, DOI 10.1159/000484742; Wheeler EF, 1998, J COMP NEUROL, V391, P407; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496	32	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5836	5842		10.1038/sj.onc.1202963	http://dx.doi.org/10.1038/sj.onc.1202963			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523865				2022-12-25	WOS:000083095100013
J	Zorbas, M; Sicurella, C; Bertoncello, I; Venter, D; Ellis, S; Mucenski, ML; Ramsay, RG				Zorbas, M; Sicurella, C; Bertoncello, I; Venter, D; Ellis, S; Mucenski, ML; Ramsay, RG			c-Myb is critical for murine colon development	ONCOGENE			English	Article						c-Myb; epithelium; gut; gene knockout; apoptosis	BCL-2 EXPRESSION; FORCED EXPRESSION; DOWN-REGULATION; CELL-DEATH; GASTROINTESTINAL-TRACT; INTESTINAL EPITHELIUM; POLYCYSTIC KIDNEY; MICE LACKING; BETA-CATENIN; APOPTOSIS	The mammalian colon develops from a simple tube of undifferentiated cells into a complex, highly ordered organ,,vith a continuously self-renewing epithelial layer, We have previously described c-Myb expression in the epithelia of murine and human colon crypts and documented increased expression in colorectal adenocarcinoma cells. To investigate the role of c-Myb in colonic epithelium development, we have used embryos with a disrupted c-myb gene, Prior to the in utero death of these embryos at E15, we excised colon tissue and transplanted it under the kidney capsule of recipient mice to allow further development and cyto-differentiation. Compared to the colons of wildtype and heterozygous littermates, the c-myb homozygous knockout colon is highly irregular with a disordered epithelium and abnormal crypts, In addition, the expression of Bcl-2, a known target of c-Myb, is reduced and apoptosis is increased, indicating a critical requirement for c-Myb in normal colon development.	Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia; Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Peter Maccallum Cancer Center; Cincinnati Children's Hospital Medical Center	Ramsay, RG (corresponding author), Peter MacCallum Canc Inst, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.		Ramsay, Robert G/C-3291-2015; Bertoncello, Ivan/B-9235-2008	Ramsay, Robert G/0000-0001-5003-0433; Ellis, Sarah/0000-0002-5772-6051				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BEDI A, 1995, CANCER RES, V55, P1811; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GABRIEL A, 1992, ANAT REC, V234, P281, DOI 10.1002/ar.1092340214; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL PA, 1994, J CELL SCI, V107, P3569; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IWANAGA T, 1995, ARCH HISTOL CYTOL, V58, P151, DOI 10.1679/aohc.58.151; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; KAMADA S, 1995, CANCER RES, V55, P354; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MCMAHON J, 1988, ONCOGENE, V3, P717; MELANI C, 1991, CANCER RES, V51, P2897; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NOVACK DV, 1994, AM J PATHOL, V145, P61; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Resnik E, 1997, NAT GENET, V16, P9, DOI 10.1038/ng0597-9; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1998, CANCER RES, V58, P5168; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9	46	50	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5821	5830		10.1038/sj.onc.1202971	http://dx.doi.org/10.1038/sj.onc.1202971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523863				2022-12-25	WOS:000083095100011
J	Lim, S; Naisbitt, S; Yoon, J; Hwang, JI; Suh, PG; Sheng, M; Kim, E				Lim, S; Naisbitt, S; Yoon, J; Hwang, JI; Suh, PG; Sheng, M; Kim, E			Characterization of the Shank family of synaptic proteins - Multiple genes, alternative splicing, and differential expression in brain and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; TUMOR-SUPPRESSOR PROTEIN; NITRIC-OXIDE SYNTHASE; POSTSYNAPTIC DENSITY; NMDA RECEPTOR; INTERACTING PROTEIN; ALPHA-DYSTROGLYCAN; BINDING PROTEIN; PSD-95 FAMILY; PDZ DOMAIN	Shank1, Shank2, and Shank3 constitute a family of proteins that may function as molecular scaffolds in the postsynaptic density (PSD). Shank directly interacts with GKAP and Homer, thus potentially bridging the N-methyl-D-aspartate receptor-PSD-95-GKAP complex and the mGluR-Homer complex in synapses (Naisbitt, S., Kim, E., Tu, J. C., Xiao, B., Sala, S., Valtschanoff, J., Weinberg, R J., morley, P. F., and Sheng, M. (1999) Neuron 23, 569-582; Tu, J. C., Xiao, B., Naisbitt, S., Yuan, J. P., Petralia, R. S., Brakeman, P., Dean, A., Aakalu, V. K., Lanahan, A. A., Sheng, M., and Worley, P. F. (1999) Neuron 23, 583-592). Shank contains multiple domains for protein-protein interaction including ankyrin repeats, an SH3 domain, a PSD-95/DIg/ZO-1 domain, a sterile a motif domain, and a proline-rich region. By characterizing Shank cDNA clones and RT-PCR products, we found that there are four sites far alternative splicing in Shank1 and another four sites in Shank2, some of which result in deletion of specific domains of the Shank protein. In addition, the expression of the splice variants is differentially regulated in different regions of rat brain during development. Immunoblot analysis of Shank proteins in rat brain using five different Shank antibodies reveals marked heterogeneity in size (120-240 kDa) and differential. spatiotemporal expression. Shank1 immunoreactivity is concentrated at excitatory synaptic sites in adult brain, and the punctate staining of Shank1 is seen in developing rat brains as early as postnatal day 7. These results suggest that alternative splicing in the Shank family may be a mechanism that regulates the molecular structure of Shank and the spectrum of Shank-interacting proteins in the PSDs of adult and developing brain.	Pusan Natl Univ, Dept Pharmacol, Pusan 609735, South Korea; Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Pusan National University; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Pohang University of Science & Technology (POSTECH)	Kim, E (corresponding author), Pusan Natl Univ, Dept Pharmacol, Pusan 609735, South Korea.		Suh, Pann-Ghill/F-3610-2010; Kim, Eunjoon/C-1566-2011	Hwang, Jong-Ik/0000-0002-0729-1782	NINDS NIH HHS [NS35050] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035050] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alagarsamy S, 1999, NAT NEUROSCI, V2, P234, DOI 10.1038/6338; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Schultz J, 1997, PROTEIN SCI, V6, P249; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Watanabe M, 1998, EUR J NEUROSCI, V10, P478, DOI 10.1046/j.1460-9568.1998.00063.x; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	51	211	219	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29510	29518		10.1074/jbc.274.41.29510	http://dx.doi.org/10.1074/jbc.274.41.29510			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506216	hybrid			2022-12-25	WOS:000083017800095
J	Rangaraj, P; Ryle, MJ; Lanzilotta, WN; Goodwin, PJ; Dean, DR; Shah, VK; Ludden, PW				Rangaraj, P; Ryle, MJ; Lanzilotta, WN; Goodwin, PJ; Dean, DR; Shah, VK; Ludden, PW			Inhibition of iron-molybdenum cofactor biosynthesis by L127 Delta NifH and evidence for a complex formation between L127 Delta NifH and NifNE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE REDUCTION PROPERTIES; IN-VITRO SYNTHESIS; APO-MOFE PROTEIN; AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; SIGNAL-TRANSDUCTION; INVITRO SYNTHESIS; ELECTRON-TRANSFER; GENE-PRODUCT; NITROGENASE	Besides serving as the obligate electron donor to dinitrogenase during nitrogenase turnover, dinitrogenase reductase (NifH) is required for the biosynthesis of the iron-molybdenum cofactor (FeMo-co) and for the maturation of alpha(2)beta(2) apo-dinitrogenase (apo-dinitrogenase maturation). In an attempt to understand the role of NifH in FeMo-co biosynthesis, a site-specific altered form of NifH in which leucine at position 127 has been deleted, L127 Delta, was employed in in vitro FeMo-co synthesis assays, This altered form of NifH has been shown to inhibit substrate reduction by the wild-type nitrogenase complex, forming a tight protein complex with dinitrogenase. The L127 Delta NifH was found to inhibit in vitro FeMo-co synthesis by wild-type NifH as detected by the gamma gel shift assay, Increasing the concentration of NifNE and NifB-cofactor (NifB-co) relieved the inhibition of FeMo-co synthesis by L127 Delta NifH. The formation of a complex of L127 Delta NifH with NifNE was investigated by gel filtration chromatography, We herein report the formation of a complex between L127 Delta NifH and NifNE in the presence of NifB-co, This work presents evidence for one of the possible roles for NifH in FeMo-co biosynthesis, Le. the interaction of NifH with a NifNE.NifB-co complex.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Ctr Study Nitrogen Fixat, Madison, WI 53706 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Virginia Tech, Fralin Biotechnol Ctr, Dept Biochem, Blacksburg, VA 24061 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; Utah State University; Virginia Polytechnic Institute & State University	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NIGMS NIH HHS [GM 35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; Chatterjee R, 1997, J BIOL CHEM, V272, P21604, DOI 10.1074/jbc.272.34.21604; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; Fortune WB, 1938, IND ENG CHEM, V10, P0060, DOI 10.1021/ac50118a004; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SMITH PK, 1985, ANAL BIOCHEM, V150, P175; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	41	14	15	6	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29413	29419		10.1074/jbc.274.41.29413	http://dx.doi.org/10.1074/jbc.274.41.29413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506203	hybrid			2022-12-25	WOS:000083017800082
J	Kabil, O; Banerjee, R				Kabil, O; Banerjee, R			Deletion of the regulatory domain in the pyridoxal phosphate-dependent heme protein cystathionine beta-synthase alleviates the defect observed in a catalytic site mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOCYSTEINE; METABOLISM; DISEASE	The most common cause of severely elevated homocysteine or homocystinuria is inherited disorders in cystathionine beta-synthase. The latter enzyme is a unique hemeprotein that catalyzes pyridoxal phosphate (PLP)dependent condensation of serine and homocysteine to give cystathionine, thus committing homocysteine to catabolism. A point mutation, V168M,has been described in a homocystinuric cell line and is associated with a B-6-responsive phenotype. In this study, we have examined the kinetic properties of this mutant and demonstrate that the mutation affects the PLP but not the heme content. The similar to 13-fold diminution in activity because of the mutation corresponds to an similar to 7-fold decrease in the level of bound PLP. This may be explained by half of the sites activity associated with cystathionine beta-synthase. The addition of PLP results in partial but not full restoration of activity to wild type levels. Elimination of the C-terminal quarter of the mutant protein results in alleviation of the catalytic penalty imposed by the V168M mutation. The resulting truncated protein is very similar to the corresponding truncated enzyme with wild type sequence and is now able to bind the full complement of both heme and PLP cofactors. These results indicate that the V168M mutation per se does not affect binding of PLP directly and that interactions between the regulatory C terminus and the catalytic N terminus are important in modulating the co-factor content and therefore the activity of the full-length enzyme. These studies provide the first biochemical explanation for the B-6-responsive phenotype associated with a cystathionine beta-synthase-impaired homocystinuric genotype.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Kabil, Omer/AAJ-1435-2020		NHLBI NIH HHS [HL58984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; KERY V, 1994, J BIOL CHEM, V269, P25283; KRAUS JP, 1994, J INHERIT METAB DIS, V17, P383, DOI 10.1007/BF00711354; KRAUS JP, 1996, 3 WORKSH METH MET, P12; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MUDD SH, 1995, METABOLIC MOL BASIS; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; TAOKA S, 1999, IN PRESS BIOCHEMISTR, V38	19	19	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31256	31260		10.1074/jbc.274.44.31256	http://dx.doi.org/10.1074/jbc.274.44.31256			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531322	hybrid			2022-12-25	WOS:000083379400026
J	Qu, BH; Karas, M; Koval, A; LeRoith, D				Qu, BH; Karas, M; Koval, A; LeRoith, D			Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE PROTEIN; TYROSINE KINASE; IRS-1; DOMAIN; TRANSFORMATION; TRANSLOCATION; ACTIVATION; ADIPOCYTES	The insulin receptor substrates (IRSs)-1-4 play important roles in signal transduction emanating from the insulin and insulin-like growth factor (IGF)-I receptors. IRS-4 is the most recently characterized member, which has been found primarily in human cells and tissues. It interacts with SH2-containing proteins such ars phosphatidylinositol 3'-kinase (PI3K), Grb2, Crk-II, and CrkL. In this study, we transfected IRS-4 in mouse NIH-3T3 cells that overexpress IGF-I receptors. Clones expressing IRS-4 showed enhanced cellular proliferation when cells were cultured in 1% fetal bovine serum without added IGF-I. Addition of IGF-I enhanced cellular proliferation in cells overexpressing the IGF-I receptor alone but had an even greater proliferative effect in cells overexpressing both the IGF-I receptors and IRS-4. When etoposide and methylmethane sulfonate (MMS), both DNA damaging agents, were added to the cells, they uniformly induced cell cycle arrest. Fluorescence-activated cell sorter analysis demonstrated that the arrest of the cell cycle occurred at the G(1) checkpoint, and furthermore no significant degree of apoptosis was demonstrated with the use of either agent. In cells, overexpressing IGF-I receptors alone, IG;F-I addition enhanced cellular proliferation, even in the presence of etoposide and MMS. In cells overexpressing IGF-I receptors and IRS-4, the effect of IGF-I in overcoming the cell cycle arrest was even more pronounced. These results suggest that IRS-4 is implicated in the IGF-I receptor mitogenic signaling pathway.	NIDDK, Clin Endocrinol Branch, NIH, Sect Mol & Cellular Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Clin Endocrinol Branch, NIH, Sect Mol & Cellular Physiol, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.							BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 1999, ENDOCRINOLOGY, V140, P1329, DOI 10.1210/en.140.3.1329; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Ito T, 1996, MOL CELL BIOL, V16, P943; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Kuo ML, 1997, MOL CARCINOGEN, V18, P221, DOI 10.1002/(SICI)1098-2744(199704)18:4<221::AID-MC6>3.0.CO;2-G; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; UCHIDA T, 1999, AM DIAB ASS 59 SCI S, pA331; Valverde AM, 1998, MOL ENDOCRINOL, V12, P688, DOI 10.1210/me.12.5.688; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505	29	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31179	31184		10.1074/jbc.274.44.31179	http://dx.doi.org/10.1074/jbc.274.44.31179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531310	hybrid			2022-12-25	WOS:000083379400014
J	Carter, AB; Knudtson, KL; Monick, MM; Hunninghake, GW				Carter, AB; Knudtson, KL; Monick, MM; Hunninghake, GW			The p38 mitogen-activated protein kinase is required for NF-kappa B-dependent gene expression - The role of TATA-binding protein (TBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR-IIB; RNA-POLYMERASE-II; FACTOR-ALPHA GENE; INFLAMMATORY CYTOKINES; BASAL TRANSCRIPTION; IN-VITRO; PHOSPHORYLATION; LIPOPOLYSACCHARIDE; INTERLEUKIN-6	Endotoxin-induced cytokine gene transcription in monocytes and macrophages is regulated in part by NF-kappa B. We have previously shown that the p38 mitogen-activated protein (MAP) kinase is necessary for endotoxin-induced cytokine gene transcription. Due to the fact that most cytokine promoter sequences have active NF-kappa B sites, we hypothesized that the p38 MAP kinase was necessary for NF-kappa B-dependent gene expression. We found that NF-kappa B-dependent gene expression was reduced to near control levels with either SB 203580 or a dominant-negative p38 MAP kinase expression vector. Inhibition of the p38 MAP kinase did not alter NF-kappa B activation at any level, but it significantly reduced the DNA binding of TATA-binding protein (TBP) to the TATA box, The dominant-negative p38 MAP kinase expression vector interfered with the direct interaction of native TFIID (TBP) with a co-transfected p65 fusion protein. Likewise, this dominant-negative plasmid also interfered with the direct interaction of a co-transfected TBP fusion protein with the native p65 subunit. The p38 kinase also phosphorylated TFIID (TBP) in vitro, and SB 203580 inhibited phosphorylation of TFIID (TBP) in vivo. Thus, the p38 MAP kinase regulates NF-kappa B-dependent gene transcription, in part, by modulating activation of TFIID (TBP).	Univ Iowa, Coll Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Carter, AB (corresponding author), Univ Iowa Hosp & Clin, Div Pulm & Crit Care Med, C33 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL03860, HL60316] Funding Source: Medline; NIAID NIH HHS [AI35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Monick MM, 1999, J IMMUNOL, V162, P3005; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nick JA, 1996, J IMMUNOL, V156, P4867; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	45	404	416	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30858	30863		10.1074/jbc.274.43.30858	http://dx.doi.org/10.1074/jbc.274.43.30858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521478	hybrid			2022-12-25	WOS:000083276700074
J	Gaudry, CA; Verderio, E; Aeschlimann, D; Cox, A; Smith, C; Griffin, M				Gaudry, CA; Verderio, E; Aeschlimann, D; Cox, A; Smith, C; Griffin, M			Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; CROSS-LINKING ENZYMES; EXTRACELLULAR-MATRIX; 3T3 FIBROBLASTS; PROTEIN; EXPRESSION; ADHESION; COMPLEXES; DIFFERENTIATION; OSTEONECTIN	Increasing evidence indicates that tissue transglutaminase (tTG) plays a role in the assembly and remodeling of extracellular matrices and promotes cell adhesion. Using an inducible system we have previously shown that tTG associates with the extracellular matrix deposited by stably transfected 3T3 fibroblasts overexpressing the enzyme. We now show by confocal microscopy that tTG colocalizes with pericellular fibronectin in these cells, and by immunogold electron microscopy that the two proteins are found in clusters at the cell surface, Expression vectors encoding the full-length tTG or a N-terminal truncated tTG lacking the proposed fibronectin-binding site (fused to the bacterial reporter enzyme beta-galactosidase) were generated to characterize the role of fibronectin in sequestration of tTG; in the pericellular matrix. Enzyme-linked immunosorbent assay style procedures using extracts of transiently transfected COS-7 cells and immobilized fibronectin showed that the truncation abolished fibronectin binding. Similarly, the association of tTG with the pericellular matrix of cells in suspension or with the extracellular matrix deposited by cell monolayers was prevented by the truncation. These results demonstrate that tTG binds to the pericellular fibronectin coat of cells via its N-terminal beta-sandwich domain and that this interaction is crucial for cell surface association of tTG.	Nottingham Trent Univ, Dept Life Sci, Nottingham NG11 8NS, England; Univ Wisconsin, Div Orthoped Surg, Madison, WI 53792 USA; Unilever Res, Bedford, England	Nottingham Trent University; University of Wisconsin System; University of Wisconsin Madison; Unilever	Griffin, M (corresponding author), Nottingham Trent Univ, Dept Life Sci, Clifton Lane, Nottingham NG11 8NS, England.		Verderio, Elisabetta/H-2789-2016	Verderio, Elisabetta/0000-0001-9153-8997; Aeschlimann, Daniel/0000-0003-0930-7706; Griffin, Martin/0000-0003-3824-306X				ACHYUTHAN KE, 1995, J IMMUNOL METHODS, V180, P69, DOI 10.1016/0022-1759(94)00300-L; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FESUS L, 1986, EUR J BIOCHEM, V154, P371, DOI 10.1111/j.1432-1033.1986.tb09407.x; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HARSFALVI J, 1987, BIOCHIM BIOPHYS ACTA, V923, P42, DOI 10.1016/0304-4165(87)90123-1; HOHENADL C, 1995, J BIOL CHEM, V270, P23415, DOI 10.1074/jbc.270.40.23415; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IKURA K, 1990, EUR J BIOCHEM, V187, P705, DOI 10.1111/j.1432-1033.1990.tb15357.x; IKURA K, 1989, BIOCHEMISTRY-US, V28, P2344, DOI 10.1021/bi00431a054; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Johnson TS, 1997, J CLIN INVEST, V99, P2950, DOI 10.1172/JCI119490; JOHNSON TS, 1999, IN PRESS J AM SOC NE; Jones RA, 1997, J CELL SCI, V110, P2461; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; LEMOSY EK, 1992, J BIOL CHEM, V267, P7880; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; RISINGER MA, 1992, J BIOL CHEM, V267, P5680; Schittny JC, 1997, AM J RESP CELL MOL, V17, P334, DOI 10.1165/ajrcmb.17.3.2737; SHREIBER V, 1994, GENE AMST, V150, P411; SLIFE CW, 1987, ARCH BIOCHEM BIOPHYS, V257, P39, DOI 10.1016/0003-9861(87)90540-6; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TYRRELL DJ, 1988, J BIOL CHEM, V263, P8464; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284	50	121	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30707	30714		10.1074/jbc.274.43.30707	http://dx.doi.org/10.1074/jbc.274.43.30707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521459	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000083276700055
J	Shumway, SD; Maki, M; Miyamoto, S				Shumway, SD; Maki, M; Miyamoto, S			The PEST domain of I kappa B alpha is necessary and sufficient for in vitro degradation by mu-calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; CASEIN KINASE-II; CONSTITUTIVE PHOSPHORYLATION; UBIQUITIN-LIGASE; ANKYRIN REPEATS; DNA-BINDING; C-REL; PROTEOLYSIS; ACTIVATION; SEQUENCES	Polypeptide sequences enriched in proline (P), glutamate (E), serine (S), and threonine (T), dubbed PEST domains, are proposed to expedite the degradation of proteins. The proteolysis of one PEST-containing protein, I kappa B alpha, is prerequisite to the activation of the transcription factor NF-kappa B, Two mechanisms of I kappa B alpha degradation in vivo have been described, one well characterized through the ubiquitin-proteasome pathway, and another less characterized through calpain. In this report, a mutational analysis was done to identify any regions of I kappa B alpha that facilitate its recognition and proteolysis by calpain in, vitro. These studies revealed that the PEST sequence of I kappa B alpha is critical for its calpain-dependent degradation. Furthermore, the I kappa B alpha-PEST domain binds to the calmodulin-like domain of the large subunit of mu-calpain (mu CaMLD). Transfer of the I kappa B alpha-PEST domain to a protein incapable of either binding to or being degraded by mu-calpain allowed for the interaction of the chimeric protein with mu CaMLD and resulted in its susceptibility to calpain proteolysis. Moreover, the mu CaMLD of calpain acts as a competitive inhibitor of calpain-dependent I kappa B alpha degradation. Our data demonstrate that the I kappa B alpha-PEST sequence acts as a modular domain to promote the physical association with and subsequent degradation by mu-calpain and suggest a functional role for PEST sequences in other proteins as potential calpain-targeting units.	Univ Wisconsin, Sch Med, Dept Pharmacol, Clin Sci Ctr K4 554, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Program Cellular & Mol Biol, Madison, WI 53792 USA; Nagoya Univ, Sch Bioagr Sci, Lab Mol & Cellular Regulat, Chikusa Ku, Nagoya, Aichi 4648601, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Nagoya University	Miyamoto, S (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Clin Sci Ctr K4 554, 600 Highland Ave, Madison, WI 53792 USA.		Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491	NCI NIH HHS [R01CA81065] Funding Source: Medline; NIGMS NIH HHS [T32GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki T, 1996, ONCOGENE, V12, P1159; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BAUERLE PA, 1988, SCIENCE, V242, P540; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V342, P383, DOI 10.1006/abbi.1997.0132; Chen Z, 1995, GENE DEV, P1586; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HUNTER T, 1980, COLD SPRING HARB SYM, V44, P931, DOI 10.1101/SQB.1980.044.01.100; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Mykles DL, 1998, INT REV CYTOL, V184, P157, DOI 10.1016/S0074-7696(08)62181-6; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; NIXON PJ, 1995, J BIOL CHEM, V270, P14919, DOI 10.1074/jbc.270.25.14919; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JL, 1998, AM J PHYSIOL-LUNG C, V275, pL461, DOI 10.1152/ajplung.1998.275.3.L461	56	161	166	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30874	30881		10.1074/jbc.274.43.30874	http://dx.doi.org/10.1074/jbc.274.43.30874			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521480	hybrid			2022-12-25	WOS:000083276700076
J	Hiroyama, R; Takenawa, T				Hiroyama, R; Takenawa, T			Isolation of a cDNA encoding human lysophosphatidic acid phosphatase that is involved in the regulation of mitochondrial lipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; RAT-LIVER MITOCHONDRIA; PROTEIN-KINASE-C; INSITU HYBRIDIZATION; CONTACT SITES; IDENTIFICATION; MEMBRANES; CELLS; PHOSPHOLIPIDS; PURIFICATION	In this study, we isolated cDNA encoding lysophosphatidic acid (LPA) phosphatase (LPAP). The amino acid sequence deduced from the cDNA encoding I;PAP had 421 residues including a putative signal peptide and was homologous to acid phosphatase, especially at the active site. Human LPAP had 28.5% amino acid identity to human prostatic acid phosphatase. Northern blot analysis showed a ubiquitous expression of LPAP, which was marked in kidney, heart, small intestine, muscle, and liver. Human chromosome map obtained by fluorescence in situ hybridazation showed that, the gene for LPAP was localized to chromosome 1 q21. The mutant in which histidine was replaced with alanine at the active site and the putative signal peptide-deleted LPAP had no I;PA phosphatase activity. In addition, the putative signal peptide-deleted LPAP showed no mitochondrial localization. The site of intracellular localization of endogenous LPAP was also mitochondria in MDCK cells and differentiated C2C12 cells. The LPAP homologous phosphatase, human prostatic acid phosphatase, also has LPA phosphatase activity. LPAP-stable transfected NIH 3T3 cells showed less phosphatidic acid, phosphatidylglycerol, and cardiolipin. These results suggested that LPAP regulates lipid metabolism in mitochondria via the hydrolysis of LPA to monoacylglycerol.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							ARDAIL D, 1990, J BIOL CHEM, V265, P18797; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BENSON BJ, 1980, P NATL ACAD SCI-BIOL, V77, P808, DOI 10.1073/pnas.77.2.808; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodansky O, 1972, Adv Clin Chem, V15, P43, DOI 10.1016/S0065-2423(08)60159-6; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; HAJRA AK, 1968, J BIOL CHEM, V243, P3542; HAJRA AK, 1968, BIOCHEM BIOPH RES CO, V33, P929, DOI 10.1016/0006-291X(68)90401-4; HAJRA AK, 1968, J BIOL CHEM, V243, P3458; HAJRA AK, 1968, J BIOL CHEM, V243, P1617; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALLMAN M, 1975, BIOCHIM BIOPHYS ACTA, V409, P172, DOI 10.1016/0005-2760(75)90152-6; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hiroyama M, 1998, BIOCHEM J, V336, P483, DOI 10.1042/bj3360483; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KANOH H, 1992, J BIOL CHEM, V267, P25309; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; LI HC, 1984, EUR J BIOCHEM, V138, P45, DOI 10.1111/j.1432-1033.1984.tb07879.x; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIPTON JH, 1977, BIOCHIM BIOPHYS ACTA, V486, P228, DOI 10.1016/0005-2760(77)90019-4; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOK AYP, 1990, BIOCHEM CELL BIOL, V68, P1380, DOI 10.1139/o90-201; MONROY G, 1972, J BIOL CHEM, V247, P6884; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; NOEL H, 1986, EUR J BIOCHEM, V155, P99, DOI 10.1111/j.1432-1033.1986.tb09463.x; Numa S, 1974, Curr Top Cell Regul, V8, P197; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; SALBROOK J, 1989, MOL CLONING LAB MANU; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SHIN DH, 1991, J BIOL CHEM, V266, P23834; STERN W, 1978, J BIOL CHEM, V253, P8047; TAMAI Y, 1974, J BIOCHEM-TOKYO, V76, P847; THOMPSON FJ, 1994, BIOCHEM J, V300, P457, DOI 10.1042/bj3000457; Ulrix W, 1998, J BIOL CHEM, V273, P4660, DOI 10.1074/jbc.273.8.4660; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; XIE W, 1991, BIOTECHNIQUES, V11, P325	57	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29172	29180		10.1074/jbc.274.41.29172	http://dx.doi.org/10.1074/jbc.274.41.29172			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506173				2022-12-25	WOS:000083017800052
J	Miki, K; Eddy, EM				Miki, K; Eddy, EM			Single amino acids determine specificity of binding of protein kinase A regulatory subunits by protein kinase A anchoring proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-BETA; MOLECULAR CHARACTERIZATION; RI-ALPHA; LOCALIZATION; ASSOCIATION; DOMAIN; CELLS; CDNA; IDENTIFICATION; CYTOSKELETON	Cyclic AMP-dependent protein kinase is tethered to protein kinase A anchoring proteins (AKAPs) through regulatory subunits (R) by RI alpha-specific, RII alpha-specific, or RI alpha/RII alpha dual-specific binding. Ala- and Vat-scanning mutagenesis determined that hydrophobic amino acids at three homologous positions are required for binding of RI alpha to FSC1/AKAP82 domain B and RII alpha to AKAP Ht31. A mutation at the middle position reversed the binding specificity of both AKAPs, and mutations at this same position of the dual-specific domain A of FSC1/AKAP82 converted it into either an RI alpha or RII alpha binding domain. This suggests that hydrophobic amino acids at three conserved positions within the primary sequence and an amphipathic helix of AKAPs are required for cyclic AMP-dependent protein kinase binding, with the size of the aliphatic side chain at the middle position determining RI alpha or RII alpha binding specificity.	NIEHS, Gamete Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eddy, EM (corresponding author), NIEHS, Gamete Biol Sect, Reprod & Dev Toxicol Lab, NIH, MD C4-01,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070076, ZIAES070076] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FULCHER KD, 1995, BIOL REPROD, V52, P41, DOI 10.1095/biolreprod52.1.41; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Moos J, 1998, MOL REPROD DEV, V50, P79, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;79::AID-MRD10&gt;3.0.CO;2-T; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; Vijayaraghavan S, 1999, MOL ENDOCRINOL, V13, P705, DOI 10.1210/me.13.5.705; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768	32	65	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29057	29062		10.1074/jbc.274.41.29057	http://dx.doi.org/10.1074/jbc.274.41.29057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506157	hybrid			2022-12-25	WOS:000083017800036
J	Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Shioya, H; Utsugisawa, Y; Shi, Y; Weichselbaum, R; Kufe, D				Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Shioya, H; Utsugisawa, Y; Shi, Y; Weichselbaum, R; Kufe, D			Function for p300 and not CBP in the apoptotic response to DNA damage	ONCOGENE			English	Article						ionizing radiation; apoptosis; p53 tumor suppressor	ABL TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; IONIZING-RADIATION; C-ABL; GROWTH ARREST; P53; BINDING; TRANSCRIPTION; EXPRESSION	The cellular response to ionizing radiation (IR) includes the induction of apoptosis, The p300/CBP proteins possess histone acetyltransferase activity and function as transcriptional coactivators of p53. We have prepared cells deficient in p300 or CBP to define the roles of these proteins in the cellular response to DNA damage, The present results demonstrate that p300, but not CBP, contributes to IR sensitivity of cells. The results also demonstrate that IR-induced apoptosis is impaired in the p300-, but not CBP-, deficient cells. These findings indicate that p300 functions in the apoptotic response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021		NCI NIH HHS [CA55241] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	31	52	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5714	5717		10.1038/sj.onc.1202930	http://dx.doi.org/10.1038/sj.onc.1202930			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523850				2022-12-25	WOS:000083016500012
J	Seoane, J; Barbera, A; Telemaque-Potts, S; Newgard, CB; Guinovart, JJ				Seoane, J; Barbera, A; Telemaque-Potts, S; Newgard, CB; Guinovart, JJ			Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE; HEXOKINASE-I; GENE-EXPRESSION; ISOLATED ISLETS; GLUCOSE-6-PHOSPHATASE; LIVER; PHOSPHORYLASE; INSULIN; INACTIVATION; ADENOVIRUS	Zucker diabetic fatty rats develop type 2 diabetes concomitantly with peripheral insulin resistance. Hepatocytes from these rats and their control lean counter parts have been cultured, and a number of hey parameters of glucose metabolism have been determined. Glucokinase activity was 4.5-fold lower in hepatocytes from diabetic rats than in hepatocytes from healthy ones. In contrast, hexokinase activity was about a-fold higher in hepatocytes from diabetic animals than in healthy ones. Glucose-6-phosphatase activity was not significantly different. Despite the altered ratios of glucokinase to hexokinase activity, intracellular glucose 6-phosphate concentrations were similar in the two types of cells when they where incubated with 1-25 mM glucose, However, glycogen levels and glycogen synthase activity ratio were lower in hepatocytes from diabetic animals. Total pyruvate kinase activity and its activity ratio as well as fructose 2,6-bisphosphate concentration and lactate production were also lower in cells from diabetic animals. All of these data indicate that glucose metabolism is clearly impaired in hepatocytes from Zucker diabetic fatty rats. Glucokinase overexpression using adenovirus restored glucose metabolism in diabetic hepatocytes, In glucokinase-overexpressing cells, glucose 6-phosphate levels increased. Moreover, glycogen deposition was greatly enhanced due to the activation of glycogen synthase, Pyruvate kinase was also activated, and fructose-2,6-bisphosphate concentration and lactate production were increased in glucokinase-overexpressing diabetic hepatocytes, Overexpression of hexokinase I did not increase glycogen deposition. In conclusion, hepatocytes from Zucker diabetic fatty rats showed depressed glycogen and glycolytic metabolism, but glucokinase overexpression improved their glucose utilization and storage.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Guinovart, JJ (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Spain.	guino@sun.bq.ub.es	Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Barbera, Albert/0000-0003-4080-3572	PHS HHS [P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'meara NM, 1994, JOSLINS DIABETES MEL, P81; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	30	31	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31833	31838		10.1074/jbc.274.45.31833	http://dx.doi.org/10.1074/jbc.274.45.31833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542207	hybrid			2022-12-25	WOS:000083532100015
J	Mukherjee, S; Bhattacharyya, SN; Adhya, S				Mukherjee, S; Bhattacharyya, SN; Adhya, S			Stepwise transfer of tRNA through the double membrane of Leishmania mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED TRANSFER-RNAS; TRYPANOSOMA-BRUCEI; IN-VITRO; IMPORT; DONOVANI; PROTEIN; IDENTIFICATION; PROMASTIGOTES; ORGANIZATION; LOCALIZATION	Import of tRNA into Leishmania mitochondria involves transfer through a double membrane barrier. To examine whether specific sorting mechanisms for individual tRNAs direct them to different mitochondrial compartments, the distribution of tRNA transcripts, internalized in vitro, was examined by suborganellar fractionation. Significant amounts of tRNA(Tyr) were localized in the matrix and on the outer face of the inner mitochondrial membrane. With time, the matrix:membrane ratio increased. Translocation through the inner membrane apparently required the presence of a specific signal in the D arm of tRNA(Tyr), and tRNA(Gln)(CUG), lacking this sequence, was excluded. Hydrolysis of ATP was necessary at both the outer and inner membranes. However, the protonophores carbonylcyanide m-chlorophenylhydrazone and nigericin, the K+ ionophore valinomycin, and the F1F0 ATPase inhibitor oligomycin had only marginal effects on uptake through the outer membrane but severely inhibited inner membrane translocation, indicating the unusual requirement of both the electrical and chemical components of the electromotive force generated across the inner membrane, The results are consistent with a mechanism involving stepwise transfer of tRNA through distinct outer and inner membrane channels.	Indian Inst Chem Biol, Genet Engn Lab, Calcutta 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja Sc Mullick Rd, Calcutta 700032, W Bengal, India.							Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CHIU N, 1975, J MOL BIOL, V99, P37, DOI 10.1016/S0022-2836(75)80157-4; DAS A, 1993, MOL BIOCHEM PARASIT, V60, P293, DOI 10.1016/0166-6851(93)90140-S; DAS S, 1990, J BIOSCIENCES, V15, P239, DOI 10.1007/BF02702665; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; KLEINSMITH LJ, 1988, PRINCIPLES CELL BIOL, P208; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; Lima BD, 1996, RNA, V2, P429; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; MARTIN RP, 1979, BIOCHEMISTRY-US, V18, P4600, DOI 10.1021/bi00588a021; McIntosh MT, 1998, MOL BIOCHEM PARASIT, V95, P69, DOI 10.1016/S0166-6851(98)00093-0; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLOOF P, 1992, MOL BIOCHEM PARASIT, V56, P289, DOI 10.1016/0166-6851(92)90178-M; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013	34	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31249	31255		10.1074/jbc.274.44.31249	http://dx.doi.org/10.1074/jbc.274.44.31249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531321	hybrid			2022-12-25	WOS:000083379400025
J	Ratnatilleke, A; Vrijbloed, JW; Robinson, JA				Ratnatilleke, A; Vrijbloed, JW; Robinson, JA			Cloning and sequencing of the coenzyme B-12-binding domain of isobutyryl-CoA mutase from Streptomyces cinnamonensis, reconstitution of mutase activity, and characterization of the recombinant enzyme produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GLUTAMATE MUTASE; CLOSTRIDIUM-TETANOMORPHUM; A MUTASE; BINDING; EXPRESSION; SUBUNIT; B-12; SUBSTRATE; GENES	Isobutyryl-CoA mutase (ICM) catalyzes the reversible, coenzyme B-12-dependent rearrangement of isobutyryl-CoA to n-butyryl-CoA, which is similar to, but distinct from, that catalyzed by methylmalong-CoA mutase, ICM has been detected so far in a variety of aerobic and anaerobic bacteria, where it appears to play a key role in valine and fatty acid catabolism, ICM from Streptomyces cinnamonensis is composed of a large subunit (IcmA) of 62.5 kDa and a small subunit (IcmB) of 14.3 kDa, icmB encodes a protein of 136 residues with high sequence similarity to the cobalamin-binding domains of methylmalonyl-CoA mutase, glutamate mutase, methyleneglutarate mutase, and cobalamin-dependent methionine synthase, including a conserved DXHXXG cobalamin-binding motif, Using IcmA and IcmB produced separately in Escherichia coli, we show that IcmB is necessary and sufficient with IcmA and coenzyme B-12 to afford the active ICM holoenzyme. The large subunit (IcmA) forms a tightly associated homodimer, whereas IcmB alone exists as a monomer, In the absence of coenzyme B-12, the association between IcmA and IcmB is weak. The ICM holoenzyme appears to comprise an alpha(2)beta(2)-heterotetramer with up to two molecules of bound coenzyme B-12. The equilibrium constant for the ICM reaction at 30 degrees C is 1.7 in favor of isobutyryl-CoA, and the pH optimum is near 7.4, The K-m values for isobutyryl-CoA, n-butyryl-CoA, and coenzyme B-12 determined with an equimolar ratio of IcmA and IcmB are 57 +/- 13, 54 +/- 12, and 12 +/- 2 mu M, respectively. A V-max of 38 +/- 3 units/mg IcmA and a k(cat) of 39 +/- 3 s(-1) were determined under saturating molar ratios of IcmB to IcmA.	Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland	University of Zurich	Robinson, JA (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; Chen HP, 1997, BIOCHEMISTRY-US, V36, P14939, DOI 10.1021/bi971374g; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; CORNISHBOWDEN A, 1994, LEONORA COMPUTER PRO; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; HOPWOOD DA, 1985, CENETIC MANIPULATION; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KELLERMEYER RW, 1964, J BIOL CHEM, V239, P2562; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Mancia F, 1999, BIOCHEMISTRY-US, V38, P7999, DOI 10.1021/bi9903852; MARSH EN, 1989, BIOCHEM J, V260, P345, DOI 10.1042/bj2600345; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Retey J., 1982, B12, VII, P357; REYNOLDS KA, 1988, J CHEM SOC P1, P3185; Segel IH., 1993, ENZYME KINETICS BEHA; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thoma NH, 1998, BIOCHEMISTRY-US, V37, P14386, DOI 10.1021/bi981375o; Tollinger M, 1998, STRUCTURE, V6, P1021, DOI 10.1016/S0969-2126(98)00103-8; Watanabe F, 1996, MICROBIOL-SGM, V142, P2631, DOI 10.1099/00221287-142-9-2631; Zerbe-Burkhardt K, 1998, J BIOL CHEM, V273, P6508, DOI 10.1074/jbc.273.11.6508	28	41	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31679	31685		10.1074/jbc.274.44.31679	http://dx.doi.org/10.1074/jbc.274.44.31679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531377	hybrid			2022-12-25	WOS:000083379400081
J	Tapia, JA; Ferris, HA; Jensen, RT; Garcia, LJ				Tapia, JA; Ferris, HA; Jensen, RT; Garcia, LJ			Cholecystokinin activates PYK2/CAK beta by a phospholipase C-dependent mechanism and its association with the mitogen-activated protein kinase signaling pathway in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; VASCULAR SMOOTH-MUSCLE; LIVER EPITHELIAL-CELLS; N-TERMINAL KINASE; SWISS 3T3 CELLS; ANGIOTENSIN-II; COUPLED RECEPTORS; MAP-KINASE	PYK2/CAK beta is a recently described cytoplasmic tyrosine kinase related to p125 focal adhesion kinase (p125(FAK)) that can be activated by a number of stimuli including growth factors, lipids, and some G protein-coupled receptors. Studies suggest PYK2/CAK beta may be important for coupling various G protein-coupled receptors to the mitogen-activated protein kinase (MAPK) cascade. The hormone neurotransmitter cholecystokinin (CCK) is known to activate both phospholipase C-dependent cascades and MAPK signaling pathways; however, the relationship between these remain unclear. In rat pancreatic acini, CCK-8 (10 nM) rapidly stimulated tyrosine phosphorylation and! activation of PYK2/CAK beta by both activation of high affinity and low affinity CCKA receptor states. Blockage of CCK-stimulated increases in protein kinase C activity or CCK-stimulated increases in [Ca2+](i), inhibited by 40-50% PYK2/CAK beta but not p125FAK tyrosine phosphorylation. Simultaneous blockage of both phospholipase C cascades inhibited PYK2/CAK beta tyrosine phosphorylation completely and p125(FAK) tyrosine phosphorylation by 50%. CCK-8 stimulated a rapid increase in PYK2/CAK beta kinase activity assessed by both an in vitro kinase assay and autophosphorylation. Total PYK2/CAK beta under basal conditions was largely localized (77 +/- 7%) in the membrane fraction, whereas total p125(FAK) was largely localized (86 +/- 3%) in the cytosolic fraction. With CCK stimulation, both p125(FAK) and PYK2/CAK beta translocated to the plasma membrane. Moreover CCK stimulation causes a rapid formation of both PYK2/CAK beta-Grb2 and PYK2/CAK beta-Crk complexes. These results demonstrate that PYK2/CAK beta and p125(FAK) are regulated differently by CCKA receptor stimulation and that PYK2/CAK beta is probably an important mediator of downstream signals by CCK-8, especially in its ability to activate the MAPK signaling pathway, which possibly mediates CCK growth effects in normal and neoplastic tissues.	NIDDKD, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Extremadura, Dept Fisiol, Caceres 10071, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universidad de Extremadura	Jensen, RT (corresponding author), NIDDKD, Digest Dis Branch, NIH, 10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.		Garcia-Marin, Luis J/L-4680-2014; Tapia, Jose A./C-5181-2008	Garcia-Marin, Luis J/0000-0002-1795-7381; Tapia, Jose A./0000-0002-3614-6867; Ferris, Heather/0000-0002-6321-3447	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053101, Z01DK053101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Bragado MJ, 1996, CLIN SCI, V91, P365, DOI 10.1042/cs0910365; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Charlesworth A, 1996, ONCOGENE, V12, P1337; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dabrowski A, 1996, J BIOL CHEM, V271, P27125, DOI 10.1074/jbc.271.43.27125; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; FEURLE GE, 1995, PANCREAS, V10, P281, DOI 10.1097/00006676-199504000-00010; FORCE T, 1991, J BIOL CHEM, V266, P6650; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Garcia LJ, 1999, ADV MOL CELL ENDOCR, V3, P119; Garcia LJ, 1997, BBA-MOL CELL RES, V1358, P189, DOI 10.1016/S0167-4889(97)00056-6; Garcia LJ, 1997, BIOCHEM J, V327, P461; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARRO J, 1993, TRENDS PHARMACOL SCI, V14, P244, DOI 10.1016/0165-6147(93)90020-K; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HONDA T, 1993, AM J PHYSIOL, V264, pG1142; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Jensen Robert T., 1994, P1377; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; JORPES JE, 1973, HDB EXPT PHARM; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG613, DOI 10.1152/ajpgi.1994.266.4.G613; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KRIMS PE, 1988, PANCREAS, V3, P383, DOI 10.1097/00006676-198808000-00003; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Liddle RA., 1994, GUT PEPTIDES BIOCH P; LOGSDON CD, 1986, AM J PHYSIOL, V251, pG487, DOI 10.1152/ajpgi.1986.251.4.G487; LU L, 1992, AM J PHYSIOL, V263, pG327, DOI 10.1152/ajpgi.1992.263.3.G327; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; METZ DC, 1992, J BIOL CHEM, V267, P20620; MEYER BM, 1989, LANCET, V2, P12, DOI 10.1016/S0140-6736(89)90255-9; Mitaka T, 1997, AM J PATHOL, V150, P267; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORAN TP, 1994, HUM-COMPUT INTERACT, V9, P1, DOI 10.1207/s15327051hci0901_1; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Owyang C, 1996, AM J PHYSIOL-GASTR L, V271, pG1, DOI 10.1152/ajpgi.1996.271.1.G1; PEIKIN SR, 1978, AM J PHYSIOL-ENDOC M, V235, P743; Raja S, 1997, J BIOL CHEM, V272, P10941; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALMON ED, 1984, J CELL BIOL, V99, P1066, DOI 10.1083/jcb.99.3.1066; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Solomon Travis E., 1994, P1499; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yule David I., 1994, P1447; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	95	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31261	31271		10.1074/jbc.274.44.31261	http://dx.doi.org/10.1074/jbc.274.44.31261			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531323	hybrid			2022-12-25	WOS:000083379400027
J	Borowski, P; zur Wiesch, JS; Resch, K; Feucht, H; Laufs, R; Schmitz, H				Borowski, P; zur Wiesch, JS; Resch, K; Feucht, H; Laufs, R; Schmitz, H			Protein kinase C recognizes the protein kinase A-binding motif of nonstructural protein 3 of hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GROWTH-FACTOR RECEPTOR; CELLULAR-TRANSFORMATION; NS3 PROTEIN; PHOSPHORYLATION; DOMAIN; IDENTIFICATION; PEPTIDE; REQUIREMENTS; ACTIVATION	The nonstructural protein 3 (NS3) of hepatitis C virus (HCV) inhibits the nuclear transport and the enzymatic activity of the catalytic subunit of protein kinase A. This inhibition is mediated by an arginine-rich domain localized between amino acids 1487-1500 of the HCV polyprotein, The data presented here indicate that the arginine-rich domain, when embedded in recombinant fragments of NS3, interacts with the catalytic site of protein kinase C (PKC) and inhibits the phosphorylation mediated by this enzyme in vitro and in vivo. Furthermore, a direct binding of PKC to the NS3 fragments leads to an inhibition of the free shuttling of the kinase between the cytoplasm and the particulate fraction. in contrast, a peptide corresponding to the arginine-rich domain (HCV (1487-1500)), despite also being a PFC inhibitor, did not influence the PRC shuttling process and was transported to the particulate fraction by the translocating kinase upon activation with tetradecanoylphorbol-13-acetate. Using the tetradecanoylphorbol-13-acetate -stimulated respiratory burst of NS3-introduced neutrophils as a model system, we could demonstrate that NS3 is able to block. PKC-mediated functions within intact cells, Our data support the possibility that NS3 disrupts the PKC-mediated signal transduction.	Bernhard Nocht Inst Trop Med, Abt Virol, D-20359 Hamburg, Germany; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Mikrobiol & Immunol, D-20246 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg	Borowski, P (corresponding author), Bernhard Nocht Inst Trop Med, Abt Virol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	borowski@bni.uni-hamburg.de	Wiesch, Julian Schulze zur/AAT-8452-2021					BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; Borowski P, 1996, EUR J BIOCHEM, V237, P611, DOI 10.1111/j.1432-1033.1996.0611p.x; Borowski P, 1997, J VIROL, V71, P2838, DOI 10.1128/JVI.71.4.2838-2843.1997; Borowski P, 1999, BIOL CHEM, V380, P403, DOI 10.1515/BC.1999.054; Borowski P, 1996, BIOCHEM MOL BIOL INT, V39, P635; BOROWSKI P, 1999, IN PRESS BIOL CHEM H; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEUCHT HH, 1995, J CLIN MICROBIOL, V33, P620, DOI 10.1128/JCM.33.3.620-624.1995; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JUDD RC, 1982, INFECT IMMUN, V37, P632, DOI 10.1128/IAI.37.2.632-641.1982; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMONS R, 1988, ANAL BIOCHEM, V172, P219, DOI 10.1016/0003-2697(88)90435-6; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MULLER GH, 1980, J CELL SCI, V43, P319; Muramatsu S, 1997, J VIROL, V71, P4954, DOI 10.1128/JVI.71.7.4954-4961.1997; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROGUE P, 1990, J BIOL CHEM, V265, P4161; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SMITH MK, 1990, J BIOL CHEM, V265, P1837; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; THOMPSON NT, 1988, BIOCHEM J, V255, P417, DOI 10.1042/bj2550417; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDOORN LJ, 1994, J MED VIROL, V43, P345, DOI 10.1002/jmv.1890430406; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	49	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30722	30728		10.1074/jbc.274.43.30722	http://dx.doi.org/10.1074/jbc.274.43.30722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521461	hybrid			2022-12-25	WOS:000083276700057
J	Knoops, B; Clippe, A; Bogard, C; Arsalane, K; Wattiez, R; Hermans, C; Duconseille, E; Falmagne, P; Bernard, A				Knoops, B; Clippe, A; Bogard, C; Arsalane, K; Wattiez, R; Hermans, C; Duconseille, E; Falmagne, P; Bernard, A			Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; PEROXISOMAL-TARGETING SIGNAL-1; ALKYL HYDROPEROXIDE REDUCTASE; THIOREDOXIN PEROXIDASE; ASPERGILLUS-FUMIGATUS; CONSERVED CYSTEINE; HYDROGEN-PEROXIDE; PROTEIN IMPORT; APOPTOSIS; BRAIN	Using two-dimensional electrophoresis, we have recently identified in human bronchoalveolar lavage fluid a novel protein, termed B166, with a molecular mass of 17 kDa. Here, we report the cloning of human and rat cDNAs encoding B166, which has been renamed AOEB166 for (a) under bar nti (o) under bar xidant enzyme <(B166)under bar>. Indeed, the deduced amino acid sequence reveals that AOEB166 represents a new mammalian subfamily of AhpC/TSA peroxiredoxin antioxidant enzymes. Human AOEB166 shares 63% similarity with Escherichia coli AhpC22 alkyl hydroperoxide reductase and 66% similarity with a recently identified Saccharomyces cerevisiae alkyl hydroperoxide reductase/thioredoxin peroxidase. Moreover, recombinant AOEB166 expressed in E. coli exhibits a peroxidase activity, and an antioxidant activity comparable with that of catalase was demonstrated with the glutamine synthetase protection assay against dithiothreitol/Fe3+/O-2 oxidation. The analysis of AOEB166 mRNA distribution in 30 different human tissues and in 10 cell lines shows that the gene is widely expressed in the body. Of interest, the analysis of N- and C-terminal domains of both human and rat AOEB166 reveals amino acid sequences presenting features of mitochondrial and peroxisomal targeting sequences. Furthermore, human AOEB166 expressed as a fusion protein with GFP in HepG2 cell line is sorted to these organelles. Finally, acute inflammation induced in rat lung by lipopolysaccharide is associated with an increase of AOEB166 mRNA levels in lung, suggesting a protective role for AOEB166 in oxidative and inflammatory processes.	Catholic Univ Louvain, Cell Biol Lab, Dept Biol, B-1348 Louvain, Belgium; Catholic Univ Louvain, Sch Med, Unit Ind Toxicol & Occupat Med, B-1200 Brussels, Belgium; Univ Mons, Dept Biol Chem, B-7000 Mons, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Mons	Knoops, B (corresponding author), Catholic Univ Louvain, Cell Biol Lab, Dept Biol, Pl Croix Sud 5, B-1348 Louvain, Belgium.	knoops@bani.ucl.ac.be	BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743; wattiez, ruddy/0000-0003-2071-4310				BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; FELSENSTEIN J, 1993, PHYLIP VERSION 3572; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Ichimiya S, 1997, DNA CELL BIOL, V16, P311, DOI 10.1089/dna.1997.16.311; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KAWAI S, 1994, J BIOCHEM-TOKYO, V115, P641, DOI 10.1093/oxfordjournals.jbchem.a124388; KIM KW, 1988, J BIOL CHEM, V263, P4704; Knoops B, 1997, NEUROREPORT, V8, P795, DOI 10.1097/00001756-199702100-00043; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; Mano T, 1997, HORM METAB RES, V29, P351; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MOSLEN MT, 1994, ADV EXP MED BIOL, V366, P17; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Rabilloud T, 1995, BIOCHEM J, V312, P699, DOI 10.1042/bj3120699; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vanhooren JCT, 1996, EUR J BIOCHEM, V239, P302, DOI 10.1111/j.1432-1033.1996.0302u.x; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Wattiez R, 1999, ELECTROPHORESIS, V20, P1634, DOI 10.1002/(SICI)1522-2683(19990601)20:7<1634::AID-ELPS1634>3.0.CO;2-J; YIM MB, 1994, J BIOL CHEM, V269, P1621; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	47	206	218	4	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30451	30458		10.1074/jbc.274.43.30451	http://dx.doi.org/10.1074/jbc.274.43.30451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521424	hybrid			2022-12-25	WOS:000083276700020
J	Kumar, S; Avraham, S; Bharti, A; Goyal, J; Pandey, P; Kharbanda, S				Kumar, S; Avraham, S; Bharti, A; Goyal, J; Pandey, P; Kharbanda, S			Negative regulation of PYK2/related adhesion focal tyrosine kinase signal transduction by hematopoietic tyrosine phosphatase SHPTP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; MYELOID-LEUKEMIA CELLS; GRB2-MEDIATED ASSOCIATION; DIFFERENTIAL REGULATION; C-ABL; PYK2; DNA; PP125(FAK); SRC; EXPRESSION	Related adhesion focal tyrosine kinase (RAFTK) (also known as PYK2) is a cytoplasmic tyrosine kinase related to the focal adhesion kinase (FAK) p125(FAK). RAFTK is rapidly phosphorylated on tyrosine residues in response to various stimuli, such as tumor necrosis factor-alpha, changes in osmolarity, elevation in intracellular calcium concentration, lysophosphatidic acid, and bradykinin. Overexpression of RAFTK induces activation of c-Jun amino-terminal kinase (also known as stress-activated protein kinase), mitogen-activated protein kinase (MAPK), and p38 MAPK. The present studies demonstrate that RAFTK binds constitutively to the protein tyrosine phosphatase SHPTP1. In contrast to PTP1B, overexpression of wild-type SHPTP1 blocks tyrosine phosphorylation of RAFTK. The results further demonstrate that RAFTK is a direct substrate of SHPTP1 in vitro. Moreover, treatment of PC12 cells with bradykinin is associated with inhibition in tyrosine phosphorylation of RAFTK in the presence of SHPTP1. Furthermore, in contrast to the phosphatase-dead SHPTP1 C4535 mutant, overexpression of wild-type SHPTP1 blocks interaction of RAFTK with the SH2-domain of c-Src and inhibits RAFTK-mediated MAPK activation. Significantly, cotransfection of RAFTK with SHPTP1 did not inhibit RAFTK-mediated c-Jun amino-terminal kinase activation. Taken together, these findings suggest that SHPTP1 plays a negative role in PYK2/RAFTK signaling by dephosphorylating RAFTK.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tufts Medical Center	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Jeschke M, 1998, J BIOL CHEM, V273, P11354, DOI 10.1074/jbc.273.18.11354; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pandey P, 1999, J BIOL CHEM, V274, P8618, DOI 10.1074/jbc.274.13.8618; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Raja S, 1997, J BIOL CHEM, V272, P10941; SALEEM A, 1995, J IMMUNOL, V154, P4150; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	36	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30657	30663		10.1074/jbc.274.43.30657	http://dx.doi.org/10.1074/jbc.274.43.30657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521452	hybrid			2022-12-25	WOS:000083276700048
J	Lei, SB; Lu, WY; Xiong, ZG; Orser, BA; Valenzuela, CF; MacDonald, JF				Lei, SB; Lu, WY; Xiong, ZG; Orser, BA; Valenzuela, CF; MacDonald, JF			Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE-2; D-ASPARTATE RECEPTORS; SMOOTH-MUSCLE CELLS; SRC TYROSINE KINASE; COUPLED RECEPTORS; CYCLIC-AMP; ADENYLYL CYCLASES; NMDA RECEPTORS; NR1 SUBUNIT	Growth factor receptors provide a major mechanism for the activation of the nonreceptor tyrosine kinase c-Src, and this kinase in turn up-regulates the activity of N-methyl-D-aspartate (NMDA) receptors in CA1 hippocampal neurons (1). Unexpectedly, applications of platelet-derived growth factor (PDGF)-BB to cultured and isolated CA1 hippocampal neurons depressed NMDA-evoked currents. The PDGF-induced depression was blocked by a PDGF-selective tyrosine kinase inhibitor, by a selective inhibitor of phospholipase C-gamma, and by blocking the intracellular release of Ca2+. Inhibitors of cAMP-dependent protein kinase (PKA) also eliminated the PDGF-induced depression, whereas a phosphodiesterase inhibitor enhanced it. The NMDA receptor-mediated component of excitatory synaptic currents was also inhibited by PDGF, and this inhibition was prevented by co-application of a PKA inhibitor. Src inhibitors also prevented this depression. In recordings from inside-out patches, the catalytic fragment of PKA did not itself alter NMDA single channel activity, but it blocked the up-regulation of these channels by a Src activator peptide. Thus, PDGF receptors depress NMDA channels through a Ca2+- and PHA-dependent inhibition of their modulation by c-Src.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON M5S 1A8, Canada; Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA	University of Toronto; University of Toronto; University of Toronto; University of New Mexico; University of New Mexico's Health Sciences Center	MacDonald, JF (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	j.macdonald@utoronto.ca	Lu, Wei-Yang/K-4404-2013					Antoni F A, 1998, Adv Second Messenger Phosphoprotein Res, V32, P153; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hansen K, 1997, BIOCHEM BIOPH RES CO, V241, P355, DOI 10.1006/bbrc.1997.7743; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; Mathias RS, 1998, AM J PHYSIOL-CELL PH, V274, pC1456, DOI 10.1152/ajpcell.1998.274.6.C1456; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PYNE NJ, 1994, BIOCHEM J, V304, P611, DOI 10.1042/bj3040611; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sawutz DG, 1996, BIOCHEM PHARMACOL, V51, P1631, DOI 10.1016/0006-2952(96)00112-8; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Valenzuela CF, 1995, MOL PHARMACOL, V48, P1099; Valenzuela CF, 1997, BRAIN RES REV, V24, P77; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALKER F, 1993, J BIOL CHEM, V268, P19552; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WANG LY, 1995, J PHYSIOL-LONDON, V486, P83, DOI 10.1113/jphysiol.1995.sp020792; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	48	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30617	30623		10.1074/jbc.274.43.30617	http://dx.doi.org/10.1074/jbc.274.43.30617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521446	hybrid			2022-12-25	WOS:000083276700042
J	Munshi, C; Thiel, DJ; Mathews, II; Aarhus, R; Walseth, TF; Lee, HC				Munshi, C; Thiel, DJ; Mathews, II; Aarhus, R; Walseth, TF; Lee, HC			Characterization of the active site of ADP-ribosyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-SPECIFIC NADASE; INOSITOL TRISPHOSPHATE; CRYSTAL-STRUCTURE; 2ND-MESSENGER ENZYME; CYCLIC METABOLITE; CD38; CYCLIZATION; HYDROLYSIS; BST-1; FERMENTATION	ADP-ribosyl cyclase synthesizes two Ca2+ messengers by cyclizing NAD to produce cyclic ADP-ribose and exchanging nicotinic acid with the nicotinamide group of NADP to produce nicotinic acid adenine dinucleotide phosphate, Recombinant Aplysia cyclase was expressed in yeast and co-crystallized with a substrate, nicotinamide. x-ray crystallography showed that the nicotinamide was bound in a pocket formed in part by a conserved segment and was near the central cleft of the cyclase. Glu(98), Asn(107) and Trp(140) were within 3.5 Angstrom of the bound nicotinamide and appeared to coordinate it. Substituting Glu(98) With either Gln, Gly, Leu, or Asn reduced the cyclase activity by 16-222-fold, depending on the substitution. The mutant N107G exhibited only a 2-fold decrease in activity, while the activity of W140G was essentially eliminated. The base exchange activity of all mutants followed a similar pattern of reduction, suggesting that both reactions occur at the same active site. In addition to NAD, the wild-type cyclase also cyclizes nicotinamide guanine dinucleotide to cyclic GDP-ribose, AU mutant enzymes had at least half of the GDP-ribosyl cyclase activity of the wild type, some even 2-3-fold higher, indicating that the three coordinating amino acids are responsible for positioning of the substrate but not absolutely critical for catalysis. To search for the catalytic residues, other amino acids in the binding pocket were mutagenized, E179G: was totally devoid of GDP-ribosyl cyclase activity, and both its ADP-ribosyl cyclase and the base exchange activities were reduced by 10,000- and 18,000-fold, respectively. Substituting Glu(179) With either Asn, Leu, Asp, or Gln produced similar inactive enzymes; and so was the conversion of Trp(77) to Gly, However, both E179G and the double mutant E179G/W77G retained NAD-binding ability as shown by photoaffinity labeling with [P-32]8-azido-NAD, These results indicate that both Glu(179) and Trp(77) are crucial for catalysis and that Glu(179) may indeed be the catalytic residue.	Univ Minnesota, Dept Physiol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cornell University	Lee, HC (corresponding author), Univ Minnesota, Dept Physiol, 435 Delaware St SE,6-255 Millard Hall, Minneapolis, MN 55455 USA.		Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA11806] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; Franco L, 1998, FASEB J, V12, P1507; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Hussain AMM, 1998, PROTEIN EXPRES PURIF, V12, P133, DOI 10.1006/prep.1997.0811; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; JONES TA, 1992, MOL REPLACEMENT, P91; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIM H, 1993, BIOCHEM BIOPH RES CO, V194, P1143, DOI 10.1006/bbrc.1993.1941; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE B, 1991, HOUS POLICY DEBATE, V2, P3; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; MullerSteffner HM, 1996, J BIOL CHEM, V271, P23967, DOI 10.1074/jbc.271.39.23967; Munshi C, 1997, PROTEIN EXPRES PURIF, V11, P104, DOI 10.1006/prep.1997.0773; Munshi C, 1998, BBA-PROTEIN STRUCT M, V1388, P428, DOI 10.1016/S0167-4838(98)00204-0; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; Sauve AA, 1998, BIOCHEMISTRY-US, V37, P13239, DOI 10.1021/bi981248s; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; THIEL DJ, 1996, REV SCI INSTRUM, V67, P1; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; WALSETH TF, 1993, J BIOL CHEM, V268, P26686	44	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30770	30777		10.1074/jbc.274.43.30770	http://dx.doi.org/10.1074/jbc.274.43.30770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521467	hybrid			2022-12-25	WOS:000083276700063
J	Danilkovitch, A; Miller, M; Leonard, EJ				Danilkovitch, A; Miller, M; Leonard, EJ			Interaction of macrophage-stimulating protein with its receptor - Residues critical for beta chain binding and evidence for independent alpha chain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; MET PROTOONCOGENE; GENE-PRODUCT; EXPRESSION; DOMAIN; FAMILY; MSP; IDENTIFICATION; SPECIFICITY	Macrophage-stimulating protein (MSP) and hepatocyte growth factor/scatter factor (HGF/SF) are plasminogen-related growth and motility factors that interact with cell-surface protein tyrosine kinase receptors. Each one is a heterodimeric protein comprising a disulfide-linked alpha chain and a serine protease-like beta chain. Despite structural similarities between MSP and HGF, the primary receptor binding site is located on the alpha chain of HGF/SF but on the beta chain of MSP. To obtain insight into the structural basis for MSP beta chain binding, beta chain structure was modeled from coordinates of an existing model of the HGF beta chain. The model revealed that the region corresponding to the S1 specificity pocket in trypsin is filled by the Asn(682)/Glu(648) interacting pair, leaving a shallow cavity far possible beta chain interaction with the receptor. Mutants in this region were created, and their binding characteristics were determined. A double mutation of Asn(682)/Glu(648) caused diminished binding of the P chain to the MSP receptor, and a single mutation of neighboring Arg(683) completely abolished binding. Thus, this region of the molecule is critical for binding. We also found that at equimolar concentrations of free alpha and beta chains, LY chain binding to receptor was detectable, at levels considerably lower than beta chain binding. The EC(50) values determined by quantitative enzyme-linked immunosorbent assay are 0.25 and 16.9 nM for beta and alpha chain, respectively. The data suggest that MSP has two independent binding sites with high and low affinities located in beta and alpha chain, respectively, and that the two sites together mediate receptor dimerization and subsequent activation.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol Struct Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Danilkovitch, A (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Bldg 560,Rm 12-46, Frederick, MD 21702 USA.	danilkovitch@mail.ncifcrf.gov	Miller, Maria/I-1636-2013	Miller, Maria/0000-0003-0252-5348				BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Danilkovitch A, 1999, J LEUKOCYTE BIOL, V65, P345, DOI 10.1002/jlb.65.3.345; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Khan AR, 1998, PROTEIN SCI, V7, P815; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; Miller M, 1998, FEBS LETT, V429, P1, DOI 10.1016/S0014-5793(98)00533-X; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Wahl RC, 1997, J BIOL CHEM, V272, P15053, DOI 10.1074/jbc.272.24.15053; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WANG MH, 1994, J BIOL CHEM, V269, P3436; Yoshikawa W, 1999, ARCH BIOCHEM BIOPHYS, V363, P356, DOI 10.1006/abbi.1998.1090; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	36	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29937	29943		10.1074/jbc.274.42.29937	http://dx.doi.org/10.1074/jbc.274.42.29937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514476	hybrid			2022-12-25	WOS:000083176400055
J	Dorin, D; Alano, P; Boccaccio, I; Ciceron, L; Doerig, C; Sulpice, R; Parzy, D; Doerig, C				Dorin, D; Alano, P; Boccaccio, I; Ciceron, L; Doerig, C; Sulpice, R; Parzy, D; Doerig, C			An atypical mitogen-activated protein kinase (MAPK) homologue expressed in gametocytes of the human malaria parasite Plasmodium falciparum - Identification of a MAPK signature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE; CLONING; SPECIFICITY; CEREVISIAE; SEQUENCE; MOSQUITO; FAMILY; FUS3; ERK2	The cDNA encoding Pfmap-2, an enzyme of the human malaria parasite Plasmodium falciparum, was cloned, sequenced, and expressed in Escherichia coli, The open reading frame carried by the Pfmap-2 cDNA encodes a 508-amino acid polypeptide of 59.2 kDa with maximal homology to mitogen-activated protein kinases (MAPKs) from various organisms. The purified recombinant enzyme displayed functional characteristics of MAPKs such as (i) ability to undergo autophosphorylation, (ii) ability to phosphorylate myelin basic protein, a classical MAPK substrate, (iii) regulation of kinase activity by a MAPK-specific phosphatase, and (iv) ability to be activated by component(s) present in cell extracts. Mutational analysis of the recombinant protein allowed the identification of residues that are important for enzymatic activity. Northern blot analysis and immunofluorescence assays indicated that Pfmap-2 is expressed specifically in gametocytes, the form that is responsible for transmission of the parasite to the mosquito vector. Gametocyte extracts activated recombinant Pfmap-2 more efficiently than extracts from asexual parasites, which is consistent with this stage specificity, Despite its overall high level of homology to MAPKs, Pfmap-2 presents the peculiarity of not possessing the conserved threonine-X-tyrosine activation motif usually found in enzymes of this family; instead, it has a threonine-serine-histidine at the same location. This atypical feature formed the basis for a detailed analysis of the primary structure of MAPKs, allowing us to define an operational MAPK signature, which is shared by Pfmap-2. The fact that no MAPK from vertebrates diverge in the activation motif suggests that the fine mechanisms of Pfmap-2 regulation may offer an opportunity for antimalarial drug targeting.	INSERM, U511, F-75013 Paris, France; Ist Super Sanita, I-00161 Rome, Italy; INSERM U399, F-13005 Marseille, France; Inst Trop Med, Serv Sante Armees, F-13007 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Istituto Superiore di Sanita (ISS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Doerig, C (corresponding author), INSERM, U511, 91 Bd Hop, F-75013 Paris, France.	doerig@ext.jussieu.fr	ALANO, PIETRO/C-2946-2016; Sulpice, Ronan/I-2738-2013; Doerig, Christian/Q-9900-2019	ALANO, PIETRO/0000-0003-0092-9840; Sulpice, Ronan/0000-0002-6113-9570; Doerig, Christian/0000-0002-3188-094X; Huynh, Chien/0000-0001-9801-845X				ALANO P, 1990, ANNU REV MICROBIOL, V44, P429, DOI 10.1146/annurev.mi.44.100190.002241; Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3; ALANO P, 1991, MOL BIOCHEM PARASIT, V46, P81, DOI 10.1016/0166-6851(91)90201-G; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; BRIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295; Carter R, 1993, Methods Mol Biol, V21, P67; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DOERIG C, 1995, MOL BIOCHEM PARASIT, V70, P167, DOI 10.1016/0166-6851(95)00033-W; Doerig CM, 1996, GENE, V177, P1, DOI 10.1016/0378-1119(96)00281-8; DONTFRAID FF, 1994, BIOCHEM BIOPH RES CO, V201, P423, DOI 10.1006/bbrc.1994.1718; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Graeser R, 1997, MOL MICROBIOL, V23, P151, DOI 10.1046/j.1365-2958.1997.2071571.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAPPES B, 1995, MOL BIOCHEM PARASIT, V72, P163, DOI 10.1016/0166-6851(95)00075-C; Lin DT, 1996, MOL BIOCHEM PARASIT, V78, P67, DOI 10.1016/S0166-6851(96)02608-4; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZOGUCHI T, 1993, FEBS LETT, V336, P440, DOI 10.1016/0014-5793(93)80852-L; Nakashima S, 1999, J BIOL CHEM, V274, P9976, DOI 10.1074/jbc.274.15.9976; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SAMBROOK J, 1989, MOL CLONING, V1, P7; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; SULTAN AA, 1994, MOL BIOCHEM PARASIT, V65, P331, DOI 10.1016/0166-6851(94)90083-3; THOMPSON J, 1994, MOL BIOCHEM PARASIT, V68, P189, DOI 10.1016/0166-6851(94)90164-3; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; White NJ, 1998, ANN TROP MED PARASIT, V92, P449, DOI 10.1080/00034989859429; World Health Organization, 1997, Weekly Epidemiological Record, V72, P269; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	37	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29912	29920		10.1074/jbc.274.42.29912	http://dx.doi.org/10.1074/jbc.274.42.29912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514473	hybrid			2022-12-25	WOS:000083176400052
J	Fagan, AM; Holtzman, DM; Munson, G; Mathur, T; Schneider, D; Chang, LK; Getz, GS; Reardon, CA; Lukens, J; Shah, JA; LaDu, MJ				Fagan, AM; Holtzman, DM; Munson, G; Mathur, T; Schneider, D; Chang, LK; Getz, GS; Reardon, CA; Lukens, J; Shah, JA; LaDu, MJ			Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RECEPTOR-RELATED PROTEIN; HUMAN APOLIPOPROTEIN-E; AMYLOID-BETA-PEPTIDE; E MESSENGER-RNA; HUMAN CEREBROSPINAL-FLUID; HIGH-DENSITY-LIPOPROTEIN; ISOFORM-SPECIFIC BINDING; ALZHEIMERS-DISEASE; HUMAN PLASMA	Composition of central nervous system lipoproteins affects the metabolism of lipoprotein constituents within the brain. The epsilon 4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer's disease via an unknown mechanism(s). As glia are the primary central nervous system cell type that synthesize apoE, we characterized lipoproteins secreted by astrocytes from wild type (WT), apoE (-/-), and apoE transgenic mice expressing human apoE3 or apoE4 in a mouse apoE (-/-) background. Nondenaturing size exclusion chromatography demonstrates that WT, apoE3, and apoE4 astrocytes secrete particles the size of plasma high density lipoprotein (HDL) composed of phospholipid, free cholesterol, and protein, primarily apoE and apoJ. However, the lipid:apoE ratio of particles containing human apoE is significantly lower than WT. ApoE localizes across HDL-like particle sizes. ApoJ localizes to the smallest HDL-like particles. ApoE (-/-) astrocytes secrete little phospholipid or free cholesterol despite comparable apoJ expression, suggesting that apoE is required for normal secretion of astrocyte lipoproteins. Further, particles were not detected in apoE (-/-) samples by electron microscopy. Nondenaturing immunoprecipitation experiments indicate that apoE and apoJ reside predominantly on distinct particles. These studies suggest that apoE expression influences the unique structure of astrocyte lipoproteins, a process further modified by apoE species.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Chicago	Fagan, AM (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Shah, Javeed/J-4906-2017; Shah, Javeed/J-2716-2019	Shah, Javeed/0000-0002-2997-7988; Shah, Javeed/0000-0002-2997-7988; LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL INSTITUTE ON AGING [R01AG013956, R37AG013956, P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG013956, AG00861-01, AG13956, AG05681-16] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Boggs LN, 1996, J NEUROCHEM, V67, P1324; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CASTRO GR, 1984, J LIPID RES, V25, P58; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Guyton JR, 1998, J NEUROCHEM, V70, P1235; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Hochstrasser A C, 1988, Appl Theor Electrophor, V1, P73; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JENNE DE, 1991, J BIOL CHEM, V266, P11030; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kouzmin A., 1993, J CONTING CRISIS MAN, V1, P1, DOI DOI 10.1111/JCCM.1993.1.ISSUE-1; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRUL ES, 1988, J LIPID RES, V29, P1309; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Ma JY, 1996, NEUROBIOL AGING, V17, P773; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; Nishida HI, 1997, BBA-LIPID LIPID MET, V1349, P222, DOI 10.1016/S0005-2760(97)00133-1; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; ODA T, 1994, BIOCHEM BIOPH RES CO, V204, P1131, DOI 10.1006/bbrc.1994.2580; PASINETTI GM, 1993, NEUROSCIENCE, V53, P199; PASINETTI GM, 1994, J COMP NEUROL, V339, P387, DOI 10.1002/cne.903390307; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Reardon CA, 1998, J LIPID RES, V39, P1372; REBECK GW, 1993, NEURON, V11, P575; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHREIBER SS, 1993, NEUROSCI LETT, V153, P17, DOI 10.1016/0304-3940(93)90066-T; SLOOP CH, 1987, J LIPID RES, V28, P225; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sun YL, 1998, J NEUROSCI, V18, P3261; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229; [No title captured]	72	165	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30001	30007		10.1074/jbc.274.42.30001	http://dx.doi.org/10.1074/jbc.274.42.30001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514484	hybrid			2022-12-25	WOS:000083176400063
J	Gorgani, NN; Parish, CR; Altin, JG				Gorgani, NN; Parish, CR; Altin, JG			Differential binding of histidine-rich glycoprotein (HRG) to human IgG subclasses and IgG molecules containing kappa and lambda light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE IMMUNE-COMPLEXES; RESONANT MIRROR; BIOMOLECULAR INTERACTIONS; IONIC-STRENGTH; PROLINE; COMPLEMENT; PLASMA; ZINC; ANTIBODIES; NEUTRALIZATION	In previous studies we showed that the plasma protein histidine-rich glycoprotein (HRG) binds strongly to pooled human IgG. In the present work myeloma proteins consisting of different human IgG subclasses were examined for their ability to interact with human HRG. Using an IAsys optical biosensor we found initially that IgG subclasses differ substantially in their affinity of interaction with HRG. However, the most striking finding was the observation that the kinetics of the HRG interaction was dramatically affected by whether the IgG subclasses contained the kappa or lambda light (L)-chains. Thus, the on-rate for the binding of HRG to the kappa L-chain containing IgG1 and IgG2 (IgG1 kappa and IgG2 kappa) was similar to 4- and similar to 10-fold faster than that for the binding of HRG to lambda L-chain containing IgG1 and IgG2 (IgG1 lambda and IgG2 lambda), respectively, with the dissociation constants (K-d) in the range 3-5 nM and 112-189 nM for the kappa and lambda isoforms, respectively. In contrast, the on-rate for the binding of HRG to IgG3 kappa and IgG4 kappa was found to be 9- and 20-fold slower than that for the binding of HRG to IgG3 lambda and IgG4 lambda, respectively, with the K-d in the range 147-268 nM and 96-109 nM for the kappa and lambda isoforms, respectively. The binding of HRG to immunoglobulins containing the kappa L-chain (particularly IgG1 kappa) was generally potentiated in the presence of a physiological concentration (20 mu M) of Zn2+ (K-d decreased to 0.60 +/- 0.01 for IgG1 kappa), but Zn2+ had no effect or slightly inhibited the binding of HRG to immobilized IgG subclasses possessing the lambda L-chain. Interestingly, HRG also bound differentially to, pence Jones (BJ) proteins containing kappa and lambda L-chains, with HRG having a 14-fold lower K-d for BJ kappa than for BJ lambda when 20 mu M Zn2+ was present. HRG also bound to IgM (IgM kappa), but the affinity of this interaction (K-d similar to 1.99 +/- 0.05 mu M) was markedly lower than the interaction with IgG, and the affinity was actually decreased 4-fold in the presence of Zn2+. The results demonstrate that both the heavy (H)- and L-chain type have a profound effect on the binding of HRG to different IgG subclasses and provide the first evidence of a functional difference between the kappa and lambda L-chains of immunoglobulins.	Australian Natl Univ, Fac Sci, Sch Life Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, Fac Sci, Sch Life Sci, John Curtin Sch Med Res,Div Immunol & Cell Biol, Canberra, ACT 0200, Australia	Australian National University; Australian National University; John Curtin School of Medical Research	Altin, JG (corresponding author), Australian Natl Univ, Fac Sci, Sch Life Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia.		Altin, Joseph G/C-9935-2009; Gorgani, Nick/GXF-5438-2022	Parish, Christopher/0000-0001-7740-0430				ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P45; Abrass Christine K., 1997, P291; AIKEN SP, 1992, J PHYSIOL-LONDON, V445, P69, DOI 10.1113/jphysiol.1992.sp018912; Bellotti V, 1996, BBA-MOL BASIS DIS, V1317, P161, DOI 10.1016/S0925-4439(96)00049-X; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BROWN PB, 1982, ARTHRITIS RHEUM-US, V25, P1101, DOI 10.1002/art.1780250911; BUCKLE PE, 1993, BIOSENS BIOELECTRON, V8, P355, DOI 10.1016/0956-5663(93)80074-Y; BUXANIRICE S, 1994, J NEUROCHEM, V62, P665; Carayannopoulos Leon, 1993, P283; CHANG NS, 1992, BLOOD, V79, P2973; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; Drasin T, 1996, THROMB RES, V84, P179, DOI 10.1016/0049-3848(96)00174-0; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 1996, BBA-MOL BASIS DIS, V1317, P45, DOI 10.1016/0925-4439(96)00036-1; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; HEBERT LA, 1991, AM J KIDNEY DIS, V17, P877; HEIMER R, 1982, ARTHRITIS RHEUM, V25, P1298, DOI 10.1002/art.1780251105; Kluszynski BA, 1997, J BIOL CHEM, V272, P13541, DOI 10.1074/jbc.272.21.13541; LAMBWHARTON RJ, 1993, CELL IMMUNOL, V152, P544, DOI 10.1006/cimm.1993.1311; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LEUNG LLK, 1984, J CLIN INVEST, V73, P5, DOI 10.1172/JCI111206; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; NASU H, 1980, CLIN EXP IMMUNOL, V42, P378; Olsen HM, 1996, IMMUNOLOGY, V88, P198, DOI 10.1111/j.1365-2567.1996.tb00005.x; PARISH CR, 1984, J CELL SCI, V67, P145; PREUDHOMME JL, 1994, KIDNEY INT, V46, P965, DOI 10.1038/ki.1994.355; RANDEN J, 1993, SCAND J IMMUNOL, V37, P638; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; SAEZ CT, 1995, BIOCHEMISTRY-US, V34, P2496, DOI 10.1021/bi00008a013; SCHIFFERLI JA, 1987, IMMUNOL LETT, V14, P225, DOI 10.1016/0165-2478(87)90105-2; SHATSKY M, 1989, J BIOL CHEM, V264, P8254; SOLOMON A, 1991, NEW ENGL J MED, V324, P1845, DOI 10.1056/NEJM199106273242603; SOLOMONS NW, 1979, AM J CLIN NUTR, V32, P856, DOI 10.1093/ajcn/32.4.856; Walport MJ, 1996, RES IMMUNOL, V147, P103, DOI 10.1016/0923-2494(96)87182-3	39	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29633	29640		10.1074/jbc.274.42.29633	http://dx.doi.org/10.1074/jbc.274.42.29633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514432	hybrid			2022-12-25	WOS:000083176400011
J	Sugars, JM; Cellek, S; Manifava, M; Coadwell, J; Ktistakis, NT				Sugars, JM; Cellek, S; Manifava, M; Coadwell, J; Ktistakis, NT			Fatty acylation of phospholipase D1 on cysteine residues 240 and 241 determines localization on intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING MOLECULES; D DEFINES; TRANSPORT; ISOFORM	We have reported previously that phospholipase D1 (PLD1) is labeled specifically with [H-3]palmitate following transient expression and immunoprecipitation and that this modification appeared important both for membrane localization and catalytic activity, In this work we identify by mutagenesis that the acylation sites on PLD1 are cysteine residues 240 and 241, with the cysteine at position 241 accounting for most but not all of the modification, Replacement of both cysteine residues with either serines or alanines resulted in a mutant protein that contained undetectable [H-3]palmitate. In comparison with the wild type protein, the double mutant showed reduced catalytic activity in vivo, whereas its activity in vitro was unchanged. In addition, the localization of the double mutant was altered in comparison with the wild type protein, whereas wild type PLD1 is primarily on intracellular membranes and on punctate structures, the double mutant was on plasma membrane. Because cysteines 240 and 241 lie within a putative pleckstrin homology domain of PLD1, it is likely that fatty acylation on these residues modulates the function of the PLD1 pleckstrin homology domain.	Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Ktistakis, NT (corresponding author), Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England.			Cellek, Selim/0000-0002-4856-285X				Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Ktistakis NT, 1998, BIOESSAYS, V20, P495; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SINGER WD, 1997, ANNU REV BIOCHEM, V66, P457; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	16	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30023	30027		10.1074/jbc.274.42.30023	http://dx.doi.org/10.1074/jbc.274.42.30023			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514487	hybrid			2022-12-25	WOS:000083176400066
J	Kedzierski, W; Weng, J; Travis, GH				Kedzierski, W; Weng, J; Travis, GH			Analysis of the rds/peripherin center dot rom1 complex in transgenic photoreceptors that express a chimeric protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RDS MUTANT MICE; DEGENERATION SLOW RDS; RETINAL DEGENERATION; RETINITIS-PIGMENTOSA; MEMBRANE-PROTEIN; PERIPHERIN-RDS; MESSENGER-RNA; LOCALIZATION; MOUSE; GENE	Mice homozygous for the retinal degeneration slow (rds) mutation completely lack photoreceptor outer segments, The rds gene encodes rds/peripherin (rds), a membrane glycoprotein in the rims of rod and cone outer segment discs. rds is present as a complex with the related protein, rom1, Here, we generated transgenic mice that express a chimeric protein (rom/D2) containing the intradiscal D2 loop of rds in the context of rom1, rom/D2 was N-glycosylated, formed covalent homodimers, and interacted non-covalently with itself, rds, and rom1, The rds.rom/D2 interaction was significantly more stable than the non-covalent interaction between rds and rom1 by detergent/urea titration. Analysis of mice expressing rom/D2 revealed that rds is 2,5-fold more abundant than rom1, interacts non-covalently with itself and rom1 via the D2 loop, and forms a high order complex that may extend the entire circumference of the disc, Expression of rom/D2 fully rescued the ultrastructural phenotype in rds+/- mutant mice, but it had no effect on the phenotype in rds-/- mutants. Together, these observations explain the striking differences in null phenotypes and frequencies of disease-causing mutations between the RDS and ROM1 genes.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Travis, GH (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493				BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CHU FK, 1986, J BIOL CHEM, V261, P172; Clarke G. A., 1998, IOVS, V39, pS962; COHEN AI, 1983, INVEST OPHTH VIS SCI, V24, P832; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CORLESS JM, 1987, J COMP NEUROL, V257, P1, DOI 10.1002/cne.902570102; Deretic D, 1998, P NATL ACAD SCI USA, V95, P10620, DOI 10.1073/pnas.95.18.10620; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; JANSEN HG, 1984, J COMP NEUROL, V224, P71, DOI 10.1002/cne.902240107; JANSEN HG, 1987, EXP EYE RES, V44, P347, DOI 10.1016/S0014-4835(87)80170-7; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Kedzierski W, 1999, J NEUROCHEM, V72, P430, DOI 10.1046/j.1471-4159.1999.0720430.x; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; KEDZIERSKI W, 1990, MOL BRAIN RES, V7, P45, DOI 10.1016/0169-328X(90)90072-L; Keen TJ, 1996, HUM MUTAT, V8, P297; MA JS, 1995, GENOMICS, V28, P212, DOI 10.1006/geno.1995.1133; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; NIR I, 1986, INVEST OPHTH VIS SCI, V27, P836; Noell W K, 1966, Invest Ophthalmol, V5, P450; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; Shastry BS, 1997, CELL MOL LIFE SCI, V53, P419, DOI 10.1007/s000180050050; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; USUKURA J, 1987, EXP EYE RES, V45, P501, DOI 10.1016/S0014-4835(87)80061-1; VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392	34	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29181	29187		10.1074/jbc.274.41.29181	http://dx.doi.org/10.1074/jbc.274.41.29181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506174	hybrid			2022-12-25	WOS:000083017800053
J	Marin, O; Meggio, F; Sarno, S; Cesaro, L; Pagano, MA; Pinna, LA				Marin, O; Meggio, F; Sarno, S; Cesaro, L; Pagano, MA; Pinna, LA			Tyrosine versus serine/threonine phosphorylation by protein kinase casein kinase-2 - A study with peptide substrates derived from immunophilin Fpr3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY; CELLULAR-REGULATION; CATALYTIC SUBUNIT; SITE-SPECIFICITY; ALPHA-SUBUNIT; CK2; YEAST; RESIDUES; INHIBITORS; RECOGNITION	Protein kinase casein kinase-2 (CK2) is a spontaneously active, ubiquitous, and pleiotropic enzyme that phosphorylates seryl/threonyl residues specified by multiple negatively charged side chains, the one at position n + 3 being of crucial importance (minimum consensus S/T-x-x-E/D/S(P)/T(P). Recently CK2 has been reported to catalyze phosphorylation of the yeast nucleolar immunophilin Fpr3 at a tyrosyl residue (Tyr(184)) fulfilling the consensus sequence of Ser/Thr substrates (Wilson, L.K, Dhillon, N., Thorner, J., and Martin, G.S. (1997) J. Biol Chem. 272, 12961-12967). Here we show that, by contrast to other tyrosyl peptides fulfilling the consensus sequence for CK2, a peptide reproducing the sequence around Fpr3 Tyr(184) (DEDADIY(184)DEEDYDL) is phosphorylated by CK2, albeit with much higher K-m (384 versus 4.3 mu M) and lower V-max (8.4 versus 1,132 nmol.min(-1). mg(-1)) than its derivative with Tyr(184) replaced by serine. The replacement of Asp at position n + 1 with alanine and, to a lesser extent, of Ile at n - 1 with Asp are especially detrimental to tyrosine phosphorylation as compared with serine phosphorylation, which is actually stimulated by the ne to Asp modification. In contrast the replacement of Glu at n + 3 with alanine almost suppresses serine phosphorylation but not tyrosine phosphorylation. It can be concluded that CK2 is capable to phosphorylate, under special circumstances, tyrosyl residues, which are specified by structural features partially different from those that optimize Ser/Thr phosphorylation.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Studio Biomembrane, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Pinna, LA (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.			Cesaro, Luca/0000-0002-6707-2282; Pagano, Mario Angelo/0000-0003-4186-7658				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CHARDOT T, 1995, CR ACAD SCI III-VIE, V318, P937; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; MEGGIO F, 1989, BIOCHIM BIOPHYS ACTA, V1010, P128, DOI 10.1016/0167-4889(89)90193-6; MEGGIO F, 1976, ANAL BIOCHEM, V71, P583, DOI 10.1016/S0003-2697(76)80028-0; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Pulgar V, 1996, EUR J BIOCHEM, V242, P519, DOI 10.1111/j.1432-1033.1996.0519r.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sarno S, 1999, MOL CELL BIOCHEM, V191, P13, DOI 10.1023/A:1006857016712; Sarno S, 1996, J BIOL CHEM, V271, P10595, DOI 10.1074/jbc.271.18.10595; Sarno S, 1997, BIOCHEMISTRY-US, V36, P11717, DOI 10.1021/bi9705772; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; STERN D, 1991, MOL CELL BIOL, V111, P987; Vaglio P, 1996, FEBS LETT, V380, P25, DOI 10.1016/0014-5793(95)01542-6; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; WILSON LK, 1995, J BIOL CHEM, V270, P25185, DOI 10.1074/jbc.270.42.25185; Wilson LK, 1997, J BIOL CHEM, V272, P12961, DOI 10.1074/jbc.272.20.12961; YUAN CJ, 1993, J BIOL CHEM, V268, P17683	42	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29260	29265		10.1074/jbc.274.41.29260	http://dx.doi.org/10.1074/jbc.274.41.29260			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506183	hybrid			2022-12-25	WOS:000083017800062
J	Nakhost, A; Dyer, JR; Pepio, AM; Fan, XT; Sossin, WS				Nakhost, A; Dyer, JR; Pepio, AM; Fan, XT; Sossin, WS			Protein kinase C phosphorylated at a conserved threonine is retained in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; IN-VIVO; PERSISTENT ACTIVATION; APLYSIA; AUTOPHOSPHORYLATION; MAINTENANCE; INDUCTION; DOMAINS; ALPHA; ZETA	Phosphorylation of calcium-activated protein kinase Cs (PKCs) at threonine 634 and/or threonine 641 increases during long term potentiation or associative learning in rodents. In the marine mollusk Aplysia, persistent activation of the calcium-activated PKC Apl I occurs during long term facilitation. We have raised an antibody to a peptide from PKC Apl I phosphorylated at threonines 613 and 620 (sites homologous to threonines 634 and 641). This antibody recognizes PKC Apl I only when it is phosphorylated at threonine 613. Both phorbol esters and serotonin increase the percentage of kinase phosphorylated at threonine 613 in Aplysia neurons. Furthermore, the pool of PKC that is phosphorylated at threonine 613 in neurons is resistant to both membrane translocation and down-regulation. Replacement of threonine 613 with alanine increased the affinity of PKC Apl I for calcium, suggesting that phosphorylation of this site may reduce the ability of PKC Apl I to translocate to membranes in the presence of calcium. We propose that phosphorylation of this site is important for removal of PKC from the membrane and may be a mechanism for negative feedback of PKC activation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Rm 776,3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.							Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Dyer JR, 1996, J NEUROCHEM, V67, P932; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FARLEY J, 1991, P NATL ACAD SCI USA, V88, P2016, DOI 10.1073/pnas.88.5.2016; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Gatti A, 1996, J BIOL CHEM, V271, P31718, DOI 10.1074/jbc.271.49.31718; Grunbaum L, 1998, J NEUROSCI, V18, P4384; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1991, J BIOL CHEM, V266, P24253; KRUGER KE, 1991, J NEUROSCI, V11, P2303; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Nakhost A, 1998, J NEUROCHEM, V71, P1221; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; Pepio AM, 1998, J BIOL CHEM, V273, P19040, DOI 10.1074/jbc.273.30.19040; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Sossin W S, 1994, Learn Mem, V1, P189; SOSSIN WS, 1994, MOL BRAIN RES, V24, P210, DOI 10.1016/0169-328X(94)90134-1; SOSSIN WS, 1993, J BIOL CHEM, V268, P5763; Sossin WS, 1997, LEARN MEMORY, V3, P389, DOI 10.1101/lm.3.5.389; Sossin WS, 1996, J NEUROSCI, V16, P10; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	37	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28944	28949		10.1074/jbc.274.41.28944	http://dx.doi.org/10.1074/jbc.274.41.28944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506140	hybrid			2022-12-25	WOS:000083017800019
J	Perez-Ruiz, M; Barroso-delJesus, A; Berzal-Herranz, A				Perez-Ruiz, M; Barroso-delJesus, A; Berzal-Herranz, A			Specificity of the hairpin ribozyme - Sequence requirements surrounding the cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; SELECTION	Substrate sequence requirements of the hairpin ribozyme have been partially defined by both mutational and in vitro selection experiments, It was considered that the best targets were those that included the N down arrow GUC sequence surrounding the cleavage site. In contrast to previous studies that failed to evaluate all possible combinations of these nucleotides, we have performed an exhaustive analysis of the cleavage of 64 substrate variants, They represent all possible sequence combinations of the J2/1 nucleotides except the well established G(+1). No cleavage was observed with 24 sequences, C+2 variants showed little or no cleavage, whereas U+2 substrates were all cleavable, The maximal cleavage rate was obtained with the AGUC substrate, Cleavage rates of sequences HGUC (H = A, C, or U), GGUN, GGGR (R = A or G), AGUU; and UGUA were up to 5 times lower than the AGUC one. This shows that other sequences besides NGUC could also be considered as good targets. A second group of sequences WGGG (W = A or U), UGUK (K = G or U), MGAG (M = A or C), AGUA, and UGGA were cleaved between 6 and 10 times less efficiently. Furthermore, the UGCU sequence of a noncleavable viral target was mutated to AGUC resulting in a proficiently cleavable substrate by its cognate hairpin ribozyme, This indicates that our conclusions may be extrapolated to other hairpin ribozymes with different specificity.	CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Berzal-Herranz, A (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Ventanilla 11, Granada 18001, Spain.		Berzal-Herranz, Alfredo/K-8614-2014	Berzal-Herranz, Alfredo/0000-0003-3722-7973; Barroso-delJesus, Alicia/0000-0001-8558-0056				ANDERSON P, 1994, NUCLEIC ACIDS RES, V22, P1096, DOI 10.1093/nar/22.6.1096; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; Earnshaw DJ, 1997, J MOL BIOL, V274, P197, DOI 10.1006/jmbi.1997.1405; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Hampel A, 1998, PROG NUCLEIC ACID RE, V58, P1; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; Perez-Ruiz M, 1999, ANTISENSE NUCLEIC A, V9, P33, DOI 10.1089/oli.1.1999.9.33; Yu Q, 1998, J BIOL CHEM, V273, P23524, DOI 10.1074/jbc.273.36.23524	12	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29376	29380		10.1074/jbc.274.41.29376	http://dx.doi.org/10.1074/jbc.274.41.29376			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506198	hybrid			2022-12-25	WOS:000083017800077
J	Wright, PM; Yu, JA; Cillo, J; Lu, AL				Wright, PM; Yu, JA; Cillo, J; Lu, AL			The active site of the Escherichia coli MutY DNA adenine glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH-CONTAINING DNA; G-A MISPAIRS; ENDONUCLEASE-III; REPAIR ENZYME; SUBSTRATE-SPECIFICITY; CATALYTIC MECHANISM; EXCISION-REPAIR; DAMAGED DNA; BASE-PAIR; DIRECTED MUTAGENESIS	Escherichia coli MutY is an adenine DNA glycosylase active on DNA substrates containing A/G, AIC, or A/8-oxoG mismatches. Although MutY can form a covalent intermediate with its DNA substrates, its possession of 3' apurinic lyase activity is controversial. To study the reaction mechanism of MutY, the conserved Asp-138 was mutated to Asn and the reactivity of this mutant MutY protein determined. The glycosylase activity was completely abolished in the D138N MutY mutant. The D138N mutant and wild-type MutY protein also possessed different DNA binding activities with various mismatches. Several lysine residues were identified in the proximity of the active site by analyzing the imino covalent MutY-DNA intermediate. Mutation of Lys-157 and Lys-158 both individually and combined, had no effect on MutY activities but the K142A mutant protein was unable to form Schiff base intermediates with DNA substrates. However, the MutY K142A mutant could still bind DNA substrates and had adenine glycosylase activity. Surprisingly, the K142A mutant MutY, but not the wild-type enzyme, could promote a beta/delta-elimination on apurinic DNA. Our results suggest that Asp-138 acts as a general base to deprotonate either the epsilon-amine group of Lys-142 or to activate a water molecule and the resulting apurinic DNA then reacts with Lys-142 to form the Schiff base intermediate with DNA. With the H142A mutant, Asp-138 activates a water molecule to attack the C1' of the adenosine; the resulting apurinic DNA is cleaved through beta/delta-elimination without Schiff' base formation.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	aluchang@umaryland.edu	Cillo, Joseph/AAS-4294-2020		NIGMS NIH HHS [GM 35132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P113; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Lu AL, 1996, J BIOL CHEM, V271, P24138, DOI 10.1074/jbc.271.39.24138; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PIERRE J, 1981, J BIOL CHEM, V256, P217; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SU SS, 1988, J BIOL CHEM, V263, P6829; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	59	45	47	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29011	29018		10.1074/jbc.274.41.29011	http://dx.doi.org/10.1074/jbc.274.41.29011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506150	hybrid			2022-12-25	WOS:000083017800029
J	Rasola, A; Far, DF; Hofman, P; Rossi, B				Rasola, A; Far, DF; Hofman, P; Rossi, B			Lack of intenucleosomal DNA fragmentation is related to C1(-) efflux impairment in hematopoietic cell apoptosis	FASEB JOURNAL			English	Article						CAD; DFF; hyperosmotic shock; ICAD	CASPASE-ACTIVATED DNASE; CYTOCHROME-C; CHROMATIN CONDENSATION; CD95-INDUCED APOPTOSIS; DEPENDENT ACTIVATION; ICE/CED-3 PROTEASE; CHLORIDE CHANNEL; PLASMA-MEMBRANE; IN-VIVO; MITOCHONDRIAL	The heterodimeric DNA fragmentation factor (DFF) is responsible for DNA degradation into nucleosomal units during apoptosis, This process needs the caspase-dependent release of ICAD/DFF-45, the inhibitory subunit of DFF, Here we report that triggering apoptosis via a hyperosmotic shock in hematopoietic cells causes the appearance of mitochondrial and cytosolic alterations, activation of caspases, chromatin condensation, nuclear disruption, and DNA fragmentation, However, oligonucleosomal but not high molecular weight (50-150 kb) DNA cleavage is abolished if Cl- efflux is prevented by using NaCl to raise extracellular osmolarity or by Cl- channel blockers, even when apoptosis is initiated by other agents (staurosporine, anti-Fas antibody), In these conditions, all the apoptosis hallmarks investigated remain detectable, including the cleavage of ICAD/DFF-45. In vitro assays with lysates of cells in which Cl- efflux is blocked confirm the lack of internucleosomal DNA degradation, These findings establish that neither caspase activation nor ICAD/DFF-45 processing per se is sufficient to induce oligonucleosomal DNA fragmentation and that high molecular weight DNA degradation and chromatin condensation appear independently of it, Finally, they suggest that Cl- efflux is a necessary cofactor that intervenes specifically in the activation of the DFF endonuclease.-Rasola, A., Farahi Far, D., Hofman, P., Rossi, B. Lack of internucleosomal DNA fragmentation is related to Cl- efflux impairment in hematopoietic cell apoptosis.	Fac Med, Inserm U364, Unite Rech Immunol Cellulaire & Mol, F-06107 Nice 2, France; Hop Louis Pasteur, Anat Pathol Lab, F-06002 Nice 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice	Rossi, B (corresponding author), Fac Med, Inserm U364, Unite Rech Immunol Cellulaire & Mol, Ave Valombrose, F-06107 Nice 2, France.	1anteri@unice.fr	Hofman, Paul/P-7654-2018	Hofman, Paul/0000-0003-0431-9353; Rasola, Andrea/0000-0003-4522-3008				Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; Castedo M, 1996, J IMMUNOL, V157, P512; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Dallaporta B, 1998, J IMMUNOL, V160, P5605; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GALIETTA LJV, 1991, BIOCHEM BIOPH RES CO, V179, P1155, DOI 10.1016/0006-291X(91)91692-6; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LUKACS GL, 1991, FEBS LETT, V288, P17, DOI 10.1016/0014-5793(91)80992-C; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; RASOLA A, 1992, BIOCHIM BIOPHYS ACTA, V1139, P319, DOI 10.1016/0925-4439(92)90108-Y; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walker PR, 1997, BIOCHEM CELL BIOL, V75, P287, DOI 10.1139/bcb-75-4-287; Wyllie A, 1998, NATURE, V391, P20, DOI 10.1038/34040; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	43	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1711	1723		10.1096/fasebj.13.13.1711	http://dx.doi.org/10.1096/fasebj.13.13.1711			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506574				2022-12-25	WOS:000083063400006
J	Suttner, DM; Dennery, PA				Suttner, DM; Dennery, PA			Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron	FASEB JOURNAL			English	Article						heme; hyperoxia; doxycycline; carbon monoxide; bilirubin	FIBROBLAST GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; HEME OXYGENASE GENE; CARBON-MONOXIDE; OXIDANT STRESS; MESSENGER-RNA; BIOLOGICAL-SYSTEMS; ENDOTHELIAL-CELLS; GUANYLYL CYCLASE; EPITHELIAL-CELLS	It is often postulated that the cytoprotective nature of heme oxygenase (HO-1) explains the inducible nature of this enzyme, However, the mechanisms by which protection occurs are not verified by systematic evaluation of the physiological effects of HO. To explain how induction of HO-1 results in protection against oxygen toxicity, hamster fibroblasts (HA-1) were stably transfected with a tetracycline response plasmid containing the full-length rat HO-1 cDNA construct to allow for regulation of gene expression by varying concentrations of doxycycline (Dox), Transfected cells were exposed to hyperoxia (95% O-2/5% CO2) for 24 h and several markers of oxidative injury were measured. With varying concentrations of Dox, HO activity was regulated between 3- and 17-fold. Despite cytoprotection with low (less than fivefold) HO activity, high levels of HO-1 expression (greater than 15-fold) were associated with significant oxygen cytotoxicity. Levels of non-heme reactive iron correlated with cellular injury in hyperoxia whereas lower levels of heme were associated with cytoprotection, Cellular levels of cyclic GMP and bilirubin were not significantly altered by modification of HO activity, precluding a substantial role for activation of guanylate cyclase by carbon monoxide or for accumulation of bile pigments in the physiological consequences of HO-1 overexpression. Inhibition of HO activity or chelation of cellular iron prior to hyperoxic exposure decreased reactive iron levels in the samples and significantly reduced oxygen toxicity, We conclude that there is a beneficial threshold of HO-1 overexpression related to the accumulation of reactive iron released in the degradation of heme. Therefore, despite the ready induction of HO-1 in oxidant stress, accumulation of reactive iron formed makes it unlikely that exaggerated expression of HO-1 is a cytoprotective response..	Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA	Stanford University	Dennery, PA (corresponding author), Stanford Univ, Sch Med, Dept Pediat, 750 Welch Rd 315, Palo Alto, CA 94304 USA.		Dennery, Phyllis/GQG-9113-2022		NHLBI NIH HHS [HL25701] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; APPLEGATE LA, 1991, CANCER RES, V51, P974; BALLA G, 1992, J BIOL CHEM, V267, P18148; Bloch KD, 1997, AM J PHYSIOL-LUNG C, V272, pL400, DOI 10.1152/ajplung.1997.272.3.L400; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Coceani F, 1996, BRIT J PHARMACOL, V118, P1689, DOI 10.1111/j.1476-5381.1996.tb15593.x; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dennery PA, 1996, AM J PHYSIOL-LUNG C, V271, pL672, DOI 10.1152/ajplung.1996.271.4.L672; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; EVANS PJ, 1994, METHOD ENZYMOL, V233, P82; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; FERREIRA GC, 1995, BIOCHEM BIOPH RES CO, V214, P875, DOI 10.1006/bbrc.1995.2368; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; GLADSTONE IM, 1994, PEDIATRICS, V93, P764; GUTTERIDGE JM, 1982, BIOCHEM J, V206, P625; GUTTERIDGE JMC, 1994, THORAX, V49, P707, DOI 10.1136/thx.49.7.707; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P263, DOI 10.1042/bj1990263; Gutteridge JMC, 1996, BIOCHEM BIOPH RES CO, V229, P806, DOI 10.1006/bbrc.1996.1884; Hsu PI, 1997, ANTICANCER RES, V17, P2803; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; Inoue Y, 1996, AM J PATHOL, V149, P2037; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Liebler JM, 1997, GROWTH FACTORS, V14, P25, DOI 10.3109/08977199709021508; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; Madden SL, 1996, CANCER RES, V56, P5384; McDonagh AF, 1998, MONATSH CHEM, V129, P649, DOI 10.1007/PL00013473; NUTTER LM, 1994, J LAB CLIN MED, V123, P506; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; RAHMAN IU, 1991, AM J PHYSIOL, V260, pL412, DOI 10.1152/ajplung.1991.260.6.L412; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Ryan TP, 1997, FREE RADICAL BIO MED, V22, P901, DOI 10.1016/S0891-5849(96)00483-2; SCHACTER E, 1994, FREE RADICAL BIO MED, V17, P429; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUTTNER DM, 1999, AM J PHYSIOL, V276, P463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaillant P, 1996, Monaldi Arch Chest Dis, V51, P145; VARSILA E, 1995, ACTA PAEDIATR, V84, P1296, DOI 10.1111/j.1651-2227.1995.tb13552.x; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VIGNE P, 1995, BIOCHEM BIOPH RES CO, V214, P1, DOI 10.1006/bbrc.1995.2248; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; Willis D., 1995, Inflammation Research, V44, pS218, DOI 10.1007/BF01778342; WRIGHT JR, 1981, ARCH BIOCHEM BIOPHYS, V206, P296, DOI 10.1016/0003-9861(81)90095-3; Yee EL, 1996, AM J PHYSIOL-LUNG C, V271, pL512, DOI 10.1152/ajplung.1996.271.4.L512; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; ZAIDI A, 1995, EUR J PHARM-MOLEC PH, V290, P133, DOI 10.1016/0922-4106(95)90025-X; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140, DOI 10.1164/ajrccm.156.4.96-08056	62	338	350	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1800	1809		10.1096/fasebj.13.13.1800	http://dx.doi.org/10.1096/fasebj.13.13.1800			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506583				2022-12-25	WOS:000083063400015
J	Hasegawa, M; Hidaka, Y; Matsumoto, Y; Sanni, T; Shimonishi, Y				Hasegawa, M; Hidaka, Y; Matsumoto, Y; Sanni, T; Shimonishi, Y			Determination of the binding site on the extracellular domain of guanylyl cyclase C to heat-stable enterotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIGENIC ESCHERICHIA-COLI; AMINO-ACID-SEQUENCE; FUNCTIONAL EXPRESSION; RECEPTOR; IDENTIFICATION; INTESTINE; PROTEINS; HORMONE; PEPTIDE; ANALOG	Guanylyl cyclase C, one of the family of membrane-bound guanylyl cyclases, consists of an extracellular domain and an intracellular domain, which are connected by a single transmembrane polypeptide. The extracellular domain binds unique small polypeptides with high specificity, which include the endogenous peptide hormones, guanylin and uroguanylin, as well as an exogenous enterotoxigenic peptide, heat-stable enterotoxin, secreted by pathogenic Escherichia coli. Information on this specific binding is propagated into the intracellular domain, followed by the synthesis of cGMP, a second messenger that regulates a variety of intracellular physiological processes. This study reports the design of a photoaffinity labeled analog of heat-stable enterotoxin (biotinyl-(AC(5))(2)-[Gly(4),Pap(11)]STp(4-17)), which incorporates a Pap residue (p-azidophenylalanine) at position 11 and a biotin moiety at the N terminus, and the use of this analog to determine the ligand-binding region of the extracellular domain of guanylyl cyclase C, The endoproteinase Lys-C digestion of the extracellular domain, which was covalently labeled by this ligand, and mass spectrometric analyses of the digest revealed that the ligand specifically binds to the region (residue 387 to residue 393) of guanylyl cyclase C. This region is localized close to the transmembrane portion of guanylyl cyclase C on the external cellular surface. This result was further confirmed by characterization of site-directed mutants of guanylyl cyclase C in which each amino acid residue was substituted by an Ala residue instead of residues normally located in the region. This experiment provides the first direct demonstration of the ligand-binding site of guanylyl cyclase C and will contribute toward an understanding of the receptor recognition of a ligand and the modeling of the interaction of the receptor and its ligand at the molecular level.	Osaka Univ, Inst Prot Res, Div Prot Organ Chem, Suita, Osaka 5650871, Japan	Osaka University	Shimonishi, Y (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Organ Chem, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	simonisi@protein.osaka-u.ac.jp		HIDAKA, YUJI/0000-0002-3131-2619				AIMOTO S, 1983, BIOCHEM BIOPH RES CO, V112, P320, DOI 10.1016/0006-291X(83)91833-8; AIMOTO S, 1982, EUR J BIOCHEM, V129, P257, DOI 10.1111/j.1432-1033.1982.tb07047.x; Bayley H, 1977, Methods Enzymol, V46, P69; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; EBERLE AN, 1985, METHOD ENZYMOL, V109, P129; GARBERS DL, 1992, CELL, V71, P1; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; Hasegawa M, 1997, LETT PEPT SCI, V4, P1; Hasegawa M, 1999, PROTEIN EXPRES PURIF, V15, P271, DOI 10.1006/prep.1998.1019; KUBOTA H, 1989, BIOCHEM BIOPH RES CO, V161, P229, DOI 10.1016/0006-291X(89)91585-4; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; OZAKI H, 1991, J BIOL CHEM, V266, P5934; PANDEY KN, 1986, BIOCHEMISTRY-US, V25, P8467, DOI 10.1021/bi00374a022; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUDNER XL, 1995, P NATL ACAD SCI USA, V92, P5169, DOI 10.1073/pnas.92.11.5169; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; TAKAO T, 1983, FEBS LETT, V152, P1, DOI 10.1016/0014-5793(83)80469-4; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; Wada A, 1996, INFECT IMMUN, V64, P5144, DOI 10.1128/IAI.64.12.5144-5150.1996; WADA A, 1994, MICROBIOL IMMUNOL, V38, P535, DOI 10.1111/j.1348-0421.1994.tb01819.x; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X; YAMASAKI S, 1990, B CHEM SOC JPN, V63, P2063, DOI 10.1246/bcsj.63.2063	28	24	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31713	31718		10.1074/jbc.274.44.31713	http://dx.doi.org/10.1074/jbc.274.44.31713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531382	hybrid			2022-12-25	WOS:000083379400086
J	Snyder, CH; Trumpower, BL				Snyder, CH; Trumpower, BL			Ubiquinone at center N is responsible for triphasic reduction of cytochrome b in the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; PROTONMOTIVE-Q-CYCLE; IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; C OXIDOREDUCTASE; Q-POOL; MITOCHONDRIAL; YEAST; EQUILIBRIUM; SUCCINATE	We have examined the pre-steady state reduction kinetics of the Saccharomyces cerevisiae cytochrome bc(1) complex by menaquinol in the presence and absence of endogenous ubiquinone to elucidate the mechanism of triphasic cytochrome b reduction. With cytochrome bc(1) complex from wild type yeast, cytochrome b reduction was triphasic, consisting of a rapid partial reduction phase, an apparent partial reoxidation phase, and a slow rereduction phase. Absorbance spectra taken by rapid scanning spectroscopy at 1-ms intervals before, during, and after the apparent reoxidation phase showed that this was caused by a bona fide reoxidation of cytochrome b and not by any negative spectral contribution from cytochrome c(1). With cytochrome bc(1) complex from a yeast mutant that cannot synthesize ubiquinone, cytochrome b reduction by either menaquinol or ubiquinol was rapid and monophasic, Addition of ubiquinone restored triphasic cytochrome b reduction, and the duration of the reoxidation phase increased as the ubiquinone concentration increased. When reduction of the cytochrome bc(1) complex through center P was blocked, cytochrome b reduction through center N was biphasic and was slowed by the addition of exogenous ubiquinone. These results show that ubiquinone residing at center N in the oxidized cytochrome bc(1) complex is responsible for the triphasic reduction of cytochrome b.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.				NIGMS NIH HHS [GM 20379, GM 18811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CHEN M, 1986, BIOCHIM BIOPHYS ACTA, V851, P457, DOI 10.1016/0005-2728(86)90082-4; DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; KAUTEN R, 1987, J BIOL CHEM, V262, P8658; Kroger A., 1985, COENZYME Q, P285; LINKE P, 1986, EUR J BIOCHEM, V158, P615, DOI 10.1111/j.1432-1033.1986.tb09799.x; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RICH PR, 1983, BIOCHIM BIOPHYS ACTA, V722, P271, DOI 10.1016/0005-2728(83)90073-7; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; TANG HL, 1986, J BIOL CHEM, V261, P6209; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, BIOCHIM BIOPHYS ACTA, V722, P349, DOI 10.1016/0005-2728(83)90083-X; TSOU CL, 1982, BIOCHIM BIOPHYS ACTA, V682, P315, DOI 10.1016/0005-2728(82)90044-5; VANHOEK AN, 1987, BIOCHIM BIOPHYS ACTA, V892, P152, DOI 10.1016/0005-2728(87)90257-X; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1981, BIOCHIM BIOPHYS ACTA, V639, P99, DOI 10.1016/0304-4173(81)90007-0; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31209	31216		10.1074/jbc.274.44.31209	http://dx.doi.org/10.1074/jbc.274.44.31209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531315	hybrid			2022-12-25	WOS:000083379400019
J	Hoying, JB; Yin, MY; Diebold, R; Ormsby, I; Becker, A; Doetschman, T				Hoying, JB; Yin, MY; Diebold, R; Ormsby, I; Becker, A; Doetschman, T			Transforming growth factor beta 1 enhances platelet aggregation through a non-transcriptional effect on the fibrinogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TGF-BETA; LIGAND-BINDING; SHAPE-CHANGE; ACTIVATION; MICE; GENE; FACTOR-BETA-1; BLOOD; PROTEIN	Upon activation, platelets store and release large amounts of the peptide transforming growth factor beta 1 (TGF beta 1). The released TGF beta 1 can then act on nearby vascular cells to mediate subsequent vessel repair. In addition, TGF beta 1 may circulate to bone marrow and regulate megakaryocyte activity. It is not known what effect, if any, TGF beta 1 has on platelets. Adult TGF beta 1-deficient mice exhibit thrombocythemia and a mild bleeding disorder that is shown to result, from faulty platelet aggregation. TGF beta 1-deficient platelets are shown to contain functional receptors, and preincubation with recombinant TGF beta 1 improves aggregation, demonstrating that TGF beta 1 plays an active role in platelet aggregation, TGF beta 1-deficient platelets fail to retain bound fibrinogen in response to aggregation agonists, but they possess normal levels of the alpha(IIb)/beta(3) fibrinogen receptor. Signaling from agonist receptors is normal because the platelets change shape, produce thromboxane A(2), and present P-selectin in response to stimulation, Consequently, activation and maintenance of alpha(IIb)/beta(3) into a fibrinogen-binding conformation is impaired in the absence of TGF beta 1. 4-Phorbol 12-myristate 13-acetate treatment and protein kinase C activity measurements suggest a defect downstream of protein kinase C in its activation cascade. Because platelets lack nuclei, these data demonstrate for the first time a non-transcriptionally mediated TGF beta 1 signaling pathway that enhances the activation and maintenance of integrin function.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Program Excellence Mol Biol, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp, Div Hematol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Doetschman, T (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Program Excellence Mol Biol, 231 Bethesda Ave,ML 524, Cincinnati, OH 45267 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NICHD NIH HHS [HD26471] Funding Source: Medline; NIEHS NIH HHS [ES05652] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BOIVIN GP, 1995, AM J PATHOL, V146, P276; CARLINO JA, 1992, EXP HEMATOL, V20, P943; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; DORN GW, 1991, AM J PHYSIOL, V260, pH327, DOI 10.1152/ajpheart.1991.260.2.H327; FINDER J, 1995, AM J PHYSIOL-LUNG C, V268, pL862, DOI 10.1152/ajplung.1995.268.5.L862; GAMBLE JR, 1988, SCIENCE, V242, P97; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; ISHIBASHI T, 1987, BLOOD, V69, P1737; Johnson EN, 1998, P NATL ACAD SCI USA, V95, P3100, DOI 10.1073/pnas.95.6.3100; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kropf J, 1997, CLIN CHEM, V43, P1965; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; KUTER DJ, 1992, BLOOD, V79, P619; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; OYEKAN AO, 1991, HAEMOSTASIS, V21, P360; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shi Y, 1996, ARTERIOSCL THROM VAS, V16, P1298, DOI 10.1161/01.ATV.16.10.1298; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Tobelem G, 1989, Baillieres Clin Haematol, V2, P719, DOI 10.1016/S0950-3536(89)80040-X; TURITTO VT, 1985, BLOOD, V65, P823; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; VLODAVSKY I, 1982, THROMB RES, V28, P179, DOI 10.1016/0049-3848(82)90260-2; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WARKENTIN TE, 1990, BRIT J HAEMATOL, V76, P387, DOI 10.1111/j.1365-2141.1990.tb06373.x; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; Wehmeier A, 1997, SEMIN THROMB HEMOST, V23, P391, DOI 10.1055/s-2007-996114; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	41	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31008	31013		10.1074/jbc.274.43.31008	http://dx.doi.org/10.1074/jbc.274.43.31008			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521498	hybrid			2022-12-25	WOS:000083276700094
J	Suzuki, H; Nishiyama, K; Tokuda, H				Suzuki, H; Nishiyama, K; Tokuda, H			Increases in acidic phospholipid contents specifically restore protein translocation in a cold-sensitive secA or secG null mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; ESCHERICHIA-COLI; MEMBRANE-VESICLES; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; LOW-TEMPERATURE; PREPROTEIN TRANSLOCATION; PRESECRETORY PROTEINS; PLASMA-MEMBRANE; ATP; MACHINERY	Both the secAcsR11 and Delta secG::kan mutations cause cold-sensitive growth, although the growth defect due to the latter mutation occurs in a strain-specific manner. Overexpression of pgsA encoding phosphatidylglycerophosphate synthase suppresses the growth defects of the two mutants. We investigated the mechanism underlying the pgsA-dependent suppression of the two mutations using purified mutant SecA and inverted membrane vesicles (IMVs) prepared from pgsA-overexpressing cells. The acidic phospholipid content increased by about 10% upon pgsA overexpression. This increase resulted in the stimulation of proOmpA translocation only when mutant SecA or SecG-depleted IMVs were used. The translocation-coupled ATPase activity of SecA was significantly defective with the mutant SecA or SecG-depleted IMVs, but it recovered to a near normal level when the acidic phospholipid level was increased. The stimulation of ATPase activity was observed only at low temperature. The steady-state level of membrane-inserted SecA was low with the mutant SEcA or SecG-depleted IMVs, and ii decreased further upon the increase in the acidic phospholipid content. However, the level of SecA insertion markedly increased upon the inhibition of SecA deinsertion by the addition of beta,gamma-imido adenosine 5'-triphosphate (AMP-PNP), especially with IMVs containing increased levels of acidic phospholipids. These results indicate that the increase in the level of acidic phospholipids stimulates the SecA cycle in the two mutants by facilitating both the insertion and deinsertion of SecA.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							AKITA M, 1990, J BIOL CHEM, V265, P8164; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; DENBLAAUWEN T, 1996, BIOCHEMISTRY-US, V35, P11194; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GOPALAKRISHNAN AS, 1986, J BIOL CHEM, V261, P1329; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanada M, 1996, FEBS LETT, V381, P25, DOI 10.1016/0014-5793(96)00066-X; Ito K, 1996, GENES CELLS, V1, P337, DOI 10.1046/j.1365-2443.1996.34034.x; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KONTINEN VP, 1995, FEBS LETT, V364, P157, DOI 10.1016/0014-5793(95)00378-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LILL R, 1990, CELL, V60, P259; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V279, P233; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; RIGGS PD, 1988, GENETICS, V118, P571; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; Shimizu H, 1997, MOL MICROBIOL, V26, P1013, DOI 10.1046/j.1365-2958.1997.6392003.x; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; USUI M, 1994, J BACTERIOL, V176, P3389, DOI 10.1128/jb.176.11.3389-3392.1994; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31020	31024		10.1074/jbc.274.43.31020	http://dx.doi.org/10.1074/jbc.274.43.31020			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521500	hybrid			2022-12-25	WOS:000083276700096
J	Walker, CS; Steel, D; Jacobsen, RB; Lirazan, MB; Cruz, LJ; Hooper, D; Shetty, R; DelaCruz, RC; Nielsen, JS; Zhou, LM; Bandyopadhyay, P; Craig, AG; Olivera, BM				Walker, CS; Steel, D; Jacobsen, RB; Lirazan, MB; Cruz, LJ; Hooper, D; Shetty, R; DelaCruz, RC; Nielsen, JS; Zhou, LM; Bandyopadhyay, P; Craig, AG; Olivera, BM			The T-superfamily of conotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; K-DEPENDENT CARBOXYLASE; CONUS SNAIL; CHANNEL; PRECURSOR; PEPTIDES; TARGETS	We report the discovery and initial characterization of the T-superfamily of conotoxins. Eight different T-superfamily peptides from five Conus species were identified; they share a consensus signal sequence, and a conserved arrangement of cysteine residues (- -CC--CC-), T-superfamily peptides were found expressed in venom ducts of all major feeding types of Conus; the results suggest that the T-superfamily will be a large and diverse group of peptides, widely distributed in the 500 different Conus species. These peptides are likely to be functionally diverse; although the peptides are small (11-17 amino acids), their sequences are strikingly divergent, with different peptides of the superfamily exhibiting varying extents of post-translational modification. Of the three peptides tested for in vivo biological activity, only one was active on mice but all three had effects on fish. The peptides that have been extensively characterized are as follows: p5a, GCCP-KQMRCCTL*; tx5a, gamma CC gamma DGW(+)CCT AAO; and au5a, FC-CPFIRYCCW (where gamma = gamma-carboxyglutamate, W+ = bromotryptophan, O = hydroxyproline, T = glycosylated threonine, and * = COOH-terminal amidation). We also demonstrate that the precursor of tx5a contains a functional gamma-carboxylation recognition signal in the -1 to -20 propeptide region, consistent with the presence of gamma-carboxyglutamate residues in this peptide.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Philippines, Dept Phys Sci & Math, Manila 1000, Philippines; Univ Philippines, Inst Marine Sci, Quezon 1101, Philippines; Cognetix Inc, Salt Lake City, UT 84108 USA; Salk Inst, Clayton Fdn Labs Peptide Biol, San Diego, CA 92186 USA	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Manila; University of the Philippines System; University of the Philippines Diliman; Salk Institute	Olivera, BM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.			Hooper, David/0000-0001-8732-4291	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], 1995, MANUAL LIVING CONIDA; Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Cartier G. E., 1996, Society for Neuroscience Abstracts, V22, P268; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; COTTER RJ, 1989, BIOMED ENVIRON MASS, V18, P513, DOI 10.1002/bms.1200180803; Craig AG, 1999, J BIOL CHEM, V274, P13752, DOI 10.1074/jbc.274.20.13752; DORFMAN DM, 1989, BIOTECHNIQUES, V7, P568; *GEN COMP GROUP, 1997, AN WISC PACK VERS 9; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; KOHN AJ, 1960, ANN NY ACAD SCI, V90, P706, DOI 10.1111/j.1749-6632.1960.tb26416.x; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONJE VD, 1993, NEUROPHARMACOLOGY, V32, P1141, DOI 10.1016/0028-3908(93)90008-Q; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Sambrook J., 2002, MOL CLONING LAB MANU; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8	25	118	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30664	30671		10.1074/jbc.274.43.30664	http://dx.doi.org/10.1074/jbc.274.43.30664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521453	hybrid			2022-12-25	WOS:000083276700049
J	Wong, UW; Tang, YZ; Feyfant, E; Sali, A; Li, LX; Li, Y; Huang, CF; Friend, DS; Krilis, SA; Stevens, RL				Wong, UW; Tang, YZ; Feyfant, E; Sali, A; Li, LX; Li, Y; Huang, CF; Friend, DS; Krilis, SA; Stevens, RL			Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEASES; SERINE PROTEASES; GEL-ELECTROPHORESIS; HEMATOPOIETIC-CELLS; COMPLEMENTARY-DNA; MESSENGER-RNA; EXPRESSION; CLONING; SEQUENCE; PURIFICATION	Mapping of the tryptase locus on chromosome 17 revealed a novel gene 2.3 kilobase 3' of the mouse mast cell protease (mMCP) 6 gene. This 3.7-kilobase gene encodes the first example of a protease in the tryptase family that contains a membrane-spanning segment located at its COOH terminus. Comparative structural studies indicated that the putative transmembrane tryptase (TMT) possesses a unique substrate-binding cleft. As assessed by RNA blot analyses, mTMT is expressed in mice in both strain- and tissue-dependent manners. Thus, different transcriptional and/or post-transcriptional mechanisms are used to control the expression of mTMT in vivo. Analysis of the corresponding tryptase locus in the human genome resulted in the isolation and characterization of the hTMT gene. The hTMT transcript is expressed in numerous tissues and is also translated. Analysis of the tryptase family of genes in mice and humans now indicates that a primordial serine protease gene duplicated early and often during the evolution of mammals to generate a panel of homologous tryptases in each species that differ in their tissue expression, substrate specificities, and physical properties.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Rockefeller Univ, New York, NY 10021 USA; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Univ New S Wales, Kogarah, NSW 2217, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University; St George Hospital; University of New South Wales Sydney	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506; Li, Yong/0000-0002-8910-9787	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R01GM054762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BENYON RC, 1993, J IMMUNOL, V151, P2699; BRAGANZA VJ, 1991, BIOCHEMISTRY-US, V30, P4997, DOI 10.1021/bi00234a023; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; EKLUND KK, 1993, J IMMUNOL, V151, P4266; Friend DS, 1998, J IMMUNOL, V160, P5537; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HUANG C, 1998, J IMMUNOL, V160, P5537; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Hunt JE, 1997, J BIOL CHEM, V272, P29158, DOI 10.1074/jbc.272.46.29158; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MORRI E, 1996, BLOOD, V88, P2488; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PERSONA JJ, 1995, PROTEIN SCI, V4, P337; RAYMOND WW, 1995, J BIOL CHEM, V270, P13164, DOI 10.1074/jbc.270.22.13164; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SALI A, 1993, J BIOL CHEM, V268, P9023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747	47	80	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30784	30793		10.1074/jbc.274.43.30784	http://dx.doi.org/10.1074/jbc.274.43.30784			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521469	hybrid			2022-12-25	WOS:000083276700065
J	Ansari, K; Martin, S; Farkasovsky, M; Ehbrecht, IM; Kuntzel, H				Ansari, K; Martin, S; Farkasovsky, M; Ehbrecht, IM; Kuntzel, H			Phospholipase C binds to the receptor-like GPR1 protein and controls pseudohyphal differentiation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; FILAMENTOUS GROWTH; COUPLED RECEPTOR; SHUTTLE VECTORS; YEAST; GENE; KINASE; RAS; ISOZYMES; ELEMENTS	The hormone receptor-like protein Gpr1p physically interacts with phosphatidylinositol-specific phospholipase C (Plc1p) and with the G alpha protein Gpa2p, as shown by two-hybrid assays and co-immune precipitation of epitope-tagged proteins. Plc1p binds to Gpr1p in either the presence or absence of Gpa2, whereas the Gpr1p/Gpa2p association depends on the presence of Plc1p. Genetic interactions between the null mutations plc1D, gpr1D, gpa2 Delta, and ras2 Delta suggest that Plc1p acts together with Gpr1p and Gpa2p in a growth control pathway operating in parallel to the Ras2p function, Diploid cells lacking Gpr1p, Plc1p, or Gpa2p fail to form pseudohyphae upon nitrogen depletion, and the filamentation defect of gpr1D and plc1D strains is rescued by activating a mitogen-activated protein kinase pathway via STE11-4 or by activating a cAMP pathway via overexpressed Tpk2p, Plc1p is also required for efficient expression of the FG(TyA)::lacZ reporter gene under nitrogen depletion. In conclusion, we have identified two physically interacting proteins, Gpr1p and Plc1p, as novel components of a nitrogen signaling pathway controlling the developmental switch from yeast-like to pseudohyphal growth. Our data suggest that phospholipase C modulates the interaction of the putative nutrient sensor Gpr1p with the G alpha protein Gpa2p as a downstream effector of filamentation control.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia	Max Planck Society; Slovak Academy of Sciences	Kuntzel, H (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.							Ashcroft FM, 1998, SCIENCE, V282, P1059, DOI 10.1126/science.282.5391.1059; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; FARKASOVSKY M, 1995, J CELL BIOL, V131, P1003, DOI 10.1083/jcb.131.4.1003; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Flick JS, 1998, GENETICS, V148, P33; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KORMANEC J, 1991, MOL GEN GENET, V230, P277, DOI 10.1007/BF00290678; Kubler E, 1997, J BIOL CHEM, V272, P20321, DOI 10.1074/jbc.272.33.20321; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; MARTIN S, 1998, THESIS U GOTTINGEN; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; SCHOMERUS C, 1992, FEBS LETT, V307, P249, DOI 10.1016/0014-5793(92)80688-D; Sherman F., 1986, METHODS YEAST GENETI, P163; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; Yun CW, 1998, BIOCHEM BIOPH RES CO, V252, P29, DOI 10.1006/bbrc.1998.9600	39	67	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30052	30058		10.1074/jbc.274.42.30052	http://dx.doi.org/10.1074/jbc.274.42.30052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514491	hybrid			2022-12-25	WOS:000083176400070
J	Halim, AB; LeGros, L; Geller, A; Kotb, M				Halim, AB; LeGros, L; Geller, A; Kotb, M			Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; MOLECULAR MECHANISMS; NUCLEOTIDE-SEQUENCE; HUMAN-ERYTHROCYTES; HUMAN-LYMPHOCYTES; ISOZYMES; CLONING; METHYLTRANSFERASES; FRACTIONATION	Methionine adenosyltransferase (MAT) catalyzes the synthesis of S-adenosylmethionine (AdoMet). The mammalian MAT II isozyme consists of catalytic alpha(2) and regulatory beta subunits, The aim of this study was to investigate the interaction and kinetic behavior of the human MAT II subunit proteins in mammalian cells. COS-1 cells were transiently transfected with pTargeT vector harboring fall-length cDNA that encodes for the MAT II alpha(2) or beta subunits. Expression of the His-tagged recombinant alpha(2) (r alpha(2)) subunit in COS-1 cells markedly increased MAT II activity and resulted in a shift in the K-m, for L-methionine (L-Met) from 15 mu M (endogenous MAT II) to 75 mu M (r alpha(2)), and with the apparent existence of two kinetic forms of MAT in the transfected COS-I cell extracts, By contrast, expression of the recombinant beta (r beta) subunit had no effect on the K-m for L-Met of the endogenous MAT II, while it did cause an increase in both the V-max and the specific activity of endogenous MAT. Go-expression of both r alpha(2) and r beta subunits resulted in a significant increase of MAT specific activity with the appearance of a single kinetic form of MAT (K-m = 20 mu M). The recombinant MAT II alpha(2) and r beta suibunit associated spontaneously either in cell-free system or in COS-1 cells coexpressing both subunits, Analysis of nickel-agarose-purified His-tagged r alpha(2) subunit from COS-1 cell extracts showed that the beta subunit co-purified with the alpha(2) subunit. Furthermore, the alpha(2) and beta subunits co-migrated in native polyacrylamide gels. Together, the data provide evidence for alpha(2) and beta MAT subunit association. In addition, the beta subunit regulated MAT II activity by reducing its K-m for L-Met and by rendering the enzyme more susceptible to feedback inhibition by AdoMet. We believe that the previously described differential expression of MAT II beta subunit may be an important mechanism by which MAT activity can be modulated to provide different levels of AdoMet that may be required at different stages of cell growth and differentiation.	Univ Tennessee, Dept Surg, Memphis, TN 38104 USA; Univ Tennessee, Dept Immunol & Microbiol, Memphis, TN 38104 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38104 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kotb, M (corresponding author), Univ Tennessee, 956 Court Ave,Suite A-202, Memphis, TN 38163 USA.				NIGMS NIH HHS [GM-54892-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; CANTONI GL, 1953, J BIOL CHEM, V204, P403; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1990, HEPATOLOGY, V11, P216, DOI 10.1002/hep.1840110210; DELAROSA J, 1991, BIOCHIM BIOPHYS ACTA, V1077, P225, DOI 10.1016/0167-4838(91)90062-5; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FUJIOKA M, 1992, INT J BIOCHEM, V24, P1917, DOI 10.1016/0020-711X(92)90287-B; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Kotb M, 1997, TRENDS GENET, V13, P51; Koth M, 1985, J BIOL CHEM, V260, P3923; LANGKAMPHENKEN B, 1994, BBA-GEN SUBJECTS, V1201, P397, DOI 10.1016/0304-4165(94)90068-X; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LIAU MC, 1979, CANCER RES, V39, P162; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1995, MOL METABOLIC BASIS; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240	33	78	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29720	29725		10.1074/jbc.274.42.29720	http://dx.doi.org/10.1074/jbc.274.42.29720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514445	hybrid			2022-12-25	WOS:000083176400024
J	Mulvaney, JM; Zhang, T; Fewtrell, C; Roberson, MS				Mulvaney, JM; Zhang, T; Fewtrell, C; Roberson, MS			Calcium influx through L-type channels is required for selective activation of extracellular signal-regulated kinase by gonadotropin-releasing hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-T3-1 CELL-LINE; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; PITUITARY GONADOTROPHS; GENE-EXPRESSION; TRANSDUCTION PATHWAYS; CA2+ CHANNELS; MAP KINASE; PHOSPHORYLATION; DEPOLARIZATION	The hypothalamic decapeptide gonadotropin-releasing hormone stimulates mobilization of two discrete pools of calcium in clonal (alpha T3-1) and primary pituitary gonadotropes, A multidisciplinary approach was implemented to investigate the effects of discrete calcium fluctuations on the signaling pathways linking the gonadotropin-releasing hormone receptor to activation of mitogen-activated protein kinases and immediate early genes. Blockade of calcium influx through nifedipine-sensitive voltage-gated calcium channels reduced buserelin-induced activation of extracellular signal-regulated kinase (ERK) and c-Fos while activation of c-Jun N-terminal kinase and c-Jun was unaffected, Inhibition of buserelin-stimulated ERK activity by nifedipine was also observed in rat pituitary cells in primary culture. Direct activation of alpha T3-1 cell L-type calcium channels with the agonist Bay-K 8644 resulted in phosphorylation of ERK. and induction of c-Fos. However, simple voltage-induced channel activation did not produce a sufficient calcium signal, since depolarization with 35 mM KCl failed to induce activation of ERR, Depletion of intracellular calcium stores with thapsigargin did not affect buserelin-induced ERR activation. An inhibitor of protein kinase C decreased calcium influx through nifedipine-sensitive calcium channels and phosphorylation of ERK induced by buserelin. pharmacological inhibition of protein kinase C did not block Bay-K 8644-induced ERK activation. These observations suggest that calcium influx through L-type channels is required for GnRH-induced activation of ERK and c-Fos and that the influence of calcium lies downstream of protein kinase C.	Cornell Univ, Dept Biomed Sci, Coll Vet Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA	Cornell University; Cornell University	Roberson, MS (corresponding author), Cornell Univ, Dept Biomed Sci, Coll Vet Med, T6-008A Vet Res Tower, Ithaca, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034722] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011105] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34722] Funding Source: Medline; NIMH NIH HHS [MH11105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Evans JJ, 1997, ENDOCRINOLOGY, V138, P2049, DOI 10.1210/en.138.5.2049; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; HADLEY RW, 1992, AM J PHYSIOL, V262, pH472, DOI 10.1152/ajpheart.1992.262.2.H472; HAMERNIK DL, 1988, ENDOCRINOLOGY, V122, P959, DOI 10.1210/endo-122-3-959; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HOLSTOCK JG, 1996, MOL ENDOCRINOL, V10, P1308; HOSHI T, 1987, J NEUROSCI, V7, P571; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; IZUMI S, 1990, BIOCHEM BIOPH RES CO, V170, P359, DOI 10.1016/0006-291X(90)91282-W; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KRUSE HJ, 1994, J CARDIOVASC PHARM, V24, P328, DOI 10.1097/00005344-199424020-00020; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; MCARDLE CA, 1992, MOL CELL NEUROSCI, V3, P124, DOI 10.1016/1044-7431(92)90016-U; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; PREVARSKAYA N, 1994, MOL CELL NEUROSCI, V5, P699, DOI 10.1006/mcne.1994.1084; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Saunders BD, 1998, ENDOCRINOLOGY, V139, P1835, DOI 10.1210/en.139.4.1835; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Vichi P, 1999, AM J RESP CELL MOL, V20, P99, DOI 10.1165/ajrcmb.20.1.3210; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Yamaoka K, 1998, PFLUG ARCH EUR J PHY, V435, P329, DOI 10.1007/s004240050519	39	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29796	29804		10.1074/jbc.274.42.29796	http://dx.doi.org/10.1074/jbc.274.42.29796			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514457	hybrid			2022-12-25	WOS:000083176400036
J	Skuta, G; Ho, CH; Grinnell, F				Skuta, G; Ho, CH; Grinnell, F			Increased myosin light chain phosphorylation is not required for growth factor stimulation of collagen matrix contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; LYSOPHOSPHATIDIC ACID; WOUND CONTRACTION; CELL-MIGRATION; CYCLIC-AMP; MORPHOLOGICAL-CHANGES; LATTICE CONTRACTION; ACTIN CYTOSKELETON; STRESS-RELAXATION; PROTEIN-KINASE	Previous research suggested the possibility that contraction of floating collagen matrices by human fibroblasts required increased myosin light chain (MLC) phosphorylation. In the current studies, we show that increased MLC phosphorylation was neither necessary for platelet-derived growth factor (PDGF)-dependent matrix contraction nor sufficient for lysophosphatidic acid (LPA)-dependent contraction. In contrast, increased MLC phosphorylation did appear to be coupled to the formation of stress fibers by cells spreading in monolayer culture. Signal transduction pathways required for PDGF- and LPA-dependent matrix contraction involved phosphatidylinositol 3-kinase and the G(i) class of heterotrimeric G proteins, respectively. Our re,suits indicate that PDGF- and LPA-dependent contraction of floating collagen matrices can be uncoupled from an increase in MLC phosphorylation.	Univ Texas, SW Med Sch, Dept Neurosci & Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, SW Med Sch, Dept Neurosci & Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	frederick.grinnell@email.swmed.edu			NIGMS NIH HHS [GM31321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031321, R37GM031321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Ahlen K, 1998, CELL ADHES COMMUN, V5, P461, DOI 10.3109/15419069809005604; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; EHRLICH HP, 1991, J CELL PHYSIOL, V146, P1, DOI 10.1002/jcp.1041460102; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; EHRLICH HP, 1984, J INVEST DERMATOL, V83, P230, DOI 10.1111/1523-1747.ep12263616; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GROSS J, 1995, P NATL ACAD SCI USA, V92, P5982, DOI 10.1073/pnas.92.13.5982; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HE YJ, 1994, J CELL BIOL, V126, P457, DOI 10.1083/jcb.126.2.457; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOLODNEY MS, 1995, P NATL ACAD SCI USA, V92, P10252, DOI 10.1073/pnas.92.22.10252; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin YC, 1997, MOL BIOL CELL, V8, P59, DOI 10.1091/mbc.8.1.59; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TANG DC, 1992, J BIOL CHEM, V267, P11839; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; VANBOCKXMEER FM, 1984, EXP CELL RES, V155, P413, DOI 10.1016/0014-4827(84)90202-7; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WORD RA, 1991, AM J PHYSIOL, V260, pC861, DOI 10.1152/ajpcell.1991.260.4.C861; Zent R, 1998, EXP CELL RES, V240, P134, DOI 10.1006/excr.1998.4008	51	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30163	30168		10.1074/jbc.274.42.30163	http://dx.doi.org/10.1074/jbc.274.42.30163			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514506	hybrid			2022-12-25	WOS:000083176400085
J	Osborn, MT; Berry, A; Ruberu, MS; Ning, BT; Bell, LM; Chambers, TC				Osborn, MT; Berry, A; Ruberu, MS; Ning, BT; Bell, LM; Chambers, TC			Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways	ONCOGENE			English	Article						MDR1 expression; P-glycoprotein; phorbol ester; PKC; MAPK; K562 cells	MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; TRANSCRIPTIONAL REGULATION; CALPHOSTIN-C; INHIBITOR; RAF-1; PROMOTER; STRESS; TRANSDUCTION; POTENT	The MDR1 gene encoding the multidrug pump P-glycoprotein is transcriptionally activated in response to diverse extracellular stimuli, including the tumor promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Hone, er, the signal transduction pathway responsible is unknown. Downstream of protein kinase C (PKC), the effects of TPA are often mediated by the Raf-1/MEK/ERK mitogen-activated protein kinase (MAPK) cascade, and Raf-1 has been implicated in MDR1 induction by serum and mitogens, Therefore, we examined the potential role of MAK activation in TPA-mediated MDR1 induction in human leukemia K562 cells. MDR1 mRNA expression was significantly increased by TPA in the concentration range of 4-100 nM, with a maximal response 5-10 h after TPA addition. TPA-mediated MDR1 induction was inhibited by several PKC inhibitors including staurosporine, H7 and calphostin C, TPA stimulated the subcellular translocation of PKC alpha from the cytosol to the membrane and nucleus but did not affect other PKC isozymes, TPA also activated the Raf1/MEK/ERK cascade and activated another MAPK member, p38, but not JNK, In order to determine the potential role of MAPKs in MDR1 induction by TPA, specific inhibitors were utilized. The MEK inhibitor PD 098059, as well as the PKC inhibitors, completely blocked TPA-mediated ERK activation. However, under identical conditions, MDR1 induction by TPA was completely unaffected by PD 098059, Furthermore, SB 202190, which effectively inhibited TPA-mediated p38 activation, failed to inhibit TPA-induced MDR1 mRNA expression. These data demonstrate that MDR1 induction by TPA occurs via a PKC-dependent mechanism that operates independently of ERK, p38 or JNK pathways, and thus have important implications for understanding the mechanisms of MDR1 induction by extracellular stimuli.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.			Ning, Baitang/0000-0003-0798-0331	NCI NIH HHS [CA75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1996, MULTIDRUG RESISTANCE, P273; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; CORNWELL MM, 1996, MULTIDRUG RESISTANCE, P39; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GLAZER RI, 1994, BREAST CANCER RES TR, V31, P263, DOI 10.1007/BF00666159; GOTTESMAN MM, 1991, MOL CELLULAR BIOL MU, P279; IGNATOVA TN, 1996, MULTIDRUG RESISTANCE, P177; INCE TA, 1997, ENCY CANC, V3, P1751; Izquierdo MA, 1996, EUR J CANCER, V32A, P979, DOI 10.1016/0959-8049(96)00053-6; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NOONAN KE, 1991, MOL CELLULAR BIOL MU, P319; OHKAWA T, 1996, MULTIDRUG RESISTANCE, P413; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; RISCHIN D, 1993, LEUKEMIA ADV RES TRE, P269; Simon C, 1998, CANCER RES, V58, P1135; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Thorgeirsson S S, 1994, Cancer Treat Res, V73, P57; UEDA K, 1987, J BIOL CHEM, V262, P505; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; ZHENG B, 1994, J BIOL CHEM, V269, P12332; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	44	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5756	5764		10.1038/sj.onc.1202943	http://dx.doi.org/10.1038/sj.onc.1202943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523856				2022-12-25	WOS:000083095100004
J	Genth, H; Aktories, K; Just, I				Genth, H; Aktories, K; Just, I			Monoglucosylation of RhoA at threonine 37 blocks cytosol-membrane cycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE; REGULATORY PROTEIN; CLOSTRIDIUM-BOTULINUM; ACTIVATING PROTEIN; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; BRAIN CYTOSOL; GENE-PRODUCT	The small GTPases Rho, Rac, and Cdc42 are monoglucosylated at effector domain amino acid threonine 37/35 by Clostridium difficile toxins A and B. Glucosylation renders the Rho proteins inactive by inhibiting effector coupling To understand the functional consequences, effects of glucosylation on subcellular distribution and cycling of Rho GTPases between cytosol and membranes were analyzed. In intact cells and in cell lysates, glucosylation leads to a translocation of the majority of RhoA GTPase to the membranes whereas a minor fraction is monomeric in the cytosol without being complexed with the guanine nucleotide dissociation inhibitor (GDI-1). Rho complexed with GDI-1 is not substrate for glucosylation, and modified Rho does not bind to GDI-1. However, a membranous factor inducing release of Rho from the GDI complex makes cytosolic Rho available as a substrate for glucosylation. The binding of glucosylated RhoA to the plasma membranes is saturable, competable with unmodified Rho-GTP gamma S guanosine 5'-O-(3-thiotriphosphate), and takes place at a membrane protein with a molecular mass of about 70 kDa. Membrane-bound glucosylated Rho is not extractable by GDI-1 as unmodified Rho is, leading to accumulation of modified Rho at membranous binding sites. Thus, in addition to effector coupling inhibition, glucosylation also inhibits Rho cycling between cytosol and membranes, a prerequisite for Rho activation.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Just, I (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Genth, Harald/HHS-0118-2022; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Amano M, 1998, TRENDS CARDIOVAS MED, V8, P162, DOI 10.1016/S1050-1738(97)00145-X; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Boukharov AA, 1998, BIOCHEM J, V330, P1391, DOI 10.1042/bj3301391; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; Bretscher A, 1997, J CELL SCI, V110, P3011; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gong MC, 1997, J BIOL CHEM, V272, P10704; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Just I., 1997, BACTERIAL TOXINS TOO, P159; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; UEDA T, 1990, J BIOL CHEM, V265, P9373; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	52	76	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29050	29056		10.1074/jbc.274.41.29050	http://dx.doi.org/10.1074/jbc.274.41.29050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506156	hybrid			2022-12-25	WOS:000083017800035
J	Hyun, YL; Zhu, ZY; Davidson, VL				Hyun, YL; Zhu, ZY; Davidson, VL			Gated and ungated electron transfer reactions from aromatic amine dehydrogenase to azurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN TRYPTOPHYLQUINONE ENZYMES; ZINC CYTOCHROME-C; METHYLAMINE DEHYDROGENASE; TRANSFER COMPLEX; CRYSTAL-STRUCTURE; REDOX PROPERTIES; PROTON-TRANSFER; AMICYANIN; COFACTOR; DEPENDENCE	Interprotein electron transfer (ET) occurs between the tryptophan tryptophylquinone (TTQ) prosthetic group of aromatic amine dehydrogenase (AADH) and copper of azurin, The ET reactions from two chemically distinct reduced forms of TTQ were studied: an O-quinol form that was generated by reduction by dithionite, and an N-quinol form that was generated by reduction by substrate. It was previously shown that on reduction by substrate, an amino group displaces a carbonyl oxygen on TTQ, and that this significantly alters the rate of its oxidation by azurin (Hyun, Y-L., and Davidson V, L, (1995) Biochemistry 34, 12249-12254). To determine the basis for this change in reactivity, comparative kinetic and thermodynamic analyses of the ET reactions from the O-quinol and N-quinol forms of TTQ in AADH to the copper of azurin were performed. The reaction of the O-quinol exhibited values of electronic coupling (H-AB) Of 0.13 cm(-1) and reorganizational energy (lambda) of 1.6 eV, and predicted an ET distance of approximately 15 Angstrom, These results are consistent with the ET event being the rate-determining step for the redox reaction, Analysis of the reaction of the N-quinol by Marcus theory yielded an H-AB,which exceeded the nonadiabatic limit and predicted a negative ET distance. These results are diagnostic of a gated ET reaction. Solvent deuterium kinetic isotope effects of 1.5 and 3.2 were obtained, respectively, for the ET reactions from O-quinol and N-quinoI AADH indicating that transfer of an exchangeable proton was involved in the rate-limiting reaction step which gates ET from the N-quinol, but not the O-quinol, These results are compared with those for the ET reactions from another TTQ enzyme, methylamine dehydrogenase, to amicyanin, The mechanism by which the ET reaction of the N-quinol is gated is also related to mechanisms of other gated interprotein ET reactions.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Davidson, VL (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.			Davidson, Victor/0000-0002-1966-7302	NIGMS NIH HHS [GM-41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041574, R37GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISHOP GR, 1995, BIOCHEMISTRY-US, V34, P12082, DOI 10.1021/bi00037a052; Bishop GR, 1998, BIOCHEMISTRY-US, V37, P11026, DOI 10.1021/bi980265e; Bishop GR, 1997, BIOCHEMISTRY-US, V36, P13586, DOI 10.1021/bi970586a; Bishop GR, 1998, BIOCHEM J, V330, P1159, DOI 10.1042/bj3301159; BROOKS HB, 1994, J AM CHEM SOC, V116, P11201, DOI 10.1021/ja00103a063; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; BRUNSCHWIG BS, 1989, J AM CHEM SOC, V111, P7454, DOI 10.1021/ja00201a028; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Crnogorac MM, 1996, BIOCHEMISTRY-US, V35, P16465, DOI 10.1021/bi961914u; Davidson VL, 1998, BIOCHEMISTRY-US, V37, P7371, DOI 10.1021/bi973020v; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; EDWARDS SL, 1995, J BIOL CHEM, V270, P4293, DOI 10.1074/jbc.270.9.4293; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HARRIS TK, 1994, BIOCHEMISTRY-US, V33, P12600, DOI 10.1021/bi00208a010; HOFFMAN BM, 1988, J AM CHEM SOC, V110, P8267, DOI 10.1021/ja00232a067; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; HYUN YL, 1995, BIOCHEMISTRY-US, V34, P12249, DOI 10.1021/bi00038a020; HYUN YL, 1995, BIOCHEMISTRY-US, V34, P816, DOI 10.1021/bi00003a015; ITOH S, 1995, J AM CHEM SOC, V117, P1485, DOI 10.1021/ja00110a004; IvkovicJensen MM, 1997, BIOCHEMISTRY-US, V36, P8135, DOI 10.1021/bi970327l; Lanzilotta WN, 1998, BIOCHEMISTRY-US, V37, P399, DOI 10.1021/bi971681m; Lee HJ, 1998, BIOCHEMISTRY-US, V37, P15513, DOI 10.1021/bi981853v; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATHESON IBC, 1989, COMPUT CHEM, V13, P299, DOI 10.1016/0097-8485(89)80036-1; MATHESON IBC, 1987, ANAL INSTRUM, V16, P345; MATHESON IBC, 1990, COMPUT CHEM, V14, P49, DOI 10.1016/0097-8485(90)80007-O; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MCLENDON G, 1992, CHEM REV, V92, P481, DOI 10.1021/cr00011a007; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; ROSEN P, 1981, EUR J BIOCHEM, V120, P339, DOI 10.1111/j.1432-1033.1981.tb05709.x; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WARNCKE K, 1995, J AM CHEM SOC, V117, P10063, DOI 10.1021/ja00145a018; WINKLER JR, 1992, CHEM REV, V92, P369, DOI 10.1021/cr00011a001; Zhu ZY, 1998, BIOCHEMISTRY-US, V37, P17128, DOI 10.1021/bi9817919; Zhu ZY, 1998, J BIOL CHEM, V273, P14254, DOI 10.1074/jbc.273.23.14254	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29081	29086		10.1074/jbc.274.41.29081	http://dx.doi.org/10.1074/jbc.274.41.29081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506161	hybrid			2022-12-25	WOS:000083017800040
J	Ilouz, N; Branski, L; Parnis, J; Parnas, H; Linial, M				Ilouz, N; Branski, L; Parnis, J; Parnas, H; Linial, M			Depolarization affects the binding properties of muscarinic acetylcholine receptors and their interaction with proteins of the exocytic apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM CHANNELS; CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; N-TYPE; SNARE PROTEINS; FUNCTIONAL IMPLICATIONS; SYMPATHETIC NEURONS; INTERACTION SITE; HIGH-AFFINITY; RAT-BRAIN	Membrane depolarization is the signal that triggers release of neurotransmitter from nerve terminals. As a result of depolarization, voltage-dependent Ca2+ channels open, level of intracellular Ca2+ increases. and release of neurotransmitter commences. Previous study had shown that in rat brain synaptosomes, muscarinic acetylcholine (ACh) receptors (mAChRs) interact with soluble NSF attachment protein receptor proteins of the exocytic machinery in a voltage-dependent manner. It was suggested that this interaction might control the rapid, synchronous release of acetylcholine, The present study investigates the mechanism for such a voltage-dependent interaction. Here we show that depolarization shifts mAChRs, specifically the m2 receptor subtype, to a low affinity state toward its agonists, At resting potential, mAChRs are in a high affinity state (K-d of similar to 20 nM) and they shift to a low affinity state (K-d of tens of mu M) upon membrane depolarization. In addition, interaction between m2 receptor subtype and the exocytic machinery increases with receptor occupancy. Both phenomena are independent of Ca2+ influx. We propose that these results may explain control of ACh release from nerve terminals. At resting potential the exocytic machinery is clamped due to its interaction with the occupied mAChR and depolarization relieves this interaction. This, together with Ca2+ influx, enables release of ACh to commence.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Otto Loewi Ctr Mol & Cellular Neurobiol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Linial, M (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	michall@leonardo.ls.huji.ac.il	Linial, Michal/B-9143-2011; Parnis, Julia/D-1751-2013	Linial, Michal/0000-0002-9357-4526				ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRDSALL NJM, 1978, MOL PHARMACOL, V14, P723; BOEHM S, 1995, NEUROSCIENCE, V69, P221, DOI 10.1016/0306-4522(95)00235-B; BRANN MR, 1993, PROG BRAIN RES, V98, P121; BURGERMEISTER W, 1978, MOL PHARMACOL, V14, P751; CANDURA SM, 1992, NEUROCHEM RES, V17, P1133, DOI 10.1007/BF00967291; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Green MA, 1997, BIOCHEMISTRY-US, V36, P7380, DOI 10.1021/bi961940s; GURWITZ D, 1985, MOL PHARMACOL, V28, P297; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HIRNING LD, 1990, BRAIN RES, V532, P120, DOI 10.1016/0006-8993(90)91751-2; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Linial M, 1997, J NEUROCHEM, V69, P1781; Linial M, 1997, J PHYSIOL-LONDON, V504, P251, DOI 10.1111/j.1469-7793.1997.251be.x; Linial M, 1996, BBA-REV BIOMEMBRANES, V1286, P117, DOI 10.1016/0304-4157(96)00007-X; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LUETJE CW, 1988, J NEUROCHEM, V50, P1775, DOI 10.1111/j.1471-4159.1988.tb02478.x; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MAUBECIN VA, 1995, J NEUROCHEM, V64, P2544; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; Mochida S, 1997, NEUROSCIENCE, V77, P937; Mochida S, 1998, P NATL ACAD SCI USA, V95, P14523, DOI 10.1073/pnas.95.24.14523; Nathanson NM, 1996, PROG BRAIN RES, V109, P165; PEARCE LB, 1991, J NEUROCHEM, V57, P636, DOI 10.1111/j.1471-4159.1991.tb03795.x; RAMACHANDRAN J, 1989, BIOESSAYS, V10, P54, DOI 10.1002/bies.950100205; Rhim H, 1996, BRIT J PHARMACOL, V118, P1341, DOI 10.1111/j.1476-5381.1996.tb15543.x; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; Seagar M, 1998, J BIOENERG BIOMEMBR, V30, P347, DOI 10.1023/A:1021937605818; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Stefani A, 1996, MOL NEUROBIOL, V13, P81, DOI 10.1007/BF02740753; YAWO H, 1993, NATURE, V365, P256, DOI 10.1038/365256a0; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3	50	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29519	29528		10.1074/jbc.274.41.29519	http://dx.doi.org/10.1074/jbc.274.41.29519			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506217	hybrid			2022-12-25	WOS:000083017800096
J	Szczesna, D; Zhang, R; Zhao, JJ; Jones, M; Potter, JD				Szczesna, D; Zhang, R; Zhao, JJ; Jones, M; Potter, JD			The role of the NH2- and COOH-terminal domains of the inhibitory region of troponin I in the regulation of skeletal muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BIOLOGICAL-ACTIVITY; THIN FILAMENT; ATPASE ACTIVITY; RABBIT; ACTIN; BINDING; CA2+; SEQUENCE; PEPTIDE	The role of the inhibitory region of troponin (Tn) I in the regulation of skeletal muscle contraction was studied with three deletion mutants of its inhibitory region: I) complete (TnI-(Delta 96-116)), 2) the COOH-terminal domain (TnI-(Delta 105-115)), and 3) the NH2-terminal domain (TnI-(Delta 95-106)). Measurements of Ca2+-regulated force and relaxation were performed in skinned skeletal muscle fibers whose endogenous TnI (along with TnT and TnC) was displaced with high concentrations of added troponin T. Reconstitution of the Tn-displaced fibers with a TnI TnC complex restored the Ca2+ sensitivity of force; however, the levels of relaxation and force development varied. Relaxation of the fibers (pCa 8) was drastically impaired with two of the inhibitory region deletion mutants, TnT-(Delta 96-116).TnC and TnI-(Delta 105-115).TnC. The TnI-(Delta 95-106).TnC mutant retained similar to 55% relaxation when reconstituted in the Tn-displaced fibers. Activation in skinned skeletal muscle fibers was enhanced with all TnI mutants compared with wild-type TnI. Interestingly, all three mutants of TnI increased the Ca2+ sensitivity of contraction. None of the TnI deletion mutants, when reconstituted into Tn, could inhibit actin-tropomyosin-activated myosin ATPase in the absence of Ca2+, and two of them (TnT-(Delta 96-116) and TnI(Delta 105-115)) gave significant activation in the absence of Ca2+. These results suggest that the COOH terminus of the inhibitory region of TnI (residues 105-115) is much more critical for the biological activity of TnI than the NH2-terminal region, consisting of residues 95-106. Presumably, the COOH-terminal domain of the inhibitory region of TnI is a part of the Ca2+-sensitive molecular switch during muscle contraction.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Jones, M (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045391] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45391-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; FARAH CS, 1994, J BIOL CHEM, V269, P5230; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gergely J, 1998, ADV EXP MED BIOL, V453, P169; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Hill AV, 1910, J PHYSIOL-LONDON, V40, P190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Reinach FC, 1997, CELL STRUCT FUNCT, V22, P219, DOI 10.1247/csf.22.219; SHIRAISHI F, 1994, J BIOCHEM-TOKYO, V115, P171, DOI 10.1093/oxfordjournals.jbchem.a124296; STEPKOWSKI D, 1985, BIOCHIM BIOPHYS ACTA, V831, P321, DOI 10.1016/0167-4838(85)90114-1; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; SZCZESNA D, 1999, MOL INTERACTIONS ACT, V2; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847	35	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29536	29542		10.1074/jbc.274.41.29536	http://dx.doi.org/10.1074/jbc.274.41.29536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506219	hybrid			2022-12-25	WOS:000083017800098
J	van der Ploeg, JR; Iwanicka-Nowicka, R; Bykowski, T; Hryniewicz, MM; Leisinger, T				van der Ploeg, JR; Iwanicka-Nowicka, R; Bykowski, T; Hryniewicz, MM; Leisinger, T			The Escherichia coli ssuEADCB gene cluster is required for the utilization of sulfur from aliphatic sulfonates and is regulated by the transcriptional activator Cbl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; SULFATE-STARVATION RESPONSE; SALMONELLA-TYPHIMURIUM; PHYSICAL MAP; LYSR FAMILY; EXPRESSION; PROTEIN; OPERON; CYSB; PROMOTERS	The growth properties of an Escherichia colt strain carrying a chromosomal deletion of the ssuEADCB genes (formerly designated ycbPONME) indicated that the products of this gene cluster are required for the utilization of sulfur from aliphatic sulfonates. Sequence similarity searches indicated that the proteins encoded by ssuA, ssuB, and ssuC are likely to constitute an ABC type transport system, whereas ssuD and ssuE encode an FMNH2-dependent monooxygenase and an NAD(P)H-dependent FMN reductase, respectively (Eichhorn, E., van der Ploeg, J. R., and Leisinger, T. (1999) J. BioL Chem 274, 26639-26646). Synthesis of beta-galactosidase fi om a transcriptional chromosomal ssuE'-lacZ fusion was repressed by sulfate or cystine and depended on the presence of a functional cbl gene, which encodes a LysR-type transcriptional regulator, Electrophoretic mobility shift assays with the ssu promoter region and measurements of beta-galactosidase from plasmid-encoded ssuE'-lacZ fusions showed that full expression of the ssu operon required the presence of a Cbl-binding site upstream of the -35 region. CysB, the LysR transcriptional regulator for the cys genes, was not required for expression of a chromosomal ssuE'-lacZ fusion although the ssu promoter region contained three CysB-binding sites. Integration host factor could also occupy three binding sites in the ssu promoter region but had no influence on expression of a chromosomal ssuE'-lacZ fusion.	ETH Zentrum, Inst Mikrobiol, CH-8092 Zurich, Switzerland; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Leisinger, T (corresponding author), ETH Zentrum, Inst Mikrobiol, CH-8092 Zurich, Switzerland.		Iwanicka-Nowicka, Roksana/M-4910-2019					Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Babst M, 1996, MOL MICROBIOL, V19, P827, DOI 10.1046/j.1365-2958.1996.438968.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bykowski T, 1998, BIOCHIMIE, V80, P987, DOI 10.1016/S0300-9084(99)80004-2; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; Eichhorn E, 1999, J BIOL CHEM, V274, P26639, DOI 10.1074/jbc.274.38.26639; EISENSTEIN BI, 1987, P NATL ACAD SCI USA, V84, P6506, DOI 10.1073/pnas.84.18.6506; Engelhorn M, 1998, MOL MICROBIOL, V30, P431, DOI 10.1046/j.1365-2958.1998.01078.x; FOGLINO M, 1986, GENE, V49, P303, DOI 10.1016/0378-1119(86)90366-5; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; HEURGUEHAMARD V, 1995, NUCLEIC ACIDS RES, V23, P2801, DOI 10.1093/nar/23.14.2801-a; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HRYNIEWICZ MM, 1991, J BACTERIOL, V173, P5876, DOI 10.1128/jb.173.18.5876-5886.1991; Hummerjohann J, 1998, MICROBIOL-SGM, V144, P1375, DOI 10.1099/00221287-144-5-1375; IWANICKANOWICKA R, 1995, GENE, V166, P11, DOI 10.1016/0378-1119(95)00606-8; JAGURA-BURDZY G, 1981, J BACTERIOL, V147, P744, DOI 10.1128/JB.147.3.744-751.1981; Kertesz MA, 1999, J BACTERIOL, V181, P1464, DOI 10.1128/JB.181.5.1464-1473.1999; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KREDICH NM, 1992, MOL MICROBIOL, V6, P2747, DOI 10.1111/j.1365-2958.1992.tb01453.x; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; Li MMZ, 1996, J BACTERIOL, V178, P6409, DOI 10.1128/jb.178.22.6409-6418.1996; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Quadroni M, 1996, EUR J BIOCHEM, V239, P773, DOI 10.1111/j.1432-1033.1996.0773u.x; ROBERTS RB, 1955, STUDIES BIOSYNTHESIS, P318; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SIRKO A, 1993, J BACTERIOL, V175, P5769, DOI 10.1128/JB.175.18.5769-5777.1993; Sirko A, 1998, MOL GEN GENET, V258, P174, DOI 10.1007/s004380050720; TOMMASSEN J, 1982, MOL GEN GENET, V185, P105, DOI 10.1007/BF00333798; Tyrrell R, 1997, STRUCTURE, V5, P1017, DOI 10.1016/S0969-2126(97)00254-2; URIANICKELSEN MR, 1993, J GEN MICROBIOL, V139, P203, DOI 10.1099/00221287-139-2-203; van der Ploeg JR, 1998, MICROBIOL-SGM, V144, P2555, DOI 10.1099/00221287-144-9-2555; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; vanderPloeg JR, 1997, J BACTERIOL, V179, P7671, DOI 10.1128/jb.179.24.7671-7678.1997	38	92	99	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29358	29365		10.1074/jbc.274.41.29358	http://dx.doi.org/10.1074/jbc.274.41.29358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506196	hybrid			2022-12-25	WOS:000083017800075
J	Wolzt, M; MacAllister, RJ; Davis, D; Feelisch, M; Moncada, S; Vallance, P; Hobbs, AJ				Wolzt, M; MacAllister, RJ; Davis, D; Feelisch, M; Moncada, S; Vallance, P; Hobbs, AJ			Biochemical characterization of S-nitrosohemoglobin - Mechanisms underlying synthesis, no release, and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; PLATELET-AGGREGATION; SERUM-ALBUMIN; NITROXYL HNO; PEROXYNITRITE; NITROSOTHIOLS; NITROSYLATION; NITROSATION; NITRATION	S-Nitrosohemoglobin (SNO-Hb) has been suggested to act as an endogenous NO donor and physiological regulator of blood pressure. However, the mechanisms responsible for the formation of SNO-Hb and those underlying the release of NO and subsequent biological activity have yet to be elucidated. In the present study, a number of nitrosated oxyhemoglobin (HbO(2)) derivatives have been synthesized and characterized. HbO, can be nitrosated at up to three distinct residues, one in the alpha-globin chain and two in the beta-chain, A beta-chain mononitrosated species (designated "SNO-Hb"), generated by the reaction of HbO(2) and S-nitrosoglutathione, released NO via a thiol-dependent mechanism involving nucleophilic attack at the nitrosated thiol functionality of SNO-Hb; in the case of glutathione, this process was associated with the formation of a mixed disulfide, In contrast, multinitrosated hemoglobin species released NO and relaxed vascular smooth muscle by a thiol-independent mechanism. HbO, scavenged potently NO released from SNO-Hb and inhibited its vasorelaxant properties. These data show that the predominant vasoactive species released from SNO-Hb is NO, with HNO a putative intermediate; the presence of a low molecular weight thiol is a prerequisite for this process. Such observations have important implications for the generation, metabolic fate, and biological activity of S-nitrosothiols.	Univ London Univ Coll, Wolfson Inst Biomed Res, Rayne Inst, London WC1E 6JJ, England; Univ London Univ Coll, Ctr Clin Pharmacol, London WC1E 6JJ, England; Univ London Univ Coll, Dept Med Chem, London WC1E 6JJ, England	University of London; King's College London; University College London; University of London; University College London; University of London; University College London	Hobbs, AJ (corresponding author), Univ London Univ Coll, Wolfson Inst Biomed Res, Rayne Inst, 5 Univ St, London WC1E 6JJ, England.	a.hobbs@ucl.ac.uk	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158; Hobbs, Adrian/0000-0002-3589-7108; Wolzt, Michael/0000-0001-6049-1890				BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CHIANCONE E, 1970, J BIOL CHEM, V245, P4105; Ferranti P, 1997, FEBS LETT, V400, P19, DOI 10.1016/S0014-5793(96)01258-6; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; HARANO K, 1984, FEBS LETT, V173, P45, DOI 10.1016/0014-5793(84)81014-5; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Keefer L.K., 1996, METHODS NITRIC OXIDE, P509; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Liu ZG, 1998, J PHARMACOL EXP THER, V284, P526; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 1998, CIRCULATION, V97, P263, DOI 10.1161/01.CIR.97.3.263; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Torres IP, 1996, MICROVASC RES, V51, P202; VALLANCE P, 1992, EUR J CLIN PHARMACOL, V42, P37, DOI 10.1007/BF00314917; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271; Zheng L, 1996, AM J PHYSIOL-HEART C, V271, pH365, DOI 10.1152/ajpheart.1996.271.1.H365	28	101	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28983	28990		10.1074/jbc.274.41.28983	http://dx.doi.org/10.1074/jbc.274.41.28983			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506146	hybrid			2022-12-25	WOS:000083017800025
J	Agochiya, M; Brunton, VG; Owens, DW; Parkinson, EK; Paraskeva, C; Keith, WN; Frame, MC				Agochiya, M; Brunton, VG; Owens, DW; Parkinson, EK; Paraskeva, C; Keith, WN; Frame, MC			Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells	ONCOGENE			English	Article						focal adhesion kinase; tyrosine kinase; protein expression; cancer; FAK	PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-SRC; TERMINAL DOMAIN; PP125(FAK); ASSOCIATION; CARCINOMA; PAXILLIN; EXPRESSION; APOPTOSIS	Focal adhesion kinase (pp125(FAK)) is present at sites of cell/extracellular matrix adhesion and has been implicated in the control of cell behaviour. In particular, as a key component of integrin-stimulated signal transduction pathways, pp125(FAK) is involved in cellular processes such as spreading, motility, growth and survival. In addition, a number of reports have indicated that pp125(FAK) may be up-regulated in human tumour cells of diverse origin, and consequently, a role has been proposed for pp125(FAK) in the development of invasive cancers. However, to date the mechanisms that lead to elevated pp125(FAK) expression in tumour cells have not been determined. Here ne used iii situ hybridization to confirm chromosome 8q as the genomic location of the human fak gene and report that elevation of pp125(FAK) protein in cell lines derived from invasive squamous cell carcinomas is accompanied by gains in copy number of the fak gene in all cases examined, In addition,,ve observed increased fak copy number in frozen sections of squamous cell carcinomas. Furthermore, increased dosage of the fak gene was also observed in many cell lines derived from human tumours of lung, breast and colon, including two cell lines Calu3 and HT29, in which fak was amplified. In addition, in an in vitro model for human colon cancer progression there was a copy number gain of the fak gene during conversion from adenoma to carcinoma, which was associated with increased pp125(FAK) protein expression, Thus, ne show for the first time that many cell lines derived from invasive epithelial tumours hare increased dosage of the fak gene, which may contribute to the elevated protein expression commonly observed, Although other genes near the fak locus are coamplified or increased in copy number, including the proto-oncogene c-myc, the biological properties of pp125(FAK) in controlling the growth, survival and invasiveness of tumour cells, suggest that it may contribute to the selection pressure for maintaining increased dosage of the region of chromosome 8q that encodes these genes.	Beatson Inst Canc Res, CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Univ Glasgow, Dept Med Oncol, CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Bristol; Beatson Institute; University of Glasgow	Frame, MC (corresponding author), Beatson Inst Canc Res, CRC Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FIEDOREK FT, 1995, MAMM GENOME, V6, P123, DOI 10.1007/BF00303256; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MANNING AM, 1991, ONCOGENE, V6, P1471; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; MURPHY LM, 1995, J SYNCHROTRON RADIAT, V2, P64, DOI 10.1107/S0909049594010861; OWENS LV, 1995, CANCER RES, V55, P2752; PARKINSON EK, 1986, INT J RADIAT BIOL, V50, P717, DOI 10.1080/09553008614551111; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; TURNER CE, 1994, J CELL SCI, V107, P1583; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	43	204	213	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5646	5653		10.1038/sj.onc.1202957	http://dx.doi.org/10.1038/sj.onc.1202957			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523844	Bronze			2022-12-25	WOS:000083016500005
J	Padera, R; Venkataraman, G; Berry, D; Godavarti, R; Sasisekharan, R				Padera, R; Venkataraman, G; Berry, D; Godavarti, R; Sasisekharan, R			FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling	FASEB JOURNAL			English	Article						FGF receptor; thermodynamic parameters; extracellular matrix	FIBROBLAST GROWTH; HEPARAN-SULFATE; CELL-SURFACE; FACTOR-II; BINDING; PROTEOGLYCAN; MITOGENESIS; RECEPTORS; AFFINITY; BFGF	Heparin-like glycosaminoglycans (HLGAGs) play a central role in the biological activity and signaling behavior of basic fibroblast growth factor (FGF-P), Recent studies, however, indicate that FGF-2 may be able to signal in the absence of HLGAG, raising the question of the nature of the role of HLGAG in FGF-2 signaling, In this study, we present a conceptual framework for FGF-2 signaling and derive a simple model from it that describes signaling via both HLGAG-independent and HLGAG-dependent pathways. The model is validated with F32 cell proliferation data using wild-type FGF-S, heparin binding mutants (K26A, K119A/R120A, K125A), and receptor binding mutants (Y103A, Y111A/W114A). In addition, this model can predict the cellular response of FGF-2 and its mutants as a function of FGF-2 and HLGAG concentration based on experimentally determined thermodynamic parameters. We show that FGF-2-mediated cellular response is a function of both FGF-2 and HLGAG concentrations and that a reduction of one of the components can be compensated for by an increase in the other to achieve the same measure of cellular response, Analysis of the mutant FGF-S molecules show that reduction in heparin binding interactions and primary receptor site binding interactions can also be compensated for in the same manner. These results suggest a molecular mechanism that could be used by cells in physiological systems to modulate the FGF-2-mediated cellular response by controlling HLGAG expression.-Padera, R., Venkataraman, G., Berry, D., Godavarti, R., Sasisekharan, R. FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 77 Massachusetts Ave,Bldg 16-561, Cambridge, MA 02139 USA.							AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BIKFALVI A, 1997, ANGIOGENESIS, V1, P155; CONRAD E, 1998, HEPARIN BINDING PROT, P301; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Higuchi R., 1990, PCR PROTOCOLS GUIDE; KAN M, 1993, SCIENCE, V259, P19918; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klein S, 1997, EXS, V79, P159; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; LI LY, 1994, BIOCHEMISTRY-US, V34, P731; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	44	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1677	1687		10.1096/fasebj.13.13.1677	http://dx.doi.org/10.1096/fasebj.13.13.1677			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506571				2022-12-25	WOS:000083063400003
J	Blanchard, CZ; Chapman-Smith, A; Wallace, JC; Waldrop, GL				Blanchard, CZ; Chapman-Smith, A; Wallace, JC; Waldrop, GL			The biotin domain peptide from the biotin carboxyl carrier protein of Escherichia coli acetyl-CoA carboxylase causes a marked increase in the catalytic efficiency of biotin carboxylase and carboxyltransferase relative to free biotin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PURIFICATION; SUBUNIT; EXPRESSION; BINDING	Acetyl-CoA carboxylase catalyzes the first committed step in the biosynthesis of long-chain fatty acids. The Escherichia coli form of the enzyme consists of a biotin carboxylase activity, a biotin carboxyl carrier protein, and a carboxyltransferase activity. The C-terminal 87 amino acids of the biotin carboxyl carrier protein (BCCP87) form a domain that can be independently expressed, biotinylated, and purified (Chapman-Smith, A., Turner, D. L., Cronan, J. E., Morris, T. W., and Wallace, J, C, (1994) Biochem, J, 302, 881-887), The ability of the biotinylated form of this 87-residue protein (holo BCCP87) to act as a substrate for biotin carboxylase and carboxyltransferase was assessed and compared with the results with free biotin, In the case of biotin carboxylase holoBCCP87 was an excellent substrate with a K-m, of 0.16 +/- 0.05 mM and V-max of 1000.8 +/- 182.0 min(-1). The V/K or catalytic efficiency of biotin carboxylase with holoBCCP87 as substrate was 8000-fold greater than with biotin as substrate. Stimulation of the ATP synthesis reaction of biotin carboxylase where carbamyl phosphate reacted with ADP by holoBCCP87 was 5-fold greater than with an equivalent amount of biotin, The interaction of holoBCCP87 with carboxyltransferase was characterized in the reverse direction where malonyl-CoA reacted with holoBCCP87 to form acetyl-CoA and carboxyholoBCCP87, The K-m for holoBCCP87 was 0.45 +/- 0.07 mM while the V-max was 2031.8 +/- 231.0 min(-1). The V/K or catalytic efficiency of carboxyltransferase.	Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	Louisiana State University System; Louisiana State University; University of Adelaide	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Biol Sci, Div Biochem & Mol Biol, Rm 508 Life Sci Bldg, Baton Rouge, LA 70803 USA.		, John/AAP-5150-2020		NIGMS NIH HHS [GM51261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ChapmanSmith A, 1997, J BIOL CHEM, V272, P26017, DOI 10.1074/jbc.272.41.26017; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; FALL RR, 1973, J BIOL CHEM, V248, P2078; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; JENCKS WP, 1987, COLD SPRING HARB SYM, V52, P65, DOI 10.1101/SQB.1987.052.01.010; KONDO H, 1983, B CHEM SOC JPN, V56, P1176, DOI 10.1246/bcsj.56.1176; Lane M D, 1974, Curr Top Cell Regul, V8, P139; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WHITTY A, 1995, BIOCHEMISTRY-US, V34, P11678, DOI 10.1021/bi00037a005; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; Yao X, 1999, PROTEIN SCI, V8, P307	22	27	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31767	31769		10.1074/jbc.274.45.31767	http://dx.doi.org/10.1074/jbc.274.45.31767			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542197	hybrid			2022-12-25	WOS:000083532100005
J	Wilkens, S; Vasilyeva, E; Forgac, M				Wilkens, S; Vasilyeva, E; Forgac, M			Structure of the vacuolar ATPase by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; V-TYPE ATPASE; H+-ATPASE; ESCHERICHIA-COLI; NEUROSPORA-CRASSA; 2ND STALK; SUBUNIT; SYNTHASE; COMPLEX; F-0	The structure of the vacuolar ATPase from bovine brain clathrin-coated vesicles has been determined by electron microscopy of negatively stained, detergent-solubilized enzyme molecules. Preparations of both lipid-containing and delipidated enzyme have been analyzed, The complex is organized in two major domains, a V-1 and V-0, with overall dimensions of 28 x 14 x 14 nm, The V-1 is a more or less spherical molecule with a central cavity. The V-0 has the shape of a flattened sphere or doughnut with a radius of about 100 Angstrom. The V-1 and V-0 are joined by a 60-Angstrom long and 40-Angstrom wide central stalk, consisting of several individual protein densities. Two kinds of smaller densities are visible at the top periphery of the V-1, and one of these seems to extend all the way down to the stalk domain in some averages. Images of both the lipid-containing and the delipidated complex show a 30-50-kDa protein density on the lumenal side of the complex, opposite the central stalk, centered in the ring of c subunits. A large trans-membrane mass, probably the C-terminal domain of the 100-kDa subunit a, is seen at the periphery of the c subunit ring in some projections. This large mass has both a lumenal and a cytosolic domain, and it is the cytosolic domain that interacts with the central stalk. Two to three additional protein densities can be seen in the V-1-V-0 interface, all connected to the central stalk. Overall, the structure of the V-ATPase is similar to the structure of the related F1F0-ATP synthase, confirming their common origin.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University of California System; University of California Riverside; Tufts University	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fillingame RH, 1997, J EXP BIOL, V200, P217; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HO MN, 1993, J BIOL CHEM, V268, P18286; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KANE PM, 1995, J BIOL CHEM, V270, P17025; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PALI T, 1995, BIOCHEMISTRY-US, V34, P9211, DOI 10.1021/bi00028a034; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEK F, 1994, J BIOL CHEM, V269, P24102; Supekova L, 1996, J EXP BIOL, V199, P1147; TAIZ SL, 1991, BOT ACTA, V104, P117, DOI 10.1111/j.1438-8677.1991.tb00206.x; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; XIE XS, 1994, J BIOL CHEM, V269, P25809; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	40	122	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31804	31810		10.1074/jbc.274.45.31804	http://dx.doi.org/10.1074/jbc.274.45.31804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542203	hybrid			2022-12-25	WOS:000083532100011
J	Bertrand, F; Desbois-Mouthon, C; Cadoret, A; Prunier, C; Robin, H; Capeau, J; Atfi, A; Cherqui, G				Bertrand, F; Desbois-Mouthon, C; Cadoret, A; Prunier, C; Robin, H; Capeau, J; Atfi, A; Cherqui, G			Insulin antiapoptotic signaling involves insulin activation of the nuclear factor kappa B-dependent survival genes encoding tumor necrosis factor receptor-associated factor 2 and manganese-superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; INDUCED APOPTOSIS; FACTOR-KB; TNF; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION; RESISTANCE; INDUCTION; PROTEIN	We recently showed that the antiapoptotic function of insulin requires nuclear factor kappa B (NF-kappa B) activation (Bertrand, F., Atfi, A, Cadoret, A., L'Allemain, G., Robin, H., Lascols, O., Capeau, J., and Cherqui, G. (1998) J. Biol. Chem. 273, 2931-2938). Here we sought to identify the NF-kappa B-dependent survival genes that are activated by insulin to mediate this function. Insulin increased the expression of tumor necrosis factor receptor-associated factor 2 (TRAF2) mRNA and protein in Chinese hamster ovary cells overexpressing insulin receptors (IRs). This effect required (i) IR activation since it was abrogated by IR mutation at tyrosines 1162 and 1163 and (ii) NF-kappa B activation since it was abolished by overexpression of dominant-negative I kappa B-alpha(A32/36) and mimicked by overexpression of the NF-kappa B c-Rel subunit. TRAF2 contributed to insulin protection against serum withdrawal-induced apoptosis since TRAF2 overexpression mimicked insulin protection, whereas overexpression of dominant-negative TRAF2-(87-501) reduced this process. Along with its protective effect, overexpressed TRAF2 increased basal and insulin-stimulated NF-kappa B activities. All effects were inhibited by I kappa B-alpha(A32/36), suggesting that an amplification loop involving TRAF2 activation of NF-kappa B is implicated in insulin antiapoptotic signaling. We also show that insulin increased manganese-superoxide dismutase (Mn-SOD) mRNA expression through NF-kappa B activation and that Mn-SOD contributed to insulin antiapoptotic signaling since expression of antisense Mn-SOD RNA decreased this process. This study provides the first evidence that insulin activates the NF-kappa B-dependent survival genes encoding TRAF2 and Mn-SOD and thereby clarifies the role of NF-kappa B in the antiapoptotic function of insulin.	Fac Med St Antoine, INSERM, U402, Paris, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, INSERM, U402, 27 Rue Chaligny, Paris, France.		Frottier, Celine Prunier/G-8259-2017; Desbois-Mouthon, Christele/M-7076-2017; Cadoret, Axelle/L-2529-2017	Frottier, Celine Prunier/0000-0002-7784-0273; Desbois-Mouthon, Christele/0000-0002-0772-1711; Cadoret, Axelle/0000-0002-4283-6864				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Min W, 1998, J IMMUNOL, V161, P319; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	36	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30596	30602		10.1074/jbc.274.43.30596	http://dx.doi.org/10.1074/jbc.274.43.30596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521443	hybrid			2022-12-25	WOS:000083276700039
J	Essler, M; Retzer, M; Bauer, M; Heemskerk, JW; Aepfelbacher, M; Siess, W				Essler, M; Retzer, M; Bauer, M; Heemskerk, JW; Aepfelbacher, M; Siess, W			Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; RHO-KINASE; PROTEIN-KINASE; REORGANIZATION; SENSITIZATION; PERMEABILITY; CYTOSKELETON; RECEPTOR; FAMILY; ALPHA	Mildly oxidized low density lipoprotein (mox-LDL) is critically involved in the early atherogenic responses of the endothelium and increases endothelial permeability through an unknown signal pathway. Here we show that (i) exposure of confluent human endothelial cells (HUVEC) to mox-LDL but not to native LDL induces the formation of actin stress fibers and intercellular gaps within minutes, leading to an increase in endothelial permeability; (ii) mox-LDL induces a transient decrease in myosin light chain (MLC) phosphatase that is paralleled by an increase in MLC phosphorylation; (iii) phosphorylated MLC stimulated by mox-LDL is incorporated into stress fibers; (iv) cytoskeletal rearrangements and MLC phosphorylation are inhibited by C3 transferase from Clostridium botulinum, a specific Rho inhibitor, and Y-27632, an inhibitor of Rho kinase; and (v) mox-LDL does not increase intracellular Ca2+ concentration. Our data indicate that mox-LDL induces endothelial cell contraction through activation of Rho and its effector Rho kinase which inhibits MLC phosphatase and phosphorylates MLC. We suggest that inhibition of this novel cell signaling pathway of mox-LDL could be relevant for the prevention of atherosclerosis.	Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munich, Germany; Max Von Pettenkofer Inst Med Mikrobiol, D-80336 Munich, Germany; Univ Maastriccht, Cardiovasc Res Inst, Dept Biochem, NL-6200 MD Maastricht, Netherlands	University of Munich; University of Munich; Maastricht University	Essler, M (corresponding author), Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.		Heemskerk, Johan/AAM-8323-2021; Siess, Wolfgang/A-6430-2009	Heemskerk, Johan/0000-0002-2848-5121; Siess, Wolfgang/0000-0003-0698-6416				Auge N, 1996, CIRC RES, V79, P871, DOI 10.1161/01.RES.79.4.871; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Colangelo S, 1998, ARTERIOSCL THROM VAS, V18, P52, DOI 10.1161/01.ATV.18.1.52; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Essler M, 1998, J IMMUNOL, V161, P5640; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIAO LX, 1995, ARTERIOSCL THROM VAS, V15, P2305, DOI 10.1161/01.ATV.15.12.2305; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; RANGASWAMY S, 1997, CIRC RES, V80, P73; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Somlyo AP, 1997, NATURE, V389, P908, DOI 10.1038/40002; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; vanHinsbergh VWM, 1997, ARTERIOSCL THROM VAS, V17, P1018, DOI 10.1161/01.ATV.17.6.1018; vanIJzendoorn SCD, 1996, BBA-MOL CELL RES, V1311, P64, DOI 10.1016/0167-4889(95)00191-3; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B	25	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30361	30364		10.1074/jbc.274.43.30361	http://dx.doi.org/10.1074/jbc.274.43.30361			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521411	hybrid			2022-12-25	WOS:000083276700007
J	Yokota, N; Kuroda, T; Matsuyama, S; Tokuda, H				Yokota, N; Kuroda, T; Matsuyama, S; Tokuda, H			Characterization of the LolA-LolB system as the general lipoprotein localization mechanism of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; CYTOPLASMIC MEMBRANE; CHROMOSOME; SEQUENCE; BACTERIA; CLONING; PROTEIN	The major outer membrane lipoprotein (Lpp) of Escherichia coli requires LolA for its release from the cytoplasmic membrane, and LolB for its localization to the outer membrane. We examined the significance of the LolA-LolB system as to the outer membrane localization of other lipoproteins, All lipoproteins possessing an outer membrane-directed signal at the N-terminal second position were efficiently released from the inner membrane in the presence of LolA, Some lipoproteins were released in the absence of externally added LolA, albeit at a slower rate and to a lesser extent. This LolA-independent release was also strictly dependent on the outer membrane sorting signal. A lipoprotein-LolA complex was formed when the release took place in the presence of LolA, whereas lipoproteins released in the absence of LolA existed as heterogeneous complexes, suggesting that the release and the formation of a complex with LolA are distinct events. The release of LolB, an outer membrane lipoprotein functioning as the receptor for a lipoprotein-LolA complex, occurred with a trace amount of LolA, and therefore was extremely efficient. The LolA-dependent release of lipoproteins was found to be crucial for the specific incorporation of lipoproteins into the outer membrane, whereas lipoproteins released in the absence of LolA were nonspecifically and inefficiently incorporated into the membrane. The outer membrane incorporation of lipoproteins including LolB per se was dependent on LolB in the outer membrane. From these results, we conclude that lipoproteins in E. coli generally utilize the LolA-LolB system for efficient release from the inner membrane and specific localization to the outer membrane.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							ALEXANDER DM, 1994, MOL MICROBIOL, V11, P1059, DOI 10.1111/j.1365-2958.1994.tb00383.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOUVIER J, 1991, J BACTERIOL, V173, P5523, DOI 10.1128/jb.173.17.5523-5531.1991; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miller J.H., 1972, EXPT MOL GENETICS; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; TAKASE I, 1987, J BACTERIOL, V169, P5692, DOI 10.1128/jb.169.12.5692-5699.1987; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1986, J BIOL CHEM, V261, P2284	22	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30995	30999		10.1074/jbc.274.43.30995	http://dx.doi.org/10.1074/jbc.274.43.30995			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521496	hybrid			2022-12-25	WOS:000083276700092
J	Shaulian, E; Karin, M				Shaulian, E; Karin, M			Stress-induced JNK: Activation is independent of Gadd45 induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; P53-REGULATED PROTEIN; TYROSINE KINASES; UV-IRRADIATION; GROWTH-FACTOR; CELL-DEATH; DNA-DAMAGE; APOPTOSIS; GENE; P53	DNA damage and environmental stress activate signaling and induce genes involved in cell cycle and cell death. Expression of the Gadd45 protein is induced following DNA damage and other stress. Gadd45 is believed to play a role in growth arrest and possibly in cell death. The JNK signaling pathway is also activated by some DNA-damaging agents. This activation leads to phosphorylation and activation of transcription factors, such as c-Jun/AP-1 and ATF2, which mediate immediate early gene induction. Recently Gadd45 was suggested to be involved in JNK activation. However, as this suggestion relied on in vitro experiments and ectopic overexpression of Gadd45 protein, we examined whether physiological levels of Gadd45 that are induced following exposure to DNA damaging agents and stress can lead to JNK induction. We found that JNK activation by UV irradiation and anisomycin treatment precedes the induction of gadd45 mRNA by these agents. Gadd45 protein induction by methyl methanesulfonate also lagged behind JNK activation. The use of protein synthesis inhibitors suggested that newly synthesized proteins, including the stress-induced Gadd45, make only a marginal contribution to JNK activation. We also found that stresses such as gamma irradiation induce Gadd45 and do not activate JNK in mouse fibroblasts. Therefore, stress-induced JNK does not depend on Gadd45 induction.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.				NCI NIH HHS [CA76188] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Goldwasser F, 1996, ONCOL RES, V8, P317; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Ohtani-Fujita N, 1998, BIOCHEM BIOPH RES CO, V251, P648, DOI 10.1006/bbrc.1998.9511; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Torp R, 1998, NEUROBIOL DIS, V5, P245, DOI 10.1006/nbdi.1998.0201; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAN Q, 1999, ONCOGENE, V18, P7485; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	35	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29595	29598		10.1074/jbc.274.42.29595	http://dx.doi.org/10.1074/jbc.274.42.29595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514425	hybrid			2022-12-25	WOS:000083176400004
J	Svensson, S; Stromberg, P; Hoog, JO				Svensson, S; Stromberg, P; Hoog, JO			A novel subtype of class II alcohol dehydrogenase in rodents - Unique Pro(47) and Ser(182) modulates hydride transfer in the mouse enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; HORSE LIVER; ALDEHYDE DEHYDROGENASE; MOLECULAR-PROPERTIES; HUMAN BETA-1-BETA-1; TERNARY COMPLEX; PI-ADH; CLONING; MECHANISM; BINDING	Mice and rats were found to possess class II alcohol dehydrogenases with novel enzymatic and structural properties. A cDNA was isolated from mouse liver and the encoded alcohol dehydrogenase showed high identity (93.1%) with the rat class II alcohol dehydrogenase which stands in contrast to the pronounced overall variability of the class II: line. The two heterologously expressed rodent class II enzymes exhibited over 100-fold lower catalytic efficiency (k(cat)/K-m) for oxidation of alcohols as compared with other alcohol dehydrogenases and were not saturated with ethanol. Hydride transfer limited the rate of octanol oxidation as indicated by a deuterium isotope effect of 4.8. The mutation P47H improved hydride transfer and turnover rates were increased to the same level as for the human class II enzyme. Michaelis constants for alcohols and aldehydes were decreased while they were increased for the coenzyme. The rodent class Ii enzymes catalyzed reduction of p-benzoquinone with about the same maximal turnover as for the human form. This activity was not affected by the P47H mutation while a S182T mutation increased the K-m value for benzoquinone 10-fold. omega-Hydroxy fatty acids were catalyzed extremely slow but functioned as patent inhibitors by binding to the enzyme-NAD(+) complex, AU these data indicate that the mammalian class II alcohol dehydrogenase line is divided into two structurally and functionally distinct subgroups.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet	Hoog, JO (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.							ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; CHEN S, 1993, ARCH BIOCHEM BIOPHYS, V302, P72, DOI 10.1006/abbi.1993.1182; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVIS GJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P307, DOI 10.1006/abbi.1994.1242; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DITLOW CC, 1984, BIOCHEMISTRY-US, V23, P6363, DOI 10.1021/bi00321a012; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; EDENBERG HJ, 1985, P NATL ACAD SCI USA, V82, P2262, DOI 10.1073/pnas.82.8.2262; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; Estonius M, 1996, FEBS LETT, V397, P338, DOI 10.1016/S0014-5793(96)01204-5; ESTONIUS M, 1993, EUR J BIOCHEM, V215, P497, DOI 10.1111/j.1432-1033.1993.tb18059.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fersht A., 1984, ENZYME STRUCTURE MEC; Fromm H J, 1979, Methods Enzymol, V63, P467; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; HENNECKE M, 1983, BIOCHEMISTRY-US, V22, P3721, DOI 10.1021/bi00285a001; HJELMQVIST L, 1995, P NATL ACAD SCI USA, V92, P10904, DOI 10.1073/pnas.92.24.10904; HOLMES RS, 1977, GENETICS, V87, P709; HOOG JO, 1995, ADV EXP MED BIOL, V372, P355; HOOG JO, 1995, FEBS LETT, V368, P445, DOI 10.1016/0014-5793(95)00707-G; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; Inoue J, 1998, BIOCHEMISTRY-US, V37, P3305, DOI 10.1021/bi970726g; JORNVALL H, 1995, ALCOHOL ALCOHOLISM, V30, P153; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; Kedishvili NY, 1997, J BIOL CHEM, V272, P7494, DOI 10.1074/jbc.272.11.7494; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LI TK, 1977, P NATL ACAD SCI USA, V74, P4378, DOI 10.1073/pnas.74.10.4378; LIGHT DR, 1992, J BIOL CHEM, V267, P12592; MARDH G, 1986, P NATL ACAD SCI USA, V83, P8908, DOI 10.1073/pnas.83.23.8908; MARDH G, 1986, BIOCHEMISTRY-US, V25, P7279, DOI 10.1021/bi00371a005; MASKOS Z, 1994, J BIOL CHEM, V269, P31579; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; OKUDA A, 1983, J BIOL CHEM, V258, P2899; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; Ramaswamy S, 1996, PROTEIN SCI, V5, P663; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; SELLIN S, 1991, BIOCHEMISTRY-US, V30, P2514, DOI 10.1021/bi00223a031; STONE CL, 1993, J BIOL CHEM, V268, P892; Svensson S, 1998, EUR J BIOCHEM, V251, P236, DOI 10.1046/j.1432-1327.1998.2510236.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	56	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29712	29719		10.1074/jbc.274.42.29712	http://dx.doi.org/10.1074/jbc.274.42.29712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514444	hybrid			2022-12-25	WOS:000083176400023
J	Frevel, MAE; Sowerby, SJ; Petersen, GB; Reeve, AE				Frevel, MAE; Sowerby, SJ; Petersen, GB; Reeve, AE			Methylation sequencing analysis refines the region of H19 epimutation in Wilms tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; GROWTH-FACTOR-II; EPIGENETIC CHANGES; GENE; IGF2; LOCUS; RELAXATION; EXPRESSION; IMPRINT; TUMORIGENESIS	Differential DNA methylation of the parental alleles has been implicated in the establishment and maintenance of the monoallelic expression of imprinted genes. H19 and IGF2 are oppositely imprinted with only the maternal and the paternal alleles expressed, respectively. In Wilms tumor, a childhood renal neoplasm, loss of the H19/IGF2 imprinted expression pattern results in silencing of H19 and biallelic expression of IGF2. This was shown to be associated with biallelic methylation of the H19 promoter in the tumor and the adjacent kidney tissue suggesting that epigenetic H19 silencing is an early event in Wilms tumorigenesis, An imprinting mark region characterized by paternal allele-specific methylation has been suggested to reside in a GC-rich region of 400-base pair direct repeats starting at -2 kilobase pairs (kb) relative to the H19 transcription start and extending upstream. The upstream boundary of the potential paternal methylation imprint of the H19 gene has yet to be defined. We sought to define this upstream imprint boundary and investigate whether Wilms tumors with loss of imprinting are biallelically methylated in this imprinting mark region. The analysis of 6.6 kb of new upstream H19 sequence determined in this study identified a series of the direct 400-base pair repeats that extends to approximately -5.3 kb relative to the transcription start. DNA methylation analyses indicated that the upstream boundary of the potential imprint may coincide with the 5' end of the direct repeats. We found that Wilms tumors with loss of imprinting are biallelically methylated in the H19 upstream repeat region, and we suggest that pathological methylation in this region is the epigenetic error that initiates H19 silencing.	Univ Otago, Dept Biochem, Canc Genet Lab, Dundee 9001, Scotland		Frevel, MAE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave,NB40, Cleveland, OH 44195 USA.		Sowerby, Stephen J/G-7601-2011					BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui HM, 1997, CANCER RES, V57, P4469; Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	31	85	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29331	29340		10.1074/jbc.274.41.29331	http://dx.doi.org/10.1074/jbc.274.41.29331			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506193	hybrid			2022-12-25	WOS:000083017800072
J	Heitmeier, MR; Scarim, AL; Corbett, JA				Heitmeier, MR; Scarim, AL; Corbett, JA			Prolonged STAT1 activation is associated with interferon-gamma priming for interleukin-1-induced inducible nitric-oxide synthase expression by islets of Langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES GENE-TRANSCRIPTION; NONOBESE DIABETIC MICE; PANCREATIC BETA-CELLS; INSULIN-SECRETION; NOD MICE; KAPPA-B; INHIBITION; RAT; DESTRUCTION; CYTOKINES	In this study, the ability of interferon-gamma (IFN-gamma) to prime rat and nonobese diabetic (NOD) mouse islets for interleukin-1 (IL-1)-stimulated expression of inducible nitric-oxide synthase (iNOS) has been examined. IL-1-induced iNOS expression by rat islets is concentration-dependent with maximal expression occurring in response to 1.0 unit/ml. Individually, neither 0.1 unit/ml IL-1 nor 150 units/ml IFN-gamma stimulates iNOS expression or nitrite production by rat islets. However, a 30-60-min pulse of rat islets with IFN-gamma, followed by washing to remove the cytokine and continued culture with 0.1 unit/ml IL-1 for 40 h, results in iNOS expression and nitrite production to levels similar in magnitude to the individual effects of 1.0 unit/ml IL-1. A 1-h pulse with IFN-gamma primes for IL-1-induced islet degeneration that is mediated by the expression of iNOS and increased production of nitric oxide. IFN-gamma also primes for IL-1-induced iNOS expression and nitrite formation by NOD mouse islets. The priming actions of IFN-gamma appear to be selective for beta-cells, as IFN-gamma primes for IL-1-induced nitrite formation by primary beta-cells and RINm5F insulinoma cells, but not primary alpha-cells. The priming actions of IFN-gamma for IL-1-induced iNOS expression do not require de nova protein synthesis as preincubation of RINm5F cells with cycloheximide does not inhibit iNOS mRNA accumulation under priming conditions. The priming actions of IFN-gamma on IL-1-induced iNOS expression persists for extended periods of up to 7 days and are associated with persistent signal transducers and activators of transcription (STAT)-1 activation. A 30-min pulse of rat islets with IFN-gamma stimulates STAT1 phosphorylation, and STAT1 remains phosphorylated for up to 7 days following IFN-gamma removal. In addition, STAT1 remains nuclear for up to 7 days after IFN-gamma removal. These results indicate that IFN-gamma primes for IL-1-induced islet degeneration via a nitric oxide-dependent mechanism. These findings also provide evidence that the priming actions of IFN-gamma for IL-1-induced iNOS expression by islets are associated with the prolonged phosphorylation and activation of STAT1.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NIAID NIH HHS [AI44458] Funding Source: Medline; NIDDK NIH HHS [DK-52194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Arnush M, 1998, J IMMUNOL, V160, P2684; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; BAQUERIZO H, 1990, Journal of Autoimmunity, V3, P123; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P8992, DOI 10.1073/pnas.90.19.8992; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; CORBETT JA, 1995, DIABET ANN, V9, P265; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; Hultgren B, 1996, DIABETES, V45, P812, DOI 10.2337/diabetes.45.6.812; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LACY PE, 1991, AM J PATHOL, V138, P1183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDRUPPOULSEN T, 1985, ALLERGY, V40, P424, DOI 10.1111/j.1398-9995.1985.tb02681.x; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; ONO J, 1977, ENDOCRINOL JAPON, V24, P265; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Rabinovitch A, 1996, ENDOCRINOLOGY, V137, P2093, DOI 10.1210/en.137.5.2093; Reddy S, 1997, HISTOCHEM J, V29, P53, DOI 10.1023/A:1026416918339; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; Wang B, 1997, P NATL ACAD SCI USA, V94, P13844, DOI 10.1073/pnas.94.25.13844; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	39	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29266	29273		10.1074/jbc.274.41.29266	http://dx.doi.org/10.1074/jbc.274.41.29266			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506184	hybrid			2022-12-25	WOS:000083017800063
J	Hiratsuka, T				Hiratsuka, T			ATP-induced opposite changes in the local environments around Cys(697) (SH2) and Cys(707) (SH1) of the myosin motor domain revealed by the prodan fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; ADENOSINE-TRIPHOSPHATASE; 3-DIMENSIONAL STRUCTURE; SPECTRAL PROPERTIES; TRYPTIC PEPTIDE; HEAVY-CHAIN; SUBFRAGMENT-1; MOVEMENT; PROBE; ACTIN	To obtain a consistent view of the nucleotide-induced conformational changes around Cys(697) (SH2) and Cys(707) (SH1) in skeletal myosin subfragment-1 (S-1), the two thiols were labeled with the same environmentally sensitive fluorophore, 6-acyl-2-dimethylaminonaphthalene group, using 6-acryloyl-2-dimethylaminonaphthalene (acrylodan, AD) and 6-bromoacetyl-2-dimethylaminonaphthalene (BD), respectively. The resultant fluorescent derivatives, AD-S-1 and BD-S-1, have the same fluorophore at either SH2 or SH1, which was verified by inspections of changes in the ATPases and the localization of fluorescence after tryptic digestion and CNBr cleavage for the two derivatives. Especially, AD was found to be a very useful fluorescent reagent that readily reacts with only SH2 of S-1. Measurements of the nucleotide-induced changes in fluorescence emission spectra of ADS-1 and BD-S-1 suggested that during ATP hydrolysis the environment around the fluorophore at SH2 is very distinct from that around the fluorophore at SH1, being defined as that the former has the hydrophobic and closed characteristics, whereas the latter has the hydrophilic and open ones, The KI quenching study of the fluorescence of the two S-1 derivatives confirmed these results. The most straightforward interpretation for the present results is that during ATP hydrolysis, the helix containing SH2 is buried in hydrophohic side chains and rather reinforced, whereas the adjacent helix containing SH1 moves away from its stabilizing tertiary structural environment.	Asahikawa Med Coll, Dept Chem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Hiratsuka, T (corresponding author), Asahikawa Med Coll, Dept Chem, Asahikawa, Hokkaido 0788510, Japan.	toshiaki@asahikawa-med.ac.jp						AJTAI K, 1989, BIOCHEMISTRY-US, V28, P2204, DOI 10.1021/bi00431a035; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELZINGA M, 1977, P NATL ACAD SCI USA, V74, P4281, DOI 10.1073/pnas.74.10.4281; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Fiske CH, 1925, J BIOL CHEM, V66, P375; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; HIRATSUKA T, 1989, J BIOL CHEM, V264, P18188; Hiratsuka T, 1998, BIOCHEMISTRY-US, V37, P7167, DOI 10.1021/bi973083d; HIRATSUKA T, 1993, J BIOL CHEM, V268, P24742; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; KASPRZAK AA, 1989, BIOCHEMISTRY-US, V28, P9230, DOI 10.1021/bi00449a040; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KUNZ PA, 1977, FEBS LETT, V83, P137, DOI 10.1016/0014-5793(77)80658-3; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; MUELLER H, 1962, BIOCHEM J, V85, P431, DOI 10.1042/bj0850431; Patterson B, 1997, J BIOL CHEM, V272, P27612, DOI 10.1074/jbc.272.44.27612; Phan BC, 1997, EUR J BIOCHEM, V243, P636, DOI 10.1111/j.1432-1033.1997.00636.x; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RAJASEKHARAN KN, 1989, J BIOL CHEM, V264, P10810; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; REISLER E, 1982, METHOD ENZYMOL, V85, P84; SCHAUB MC, 1978, BIOCHEMISTRY-US, V17, P246, DOI 10.1021/bi00595a009; Stern O, 1919, PHYS Z, V20, P183; SUTOH K, 1981, BIOCHEMISTRY-US, V20, P3281, DOI 10.1021/bi00514a046; TAKASHI R, 1976, ARCH BIOCHEM BIOPHYS, V175, P279, DOI 10.1016/0003-9861(76)90509-9; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XING J, 1995, BIOCHEMISTRY-US, V34, P6475, DOI 10.1021/bi00019a029	37	22	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29156	29163		10.1074/jbc.274.41.29156	http://dx.doi.org/10.1074/jbc.274.41.29156			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506171	hybrid			2022-12-25	WOS:000083017800050
J	Miyakawa, K; Hatsuzawa, K; Kurokawa, T; Asada, M; Kuroiwa, T; Imamura, T				Miyakawa, K; Hatsuzawa, K; Kurokawa, T; Asada, M; Kuroiwa, T; Imamura, T			A hydrophobic region locating at the center of fibroblast growth factor-9 is crucial for its secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN OVALBUMIN CONTAINS; SIGNAL SEQUENCE; FACTOR FAMILY; PROTEIN TRANSLOCATION; NERVOUS-SYSTEM; ENDOPLASMIC-RETICULUM; CLEAVAGE SITES; FACTOR FGF; RECEPTOR; RECOGNITION	Fibroblast growth factor (FGF)-9 is a glycosylated neurotrophic polypeptide highly expressed in brain. The mechanism for its secretion from expressing cells is unclear, because its primary structure lacks a cleavable signal sequence. me, therefore, investigated the mechanism and structural requirements for secretion of FGF-9. As with other secreted proteins, in vitro translation of FGF-9 was inhibited by signal recognition particle, which binds to the signal sequence. When translated in vitro, full-length FGF-9 was translocated into microsomes, glycosylated, and protected from trypsin digestion. By using various FGF-9 deletion mutants, we found that two hydrophobic domains, located at the N terminus and at the center of the FGF-9 primary structure, were crucial for translocation. Examination of various point mutants revealed that local hydrophobicity of the central hydrophobic domain, but not the N terminus, was crucial for translocation. Analogous results mere obtained with respect to FGF-9 secretion from transfectant cells. Upon deletion of the complete sequence preceding it, the previously uncleavable hydrophobic domain appeared to serve as a cleavable signal sequence. Our results suggest that nascent FGF-9 polypeptides translocate into endoplasmic reticulum without peptide cleavage via a co-translational pathway in which both the N terminus and the central hydrophobic domain are important;thereafter, FGF-9 is glycosylated and secreted.	Natl Inst Biosci & Human Technol, Biosignaling Dept, Tsukuba, Ibaraki 3058566, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan; Takeda Chem Ind Ltd, Discovery Res Labs 1, Ibaraki, Osaka 3004293, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; Tokyo University of Pharmacy & Life Sciences; Takeda Chemical Industries	Imamura, T (corresponding author), Natl Inst Biosci & Human Technol, Biosignaling Dept, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.							Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; LINGAPPA VR, 1978, J CELL BIOL, V79, P567, DOI 10.1083/jcb.79.2.567; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MatsumotoYoshitomi S, 1997, INT J CANCER, V71, P442; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Miyakawa K, 1999, GROWTH FACTORS, V16, P191, DOI 10.3109/08977199909002129; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; NARUO K, 1993, J BIOL CHEM, V268, P2857; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Song JW, 1996, DEV DYNAM, V206, P427, DOI 10.1002/(SICI)1097-0177(199608)206:4<427::AID-AJA8>3.0.CO;2-K; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; UNSICKER K, 1987, P NATL ACAD SCI USA, V84, P5459, DOI 10.1073/pnas.84.15.5459; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YE RD, 1988, J BIOL CHEM, V263, P4869	32	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29352	29357		10.1074/jbc.274.41.29352	http://dx.doi.org/10.1074/jbc.274.41.29352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506195	hybrid			2022-12-25	WOS:000083017800074
J	Oettgen, P; Kas, K; Dube, A; Gu, XS; Grall, F; Thamrongsak, U; Akbarali, Y; Finger, E; Boltax, J; Endress, G; Munger, K; Kunsch, C; Libermann, TA				Oettgen, P; Kas, K; Dube, A; Gu, XS; Grall, F; Thamrongsak, U; Akbarali, Y; Finger, E; Boltax, J; Endress, G; Munger, K; Kunsch, C; Libermann, TA			Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; SALIVARY-GLAND; TERMINAL DIFFERENTIATION; REGULATES EXPRESSION; MYELOID-LEUKEMIA; GENE-EXPRESSION; FAMILY PROTEINS; ENDOA ENHANCER; GROWTH-FACTOR; FUSION	Epithelial cell differentiation is tightly controlled by distinct sets of transcription factors that regulate the expression of stage-specific genes. We recently isolated the first epithelium-specific Ets transcription factor (ESE-1), Here we describe the characterization of ESE-2, a second epithelium-restricted ESE-1-related Ets factor. Like ESE-1, ESE-2 is induced during keratinocyte differentiation. However, whereas ESE-1 is expressed in the majority of epithelial cell types, ESE-2 expression is restricted to differentiated keratinocytes and glandular epithelium such as salivary gland, prostate, mammary gland, and kidney. In contrast to ESE-1, full-length ESE-2 binds poorly to DNA due to the presence of a negative regulatory domain at the amino terminus. Furthermore, although ESE-1 and the amino-terminally deleted ESE-2 bind with similar affinity to the canonical E74 Ets site, ESE-2 and ESE-1 differ strikingly in their relative affinity toward binding sites in the c-MET and PSMA promoters. Similarly, ESE-1 and ESE-2 drastically differ in their ability to transactivate epithelium-specific promoters, Thus, ESE-2, but not ESE-1, transactivates the parotid gland specific PSP promoter and the prostate-specific PSA promoter. In contrast, ESE-1 transactivates the keratinocyte-specific SPRR2A promoter Ets site and the prostate-specific PSMA promoter significantly better than ESE-2, Our results demonstrate the existence of a unique class of related epithelium-specific Ets factors with distinct functions in epithelial cell gene regulation.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Univ Louvain, Ctr Human Genet, Oncol Mol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Human Genome Sci Inc, Rockville, MD 20850 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; GlaxoSmithKline; Human Genome Sciences Inc; Harvard University; Harvard Medical School	Libermann, TA (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,New England Baptist Bone & Joint Inst, 4 Blackfan Circle, Boston, MA 02115 USA.	tliberma@bidmc.harvard.edu	Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [P01CA072009, K08CA071429] Funding Source: NIH RePORTER; NCI NIH HHS [P01/CA 72009, K08/CA 71429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Ann DK, 1997, CRIT REV ORAL BIOL M, V8, P244, DOI 10.1177/10454411970080030101; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FUJIMURA Y, 1994, NUCLEIC ACIDS RES, V22, P613, DOI 10.1093/nar/22.4.613; Gambarotta G, 1996, ONCOGENE, V13, P1911; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; Laursen J, 1997, GENE, V198, P367, DOI 10.1016/S0378-1119(97)00339-9; Laursen J, 1998, TRANSGENIC RES, V7, P413, DOI 10.1023/A:1008806325102; Lee JH, 1996, J BIOL CHEM, V271, P4561; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; McLean TW, 1996, BLOOD, V88, P4252; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; NOLET S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P247, DOI 10.1016/0167-4781(91)90016-F; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rheinwald J G, 1982, Natl Cancer Inst Monogr, V60, P133; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Schultz J, 1997, PROTEIN SCI, V6, P249; SETH A, 1994, ONCOGENE, V9, P469; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Svendsen P, 1998, NUCLEIC ACIDS RES, V26, P2761, DOI 10.1093/nar/26.11.2761; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198	61	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29439	29452		10.1074/jbc.274.41.29439	http://dx.doi.org/10.1074/jbc.274.41.29439			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506207	hybrid			2022-12-25	WOS:000083017800086
J	Wadd, S; Bryant, H; Filhol, O; Scott, JE; Hsieh, TY; Everett, RD; Clements, JB				Wadd, S; Bryant, H; Filhol, O; Scott, JE; Hsieh, TY; Everett, RD; Clements, JB			The multifunctional herpes simplex virus IE63 protein interacts with heterogeneous ribonucleoprotein K and with casein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; RNA-BINDING; HNRNP-K; NUCLEAR COMPARTMENTS; TYPE-1 ICP27; IN-VITRO; DNA; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	Herpes simplex virus type 1 (HSV-1), the prototype alpha-herpesvirus, causes several prominent diseases. The HSV-1 immediate early (IE) protein IE63 (ICP27) is the only regulatory gene with a homologue in every mammalian and avian herpesvirus sequenced so far, IE63 is a multifunctional protein affecting transcriptional and post-transcriptional processes, and it can shuttle from the nucleus to the cytoplasm, To identify interacting cellular proteins, a HeLa cDNA library was screened in the yeast two-hybrid system using IE63 as bait. Several interacting proteins were identified including heterogeneous nuclear ribonucleoprotein K (hnRNP K), a multifunctional protein like IE63, and the beta subunit of casein kinase 2 (CK2), a protein kinase, and interacting regions were mapped. Confirmation of interactions was provided by fusion protein binding assays, co-immunoprecipitation from infected cells, and CK2 activity assays. hnRNP K co-immunoprecipitated from infected cells with anti-IE63 serum was a more rapidly migrating subfraction than hnRNP K immunoprecipitated by anti-hnRNP K serum. Using anti-IE63 serum, both IE63 and hnRNP K were phosphorylated in vitro by CK2, while in immunoprecipitates using anti-hnRNP K serum, IE63 but not hnRNP K was phosphorylated by CK2. These data provide important new insights into how this key viral regulatory protein exerts its functions.	Univ Glasgow, Inst Virol, Glasgow G11 5JR, Lanark, Scotland; INSERM, Lab Biochim Regulat Cellulaires Endocrines, F-38054 Grenoble, France; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Glasgow; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Southern California	Clements, JB (corresponding author), Univ Glasgow, Inst Virol, Church St, Glasgow G11 5JR, Lanark, Scotland.		Filhol-Cochet, Odile/I-3962-2016; bryant, helen/AHB-1139-2022	bryant, helen/0000-0003-2720-7020; Filhol, Odile/0000-0003-1964-7958				ACKERMANN M, 1984, J VIROL, V52, P108, DOI 10.1128/JVI.52.1.108-118.1984; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BLAHO JA, 1993, J VIROL, V67, P3891, DOI 10.1128/JVI.67.7.3891-3900.1993; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; CLEMENTS JB, 1977, CELL, V12, P275; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grein S, 1999, MOL CELL BIOCHEM, V191, P105, DOI 10.1023/A:1006814428582; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HARDY WR, 1994, J VIROL, V68, P7790, DOI 10.1128/JVI.68.12.7790-7799.1994; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; HONESS RW, 1975, P NATL ACAD SCI USA, V72, P1276, DOI 10.1073/pnas.72.4.1276; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Leroy D, 1999, MOL CELL BIOCHEM, V191, P43, DOI 10.1023/A:1006832312169; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; McGeoch D.J., 1999, ORIGIN EVOLUTION VIR, P441; MCGEOCH DJ, 1993, GENETIC MAPS, V1, P147; McGregor F, 1996, J VIROL, V70, P1931, DOI 10.1128/JVI.70.3.1931-1940.1996; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; Mears WE, 1998, VIROLOGY, V242, P128, DOI 10.1006/viro.1997.9006; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Mitchell C, 1997, J BIOL CHEM, V272, P25394, DOI 10.1074/jbc.272.40.25394; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; PANGIOTIDIS CA, 1997, J VIROL, V71, P1547; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phelan A, 1998, SEMIN VIROL, V8, P309, DOI 10.1006/smvy.1997.0133; PHELAN A, 1993, P NATL ACAD SCI USA, V90, P9056, DOI 10.1073/pnas.90.19.9056; Phelan A, 1996, J VIROL, V70, P5255, DOI 10.1128/JVI.70.8.5255-5265.1996; Phelan A, 1997, J GEN VIROL, V78, P3327, DOI 10.1099/0022-1317-78-12-3327; Quinn JP, 1998, J GEN VIROL, V79, P2529, DOI 10.1099/0022-1317-79-10-2529; RICE SA, 1994, J VIROL, V68, P823, DOI 10.1128/JVI.68.2.823-833.1994; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; SACKS WR, 1985, J VIROL, V55, P796, DOI 10.1128/JVI.55.3.796-805.1985; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; SandriGoldin RM, 1996, J VIROL, V70, P108, DOI 10.1128/JVI.70.1.108-118.1996; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; Soliman TM, 1997, J VIROL, V71, P9188, DOI 10.1128/JVI.71.12.9188-9197.1997; STEVELY WS, 1985, J GEN VIROL, V66, P661, DOI 10.1099/0022-1317-66-4-661; TSIEH TY, 1998, J BIOL CHEM, V273, P17651; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; VAUGHAN PJ, 1992, VIROLOGY, V189, P377, DOI 10.1016/0042-6822(92)90720-A; Xia K, 1996, J VIROL, V70, P1050, DOI 10.1128/JVI.70.2.1050-1060.1996; XIA K, 1996, J VIROL, V70, P108; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469; Zhi Y, 1999, J VIROL, V73, P3246, DOI 10.1128/JVI.73.4.3246-3257.1999; Zhi Y, 1999, VIROLOGY, V257, P341, DOI 10.1006/viro.1999.9698; Zhong L, 1997, J VIROL, V71, P3146, DOI 10.1128/JVI.71.4.3146-3160.1997	61	72	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28991	28998		10.1074/jbc.274.41.28991	http://dx.doi.org/10.1074/jbc.274.41.28991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506147	hybrid			2022-12-25	WOS:000083017800026
J	Brendza, KM; Rose, DJ; Gilbert, SP; Saxton, WM				Brendza, KM; Rose, DJ; Gilbert, SP; Saxton, WM			Lethal kinesin mutations reveal amino acids important for ATPase activation and structural coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-PROTEIN COMPLEX; DIMERIC KINESIN; HEAVY-CHAIN; MICROTUBULE PROTOFILAMENTS; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; DROSOPHILA KINESIN; KINETIC MECHANISM; CRYSTAL-STRUCTURE; ADP RELEASE	To study the relationship between conventional kinesin's structure and function, we identified 13 lethal mutations in the Drosophila kinesin heavy chain motor domain and tested a subset for effects on mechanochemistry, S246F is a moderate mutation that occurs in loop 11 between the ATP- and microtubule-binding sites. While ATP and microtubule binding appear normal, there is a 3-fold decrease in the rate of ATP turnover, This is consistent with the hypothesis that loop 11 provides a structural link that is important for the activation of ATP turnover by microtubule binding. T291M is a severe mutation that occurs in alpha-helix 5 near the center of the microtubule-binding surface. It impairs the microtubule-kinesin interaction and directly effects the ATP-binding pocket, allowing an increase in ATP turnover in the absence of microtubules. The T291M mutation may mimic the structure of a microtubule-bound, partially activated state. E164K is a moderate mutation that occurs at the beta-sheet 5a/loop 8b junction, remote from the ATP pocket. Surprisingly, it causes both tighter ATP-binding and a 2-fold decrease in ATP turnover We propose that E164 forms an ionic bridge with alpha-helix 5 and speculate that it helps coordinate the alternating site catalysis of dimerized kinesin heavy chain motor domains.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Indiana University System; Indiana University Bloomington; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Saxton, WM (corresponding author), Indiana Univ, Dept Biol, Jordan Hall 336, Bloomington, IN 47405 USA.				NIGMS NIH HHS [R37 GM054141, R01 GM054141, R01 GM046295-09, GM-54141, R01 GM046295, GM-46295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM046295, R01GM054141] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; DECUEVAS M, 1993, ANAL STALK DROSOPHIL; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; GOODSON HV, 1994, J CELL SCI, V107, P1875; Grummt M, 1998, EMBO J, V17, P5536, DOI 10.1093/emboj/17.19.5536; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1995, NATURE, V377, P488; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hoenger A, 1996, J MOL BIOL, V263, P114, DOI 10.1006/jmbi.1996.0561; Hoenger A, 1997, J MOL BIOL, V265, P553, DOI 10.1006/jmbi.1996.0757; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Hoenger A, 1998, J CELL BIOL, V141, P419, DOI 10.1083/jcb.141.2.419; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Thormahlen' M, 1998, J MOL BIOL, V275, P795, DOI 10.1006/jmbi.1997.1503; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	59	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31506	31514		10.1074/jbc.274.44.31506	http://dx.doi.org/10.1074/jbc.274.44.31506			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531353	Green Accepted, hybrid			2022-12-25	WOS:000083379400057
J	Crottet, P; Corthesy, B				Crottet, P; Corthesy, B			Mapping the interaction between murine IgA and murine secretory component carrying epitope substitutions reveals a role of domains II and III in covalent binding to IgA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; LIGAND; LIVER; ANTIBODIES; PROTEINS; PURIFICATION; EXPRESSION; SUBUNIT; DIMERS; CELLS	We have identified sites for epitope insertion in the murine secretory component (SC) by replacing individual surface-exposed loops in domains I, II, and III with the FLAG sequence (Crottet, P., Peitsch, M. C., Servis, C., and Corthesy, B. (1999) J. Biol Chem. 274, 31445-31455). We had previously shown that epitope-carrying SC reassociated with dimeric IgA (IgA(d)) can serve as a mucosal delivery vehicle. When analyzing the capacity of SC mutants to associate with IgA(d), we found that all domain II and III mutants bound specifically with immobilized IgA(d), and their affinity for IgA(d) was comparable to that of the wild type protein (IC50 similar to 1 nM), We conclude that domains II and III in SC are permissive to local mutation and represent convenient sites to antigenize the SC molecule. No mutant bound to monomeric IgA SC mutants exposing the FLAG at their surface maintained this property once bound to IgA(d), thereby defining regions not required for high affinity binding to IgA(d), Association of IgA(d) with SC mutants carrying a buried FLAG did not expose de novo the epitope, consistent with limited, local changes in the SC structure upon binding. Only wild type and two mutant SCs bound covalently to IgA(d), thus implicating domains II and III in the correct positioning of the reactive cysteine in SC. This establishes that the integrity of murine SC domains II and III is not essential to preserve specific IgA(d) binding but is necessary for covalency to take place. Finally, SC mutants existing in the monomeric and dimeric forms exhibit-ed the same IgA(d) binding capacity as monomeric wild type SC known to bind with a 1:1 stoichiometry.	CHU Vaudois, Div Immunol & Allergie, CH-1011 Lausanne, Switzerland; Inst Suisse Rech Expt Canc, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Corthesy, B (corresponding author), CHU Vaudois, Div Immunol & Allergie, BH18-701,Rue Bugnon, CH-1011 Lausanne, Switzerland.							BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1993, J IMMUNOL, V151, P1346; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BAKOS MA, 1991, J IMMUNOL, V146, P162; BEALE D, 1988, INT J BIOCHEM, V20, P873, DOI 10.1016/0020-711X(88)90077-8; Brandtzaeg P, 1994, HDB MUCOSAL IMMUNOLO, P113; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Corthesy B, 1996, J BIOL CHEM, V271, P33670, DOI 10.1074/jbc.271.52.33670; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; CUNNINGHAMRUNDLES C, 1975, J BIOL CHEM, V250, P1987; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; Enrich C, 1996, HEPATOLOGY, V24, P226, DOI 10.1002/hep.510240136; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; FRUTIGER S, 1987, J BIOL CHEM, V262, P1712; KNIGHT KL, 1975, J IMMUNOL, V115, P595; KUHN LC, 1979, J BIOL CHEM, V254, P1066; KUHN LC, 1981, J BIOL CHEM, V256, P2490; LINDH E, 1976, EUR J BIOCHEM, V62, P263, DOI 10.1111/j.1432-1033.1976.tb10156.x; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; MESTECKY J, 1987, ADV IMMUNOL, V40, P515; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Nion S, 1997, BIOCHEM J, V328, P415, DOI 10.1042/bj3280415; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; PARR EL, 1995, J IMMUNOL METHODS, V180, P147, DOI 10.1016/0022-1759(94)00310-S; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; SOLARI R, 1985, J BIOL CHEM, V260, P1141; SONG WX, 1995, J IMMUNOL, V155, P715; TAMER CM, 1995, J IMMUNOL, V155, P707; WEICKER J, 1975, J IMMUNOL, V114, P1337; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; Zeng FY, 1996, GLYCOBIOLOGY, V6, P247, DOI 10.1093/glycob/6.3.247	36	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31456	31462		10.1074/jbc.274.44.31456	http://dx.doi.org/10.1074/jbc.274.44.31456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531347	hybrid			2022-12-25	WOS:000083379400051
J	Ho, HH; Du, DY; Gershengorn, MC				Ho, HH; Du, DY; Gershengorn, MC			The N terminus of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; CHEMOTACTIC CYTOKINES; CALCITONIN RECEPTOR; ACTIVATION; LIGAND; DOMAIN; DETERMINANTS; EXPRESSION; ANTIGEN; GENES	Kaposi's sarcoma-associated herpesvirus (KSHV) contains a gene encoding a G protein-coupled receptor (KSHV-GPCR) that is homologous to mammalian chemokine receptors, KSHV-GPCR signals constitutively (in an agonist-independent manner) via the phosphoinositide-inositol 1,4,5-trisphosphate pathway. Because it has been proposed that the N terminus (N-TERM) of other GPCRs may act as tethered agonists, we determined whether the N-TERM of KSHV-GPCR is necessary for constitutive signaling activity or ligand binding or both. We show that replacement of the entire N-TERM of KSHV-GPCR with those of two other GPCRs, deletion of residues within the N-TERM, and disruption of a putative disulfide bond that may hold the N-TERM in close proximity to extracellular loop 3 do not affect constitutive signaling activity but decrease chemokine binding. There were differences in the effects of mutation of the N-TERM on binding of the chemokines growth-related oncogene a, which is an agonist, and interferon-gamma-inducible protein-10, which is an inverse agonist. The effects on chemokine binding were accompanied by changes in chemokine regulation of KSHV-GPCR signaling. We conclude that the N-TERM is not necessary for constitutive KSHV-GPCR signaling, i.e. the N-TERM is not a tethered agonist, but plays a crucial role in binding of chemokine ligands and of chemokine regulation of KSHV-GPCR signaling.	Cornell Univ, Weill Med Coll, Program Mol Med, Dept Med,Div Mol Med, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Mol Med, New York, NY 10021 USA	Cornell University; Cornell University	Gershengorn, MC (corresponding author), Cornell Univ, Weill Med Coll, Program Mol Med, Dept Med,Div Mol Med, 1300 York Ave,Rm A328, New York, NY 10021 USA.				NCI NIH HHS [CA 75918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; CHEN J, 1994, J BIOL CHEM, V269, P16041; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Herzig MCS, 1996, J BIOL CHEM, V271, P29746, DOI 10.1074/jbc.271.47.29746; Ho HH, 1999, BIOCHEMISTRY-US, V38, P1866, DOI 10.1021/bi981195e; IMAI A, 1987, METHOD ENZYMOL, V141, P100; Laakkonen L, 1996, MOL PHARMACOL, V49, P1092; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lu DS, 1998, MOL ENDOCRINOL, V12, P592, DOI 10.1210/me.12.4.592; LU ZH, 1995, J BIOL CHEM, V270, P26239; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; OSMAN R, 1999, STRUCTURE FUNCTION G; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Tournamille C, 1997, J BIOL CHEM, V272, P16274, DOI 10.1074/jbc.272.26.16274; Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288	31	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31327	31332		10.1074/jbc.274.44.31327	http://dx.doi.org/10.1074/jbc.274.44.31327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531332	hybrid			2022-12-25	WOS:000083379400036
J	Bertrand, L; Alessi, DR; Deprez, J; Deak, M; Viaene, E; Rider, MH; Hue, L				Bertrand, L; Alessi, DR; Deprez, J; Deak, M; Viaene, E; Rider, MH; Hue, L			Heart 6-phosphofructo-2-kinase activation by insulin results from Ser-466 and Ser-483 phosphorylation and requires 3-phosphoinositide-dependent kinase-1, but not protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; MECHANISM; MUTAGENESIS; GLYCOLYSIS; INHIBITION; PATHWAY; DOMAIN; IGF-1; B/AKT; SITE	Previous studies have shown that (i) the insulin-induced activation of heart 6-phosphofructo-2-kinase (PFK-2) is wortmannin-sensitive, but is insensitive to rapamycin, suggesting the involvement of phosphatidylinositol 3-kinase; and (ii) protein kinase B (PKB) activates PFK-S in vitro by phosphorylating Ser-466 and Ser-483, In this work, we have studied the effects of phosphorylation of these residues on PFK-2 activity by replacing each or both residues with glutamate. Mutation of Ser-466 increased the V-max of PFK-2, whereas mutation of Ser-483 decreased citrate inhibition. Mutation of both residues was required to decrease the K-m for fructose 6-phosphate. We also studied the insulin-induced activation of heart PFK-2 in transfection experiments performed in human embryonic kidney 293 cells. Insulin activated transfected PFK-S by phosphorylating Ser-466 and Ser-483. Kinase-dead (KD) PKB and KD 3-phosphoinositide-dependent kinase-1 (PDK-1) cotransfectants acted as dominant negatives because both prevented the insulin-induced activation of PKB as well as the inactivation of glycogen-synthase kinase-3, an established substrate of PKB. However, the insulin-induced activation of PFK-2 was prevented only by KD PDK-1, but not by KD PKB. These results indicate that the insulin-induced activation of heart PFK-S its mediated by a PDK-1-activated protein kinase other than PKB.	Univ Catholique Louvain, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Inst Cellular Pathol, B-1200 Brussels, Belgium; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	Universite Catholique Louvain; University of Dundee	Hue, L (corresponding author), ICP UCL 75 29, HORM Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.			Bertrand, Luc/0000-0003-0655-7099; Alessi, Dario/0000-0002-2140-9185				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLEN G, 1989, SEQUENCING PROTEINS, P140; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Bertrand L, 1998, EUR J BIOCHEM, V254, P490, DOI 10.1046/j.1432-1327.1998.2540490.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coffer PJ, 1998, BIOCHEM J, V335, P1; CREPIN KM, 1993, J BIOL CHEM, V268, P15277; CROSS DAE, 1995, NATURE, V378, P229; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Depre C, 1998, EUR J BIOCHEM, V258, P277, DOI 10.1046/j.1432-1327.1998.2580277.x; Depre C, 1998, J CLIN INVEST, V101, P390, DOI 10.1172/JCI1168; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang QH, 1999, MOL CELL BIOL, V19, P4008	26	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30927	30933		10.1074/jbc.274.43.30927	http://dx.doi.org/10.1074/jbc.274.43.30927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521487	hybrid			2022-12-25	WOS:000083276700083
J	Morris, SK; Lindsley, JE				Morris, SK; Lindsley, JE			Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; DRUG-INTERACTION DOMAINS; STEADY-STATE ANALYSIS; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; TARGETED DRUGS; ANTINEOPLASTIC DRUGS; CRYSTAL-STRUCTURE; ANTITUMOR DRUGS	Topoisomerase II-catalyzed DNA transport requires coordination between two distinct reactions: ATP hydrolysis and DNA cleavage/religation. To further understand how these reactions are coupled, inhibition by the clinically used anticancer drug etoposide was studied. The IC50 for perturbing the DNA cleavage/religation equilibrium is nucleotide-dependent; its value is 6 mu M in the presence of ATP, 25 mu M in the presence of a nonhydrolyzable ATP analog, and 45 mu M, in the presence of ADP or no nucleotide. This inhibition was further characterized using steady-state and pre-steady-state ATPase and decatenation assays. Etoposide is a hyperbolic noncompetitive inhibitor of the ATPase activity with a K-i(app) of 5.6 mu M; no inhibition of ATP hydrolysis is seen in the absence of DNA cleavage. In order to determine which steps of the ATPase mechanism etoposide inhibits, pre; steady-state analysis was performed. These results showed that etoposide does not reduce the rate of binding two ATP, hydrolyzing the first ATP, or releasing the second ADP. Inhibition is therefore associated with the first product release step or hydrolysis of the second ATP, suggesting that DNA religation normally occurs at one of these two steps. Multiple turnover decatenation is inhibited when etoposide is present; however, single turnover decatenation occurs normally. The implications of these results are discussed in terms of their contribution to our current model for the topoisomerase II mechanism.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NIGMS NIH HHS [5T32GM08753, GM51194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008753, R01GM051194] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; BAIRD CL, 1999, IN PRESS P NATL ACAD; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Cline SD, 1997, BIOCHEMISTRY-US, V36, P13095, DOI 10.1021/bi971770z; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HUFF AC, 1990, J BIOL CHEM, V265, P20496; Kingma PS, 1999, BIOCHEMISTRY-US, V38, P3457, DOI 10.1021/bi982855i; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1994, DNA TOPOISOMERASES T, P1; Maxwell A, 1999, BIOCHEM SOC T, V27, P48, DOI 10.1042/bst0270048; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; NITISS JL, 1994, DNA TOPOISOMERASES T, P201; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Rubnitz JE, 1998, J PEDIAT HEMATOL ONC, V20, P1, DOI 10.1097/00043426-199801000-00001; SANDER M, 1983, J BIOL CHEM, V258, P8421; Segel IH., 1993, ENZYME KINETICS BEHA; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	42	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30690	30696		10.1074/jbc.274.43.30690	http://dx.doi.org/10.1074/jbc.274.43.30690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521457	hybrid			2022-12-25	WOS:000083276700053
J	Barton, RM; Worman, HJ				Barton, RM; Worman, HJ			Prenylated prelamin A interacts with Narf, a novel nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; LAMIN-A PRECURSOR; INTERMEDIATE FILAMENT PROTEINS; RETINOBLASTOMA GENE-PRODUCT; CHROMATIN BINDING-SITE; GAMMA-SUBUNIT; MEMBRANE ATTACHMENT; GTP-BINDING; CELL-LINE; RAS	Prelamin A is farnesylated and methylated on the cysteine residue of a carboxyl-terminal CaaX motif, In the nucleus, prelamin A is processed to lamin A by endoproteolytic removal of the final 18 amino acids, including the farnesylated cysteine residue, Using the yeast two-hybrid assay, we isolated a novel human protein, Narf, that binds the carboxyl-terminal tail of prelamin A. Narf has limited homology to iron-only bacterial hydrogenases and eukaryotic proteins of unknown function. Narf is encoded by a 2-kilobase mRNA expressed in all human cell lines and tissues examined. The protein is detected in the nuclear fraction of HeLa cell lysates on Western blots and can be extracted from nuclear envelopes with 0.5 M NaCl. When a FLAG epitope-tagged Narf is expressed in HeLa cells, it is exclusively nuclear and partially co-localizes with the nuclear lamina, The farnesylation status of prelamin A determines its ability to bind to Narf. Inhibition of farnesyltransferase and mutation or deletion of the CaaX motif from the prelamin A tail domain inhibits Narf binding in yeast two-hybrid and in vitro binding assays. The prenyl-dependent binding of Narf to prelamin A is an important first step in understanding the functional significance of the lamin A precursor.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Worman, HJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168th St,P&S 10-508, New York, NY 10032 USA.				NCI NIH HHS [5-P30-CA13696, CA66974] Funding Source: Medline; NCRR NIH HHS [1S10-RR10506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066974, P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams MWW, 1998, SCIENCE, V282, P1842, DOI 10.1126/science.282.5395.1842; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; BRIDGER JM, 1993, J CELL SCI, V104, P297; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CANCE WG, 1992, J EXP CLIN CANC RES, V11, P233; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOLDMAN AE, 1992, J CELL BIOL, V119, P725, DOI 10.1083/jcb.119.4.725; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUILLY MN, 1990, EXP CELL RES, V189, P145, DOI 10.1016/0014-4827(90)90267-E; GUILLY MN, 1987, EMBO J, V6, P3795, DOI 10.1002/j.1460-2075.1987.tb02715.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HENNEKES H, 1994, J CELL SCI, V107, P1019; HOZAK P, 1995, J CELL SCI, V108, P635; Kilic F, 1997, J BIOL CHEM, V272, P5298, DOI 10.1074/jbc.272.8.5298; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEBEL S, 1987, J CELL BIOL, V105, P1099, DOI 10.1083/jcb.105.3.1099; LIN F, 1993, J BIOL CHEM, V268, P16321; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; MUSHA T, 1992, J BIOL CHEM, V267, P9821; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OZAKI T, 1994, ONCOGENE, V9, P2649; PAULINLEVASSEUR M, 1988, EUR J CELL BIOL, V47, P121; PAULINLEVASSEUR M, 1989, J CELL SCI, V92, P361; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; ROBER RA, 1989, DEVELOPMENT, V105, P365; Sambrook J., 2002, MOL CLONING LAB MANU; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SASSEVILLE AMJ, 1995, J CELL SCI, V108, P273; SINENSKY M, 1994, J CELL SCI, V107, P61; SINENSKY M, 1994, J CELL SCI, V107, P2215; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YUAN J, 1991, J BIOL CHEM, V266, P9211; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	64	86	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30008	30018		10.1074/jbc.274.42.30008	http://dx.doi.org/10.1074/jbc.274.42.30008			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514485	hybrid			2022-12-25	WOS:000083176400064
J	Esposti, MD; Hatzinisiriou, I; McLennan, H; Ralph, S				Esposti, MD; Hatzinisiriou, I; McLennan, H; Ralph, S			Bcl-2 and mitochondrial oxygen radicals - New approaches with reactive oxygen species-sensitive probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; CERAMIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; HYDROGEN-PEROXIDE; HEART MITOCHONDRIA; RESPIRATORY-CHAIN; GENERATION; SUPEROXIDE; INVOLVEMENT	Investigations into the capacity of the Bcl-2 protein to prevent apoptosis have targeted mitochondria as key sites of the preventative action accorded by Bcl-2 to cells. Using novel approaches with fluorescence probes and autofluorescence detection of endogenous NAD(P)H, we have examined the effects of expressing Bcl-2 in the Bcl-2 negative Burkitt's lymphoma cell line Daudi. We evaluated for the first time the effect of Bcl-2 expression on the intracellular distribution and production of hydrogen peroxide, under basal conditions and after treatment with apoptosis inducing agents, ceramide analogs and tumor necrosis factor (TNF)-alpha. Increased availability of mitochondrial NAD(P)H was detected in Bcl-2-expressing cells and was correlated with an increased constitutive mitochondrial production of hydrogen peroxide. Although production of hydrogen peroxide was increased by either C-6-ceramide or TNF-alpha in Bcl-2 negative Daudi cells commensurate with the early phases of apoptosis, this increase did not occur in Bcl-2-expressing cells. Thus, Bcl-2 appears to allow cells to adapt to an increased state of oxidative stress, fortifying the cellular anti-oxidant defenses and counteracting the radical overproduction imposed by different cell death stimuli. Furthermore, we report altered cytological features of mitochondria during the early phases of apoptosis induced by C-6-ceramide and TNF-alpha. In particular, mitochondria changed in appearance, clustering in the perinuclear region and Bcl-2 expression prevented these changes from occurring.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Monash University	Esposti, MD (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3168, Australia.	maurolit@hotmail.com		Degli Esposti, Mauro/0000-0002-0977-119X; Ralph, Stephen/0000-0002-4335-092X				BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; DiPietro R, 1997, CYTOKINE, V9, P463, DOI 10.1006/cyto.1996.0189; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; Esposti MD, 1996, ARCH BIOCHEM BIOPHYS, V330, P395, DOI 10.1006/abbi.1996.0267; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; Haugland R.P., 1996, HDB FLUORESCENT PROB, P491; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOEK JB, 1988, BIOCHEM J, V254, P1; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Virgili F, 1998, FREE RADICAL BIO MED, V24, P93, DOI 10.1016/S0891-5849(97)00215-3; VLESSIS AA, 1990, J BIOL CHEM, V265, P1448; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864	54	138	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29831	29837		10.1074/jbc.274.42.29831	http://dx.doi.org/10.1074/jbc.274.42.29831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514462	hybrid			2022-12-25	WOS:000083176400041
J	Guo, SY; Tabor, S; Richardson, CC				Guo, SY; Tabor, S; Richardson, CC			The linker region between the helicase and primase domains of the bacteriophage T7 gene 4 protein is critical for hexamer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; NUCLEOTIDE-BINDING SITE; DNA-POLYMERASE ACTIVITY; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; CONFERS PROCESSIVITY; TEMPLATE RECOGNITION; CRYSTAL-STRUCTURE; REPLICATION FORK	The gene 4 protein of bacteriophage T7, a functional hexamer, comprises DNA helicase and primase activities. Both activities depend on the unidirectional movement of the protein along single-stranded DNA in a reaction coupled to the hydrolysis of dTTP, We have characterized dTTPase activity and hexamer formation for the full-length gene 4 protein (gp4) as well as for three carboxyl-terminal fragments starting at residues 219 (gp4-C219), 241 (gp4-C241), and 272 (gp4-C272), The region between residues 242 and 271, residing between the primase and helicase domains, is critical for oligomerization of the gene 4 protein. A functional TPase active site is dependent on oligomerization, During native gel electrophoresis, gp4, gp4-C219, and gp4-C241 migrate as oligomers, whereas gp4-C272 is monomeric, The steady-state k(cat) for dTTPase activity of gp4-C272 increases sharply with protein concentration, indicating that it forms oligomers only at high concentrations. gp4-C219 and gp4-C241 both form a stable complex with gp4, whereas gp4-C272 interacts only weakly with gp4, Measurements of surface plasmon resonance indicate that a monomer of T7 DNA polymerase binds to a dimer of gp4, gp4-C219, or gp4-C241 but to a monomer of gp4-C272, Like the homologous RecA and F-1-ATPase proteins, the oligomerization domain of the gene 4 protein is adjacent to the amino terminus of the NTP-binding domain.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; GRIEP MA, 1995, INDIAN J BIOCHEM BIO, V32, P171; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HUBER HE, 1986, J BIOL CHEM, V261, P5006; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOLODNER R, 1978, J BIOL CHEM, V253, P566; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1986, J BIOL CHEM, V261, P5208; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	50	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30303	30309		10.1074/jbc.274.42.30303	http://dx.doi.org/10.1074/jbc.274.42.30303			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514525	hybrid, Green Published			2022-12-25	WOS:000083176400104
J	Stark, JM; Cooper, TA; Roth, MB				Stark, JM; Cooper, TA; Roth, MB			The relative strengths of SR protein-mediated associations of alternative and constitutive exons can influence alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TROPONIN-T-GENE; ENHANCER; MUSCLE; RECOGNITION; COMPLEX; BINDING; INTRON; SITES	We have characterized the functional role of SR protein-mediated exon/exon associations in the alternative splicing of exon 5 of chicken cardiac troponin T (cTnT). We have previously shown that SR proteins can promote the association of the alternative exon 5 with the flanking constitutive exon 6 of this pre-mRNA. In this study, we have shown that when exons 2, 3, and 4 of the cTnT pre-mRNA are spliced together, the composite exon 2/3/4 contains an additional SR protein binding site. Furthermore, we have found that SR proteins can also promote interactions between the pairs of exons 2/3/4-5 and 2/3/ 4-6. We then asked whether the SR protein binding sites in these exons play a role in cTnT alternative splicing in vivo. We found that the SR protein binding sites in exons 2/3/4 and 6 promote exon 5 skipping, and it has previously been shown that the SR protein binding site in exon 5 promotes exon 5 inclusion. Consistent with these results, we find that the SR protein-mediated association of exon 2/3/4 with 6 is preferred over associations involving exon 5, in that exons 2/3/4 and 6 are more efficient than exon 5 in competing an SR protein-mediated exon/exon association. We suggest that the relative strengths of SR protein-mediated associations of alternative and constitutive exons play a role in determining alternative splicing patterns.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98104 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Roth, MB (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045565, R01HL045565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM048435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45565] Funding Source: Medline; NIGMS NIH HHS [GM48435, T32 GM07270] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLACK DL, 1995, RNA, V1, P763; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8443, DOI 10.1093/nar/16.17.8443; Cooper TA, 1998, MOL CELL BIOL, V18, P4519, DOI 10.1128/MCB.18.8.4519; COOPER TA, 1985, J BIOL CHEM, V260, P1140; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MOORE JM, 1993, RNA WORLD, P303; Nagel RJ, 1998, RNA, V4, P11; NASIM F, 1990, GENE DEV, V7, P1172; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Stark JM, 1998, P NATL ACAD SCI USA, V95, P2163, DOI 10.1073/pnas.95.5.2163; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; WANG Z, 1995, RNA, V1, P21; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	25	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29838	29842		10.1074/jbc.274.42.29838	http://dx.doi.org/10.1074/jbc.274.42.29838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514463	hybrid			2022-12-25	WOS:000083176400042
J	Stephens, DJ; Banting, G				Stephens, DJ; Banting, G			Direct interaction of the trans-Golgi network membrane protein, TGN38, with the F-actin binding protein, neurabin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; CYTOSOLIC DOMAIN; ADAPTER-COMPLEX; CELL-SURFACE; MONOCLONAL-ANTIBODY; MYOSIN-II; LOCALIZATION; RECEPTOR; IDENTIFICATION; CYTOSKELETON	TGN38 is a type I integral membrane protein that constitutively cycles between the trans-Golgi network (TGN) and plasma membrane. The cytosolic domain of TGN38 interacts with AP2 clathrin adaptor complexes via the tyrosine-containing motif (-SDYQRL-) to direct internalization from the plasma membrane, This motif has previously been shown to direct both internalization and subsequent TGN targeting of TGN38. We have used the cytosolic domain of TGN38 in a two-hybrid screen, and we have identified the brain-specific F-actin binding protein neurabin-I as a TGN38-binding protein. We demonstrate a direct interaction between TGN38 and the ubiquitous homologue of neurabin-I, neurabin-II (also called spinophilin), We have used a combination of yeast two-hybrid and in vitro protein interaction assays to show that this interaction is dependent on the serine (but not tyrosine) residue of the known TGN38 trafficking motif, We shaw that TGN38 interacts with the coiled coil region of neurabin in vitro and binds preferentially with the dimeric form of neurabin. TGN38 and neurabin also interact in vivo as demonstrated by coimmunoprecipitation from stably transfected PC12 cells, These data suggest that neurabin provides a direct physical link between TGN38-containing membranes and the actin cytoskeleton.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Banting, G (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			Stephens, David/0000-0001-5297-3240; Banting, George/0000-0001-8249-1621				Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; BARON MD, 1990, J BIOL CHEM, V265, P19928; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Crump CM, 1998, J BIOL CHEM, V273, P28073, DOI 10.1074/jbc.273.43.28073; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Durrbach A, 1996, J CELL SCI, V109, P457; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REAVES B, 1992, BIOCHEM J, V283, P313, DOI 10.1042/bj2830313; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALMON ED, 1989, CURR OPIN CELL BIOL, V1, P89; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Stephens DJ, 1997, FEBS LETT, V416, P27, DOI 10.1016/S0014-5793(97)01165-4; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; Stow JL, 1998, TRENDS CELL BIOL, V8, P138, DOI 10.1016/S0962-8924(98)01238-0; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; VAJTEK AB, 1993, CELL, V74, P205; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WHITBY FG, 1992, J MOL BIOL, V227, P441, DOI 10.1016/0022-2836(92)90899-U; WILDE A, 1992, FEBS LETT, V313, P235, DOI 10.1016/0014-5793(92)81199-V; WONG SH, 1993, J BIOL CHEM, V268, P22853; ZEHAVIFEFERMAN R, 1995, FEBS LETT, V368, P122, DOI 10.1016/0014-5793(95)00613-E	58	41	45	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30080	30086		10.1074/jbc.274.42.30080	http://dx.doi.org/10.1074/jbc.274.42.30080			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514494	hybrid			2022-12-25	WOS:000083176400073
J	Menard, C; Pupier, S; Mornet, D; Kitzmann, M; Nargeot, J; Lory, P				Menard, C; Pupier, S; Mornet, D; Kitzmann, M; Nargeot, J; Lory, P			Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; RAT-HEART; RXR-ALPHA; VENTRICULAR MYOCYTES; PRIMARY CULTURE; MESSENGER-RNA; CA2+ CHANNEL; LINE; RECEPTORS; CURRENTS	The molecular mechanisms underlying the developmental regulation of L-type voltage-dependent Ca2+ channels (VDCCs) are still unknown, In this study, we have characterized the expression patterns of skeletal (alpha(1S)) and cardiac (alpha(1C)) L-type VDCCs during cardiogenic differentiation in H9C2 cells that derived from embry onic rat heart. We report that chronic treatment of H9C2 cells with 10 an all-trans-retinoic acid (all-trans-RA) enhanced cardiac Ca2+ channel expression, as demonstrated by reverse transcription-polymerase chain reaction, immunoblotting, and indirect immunofluorescence studies, as well as patch-clamp experiments. In addition, RA treatment prevented expression of functional skeletal L-type VDCCs, which were restricted to myotubes that spontaneously appear in control H9C2 cultures undergoing myogenic transdifferentiation. The use of specific skeletal and cardiac markers indicated that RA, by preventing myogenic transdifferentiation, preserves cardiac differentiation of this cell line, Altogether, we provide evidence that cardiac and skeletal subtype-specific L-type Ca2+ channels are relevant functional markers of differentiated cardiac and skeletal myocytes, respectively, In conclusion our data demonstrate that in vitro RA stimulates cardiac (alpha(1C)) L-type Ca2+ channel expression, therefore supporting the hypothesis that the RA pathway might be involved in the tissue specific expression of Ca2+ channels in mature cardiac cells.	IGH, CNRS, UPR 1142, F-34396 Montpellier 05, France; INSERM, F-34000 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Lory, P (corresponding author), IGH, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 05, France.	philippe.lory@igh.cnrs.fr		LORY, philippe/0000-0002-1638-7604; Nargeot, Joel/0000-0003-2893-5636				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; Bulteau L, 1998, J CELL SCI, V111, P2149; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cerbai E, 1997, CIRCULATION, V95, P568, DOI 10.1161/01.CIR.95.3.568; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; Chen J, 1998, DEVELOPMENT, V125, P1943; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYCOMB WC, 1983, DEV BIOL, V99, P331, DOI 10.1016/0012-1606(83)90283-X; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; COGNARD C, 1993, DEVELOPMENT, V117, P1153; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EGHBALI M, 1991, P NATL ACAD SCI USA, V88, P795, DOI 10.1073/pnas.88.3.795; Eisenberg CA, 1996, CIRC RES, V78, P205, DOI 10.1161/01.RES.78.2.205; Gaughan JP, 1998, AM J PHYSIOL-HEART C, V275, pH577, DOI 10.1152/ajpheart.1998.275.2.H577; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; HAASE H, 1994, RECEPTOR CHANNEL, V2, P41; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LORY P, 1993, FEBS LETT, V315, P167, DOI 10.1016/0014-5793(93)81156-T; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; Lory P., 1995, Biophysical Journal, V68, pA259; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MEJIAALVAREZ R, 1994, J PHYSIOL-LONDON, V478, P315, DOI 10.1113/jphysiol.1994.sp020252; MENARD C, 1998, J MOL CELL CARDIOL, V30, pA126; MINER JH, 1992, DEVELOPMENT, V114, P853; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; NUSS HB, 1993, CIRC RES, V73, P777, DOI 10.1161/01.RES.73.4.777; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Philips A, 1999, ONCOGENE, V18, P1819, DOI 10.1038/sj.onc.1202530; Powell JA, 1996, J CELL BIOL, V134, P375, DOI 10.1083/jcb.134.2.375; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; RUDNICKI MA, 1989, DEVELOPMENT, V107, P361; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Sucov HM, 1996, BIOCHEM SOC SYMP, P143; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; WU J, 1995, AM J PHYSIOL-ENDOC M, V268, pE1108, DOI 10.1152/ajpendo.1995.268.6.E1108; XIAO YH, 1995, J CELL BIOL, V129, P1345, DOI 10.1083/jcb.129.5.1345; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	48	141	142	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29063	29070		10.1074/jbc.274.41.29063	http://dx.doi.org/10.1074/jbc.274.41.29063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506158	hybrid			2022-12-25	WOS:000083017800037
J	Sun, HZ; Li, HY; Harvey, I; Sadler, PJ				Sun, HZ; Li, HY; Harvey, I; Sadler, PJ			Interactions of bismuth complexes with metallothionein(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURE; THIOLATE CLUSTERS; CRYSTAL-STRUCTURE; RENAL TOXICITY; BINDING-SITE; SPIN SYSTEMS; RABBIT; LIVER; SPECTROSCOPY	Bismuth complexes are widely used as anti-ulcer drugs and can significantly reduce the side effects of platinum anti-cancer drugs. Bismuth is known to induce the synthesis of metallothionein (MT) in the kidney, but there are few chemical studies on the interactions of bismuth complexes with metallothionein. Here we show that Bi3+ binds strongly to metallothionein with a stoichiometry bismuth:MT = 7:1 (Bi7MT) and can readily displace Zn2+ and Cd2+. Bismuth is still bound to the protein even in strongly acidic solutions (pH 1). Reactions of bismuth citrate with MT are faster than those of [Bi(EDTA)](-), and both exhibit biphasic kinetics. H-1 NMR data show that Zn2+ is displaced faster than Cd2+, and that both Zn2+ and Cd2+ in the beta-domain (three metal cluster) of NPT are displaced by Bi3+ much faster than from the alpha-domain (four metal cluster). The extended x-ray absorption fine structure spectrum of Bi7MT is very similar to that for the glutathione and N-acetyl-L-cysteine complexes [Bi(GS)(3)] and [Bi(NAC)(3)] with an inner coordination sphere of three sulfur atoms and average Bi-S distances of 2.55 Angstrom Some sites appear to contain additional short Bi-O bonds of 2.2 Angstrom and longer Bi-S bonds of 3.1 Angstrom The Bi3+ sites in Bi7MT are therefore highly distorted in comparison with those of Zn2+ and Cd2+.	Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; SERC, Daresbury Lab, Cent Lab, Warrington WA4 4AD, Cheshire, England	University of Edinburgh; STFC Daresbury Laboratory	Sadler, PJ (corresponding author), Univ Edinburgh, Dept Chem, Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.		/D-3123-2009	/0000-0001-6697-6899				ANTHONY P, 1997, J CHEM SOC DA, P977; ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; ATWOOD DA, 1993, INORG CHEM, V32, P2972, DOI 10.1021/ic00065a030; Barrie PJ, 1996, J CHEM SOC DALTON, P2417, DOI 10.1039/dt9960002417; BAXTER GF, 1992, CHEM BRIT, V28, P445; BAXTER GF, 1989, PHARM J, V243, P805; BERNHARD W, 1983, INORG CHIM A-BIOINOR, V79, P154, DOI 10.1016/S0020-1693(00)95191-0; Binsted N., 1998, EXCURV 98 CCLRC DARE; BOOGAARD PJ, 1991, BIOCHEM PHARMACOL, V41, P369, DOI 10.1016/0006-2952(91)90533-B; BOULANGER Y, 1982, J BIOL CHEM, V257, P13717; BROUWER M, 1993, BIOCHEM J, V294, P219, DOI 10.1042/bj2940219; Cols N, 1997, J INORG BIOCHEM, V68, P157, DOI 10.1016/S0162-0134(97)00085-8; Daniels MJ, 1998, J BIOL CHEM, V273, P22957, DOI 10.1074/jbc.273.36.22957; DiSilvestro RA, 1996, RES COMMUN MOL PATH, V93, P163; ELLIS PD, 1995, STUDIES METALLOPROTE; ELLIS PJ, 1996, XFIT WINDOWS 95 AUST; ENDRESEN L, 1983, CANCER RES, V43, P2918; FARRUGIA LJ, 1995, J CHEM SOC DALTON, P1163, DOI 10.1039/dt9950001163; Fowle DA, 1997, J BIOMOL STRUCT DYN, V14, P393, DOI 10.1080/07391102.1997.10508139; GAN T, 1995, J BIOL CHEM, V270, P5339, DOI 10.1074/jbc.270.10.5339; Gui Z, 1996, INORG CHEM, V35, P6520, DOI 10.1021/ic951624m; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HERRMANN WA, 1993, CHEM BER-RECL, V126, P895, DOI 10.1002/cber.19931260407; HIGHAM DP, 1984, SCIENCE, V225, P1043, DOI 10.1126/science.225.4666.1043; HIGHAM DP, 1986, ENVIRON HEALTH PERSP, V65, P157, DOI 10.2307/3430176; HIGHAM DP, 1983, INORG CHIM A-BIOINOR, V79, P140, DOI 10.1016/S0020-1693(00)95177-6; JIANG DT, 1994, J AM CHEM SOC, V116, P11004, DOI 10.1021/ja00103a016; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; JONES WB, 1994, INORG CHEM, V33, P5571, DOI 10.1021/ic00102a034; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; LEMKUIL DC, 1994, J BIOL CHEM, V269, P24792; LERCH K, 1980, NATURE, V284, P368, DOI 10.1038/284368a0; LI TY, 1980, P NATL ACAD SCI-BIOL, V77, P6334, DOI 10.1073/pnas.77.11.6334; LI TY, 1981, BIOCHEM J, V193, P441, DOI 10.1042/bj1930441; MARGOSHES M, 1957, J AM CHEM SOC, V79, P4813, DOI 10.1021/ja01574a064; MESSERLE BA, 1990, J MOL BIOL, V214, P765, DOI 10.1016/0022-2836(90)90291-S; MESSERLE BA, 1992, J MOL BIOL, V225, P433, DOI 10.1016/0022-2836(92)90930-I; Morcillo MA, 1996, BIOMETALS, V9, P213, DOI 10.1007/BF00817918; MORELOCK MM, 1988, INORG CHEM, V27, P3137, DOI 10.1021/ic00291a017; NAGANUMA A, 1987, CANCER RES, V47, P983; NEUHAUS D, 1985, EUR J BIOCHEM, V151, P257, DOI 10.1111/j.1432-1033.1985.tb09096.x; NEUHAUS D, 1984, EUR J BIOCHEM, V143, P659, DOI 10.1111/j.1432-1033.1984.tb08419.x; NIELSON KB, 1985, J BIOL CHEM, V260, P5342; Nordberg M., 1979, METALLOTHIONEIN, P41; OTVOS JD, 1980, P NATL ACAD SCI-BIOL, V77, P7094, DOI 10.1073/pnas.77.12.7094; PATTANAIK A, 1992, J BIOL CHEM, V267, P16121; PRINZ R, 1975, H-S Z PHYSIOL CHEM, V356, P767, DOI 10.1515/bchm2.1975.356.s1.767; RAUSER WE, 1980, NATURE, V287, P563, DOI 10.1038/287563a0; RICHARDS MP, 1989, J NUTR, V119, P1062, DOI 10.1093/jn/119.7.1062; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; Ross JF, 1996, BRAIN RES, V725, P137; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V533, P209, DOI 10.1016/0005-2795(78)90565-2; Sadler PJ, 1996, CHEM-EUR J, V2, P701, DOI 10.1002/chem.19960020615; Saito S, 1996, RES COMMUN MOL PATH, V93, P101; Satoh M, 1997, CANCER CHEMOTH PHARM, V40, P358, DOI 10.1007/s002800050670; SATOH M, 1988, TOXICOLOGY, V53, P231; SCHULTZE P, 1988, J MOL BIOL, V203, P251, DOI 10.1016/0022-2836(88)90106-4; SHAW CF, 1992, METALLOTHIONEINS SYN, P144; SUMMERS SP, 1994, INORG CHEM, V33, P88, DOI 10.1021/ic00079a017; Sun HZ, 1997, CHEM BER-RECL, V130, P669, DOI 10.1002/cber.19971300602; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; UCHIDA Y, 1993, METALLOTHIONEIN, V3, P315; VASAK M, 1981, P NATL ACAD SCI-BIOL, V78, P6709, DOI 10.1073/pnas.78.11.6709; VASAK M, 1983, MET IONS BIOL SYST, V15, P213	65	121	123	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29094	29101		10.1074/jbc.274.41.29094	http://dx.doi.org/10.1074/jbc.274.41.29094			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506163	hybrid, Green Published			2022-12-25	WOS:000083017800042
J	Zheng, CJ; Xiang, JL; Hunter, T; Lin, AN				Zheng, CJ; Xiang, JL; Hunter, T; Lin, AN			The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE/CED-3 FAMILY PROTEASES; B-INDUCING KINASE; SIGNAL-TRANSDUCTION; MAP KINASES; CYTOPLASMIC LOCALIZATION; NUCLEAR TRANSLOCATION; NH2-TERMINAL KINASE; MOLECULAR-CLONING; ACTIVATION DOMAIN; TERMINAL KINASE	c-Jun N-terminal protein kinase (JNK), a member of the mitogen-activated protein (MAP) kinase family, regulates gene expression in response to various extracellular stimuli. JNK is activated by JNK-activating kinase (JNKK1 and JNKK2), a subfamily of the dual specificity MAP kinase kinase (MEK) family, through phosphorylation on threonine (Thr) 183 and tyrosine (Tyr) 185 residues. The physiological functions of the JNK pathway, however, are not completely understood. A major obstacle is the lack of specific and activated kinase components that: can stimulate the JNK pathway in the absence of any stimulus. Here we show that fusion of JNK1 to its upstream activator JNKK2 resulted in its constitutive activation. In HeLa cells, the JNKK2-JNK1 fusion protein showed significant JNK activity, which was comparable with that of JNK1 activated by many stimuli and activators, including EGF, TNF-alpha, anisomycin, UV irradiation, MEKK1, and small GTP binding proteins Rad and Cdc42Hs. Immunoblotting analysis indicated that JNK1 was phosphorylated by JNKK2 in the fusion protein on both Thr(183) and Tyr(185) residues. Like JNKK2, the JNKK2-JNK1 fusion protein was highly specific for the JNK pathway and did not activate either p38 or ERK2. Transient transfection assays demonstrated that the JNKK2-JNK1 fusion protein was sufficient to stimulate c-Jun transcriptional activity in the absence of any stimulus. Immunofluorescence analysis revealed that the JNKK2-JNK1 fusion protein was predominantly located in the nucleus of transfected HeLa cells. These results indicate that the JNKK2-JNK1 fusion protein is a constitutively active Jun kinase, which will facilitate the investigation of the physiological roles of the JNK pathway.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Gene Therapy Ctr, Birmingham, AL 35294 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Salk Institute	Lin, AN (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R29CA073740] Funding Source: NIH RePORTER; NCI NIH HHS [CA73740] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MACRUS S, 1994, P NATL ACAD SCI USA, V91, P7762; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PRINTEN JA, 1994, GENETICS, V138, P609; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	60	100	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28966	28971		10.1074/jbc.274.41.28966	http://dx.doi.org/10.1074/jbc.274.41.28966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506143	hybrid			2022-12-25	WOS:000083017800022
J	Hess, DA; Sisson, ME; Suria, H; Wijsman, J; Puvanesasingham, R; Madrenas, J; Reider, MJ				Hess, DA; Sisson, ME; Suria, H; Wijsman, J; Puvanesasingham, R; Madrenas, J; Reider, MJ			Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole	FASEB JOURNAL			English	Article						cytochrome P450; MACS; apoptosis; cell viability	ADVERSE DRUG-REACTIONS; ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; IN-VITRO CYTOTOXICITY; TRIMETHOPRIM-SULFAMETHOXAZOLE; HYPERSENSITIVITY REACTIONS; HOSPITALIZED-PATIENTS; ANNEXIN-V; TUMOR-NECROSIS; HIV-INFECTION	Treatment with sulfonamide antibiotics in HIV-infected patients is associated with a high incidence (> 40%) of adverse drug events, including severe hypersensitivity reactions. Sulfonamide reactive metabolites have been implicated in the pathogenesis of these adverse reactions, Sulfamethoxazole hydroxylamine (SMX-HA) induces lymphocyte toxicity and suppression of proliferation in vitro; the mechanism(s) of these immunomodulatory effects remain unknown, We investigated the cytotoxicity of SMX-HA via apoptosis on human peripheral blood mononuclear cells and purified cell subpopulations in vitro. CD19(+), CD4(+), and CD8(+) cells were isolated from human peripheral blood by positive selection of cell surface molecules by magnetic bead separation. SMX-HA induced significant CD8(+) cell death (67 +/- 7%) at 100 mu M SMX-HA, with only minimal CD4(+) cell death (8 +/- 4%). No significant subpopulation toxicity was shown when incubated with parent drug (SMX). Flow cytometry measuring phosphatidylserine externalization 24 h after treatment with 100 mu M and 400 mu M SMX-HA revealed 14.1 +/- 0.7% and 25.6 +/- 4.2% annexin-positive cells, respectively, compared to 3.7 +/- 1.2% in control PBMCs treated with 400 mu M SMX. Internucleosomal DNA fragmentation was observed in quiescent and stimulated PBMCs 48 h after incubation with SMX-HA. Our data show that CD8(+) cells are highly susceptible to the toxic effects of SMX-HA through enhanced cell death by apoptosis.-Hess, D. A., Sisson, M. E., Suria, H., Wijsman, J., Puvanesasingham, R., Madrenas, J., Rieder, M. J. Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole.	Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pediat, John P Robarts Res Inst,Gene Therapy & Mol Virol, London, ON N6J 1Y5, Canada; Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pharmacol & Toxicol, John P Robarts Res Inst,Gene Therapy & Mol Virol, London, ON N6J 1Y5, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON, Canada; Univ Western Ontario, John P Robarts Res Inst, Transplantat & Immunobiol Grp, Dept Med, London, ON, Canada; Univ Western Ontario, John P Robarts Res Inst, Transplantat & Immunobiol Grp, Dept Immunol & Microbiol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Reider, MJ (corresponding author), Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pediat, John P Robarts Res Inst,Gene Therapy & Mol Virol, 800 Commissioners Rd E, London, ON N6J 1Y5, Canada.	mrieder@julian.uwo.ca	Madrenas, Quim/P-5008-2019; Hess, David A/M-2828-2013; Rieder, Michael J/L-2397-2013					Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BATTYE FL, 1991, CURR OPIN IMMUNOL, V3, P238; CAMPBELL ME, 1987, CLIN PHARMACOL THER, V42, P157, DOI 10.1038/clpt.1987.126; CARR A, 1993, CLIN EXP IMMUNOL, V94, P21; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; CARR A, 1994, AIDS, V8, P333, DOI 10.1097/00002030-199403000-00006; CARR A, 1993, J ACQ IMMUN DEF SYND, V6, pS56; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Cotter T G, 1992, Semin Immunol, V4, P399; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; COTTER TG, 1992, ANTICANCER RES, V12, P773; CRIBB AE, 1990, MOL PHARMACOL, V38, P744; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; Cribb AE, 1997, J PHARMACOL EXP THER, V282, P1064; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; CRIBB AE, 1993, BIOCHEM PHARMACOL, V45, P1277, DOI 10.1016/0006-2952(93)90280-A; CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784; FADOK VA, 1992, J IMMUNOL, V148, P2207; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; FURIE MB, 1995, AM J PATHOL, V146, P1287; Green D R, 1992, Semin Immunol, V4, P355; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; Gruchalla RS, 1998, J ALLERGY CLIN IMMUN, V101, P371, DOI 10.1016/S0091-6749(98)70250-7; HAUSNER MA, 1993, J IMMUNOL METHODS, V157, P181, DOI 10.1016/0022-1759(93)90085-L; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Hess DA, 1998, CLIN PHARMACOL THER, V63, P138; Hess DA, 1997, J PHARMACOL EXP THER, V281, P540; KIZAKI H, 1992, IMMUNOPHARMACOLOGY, V24, P219, DOI 10.1016/0162-3109(92)90077-P; Lawrence DA, 1996, J LEUKOCYTE BIOL, V60, P611, DOI 10.1002/jlb.60.5.611; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEEDER JS, 1988, J PHARMACOL EXP THER, V245, P956; LEEDER JS, 1991, BIOCHEM PHARMACOL, V41, P575; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Mannel D, 1996, IMMUNOL TODAY, V17, P254, DOI 10.1016/0167-5699(96)80539-1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; RADBRUCH A, 1994, METHOD CELL BIOL, V42, P387; Reilly TP, 1998, BIOCHEM PHARMACOL, V55, P803, DOI 10.1016/S0006-2952(97)00547-9; RIEDER MJ, 1992, INT J IMMUNOPHARMACO, V14, P1175, DOI 10.1016/0192-0561(92)90052-M; RIEDER MJ, 1995, TOXICOLOGY, V95, P141, DOI 10.1016/0300-483X(94)02900-F; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1993, J CLIN PHARMACOL, V33, P316, DOI 10.1002/j.1552-4604.1993.tb04663.x; RIEDER MJ, 1995, J ACQ IMMUN DEF SYND, V8, P134, DOI 10.1097/00042560-199502000-00004; Rieder MJ, 1997, PEDIATR CLIN N AM, V44, P93, DOI 10.1016/S0031-3955(05)70465-X; RIEDER MJ, 1994, DRUG SAFETY, V11, P196, DOI 10.2165/00002018-199411030-00005; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3; RIEDER MJ, 1992, CAN J PHYSIOL PHARM, V70, P719, DOI 10.1139/y92-094; Rieder MJ, 1997, PEDIATR INFECT DIS J, V16, P1028, DOI 10.1097/00006454-199711000-00005; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; Rudin C M, 1996, Curr Opin Hematol, V3, P35; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; Schlegel RA, 1996, ADV EXP MED BIOL, V406, P21; SHEAR NH, 1985, BRIT J DERMATOL, V113, P112, DOI 10.1111/j.1365-2133.1985.tb15637.x; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; Sisson ME, 1997, INT J IMMUNOPHARMACO, V19, P299, DOI 10.1016/S0192-0561(97)00027-1; SPIELBERG SP, 1985, CAN J PHYSIOL PHARM, V63, P468, DOI 10.1139/y85-081; THOMAS TE, 1992, J IMMUNOL METHODS, V154, P245, DOI 10.1016/0022-1759(92)90198-3; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01	72	49	53	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1688	1698		10.1096/fasebj.13.13.1688	http://dx.doi.org/10.1096/fasebj.13.13.1688			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506572				2022-12-25	WOS:000083063400004
J	Shi, H; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB				Shi, H; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB			Role of the sulfonylurea receptor in regulating human adipocyte metabolism	FASEB JOURNAL			English	Article						adipocytes; intracellular Ca2+; fatty acid synthase; SUR	CYTOSOLIC FREE CALCIUM; OBESE ZUCKER RATS; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; K+-CHANNELS; AGOUTI GENE; DIAZOXIDE; STIMULATION; GLIMEPIRIDE; UPDATE	A regulatory role for intracellular Ca2+ ([Ca2+](i)) in adipocyte lipogenesis, lipolysis and triglyceride accumulation has been demonstrated. Compounds acting on the pancreatic sulfonylurea receptor (SUR) to increase (e.g., glibenclamide) or decrease (e.g., diazoxide) [Ca2+](i) cause corresponding increases and decreases in weight gain. However, these weight gain and loss effects have been attributed to insulin release rather than to the primary effects of these compounds on the adipocyte SUR and its associated K-ATP channel, Accordingly, we have evaluated the direct role of the human adipocyte SUR in regulating adipocyte metabolism. We used RT-PCR with primers for a highly conserved region of SUR1 to demonstrate that human adipocytes express SUR1. The PCR product was confirmed by sequence analysis and used as a probe to demonstrate adipocyte SUR1 expression by Northern blot analysis, Adipocytes exhibited glibenclamide dose-responsive (0-20 mM) increases in [Ca2+](i) (P<0.05). Similarly, glibenclamide (10 mM) caused a 67% increase in adipocyte fatty acid synthase activity (P<0.001), a 48% increase in glycerol-3-phosphate dehydrogenase activity (P<0.01) and a 68% inhibition in lipolysis (P<0.01), whereas diazoxide (10 mM) completely prevented each of these effects, These data demonstrate that human adipocytes express a SUR that regulates [Ca2+](i) and, consequently, exerts coordinate control over lipogenesis and lipolysis. Accordingly, the adipocyte SUR1 may represent an important target for the development of therapeutic interventions in obesity.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; ZenBio Inc, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.		Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030; Zemel, Michael/0000-0003-4104-5750				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alemzadeh R, 1996, METABOLISM, V45, P334, DOI 10.1016/S0026-0495(96)90287-5; ALEMZADEH R, 1993, ENDOCRINOLOGY, V133, P705, DOI 10.1210/en.133.2.705; Alemzadeh R, 1998, J CLIN ENDOCR METAB, V83, P1911, DOI 10.1210/jc.83.6.1911; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; Chagnon YC, 1998, OBES RES, V6, P76, DOI 10.1002/j.1550-8528.1998.tb00318.x; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, DIABETES, V36, P174, DOI 10.2337/diabetes.36.2.174; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; GILON P, 1993, J BIOL CHEM, V268, P22265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hani E, 1997, DIABETES, V46, P688, DOI 10.2337/diabetes.46.4.688; INAGAKI N, 1996, SCIENCE, V270, P1167; JACOBS DB, 1985, J BIOL CHEM, V260, P2593; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; MALOFF BL, 1981, J CLIN INVEST, V68, P85, DOI 10.1172/JCI110257; MARTZ A, 1989, J BIOL CHEM, V264, P13672; Moustaid N, 1996, J NUTR, V126, P865, DOI 10.1093/jn/126.4.865; Muller G, 1996, HORM METAB RES, V28, P469, DOI 10.1055/s-2007-979839; MULLER G, 1994, BIOCHEM PHARMACOL, V48, P985, DOI 10.1016/0006-2952(94)90369-7; PHILIPSON LH, 1995, SCIENCE, V270, P1159, DOI 10.1126/science.270.5239.1159; RAJAN AS, 1994, ENDOCRINOLOGY, V134, P1581, DOI 10.1210/en.134.3.1581; STURGESS NC, 1985, LANCET, V2, P474; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	32	53	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1833	1838		10.1096/fasebj.13.13.1833	http://dx.doi.org/10.1096/fasebj.13.13.1833			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506587				2022-12-25	WOS:000083063400019
J	Vila-Coro, AJ; Rodriguez-Frade, JM; De Ana, AM; Moreno-Ortiz, MC; Martinez, C; Mellado, M				Vila-Coro, AJ; Rodriguez-Frade, JM; De Ana, AM; Moreno-Ortiz, MC; Martinez, C; Mellado, M			The chemokine SDF-1 alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway	FASEB JOURNAL			English	Article						chemotactic response; tyrosine phosphorylation; Shp1; G-proteins	CELL-DERIVED FACTOR-1; LYMPHOCYTE CHEMOATTRACTANT; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; T-CELLS; PROTEIN; KINASE; SDF-1; HIV-1	The chemokine stromal cell-derived factor (SDF-1 alpha), the ligand for the CXCR4 receptor, induces a wide variety of effects that include calcium mobilization, chemotactic responses, bone marrow myelopoiesis, neuronal patterning, and prevention of HIV-1 infection. Nonetheless, little is known of the biochemical pathways required to achieve this variety of responses triggered after receptor- chemokine interaction. We developed a set of monoclonal antibodies that specifically recognize the CXCR4 receptor and used them to identify the signaling pathway activated after SDF-1 alpha binding in human T cell lines. Here we demonstrate that SDF-1 alpha activation promotes the physical association of G alpha(i) with the CXCR4, Furthermore, within seconds of SDF-1 alpha activation, the CXCR4 receptor becomes tyrosine phosphorylated through the activation and association with the receptor of JAK2 and JAK3 kinases. After SDF-1 alpha binding, JAK2 and JAK3 associate with CXCR4 and are activated, probably by transphosphorylation, in a G alpha(i)-independent manner. This activation enables the recruitment and tyrosine phosphorylation of several members of the STAT family of transcription factors. Finally, we have also observed SDF-1 alpha-induced activation and association of the tyrosine phosphatase Shp1 with the CXCR4 in a G alpha(i)-dependent manner, As occurs with the cytokine receptors in response to cytokines, the CXCR4 undergoes receptor dimerization after SDF-1 alpha binding and is a critical step in triggering biological responses. We present compelling evidence that the chemokines signal through mechanisms similar to those activated by cytokines.-Vila-Coro, A. J., Rodriguez-Frade, J. M., Martin de Ana, A., Moreno-Ortiz, M. C., Martinez-A., C., Mellado, M. The chemokine SDF-1 alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Martinez, C (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Frade, Jose Miguel Rodriguez/K-4266-2014; Mellado, Mario/M-9893-2014	Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Mellado, Mario/0000-0001-6325-1630				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENKIRANE M, 1997, J BIOL CHEM, V272, P30602; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FRADE JMR, 1997, J CLIN INVEST, V100, P1; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; KENNEDY J, 1995, J IMMUNOL, V155, P203; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 1996, J CLIN ENDOCR METAB, V81, P1613, DOI 10.1210/jc.81.4.1613; Mellado M, 1997, IMMUNOLOGY METHODS M, P1145; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Petricoin E, 1996, MOL CELL BIOL, V16, P1419; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	47	423	440	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1699	1710		10.1096/fasebj.13.13.1699	http://dx.doi.org/10.1096/fasebj.13.13.1699			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506573	Bronze			2022-12-25	WOS:000083063400005
J	Warpeha, KM; Xu, W; Liu, L; Charles, IG; Patterson, CC; Ah-Fat, F; Harding, S; Hart, PM; Chakravarthy, U; Hughes, AE				Warpeha, KM; Xu, W; Liu, L; Charles, IG; Patterson, CC; Ah-Fat, F; Harding, S; Hart, PM; Chakravarthy, U; Hughes, AE			Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy	FASEB JOURNAL			English	Article						microvascular; transcription; NOS2A promoter; pentanucleotide repeat	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; HIGH-GLUCOSE; GENE; EXPRESSION; PROMOTER; MELLITUS; CLONING; AORTA	Accumulating evidence shows that the severity and rapidity of onset of diabetic retinopathy are influenced by genetic factors. Expression of the nitric oxide synthases is altered in the retinal vasculature in the early stages of diabetic retinopathy. We analyzed the allele distribution of a polymorphic pentanucleotide repeat within the 5' upstream promoter region of the NOS2A gene in samples of diabetic patients. In diabetic patients from Northern Ireland, the 14-repeat allele of the NOS2A marker was significantly associated with the absence of diabetic retinopathy. Carriers of this repeat had 0.21-fold the relative risk of developing diabetic retinopathy than noncarriers of this allele. They also had significantly fewer renal and cardiovascular complications. The ability of differing numbers of (CCTTT)(n) pentanucleotide repeats to induce transcription of the NOS2A gene was analyzed using a luciferase reporter gene assay in transfected colonic carcinoma cells. Interleukin 1b (IL-1b) induction was most effective in constructs carrying the 14-repeat allele. When cells were incubated in 25 mM glucose to mimic the diabetic state, IL-1 beta induction was inhibited in all cases, but to a significantly lesser extent with the 14-repeat allele. These unique properties of the 14-repeat allele may confer selective advantages in diabetic individuals, which may delay or prevent microvascular complications of diabetes.	Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland; Royal Liverpool Hosp, Eye Unit, Liverpool L7 8XP, Merseyside, England; UCL, Rayne Inst, Wolfson Inst Biomed Res, London, England	Queens University Belfast; Queens University Belfast; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of London; King's College London; University College London	Chakravarthy, U (corresponding author), Inst Clin Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.		Hughes, Anne/A-1307-2012; Xu, Weiming/A-6274-2008	Xu, Weiming/0000-0002-7085-7814; Chakravarthy, Usha/0000-0002-2606-3734; Harding, Simon/0000-0003-4676-1158				Agardh D, 1996, DIABETOLOGIA, V39, P1313, DOI 10.1007/s001250050575; AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; Chakravarthy U, 1997, INVEST OPHTH VIS SCI, V38, P2144; Chakravarthy U, 1998, DIABETES, V47, P945, DOI 10.2337/diabetes.47.6.945; Chappey O, 1996, CELL BIOL TOXICOL, V12, P199, DOI 10.1007/BF00438146; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; DORNAN TL, 1982, DIABETES, V31, P226, DOI 10.2337/diabetes.31.3.226; FEENER EP, 1997, LANCET S1, V350, P9; GELLER DA, 1995, J IMMUNOL, V155, P4890; GRAIER WF, 1993, DIABETES, V42, P2497; Guillausseau PJ, 1997, DIABETES METAB, V23, P14; HUGHES AE, 1993, GENOMICS, V15, P433, DOI 10.1006/geno.1993.1083; JEANPIERRE M, 1993, AM J HUM GENET, V53, P757; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; LESLIE RDG, 1982, DIABETES, V31, P19, DOI 10.2337/diabetes.31.1.19; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061; MULHERN M, 1989, BRIT J PHARMACOL, V97, P1007, DOI 10.1111/j.1476-5381.1989.tb12555.x; Muniyappa R, 1998, HYPERTENSION, V31, P289, DOI 10.1161/01.HYP.31.1.289; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; POSTON L, 1995, CLIN SCI, V88, P245, DOI 10.1042/cs0880245; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Sheng H, 1996, PHARMACOL RES, V33, P29, DOI 10.1006/phrs.1996.0005; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Stehouwer CDA, 1997, CARDIOVASC RES, V34, P55, DOI 10.1016/S0008-6363(96)00272-6; TESFAMARIAM B, 1990, J CLIN INVEST, V85, P929, DOI 10.1172/JCI114521; VIALETTES B, 1994, DIABETES METAB, V20, P229; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008; Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6; Xu WM, 1996, BIOCHEM BIOPH RES CO, V219, P784, DOI 10.1006/bbrc.1996.0311; YE XO, 1990, INVEST OPHTH VIS SCI, V31, P1731	38	129	138	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1825	1832		10.1096/fasebj.13.13.1825	http://dx.doi.org/10.1096/fasebj.13.13.1825			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506586				2022-12-25	WOS:000083063400018
J	Liao, J; Piwien-Pilipuk, G; Ross, SE; Hodge, CL; Sealy, L; MacDougald, OA; Schwartz, J				Liao, J; Piwien-Pilipuk, G; Ross, SE; Hodge, CL; Sealy, L; MacDougald, OA; Schwartz, J			CCAAT/enhancer-binding protein beta (C/EEP beta) and C/EBP delta contribute to growth hormone-regulated transcription of c-fos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; 3T3-L1 ADIPOCYTES; ACTIVATOR PROTEIN; LEUCINE ZIPPER; ALPHA-GENE; KINASE-A; IN-VIVO; FAMILY	Using the c-fos enhancer as a model to analyze growth hormone (GH)-promoted gene expression, the roles of CCAAT/enhancer-binding proteins (C/EBPs) in GH-regulated transcription were investigated. In 3T3-F442A fibroblasts stably expressing the c-fos promoter mutated at the C/EBP binding site upstream of luciferase, c-fos promoter activity is stimulated by GH 6-7-fold; wild type c-fos promoter shows only a 2-fold induction by GH, This suggests that C/EBP restrains GH-stimulated expression of c-fos. Electrophoretic mobility shift assays with nuclear extracts from 3T3-F442A cells indicate that GH rapidly (2-5 min) increases binding of C/EBP beta and C/EBP delta, to the c-fos C/EBP binding site. Both liver activating protein (LAP) and liver inhibitory protein (LIP), forms of C/EBP delta, are detected in 3T3-F442A cells by immunoblotting, GH increases the binding of LAP/LAP and LAP/LIP dimers, Overexpression elf LIP interferes with GH-promoted reporter expression in CHO cells expressing GH receptors, consistent with the possibility that LIP restrains GH-stimulated c-fos expression. Overexpression of LAP elevates basal luciferase activity but does not influence promoter activation by GH, while overexpressed C/EBP delta elevates basal promoter activity and enhances the stimulation by GH. GH stimulates the expression of mRNA for C/EBP beta and -delta and increases levels of C/EBP delta. Although C/EBP beta is not detectably altered, GH induces a shift to more rapidly migrating forms of LIP and LAP upon immunoblotting. Treatment of extracts from GH-treated cells with alkaline phosphatase causes a shift of the slower migrating form to the rapidly migrating form, consistent with GH promoting dephosphorylation of LIP and LAP. These studies implicate C/EBP beta and -delta in GH-regulated gene expression. They also indicate that GH stimulates the blinding of C/EBP beta and -delta to the c-fos promoter and promotes the dephosphorylation of LIP and LAP. These events may contribute to the ability of C/EBP beta and -delta to regulate GH-stimulated expression of c-fos.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Vanderbilt University	Schwartz, J (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.			MacDougald, Ormond/0000-0001-6907-7960	NCI NIH HHS [CA43720] Funding Source: Medline; NIDDK NIH HHS [DK 51563, DK 46072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA043720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563, R01DK046072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hemati N, 1998, BIOCHEM BIOPH RES CO, V244, P20, DOI 10.1006/bbrc.1998.8204; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RICHTER H, 1998, 80 M END SOC, P85; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448	46	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31597	31604		10.1074/jbc.274.44.31597	http://dx.doi.org/10.1074/jbc.274.44.31597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531366	hybrid			2022-12-25	WOS:000083379400070
J	Ren, H; Dou, C; Stelzer, MS; Allison, WS				Ren, H; Dou, C; Stelzer, MS; Allison, WS			Oxidation of the alpha(3)(beta D311C/R333C)(3)gamma subcomplex of the thermophilic Bacillus PS3F(1)-ATPase indicates that only two beta subunits can exist in the closed conformation simultaneously	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL F1-ATPASE; CATALYTIC SITES; NONCATALYTIC SITES; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; ALPHA(3)BETA(3)GAMMA COMPLEX; WILD-TYPE; ATP; PS3; ADP	In the crystal structure of the bovine heart mitochondrial F-1-ATPase (Abrahams, J.P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), the two liganded beta subunits, one with MgAMP-PNP bound to the catalytic site (beta(T)) and the other with MgADP bound (beta(D)) have closed conformations. The empty beta subunit (beta(E)) has an open conformation. In beta(T) and beta(D), the distance between the carboxylate of beta-Asp(315) and the guanidinium of beta-Arg(337) is 3.0-4.0 Angstrom. These side chains are at least 10 Angstrom apart in beta(E). The alpha(3)(beta D311C/R333C)(3)gamma subcomplex of TF1 with the corresponding residues substituted with cysteine has very low ATPase activity unless it is reduced prior to assay or assayed in the presence of dithiothreitol. The reduced subcomplex hydrolyzes ATP at 50% the rate of wild-type and is rapidly inactivated by oxidation by CuCl2 with or without magnesium nucleotides bound to catalytic sites. Titration of the subcomplex with iodo[C-14]acetamide after prolonged treatment with CuCl2 in the presence or absence of 1 mM MgADP revealed nearly two free sulfhydryl groups/mol of enzyme. Therefore, one pair of introduced cysteines is located on a beta subunit that exists in the open or partially open conformation even when catalytic sites are saturated with MgADP. Since V-max of ATP hydrolysis is attained when three catalytic sites of F-1 are saturated, the catalytic site that binds ATP must be closing as the catalytic site that releases products is opening.	Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Allison, WS (corresponding author), Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA.	wsa@checfs2.ucsd.edu			NIGMS NIH HHS [GM16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 1998, ACCOUNTS CHEM RES, V31, P819, DOI 10.1021/ar960257v; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; Grodsky NB, 1998, BIOCHEMISTRY-US, V37, P1007, DOI 10.1021/bi972349d; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1994, J BIOL CHEM, V269, P319; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P20126	20	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31366	31372		10.1074/jbc.274.44.31366	http://dx.doi.org/10.1074/jbc.274.44.31366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531337	hybrid			2022-12-25	WOS:000083379400041
J	Tran, POT; Gleason, CE; Poitout, V; Robertson, RP				Tran, POT; Gleason, CE; Poitout, V; Robertson, RP			Prostaglandin E-2 mediates inhibition of insulin secretion by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ISLETS; HIT CELLS; PANCREATIC-ISLETS; PGE2 INHIBITION; PERTUSSIS TOXIN; CAMP METABOLISM; IN-VITRO; CYCLOOXYGENASE-2; LANGERHANS; EXPOSURE	Interleukin-1 beta (IL-1 beta) and prostaglandin E-2 (PGE(2)), frequently co-participants in inflammatory states, are two well recognized inhibitors of glucose-induced insulin secretion. Previous reports have concluded that the inhibitory effects of these two autacoids on pancreatic beta cell function are not related because indomethacin, a potent prostaglandin synthesis inhibitor, does not prevent IL-1 beta effects. However, indomethacin is not a specific cyclooxygenase inhibitor, and its other pharmacologic effects are likely to inhibit insulin secretion independently. Since we recently observed that IL-1 beta induces cyclooxygenase-2 (COX-2) gene expression and PGE(2) synthesis in islet beta cells, we have reassessed the possibility that PGE(2) mediates IL-1 beta effects on beta function. By using two cell lines (HIT-T15 and beta HC13) as well as Wistar rat isolated pancreatic islets, we examined the ability of two COX-2-specific antagonists, NS-398 and SC-236, to prevent IL-1 beta inhibition of insulin secretion. Both drugs prevented IL-1 beta from inducing PGE(2) synthesis and inhibiting insulin secretion; adding back exogenous PGE(2) re-established inhibition of insulin secretion in the presence of IL-1 beta. We also found that EP3, the PGE(2) receptor subtype whose post-receptor effect is to decrease adenylyl cyclase activity and, thereby, insulin secretion, is the dominant mRNA subtype expressed. We conclude that endogenous PGE(2) mediates the inhibitory effects of exogenous IL-1 beta on beta cell function.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Med & Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.		Roberston, R Paul/AAX-5613-2021	Poitout, Vincent/0000-0002-6555-5053				Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; BURR IM, 1974, ENDOCRINOLOGY, V94, P835, DOI 10.1210/endo-94-3-835; CHEN M, 1979, PROSTAGLANDINS, V18, P557, DOI 10.1016/0090-6980(79)90023-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMENS PG, 1987, DIABETES, V36, P963, DOI 10.2337/diabetes.36.8.963; EIZIRIK DL, 1991, ENDOCRINOLOGY, V128, P1611, DOI 10.1210/endo-128-3-1611; FUJIMOTO WY, 1984, DIABETES, V33, P872, DOI 10.2337/diabetes.33.9.872; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GIUGLIANO D, 1983, AM J PHYSIOL, V245, pE591, DOI 10.1152/ajpendo.1983.245.6.E591; HELQVIST S, 1994, DAN MED BULL, V41, P151; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; METZ SA, 1981, DIABETES, V30, P551, DOI 10.2337/diabetes.30.7.551; PALMER JP, 1989, DIABETES, V38, P1211, DOI 10.2337/diabetes.38.10.1211; Robertson R P, 1977, Trans Assoc Am Physicians, V90, P353; ROBERTSON RP, 1974, J CLIN INVEST, V54, P310, DOI 10.1172/JCI107766; ROBERTSON RP, 1983, DIABETES, V32, P231, DOI 10.2337/diabetes.32.3.231; ROBERTSON RP, 1987, DIABETES, V36, P1047, DOI 10.2337/diabetes.36.9.1047; SACCA L, 1975, ACTA ENDOCRINOL-COP, V79, P266, DOI 10.1530/acta.0.0790266; SEAQUIST ER, 1989, DIABETES, V38, P1439, DOI 10.2337/diabetes.38.11.1439; Sjoholm A, 1996, BBA-MOL CELL RES, V1313, P106; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; ZAWALICH WS, 1989, ENDOCRINOLOGY, V124, P2350, DOI 10.1210/endo-124-5-2350; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	26	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31245	31248		10.1074/jbc.274.44.31245	http://dx.doi.org/10.1074/jbc.274.44.31245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531320	hybrid			2022-12-25	WOS:000083379400024
J	Coulon, V; Veyrune, JL; Tourkine, N; Vie, A; Hipskind, RA; Blanchard, JM				Coulon, V; Veyrune, JL; Tourkine, N; Vie, A; Hipskind, RA; Blanchard, JM			A novel calcium signaling pathway targets the c-fos intragenic transcriptional pausing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE-EARLY GENES; MULTIPLE SEQUENCE ELEMENTS; MESSENGER-RNA DEGRADATION; EPIDERMAL GROWTH-FACTOR; EXPRESSION; PROMOTER; CELLS; ACTIVATION; INDUCTION	In many cell types, increased intracellular calcium gives rise to a robust induction of c-fos gene expression. Here we show that in mouse Ltk(-) fibroblasts, calcium ionophore acts in synergy with either cAMP or PMA to strongly induce the endogenous c-fos gene. Run-on analysis shows that this corresponds to a substantial increase in active polymerases on downstream gene sequences, i.e. relief of an elongation block by calcium. Correspondingly a chimeric gene, in which the human metallothionein promoter is fused to the fos gene, is strongly induced by ionophore alone, unlike a c-fos promoter/beta-globin coding unit chimeric construct. Internal deletions in the hMT-fos reporter localize the intragenic calcium regulatory element to the 5' portion of intron 1, thereby confirming and extending previous in vitro mapping data. Ionophore induced cAMP response element-binding protein phosphorylation on Ser(133) without affecting the extracellular signal-regulated kinase cascade. Surprisingly, induction involved neither CaM-Ks nor calcineurin, while the calmodulin antagonist W7 activated c-fos transcription on its own. These data suggest that a novel calcium signaling pathway mediates intragenic regulation of c-fos expression via suppression of a transcriptional pause site.	Inst Genet Mol, CNRS, UMR 5535, IFR24, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR24, 1919 Route Mende, Montpellier 5, France.		Coulon, Vincent/B-2437-2009; Coulon, Vincent/AFF-7934-2022	Coulon, Vincent/0000-0002-3168-8755; Coulon, Vincent/0000-0002-3168-8755				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BONNIEU A, 1989, ONCOGENE, V4, P881; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Bravo R, 1990, Semin Cancer Biol, V1, P37; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COLLART MA, 1989, ONCOGENE, V4, P237; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1992, J PHYSIOLOGY-PARIS, V86, P99, DOI 10.1016/S0928-4257(05)80013-0; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; Krebs J, 1996, BBA-MOL CELL RES, V1313, P217, DOI 10.1016/0167-4889(96)00092-4; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LI SL, 1994, J MOL ENDOCRINOL, V13, P303, DOI 10.1677/jme.0.0130303; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LUCIBELLO FC, 1991, NUCLEIC ACIDS RES, V19, P3583, DOI 10.1093/nar/19.13.3583; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; PLET A, 1995, ONCOGENE, V10, P319; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang Y, 1996, MOL CELL BIOL, V16, P5915; WERLEN G, 1993, J BIOL CHEM, V268, P16596; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	67	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30439	30446		10.1074/jbc.274.43.30439	http://dx.doi.org/10.1074/jbc.274.43.30439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521422	hybrid			2022-12-25	WOS:000083276700018
J	Falcon, CM; Matthews, KS				Falcon, CM; Matthews, KS			Glycine insertion in the hinge region of lactose repressor protein alters DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; AMINO-TERMINAL FRAGMENT; TRYPSIN-RESISTANT CORE; LAC-REPRESSOR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PURINE REPRESSOR; GLUCOCORTICOID RECEPTOR; OPERATOR BINDING	Amino acid alterations were designed at the C terminus of the hinge segment (amino acids similar to 51-59) that links two functional domains within lactose repressor protein (LacI), Gly was introduced between Gly(58) and Lys(59) to generate Gly(58+1); Gln(60) was changed to Gly or Pro, and up to three additional glycines were inserted following Gln(60) --> Gly, All mutant proteins exhibited purification behavior, CD spectra, assembly state, and inducer binding properties similar to wild-type LacI and only small differences in trypsin proteolysis patterns. In contrast, significant differences were observed in DNA binding properties. Gly(58+1) exhibited a decrease of similar to 100-fold in affinity for O-1 operator, and sequential Gly insertion C-terminal to Gln(60) --> Gly resulted in progressively decreased affinity for O-1 operator, approaching nonspecific levels for insertion of greater than or equal to 2 glycines. Where sufficient affinity for O-1 operator existed, decreased binding to O-1 in the presence of inducer indicated no disruption in the allosteric response for these proteins. Collectively, these results indicate that flexibility and/or spacing between the core and N-terminal domains did not significantly affect folding or assembly, but these alterations in the hinge domain profoundly altered affinity of the lactose repressor protein for its wild-type target sequence.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	Rice University	Matthews, KS (corresponding author), Rice Univ, Dept Biochem & Cell Biol, POB 1892, Houston, TX 77251 USA.				NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Barry JK, 1997, BIOCHEMISTRY-US, V36, P15632, DOI 10.1021/bi971685r; Barry JK, 1999, BIOCHEMISTRY-US, V38, P3579, DOI 10.1021/bi982577n; BOELENS R, 1987, J MOL BIOL, V193, P213, DOI 10.1016/0022-2836(87)90638-3; Bourgeois S, 1976, Adv Protein Chem, V30, P1, DOI 10.1016/S0065-3233(08)60478-7; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BUCK F, 1978, FEBS LETT, V96, P335, DOI 10.1016/0014-5793(78)80430-X; Capp MW, 1996, J MOL BIOL, V258, P25, DOI 10.1006/jmbi.1996.0231; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; Dickerson RE, 1997, BIOPOLYMERS, V44, P361, DOI 10.1002/(SICI)1097-0282(1997)44:4<361::AID-BIP4>3.0.CO;2-X; FILES JG, 1976, J BIOL CHEM, V251, P3386; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GEISLER N, 1978, FEBS LETT, V87, P215, DOI 10.1016/0014-5793(78)80335-4; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; Gunasekaran K, 1998, J MOL BIOL, V275, P917, DOI 10.1006/jmbi.1997.1505; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL ROBERT L., 1965, ADVANCE PROTEIN CHEM, V20, P37, DOI 10.1016/S0065-3233(08)60388-5; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; Kaptein R, 1995, TOXICOL LETT, V82-3, P591, DOI 10.1016/0378-4274(95)03586-9; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KHOURY AM, 1991, J MOL BIOL, V219, P623, DOI 10.1016/0022-2836(91)90659-T; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAIKEN SL, 1972, J MOL BIOL, V66, P143, DOI 10.1016/S0022-2836(72)80012-3; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; Lu F, 1998, BIOCHEMISTRY-US, V37, P15680, DOI 10.1021/bi981617k; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; Miller J. H., 1980, OPERON; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; Pace HC, 1997, TRENDS BIOCHEM SCI, V22, P334, DOI 10.1016/S0968-0004(97)01104-3; PLATT T, 1973, J BIOL CHEM, V248, P110; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Slijper M, 1996, J MOL BIOL, V259, P761, DOI 10.1006/jmbi.1996.0356; Smyth DG., 1967, METHOD ENZYMOL, V11, P214; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; Suckow J, 1996, J MOL BIOL, V261, P509, DOI 10.1006/jmbi.1996.0479; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WADEJARDETZKY N, 1979, J MOL BIOL, V128, P259, DOI 10.1016/0022-2836(79)90129-3; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZUIDERWEG ERP, 1985, BIOCHIMIE, V67, P707, DOI 10.1016/S0300-9084(85)80158-9	72	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30849	30857		10.1074/jbc.274.43.30849	http://dx.doi.org/10.1074/jbc.274.43.30849			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521477	hybrid			2022-12-25	WOS:000083276700073
J	Gogos, A; Clarke, ND				Gogos, A; Clarke, ND			Characterization of an 8-oxoguanine DNA glycosylase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; CATALYTIC MECHANISM; OGG1 GENE; 7,8-DIHYDRO-8-OXOGUANINE; CLONING; REPAIR; CLEAVAGE; PROTEIN; ENZYME	A thermostable 8-oxoguanine (oxoG) DNA glycosylase from Methanococcus jannaschii has been expressed in Escherichia coli, purified, and characterized. The enzyme, which has been named mjOgg, belongs to the same diverse DNA glycosylase superfamily as the 8-oxoguanine DNA glycosylases from yeast (yOgg1) and human (hOgg1) but is substantially different in sequence. In addition, unlike its eukaryotic counterparts, which have a strong preference for oxoG.C base pairs, mjOgg has little specificity for the base opposite oxoG. mjOgg has both DNA glycosylase and DNA lyase (beta-elimination) activity, and the combined glycosylase/lyase activity occurs at a rate comparable with the glycosylase activity alone. Mutation of Lys-129, analogous to Lys-241 of yOgg1, abolishes glycosylase activity.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Clarke, ND (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Clarke, Neil/D-9613-2014	Gogos, Arhonda/0000-0003-3634-0114				Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197	16	23	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30447	30450		10.1074/jbc.274.43.30447	http://dx.doi.org/10.1074/jbc.274.43.30447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521423	hybrid			2022-12-25	WOS:000083276700019
J	Cline, SD; Osheroff, N				Cline, SD; Osheroff, N			Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARA-C; POLYMERASE-ALPHA; ABASIC SITES; CELL-CYCLE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE INCORPORATION; DEOXYADENOSINE STACKS; HELIX OPPOSITE; PROTON-NMR; ARABINOSYLCYTOSINE; BETA	Cytosine arabinoside (araC) is an important drug used for the treatment of human leukemias. In order to exert its cytotoxic effects, araC must be incorporated into chromosomal DNA,Although specific DNA lesions that involve base loss or modification stimulate nucleic acid cleavage mediated by type II topoisomerases, the effects of deoxyribose sugar ring modification on enzyme activity have not been examined. Therefore, the effects of incorporated araC residues on the DNA cleavage/religation equilibrium of human topoisomerase II alpha and beta were characterized. AraC lesions were position-specific topoisomerase II poisons and stimulated DNA scission mediated by both human type II enzymes. However, the positional specificity of araC residues differed from that previously reported for other cleavage-enhancing DNA lesions. Finally, additive or synergistic increases in DNA cleavage were observed in the presence of araC lesions and etoposide. These findings broaden the range of DNA lesions known to alter topoisomerase II function and raise the possibility that this enzyme may mediate some of the cellular effects of araC.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008320] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM08320, GM53960] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; BAKIC M, 1987, BIOCHEM PHARMACOL, V36, P4067, DOI 10.1016/0006-2952(87)90563-6; BERGER RD, 1998, J BIOL CHEM, V273, P15565; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chabner BA, 1996, CANC CHEMOTHERAPY BI, P213; CLINE SD, 1998, AM ASS CANC RES SPEC, P8; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; FELIX CA, 1995, CANCER RES, V55, P4287; FRAM RJ, 1983, LEUKEMIA RES, V7, P243, DOI 10.1016/0145-2126(83)90014-0; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; Gmeiner WH, 1999, BIOCHEMISTRY-US, V38, P1166, DOI 10.1021/bi981702s; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; Goz B, 1997, MUTAT RES-DNA REPAIR, V384, P89, DOI 10.1016/S0921-8777(97)00016-5; Grant S, 1998, ADV CANCER RES, V72, P197; HARRINGTON C, 1995, J BIOL CHEM, V270, P26664, DOI 10.1074/jbc.270.44.26664; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HOLDEN JA, 1992, ONCOL RES, V4, P157; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; JONES PA, 1976, CANCER RES, V36, P3789; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUFE DW, 1985, SEMIN ONCOL, V12, P34; LIU LF, 1983, J BIOL CHEM, V258, P5365; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; OHNO Y, 1988, CANCER RES, V48, P1494; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PLAGEMANN PGW, 1978, CANCER RES, V38, P978; RAAP J, 1987, J BIOMOL STRUCT DYN, V5, P219, DOI 10.1080/07391102.1987.10506391; RASHBAUM SA, 1976, NATURE, V264, P679, DOI 10.1038/264679a0; RIVERA G, 1975, EUR J CANCER, V11, P639, DOI 10.1016/0014-2964(75)90099-7; SCHWEITZER BI, 1994, BIOCHEMISTRY-US, V33, P11460, DOI 10.1021/bi00204a008; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WANG KY, 1997, BIOCHEMISTRY-US, V36, P11626; Whitlock JA, 1997, LEUKEMIA, V11, P185, DOI 10.1038/sj.leu.2400572; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOODCOCK DM, 1979, EXP CELL RES, V123, P157, DOI 10.1016/0014-4827(79)90432-4; WOODCOCK DM, 1979, CANCER RES, V39, P1418; WOODCOCK DM, 1982, CANCER RES, V42, P4744; YOSHIDA S, 1977, BIOCHIM BIOPHYS ACTA, V477, P144, DOI 10.1016/0005-2787(77)90230-1	55	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29740	29743		10.1074/jbc.274.42.29740	http://dx.doi.org/10.1074/jbc.274.42.29740			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514448	hybrid			2022-12-25	WOS:000083176400027
J	Jiang, SN; Cai, JY; Wallace, DC; Jones, DP				Jiang, SN; Cai, JY; Wallace, DC; Jones, DP			Cytochrome c-mediated apoptosis in cells lacking mitochondrial DNA - Signaling pathway involving release and caspase 3 activation is conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; BCL-2; MEMBRANE; PROTEIN; DEATH; GLUTATHIONE; REQUIREMENT; SUPEROXIDE; GENERATION; INHIBITION	Mitochondria serve as a pivotal component of the apoptotic cell death machinery. However, cells that lack mitochondrial DNA (rho(0) cells) retain apparently normal apoptotic signaling. In the present study, we examined mitochondrial mechanisms of apoptosis in rho(0) osteosarcoma cells treated with staurosporine. Immunohistochemistry revealed that rho(0) cells maintained a normal cytochrome c distribution in mitochondria even though these cells were deficient in respiration. Upon staurosporine treatment, cytochrome c was released concomitantly with activation of caspase 3 and loss of mitochondrial membrane potential (Delta psi(m)). After mitochondrial loss of cytochrome c, rho(0) cells underwent little change in glutathione (GSH) redox potential whereas a dramatic oxidation in GSH/glutathione disulfide (GSSG) pool occurred in parental rho(+) cells. These results show that mitochondrial signaling of apoptosis via cytochrome c release was preserved in cells lacking mtDNA. However, intracellular oxidation that normally accompanies apoptosis was lost, indicating that the mitochondrial respiratory chain provides the major source of redox signaling in apoptosis.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University; Emory University	Jones, DP (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NIEHS NIH HHS [ES09047] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009047] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAI CL, 1989, ANAL BIOCHEM, V179, P114, DOI 10.1016/0003-2697(89)90209-1; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang SN, 1997, CELL DEATH DIFFER, V4, P39, DOI 10.1038/sj.cdd.4400204; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LI K, 1995, AM J PHYSIOL-CELL PH, V269, pC1265, DOI 10.1152/ajpcell.1995.269.5.C1265; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, CANCER RES, V56, P2033; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Murphy RC, 1998, FEBS LETT, V425, P259, DOI 10.1016/S0014-5793(98)00245-2; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; QUILLETMARY A, 1997, J BIOL CHEM, V272, P21338; RATAN RR, 1994, J NEUROCHEM, V62, P376; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	152	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29905	29911		10.1074/jbc.274.42.29905	http://dx.doi.org/10.1074/jbc.274.42.29905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514472	hybrid			2022-12-25	WOS:000083176400051
J	Maestes, DC; Potter, RM; Prossnitz, ER				Maestes, DC; Potter, RM; Prossnitz, ER			Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CHEMOATTRACTANT RECEPTORS; BETA-ARRESTIN; KINASES; CELLS; MECHANISMS; ACTIVATION; CLONING	Following activation by ligand, most G protein-coupled receptors undergo rapid phosphorylation, This is accompanied by a drastic decrease in the efficacy of continued or repeated stimulation, due to receptor uncoupling from G protein and receptor internalization. Such processing steps have been shown to be absolutely dependent on receptor phosphorylation in the case of the N-formyl peptide receptor (FPR), In this study, we report results that indicate that the mechanisms responsible for desensitization and internalization are distinct. Using site-directed mutagenesis of the serine and threonine residues of the FPR carboxyl terminus, we have characterized regions that differentially regulate these two processes. Whereas substitution of all 11 Ser/Thr residues in the carboxyl terminus prevents both desensitization and internalization, substitution of four Ser/Thr residues between 328-332 blocks desensitization but has no effect on internalization, Similarly, substitution of four Ser/Thr residues between positions 334 and 339 results in a deficit in desensitization but again no decrease in internalization, suggesting that phosphorylation at either site evokes receptor internalization, whereas maximal desensitization requires phosphorylation at both sites. These results also indicate that receptor internalization is not involved in the process of desensitization. Further analysis of the residues between 328-332 revealed that restoration either of Ser(328) and Thr(329) or of Thr(331) and Ser(332) was sufficient to restore desensitization, suggesting that phosphorylation within either of these two sites, in addition to sites between residues 334 and 339, is sufficient to produce desensitization. Taken together, these results indicate that the mechanisms involved in FPR processing ( uncoupling from G; proteins and internalization) are regulated differentially by phosphorylation at distinct sites within the carboxyl terminus of the FPR, The relevance of this paradigm to other G protein-coupled receptors is discussed.	Univ New Mexico, Ctr Hlth Sci, Dept Physiol & Cell Biol, Albuquerque, NM 87131 USA	University of New Mexico	Prossnitz, ER (corresponding author), Univ New Mexico, Ctr Hlth Sci, Dept Physiol & Cell Biol, Albuquerque, NM 87131 USA.		Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036357, R29AI036357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40115, AI36357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; Choe H, 1998, ARCH PHARM RES, V21, P634, DOI 10.1007/BF02976749; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hartig P R, 1993, Psychopharmacol Ser, V10, P15; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NAWATA H, 1995, STEROIDS, V60, P28, DOI 10.1016/0039-128X(94)00022-5; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; Vilven JC, 1998, J RECEPT SIGNAL TR R, V18, P187, DOI 10.3109/10799899809047744; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	28	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29791	29795		10.1074/jbc.274.42.29791	http://dx.doi.org/10.1074/jbc.274.42.29791			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514456	hybrid			2022-12-25	WOS:000083176400035
J	Nosaka, Y; Arai, A; Miyasaka, N; Miura, O				Nosaka, Y; Arai, A; Miyasaka, N; Miura, O			CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; CHRONIC MYELOGENOUS LEUKEMIA; NERVE GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; ADAPTER PROTEIN; MAP KINASE; V-CRK; MEGAKARYOCYTIC DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE	CrkL is an SH2 and SH3 domain-containing adaptor protein implicated in pathogenesis of chronic myelogenous leukemia. Here, we demonstrate that overexpression of CrkL enhances the erythropoietin (Epo)- or interleukin (IL)-3-induced activation of Elk-1 and the c-fos gene promoter activity in 32D/EpoR-Wt cells. Moreover, the Epo-induced activation of ERK1 and ERK2 was augmented and prolonged in cells inducibly overexpressing CrkL. A moderate increase in Epo-induced activation of JNK was also observed in cells overexpressing CrkL. Overexpression of C3G enhanced the Elk-l activation synergistically with CrkL, while a C3G mutant lacking the guanine nucleotide exchange domain showed an inhibitory effect. Studies using a dominant negative Ha-Ras mutant demonstrated that the Elk-1 and ERK2 activation enhanced by CrkL and C3G was dependent on Ras. Consistent with this, the Epo-induced activation of Ras was augmented in cells inducibly overexpressing CrkL. Most importantly, a CrkL mutant defective in the SH2 or N-terminal SH3 domain showed an inhibitory effect on the Epo-induced activation of ERK2. These data indicate that the CrkL-C3G; complex plays a role in Epo- or IL-L-induced, Ras-dependent activation of the Raf/ERK pathway leading to the activation of Elk-l and the c-fos gene transcription.	Tokyo Med & Dent Univ, Dept Internal Med 1, Bunkyo Ku, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 1, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	miura.med1@med.tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Chin H, 1998, BLOOD, V91, P3734; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1995, ONCOGENE, V10, P1465; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NICHOLS GL, 1994, BLOOD, V84, P2912; Oda A, 1996, BLOOD, V88, P4304; ODA T, 1994, J BIOL CHEM, V269, P22925; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Sattler M, 1997, J BIOL CHEM, V272, P10248; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	62	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30154	30162		10.1074/jbc.274.42.30154	http://dx.doi.org/10.1074/jbc.274.42.30154			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514505	hybrid			2022-12-25	WOS:000083176400084
J	Sidoux-Walter, F; Lucien, N; Olives, B; Gobin, R; Rousselet, G; Kamsteeg, EJ; Ripoche, P; Deen, PMT; Cartron, JP; Bailly, P				Sidoux-Walter, F; Lucien, N; Olives, B; Gobin, R; Rousselet, G; Kamsteeg, EJ; Ripoche, P; Deen, PMT; Cartron, JP; Bailly, P			At physiological expression levels the Kidd blood group/urea transporter protein is not a water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA TRANSPORTER; MESSENGER-RNA; FUNCTIONAL EXPRESSION; RAT-KIDNEY; RED-CELLS; CLONING; GENE; UT3; MICROSCOPY; MUTATIONS	The Kidd (JK) blood group locus encodes a urea transporter that is expressed on human red cells and on endothelial cells of the vasa recta in the kidney, Here, we report the identification in human erythroblasts of a novel cDNA, designated HUT11A, which encodes a protein identical to the previously reported erythroid HUT11 urea transporter, except for a Lys(44) --> Glu substitution and a Val-Gly dipeptide deletion after proline 227, which leads to a polypeptide of 389 residues versus 391 in HUT11. Genomic typing by polymerase chain reaction and transcript analysis by ribonuclease protection assay demonstrated that HUT11A encodes the true Kidd blood group/urea transporter protein, which carries only 2 Val-Gly motifs. Upon expression at high levels in Xenopus oocytes, the physiological Kidd/urea transporter HUT11A conferred a rapid transfer of urea (which was insensitive to p-chloromercuribenzene sulfonate or phloretin), a high water permeability, and a selective uptake of small solutes including amides and diols, but not glycerol and meso-erythritol. However, at plasma membrane expression levels close to the level observed in the red cell membrane, HUT11A-mediated water transport and small solutes uptake were absent and the urea transport was poorly inhibited by p-chloromercuribenzene sulfonate, but strongly inhibited by phloretin. These findings show that, at physiological expression levels, the HUT11A transporter confers urea permeability but not water permeability, and that the observed water permeability is a feature of the red cell urea transporter when expressed at unphysiological high levels.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; CEA Saclay, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; Univ Nijmegen, Dept Cell Physiol, NL-6500 HB Nijmegen, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; UDICE-French Research Universities; Universite Paris Saclay; Radboud University Nijmegen	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.		Deen, Peter MT/B-9854-2013; Kamsteeg, Erik-Jan/L-4421-2015; Rousselet, Germain/E-3525-2018; Deen, P.M.T./H-8023-2014	Deen, Peter MT/0000-0002-7868-4655; Rousselet, Germain/0000-0002-1710-1639; Deen, P.M.T./0000-0002-7868-4655				ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; BANKIR L, 1995, KIDNEY, P571; Berger UV, 1998, ANAT EMBRYOL, V197, P405, DOI 10.1007/s004290050152; BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; Couriaud C, 1996, BBA-GENE STRUCT EXPR, V1309, P197, DOI 10.1016/S0167-4781(96)00172-8; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DIX JA, 1985, BIOCHIM BIOPHYS ACTA, V821, P243, DOI 10.1016/0005-2736(85)90093-8; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; GILLIN AG, 1993, SEMIN NEPHROL, V13, P146; Hediger MA, 1996, KIDNEY INT, V49, P1615, DOI 10.1038/ki.1996.235; IZRAELI S, 1991, NUCLEIC ACIDS RES, V19, P6051; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; MACEY RI, 1988, AM J PHYSIOL, V254, pC669, DOI 10.1152/ajpcell.1988.254.5.C669; Maillet P, 1996, HUM MUTAT, V7, P61, DOI 10.1002/(SICI)1098-1004(1996)7:1<61::AID-HUMU9>3.3.CO;2-T; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; Martial S, 1996, AM J PHYSIOL-RENAL, V271, pF1264, DOI 10.1152/ajprenal.1996.271.6.F1264; MARTIAL S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P86, DOI 10.1016/0167-4781(91)90040-S; MASOUREDIS SP, 1980, BLOOD, V56, P969; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Olives B, 1997, HUM MOL GENET, V6, P1017, DOI 10.1093/hmg/6.7.1017; OLIVES B, 1994, J BIOL CHEM, V269, P31649; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; PALLONE TL, 1994, AM J PHYSIOL, V267, pR260, DOI 10.1152/ajpregu.1994.267.1.R260; Promeneur D, 1996, J AM SOC NEPHROL, V7, P852; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 1997, AM J PHYSIOL-RENAL, V273, pF321, DOI 10.1152/ajprenal.1997.273.3.F321; Smith CP, 1999, AM J PHYSIOL-REG I, V276, pR622, DOI 10.1152/ajpregu.1999.276.2.R622; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; VERBAVATZ JM, 1996, AM SOC NEPHROL, V7, P1274; Xu YC, 1997, KIDNEY INT, V51, P138, DOI 10.1038/ki.1997.17; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	38	47	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30228	30235		10.1074/jbc.274.42.30228	http://dx.doi.org/10.1074/jbc.274.42.30228			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514515	Green Published, hybrid			2022-12-25	WOS:000083176400094
J	Yamashita, H; Avraham, S; Jiang, SX; London, R; Van Veldhoven, PP; Subramani, S; Rogers, RA; Avraham, H				Yamashita, H; Avraham, S; Jiang, SX; London, R; Van Veldhoven, PP; Subramani, S; Rogers, RA; Avraham, H			Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL PEROXIDASE-ACTIVITY; CANDIDA-BOIDINII; TARGETING SIGNAL-1; PTS1 RECEPTOR; MEMBRANE; IMPORT; BIOGENESIS; PROLIFERATION; DISORDERS; PATHWAYS	We have isolated the cDNAs encoding human and mouse homologues of a yeast protein, termed peroxisomal membrane protein 20 (PMP20). Comparison of the amino acid sequences of human (HsPMP20) and mouse (MmPMP20) PMP20 proteins revealed a high degree of identity (93%), whereas resemblance to the yeast Candida boidinii PMP20A and PMP20B (CbPMP20A and CbPMP20B) was less (30% identity). Both HsPMP20 and MmPMP20 lack transmembrane regions, as do CbPMP20A and CbPMP20B. HsPMP20 mRNA expression was low in human fetal tissues, especially in the brain, in adult tissues, HsPMP20 mRNA was expressed in the majority of tissues tested. HsPMP20 and MmPMP20 contained the C-terminal tripeptide sequence Ser-Gln-Leu (SQL), which is similar to the peroxisomal targeting signal 1 utilized for protein im. port into peroxisomes. HsPMP20 bound directly to the human peroxisomal targeting signal 1 receptor, HsPEX5. Mutagenesis analysis showed that the C-terminal tripeptide sequence, SQL, of HsPMP20 is necessary for its binding to HsPEX5. Subcellular fractionation of HeLa cells, expressing epitope-tagged PMP20, revealed that HsPMP20 is localized in the cytoplasm and in a particulate fraction containing peroxisomes. Double-staining immunofluorescence studies showed colocalization of HsPMP20 and thiolase, a bona fide peroxisomal protein. The amino acid sequence alignment of HsPMP20, MmPMP20, CbPMP20A, and CbPMP20B displayed high similarity to thiol-specific antioxidant proteins. HsPMP20 exerted an inhibitory effect on the inactivation of glutamine synthetase in the thiol metal-catalyzed oxidation system but not in the nonthiol metal-catalyzed oxidation system, suggesting that HsPMP20 possesses thiol-specific antioxidant activity. in addition, HsPMP20 removed hydrogen peroxide by its thiol-peroxidase activity. These results indicate that HsPMP20 is imported into the peroxisomal matrix via PEX5p and may work to protect peroxisomal proteins against oxidative stress. Because some portion of PMP20 might also be present in the cytosol, HsPMP20 may also have a protective effect in the cytoplasm.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Sch Med, Boston, MA 02115 USA; Katholieke Univ Leuven, Afdeling Farmakol, B-3000 Louvain, Belgium; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Harvard Univ, Med Sch Publ Hlth, BioMed Imaging Lab, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; KU Leuven; University of California System; University of California San Diego; Harvard University; Harvard T.H. Chan School of Public Health	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Sch Med, 4 Blackfan Circle, Boston, MA 02115 USA.		, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445, R01HL051456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAO Y, 1994, CANCER RES, V54, P2468; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Cha MK, 1996, BIOCHEM BIOPH RES CO, V222, P619, DOI 10.1006/bbrc.1996.0793; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; GOODMAN JM, 1990, J CELL SCI, V97, P193; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MANNAERTS GP, 1999, IN PRESS CELL BIOCH; Marshall PA, 1996, J CELL BIOL, V135, P123, DOI 10.1083/jcb.135.1.123; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Sheikh FG, 1998, P NATL ACAD SCI USA, V95, P2961, DOI 10.1073/pnas.95.6.2961; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VEENHUIS M, 1990, J CELL SCI, V96, P583; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51	32	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29897	29904		10.1074/jbc.274.42.29897	http://dx.doi.org/10.1074/jbc.274.42.29897			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514471	hybrid			2022-12-25	WOS:000083176400050
J	Dudenhoffer, C; Kurth, M; Janus, F; Deppert, W; Wiesmuller, L				Dudenhoffer, C; Kurth, M; Janus, F; Deppert, W; Wiesmuller, L			Dissociation of the recombination control and the sequence-specific transactivation function of P53	ONCOGENE			English	Article						genetic stability; homologous recombination; mismatch recognition; p53; C-terminus; MDM2	WILD-TYPE P53; CARBOXY-TERMINAL DOMAIN; DNA-BINDING ACTIVITY; CELL-CYCLE CONTROL; HOMOLOGOUS RECOMBINATION; MUTANT P53; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SINGLE STRANDS; ENDOGENOUS P53	Recently, we described a new biological function of p53 in inhibiting recombination processes when encountering mismatches in heteroduplexes (Dudenhoffer et al,, 1998). Here, we characterized protein domains of p53 participating in this process by in vitro analysis of mutated p53 proteins, and by applying our SV40-based assay system on monkey cells, which express different p53 variants. We present evidence that both binding of artificial recombination intermediates and p53-dependent recombination control require an intact p53 core and the oligomerization domain, strongly suggesting that the recognition of DNA undergoing recombination represents an essential step of this genomic surveillance mechanism, Further analyses indicated a role of the C-terminus in negatively regulating recombination control, an effect which can be neutralized by concurrent mismatch recognition. p53 lacking the oligomerization domain totally lost its ability to suppress homologous recombination. The cancer-related mutant p53(273H) was also significantly defective in this function, although we observed only twofold reductions in the corresponding transactivation activities on p53-response elements in episomal constructs. HDM2, an inhibitor of p53's transcriptional and growth regulatory activities, interfered with the inhibition of DNA exchange processes by p53 only weakly, Thus, functions of p53 in recombination control can be structurally dissociated from p53-dependent transcriptional transactivation.	Univ Hamburg, Dept Dermatol, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Hamburg, Dept Dermatol, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Albor A, 1998, CANCER RES, V58, P2091; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAIN R, 1994, ONCOGENE, V9, P1775; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CARDER P, 1993, ONCOGENE, V8, P1397; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Janus F, 1999, MOL CELL BIOL, V19, P2155; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARK DJ, 1994, ONCOGENE, V9, P1899; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Prasad KAN, 1997, BIOCHEM BIOPH RES CO, V232, P14, DOI 10.1006/bbrc.1997.6212; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; SCHNEIDER E, 1998, 9 P53 WORKSH MAY 9 1, P176; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SIEGEL J, 1995, ONCOGENE, V11, P1363; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUBLER MA, 1994, ONCOGENE, V9, P1351; Tarunina M, 1996, ONCOGENE, V13, P589; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wiesmuller L, 1996, J VIROL, V70, P737; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	82	73	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5773	5784		10.1038/sj.onc.1202964	http://dx.doi.org/10.1038/sj.onc.1202964			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523858				2022-12-25	WOS:000083095100006
J	Mazzaro, G; Bossi, G; Coen, S; Sacchi, A; Soddu, S				Mazzaro, G; Bossi, G; Coen, S; Sacchi, A; Soddu, S			The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells	ONCOGENE			English	Article						p53; differentiation; satellite cell; bone marrow; transformation	BIOCHEMICAL DIFFERENTIATION; GENE AMPLIFICATION; DNA-SYNTHESIS; EXPRESSION; APOPTOSIS; TUMORS; PROTEIN; TRANSFORMATION; IDENTIFICATION; PROGRESSION	Experiments previously performed on 32D and C2C12 cell lines indicated that wild type p53 (wtp53) protein has a role in granulocyte and myotube differentiation. Since these are immortal cells, we asked whether the inhibition of differentiation induced by the expression of dominant-negative p53 (dnp53) proteins was dependent on the immortalization-determined microenvironment. Thus, we evaluated the effects produced by interfering with the endogenous p53 gene in murine primary hemopoietic and muscle cells. Expression of dnp53 protein reduced the differentiation of bone marrow cells into granulocytes and macrophages. Moreover, p53 activation was measurable during the differentiation process of primary myoblasts, while interference with this activation led to a consistent slow down of terminal differentiation. Since the impairment of the differentiation was not accompanied by alterations in the cell cycle withdrawal and in the rate of apoptosis which are coupled with these types of differentiation, the data here reported support a specific role for p53 in the differentiation process. However, the difference in the intensity of inhibition between immortal and primary cells, i.e., complete versus slow down, respectively, suggests that the immortalization process might render the cells more sensitive to the loss of wtp53 activity for the differentiation process.	CRS, Regina Elena Canc Inst, Mol Oncogenesis Lab, I-00158 Rome, Italy		Soddu, S (corresponding author), CRS, Regina Elena Canc Inst, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Soddu, Silvia/ABH-6774-2020; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/B-9394-2017; Soddu, Silvia/K-2467-2018; Bossi, Gianluca/ABH-6846-2020	Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063	Telethon [857] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; CHAMPLIN RE, 1985, BLOOD, V65, P1309; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAGIN JA, 1994, THYROID TODAY, V17, P1; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; ROBBINS SL, 1989, PATHOLOGIC BASIS DIS; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; SUNGRUE MM, 1997, P NATL ACAD SCI USA, V94, P9648; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WRIGHT PA, 1991, ONCOGENE, V6, P1693; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5831	5835		10.1038/sj.onc.1202962	http://dx.doi.org/10.1038/sj.onc.1202962			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523864				2022-12-25	WOS:000083095100012
J	Poele, RHT; Okorokov, AL; Joel, SP				Poele, RHT; Okorokov, AL; Joel, SP			RNA synthesis block by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells	ONCOGENE			English	Article						5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole; (DRB); RNA synthesis; p53; apoptosis	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; DNA-DAMAGE; GENE-MUTATIONS; BREAST-CANCER; POLYMERASE-II; TRANSCRIPTION; LEUKEMIA; PROTEIN; CYCLE	Most modern chemo- and radiotherapy treatments of human cancers use the DNA damage pathway, which induces a p53 response leading to either G1 arrest or apoptosis. However, such treatments can induce mutations and translocations leading to secondary malignancies or recurrent disease, which often have a poor prognosis because of resistance to therapy. Here we report that 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), an inhibitor of CDK7 TFIIH-associated kinase, CKI and CKII kinases, blocking RNA polymerase II in the early elongation stage, triggers p53-dependent apoptosis in human colon adenocarcinoma cells in a transcription independent manner. The fact that DRB kills tumour-derived cells without employment of DNA damage gives rise to the possibility of the development of a new alternative chemotherapeutic treatment of tumours expressing wild type p53, with a decreased risk of therapy-related, secondary malignancies.	St Bartholomews Hosp, ICRF Dept Med Oncol, Barry Reed Oncol Lab, London EC1A 7BE, England; Univ York, Dept Biol, Yorkshire Canc Res Res Grp P53, York YO10 5DD, N Yorkshire, England	University of London; Queen Mary University London; University of York - UK	Poele, RHT (corresponding author), St Bartholomews Hosp, ICRF Dept Med Oncol, Barry Reed Oncol Lab, London EC1A 7BE, England.			Okorokov, Andrei/0000-0003-2477-3254				AALTONEN LA, 1994, ANTICANCER RES, V14, P1657; Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BAKER SJ, 1990, CANCER RES, V50, P7717; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dunton CJ, 1997, SEMIN ONCOL, V24, pS2; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gordon A, 1997, Clin Oncol (R Coll Radiol), V9, P338, DOI 10.1016/S0936-6555(05)80069-X; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiddemann W, 1995, EUR J CANCER, V31A, P2141, DOI 10.1016/0959-8049(95)00367-3; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pui Ching-Hon, 1995, Current Opinion in Oncology, V7, P36; Reuss K, 1996, ANN ONCOL, V7, P109; ROLLEY N, 1995, ONCOGENE, V11, P763; SHUGAR D, 1994, CELL MOL BIOL RES, V40, P411; TISHLER RB, 1993, CANCER RES, V53, P2212; vanBasten JP, 1997, EUR J SURG ONCOL, V23, P354, DOI 10.1016/S0748-7983(97)90966-5; WILLIAMS AC, 1995, ONCOGENE, V11, P141; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167	57	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5765	5772		10.1038/sj.onc.1202961	http://dx.doi.org/10.1038/sj.onc.1202961			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523857				2022-12-25	WOS:000083095100005
J	Qin, HW; Sun, Y; Benveniste, EN				Qin, HW; Sun, Y; Benveniste, EN			The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLIOMA-CELLS; HUMAN TUMOR-CELLS; PROTEIN-KINASE-C; IV COLLAGENASE; GELATINASE-A; TISSUE INHIBITORS; IFN-GAMMA; IN-VITRO; CYTOKINE REGULATION; BRAIN-TUMORS	Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that contribute to pathological conditions associated with angiogenesis and tumor invasion. MMP-2 is highly expressed in human astroglioma cells, and contributes to the invasiveness of these cells. The human MMP-2 promoter contains potential cis-acting regulatory elements including cAMP response element-binding protein, AP-1, AP-2, PEA3, C/EBP, and Sp1. Deletion and site-directed mutagenesis analysis of the MMP-2 promoter demonstrates that the Sp1 site at -91 to -84 base pairs and the AP-2 site at -61 to -53 base pairs are critical for constitutive activity of this gene in invasive astroglioma cell lines, Electrophoretic gel shift analysis demonstrates binding of specific DNA-protein complexes to the Sp1 and AP-2 sites: Sp1 and Sp3 bind to the Spl site, while the AP-2 transcription factor binds the AP-2 element. Co-transfection expression experiments in Drosophilia SL2 cells lacking endogenous Sp factors demonstrate that Sp1 and Sp3 function as activators of the MMP-2 promoter and synergize for enhanced MMP-2 activation. Overexpression of AP-2 in AP-2-deficient HepG2 cells enhances MMP-2 promoter activation. These findings document the functional importance of Sp1, Sp3, and AP-2 in regulating constitutive expression of MMP-2. Delineation of MMP-2 regulation may have implications for development of new therapeutic strategies to arrest glioma invasion.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA	University of Alabama System; University of Alabama Birmingham; Pfizer	Benveniste, EN (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, 1918 Univ Blvd,MCLM 350, Birmingham, AL 35294 USA.	tika@uab.edu			NIMH NIH HHS [MH-55795] Funding Source: Medline; NINDS NIH HHS [NS-34856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; APODACA G, 1990, CANCER RES, V50, P2322; Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Deryugina EI, 1998, CANCER RES, V58, P3743; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Garcia MA, 1996, J NEUROSCI, V16, P7550; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Itoh T, 1998, CANCER RES, V58, P1048; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee YJ, 1997, J IMMUNOL, V158, P2065; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P31, DOI 10.1097/00005072-199301000-00005; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; PANEK RB, 1994, J IMMUNOL, V153, P4555; Qin HW, 1998, J IMMUNOL, V161, P6664; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; RIES C, 1995, BIOL CHEM H-S, V376, P345; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STETLERSTEVENSO.WG, 1996, CANC BIOL, V7, P147; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; Uhm JH, 1997, CAN J NEUROL SCI, V24, P3, DOI 10.1017/S0317167100021028; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Winkler MK, 1998, GLIA, V22, P171, DOI 10.1002/(SICI)1098-1136(199802)22:2<171::AID-GLIA8>3.0.CO;2-A; Yamamoto M, 1996, CANCER RES, V56, P384; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088	50	249	258	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29130	29137		10.1074/jbc.274.41.29130	http://dx.doi.org/10.1074/jbc.274.41.29130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506168	hybrid			2022-12-25	WOS:000083017800047
J	Manya, H; Aoki, J; Kato, H; Ishii, J; Hino, S; Arai, H; Inoue, K				Manya, H; Aoki, J; Kato, H; Ishii, J; Hino, S; Arai, H; Inoue, K			Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SUBUNIT; PURIFICATION; EXPRESSION	Brain intracellular platelet-activating factor acetylhydrolase (PAF-AH) isoform I is a member of a family of complex enzymes composed of mutually homologous alpha(1) and alpha(2) subunits, both of which account for catalytic activity, and the beta subunit. We previously demonstrated that the expression of one catalytic subunit, alpha(1), is developmentally regulated, resulting in a switching of the catalytic complex from alpha(1)/alpha(2) to alpha(2)/alpha(2) during brain development (Manya, H., Aoki, J., Watanabe, M., Adachi, T., Asou, H., Inoue, Y., Arai, H., and Inoue, K. (1998) J. Biol. Chem. 273, 18567-18572). In this study, we explored the biochemical differences in three possible catalytic dimers, alpha(1)/alpha(1), alpha(1)/alpha(2), and alpha(2)/alpha(2). The alpha(2)/alpha(2) homodimer exhibited different substrate specificity from the alpha(1)/alpha(1) homodimer and the alpha(1)/alpha(2) heterodimer, both of which showed similar substrate specificity. The alpha(2)/alpha(2) homodimer hydrolyzed PAF and 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE) most efficiently among 1-O-alkyl-2-acetyl-phospholipids. In contrast, both alpha(1)/alpha(1) and alpha(1)/alpha(2) hydrolyzed 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid more efficiently than PAF. AAGPE was the poorest substrate for these enzymes. The beta subunit bound to all three catalytic dimers but modulated the enzyme activity in a catalytic dimer composition-dependent manner. The beta subunit strongly accelerated the enzyme activity of the alpha(2)/alpha(2) homodimer but rather suppressed the activity of the alpha(1)/alpha(1) homodimer and had little effect on that of the alpha(1)/alpha(2) heterodimer. The (His(149) to Arg) mutant beta, which has been recently identified in isolated lissencephaly sequence patients, lost the ability to either associate with the catalytic complexes or modulate their enzyme activity. The enzyme activity of PAF-AH isoform I may be regulated in multiple ways by switching the composition of the catalytic subunit and by manipulating the beta subunit.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.			Aoki, Junken/0000-0001-9435-1896; Manya, Hiroshi/0000-0003-1573-9177				Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; Baker RR, 1995, NEUROCHEM RES, V20, P1345, DOI 10.1007/BF00992510; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; LEE TC, 1992, J BIOL CHEM, V267, P19992; LO NC, 1997, HUM MOL GENET, V6, P157; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; SATOUCHI K, 1981, J BIOL CHEM, V256, P4425; Snyder F, 1996, ADV EXP MED BIOL, V416, P5; TOKUMURA A, 1992, LIFE SCI, V51, P303, DOI 10.1016/0024-3205(92)90089-8	15	48	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31827	31832		10.1074/jbc.274.45.31827	http://dx.doi.org/10.1074/jbc.274.45.31827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542206	hybrid			2022-12-25	WOS:000083532100014
J	Fukuda, M; Kanno, E; Mikoshiba, K				Fukuda, M; Kanno, E; Mikoshiba, K			Conserved N-terminal cysteine motif is essential for homo- and heterodimer formation of synaptotagmins III, V, VI, and X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; SQUID GIANT SYNAPSE; PHOSPHOLIPID-BINDING; C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; TRANSMITTER RELEASE; ANTIBODY INJECTION; VESICLE FUSION; CELLS; PROTEINS	The synaptotagmins now constitute a large family of membrane proteins characterized by one transmembrane region and two C2 domains. Dimerization of synaptotagmin (Syt) I, a putative low affinity Ca2+ sensor for neurotransmitter release, is thought to be important for expression of function during exocytosis of synaptic vesicles. However, little is known about the self-dimerization properties of other isoforms. In this study, we demonstrate that a subclass of synaptotagmins (III, V, VI, and X) (Ibata, K., Fukuda, Ri., and Mikoshiba, K. (1998) J. Biol. Chem. 273, 12267-12273) forms beta-mercaptoethanol-sensitive homodimers and identify three evolutionarily conserved cysteine residues at the N terminus (N-terminal cysteine motif, at amino acids 10, 21, and 33 of mouse Syt III) that are not conserved in other isoforms. Site-directed mutagenesis of these cysteine residues and co-immunoprecipitation experiments clearly indicate that the first cysteine residue is essential for the stable homodimer formation of Syt III, V, or VI, and heterodimer formation between Syts II, V, VI, and X. We also show that native Syt III from mouse brain forms a beta-mercaptoethanol-sensitive homodimer. Our results suggest that the cysteine-based heterodimerization between Syt III and Syt V, VI, or X, which have different biochemical properties, may modulate the proposed function of Syt III as a putative high affinity Ca2+ sensor for neurotransmitter release.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; Damer CK, 1996, J NEUROCHEM, V67, P1661; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Linial M, 1997, J NEUROCHEM, V69, P1781; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Mochida S, 1997, NEUROSCIENCE, V77, P937; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugimori M, 1998, NEUROSCIENCE, V86, P39, DOI 10.1016/S0306-4522(97)00689-1; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Thompson CC, 1996, J NEUROSCI, V16, P7832; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	44	148	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31421	31427		10.1074/jbc.274.44.31421	http://dx.doi.org/10.1074/jbc.274.44.31421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531343	hybrid			2022-12-25	WOS:000083379400047
J	Graber, R; Kasper, P; Malashkevich, VN; Strop, P; Gehring, H; Jansonius, JN; Christen, P				Graber, R; Kasper, P; Malashkevich, VN; Strop, P; Gehring, H; Jansonius, JN; Christen, P			Conversion of aspartate aminotransferase into an L-aspartate beta-decarboxylase by a triple active-site mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SULFINIC ACID; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; DIRECTED MUTAGENESIS; ENZYME; TYROSINE-225; HISTIDINE; MECHANISM; REDESIGN; MUTANT	The conjoint substitution of three active-site residues in aspartate aminotransferase (AspAT) of Escherichia coli (Y225R/R292K/R386A) increases the ratio of L-aspartate P-decarboxylase activity to transaminase activity >25 million-fold. This result was achieved by combining an arginine shift mutation (Y225R/R386A) with a conservative substitution of a substrate-binding residue (R292K), In the wild-type enzyme, Arg(386) interacts with the cw-carboxylate group of the substrate and is one of the four residues that are invariant in all aminotransferases; Tyr(225) is in its vicinity, forming a hydrogen bond with O-3' of the cofactor; and Arg(292) interacts with the distal carboxylate group of the substrate. In the triple-mutant enzyme, k(cat)' for beta-decarboxylation of L-aspartate was 0.08 s(-1), whereas k(cat)' for transamination was decreased to 0.01 s(-1). AspAT was thus converted into an L-aspartate beta-decarboxylase that catalyzes transamination as a side reaction. The major pathway of beta-decarboxylation directly produces L-alanine without intermediary formation of pyruvate, The various single- or double-mutant AspATs corresponding to the triple-mutant enzyme showed, with the exception of AspAT Y225R/R386A, no measurable or only very law beta-decarboxylase activity. The arginine shift mutation Y225R/R386A elicits beta-decarboxylase activity, whereas the R292K substitution suppresses transaminase activity, The reaction specificity of the triple-mutant enzyme is thus achieved in the same way as that of wild-tape pyridoxal 5'-phosphate-dependent enzymes in general and possibly of many other enzymes, i.e. by accelerating the specific reaction and suppressing potential side reactions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Basel, Bioctr, Abt Strukturbiol, CH-4056 Basel, Switzerland	University of Zurich; University of Basel	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	christen@biocfebs.unizh.ch						ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALMO SC, 1994, PROTEIN ENG, V7, P405, DOI 10.1093/protein/7.3.405; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADLEY M, 1991, BIOCHEMISTRY-US, V30, P6124, DOI 10.1021/bi00239a006; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; Dufour E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/bi00050a019; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FURUMO NC, 1995, ARCH BIOCHEM BIOPHYS, V319, P49, DOI 10.1006/abbi.1995.1265; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Goldberg JM, 1996, BIOCHEMISTRY-US, V35, P5280, DOI 10.1021/bi952138d; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GRABER R, 1995, EUR J BIOCHEM, V232, P686, DOI 10.1111/j.1432-1033.1995.tb20861.x; GREENGARD L, 1987, J COMPUT PHYS, V73, P325, DOI 10.1016/0021-9991(87)90140-9; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HURLEY JH, 1992, J AM CHEM SOC, V114, P4769, DOI 10.1021/ja00038a047; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; INOUE K, 1991, J BIOCHEM, V109, P570, DOI 10.1093/oxfordjournals.jbchem.a123421; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOCHHAR S, 1988, EUR J BIOCHEM, V175, P433, DOI 10.1111/j.1432-1033.1988.tb14213.x; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Leslie AGW, 1994, MOSFLM USERS GUIDE; LEUSSING DL, 1980, J AM CHEM SOC, V102, P5635, DOI 10.1021/ja00537a039; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; METZLER DE, 1977, BIOCH CHEM REACTIONS, P444; Mouratou B, 1999, J BIOL CHEM, V274, P1320, DOI 10.1074/jbc.274.3.1320; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; PARSONS B, 1984, BRAIN RES, V294, P193, DOI 10.1016/0006-8993(84)91331-3; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; SCUTTON NS, 1990, NATURE, V343, P38; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VACCA RA, 1995, EUR J BIOCHEM, V227, P481, DOI 10.1111/j.1432-1033.1995.tb20413.x; Vacca RA, 1997, J BIOL CHEM, V272, P21932, DOI 10.1074/jbc.272.35.21932; WEINSTEIN CL, 1988, J BIOL CHEM, V263, P16568; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; YANO T, 1993, BIOCHEMISTRY-US, V32, P1810, DOI 10.1021/bi00058a015; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511; YANO T, 1991, J BIOL CHEM, V266, P6079	41	36	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31203	31208		10.1074/jbc.274.44.31203	http://dx.doi.org/10.1074/jbc.274.44.31203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531314	Green Accepted, hybrid			2022-12-25	WOS:000083379400018
J	Wang, J; Frost, JA; Cobb, MH; Ross, EM				Wang, J; Frost, JA; Cobb, MH; Ross, EM			Reciprocal signaling between heterotrimeric G proteins and the pal-stimulated Protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; C PHOSPHORYLATES; BINDING PROTEIN; PERTUSSIS TOXIN; HUMAN-PLATELETS; REGULATOR; COMPLEX	p21-activated protein kinase (PAK)-1 phosphorylated G alpha(z), a member of the G alpha(i) family that is found in time brain, platelets, and adrenal medulla. Phosphorylation approached 1 mol of phosphate/mol of G alpha(z) in vitro. In transfected cells, G alpha(z) was phosphorylated both by wildtype PAK1 when stimulated by the GTP-binding protein Rad and by constitutively active PAK1 mutants. In vitro, phosphorylation occurred only at Ser(16), one of two Ser residues that are the major substrate sites for protein kinase C (PKC). PAK1 did not phosphorylate other G alpha subunits (il, i2, i3, o, s, or q), PAK1-phosphorylated G alpha(z) was resistant both to RGSZ1, a G(z)-selective GTPase-activating protein (GAP), and to RGS4, a relatively nonselective GAP for the G(i) and G(q) families of G proteins. Phosphorylation of Ser(27) by PKC did not alter sensitivity to either GAP. The previously described inhibition of G, GAPs by PKC is therefore mediated lay phosphorylation of Ser(16). Phosphorylation of either Ser(16) by PAK1 or Ser(27) by PKC decreased the affinity of G alpha(z) for G beta gamma; phosphorylation of both residues by PKC caused no further effect. PAK1 thus regulates G alpha(z) function by attenuating the inhibitory effects of both GAPs and G beta gamma. In this context, the kinase activity of PAK1 toward several protein substrates was directly inhibited by G beta gamma, suggesting that PAK1 acts as a G beta gamma-regulated effector protein. This inhibition of mammalian PAK1 by G beta gamma contrasts with the stimulation of the PAK homolog Ste20p in Saccharomyces cerevisiae by the G beta gamma homolog Ste4p/Ste18p.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	ross@utsw.swmed.edu		Cobb, Melanie/0000-0003-0833-5473; Frost, Jeffrey/0000-0001-9722-1536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16926, GM53032, GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; HINTON DR, 1990, J NEUROSCI, V10, P2763; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ishikawa Y, 1998, Adv Second Messenger Phosphoprotein Res, V32, P99; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	45	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31641	31647		10.1074/jbc.274.44.31641	http://dx.doi.org/10.1074/jbc.274.44.31641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531372	hybrid			2022-12-25	WOS:000083379400076
J	Geisbrecht, BV; Gould, SJ				Geisbrecht, BV; Gould, SJ			The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; SACCHAROMYCES-CEREVISIAE; BETA-OXIDATION; CANDIDA-TROPICALIS; TARGETING SIGNAL; MEMBRANE-PROTEIN; REFSUM-DISEASE; PTS1 RECEPTOR; FATTY-ACIDS; COA	Human PICD was identified by homology probing the data base of expressed sequence tags with the protein sequence of Saccharomyces cerevisiae Idp3p, a peroxisomal NADP(+)-dependent isocitrate dehydrogenase. The human PICD cDNA contains a 1242-base pair open reading frame, and its deduced protein sequence is 59% identical to yeast Idp3p. Expression of PICD partially rescued the fatty acid growth defect of the yeast idp3 deletion mutant suggesting that PICD is functionally homologous to Idp3p. Kinetic studies on bacterially expressed PICD demonstrated that this enzyme catalyzed the oxidative decarboxylation of isocitrate to 2-oxoglutarate with a specific activity of 22.5 units/mg and that PICD displayed K-M values of 76 mu M for isocitrate and 112 mu M for NADP(+). In subcellular fractionation experiments, we found PICD in both peroxisomes and cytoplasm of human and rat liver cells, with approximately 27% of total PICD protein associated with peroxisomes. The presence of PICD in mammalian peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2,4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. As for cytoplasmic PICD, the phenotypes of patients with glucose-6-phosphate dehydrogenase deficiency (Luzzatto, L., and Mehta, A (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) Vol. 3, 7th Ed., pp. 3367-3398, McGraw-Hill Inc., New York) suggest that PICD serves a significant role in cytoplasmic NADPH production, particularly under conditions that do not favor the use of the hexose monophosphate shunt (Luzzatto et al.).	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45787] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKERBRACHMANN C, 1998, YEAST, V14, P115; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FLINT APF, 1970, BIOCHEM J, V117, P73, DOI 10.1042/bj1170073; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Geisbrecht BV, 1999, J BIOL CHEM, V274, P25814, DOI 10.1074/jbc.274.36.25814; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; JENNINGS GT, 1994, J BIOL CHEM, V269, P23128; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KLINKEN SP, 1977, EUR J BIOCHEM, V81, P327, DOI 10.1111/j.1432-1033.1977.tb11955.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Krisans SK, 1996, ANN NY ACAD SCI, V804, P142, DOI 10.1111/j.1749-6632.1996.tb18614.x; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; LUZZATTO L, 1995, METABOLIC MOL BASES, V3, P3367; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.tb20842.x; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PLAUT GWE, 1983, BIOCHIM BIOPHYS ACTA, V760, P300, DOI 10.1016/0304-4165(83)90177-0; PLAUT GWE, 1970, CURR TOP CELL REGUL, V2, P1; RAMACHANDRAN N, 1980, J BIOL CHEM, V255, P8859; RUSNAK N, 1987, BIOCHEM BIOPH RES CO, V148, P890, DOI 10.1016/0006-291X(87)90959-4; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 1996, ANN NY ACAD SCI, V804, P450, DOI 10.1111/j.1749-6632.1996.tb18636.x; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x; YAMAMOTO S, 1995, ARCH MICROBIOL, V163, P104, DOI 10.1007/BF00381783	53	139	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30527	30533		10.1074/jbc.274.43.30527	http://dx.doi.org/10.1074/jbc.274.43.30527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521434	hybrid			2022-12-25	WOS:000083276700030
J	Sinha, R; Perumal, K; Chen, YH; Reddy, R				Sinha, R; Perumal, K; Chen, YH; Reddy, R			Post-transcriptional adenylation of signal recognition particle RNA is carried out by an enzyme different from mRNA poly(A) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; CCA-ADDING ENZYME; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; 3'-END FORMATION; MULTIPLE FORMS; HUMAN-CELLS; POLYADENYLATION; YEAST; GENE	A fraction of the signal recognition particle (SRP) RNA from human, rat, Xenopus, and Saccharomyces cerevisiae cells contains a single post-transcriptionally added adenylic acid residue on its 3'-end; in the ease of human SRP RNA, over 60% of the SRP RNA molecules contain a nontemplated adenylic acid residue on their 3'-ends (Sinha, K. M., Gu, J., Chen, Y., and Reddy, R. (1998) J. Biol. Chem. 273, 6853-6859), In this study, we investigated the enzyme that is involved in this 3'-end adenylation of SRP RNA. A U1A protein peptide conjugated to albumin completely inhibited the polyadenylation of a SV40 mRNA by HeLa cell nuclear extract in vitro; however, the 3'-end adenylation of human SRP RNA or Alu RNA which corresponds to 5' and 3'-ends of SRP RNA, was not affected by this U1A peptide conjugate. SRP RNA from mutant strains of S. cerevisiae with a temperature-sensitive mRNA poly(A) polymerase grown at a restrictive temperature of 37 degrees C also contained a post-transcriptionally added adenylic acid residue just like SRP RNA from wild-type cells and mutant cells grown at permissive temperature of 23 degrees C. In addition, binding of SRP 9/14-kDa protein heterodimer was required for adenylation of Alu RNA in vitro, These lines of evidence, along with other data, show that post-transcriptional adenylation of SRP and Alu RNAs is carried out by a novel enzyme that is distinct from the mRNA poly(A) polymerase, CCA-adding enzyme, and nonspecific terminal transferase.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Reddy, R (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	rreddy@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052901] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-52901, GM-38320] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; BASERGA SJ, 1985, GENE, V35, P305, DOI 10.1016/0378-1119(85)90009-5; Chapon C, 1997, RNA, V3, P1337; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; Chen YH, 1998, J BIOL CHEM, V273, P35023, DOI 10.1074/jbc.273.52.35023; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EIRSE DEA, 1997, EMBO J, V16, P3757; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; HE XP, 1994, J CELL SCI, V107, P903; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; Li ZW, 1998, P NATL ACAD SCI USA, V95, P12158, DOI 10.1073/pnas.95.21.12158; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Reuven NB, 1997, J BIOL CHEM, V272, P33255, DOI 10.1074/jbc.272.52.33255; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Sinha KM, 1998, J BIOL CHEM, V273, P6853, DOI 10.1074/jbc.273.12.6853; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; Szalewska-Palasz A, 1998, FEBS LETT, V432, P70, DOI 10.1016/S0014-5793(98)00834-5; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; THURESSON AC, 1994, P NATL ACAD SCI USA, V91, P979, DOI 10.1073/pnas.91.3.979; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weichenrieder O, 1997, RNA, V3, P1262; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; Yokobori S, 1997, J MOL BIOL, V265, P95, DOI 10.1006/jmbi.1996.0728; Yue DX, 1996, RNA, V2, P895; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZWIERZYNSKI TA, 1989, NUCLEIC ACIDS RES, V17, P4647, DOI 10.1093/nar/17.12.4647	40	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30826	30831		10.1074/jbc.274.43.30826	http://dx.doi.org/10.1074/jbc.274.43.30826			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521474				2022-12-25	WOS:000083276700070
J	Tirupati, HK; Shaw, LC; Lewin, AS				Tirupati, HK; Shaw, LC; Lewin, AS			An RNA binding motif in the Cbp2 protein required for protein-stimulated RNA catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-I INTRON; DOUBLE-STRANDED-RNA; PHOTOCHEMICAL CROSS-LINKING; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; HIGH-YIELD; DOMAIN; KINASE; ACID; SYNTHETASE	The fifth and terminal intron of yeast cytochrome b pre-mRNA (a group I intron) requires a protein encoded by the nuclear gene CBP2 for splicing. Because catalysis is intrinsic to the RNA, the protein is believed to promote formation of secondary and tertiary structure of the RNA, resulting in a catalytically competent intron, In vitro, this mitochondrial intron can be made to self-splice or undergo protein-facilitated splicing by varying the Mg2+ and monovalent salt concentrations. This two-component system, therefore, provides a good model for understanding the role of proteins in RNA folding. A UV cross-linking experiment was initiated to identify RNA binding sites on Cbp2 and gain insights into Cb22-intron interactions. A 12-amino acid region containing a presumptive contact site near the amino terminus was targeted for mutagenesis, and mutant proteins were characterized for RNA binding and stimulation of splicing. Mutations in this region resulted in partial or complete loss of function, demonstrating the importance of this determinant for stimulation of RNA splicing. Several of the mutations that severely reduced splicing did not significantly shift the overall binding isotherm of Cbp2 for the precursor RNA, suggesting that contacts critical for activity are not necessarily reflected in the dissociation constant. This analysis has identified a unique RNA binding motif of alternating basic and aromatic residues that is essential for protein facilitated splicing.	Univ Florida, Dept Mol Genet & Microbiol, Coll Med, Gainesville, FL 32605 USA	State University System of Florida; University of Florida	Lewin, AS (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Coll Med, Box 100266, Gainesville, FL 32605 USA.			Lewin, Alfred/0000-0002-4192-9727				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Bornstein P, 1977, Methods Enzymol, V47, P132; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHANG BY, 1993, BIOCHEM J, V294, P43, DOI 10.1042/bj2940043; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CLEGHON V, 1992, J BIOL CHEM, V267, P17872; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAY RT, 1993, NUCLEIC ACIDS RES, V21, P4592, DOI 10.1093/nar/21.19.4592; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HILL J, 1985, J BIOL CHEM, V260, P3235; HUNTER T, 1975, J BIOL CHEM, V250, P409; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Parker EJ, 1998, NUCLEIC ACIDS RES, V26, P1240, DOI 10.1093/nar/26.5.1240; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; SAFER B, 1988, MOL CELL BIOL, V8, P105, DOI 10.1128/MCB.8.1.105; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW LC, 1995, J BIOL CHEM, V270, P21552, DOI 10.1074/jbc.270.37.21552; Shaw LC, 1996, NUCLEIC ACIDS RES, V24, P3415, DOI 10.1093/nar/24.17.3415; SHAW LC, 1997, NUCLEIC ACIDS RES, V25, P1587; SHETLAR M, 1980, PHOTOCH PHOTOBIO SCI, P105; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; Vaisanen S, 1997, EUR J BIOCHEM, V248, P156, DOI 10.1111/j.1432-1033.1997.t01-1-00156.x; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	47	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30393	30401		10.1074/jbc.274.43.30393	http://dx.doi.org/10.1074/jbc.274.43.30393			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521416	hybrid			2022-12-25	WOS:000083276700012
J	Tavares, D; Tully, K; Dobner, PR				Tavares, D; Tully, K; Dobner, PR			Sequences required for induction of neurotensin receptor gene expression during neuronal differentiation of N1E-115 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; SPONTANEOUS MOTOR-ACTIVITY; VENTRAL TEGMENTAL AREA; RAT SUBSTANTIA-NIGRA; TRANSCRIPTION FACTOR; HIGH-AFFINITY; MESSENGER-RNA; NEUROMEDIN-N; FUNCTIONAL EXPRESSION; HYPOTHALAMIC PEPTIDE	The promoter region of the mouse high affinity neurotensin receptor (Ntr-1) gene was characterized, and sequences required for expression in neuroblastoma cell lines that express high affinity NT-binding sites were characterized. Me2SO-induced neuronal differentiation of N1E-115 neuroblastoma cells increased both the expression of the endogenous Ntr-1 gene and reporter genes driven by NTR-1 promoter sequences by 3-4-fold. Deletion analysis revealed that an 83-base pair promoter region containing the transcriptional start site is required for Me2SO activation. Detailed mutational analysis of this region revealed that a CACCC box and the central region of a large GC-rich palindrome are the crucial cis-regulatory elements required for Me2SO induction. The CACCC box is bound by at least one factor that is induced upon Me2SO treatment of N1E-115 cells. The Me2SO effect was found to be both selective and cell type-restricted. Basal expression in the neuroblastoma cell lines required a distinct set of sequences, including an Sp1-like sequence, and a sequence resembling an NGFI-A-binding site; however, a more distal 5' sequence was found to repress basal activity in N1E-115 cells. These results provide evidence that Ntr-1 gene regulation involves both positive and negative regulatory elements located in the 5'-flanking region and that Ntr-2 gene activation involves the coordinate activation or induction of several factors, including a CACCC box binding complex.	Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Dobner, PR (corresponding author), Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01655 USA.	paul.dobner@umassmed.edu			NHLBI NIH HHS [R01 HL333072] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; AZZI M, 1994, NEUROSCI LETT, V172, P97, DOI 10.1016/0304-3940(94)90671-8; Azzi M, 1996, MOL BRAIN RES, V42, P213, DOI 10.1016/S0169-328X(96)00124-6; Betancur C, 1997, MOL BRAIN RES, V44, P334, DOI 10.1016/S0169-328X(96)00289-6; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BOLDENWATSON C, 1993, J NEUROCHEM, V61, P1141, DOI 10.1111/j.1471-4159.1993.tb03631.x; Botto JM, 1997, NEUROSCI LETT, V223, P193, DOI 10.1016/S0304-3940(97)13437-1; Boudin H, 1996, J COMP NEUROL, V373, P76; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; BULLOCK BP, 1994, MOL BRAIN RES, V27, P232, DOI 10.1016/0169-328X(94)90005-1; CARRAWAY R, 1975, J BIOL CHEM, V250, P1907; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHOWDHURY K, 1988, EMBO J, V7, P1345, DOI 10.1002/j.1460-2075.1988.tb02950.x; Crossley M, 1996, MOL CELL BIOL, V16, P1695; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; ERVIN GN, 1981, NATURE, V291, P73, DOI 10.1038/291073a0; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; Hasan SJ, 1995, J NEUROCYTOL, V24, P984, DOI 10.1007/BF01215647; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; HERVE D, 1986, P NATL ACAD SCI USA, V83, P6203, DOI 10.1073/pnas.83.16.6203; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG ZG, 1994, J PHYSIOL-LONDON, V474, P119, DOI 10.1113/jphysiol.1994.sp020007; KALIVAS PW, 1982, EUR J PHARMACOL, V78, P471, DOI 10.1016/0014-2999(82)90491-5; KALIVAS PW, 1981, BRAIN RES, V229, P525, DOI 10.1016/0006-8993(81)91016-7; KALIVAS PW, 1984, NEUROSCIENCE, V11, P919, DOI 10.1016/0306-4522(84)90203-3; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Le F, 1997, J BIOL CHEM, V272, P1315, DOI 10.1074/jbc.272.2.1315; Maeno H, 1996, MOL BRAIN RES, V40, P97; Mazella J, 1996, J NEUROSCI, V16, P5613; MEADORWOODRUFF JH, 1989, P NATL ACAD SCI USA, V86, P7625, DOI 10.1073/pnas.86.19.7625; MERCHANT KM, 1994, J PHARMACOL EXP THER, V269, P806; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKAGAWA Y, 1984, J NEUROSCI, V4, P1653; NEMEROFF CB, 1977, BRAIN RES, V128, P485, DOI 10.1016/0006-8993(77)90173-1; NICOT A, 1994, J COMP NEUROL, V341, P407, DOI 10.1002/cne.903410310; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ouyang L, 1998, J BIOL CHEM, V273, P23019, DOI 10.1074/jbc.273.36.23019; Payen E, 1998, J BIOL CHEM, V273, P9099, DOI 10.1074/jbc.273.15.9099; PERKINS AC, 1995, NATURE, V375, P318; PINNOCK RD, 1985, BRAIN RES, V338, P151, DOI 10.1016/0006-8993(85)90258-6; POUSTIS C, 1984, J NEUROCHEM, V42, P1094, DOI 10.1111/j.1471-4159.1984.tb12715.x; REINECKE M, 1985, PROG HISTOCHEM CYTOC, V16, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI WX, 1991, BRAIN RES, V543, P315, DOI 10.1016/0006-8993(91)90043-U; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; SZIGETHY E, 1989, J COMP NEUROL, V279, P128, DOI 10.1002/cne.902790111; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wang JL, 1997, J NEUROSCI RES, V50, P23, DOI 10.1002/(SICI)1097-4547(19971001)50:1<23::AID-JNR3>3.3.CO;2-Y; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WOULFE J, 1989, BRAIN RES, V479, P402, DOI 10.1016/0006-8993(89)91649-1	69	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30066	30079		10.1074/jbc.274.42.30066	http://dx.doi.org/10.1074/jbc.274.42.30066			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514493	hybrid			2022-12-25	WOS:000083176400072
J	Bellin, RM; Sernett, SW; Becker, B; Ip, W; Huiatt, TW; Robson, RM				Bellin, RM; Sernett, SW; Becker, B; Ip, W; Huiatt, TW; Robson, RM			Molecular characteristics and interactions of the intermediate filament protein synemin - Interactions with alpha-actinin may anchor synemin-containing heterofilaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; VIMENTIN FILAMENTS; SKELETAL-MUSCLE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; RNA LOCALIZATION; DESMIN; CELLS; NITROCELLULOSE; IMMUNOELECTRON	Synemin is a cytoskeletal protein originally identified as an intermediate filament (IF)-associated protein because of its colocalization and copurification with the IF proteins desmin and vimentin in muscle cells. Our sequencing studies have shown that synemin is an unusually large member (1,604 residues, 182,187 Da) of the IF protein superfamily, with the majority of the molecule consisting of a long C-terminal tail domain. Molecular interaction studies demonstrate that purified synemin interacts with desmin, the major IF protein in mature muscle cells, and with cy-actinin, an integral myofibrillar Z-line protein. Furthermore, expressed synemin rod and tail domains interact, respectively, with desmin and a-actinin. Analysis of endogenous protein expression in SW13 clonal lines reveals that synemin is coexpressed and colocalized with vimentin Ifs in SW13.C1 vim+ cells but is absent in SW13.C2 vim - cells. Transfection studies indicate that synemin requires the presence of another IF protein, such as vimentin, in order to assemble into Ifs. Taken in tote, our results suggest synemin functions as a component of heteropolymeric Ifs and plays an important cytoskeletal cross-linking role by linking these Ifs to other components of the cytoskeleton. Synemin in striated muscle cells may enable these heterofilaments to help link Z-lines of adjacent myofibrils and, thereby, play an important role in cytoskeletal integrity.	Iowa State Univ, Muscle Biol Grp, Dept Biochem, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Biophys, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Mol Biol, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Anim Sci, Ames, IA 50011 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Iowa State University; Iowa State University; Iowa State University; Iowa State University; University of Cincinnati	Robson, RM (corresponding author), Iowa State Univ, Muscle Biol Grp, Dept Biochem, 3110 Mol Biol Bldg, Ames, IA 50011 USA.				NICHD NIH HHS [N01-HD-2-3144] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023144] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abumuhor IA, 1998, J STRUCT BIOL, V123, P187, DOI 10.1006/jsbi.1998.4040; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Athlan ES, 1997, J NEUROSCI RES, V47, P300; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BECKER B, 1995, BIOCHEM BIOPH RES CO, V213, P796, DOI 10.1006/bbrc.1995.2200; BELLIN RM, 1999, GUIDEBOOK CYTOSKELET; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; BRECKLER J, 1982, J CELL BIOL, V92, P795, DOI 10.1083/jcb.92.3.795; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN WJ, 1994, J CELL SCI, V107, P2299; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; GRANGER BL, 1982, CELL, V30, P263, DOI 10.1016/0092-8674(82)90032-0; Hemken PM, 1997, J BIOL CHEM, V272, P32489, DOI 10.1074/jbc.272.51.32489; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMINGS L, 1995, BIOCHEM SOC T, V23, P619, DOI 10.1042/bst0230619; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Hijikata T, 1999, J CELL SCI, V112, P867; HUIATT TW, 1980, J BIOL CHEM, V255, P6981; ImanakaYoshida K, 1996, CELL MOTIL CYTOSKEL, V33, P263, DOI 10.1002/(SICI)1097-0169(1996)33:4<263::AID-CM3>3.0.CO;2-A; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; IP W, 1985, ANN NY ACAD SCI, V455, P185, DOI 10.1111/j.1749-6632.1985.tb50412.x; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; KOUKLIS PD, 1993, J CELL SCI, V106, P919; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MAKAROVA I, 1994, CELL MOTIL CYTOSKEL, V28, P265, DOI 10.1002/cm.970280309; Marvin NJ, 1998, J CELL SCI, V111, P1951; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; MOON RT, 1983, P NATL ACAD SCI-BIOL, V80, P5495, DOI 10.1073/pnas.80.18.5495; Oleynikov Y, 1998, TRENDS CELL BIOL, V8, P381, DOI 10.1016/S0962-8924(98)01348-8; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; RAATS JMH, 1990, J CELL BIOL, V111, P1971, DOI 10.1083/jcb.111.5.1971; RICHARDSON FL, 1981, EUR J CELL BIOL, V26, P91; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SANDOVAL IV, 1983, J BIOL CHEM, V258, P2568; SARRIA AJ, 1994, J CELL SCI, V107, P1593; Schroder R, 1999, EUR J CELL BIOL, V78, P288, DOI 10.1016/S0171-9335(99)80062-4; Seki N, 1997, DNA Res, V4, P345, DOI 10.1093/dnares/4.5.345; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; TOKUYASU KT, 1983, J CELL BIOL, V96, P1727, DOI 10.1083/jcb.96.6.1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICHE G, 1983, J CELL BIOL, V97, P887, DOI 10.1083/jcb.97.3.887; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0; Yuan J, 1999, ARCH BIOCHEM BIOPHYS, V363, P314, DOI 10.1006/abbi.1998.1096	65	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29493	29499		10.1074/jbc.274.41.29493	http://dx.doi.org/10.1074/jbc.274.41.29493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506213	hybrid			2022-12-25	WOS:000083017800092
J	Deyrup, AT; Singh, B; Krishnan, S; Lyle, S; Schwartz, NB				Deyrup, AT; Singh, B; Krishnan, S; Lyle, S; Schwartz, NB			Chemical modification and site-directed mutagenesis of conserved HXXH and PP-loop motif arginines and histidines in the murine bifunctional ATP sulfurylase/adenosine 5 '-phosphosulfate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SULFATE-ACTIVATING ENZYMES; RAT CHONDROSARCOMA; BRACHYMORPHIC MICE; PENICILLIUM-CHRYSOGENUM; KINETIC MECHANISM; ESCHERICHIA-COLI; ACTIVE-SITE; BINDING; RESIDUES	The sulfurylase domain of the mouse bifunctional enzyme ATP sulfurylase/adenosine 5'-phosphosulfate (APS) kinase contains HXXH and PP-loop motifs. To elucidate the functional importance of these motifs and of conserved arginines and histidines, chemical modification and site-directed mutagenesis studies were performed. Chemical modification of arginines and histidines with phenylglyoxal and diethyl pyrocarbonate, respectively, renders the enzyme inactive in sulfurylase, kinase, and overall assays. Data base searches and sequence comparison of bifunctional ATP sulfurylase/APS kinase and monofunctional ATP sulfurylases shows a limited number of highly conserved arginines and histidines within the sulfurylase domain. Of these conserved residues, His-425, His-428, and Arg-421 are present within or near the HXXH motif whereas His-506, Arg-510, and Arg-522 residues are present in and around the PP-loop, The functional role of these conserved residues was further studied by site-directed mutagenesis. In the HXXH motif, none of the alanine mutants (H425A, H428A, and R421A) had sulfurylase or overall activity, whereas they all exhibited normal kinase activity. A slight improvement in reverse sulfurylase activity (<10% residual activity) and complete restoration of forward sulfurylase was observed with R421K, Mutants designed to probe the PR-loop requirements included H506A, R510A, R522A, R522K, and D523A. Of these, R510A exhibited normal sulfurylase and kinase activity, R522A and R522K showed no sulfurylase activity, and H506A had normal sulfurylase activity but produced an effect on kinase activity (<10% residual activity). The single aspartate, D523A, which is part of the highly conserved GRD sequence of the PP-loop, affected both sulfurylase and kinase activity, This mutational analysis indicates that the HXXH motif plays a role only in the sulfurylase activity, whereas the PP-loop is involved in both sulfurylase and kinase activities. Residues specific for sulfurylase activity have also been distinguished from those involved in kinase activity.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, MC5058,5841 S Maryland Ave, Chicago, IL 60637 USA.				NICHD NIH HHS [HD-07009, HD-09402, HD-17332] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS MJ, 1973, P NATL ACAD SCI USA, V70, P1968, DOI 10.1073/pnas.70.7.1968; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNONE A, 1971, J BIOL CHEM, V246, P2302; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; Chowdhury K, 1996, BIOCHEMISTRY-US, V35, P16610, DOI 10.1021/bi961462l; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; Deyrup AT, 1999, J BIOL CHEM, V274, P10751, DOI 10.1074/jbc.274.16.10751; DEYRUP AT, 1997, STRUCTURAL FUNCTIONA; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GELLER DH, 1987, J BIOL CHEM, V262, P7374; KANTROWITZ ER, 1976, J BIOL CHEM, V251, P2688; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1994, BIOCHEM J, V301, P349, DOI 10.1042/bj3010349; LYLE S, 1994, BIOCHEMISTRY-US, V33, P6822, DOI 10.1021/bi00188a010; LYLE S, 1994, BIOCHEM J, V301, P355, DOI 10.1042/bj3010355; LYLE S, 1995, BIOCHEMISTRY-US, V34, P940, DOI 10.1021/bi00003a028; LYLE S, 1993, THESIS U CHICAGO CHI; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; Miles E W, 1977, Methods Enzymol, V47, P431; MIYAMOTO Y, 1986, J BIOL CHEM, V261, P6133; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116; Sideraki V, 1996, BIOCHEMISTRY-US, V35, P15019, DOI 10.1021/bi961427e; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SOLOV'EV V V, 1991, Molekulyarnaya Biologiya (Moscow), V25, P810; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P601; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; Veitch DP, 1996, BIOCHEMISTRY-US, V35, P10743, DOI 10.1021/bi960402c; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; Venkatachalam KV, 1998, J BIOL CHEM, V273, P19311, DOI 10.1074/jbc.273.30.19311; Vos S, 1998, J MOL BIOL, V282, P875, DOI 10.1006/jmbi.1998.2051; WILLISON JC, 1993, FEMS MICROBIOL LETT, V104, P1	43	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28929	28936		10.1074/jbc.274.41.28929	http://dx.doi.org/10.1074/jbc.274.41.28929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506138	hybrid			2022-12-25	WOS:000083017800017
J	Dockal, M; Carter, DC; Ruker, F				Dockal, M; Carter, DC; Ruker, F			The three recombinant domains of human serum albumin - Structural characterization and ligand binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE PEPTIC FRAGMENT; CIBACRON-BLUE F3G-A; 2 LARGE FRAGMENTS; DRUG-BINDING; CIRCULAR-DICHROISM; WARFARIN; ACID; CHROMATOGRAPHY; SITES; CONFORMATION	In an attempt to systematically dissect the ligand binding properties of human serum albumin (HSA), the gene segments encoding each of its three domains were defined based on their conserved homologous structural motifs and separately cloned into a secretion vector for Pichia pastoris, We were able to establish a generally applicable purification protocol based on Cibacron Blue affinity chromatography, suggesting that each of the three domains carries a binding site specific for this ligand. Proteins were characterized by SDS-polyacrylamide gel electrophoresis, isoelectric focusing, gel filtration, N-terminal sequencing, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, as well as near- and far-UV CD, In addition to the affinity chromatography ligand Cibacron Blue, binding properties toward hemin, warfarin, and diazepam, each of which represents a standard ligand for HSA, respectively, were investigated by the measurement of induced circular dichroism, Clear experimental evidence is provided here for the location of the primary hemin binding site to be on domain I of HSA, and for the primary diazepam binding site to be on domain III. Further, secondary binding sites were found for hemin to be located on domains II and III, and for diazepam on domain I. The warfarin binding site was located primarily on domain II, while on domain I, a secondary binding site and/or parts of the primary binding site were found.	Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria; New Century Pharmaceut Inc, Huntsville, AL 35824 USA	University of Natural Resources & Life Sciences, Vienna	Ruker, F (corresponding author), Univ Agr Sci, Inst Appl Microbiol, Muthagasse 18, A-1190 Vienna, Austria.			Rueker, Florian/0000-0001-7639-2686				BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BOS OJM, 1988, BIOCHIM BIOPHYS ACTA, V953, P37, DOI 10.1016/0167-4838(88)90007-6; BOS OJM, 1989, J BIOL CHEM, V264, P953; BOS OJM, 1988, J CHROMATOGR-BIOMED, V424, P13, DOI 10.1016/S0378-4347(00)81071-3; BOS OJM, 1988, BIOCHEM PHARMACOL, V37, P3905, DOI 10.1016/0006-2952(88)90072-X; BOS OJM, 1989, BIOCHEM PHARMACOL, V38, P1979, DOI 10.1016/0006-2952(89)90497-8; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CARTER DC, 1990, SCIENCE, V249, P302, DOI 10.1126/science.2374930; CARTER DC, 1998, Patent No. 5780594; COMPAGNINI A, 1993, J CHROMATOGR, V639, P341, DOI 10.1016/0021-9673(93)80273-B; Compagnini A, 1996, J CHROMATOGR A, V736, P115, DOI 10.1016/0021-9673(95)01362-8; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; FEHSKE KJ, 1979, MOL PHARMACOL, V16, P778; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLATZ JFC, 1983, J BIOCHEM BIOPH METH, V8, P57, DOI 10.1016/0165-022X(83)90021-0; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HORWITZ J, 1970, J AM CHEM SOC, V92, P2119, DOI 10.1021/ja00710a054; HORWITZ J, 1969, J AM CHEM SOC, V91, P184, DOI 10.1021/ja01029a034; HRKAL Z, 1978, INT J BIOCHEM, V9, P349, DOI 10.1016/0020-711X(78)90110-6; Kjeldsen T, 1998, PROTEIN EXPRES PURIF, V13, P163, DOI 10.1006/prep.1998.0876; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDDEN DJ, 1982, BIOCHEM J, V205, P331, DOI 10.1042/bj2050331; LEE JY, 1992, J BIOL CHEM, V267, P14753; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; OHI H, 1994, MOL GEN GENET, V243, P489, DOI 10.1007/BF00284196; OTAGIRI M, 1987, J PHARM PHARMACOL, V39, P416, DOI 10.1111/j.2042-7158.1987.tb03412.x; PETERS T, 1967, J BIOL CHEM, V242, P1574; PETERS T, 1967, J BIOL CHEM, V242, P1566; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Peters T., 1996, ALL ALBUMIN BIOCH GE; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; SJODIN T, 1977, BIOCHIM BIOPHYS ACTA, V494, P61, DOI 10.1016/0005-2795(77)90135-0; SJOHOLM I, 1973, J BIOL CHEM, V248, P8434; STRICKLA.EH, 1969, BIOCHEMISTRY-US, V8, P3205, DOI 10.1021/bi00836a012; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Uversky VN, 1997, BIOCHEMISTRY-US, V36, P13638, DOI 10.1021/bi970332p; WETZEL R, 1980, EUR J BIOCHEM, V104, P469, DOI 10.1111/j.1432-1033.1980.tb04449.x; WILTING J, 1980, BIOCHIM BIOPHYS ACTA, V626, P291, DOI 10.1016/0005-2795(80)90123-3	42	340	372	2	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29303	29310		10.1074/jbc.274.41.29303	http://dx.doi.org/10.1074/jbc.274.41.29303			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506189	hybrid			2022-12-25	WOS:000083017800068
J	Kothny-Wilkes, G; Kulms, D; Luger, TK; Kubin, M; Schwarz, T				Kothny-Wilkes, G; Kulms, D; Luger, TK; Kubin, M; Schwarz, T			Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand- and CD95-induced apoptosis but not from ultraviolet radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; APO-1/FAS RECEPTOR/LIGAND SYSTEM; ALPHA-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; DRUG-INDUCED APOPTOSIS; CELL-DEATH; CANCER-THERAPY; LEUKEMIA-CELLS; LINKED IAP; ACTIVATION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a new member of the tumor necrosis factor (TNF) family, induces apoptosis primarily of transformed cells. Interleukin-1 was previously found to protect the keratinocyte cell line KB hom TRAIL-induced apoptosis, thus we studied whether interleukin-1 also protects from other apoptotic stimuli (ultraviolet radiation (UV), CD95-ligand). Interleukin-1 rescued KB cells from TRAIL- and CD95-induced apoptosis, which was critically dependent on nuclear factor kappa B, because cells transfected with a super-repressor form of the nuclear factor KB inhibitor I kappa B were less protected. in contrast, UV-mediated apoptosis was not only not prevented by interleukin-1 but even enhanced. This opposite effect of interleukin-1 was also observed for the expression of the inhibitor of apoptosis proteins (IAP). Whereas TRAIL- and CD95-mediated suppression of LAP expression was partially reversed by interleukin-1, UV-mediated down-regulation of IAPs was not reversed but even further enhanced. Increased apoptosis induced by interleukin-1 plus UV was accompanied by excessive TNF alpha release, implying that enhanced cytotoxicity is due to the additive effect of these two apoptotic stimuli. Accordingly, enhanced apoptosis was reduced by blocking the TNF receptor-1. The opposite effects of interleukin-1 indicate that different mechanisms are involved in UV-induced apoptosis compared with CD95- and TRAIL-mediated apoptosis. Furthermore, the data suggest that whether a signal acts in an antiapoptotic way or not does not only depend on the signal itself but also on the stimulus causing apoptosis.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Immunex Corp, Seattle, WA 98101 USA	University of Munster; Immunex Corporation	Schwarz, T (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Von Esmarch Str 56, D-48149 Munster, Germany.		Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Barinaga M, 1996, SCIENCE, V273, P735, DOI 10.1126/science.273.5276.735; Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960-7404(97)00015-7; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DURUM SK, 1990, IMMUNOPHYSIOLOGY ROL, P210; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Haq RW, 1998, CANCER METAST REV, V17, P233, DOI 10.1023/A:1006075007857; Haridas V, 1998, J IMMUNOL, V160, P3152; Hughes SJ, 1997, CANCER RES, V57, P5571; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Korsmeyer SJ, 1998, CURR OPIN IMMUNOL, V10, P543, DOI 10.1016/S0952-7915(98)80221-5; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUGER TA, 1992, PHARM SKIN, P283; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998	43	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28916	28921		10.1074/jbc.274.41.28916	http://dx.doi.org/10.1074/jbc.274.41.28916			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506136	hybrid			2022-12-25	WOS:000083017800015
J	Kim, GD; Choi, YH; Dimtchev, A; Jeong, SJ; Dritschilo, A; Jung, M				Kim, GD; Choi, YH; Dimtchev, A; Jeong, SJ; Dritschilo, A; Jung, M			Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; REPRESS TRANSCRIPTION; KAPPA-B; CHROMATIN; GENE; ACETYLTRANSFERASE; ACETYLATION; EXPRESSION; COMPLEX	The ATM gene is mutated in individuals with ataxia telangiectasia, a human genetic disease! characterized by extreme sensitivity to radiation. The ATM protein acts as a sensor of radiation-induced cellular damage and contributes to cell cycle regulation, signal transduction, and DNA repair; however, the mechanisms underlying these functions of ATM remain largely unknown. Binding and immunoprecipitation assays have now shown that ATM interacts with the histone deacetylase HDAC1 both in vitro and in vivo, and that the extent of this association is increased after exposure of MRC5CV1 human fibroblasts to ionizing radiation. Histone deacetylase activity was also detected in immunoprecipitates prepared from these cells with antibodies to ATM, and this activity was blocked by the histone deacetylase inhibitor trichostatin A. These results suggest a previously unanticipated role for ATM in the modification of chromatin components in response to ionizing radiation.	Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res,Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Microbiol, Div Radiat Res,Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res,Vincent T Lombardi Canc Ctr, Res Bldg,Rm E211A,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [P01 CA 74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Jung M, 1997, CANCER RES, V57, P24; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OLEINICK NL, 1994, INT J RADIAT BIOL, V66, P523, DOI 10.1080/09553009414551561; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983	31	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31127	31130		10.1074/jbc.274.44.31127	http://dx.doi.org/10.1074/jbc.274.44.31127			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531300	hybrid			2022-12-25	WOS:000083379400004
J	Dorstyn, L; Read, SH; Quinn, LM; Richardson, H; Kumar, S				Dorstyn, L; Read, SH; Quinn, LM; Richardson, H; Kumar, S			DECAY, a novel Drosophila caspase related to mammalian caspase-3 and caspase-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; APOPTOSIS; PROTEASES; IDENTIFICATION; ACTIVATION; EXPRESSION; PRECURSOR; PRODOMAIN; EFFECTOR; ELEGANS	Caspases are key effecters of programmed cell death in metazoans. In Drosophila, four caspases have been described so far. Here we describe the identification and characterization of the fifth Drosophila caspase, DECAY. DECAY shares a high degree of homology with the members of the mammalian caspase-3 subfamily, particularly caspase-3 and caspase-7, DECAY lacks a long prodomain and thus appears to be a class II effector caspase;Ectopic expression of DECAY in cultured cells induces apoptosis. Recombinant DECAY exhibited substrate specificity similar to the mammalian caspase-3 subfamily. Low levels of decay mRNA are ubiquitously expressed in Drosophila embryos during early stages of development but its expression becomes somewhat spatially restricted in some tissues. During oogenesis decay mRNA was detected in egg chambers of all stages consistent with a rob for DECAY in apoptosis of nurse cells, Relatively high levels of decay mRNA are expressed in larval salivary glands and midgut, two tissues which undergo histolysis during larval/pupal metamorphosis, suggesting that DECAY may play a role in developmentally programmed cell death in Drosophila.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5001, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia	Institute Medical & Veterinary Science Australia; University of Adelaide; University of Adelaide	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Dorstyn, Loretta/F-3673-2013; Kumar, Sharad/AAX-7787-2020; Richardson, Helena E/A-8080-2013	Dorstyn, Loretta/0000-0001-9886-0989; Kumar, Sharad/0000-0001-7126-9814; Richardson, Helena E/0000-0003-3852-4953; Quinn, Leonie/0000-0002-3911-6508				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Kumar S, 1999, CLIN EXP PHARMACOL P, V26, P295, DOI 10.1046/j.1440-1681.1999.03031.x; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WOLFF T, 1991, DEVELOPMENT, V113, P825	34	101	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30778	30783		10.1074/jbc.274.43.30778	http://dx.doi.org/10.1074/jbc.274.43.30778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521468	hybrid			2022-12-25	WOS:000083276700064
J	Kawabe, H; Hata, Y; Takeuchi, M; Ide, N; Mizoguchi, A; Takai, Y				Kawabe, H; Hata, Y; Takeuchi, M; Ide, N; Mizoguchi, A; Takai, Y			nArgBP2, a novel neural member of ponsin/ArgBP2/vinexin family that interacts with synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; TRANSFORMED CELLS; DOMAIN; DISKS; SRC; ABL	Postsynaptic density (PSD)-95/synapse-associated protein (SAP) 90 and synaptic scaffolding molecule (S-SCAM) are synaptic membrane-associated guanylate kinases. Both the proteins interact with SAP90/PSD-95-associated protein (SAPAP) (also called guanylate kinase-associated protein/Dlg-associated protein). SAPAP is a protein highly enriched in the PSD fraction and may link PSD-95/SAP90 and S-SCAM to Triton X-100-insoluble structures. We found here a novel SAPAP-interacting protein, which was specifically expressed in neural tissue and was present in the postsynaptic density fraction in brain. This protein had a sorbin homology domain in the N terminus, a zinc finger motif in the middle region, and three src homology (SB) 3 domains in the C terminus and was homologous to the ponsin/ArgBP2/vinexin family proteins, We named this protein nArgBP2 because it was the most homologous to ArgBP2. nArgBP2 is a neural member of a growing family of SH3-containing proteins. nArgBP2 bound to the proline-rich region of SAPAP via its third SH3 domain and tvas coimmunoprecipitated with SAPAP from the extract of rat brain. Furthermore, nArgBP2 was colocalized with SAPAP at synapses in cerebellum. nArgBP2 bound to not only SAPAP but also vinculin and l-afadin, known to bind to ponsin and vinexin. nArgBP2 may be implicated in the protein network around SAPAP in the PSD.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, Kobe, Hyogo 6512241, Japan; Tokyo Med & Dent Univ, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696				CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	19	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30914	30918		10.1074/jbc.274.43.30914	http://dx.doi.org/10.1074/jbc.274.43.30914			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521485	hybrid			2022-12-25	WOS:000083276700081
J	Scheid, MP; Schubert, KM; Duronio, V				Scheid, MP; Schubert, KM; Duronio, V			Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; MAP KINASE; CELL-DEATH; GENE-EXPRESSION; CYCLIC-AMP; SURVIVAL; AKT; INHIBITOR	Phosphorylation of the Bcl-2 family protein Bad may represent an important bridge between survival signaling by growth factor receptors and the prevention of apoptosis. Bead phosphorylation was examined following cytokine stimulation, which revealed phosphorylation on a critical residue, serine 112, in a MEK-dependent manner. Furthermore, Bad phosphorylation also increased on several sites distinct from serine 112 but could not be detected on serine 136, previously thought to be a protein kinase B/Akt-targeted residue. Serine 112 phosphorylation was shown to be absolutely required for dissociation of Bad from Bcl-x(L). These results demonstrate for the first time in mammalian cells the involvement of the Ras-MAPK pathway in the phosphorylation of Bad and the regulation of its function.	Univ British Columbia, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Duronio, V (corresponding author), Univ British Columbia, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada.	vduronio@vanhosp.bc.ca						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Coffer PJ, 1998, BIOCHEM J, V335, P1; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Scheid MP, 1999, BLOOD, V93, P217, DOI 10.1182/blood.V93.1.217.401k16_217_225; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	51	345	351	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31108	31113		10.1074/jbc.274.43.31108	http://dx.doi.org/10.1074/jbc.274.43.31108			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521512	hybrid			2022-12-25	WOS:000083276700108
J	Brattsand, M; Egelrud, T				Brattsand, M; Egelrud, T			Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPTIC ENZYME; ENDOGENOUS PROTEOLYSIS; DESMOGLEIN-I; PROTEINASE; SKIN; INVOLVEMENT; KERATINIZATION; DEPENDENCE; EPIDERMIS; FOLLICLES	A new human 33-kDa serine protease was purified from human epidermis, and its cDNA was domed from a keratinocyte library, from mRNA from a human keratinocyte line (HaCat) and from mRNA from human skin. Polyclonal antibodies specific for the new protein detected three groups of proteins in partially purified extracts of cornified eptihelium of human plantar skin. The three components are proposed to correspond to proenzyme, active enzyme, and proteolytically modified active enzyme. After N-deglycosylation, there was a decrease in apparent molecular mass of all detected components. Expression of the cloned cDNA in a eukaryotic virus-derived system yielded a recombinant protein that could be converted to an active protease by treatment with trypsin. Polymerase chain reaction analyses of cDNA from a number of human tissues showed high expression of the new enzyme in the skin and low expression in brain, placenta, and kidney. Homology searches yielded the highest score for porcine enamel matrix protease (55% amino acid sequence homology). High scores were also obtained for human and mouse neuropsin and for human stratum corneum chymotryptic enzyme. The function of this new protease, tentatively named stratum corneum tryptic enzyme, may be related to stratum corneum turnover and desquamation in the epidermis.	Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden	Umea University	Egelrud, T (corresponding author), Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.		Brattsand, Maria/AAG-7777-2019	Brattsand, Maria/0000-0001-7175-1336				AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; EGELRUD T, 1990, J INVEST DERMATOL, V95, P456, DOI 10.1111/1523-1747.ep12555620; EGELRUD T, 1989, ACTA DERM-VENEREOL, V69, P470; Ekholm E, 1998, ACTA DERM-VENEREOL, V78, P343; Ekholm E, 1998, BRIT J DERMATOL, V139, P585; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HORIE N, 1984, COMP BIOCHEM PHYS B, V77, P349, DOI 10.1016/0305-0491(84)90342-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Sambrook J., 2002, MOL CLONING LAB MANU; SKYTT A, 1995, BIOCHEM BIOPH RES CO, V211, P586, DOI 10.1006/bbrc.1995.1853; SONDELL B, 1995, J INVEST DERMATOL, V104, P819, DOI 10.1111/1523-1747.ep12607007; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459, DOI 10.1177/42.4.7510318; Sondell B, 1996, ACTA DERM-VENEREOL, V76, P177; SUZUKI Y, 1993, ARCH DERMATOL RES, V285, P372, DOI 10.1007/BF00371839; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; Suzuki Y, 1996, BRIT J DERMATOL, V134, P460, DOI 10.1046/j.1365-2133.1996.31794.x	27	175	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30033	30040		10.1074/jbc.274.42.30033	http://dx.doi.org/10.1074/jbc.274.42.30033			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514489	hybrid			2022-12-25	WOS:000083176400068
J	Gallis, B; Corthals, GL; Goodlett, DR; Ueba, H; Kim, F; Presnell, SR; Figeys, D; Harrison, DG; Berk, BC; Aebersold, R; Corson, MA				Gallis, B; Corthals, GL; Goodlett, DR; Ueba, H; Kim, F; Presnell, SR; Figeys, D; Harrison, DG; Berk, BC; Aebersold, R; Corson, MA			Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; ELECTROSPRAY-IONIZATION; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; BINDING DOMAIN; KINASE-II; T-CELLS; CAVEOLIN; EXPRESSION	Endothelial cells release nitric oxide (NO) acutely in response to increased laminar fluid shear stress, and the increase is correlated with enhanced phosphorylation of endothelial nitric-oxide synthase (eNOS). Phosphoamino acid analysis of eNOS from bovine aortic endothelial cells labeled with [P-32]orthophosphate demonstrated that only phosphoserine was present in eNOS under both static and flow conditions. Fluid shear stress induced phosphate incorporation into two specific eNOS tryptic peptides as early as 30 s after initiation of flow. The flow-induced tryptic phosphopeptides were enriched, separated by capillary electrophoresis with intermittent voltage drops, also known as 'peak parking," and analyzed by collision-induced dissociation in a tandem mass spectrometer. Two phosphopeptide sequences determined by tandem mass spectrometry, TQpSFSLQER and KLQTRPpSPGPPPAEQLLSQAR, were confirmed as the two flow-dependent phosphopeptides by co-migration with synthetic phosphopeptides. Because the sequence (RIR)TQpSFSLQER contains a consensus substrate site for protein kinase B (PKB or Akt), we demonstrated that LY294002, an inhibitor of the upstream activator of PKB, phosphatidylinositol 3-kinase, inhibited flow-induced eNOS phosphorylation by 97% and NO production by 68%. Finally, PKB phosphorylated eNOS in vitro at the same site phosphorylated in the cell and increased eNOS enzymatic activity by 15-20-fold.	Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Emory University; University System of Georgia; Georgia Institute of Technology	Gallis, B (corresponding author), Univ Washington, Div Cardiol, Dept Med, Box 359748, Seattle, WA 98195 USA.	bgallis@u.washington.edu	Corthals, Garry/G-9417-2016	Corthals, Garry/0000-0001-9423-5596; Berk, Bradford/0000-0002-2767-4115; Figeys, Daniel/0000-0002-5373-7546	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039006, R01HL030946] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1HL58000, 1RO1HL39006, 1RO1HL30946] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; AFFOLTER M, 1994, ANAL BIOCHEM, V223, P74, DOI 10.1006/abio.1994.1549; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Davis MT, 1998, J AM SOC MASS SPECTR, V9, P194, DOI 10.1016/S1044-0305(97)00282-1; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Figeys D, 1996, ANAL CHEM, V68, P1822, DOI 10.1021/ac960191h; Figeys D, 1996, NAT BIOTECHNOL, V14, P1579, DOI 10.1038/nbt1196-1579; Figeys D, 1999, ANAL CHEM, V71, P2279, DOI 10.1021/ac9813991; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Hidaka H, 1996, Adv Pharmacol, V36, P193, DOI 10.1016/S1054-3589(08)60583-9; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; JAMES NL, 1995, FASEB J, V9, P968, DOI 10.1096/fasebj.9.10.7615166; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kumar VB, 1999, ANAL BIOCHEM, V269, P17, DOI 10.1006/abio.1999.4013; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELTZ GA, 1987, ANAL BIOCHEM, V167, P239, DOI 10.1016/0003-2697(87)90159-X; RADOMSKI MW, 1993, CARDIOVASC RES, V27, P1380, DOI 10.1093/cvr/27.7.1380; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; TRAUB O, 1999, MECH FORCES ENDOTHEL; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	59	277	289	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30101	30108		10.1074/jbc.274.42.30101	http://dx.doi.org/10.1074/jbc.274.42.30101			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514497	hybrid			2022-12-25	WOS:000083176400076
J	Grossel, MJ; Baker, GL; Hinds, PW				Grossel, MJ; Baker, GL; Hinds, PW			cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; KINASE-ACTIVITY; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; INHIBITOR; GROWTH; P21; P16(INK4A); FAMILY	Deregulated activity of cdk4 or cdk6 can lead to inappropriate cellular proliferation and tumorigenesis accompanied by unchecked inactivation of the retinoblastoma tumor suppressor protein. Certain tumor types preferentially activate either cdk4 or cdk6, suggesting that these kinases may not be equivalently oncogenic in all cell types. Although it is clear that cdk4 can act as an oncogene at least in part by evading inhibition by p16(INK4a), the role of cdk6 in tumorigenesis is less well understood. To investigate the consequences of aberrant expression of cdk6, the requirements for proliferation caused by cdk6 overexpression were studied, cdk6-transfected U20S cells displayed an accelerated progression through G(1) phase that was dependent on kinase activity and that did not correlate with p27 binding. Furthermore, a mutation that prevents cdk6 interaction with INK4 proteins (cdk6R31C) was found to inactivate the proliferative effect of cdk6 and increase cytoplasmic localization, despite the fact that this mutant could phosphorylate the retinoblastoma protein in vitro. Together, these data suggest a role for the cdk6 INK4 interaction domain in the generation of functional, nuclear cdk6 complexes and demonstrate the importance of elevated cdk6 kinase activity in G(1) acceleration.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hinds, PW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055684] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55684] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BROTHERTON D, 1998, NATURE, V395; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Costello JF, 1997, CANCER RES, V57, P1250; Easton J, 1998, CANCER RES, V58, P2624; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Lapointe J, 1996, CANCER RES, V56, P4586; Latham KM, 1996, MOL CELL BIOL, V16, P4445; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN D, 1995, NATURE, V474, P131; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nagasawa M, 1997, J IMMUNOL, V158, P5146; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parry D, 1999, MOL CELL BIOL, V19, P1775; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	41	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29960	29967		10.1074/jbc.274.42.29960	http://dx.doi.org/10.1074/jbc.274.42.29960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514479	hybrid			2022-12-25	WOS:000083176400058
J	Jensen, NA; West, MJ; Celis, JE				Jensen, NA; West, MJ; Celis, JE			Oligodendrocyte programmed cell death and central myelination deficiency induced in transgenic mice by synergism between c-Myc and Oct-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TRANSCRIPTION FACTOR SCIP; MULTIPLE-SCLEROSIS BRAIN; CENTRAL-NERVOUS-SYSTEM; POU FACTOR OCT-6; PRE-B-CELLS; V-H-RAS; INDUCED APOPTOSIS; GENE-EXPRESSION; JC VIRUS	The basic helix-loop-helix transcription factor c-Myc is a potent trigger of programmed cell death when overexpressed during late oligodendrocyte development in transgenic mice. Here we provide evidence that c-Myc can act synergistically with the Pit, Oct, Unc homeodomain transcription factor Oct-6 to produce myelin disease pathogenesis in transgenic mice. More than 70% of c-myc/Oct-6 bitransgenic mice, obtained from crosses between phenotypically normal heterozygous mice of various My (c-Myc) and Oc (Oct-6) transgenic strains that express c-myc and oct-6 transgenes under transcriptional control of the myelin basic protein gene) developed severe neurological disturbances characterized by action tremors, recurrent seizures, and premature death. Affected bitransgenic mice exhibited multiple hypomyelinated lesions in the white matter that did not stain with myelin-specific antibodies against myelin ba sic protein, proteolipid protein, CNPase, and myelin-associated glycoprotein. The mice also exhibited a larger number of terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labeling positive cells in the white matter as well as ultrastructural evidence of glial cell death and astrogliosis. These observations indicate that the myelin lesions observed in the c-myc/oct-6 bitransgenic mice result from the untimely programmed cell death of oligodendroglia and that the c-myc and oct-6 transgenes act synergistically in producing the lesions.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Neurobiol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Jensen, NA (corresponding author), Panum Inst, Lab Expt Mol Genet, Inst Med Biochem & Genet, 6-5 Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.							ABDELRAHMAN B, 1995, HUM REPROD, V10, P2787, DOI 10.1093/oxfordjournals.humrep.a135792; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; Banerjee M, 1996, INT J CANCER, V65, P730, DOI 10.1002/(SICI)1097-0215(19960315)65:6<730::AID-IJC3>3.0.CO;2-#; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Campagnoni Anthony T., 1995, P555; CELIS JE, 1997, CELL BIOL LAB HDB, V2, P429; CELIS JE, 1997, CELL BIOL LAB HDB, P375; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Dowling P, 1997, J NEUROL SCI, V149, P1, DOI 10.1016/S0022-510X(97)05213-1; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FRANTZ GD, 1994, J NEUROSCI, V14, P472; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Hisahara S, 1997, J NEUROCHEM, V69, P10; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; Jensen NA, 1998, ELECTROPHORESIS, V19, P2014, DOI 10.1002/elps.1150191121; Jensen NA, 1998, J CLIN INVEST, V101, P1292, DOI 10.1172/JCI1807; Jensen NA, 1998, ONCOGENE, V16, P2123, DOI 10.1038/sj.onc.1201739; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LITTLEWOOD T, 1998, PROTEIN PROFILE, P1; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Morell Pierre, 1994, P117; Pedersen KM, 1999, ELECTROPHORESIS, V20, P249, DOI 10.1002/(SICI)1522-2683(19990201)20:2<249::AID-ELPS249>3.0.CO;2-F; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SCHERER SS, 1994, J NEUROSCI, V14, P1930; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; Schreiber J, 1997, J BIOL CHEM, V272, P32286, DOI 10.1074/jbc.272.51.32286; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STREIT WJ, 1995, SCI AM, V273, P54, DOI 10.1038/scientificamerican1195-54; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; Szuchet Sara, 1995, P23; Tenenbaum L, 1996, NEUROPATH APPL NEURO, V22, P302, DOI 10.1111/j.1365-2990.1996.tb01108.x; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; ZORNIG M, 1995, ONCOGENE, V10, P2397; Zwart R, 1996, MECH DEVELOP, V54, P185, DOI 10.1016/0925-4773(95)00472-6	67	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29921	29926		10.1074/jbc.274.42.29921	http://dx.doi.org/10.1074/jbc.274.42.29921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514474	hybrid			2022-12-25	WOS:000083176400053
J	Lopez, R; Carron, C; Oury, C; Gardellin, P; Bernard, O; Ghysdael, J				Lopez, R; Carron, C; Oury, C; Gardellin, P; Bernard, O; Ghysdael, J			TEL is a sequence-specific transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ETS-DOMAIN PROTEIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; FUSION PROTEIN; DROSOPHILA EYE; DNA-BINDING; GENE FUSION; KINASE; ACTIVATION; TRANSLOCATION	TEL is a gene frequently involved in specific chromosomal translocations in human leukemia and sarcoma that encodes a member of the ETS family of transcriptional regulators. TEL is unusual among other ETS proteins by its ability to self-associate in vivo, a property that is essential to the oncogenic activation of TEL-derived fusion proteins. We show here that TEL is a sequence-specific transcriptional repressor of ETS-binding site-driven transcription of model and natural promoters, Deletion of the oligomerization domain of TEL or its substitution by the homologous region of monomeric ETS1 impaired the ability of TEL to repress. In contrast, substitution of the oligomerization domain of TEL by unrelated oligomerization domains resulted in an active repressor, showing that the ability of TEL to repress depends on its ability to self-associate. The study of the properties of TEL fusions to the heterologous DNA binding domain of Gal4 identified two autonomous repression domains in TEL, distinct from its oligomerization domain, that are essential do the ability of TEL to repress ETS-binding site-containing promoters. These results have implications for the normal function of TEL, its relation to other ETS proteins, and its role in leukemogenesis.	Ctr Univ Orsay, Sect Rech, Inst Curie, CNRS UMR 146, F-91405 Orsay, France; Ctr Etud Polymorphisme Humain, INSERM U434, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ghysdael, J (corresponding author), Ctr Univ Orsay, Sect Rech, Inst Curie, CNRS UMR 146, Batiment 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013; Carron, Clémence/AAG-6304-2021; Bernard, Olivier A./E-5721-2016	Oury, Cecile/0000-0002-7561-0132; Carron, Clemence/0000-0002-8776-7380; Bernard, Olivier/0000-0002-0463-9747				AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P8; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bornemann D, 1996, DEVELOPMENT, V122, P1621; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; McLean TW, 1996, BLOOD, V88, P4252; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rogge R, 1995, DEVELOPMENT, V121, P3947; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Starck J, 1999, MOL CELL BIOL, V19, P121; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392	44	135	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30132	30138		10.1074/jbc.274.42.30132	http://dx.doi.org/10.1074/jbc.274.42.30132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514502	hybrid, Green Published			2022-12-25	WOS:000083176400081
J	Moilanen, LH; Fukushige, T; Freedman, JH				Moilanen, LH; Fukushige, T; Freedman, JH			Regulation of metallothionein gene transcription - Identification of upstream regulatory elements and transcription factors responsible for cell-specific expression of the metallothionein genes from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; SEA-URCHIN EMBRYOS; HEAVY-METALS; DROSOPHILA-MELANOGASTER; BINDING PROTEIN; MESSENGER-RNA; FACTOR GATA-1; FACTOR MTF-1; I GENES; PROMOTER	Metallothioneins are small, cysteine-rich proteins that function in metal detoxification and homeostasis. Metallothionein transcription is controlled by cell-specific factors, as well as developmentally modulated and metal-responsive pathways. By using the nematode Caenorhabditis elegans as a model system, the mechanism that controls cell-specific metallothionein transcription in vivo was investigated. The inducible expression of the C. elegans metallothionein genes, mtl-1 and mtl-2, occurs exclusively in intestinal cells. Sequence comparisons of these genes with other C. elegans intestinal cell-specific genes identified multiple repeats of GATA transcription factor-binding sites (i.e. GATA elements). In vivo deletion and site-directed mutation analyses confirm that one GATA element in mtl-1 and two in mtl-2 are required for transcription. Electrophoretic mobility shift assays show that the C, elegans GATA transcription factor ELT-2 specifically binds to these elements. Ectopic expression of ELT-S in non-intestinal cells of C. elegans activates mtl-2 transcription in these cells. Likewise, mtl-2 is not expressed in nematodes in which elt-2 has been disrupted. These results indicate that cell-specific transcription of the C. elegans metallothionein Genes is regulated by the binding of ELT-S to GATA elements in these promoters. Furthermore, a model is proposed where ELT-S constitutively activates metallothionein expression; however, a second metal-responsive factor prevents transcription in the absence of metals.	Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University; University of Calgary; Duke University	Freedman, JH (corresponding author), Duke Univ, Nicholas Sch Environm, Box 90328, Durham, NC 27708 USA.	jonf@duke.edu			NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ABEL T, 1993, DEVELOPMENT, V119, P623; Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BEMONDELLI P, 1997, FEBS LETT, V416, P254; BONNETON F, 1995, DEV GENET, V16, P253, DOI 10.1002/dvg.1020160305; Bonneton F, 1996, FEBS LETT, V380, P33, DOI 10.1016/0014-5793(95)01544-2; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; CZUPRYN M, 1992, P NATL ACAD SCI USA, V89, P10395, DOI 10.1073/pnas.89.21.10395; DURLIAT M, 1995, BIOMETALS, V8, P339; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EGAN CR, 1995, DEV BIOL, V170, P397, DOI 10.1006/dbio.1995.1225; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; FAICH N, 1995, EMBO J, V14, P801; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FITZGERALD K, 1998, AM J PHYSIOL, pG314; FOSTER R, 1988, J BIOL CHEM, V263, P11528; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Garrett SH, 1998, ENVIRON HEALTH PERSP, V106, P587, DOI 10.2307/3434234; Ghatak S, 1996, PROSTATE, V29, P91, DOI 10.1002/(SICI)1097-0045(199608)29:2<91::AID-PROS4>3.0.CO;2-K; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Gilleard JS, 1999, DEV BIOL, V208, P265, DOI 10.1006/dbio.1999.9202; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Haun C, 1998, P NATL ACAD SCI USA, V95, P5072, DOI 10.1073/pnas.95.9.5072; HAWKINS MG, 1995, J BIOL CHEM, V270, P14666, DOI 10.1074/jbc.270.24.14666; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; Imbert J, 1990, Adv Inorg Biochem, V8, P139; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KENNEDY BP, 1993, J MOL BIOL, V229, P890, DOI 10.1006/jmbi.1993.1094; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KOIZUMI S, 1991, CHEM-BIOL INTERACT, V80, P145, DOI 10.1016/0009-2797(91)90021-X; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND M, 1994, J BIOL CHEM, V269, P9234; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; LIN WH, 1995, J BIOL CHEM, V270, P25150, DOI 10.1074/jbc.270.42.25150; LINCKE CR, 1992, J MOL BIOL, V228, P701, DOI 10.1016/0022-2836(92)90855-E; Liu HD, 1996, GENE DEV, V10, P592; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MACMORRIS M, 1992, MOL CELL BIOL, V12, P1652, DOI 10.1128/MCB.12.4.1652; MADURO M, 1995, GENETICS, V141, P977; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moffatt P, 1998, DNA CELL BIOL, V17, P501, DOI 10.1089/dna.1998.17.501; NEMER M, 1991, J BIOL CHEM, V266, P6586; NEMER M, 1995, MECH DEVELOP, V50, P131, DOI 10.1016/0925-4773(94)00330-P; Nonchev S, 1996, DEVELOPMENT, V122, P543; Page BD, 1997, GENE DEV, V11, P1651, DOI 10.1101/gad.11.13.1651; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PRICEHAUGHEY J, 1987, BIOCHIM BIOPHYS ACTA, V908, P158, DOI 10.1016/0167-4781(87)90055-8; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; Searle P F, 1987, Experientia Suppl, V52, P407; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SILAR P, 1990, J MOL BIOL, V215, P217, DOI 10.1016/S0022-2836(05)80340-7; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; SPIETH J, 1985, MOL CELL BIOL, V5, P2495, DOI 10.1128/MCB.5.10.2495; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Suzuki Keiji, 1994, Biological Signals, V3, P188; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WILKINSON DG, 1987, MOL CELL BIOL, V7, P48, DOI 10.1128/MCB.7.1.48; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yoshida T, 1997, FEBS LETT, V414, P333, DOI 10.1016/S0014-5793(97)01017-X; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883; [No title captured]	95	73	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29655	29665		10.1074/jbc.274.42.29655	http://dx.doi.org/10.1074/jbc.274.42.29655			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514435	hybrid			2022-12-25	WOS:000083176400014
J	Kramer, EM; Klein, C; Koch, T; Boytinck, M; Trotter, J				Kramer, EM; Klein, C; Koch, T; Boytinck, M; Trotter, J			Compartmentation of Fyn kinase with glycosylphosphatidylinositol-anchored molecules in oligodendrocytes facilitates kinase activation during myelination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PROTEIN-TYROSINE KINASES; ENRICHED MEMBRANE SUBDOMAINS; CULTURED OLIGODENDROCYTES; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; PRECURSOR CELLS; NERVOUS-SYSTEM; T-CELLS; N-CAM	In many cell types, glycosylphosphatidylinositol (GPI)-anchored proteins are sequestered in detergent-resistant membrane rafts. These are plasma membrane microdomains enriched in glycosphingolipids and cholesterol and are suggested to be platforms for cell signaling. Concomitant with the synthesis of myelin glycosphingolipids, maturing oligodendrocytes progressively associate GPI-anchored proteins, including the adhesion molecules NCAM 120 and F3, in rafts. Here we show that these microdomains include Fyn and Lyn kinases. Both kinases are maximally active in myelin prepared from young animals, correlating with early stages of myelination. In the rafts, Fyn kinase is tightly associated with NCAM 120 and F3. In contrast, in oligodendrocyte progenitor cells lacking rafts or in raft-free membrane domains of more mature cells, F3 does not associate with Fyn. The addition of anti-F3 antibodies to oligodendrocytes results in stimulation of Fyn kinase specifically in rafts. Compartmentation of oligodendrocyte GPI-anchored proteins in rafts is thus a prerequisite for association with Fyn, permitting kinase activation. Interaction of oligodendrocyte F3 with axonal ligands such as L1 and ensuing kinase activation may play a crucial role in initiating myelination.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Trotter, J (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Eva-Maria, Kraemer-Albers/AAP-8805-2020	Eva-Maria, Kraemer-Albers/0000-0001-7994-1185				Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BHAT S, 1986, J NEUROSCI, V6, P3348; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; BROPHY PJ, 1994, MULTIDISCIPLINARY AP, V2, P71; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown RE, 1998, J CELL SCI, V111, P1; BRUMMENDORF T, 1993, NEURON, V10, P711; Carenini S, 1997, CELL TISSUE RES, V287, P3; Cervello M, 1996, J CELL SCI, V109, P699; CINEK T, 1992, J IMMUNOL, V149, P2262; Coetzee T, 1998, TRENDS NEUROSCI, V21, P126, DOI 10.1016/S0166-2236(97)01178-8; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; Collinson JM, 1998, GLIA, V23, P11, DOI 10.1002/(SICI)1098-1136(199805)23:1<11::AID-GLIA2>3.0.CO;2-7; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Doyle JP, 1993, CURR OPIN CELL BIOL, V5, P779, DOI 10.1016/0955-0674(93)90025-L; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Dupree JL, 1998, J NEUROSCI, V18, P1642; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HILDEBRAND C, 1993, PROG NEUROBIOL, V40, P319, DOI 10.1016/0301-0082(93)90015-K; Hooper NM, 1998, CURR BIOL, V8, pR114, DOI 10.1016/S0960-9822(98)70984-4; HSIEH ST, 1994, J NEUROSCI, V14, P6392; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KOCH T, 1998, THESIS U HEIDELBERG; Kramer EM, 1997, J BIOL CHEM, V272, P8937; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; LUBETZKI C, 1993, P NATL ACAD SCI USA, V90, P6820, DOI 10.1073/pnas.90.14.6820; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; MEYERFRANKE A, 1994, CURR BIOL, V4, P847; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; Niehaus A, 1999, J NEUROSCI, V19, P4948; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; NOTTERPEK LM, 1994, NEURON, V13, P473, DOI 10.1016/0896-6273(94)90361-1; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Payne HR, 1996, DEV BRAIN RES, V97, P9, DOI 10.1016/S0165-3806(96)00124-1; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH ME, 1969, J NEUROCHEM, V16, P83, DOI 10.1111/j.1471-4159.1969.tb10345.x; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Takeda Y, 1996, J NEUROCHEM, V66, P2338; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Vaughan L, 1996, SEMIN NEUROSCI, V8, P397, DOI 10.1006/smns.1996.0048; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	64	187	189	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29042	29049		10.1074/jbc.274.41.29042	http://dx.doi.org/10.1074/jbc.274.41.29042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506155	hybrid			2022-12-25	WOS:000083017800034
J	Nasonkin, I; Alikasifoglu, A; Ambrose, C; Cahill, P; Cheng, M; Sarniak, A; Egan, M; Thomas, PM				Nasonkin, I; Alikasifoglu, A; Ambrose, C; Cahill, P; Cheng, M; Sarniak, A; Egan, M; Thomas, PM			A novel sulfonylurea receptor family member expressed in the embryonic Drosophila dorsal vessel and tracheal system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; K+ CHANNEL; GENE; SEQUENCE; INFANCY; SHAKER; REGULATOR; SUBUNITS; PROTEINS; INSIGHTS	Sulfonylurea receptors (SURx) are required subunits of the ATP-sensitive potassium channel. SURx: alone is electrophysiologically inert. However, when SURx is combined with an inward rectifier Kir6.2 subunit, ATP-sensitive potassium channel activity is generated. We report the identification, characterization, and localization of Dsur, a novel Drosophila gene that is highly related to the vertebrate SUR family. The Dsur coding sequence contains structural features characteristic of the ABC transporter family and, in addition, harbors 1.7 kilobases of a distinctive sequence that does not share homology with any known gene. When Dsur alone is expressed in Xenopus oocytes glibenclamide-sensitive potassium channel activity occurs. During Drosophila embryogenesis, the Dsur gene is specifically expressed in the developing tracheal system and dorsal vessel. Studies of the Drosophila genome support that only a single Dsur gene is present. Our data reveal conservation of glibenclamide-sensitive potassium channels in Drosophila and suggest that Dsur may play an important role during Drosophila embryogenesis. The lack of gene duplication in the Drosophila system provides a unique opportunity for functional studies of SUR using a genetic approach.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Communicable Dis, Ann Arbor, MI 48109 USA; Yale Univ, Dept Pediat, New Haven, CT 06520 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University	Thomas, PM (corresponding author), Univ Michigan, Dept Pediat, MSRB III,Rm 8220A,Box 0646,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NICHD NIH HHS [HD28820] Funding Source: Medline; NIDDK NIH HHS [R01DK53428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053428] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Arias A.M., 1993, DEV DROSOPHILA, P609; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CLEGG NJ, 1993, GENETICS, V134, P221; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEHMAN R, 1994, DROSOPHILA MELANOGAS, V44; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; ROST B, 1995, PROTEIN SCI, V4, P521; SEINO S, 1996, DIABETES REV, V4, P177; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; WU CT, 1991, MOL CELL BIOL, V11, P3940, DOI 10.1128/MCB.11.8.3940	30	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29420	29425		10.1074/jbc.274.41.29420	http://dx.doi.org/10.1074/jbc.274.41.29420			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506204	hybrid			2022-12-25	WOS:000083017800083
J	Smith, L; Su, XJ; Lin, PJ; Zhi, G; Stull, JT				Smith, L; Su, XJ; Lin, PJ; Zhi, G; Stull, JT			Identification of a novel actin binding motif in smooth muscle myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; SEQUENCE; SITE; PHOSPHORYLATION; CONTRACTION; FIBROBLASTS; DOMAIN; CDNA	Phosphorylation of the 20-kDa regulatory light chain of myosin catalyzed by a Ca2+/calmodulin-dependent myosin light chain kinase is important in the initiation of smooth muscle contraction and other contractile processes in non-muscle cells. It has been previously shown that residues 1-142 of smooth muscle myosin light chain kinase are necessary for high-affinity binding to actin-containing filaments in cells (1), To further localize the region of the kinase required for binding, a series of N-terminal deletion mutants as well as several N-terminal glutathione S-transferase fusion proteins were constructed. Cosedimentation assays showed that a peptide containing residues 1-75 binds to purified smooth muscle myofilaments, Furthermore, the N-terminal peptide was sufficient for high-affinity binding to actin stress fibers in smooth muscle cells in vivo. Alanine scanning mutagenesis in the fusion protein identified residues Asp-30, Phe-31, Arg-32, and Leu-35 as important for binding in vitro. There are two additional DFRXXL motifs located at residues 2-7 and 58-63. The DFR residues in these three motifs were individually replaced by alanine residues in the full-length kinase, Each of these mutations significantly decreased myosin light chain kinase binding to myofilaments in vitro, and each abolished high-affinity binding to actin-containing filaments in smooth muscle cells in vivo. These results identify a unique structural motif comprised of three repeat consensus sequences in the N terminus of myosin light chain kinase necessary for high-affinity binding to actin-containing filaments.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Smith, L (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	jstull@mednet.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL26043-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; FAUX MC, 1993, MOL CELL BIOCHEM, V128, P81, DOI 10.1007/BF01076759; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lin PJ, 1999, J BIOL CHEM, V274, P5987, DOI 10.1074/jbc.274.9.5987; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; NUNNALLY MH, 1984, J BIOL CHEM, V259, P1776; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; STULL JT, 1988, ACTA PHYSL SCAND, V164, P471; STULL JT, 1996, BIOCH SMOOTH MUSCLE, P119; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	29	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29433	29438		10.1074/jbc.274.41.29433	http://dx.doi.org/10.1074/jbc.274.41.29433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506206	hybrid			2022-12-25	WOS:000083017800085
J	Izzi, L; Turbide, C; Houde, C; Kunath, T; Beauchemin, N				Izzi, L; Turbide, C; Houde, C; Kunath, T; Beauchemin, N			cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function	ONCOGENE			English	Article						CEA; BGP; CD66a; C-CAM; tumor suppressor; colon cancer; SHP-1; SHP-2; Tyr phosphorylation	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; MOUSE BILIARY GLYCOPROTEIN; C-CAM; GENE FAMILY; EPITHELIAL-CELLS; TYROSINE KINASE; ECTO-ATPASE; HEPATOCELLULAR CARCINOMAS; INTERCELLULAR-ADHESION	CEACAM1, also known as C-CAM, BGP and CD66a, is a member of the carcinoembryonic antigen (CEA) family which is itself part of the immunoglobulin supergene family, CEACAM1 is involved in intercellular adhesion, signal transduction and tumor cell growth regulation, CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers, We have shown in a mouse colon tumor model that CEACAM1 with a long cytoplasmic domain inhibited the development of tumors whereas a splice variant lacking the cytoplasmic domain did not, In this study, we define the subregions of the long cytoplasmic domain participating in the tumor inhibition phenotype of CEACAM1, We show that a single point mutation of Tyr488, conforming to an Immune-receptor Tyrosine Inhibition Motif (ITIM), was sufficient to reverse the in vivo tumor cell growth inhibition, Substitution or deletion of residues in the C-terminal region of the CEACAM1 cytoplasmic domain also led to reversal of tumor cell growth inhibition. This result is in agreement with our previous studies demonstrating the C-terminal region of the cytoplasmic domain influences the levels of CEACAM1 Tyr phosphorylation and its association with the protein Tyr phosphatases SHP-1 and SHP-2, Furthermore, removal of the N-terminal domain of CEACAM1, essential for intercellular adhesion, did not impair the tumor inhibitory effect. These results suggest that Tyr phosphorylation or dephosphorylation of the CEACAM1 cytoplasmic domain represents a crucial step in the control of epithelial cell proliferation.	McGill Univ, McGill Canc Ctr, Dept Biochem, Montreal, PQ, Canada; McGill Univ, McGill Canc Ctr, Dept Med & Oncol, Montreal, PQ, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, Dept Biochem, McIntyre Med Sci Bldg,Room 716,3655 Drummond St, Montreal, PQ, Canada.			Kunath, Tilo/0000-0002-8805-7356				Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BEAUCHEMIN N, 1999, UNPUB CANC RES; BRATTAIN MG, 1980, CANCER RES, V40, P2142; BRUMMER J, 1995, ONCOGENE, V11, P1649; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilantzis C, 1997, LAB INVEST, V76, P703; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PENSIERO MN, 1992, J VIROL, V66, P4028, DOI 10.1128/JVI.66.7.4028-4039.1992; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROBBINS J, 1991, GENOMICS, V10, P583, DOI 10.1016/0888-7543(91)90439-L; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P314; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Turbide C, 1997, CANCER RES, V57, P2781; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; WATT SM, 1994, BLOOD, V84, P200; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	62	69	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5563	5572		10.1038/sj.onc.1202935	http://dx.doi.org/10.1038/sj.onc.1202935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523833				2022-12-25	WOS:000082894700009
J	Chen, CC; Chiu, KT; Sun, YT; Chen, WC				Chen, CC; Chiu, KT; Sun, YT; Chen, WC			Pole of the cyclic AMP-protein kinase a pathway in lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages - Involvement of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; NF-KAPPA-B; MESANGIAL CELLS; INDUCTION; ACTIVATION; CAMP; PHARMACOLOGY; MECHANISM; TISSUE	The signaling pathway for lipopolysaccharide (LPS)-induced nitric oxide (NO) release in RAW 264.7 macrophages involves the protein kinase C and p38 activation pathways (Chen, C. C., Wang, J. K., and Lin, S. B. (1998) J. Immunol. 161, 6206-6214; Chen, C. C., and Wang, J. K. (1999) Mel. Pharmacol. 55, 481-488). In this study, the role of the cAMP-dependent protein kinase A (PKA) pathway was investigated. The PEA inhibitors, KT-5720 and H8, reduced LPS-induced NO release and inducible nitric oxide synthase (iNOS) expression. The direct PHA activator, Bt(2)cAMP, caused concentration-dependent NO release and iNOS expression, as confirmed by immunofluorescence studies. The intracellular cAMP concentration did not increase until after 6 h of LPS treatment. Two cAMP-elevating agents, forskolin and cholera toxin, potentiated the LPS-induced NO release and iNOS expression. Stimulation of cells with LPS or Bt(2)cAMP for periods of 10 min to 24 h caused nuclear factor-kappa B (NF-kappa B) activation in the nuclei, as shown by detection of NF-kappa B-specific DNA-protein binding The PKA inhibitor, H8, inhibited the NF-kappa B activation induced by 6- or 12-h treatment with LPS but not that induced after 1, 3, or 24 h. The cyclooxygenase-a (COX-2) inhibitors, NS-398 and indomethacin, attenuated LPS-induced NO release, iNOS expression, and NF-kappa B DNA-protein complex formation. LPS induced COX-2 expression in a time-dependent manner, and prostaglandin E-2 production was induced in parallel. These results suggest that 6 h of treatment with LPS increases intracellular cAMP levels via COX-2 induction and prostaglandin E-2 production, resulting in PKA activation, NF-kappa B activation, iNOS expression, and NO production.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10018, Taiwan	National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1 Jen Ai Rd,1st Sect, Taipei 10018, Taiwan.			CHEN, CHING-CHOW/0000-0002-7810-0939				Chen CC, 1999, MOL PHARMACOL, V55, P481; Chen CC, 1998, J IMMUNOL, V161, P6206; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; FOURNIER T, 1995, J IMMUNOL, V155, P2123; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; HIROKAWA K, 1994, BRIT J PHARMACOL, V112, P396, DOI 10.1111/j.1476-5381.1994.tb13085.x; JEAN YJ, 1996, MOL PHARMACOL, V50, P334; Klein T, 1998, MOL PHARMACOL, V53, P385, DOI 10.1124/mol.53.3.385; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KOIDE M, 1993, J BIOL CHEM, V268, P24959; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Mustafa SB, 1998, J BIOL CHEM, V273, P5073, DOI 10.1074/jbc.273.9.5073; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nisoli E, 1997, ENDOCRINOLOGY, V138, P676, DOI 10.1210/en.138.2.676; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; Oddis CV, 1996, AM J PHYSIOL-CELL PH, V271, pC429, DOI 10.1152/ajpcell.1996.271.1.C429; OKADA R, 1995, BIOCHIM BIOPHYS ACTA, V1268, P201; ONODERA S, 1991, CHEM PHARM BULL, V39, P991; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; RADDASSI K, 1993, CELL IMMUNOL, V149, P50, DOI 10.1006/cimm.1993.1135; Schmidlin F, 1998, MOL PHARMACOL, V53, P1009; Smith FS, 1997, BIOCHEM J, V326, P187, DOI 10.1042/bj3260187; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WALTON KM, 1992, MOL NEUROBIOL, V4, P197; XIE QW, 1994, J BIOL CHEM, V269, P4705	33	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31559	31564		10.1074/jbc.274.44.31559	http://dx.doi.org/10.1074/jbc.274.44.31559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531359	hybrid			2022-12-25	WOS:000083379400063
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			A novel alternatively spliced variant of synaptotagmin VI lacking a transmembrane domain - Implications for distinct functions of the two isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; GROWTH-FACTOR-I; PHOSPHOLIPID-BINDING; C2B DOMAIN; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; ENDOPLASMIC-RETICULUM; ANTIBODY INJECTION; RELEASE; CALCIUM; CELLS	Synaptotagmins are a family of membrane proteins that are characterized by a single transmembrane region and tandem C2 domains and that are likely to regulate constitutive and/or regulated vesicle traffic, We have shown that a subclass of synaptotagmins (III, V,VI, and X) forms homo- and heterodimers through an evolutionarily conserved cysteine motif at their N termini (Fukuda, M., Kanno, E., and Mikoshiba, K. (1999) J. Biol. Chem. 274, 31421-31427), In this study, we identified a novel alternatively spliced variant of synaptotagmin (Syt) VI that lacks the N-terminal 85 amino acids including the transmembrane region (thus designated as Syt VI Delta TM). Because it lacks the cysteine motif responsible for self-dimerization, Syt VI Delta TM could not associate with Syt VI even in the presence of Ca2+. Despite lacking the transmembrane region, Syt VI Delta TM can associate with the plasma membrane through the C-terminal 29 amino acids. In adult mouse brain, two closely comigrating bands at M-r similar to 50,000, which closely corresponded to the molecular weight of recombinant Syt VI Delta TM, were detected by anti-Syt VI antibody. These immunoreactive bands were found in both soluble and membrane fractions of mouse brain, indicating that they are membrane-associated proteins (Syt VI Delta TM), but not transmembrane proteins (Syt VI), Expression of Syt VI and Syt VI Delta TM in PC12 or COS-7 cells indicated that the two molecules have a distinct subcellular distribution: Syt VI Delta TM: is present in the cytosol or is associated with the plasma membrane or internal membrane structures, whereas Syt M is localized to the endoplasmic reticulum and/or Golgi-like perinuclear compartment, These results suggest that Syt VI and Syt VI Delta TM may play distinct roles in vesicular trafficking.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Calciosignal Net Honkomagome, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; Damer CK, 1996, J NEUROCHEM, V67, P1661; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Linial M, 1997, J NEUROCHEM, V69, P1781; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MARTIN KC, 1995, P NATL ACAD SCI USA, V92, P11307, DOI 10.1073/pnas.92.24.11307; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Mochida S, 1997, NEUROSCIENCE, V77, P937; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Perin MS, 1996, BIOCHEMISTRY-US, V35, P13808, DOI 10.1021/bi960853x; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Thompson CC, 1996, J NEUROSCI, V16, P7832; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	48	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31428	31434		10.1074/jbc.274.44.31428	http://dx.doi.org/10.1074/jbc.274.44.31428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531344	hybrid			2022-12-25	WOS:000083379400048
J	Cotlin, LF; Siddiqui, MA; Simpson, F; Collawn, JF				Cotlin, LF; Siddiqui, MA; Simpson, F; Collawn, JF			Casein kinase II activity is required for transferrin receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; DEPENDENT PROTEIN-KINASE; MEDIATED ENDOCYTOSIS; ASSEMBLY POLYPEPTIDES; DOWN-REGULATION; ASIALOGLYCOPROTEIN RECEPTOR; STRUCTURAL DETERMINANTS; SURFACE FUNCTIONS; CYTOPLASMIC TAIL; SORTING SIGNALS	The effect of protein kinase inhibitors on transferrin receptor (TR) internalization was examined in HeLa, A431, 3T3-L1 cells, and primary chicken embryo fibro- blasts. We show that TR endocytosis is not affected by tyrosine kinase or protein kinase C inhibitors, but is inhibited by one serine/threonine kinase inhibitor, H-89. Inhibition occurred within 15 min, was completely reversible after H-89 withdrawal, and was specific for endocytosis rather than pinocytosis since a TR mutant lacking an internalization signal was not affected. Interestingly, H-89 also inhibited the internalization of a TR chimera containing the major histocompatibility complex class II invariant chain cytoplasmic tail, indicating that the effect was not specific for the TR. Since H-89 inhibits a number of kinases, we employed a permeabilized cell endocytosis assay to further characterize the kinase. In permeabilized 3T3-L1 cells, addition of pseudosubstrate inhibitor peptides of casein kinase a (CKII) blocked TR internalization by more than 50%, whereas pseudosubstrates of cyclic AMP-dependent kinase A, protein kinase C, and casein kinase I had no effect. Furthermore, addition of purified CKII to the cell-free reactions containing CKII pseudosubstrates reversed the endocytosis block, suggesting that CKII or a CKII-like activity is required for constitutive endocytosis.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; Scripps Research Institute	Collawn, JF (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 392,UAB Stn, Birmingham, AL 35294 USA.		Simpson, Fiona/ABE-1276-2020; Simpson, Fiona/J-2721-2012	Simpson, Fiona/0000-0002-0271-781X; Simpson, Fiona/0000-0002-0271-781X; Collawn, James/0000-0002-2528-2759	NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Crump CM, 1999, FEBS LETT, V444, P195, DOI 10.1016/S0014-5793(99)00066-6; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DISANTO JP, 1989, IMMUNOGENETICS, V30, P494, DOI 10.1007/BF02421181; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FAWCETT DW, 1965, J HISTOCHEM CYTOCHEM, V13, P75, DOI 10.1177/13.2.75; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Goretzki L, 1997, J CELL SCI, V110, P1395; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HILL BL, 1988, J BIOL CHEM, V263, P5499; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MORARU II, 1990, FEBS LETT, V274, P93, DOI 10.1016/0014-5793(90)81337-N; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PANETTI TS, 1995, J BIOL CHEM, V270, P18593, DOI 10.1074/jbc.270.31.18593; PAULOIN A, 1984, NATURE, V311, P265, DOI 10.1038/311265a0; PAULOIN A, 1993, BIOCHEM J, V296, P409, DOI 10.1042/bj2960409; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Raman C, 1998, J IMMUNOL, V161, P5817; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	62	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30550	30556		10.1074/jbc.274.43.30550	http://dx.doi.org/10.1074/jbc.274.43.30550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521437	hybrid			2022-12-25	WOS:000083276700033
J	Qi, JJ; Peters, KW; Liu, CG; Wang, JM; Edinger, RS; Johnson, JP; Watkins, SC; Frizzell, RA				Qi, JJ; Peters, KW; Liu, CG; Wang, JM; Edinger, RS; Johnson, JP; Watkins, SC; Frizzell, RA			Regulation of the amiloride-sensitive epithelial sodium channel by syntaxin 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CFTR CHLORIDE CHANNELS; N-TYPE; CALCIUM CHANNELS; SNARE PROTEINS; PHOSPHORYLATION; TRAFFICKING; EXPRESSION; TRANSPORT; MEMBRANE	The first step in transepithelial sodium absorption lies at the apical membrane where the amiloride-sensitive, epithelial sodium channel, ENaC, facilitates sodium entry into the cell, Here we report that the vesicle traffic regulatory (SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor)) protein, syntaxin 1A (S1A), inhibits ENaC mediated sodium entry. This inhibitory effect is selective for S1A and is not reproduced by syntaxin 3, The inhibition does not require the membrane anchoring domain of syntaxin Ik It was reversed by the S1A-binding protein, Munc-18, but not by a Munc-18 mutant, which lacks syntaxin affinity. Immunostaining of epitope-tagged ENaC subunits showed that syntaxin 1A decreases ENaC current by reducing the number of ENaC channels in the plasma membrane; S1A does not interfere with ENaC protein expression. Immunoprecipitation of syntaxin 1A from the sodium-transporting epithelial cell line, A6, co-precipitates ENaC, These findings indicate that syntaxin 1A and other members of the SNARE machinery are involved in the control of plasma membrane ENaC content, and they suggest that SNARE proteins participate in the regulation of sodium absorption in relation to agonist mediated vesicle insertion-retrieval processes.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S362 BST, Pittsburgh, PA 15261 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NIDDK NIH HHS [DK47874, DK54814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814, R01DK047874] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Kokko KE, 1997, AM J PHYSIOL-CELL PH, V273, pC548, DOI 10.1152/ajpcell.1997.273.2.C548; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; Rokaw MD, 1996, J BIOL CHEM, V271, P4491; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	26	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30345	30348		10.1074/jbc.274.43.30345	http://dx.doi.org/10.1074/jbc.274.43.30345			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521407	hybrid			2022-12-25	WOS:000083276700003
J	Sorensen, P; Wintersberger, E				Sorensen, P; Wintersberger, E			Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; BINDING TRANSCRIPTION FACTORS; CELL-CYCLE; GENE PROMOTER; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; IN-VIVO; REPRESS TRANSCRIPTION; CLASS-II; EXPRESSION	Thymidine kinase (TK) genes from different species are growth- and cell cycle-regulated in a very similar manner; still, the promoter regions of these genes show little homology to each other. It was previously shown that the murine TK gene is growth-regulated by Sp1 and E2F, Here we have characterized cis-regulatory elements in the hamster promoter that are essential and sufficient to confer efficient and serum-responsive expression. The TK promoter was isolated from baby hamster kidney cells. DNase I protection experiments revealed a protected region from positions -24 to -99 relative to the transcription start site. Within this region, binding sites for the transcription factor Sp1 and a CCAAT box, which interacts with the transcription factor NF-Y, were identified. An E2F-like sequence was found not to bind protein, and its removal did not affect promoter activity. This was supported by the observation that cotransfection of a hamster TK reporter gene construct with E2F-1 does not lead to transactivation of the promoter. A 122-base pair region that contains a single Sp1 site, a CCAAT box, and a TATA element was found to be sufficient for serum-responsive expression of a reporter gene. Mutations that inactivate any one of these three elements caused a strong reduction or a loss of promoter activity.	Univ Vienna, Vienna Bioctr, Inst Mol Biol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Wintersberger, E (corresponding author), Univ Vienna, Vienna Bioctr, Inst Mol Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	Wi@Mol.Univie.Ac.At						Anderson MM, 1996, J VIROL, V70, P6304, DOI 10.1128/JVI.70.9.6304-6313.1996; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; AUBIN RJ, 1988, SOMAT CELL MOLEC GEN, V14, P155, DOI 10.1007/BF01534401; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOU QP, 1994, J BIOL CHEM, V269, P1306; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim EC, 1996, CELL GROWTH DIFFER, V7, P1741; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; LEWIS JA, 1986, MOL CELL BIOL, V6, P2262, DOI 10.1128/MCB.6.6.2262; LEWIS JA, 1986, MOL CELL BIOL, V6, P1998, DOI 10.1128/MCB.6.6.1998; LEWIS JA, 1983, MOL CELL BIOL, V3, P1815, DOI 10.1128/MCB.3.10.1815; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Tommasi S, 1997, J BIOL CHEM, V272, P30483, DOI 10.1074/jbc.272.48.30483; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WINTERSBERGER E, 1992, ADV ENZYME REGUL, V32, P241; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	42	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30943	30949		10.1074/jbc.274.43.30943	http://dx.doi.org/10.1074/jbc.274.43.30943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521489	hybrid			2022-12-25	WOS:000083276700085
J	van Santen, Y; Benen, JAE; Schroter, KH; Kalk, KH; Armand, S; Visser, J; Dijkstra, BW				van Santen, Y; Benen, JAE; Schroter, KH; Kalk, KH; Armand, S; Visser, J; Dijkstra, BW			1.68-angstrom crystal structure of endopolygalacturonase II from Aspergillus niger and identification of active site residues by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARALLEL BETA-HELIX; PHAGE-P22 TAILSPIKE PROTEIN; GLYCOSYL HYDROLASES; PECTATE LYASE; 3-DIMENSIONAL STRUCTURE; VIRULENCE FACTOR; POLYGALACTURONASES; RESOLUTION; MODELS; REFINEMENT	Polygalacturonases specifically hydrolyze polygalaturonate, a major constituent of plant cell wall pectin. To understand the catalytic mechanism and substrate and product specificity of these enzymes, we have solved the x-ray structure of endopolygalacturonase LT of Aspergillus niger and we have carried out site-directed mutagenesis studies, The enzyme folds into a right-handed parallel beta-helix with 10 complete turns. The beta-helix is composed of four parallel beta-sheets, and has one very small alpha-helix near the N terminus, which shields the enzyme's hydrophobic core. Loop regions form a cleft on the exterior of the beta-helix, Site-directed mutagenesis of Asp(180), Asp(201), Asp(202) His(223) Arg(256), and Lys(258), which are located in this cleft, results in a severe reduction of activity, demonstrating that these residues are important for substrate binding and/or catalysis, The juxtaposition of the catalytic residues differs from that normally encountered in inverting glycosyl hydrolases, A comparison of the endopolygalacturonase II active site with that of the P22 tailspike rhamnosidase suggests that Asp(180) and Asp(202) activate the attaching nucleophilic water molecule, while Asp(201) protonates the glycosidic oxygen of the scissile bond.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Wageningen Univ Agr, Sect Mol Genet & Ind Microorganisms, NL-6703 HA Wageningen, Netherlands	University of Groningen; Wageningen University & Research	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Benen JAE, 1996, PROGR BIOTECHNOL, V14, P221, DOI 10.1016/S0921-0423(96)80257-7; Biely P, 1996, FEBS LETT, V382, P249, DOI 10.1016/0014-5793(96)00171-8; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; De Vries J, 1982, CARBOHYD POLYM, V2, P25, DOI DOI 10.1016/0144-8617(82)90043-1; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Jenkins J, 1998, J STRUCT BIOL, V122, P236, DOI 10.1006/jsbi.1998.3985; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1994, CURR OPIN STRUC BIOL, V4, P802, DOI 10.1016/0959-440X(94)90259-3; Kester HCM, 1996, EUR J BIOCHEM, V240, P738, DOI 10.1111/j.1432-1033.1996.0738h.x; KESTER HCM, 1990, BIOTECHNOL APPL BIOC, V12, P150; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lietzke SE, 1996, PLANT PHYSIOL, V111, P73, DOI 10.1104/pp.111.1.73; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; OTWINOWSKI Z, 1993, P CCP 4 STUD WEEK DA; Parenicova L, 1998, EUR J BIOCHEM, V251, P72, DOI 10.1046/j.1432-1327.1998.2510072.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Pitson SM, 1998, BIOCHEM BIOPH RES CO, V242, P552, DOI 10.1006/bbrc.1997.8009; SCHOLS HA, 1995, THESIS AGR U WAGENIN; SCHROTER KH, 1994, J MOL BIOL, V243, P351, DOI 10.1006/jmbi.1994.1660; Steinbacher S, 1996, P NATL ACAD SCI USA, V93, P10584, DOI 10.1073/pnas.93.20.10584; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Suykerbuyk MEG, 1997, APPL ENVIRON MICROB, V63, P2507, DOI 10.1128/AEM.63.7.2507-2515.1997; van Asselt EJ, 1998, ACTA CRYSTALLOGR D, V54, P58, DOI 10.1107/S0907444997010330; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; WALKINSHAW MD, 1981, J MOL BIOL, V153, P1055, DOI 10.1016/0022-2836(81)90467-8; Yang Y, 1997, RAPID COMMUN MASS SP, V11, P1257; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	46	176	182	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30474	30480		10.1074/jbc.274.43.30474	http://dx.doi.org/10.1074/jbc.274.43.30474			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521427	hybrid			2022-12-25	WOS:000083276700023
J	Hattori, K; Hatakeyama, S; Shirane, M; Matsumoto, M; Nakayama, K				Hattori, K; Hatakeyama, S; Shirane, M; Matsumoto, M; Nakayama, K			Molecular dissection of the interactions among I kappa B alpha, FWD1, and Skp1 required for ubiquitin-mediated proteolysis of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; KINASE COMPLEX; CELL-CYCLE; NEGATIVE REGULATOR; LIGASE COMPLEX; BETA-TRCP; IKK-ALPHA; PHOSPHORYLATION; DEGRADATION; SIGNAL	The SCF complex containing Skp1, Cul1, and the F-box protein FWD1 (the mouse homologue of Drosophila Slimb and Xenopus beta-TrCP) functions as the ubiquitin ligase for I kappa B alpha FWD1 associates with Skp1 through the F-box domain and also recognizes the conserved DS-GXXS motif of I kappa B alpha. The structural requirements for the interactions of FWD1 with I kappa B alpha and with Skp1 have now been investigated further. The D31A mutation (but not the G33A mutation) in the DSGXXS motif of I kappa B alpha abolished the binding of I kappa B alpha to FWD1 and its subsequent ubiquitination without affecting the phosphorylation of I kappa B alpha. The I kappa B alpha mutant D31E still exhibited binding to FWD1 and underwent ubiquitination, These results suggest that, in addition to site-specific phosphorylation at Ser(32) and Ser(36), an acidic amino acid at position 31 is required for FWD1-mediated ubiquitination of I kappa B alpha. Deletion analysis of Skp1 revealed that residues 61-143 of this protein are required for binding to FWD1, On the other hand, the highly conserved residues pro(149), ILe(160), and Leu(164) in the F-box domain of FWD1 were dispensable for binding to Skp1, Together, these data delineate the structural requirements for the interactions among I kappa B alpha, FWD1, and Skp1 that underlie substrate recognition by the SCF ubiquitin ligase complex.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, K (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.		Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Iwao K, 1999, JPN J CANCER RES, V90, P205, DOI 10.1111/j.1349-7006.1999.tb00734.x; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koch A, 1999, CANCER RES, V59, P269; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ng RWM, 1998, FEBS LETT, V438, P183, DOI 10.1016/S0014-5793(98)01299-X; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Voeller HJ, 1998, CANCER RES, V58, P2520; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	64	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29641	29647		10.1074/jbc.274.42.29641	http://dx.doi.org/10.1074/jbc.274.42.29641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514433	hybrid			2022-12-25	WOS:000083176400012
J	Ono, M; Yuasa, T; Ra, C; Takai, T				Ono, M; Yuasa, T; Ra, C; Takai, T			Stimulatory function of paired immunoglobulin-like receptor-A in mast cell line by associating with subunits common to Fc receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1C; CLASS-I MOLECULES; INHIBITORY RECEPTOR; GAMMA-CHAIN; HIGH-AFFINITY; NK CELLS; MONOCLONAL-ANTIBODY; BETA-SUBUNIT; PROTEIN; ACTIVATION	Paired Ig-like receptors (PIR) are polymorphic type I transmembrane proteins belonging to an Ig superfamily encoded by multiple isotypic genes. They are expressed on immune cells such as mast cells, macrophages, and B lymphocytes. Two subtypes of PIR have been classified according to the difference in the primary structure of the PIR transmembrane and cytoplasmic regions. These subtypes are designated as PIR-A and PIR-B. In this study, the transmembrane and cytoplasmic regions of the PIR-A subtype were shown to mediate activation signal events such as cytoplasmic calcium mobilization, protein tyrosine phosphorylations, and degranulation in rat mast cell line RBL-2H3. The association of the Fc receptor gamma and beta subunits with PIR-A was shown to be responsible for PIP-A function but not required for membrane expression of PIR-A on COS-7 cells. We further revealed the role of two charged amino acid residues in the transmembrane region, namely arginine and glutamic acid, in PIR-A function and its association with the above subunits. In contrast to the inhibitory nature of the PIR-B subtype, present findings reveal that PIR-A potentially acts as a stimulatory receptor in mast cells, suggesting a mechanism for regulation of mast cell functions by the PIR, family.	Tohoku Univ, Dept Experimental Immunol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1130033, Japan	Tohoku University; Japan Science & Technology Agency (JST); Juntendo University	Takai, T (corresponding author), Tohoku Univ, Dept Experimental Immunol, Inst Dev Aging & Canc, 4-1 Seiryo, Sendai, Miyagi 9808575, Japan.							Arase N, 1997, J EXP MED, V186, P1957, DOI 10.1084/jem.186.12.1957; Arm JP, 1997, J IMMUNOL, V159, P2342; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DREAN EL, 1998, EUR J IMMUNOL, V28, P264; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Kubagawa H, 1999, J EXP MED, V189, P309, DOI 10.1084/jem.189.2.309; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nakajima H, 1999, J IMMUNOL, V162, P5; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; Olcese L, 1996, J IMMUNOL, V156, P4531; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROUSSEAUX J, 1983, J IMMUNOL METHODS, V64, P141, DOI 10.1016/0022-1759(83)90392-7; Saito K, 1995, J ALLERGY CLIN IMMUN, V96, P1152, DOI 10.1016/S0091-6749(95)70200-8; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Torkar M, 1998, EUR J IMMUNOL, V28, P3959, DOI 10.1002/(SICI)1521-4141(199812)28:12<3959::AID-IMMU3959>3.0.CO;2-2; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Yamashita Y, 1998, J IMMUNOL, V161, P4042; Yamashita Y, 1998, J BIOCHEM-TOKYO, V123, P358, DOI 10.1093/oxfordjournals.jbchem.a021945	51	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30288	30296		10.1074/jbc.274.42.30288	http://dx.doi.org/10.1074/jbc.274.42.30288			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514523	hybrid			2022-12-25	WOS:000083176400102
J	Procopio, WN; Pelavin, PI; Lee, WMF; Yeilding, NM				Procopio, WN; Pelavin, PI; Lee, WMF; Yeilding, NM			Angiopoietin-1 and-2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS; TIE2 RECEPTOR; EGF RECEPTOR; GROWTH; BINDING; EXPRESSION; DIMERIZATION	Activity of endothelial Tie2 receptor tyrosine kinase is modulated by two naturally occurring, secreted ligands, angiopoietin-1 and -2, which have opposing effects on its phosphorylation. Receptor tyrosine kinase activation requires receptor dimerization/multimerization, which, for many receptors, is mediated by homo-oligomeric ligands binding to and bridging receptor molecules, We show here that angiopoietin-1 and -2 form distinct arrays of disulfide-linked homo-oligomeric complexes. Their mobilities on nonreducing gels suggest that angiopoiedin-2 exists predominantly as a homodimer but also forms higher order multimers. In contrast, angiopoietin-1 forms some homotrimers, but predominantly exists in higher order multimers, These two structurally related, 60% homologous ligands are predominantly composed of an amino-terminal coiled coil domain and a carboxyl-terminal fibrinogen-like domain. We show that their distinct oligomerization patterns are determined by their coiled coil domains and, furthermore, that their coiled coil domains, but not their fibrinogen-like domains, are sufficient to mediate formation of disulfide-linked homo-oligomers, In contrast, the differential effects of these ligands on endothelial Tie2 phosphorylation is mediated by their fibrinogen-like domains. We conclude from these studies that the coiled coil and fibrinogen-like domains of the angiopoietins have distinct functions with the coiled coil domain mediating ligand homo-oligomerization and the fibrinogen-like domain mediating ligand activity.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Yeilding, NM (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd,BRB 2-3,Rm 351, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047147, T32GM007170] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01956] Funding Source: Medline; NIGMS NIH HHS [T32-GM07170, GM47147] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAX I, 1991, J BIOL CHEM, V266, P13828; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Peters KG, 1998, BRIT J CANCER, V77, P51, DOI 10.1038/bjc.1998.8; Sato A, 1998, INT IMMUNOL, V10, P1217, DOI 10.1093/intimm/10.8.1217; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WEBER W, 1984, J BIOL CHEM, V259, P4631; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	35	125	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30196	30201		10.1074/jbc.274.42.30196	http://dx.doi.org/10.1074/jbc.274.42.30196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514510	hybrid			2022-12-25	WOS:000083176400089
J	Sahin-Toth, M				Sahin-Toth, M			Hereditary pancreatitis associated mutation Asn(21) -> Ile stabilizes rat trypsinogen in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SERINE PROTEINASE-INHIBITOR; CATIONIC TRYPSINOGEN; BINDING POCKET; ECOTIN; SPECIFICITY; GENE	Arg(117)--> His and Asn(21) --> Ile in human trypsinogen-I have been recently associated with hereditary pancreatitis (HP), The Arg(117) --> His substitution is believed to cause pancreatitis by stabilizing trypsin against autolytic degradation, while the mechanism of action of Asn(21) --> Ile has been unknown. In an effort to understand the effect(s) of this mutation, Thr(21) in the highly homologous rat trypsinogen-II was replaced with Asn or Ile, and the recombinant zymogens and their active trypsin forms were studied. Kinetic parameters of all three trypsins were comparable, and the active enzymes suffered autolysis at similar rates, indicating that neither catalytic properties nor proteolytic stability of trypsin are influenced by mutations at position 21, When incubated at pH 8.0, 37 degrees C, pure zymogens underwent autoactivation with concomitant trypsinolytic degradation in a Ca2+-dependent fashion. Thus, in the presence of 5 mM Ca2+, autoactivation and digestion of the zymogens after Arg(117) and Lys(188) were observed, while in the presence of 1 mM EDTA autoactivation and cleavage at Lys(188) were reduced, and zymogenolysis at the Arg(117) site was enhanced. Overall rates of zymogen degradation in [Asn(21)]- and [Ile(21)]trypsinogens were higher in Ca2+ than in EDTA, while [Thr(21)]trypsinogen demonstrated inverse characteristics. Remarkably, both in the presence and absence of Ca2+, [Ile(21)]trypsinogen exhibited significantly higher stability against autoactivation and proteolysis than zymogens with Asn(21) or Thr(21). The observations suggest that autocatalytic trypsinogen degradation may be an important defense mechanism against excessive trypsin generation in the pancreas, and trypsinogen stabilization by the Asn(21) --> Ile mutation plays a role in the pathogenesis of HP.	Univ Calif Los Angeles, HHMI, MacDonald Res Labs 5 748, Dept Physiol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Sahin-Toth, M (corresponding author), Univ Calif Los Angeles, HHMI, MacDonald Res Labs 5 748, Dept Physiol, Box 951662, Los Angeles, CA 90095 USA.							COLOMB E, 1979, BIOCHIM BIOPHYS ACTA, V570, P897; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; MAROUX S, 1969, BIOCHIM BIOPHYS ACTA, V181, P59, DOI 10.1016/0005-2795(69)90227-X; Nishimori I, 1999, GUT, V44, P259, DOI 10.1136/gut.44.2.259; Pal G, 1996, FEBS LETT, V385, P165, DOI 10.1016/0014-5793(96)00376-6; PAL G, 1994, FEBS LETT, V342, P57, DOI 10.1016/0014-5793(94)80584-9; PERRAULT J, 1994, GASTROENTEROL CLIN N, V23, P743; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SMITH RL, 1969, J BIOL CHEM, V244, P4704; Steer ML, 1998, PANCREAS, V17, P31, DOI 10.1097/00006676-199807000-00003; Teich N, 1998, HUM MUTAT, V12, P39, DOI 10.1002/(SICI)1098-1004(1998)12:1<39::AID-HUMU6>3.0.CO;2-P; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; Whitcomb David C., 1999, Pancreas, V18, P1, DOI 10.1097/00006676-199901000-00001; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141	18	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29699	29704		10.1074/jbc.274.42.29699	http://dx.doi.org/10.1074/jbc.274.42.29699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514442	hybrid			2022-12-25	WOS:000083176400021
J	Jansen, AP; Colburn, NH; Verma, AK				Jansen, AP; Colburn, NH; Verma, AK			Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation	ONCOGENE			English	Article						c-Jun; phorbol ester; TPA; ODC; cell transformation	PROTEIN KINASE-C; ALPHA-DIFLUOROMETHYLORNITHINE; MOUSE SKIN; IRREVERSIBLE INHIBITOR; INDUCED TRANSFORMATION; PHORBOL ESTERS; JB6 CELLS; RECEPTOR; MYC; 12-O-TETRADECANOYLPHORBOL-13-ACETATE	Activator protein 1 (AP-1) transactivation and ornithine decarboxylase (ODC) activity have been established as essential downstream effecters of mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA), Previous studies have shown that inhibition of either AP-1 transactivation or ODC activity suppressed tumor promoter-induced transformation. By utilizing the JB6 mouse epidermal cell system, the present study determined whether TPA-induced ODC gene expression and activity is independent of AP-1 transactivation. In three independent JB6 (P+) clones, stably expressing dominant negative c-jun, TPA-induced ODC gene expression and activity were similar compared to JB6 P+ cells expressing vector-control alone, while AP-1-dependent transcription was inhibited, Transformation-insensitive JB6 (P-) cells, which lack TPA-inducible c-jun expression, also exhibited similar induction of ODC activity by TPA. alpha-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation. Taken together, the results presented indicate that TPA-induced ODC gene expression and activity are independent of AP-1 transactivation. Because inhibition of either AP-1 or ODC precludes TPA-induced transformation, and because ODC is independent of AP-1, we propose that there are at least two pathways to transformation. Each pathway is required but not sufficient for transformation.	Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Dept Human Oncol, Madison, WI 53792 USA; NCI, Lab Biochem Physiol, Frederick, MD 21702 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Verma, AK (corresponding author), Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Dept Human Oncol, K4-532,CSC,600 Highland Ave, Madison, WI 53792 USA.				NCI NIH HHS [R01 CA42585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1983, CANCER RES, V43, P4327; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BROWN LD, 1993, HEALTH AFFAIR, V12, P8, DOI 10.1377/hlthaff.12.2.7; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Carbone PP, 1998, CANCER EPIDEM BIOMAR, V7, P907; Cmarik J.L., 1997, FOOD FACTORS CANC PR, P67, DOI [10.1007/978-4-431-67017-9_13, DOI 10.1007/978-4-431-67017-9_13]; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; GILMOUR SK, 1987, CANCER RES, V47, P1221; HSIEH JT, 1990, CANCER RES, V50, P2239; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KIM YJ, 1994, MOL CARCINOGEN, V10, P169, DOI 10.1002/mc.2940100308; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Love RR, 1998, CANCER EPIDEM BIOMAR, V7, P989; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OBrien TG, 1997, CANCER RES, V57, P2630; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Ray RM, 1999, AM J PHYSIOL-GASTR L, V276, pG773, DOI 10.1152/ajpgi.1999.276.3.G773; Reddig PJ, 1996, MOL CARCINOGEN, V17, P92, DOI 10.1002/(SICI)1098-2744(199610)17:2<92::AID-MC6>3.0.CO;2-V; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TSENG CP, 1995, MOL CELL BIOCHEM, V146, P7, DOI 10.1007/BF00926875; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028	41	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5806	5813		10.1038/sj.onc.1202965	http://dx.doi.org/10.1038/sj.onc.1202965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523861				2022-12-25	WOS:000083095100009
J	Feaver, WJ; Huang, W; Friedberg, EC				Feaver, WJ; Huang, W; Friedberg, EC			The TFB4 subunit of yeast TFIIH is required for both nucleotide excision repair and RNA polymerase II transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CONSERVED RESIDUES; ACTIVATING KINASE; FACTOR-B; MUTATIONS; GENES; TEMPERATURE; MUTANTS; DNA; CTD	The N-degron strategy has been used to generate a yeast strain harboring a temperature-sensitive allele of TFB4 (tfb4(td)), the gene that encodes the 37-kDa subunit of the transcription/repair factor TFIIH. The tfb4td strain was sensitive to UV radiation and is defective in nucleotide excision repair in vitro. The mutant strain was also found to be an inositol auxotroph due at least in part to an inability to properly induce expression of the INO1 gene. These results indicate that like other subunits of TFIIH, Tfb4 is required for both RNA polymerase II transcription and DNA repair.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA.		Huang, Wenya/G-9115-2011		NCI NIH HHS [CA12420] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archambault J, 1996, GENETICS, V142, P737; ARCHAMBAULT J, 1992, MOL GEN GENET, V232, P408, DOI 10.1007/BF00266244; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Huang WY, 1998, MUTAT RES-DNA REPAIR, V408, P183, DOI 10.1016/S0921-8777(98)00031-7; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P21; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; NONET ML, 1989, GENETICS, V123, P715; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SIKORSKI RS, 1989, GENETICS, V122, P19; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Wang ZG, 1996, MUTAT RES-DNA REPAIR, V364, P33, DOI 10.1016/0921-8777(96)00019-5; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29564	29567		10.1074/jbc.274.41.29564	http://dx.doi.org/10.1074/jbc.274.41.29564			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506223	hybrid			2022-12-25	WOS:000083017800102
J	Paul, BZS; Jin, JG; Kunapuli, SP				Paul, BZS; Jin, JG; Kunapuli, SP			Molecular mechanism of thromboxane A(2)-induced platelet aggregation - Essential role for P2T(AC) and alpha(2A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROSTAGLANDIN ENDOPEROXIDE ANALOGS; INTEGRIN-ASSOCIATED PROTEIN; HUMAN-BLOOD PLATELETS; BINDING-SITES; INTRACELLULAR CALCIUM; DEFECTIVE INTERACTION; FIBRINOGEN RECEPTORS; THROMBIN RECEPTORS; PHYSIOLOGICAL-ROLE	Thromboxane A, is a positive feedback Lipid mediator produced following platelet activation. The G(q)-coupled thromboxane A(2) receptor subtype, TP alpha, and G(i)-coupled TP beta subtype have been shown in human platelets. ADP-induced platelet aggregation requires concomitant signaling hom two P2 receptor subtypes, P2Y1 and P2T(AC), coupled to G(q) and G(i) respectively. me investigated whether the stable thromboxane A(2) mimetic, (15S)-hydroxy-9,11-epoxymethanoprosta-5Z,13E-dienoic acid (U46619), also causes platelet aggregation by concomitant signaling through G(q) and G(i), through cc-activation of TP alpha and TP beta receptor subtypes. Here we report that secretion blockade with Ro 31-8220, a protein kinase C inhibitor, completely inhibited U46619-induced, but not ADP- or thrombin-induced, platelet aggregation. Ro 31-8220 had no effect on U46619-induced intracellular calcium mobilization or platelet shape change. Furthermore, U46619-induced intracellular calcium mobilization and shape change were unaffected by A3P5P, a P2Y1 receptor-selective antagonist, and/or cyproheptadine, a 5-hydroxytryptamine subtype 2A receptor antagonist. Either Ro 31-8220 or AR-C66096, a P2T(AC) receptor selective antagonist, abolished U46619-induced inhibition of adenylyl cyclase. In addition, AR-C66096 drastically inhibited U46619-mediated platelet aggregation, which was further inhibited by yohimbine, an alpha(2A)-adrenergic receptor antagonist Furthermore, inhibition of U46619-induced platelet aggregation by Ro 31-8220 was relieved by activation of the G(i) pathway by selective activation of either the P2T(AC) receptor or the alpha(2A)-adrenersc receptor. We conclude that whereas thromboxane A(2) causes intracellular calcium mobilization and shape change independently, thromboxane A(2)-induced inhibition of adenylyl cyclase and platelet aggregation depends exclusively upon secretion of other agonists that stimulate G(i)-coupled receptors.	Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Sch Med, Dept Physiol, 3420 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL60683] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVDONIN PV, 1985, THROMB RES, V40, P101, DOI 10.1016/0049-3848(85)90354-8; BERLIN I, 1991, CLIN PHARMACOL THER, V49, P362, DOI 10.1038/clpt.1991.42; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BRESSLER NM, 1979, BLOOD, V53, P167; CATTANEO M, 1992, BLOOD, V80, P2787; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; CLAESSON HE, 1977, EUR J BIOCHEM, V76, P277, DOI 10.1111/j.1432-1033.1977.tb11593.x; COSTA JL, 1975, NATURE, V255, P407, DOI 10.1038/255407a0; DANGELO DD, 1994, J PHARMACOL EXP THER, V271, P1034; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DECLERCK F, 1982, AGENTS ACTIONS, V12, P388; Dorahy DJ, 1997, J BIOL CHEM, V272, P1323, DOI 10.1074/jbc.272.2.1323; DORN GW, 1989, J CLIN INVEST, V84, P1883, DOI 10.1172/JCI114375; EDWARDS RJ, 1987, BRIT J PHARMACOL, V90, P501, DOI 10.1111/j.1476-5381.1987.tb11199.x; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; FUNK CD, 1993, MOL PHARMACOL, V44, P934; GIESBERTS AN, 1995, BIOCHEM J, V309, P613, DOI 10.1042/bj3090613; GLUSA E, 1984, BIOMED BIOCHIM ACTA, V43, P215; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HASLAM RJ, 1975, MOL PHARMACOL, V11, P528; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; Jantzen HM, 1999, THROMB HAEMOSTASIS, V81, P111; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; KAWAHARA Y, 1986, THROMB RES, V41, P811, DOI 10.1016/0049-3848(86)90379-8; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Levy-Toledano S, 1998, THROMB HAEMOSTASIS, V80, P463; MALMSTEN C, 1975, P NATL ACAD SCI USA, V72, P1446, DOI 10.1073/pnas.72.4.1446; MORINELLI TA, 1983, BLOOD, V61, P41; MORINELLI TA, 1987, AM J PHYSIOL, V253, pH1035, DOI 10.1152/ajpheart.1987.253.5.H1035; MYLECHARANE EJ, 1989, CLIN EXP PHARMACOL P, V16, P517, DOI 10.1111/j.1440-1681.1989.tb01598.x; MYLECHARANE EJ, 1991, J NEUROL, V238, P45; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; NURDEN P, 1995, J CLIN INVEST, V95, P1612, DOI 10.1172/JCI117835; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PERIYASAMY SM, 1985, EUR J PHARMACOL, V116, P17, DOI 10.1016/0014-2999(85)90180-3; Pulcinelli FM, 1998, FEBS LETT, V435, P115, DOI 10.1016/S0014-5793(98)01049-7; PULCINELLI FM, 1995, FEBS LETT, V364, P87, DOI 10.1016/0014-5793(95)00352-A; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rotondo S, 1997, THROMB HAEMOSTASIS, V78, P919; SAGE SO, 1992, FEBS LETT, V298, P199, DOI 10.1016/0014-5793(92)80056-M; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; Shen RF, 1998, J BIOMED SCI, V5, P153, DOI 10.1007/BF02253465; SHENKER A, 1991, J BIOL CHEM, V266, P9309; Sloan DC, 1997, BIOCHEM J, V328, P13; SMITH JB, 1990, ANAL BIOCHEM, V187, P173, DOI 10.1016/0003-2697(90)90437-E; Soslau G, 1997, BBA-MOL CELL RES, V1355, P131, DOI 10.1016/S0167-4889(96)00123-1; SOSLAU G, 1993, BIOCHIM BIOPHYS ACTA, V1177, P199, DOI 10.1016/0167-4889(93)90041-M; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003	61	228	233	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29108	29114		10.1074/jbc.274.41.29108	http://dx.doi.org/10.1074/jbc.274.41.29108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506165	hybrid			2022-12-25	WOS:000083017800044
J	Luscher-Firzlaff, JM; Westendorf, JM; Zwicker, J; Burkhardt, H; Henriksson, M; Muller, R; Pirollet, F; Luscher, B				Luscher-Firzlaff, JM; Westendorf, JM; Zwicker, J; Burkhardt, H; Henriksson, M; Muller, R; Pirollet, F; Luscher, B			Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation	ONCOGENE			English	Article						HFH-11; HPV; trident; WIN; winged helix	KINASE-II PHOSPHORYLATION; M-PHASE PHOSPHOPROTEINS; TYPE-16 E7; DNA-BINDING; HUMAN KERATINOCYTES; TRANSGENIC MICE; FACTOR TRIDENT; CELL-CYCLE; HPV-16 E7; HPV16 E7	The high risk human papillomavirus (HPV) type 16 E7 protein affects cell growth control and promotes transformation by interfering with functions of cellular proteins. A keg target of E7 is the tumor suppressor protein p105RB. Although this interaction is required for E7-dependent transformation, other cellular molecules must also be involved, because some E7 mutants that have reduced transforming abilities still bind to p10RB. In order to identify additional proteins that interact with E7 and that may be responsible to mediate its transforming function, we have used the C-terminal half of E7 in a yeast two-hybrid screen. We identified the fork head domain transcription factor hi phase phosphoprotein 2 (MPP2) as an interaction partner of E7, Specific interaction of the tno proteins both in ratio and in vivo in mammalian cells was detected. The interaction of MPP2 with E7 is functionally relevant since MPP2 enhances the E7/Ha-Ras co-transformation of rat embryo fibroblasts. In addition HPV16 E7, but neither non-transforming mutants of HPV16 E7 nor low risk HPV6 E7, was able to stimulate MPP2-specific transcriptional activity. Thus, MPP2 is a potentially important target for E7-mediated transformation.	Med Hsch Hannover, Inst Molekularbiol, D-30625 Hannover, Germany; CEA Grenoble, Lab Cytosquelette, DBMS, INSERM,U366, F-38054 Grenoble 9, France; Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany	Hannover Medical School; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Philipps University Marburg	Luscher-Firzlaff, JM (corresponding author), Med Hsch Hannover, Inst Molekularbiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Müller, Rolf/L-4997-2016; Pirollet, Fabienne/L-3088-2013; Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Müller, Rolf/0000-0003-3339-4248; Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BANKS L, 1990, ONCOGENE, V5, P1383; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DEVILLIERS EM, 1981, J VIROL, V40, P932, DOI 10.1128/JVI.40.3.932-935.1981; DIPAOLO JA, 1989, ONCOGENE, V4, P395; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FIRZLAFF JM, 1987, CANCER CELL, V5, P105; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDENT C, 1995, ONCOGENE, V10, P1789; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Massimi P, 1996, ONCOGENE, V12, P2325; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MAZZARELLI JM, 1995, ONCOGENE, V11, P1859; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MITELMAN F, 1994, CATALOG CHROMOSOME A; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUNGER K, 1989, J VIROL, V63, P4417; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 1996, ONCOGENE, V12, P213; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	78	91	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5620	5630		10.1038/sj.onc.1202967	http://dx.doi.org/10.1038/sj.onc.1202967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523841				2022-12-25	WOS:000083016500002
J	Haroon, ZA; Hettasch, JM; Lai, TS; Dewhirst, MW; Greenberg, CS				Haroon, ZA; Hettasch, JM; Lai, TS; Dewhirst, MW; Greenberg, CS			Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis	FASEB JOURNAL			English	Article						tissue repair; extracellular matrix; cross-linking; endothelial cells; TGF-beta	CROSS-LINKING; FACTOR-XIII; II TRANSGLUTAMINASE; BINDING-PROTEIN; CELLS; FIBRONECTIN; FIBRINOGEN; STABILIZATION; DERIVATIVES; PUTRESCINE	Tissue transglutaminase (TG) is an enzyme that stabilizes the structure of tissues by covalently ligating extracellular matrix molecules, Expression and localization of TG are not well established during wound healing; We performed punch biopsy wounds on anesthetized rats and monitored the wound healing process by histological and immunohistochemical methods. The TG antigen and activity are expressed at sites of neovascularization in the provisional fibrin matrix within 24 h of wounding. Endothelial cells, macrophages, and skeletal muscle cells expressed TG throughout the healing process. The TG antigen within the wound was active in vivo based on the detection of isopeptide bonds. The TG antigen increased four- to fivefold by day 3 postwounding and was proteolytically degraded, TG expression occurred in association with TGF-beta, TNF-alpha, IL-6, and VEGF production in the wound. Recombinant TG increased vessel length density (a measure of angiogenesis) when applied topically in rat dorsal skin flap window chambers. We have established that TG is an important tissue stabilizing enzyme that is active during wound healing and can function to promote angiogenesis.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Greenberg, CS (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 2603,MSRB, Durham, NC 27710 USA.	green032@mc.duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; , Thung-Shen/0000-0002-8791-9698	NATIONAL CANCER INSTITUTE [P50CA068438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P50HL026309] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA 68438] Funding Source: Medline; NHLBI NIH HHS [HL 26309, HL 38245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achyuthan KE, 1996, MOL CELL BIOCHEM, V162, P43; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BOWNESS JM, 1988, BIOCHIM BIOPHYS ACTA, V967, P234; BOWNESS JM, 1987, CONNECT TISSUE RES, V16, P57, DOI 10.3109/03008208709001994; CLARK RAF, 1993, DERMATOL CLIN, V11, P647, DOI 10.1016/S0733-8635(18)30218-3; COHEN I, 1982, J CELL BIOL, V93, P775, DOI 10.1083/jcb.93.3.775; DEWHIRST MW, 1992, RADIAT RES, V130, P345, DOI 10.2307/3578380; DOLYNCHUK KN, 1994, PLAST RECONSTR SURG, V93, P567, DOI 10.1097/00006534-199493030-00020; ELALAOUI S, 1993, FACTOR, V8, P135; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; GIBRAN NS, 1995, J SURG RES, V59, P378, DOI 10.1006/jsre.1995.1179; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IKURA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1540, DOI 10.1271/bbb.58.1540; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Jones LN, 1996, DERMATOL CLIN, V14, P633, DOI 10.1016/S0733-8635(05)70390-9; Kong LP, 1997, CLIN EXP METASTAS, V15, P426, DOI 10.1023/A:1018406422727; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; LAI TS, 1994, J BIOL CHEM, V269, P24596; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; ROCH AM, 1991, INT J CANCER, V48, P215, DOI 10.1002/ijc.2910480211; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; Sheehan D.C., 1980, THEORY PRACTICE HIST; VALENZUELA R, 1992, AM J PATHOL, V141, P861; VOLLBERG TM, 1992, AM J RESP CELL MOL, V7, P10, DOI 10.1165/ajrcmb/7.1.10; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583	39	210	217	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1787	1795		10.1096/fasebj.13.13.1787	http://dx.doi.org/10.1096/fasebj.13.13.1787			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506581				2022-12-25	WOS:000083063400013
J	Wong, KS; Li, YJ; Howard, J; Ben-David, Y				Wong, KS; Li, YJ; Howard, J; Ben-David, Y			Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence	ONCOGENE			English	Article						Friend leukemia; p53; Epo; immortalization; genetic instability	WILD-TYPE P53; MURINE LEUKEMIA-VIRUS; FRIEND-VIRUS; P53-DEFICIENT MICE; GENE AMPLIFICATION; TRANSGENIC MICE; ALLELIC LOSSES; CELL-LINES; MUTANT P53; C-MYC	Erythroleukemias induced by Friend Murine Leukemia Virus (F-MuLV) involve the insertional activation of the proto-oncogene Fli-1, and the inactivation of the p53 tumor suppressor gene. While the activation of Fli-1 is an early, primary transforming event, p53 mutations are correlated with the immortalization of erythroleukemic cells in culture. In this study we have further analysed the role of p53 loss in F-MuLV induced erythroleukemias by examining the progression of this disease in p53 deficient mice. We found that p53-/- mice succumb to the disease more rapidly than p53+/+ littermates. Additionally, of the 112 tumors generated, 19 gave rise to immortal cell lines, eight of which were derived from p53-/- mice, and ten of which were from p53+/- mice. The ability of these primary tumor cells to grow in culture was associated with the complete loss of wildtype p53 in these cell lines. However, cells from many of the tumors induced in p53-/- hosts did not survive in vitro. These results suggest that the loss of p53 does not directly immortalize tumor cells. Instead, we have evidence to suggest that the loss of p53 promotes the accumulation of mutations that are required for survival in culture and that are capable of accelerating tumor progression in vivo. Indeed, mutations causing expression of the growth factor gene erythropoietin (Epo), were detected in two of seven Epo-independent cell lines from p53 deficient primary erythroleukemias, Moreover, the mechanism of activation of the Epo gene in one of these two Epo-independent cell lines involved genomic rearrangement, that is a hallmark of genetic instability. We propose that, in F-MuLV induced-erythroleukemias, p53 loss may encourage the accumulation of further mutations, subsequently conferring a growth advantage and immortality to the transformed erythroblasts.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol, 2075 Bayview Ave,Res Bldg,S Wing,S-218, Toronto, ON M4N 3M5, Canada.							BAKER SJ, 1990, CANCER RES, V50, P7717; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DREYFUS F, 1990, LEUKEMIA, V4, P590; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KABAT D, 1990, CURR TOP MICROBIOL I, V148, P1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; OKAMOTO A, 1991, CANCER RES, V51, P5171; PURDIE CA, 1994, ONCOGENE, V9, P603; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105; WILLIAMS AC, 1995, ONCOGENE, V11, P141; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5525	5534		10.1038/sj.onc.1202938	http://dx.doi.org/10.1038/sj.onc.1202938			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523829				2022-12-25	WOS:000082894700005
J	Mariottini, P; Shah, ZH; Toivonen, JM; Bagni, C; Spelbrink, JN; Amaldi, F; Jacobs, HT				Mariottini, P; Shah, ZH; Toivonen, JM; Bagni, C; Spelbrink, JN; Amaldi, F; Jacobs, HT			Expression of the gene for mitoribosomal protein S12 is controlled in human cells at the levels of transcription, RNA splicing, and translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; OPEN READING FRAME; MESSENGER-RNA; XENOPUS-LAEVIS; NUCLEAR GENES; EVOLUTIONARY CONSERVATION; 5'-UNTRANSLATED REGION; MITOCHONDRIAL GENOME; RIBOSOMAL-PROTEINS; ESCHERICHIA-COLI	The human gene RPMS12 encodes a protein similar to bacterial ribosomal protein S12 and is proposed to represent the human mitochondrial orthologue, RPMS12 reporter gene expression in cultured human cells supports the idea that the gene product is mitochondrial and is localized to the inner membrane. Human cells contain at least four structurally distinct RPMS12 mRNAs that differ in their 5'-untranslated region (5'-UTR) as a result of alternate splicing and of 5' end heterogeneity. All of them encode the same polypeptide, The full 5'-UTR contains two types of sequence element implicated elsewhere in translational regulation as follows: a short upstream open reading frame and an oligopyrimidine tract similar to that found at the 5' end of mRNAs encoding other growth-regulated proteins, including those of cytosolic ribosomes, The fully spliced (short) mRNA is the predominant form in all cell types studied and is translationally down-regulated in cultured cells in response to serum starvation, even though it lacks both of the putative translational regulatory elements. By contrast, other splice variants containing one or both of these elements are not translationally regulated by growth status but are translated poorly in both growing and non-growing cells. Reporter analysis identified a 26-nucleotide tract of the 5'-UTR of the short mRNA that is essential for translational down-regulation in growth-inhibited cells. Such experiments also confirmed that the 5'-UTR of the longer mRNA variants contains negative regulatory elements for translation. Tissue representation of RPMS12 mRNA is highly variable, following a typical mitochondrial pattern, but the relative levels of the different splice variants are similar in different tissues. These findings indicate a complex, multilevel regulation of RPMS12 gene expression in response to signals mediating growth, tissue specialization, and probably metabolic needs.	Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, FIN-33101 Tampere, Finland; Univ Roma Tor Vergata, Dept Biol, I-00146 Rome, Italy; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Tampere University; Tampere University; Tampere University Hospital; University of Rome Tor Vergata; University of Glasgow	Jacobs, HT (corresponding author), Univ Tampere, Inst Med Technol, POB 607, FIN-33101 Tampere, Finland.	howy.jacobs@uta.fi	Shah, Zahid/G-9410-2014; Spelbrink, Johannes N/L-4661-2015; Toivonen, Janne M./E-5691-2011; Jacobs, Howard T/G-2434-2011	Shah, Zahid/0000-0001-7165-8780; Spelbrink, Johannes N/0000-0002-9756-2602; Toivonen, Janne M./0000-0002-7243-1737; Bagni, Claudia/0000-0002-4419-210X; Jacobs, Howard/0000-0003-1895-6003				AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; Amaldi F, 1995, BIOCHEM CELL BIOL, V73, P969, DOI 10.1139/o95-104; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BAGNI C, 1992, MOL GEN GENET, V234, P60, DOI 10.1007/BF00272345; BAGNI C, 1993, BIOCHIM BIOPHYS ACTA, V1216, P475, DOI 10.1016/0167-4781(93)90017-8; BYRNE PC, 1995, BIOCHEM BIOPH RES CO, V214, P496, DOI 10.1006/bbrc.1995.2314; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; CARDINALI B, 1993, NUCLEIC ACIDS RES, V21, P2301, DOI 10.1093/nar/21.10.2301; Choi HS, 1996, MOL CELLS, V6, P615; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Duga S, 1999, EUR J BIOCHEM, V259, P188, DOI 10.1046/j.1432-1327.1999.00029.x; Fewell SW, 1999, MOL CELL BIOL, V19, P826; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FREEDMAN LP, 1987, P NATL ACAD SCI USA, V84, P6516, DOI 10.1073/pnas.84.18.6516; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Ghilardi N, 1998, BLOOD, V92, P4023, DOI 10.1182/blood.V92.11.4023.423k54_4023_4030; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GROHMANN L, 1992, NUCLEIC ACIDS RES, V20, P5641, DOI 10.1093/nar/20.21.5641; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; Harigai M, 1996, ONCOGENE, V12, P1369; HAUSWIRTH WW, 1987, MITOCHONDRIA PRACTIC, P176; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Linz B, 1997, J BIOL CHEM, V272, P9131; Loreni F, 1997, FEBS LETT, V416, P239, DOI 10.1016/S0014-5793(97)01209-X; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Maffey L, 1997, MOL GEN GENET, V254, P365, DOI 10.1007/s004380050428; Marty L, 1997, GENOMICS, V41, P453, DOI 10.1006/geno.1997.4691; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas Oded, 1996, P65; Meyuhas Oded, 1996, V30, P363; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; PELLETIER J, 1988, MOL CELL BIOL, V8, P1103, DOI 10.1128/MCB.8.3.1103; PERROTTA G, 1996, MOL GEN GENET, V251, P327; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAGAN CI, 1987, MITOCHONDRIA PRACTIC, P80; RAPANOTTI MC, 1995, GENE, V154, P199, DOI 10.1016/0378-1119(94)00873-Q; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHATZ G, 1986, ANN REV CELL BIOL, V4, P289; Shah ZH, 1998, GENOMICS, V48, P384, DOI 10.1006/geno.1997.5166; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; YIU GK, 1994, NUCLEIC ACIDS RES, V22, P4599, DOI 10.1093/nar/22.22.4599; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773	58	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31853	31862		10.1074/jbc.274.45.31853	http://dx.doi.org/10.1074/jbc.274.45.31853			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542210	Green Published, hybrid			2022-12-25	WOS:000083532100018
J	Zhan, DJ; Santin, AD; Liu, Y; Parham, GP; Li, CL; Meyers, C; Hermonat, PL				Zhan, DJ; Santin, AD; Liu, Y; Parham, GP; Li, CL; Meyers, C; Hermonat, PL			Binding of the human papillomavirus type 16 p97 promoter by the adeno-associated virus Rep78 major regulatory protein correlates with inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ADENOASSOCIATED VIRUS; BOVINE PAPILLOMAVIRUS; GENE-PRODUCT; DNA-BINDING; IN-VITRO; MUTATIONAL ANALYSIS; HUMAN PARVOVIRUS; HERPES-SIMPLEX; REP68 PROTEIN	Human papillomavirus type 16 (HPV-16) infection is positively associated with cervical cancer, whereas adeno-associated virus (AAV) infection is negatively associated with this same cancer. In earlier studies these two virus types have been shown to directly interact, with AAV inhibiting or enhancing papillomavirus functions depending upon the specific circumstances. One defined interaction between these two viruses is the ability of the AAV Rep78 major regulatory protein to inhibit gene expression of the E6 promoter of BPV-1 (bovine papillomavirus type 1) and HPV types 16 and 18, As Rep78 is a DNA binding transcription factor, we considered whether Rep78 might bind HPV-16 DNA. Here, Rep78 is demonstrated to bind a 44-base pair region (nucleotides 14-56) within the HPV-16 p97 promoter using the electrophoretic mobility shift assay. This region is important for HPV-16 because it includes functional Spl and E2 protein binding motifs as well as part of the origin of replication. Furthermore, two Rep78 amino acid substitution mutants, at positions 77 or 64-65, were identified that did not recognize p97 DNA, Both of these Rep78 mutants were found to be defective for inhibition of p97 promoter activity in HeLa and T-47D nuclear extracts in vitro, in a transient chloramphenicol acetyltransferase assay, as well as defective for full inhibition of HPV-16-directed focus formation. These data, taken together, strongly suggest that the Rep78-p97 promoter interaction is at least partially responsible for Rep78-mediated inhibition of HPV-16, Finally, the finding that Rep78 specifically recognizes p97 DNA is surprising because the p97 promoter region contains no GAGC motifs, the core motif for Rep78 recognition. These data suggest that the p97 promoter may represent a new prototypical DNA target type for Rep78.	Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72205 USA; Penn State Univ, Coll Med, Dept Immunol & Microbiol, Hershey, PA 17033 USA	University of Arkansas System; University of Arkansas Medical Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Hermonat, PL (corresponding author), Univ Arkansas Med Sci, Dept Obstet & Gynecol, Slot 518,4301 W Markham St, Little Rock, AR 72205 USA.				NCI NIH HHS [CA55051] Funding Source: Medline; PHS HHS [IA42764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; BANTELSCHAAL U, 1984, VIROLOGY, V134, P52, DOI 10.1016/0042-6822(84)90271-X; BATCHU RB, 1995, BIOCHEM BIOPH RES CO, V210, P717, DOI 10.1006/bbrc.1995.1718; BATCHU RB, 1994, CANCER LETT, V86, P23, DOI 10.1016/0304-3835(94)90176-7; BATCHU RB, 1995, BIOCHEM BIOPH RES CO, V208, P714, DOI 10.1006/bbrc.1995.1396; BATCHU RB, 1995, FEBS LETT, V367, P267, DOI 10.1016/0014-5793(95)00584-V; Bishop BM, 1996, FEBS LETT, V397, P97, DOI 10.1016/S0014-5793(96)01149-0; BLACKLOW NR, 1967, P NATL ACAD SCI USA, V58, P1410, DOI 10.1073/pnas.58.4.1410; CHIORINI JA, 1995, J VIROL, V69, P7334, DOI 10.1128/JVI.69.11.7334-7338.1995; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GEORGFRIES B, 1984, VIROLOGY, V134, P64, DOI 10.1016/0042-6822(84)90272-1; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Han L, 1996, VIRUS GENES, V12, P47, DOI 10.1007/BF00370000; HERMONAT PL, 1991, CANCER RES, V51, P3373; HERMONAT PL, 1992, VIROLOGY, V189, P329, DOI 10.1016/0042-6822(92)90710-7; Hermonat PL, 1997, GYNECOL ONCOL, V66, P487, DOI 10.1006/gyno.1997.4789; HERMONAT PL, 1994, CANCER LETT, V81, P129, DOI 10.1016/0304-3835(94)90193-7; Hermonat PL, 1997, FEBS LETT, V401, P180, DOI 10.1016/S0014-5793(96)01469-X; HERMONAT PL, 1994, CANCER RES, V54, P2278; Hermonat PL, 1998, VIROLOGY, V245, P120, DOI 10.1006/viro.1998.9144; Hermonat PL, 1996, CANCER RES, V56, P5299; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; Hermonat PL, 1998, VIROLOGY, V247, P240, DOI 10.1006/viro.1998.9256; HERMONAT PL, 1989, VIROLOGY, V172, P258; HERMONAT PL, 1997, BIOCHEM MOL BIOL INT, V403, P409; HOPPESEYLER F, 1993, J GEN VIROL, V74, P281, DOI 10.1099/0022-1317-74-2-281; HORER M, 1995, J VIROL, V69, P5485; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; KATZ E, 1986, CANCER RES, V46, P3023; KHLEIF SN, 1991, VIROLOGY, V181, P738, DOI 10.1016/0042-6822(91)90909-U; KLEINBAUERNSCHM.P, 1992, J VIROL, V66, P419; Kokorina N A, 1998, J Hum Virol, V1, P441; KYOSTIO SRM, 1995, J VIROL, V69, P6787; LABOW MA, 1986, J VIROL, V60, P251, DOI 10.1128/JVI.60.1.251-258.1986; MAYOR HD, 1976, AM J OBSTET GYNECOL, V126, P100, DOI 10.1016/0002-9378(76)90472-5; MCCARTY DM, 1994, J VIROL, V68, P4988, DOI 10.1128/JVI.68.8.4988-4997.1994; MENDELSON E, 1986, J VIROL, V60, P823, DOI 10.1128/JVI.60.3.823-832.1986; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; NI TH, 1994, J VIROL, V68, P1128, DOI 10.1128/JVI.68.2.1128-1138.1994; Pereira DJ, 1997, J VIROL, V71, P1747, DOI 10.1128/JVI.71.3.1747-1756.1997; RITTNER K, 1992, J GEN VIROL, V73, P2977, DOI 10.1099/0022-1317-73-11-2977; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; SAMULSKI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P2077, DOI 10.1073/pnas.79.6.2077; SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421; SCHMITT J, 1989, VIROLOGY, V172, P73, DOI 10.1016/0042-6822(89)90108-6; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Smith RH, 1997, J VIROL, V71, P4461, DOI 10.1128/JVI.71.6.4461-4471.1997; Su PF, 1996, BRIT J CANCER, V73, P1533, DOI 10.1038/bjc.1996.289; TOBIASCH E, 1994, J MED VIROL, V44, P215, DOI 10.1002/jmv.1890440218; TRATSCHIN JD, 1985, MOL CELL BIOL, V5, P3251, DOI 10.1128/MCB.5.11.3251; TRATSCHIN JD, 1984, J VIROL, V51, P611, DOI 10.1128/JVI.51.3.611-619.1984; Walz C, 1997, J GEN VIROL, V78, P1441, DOI 10.1099/0022-1317-78-6-1441; Weitzman MD, 1996, J VIROL, V70, P2440, DOI 10.1128/JVI.70.4.2440-2448.1996; Wonderling RS, 1997, J VIROL, V71, P2528, DOI 10.1128/JVI.71.3.2528-2534.1997; Wonderling RS, 1996, J VIROL, V70, P4783, DOI 10.1128/JVI.70.7.4783-4786.1996; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	59	28	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31619	31624		10.1074/jbc.274.44.31619	http://dx.doi.org/10.1074/jbc.274.44.31619			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531369	hybrid			2022-12-25	WOS:000083379400073
J	Abe, R; Whitehead, IP; O'Bryan, JP; Der, CJ				Abe, R; Whitehead, IP; O'Bryan, JP; Der, CJ			Involvement of NH2-terminal sequences in the negative regulation of Vav signaling and transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; DBL ONCOGENE PRODUCT; CYCLIN D1 PROMOTER; RHO-FAMILY; PROTOONCOGENE PRODUCT; RAS TRANSFORMATION; GENE-EXPRESSION; C-JUN; ACTIVATION	Deletion of the NH2-terminal 65 amino acids of proto-Vav (to form onco-Vav) activates its transforming activity, suggesting that these sequences serve a negative regulatory role in Vav function. However, the precise role of these NH2-terminal sequences and whether additional NH2-terminal sequences are also involved in negative regulation have not been determined. Therefore, we generated additional NH2-terminal deletion mutants of proto-Vav that lack the NH2-terminal 127, 168, or 186 amino acids, and assessed their abilities to cause focus formation in NIH 3T3 cells and to activate different signaling pathways. Since Vav mutants lacking 168 or 186 NH2-terminal residues showed a several 100-fold greater focus forming activity than that seen with deletion of 65 residues, residues spanning 66 to 187 also contribute significantly to negative regulation of Vav transforming activity. The increase in Vav transforming activity correlated with the activation of the c-Jun, Elk-1, and NF-kappa B transcription factors, as well as increased transcription from the cyclin D1 promoter. Tyrosine 174 is a key site of phosphorylation by Lck in vitro and Lck-mediated phosphorylation has been shown to be essential for proto-Vav GEF function in vitro. However, we found that an NH2-terminal Vav deletion mutant lacking this tyrosine residue (Delta N-186 Vav) retained the ability to be phosphorylated by Lck in vivo and Lck still caused enhancement of Delta N-186 Vav signaling and transforming activity. Thus, Lck can stimulate Vav via a mechanism that does not involve Tyr(174) Or removal of NH2-terminal regulatory activity. Finally, we found that NH2-terminal deletion enhanced the degree of Vav association with the membrane-containing particulate fraction and that an isolated NH2-terminal fragment (residues 1-186) could impair Delta N-186 Vav signaling. Taken together, these observations suggest that the NH2 terminus may serve as a negative regulator of Vav by intramolecular interaction with COOH-terminal sequences to modulate efficient membrane association.	Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747; O'Bryan, John/0000-0001-5386-1080	NCI NIH HHS [CA55008, CA63071, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978, R01CA063071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1995, METHOD ENZYMOL, V255, P195; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Gimona M, 1998, CURR BIOL, V8, pR674; GRAZIANI G, 1989, ONCOGENE, V4, P823; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RON D, 1989, ONCOGENE, V4, P1067; Schuebel KE, 1996, ONCOGENE, V13, P363; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WHITEHEAD IP, 1999, IN PRESS MOL CELL BI; WRIGHT DD, 1994, MOL CELL BIOL, V14, P2429, DOI 10.1128/MCB.14.4.2429; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	55	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30410	30418		10.1074/jbc.274.43.30410	http://dx.doi.org/10.1074/jbc.274.43.30410			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521418	hybrid			2022-12-25	WOS:000083276700014
J	Bernatchez, PN; Soker, S; Sirois, MG				Bernatchez, PN; Soker, S; Sirois, MG			Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; TYROSINE KINASE; BINDING-SITES; ANTISENSE OLIGONUCLEOTIDES; SIGNAL-TRANSDUCTION; AFFINITY BINDING; IN-VITRO; C-MYC; RECEPTORS; EXPRESSION	Vascular endothelial growth factor (VEGF) is a potent inducer of endothelial cell (EC) proliferation and migration in vitro as well as inflammation in vivo. We showed recently that VEGF effect on vascular permeability was dependent on the synthesis of platelet-activating factor (PAF) by EC, Consequently, we sought to evaluate by antisense knockdown of gene expression the contribution of VEGF receptors (Flt-1 and Flk-1) on these events. VEGF (10(-11) to 10(-8) M) elicited a dose-dependent increase of bovine aortic EC proliferation, migration, and PAF synthesis by up to 2.05-, 1.31- and 35.9-fold above basal levels, respectively. A treatment with two modified antisense oligomers (1-5 x 10(-7) M) directed against Flk-1 mRNA blocked by 100, 91, and 85% the proliferation, migration, and PAF synthesis mediated by VEGF, respectively. A treatment with two antisense oligomers directed against Flt-1 mRNA failed to modulate these activities. The use of placenta growth factor (up to 10(-8) M), an Flt-1-specific agonist, induced only a slight increase (0.6-fold) of PAF synthesis. These data illustrate the crucial role of Flk-1 in EC stimulation by VEGF. The capacity to inhibit the protein synthesis of Flt-1 and Flk-1 by antisense oligonucleotides provides a new approach to block VEGF pathological effects in vivo.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Montreal Heart Inst, Dept Pharmacol, Montreal, PQ H1T 1C8, Canada; Childrens Hosp, Dept Urol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Universite de Montreal; Universite de Montreal; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sirois, MG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belangor St, Montreal, PQ H1T 1C8, Canada.							BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EDELMAN ER, 1995, CIRC RES, V76, P176, DOI 10.1161/01.RES.76.2.176; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gilbert RE, 1998, LAB INVEST, V78, P1017; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mochida S, 1996, BIOCHEM BIOPH RES CO, V226, P176, DOI 10.1006/bbrc.1996.1329; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAVINDRATH N, 1992, ENDOCRINOLOGY, V94, P1192; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sharma H S, 1992, EXS, V61, P255; SHIBUYA M, 1990, ONCOGENE, V5, P519; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V34, P1578; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454	47	229	244	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31047	31054		10.1074/jbc.274.43.31047	http://dx.doi.org/10.1074/jbc.274.43.31047			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521504	hybrid			2022-12-25	WOS:000083276700100
J	Hu, CY; Chen, W; Frasch, WD				Hu, CY; Chen, W; Frasch, WD			Metal ligation by Walker Homology B aspartate beta D262 at site 3 of the latent but not activated form of the chloroplast F-1-ATPase from Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ESCHERICHIA-COLI F1-ATPASE; NUCLEOTIDE BINDING-SITES; TIGHTLY BOUND ADP; CATALYTIC SITES; DIRECTED MUTAGENESIS; ADENYLATE KINASE; ATP SYNTHASE; COORDINATION; SUBUNITS	Site-directed mutations D262C, D262H, D262N, and D262T were made to the beta subunit Walker Homology B aspartate of chloroplast F-1-ATPase in Chlamydomonas, Photoautotrophic growth and photophosphorylation rates were 3-14% of wild type as were ATPase activities of purified chloroplast F-1 indicating that beta D262 is an essential residue for catalysis, The EPR spectrum of vanadyl bound to Site 3 of chloroplast F-1 as VO2+-ATP gave rise to two EPR species designated B and C in wild type and mutants. V-51-hyperfine parameters of species C, present exclusively in the activated enzyme state, did not change significantly by the mutations examined indicating that it is not an equatorial ligand to VO2+, nor is it hydrogen-bonded to a coordinated water at an equatorial position. Every mutation changed the ratio of EPR species C/B and/or the V-51-hyperfine parameters of species B, the predominant conformation of VO2+-nucleotide bound to Site 3 in the latent (down-regulated) state. The results indicate that the Walker Homology B aspartate coordinates the metal of the predominant metal-nucleotide conformation at Site 3 in the latent state but not in the conformation present exclusively upon activation and elucidates one of the specific changes in metal ligation involved with activation.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Grad Program Mol & Cellular Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Frasch, WD (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.				NIGMS NIH HHS [GM50202, R01 GM050202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; Chasteen N.D., 1981, BIOL MAGN RESON, V3, P53; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen W, 1999, J BIOL CHEM, V274, P7089, DOI 10.1074/jbc.274.11.7089; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNHAM KR, 1981, J BIOL CHEM, V256, P212; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FRASCH WD, 1982, BIOCHEMISTRY-US, V21, P3636, DOI 10.1021/bi00258a017; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; Hamstra BJ, 1997, INORG CHEM, V36, P4866, DOI 10.1021/ic970284x; Harris D. A., 1987, SPECTROPHOTOMETRY SP; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Holyk N, 1979, THESIS U NEW HAMPSHI; HOUSEMAN ALP, 1995, BIOCHEMISTRY-US, V34, P3277, DOI 10.1021/bi00010a018; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P4910, DOI 10.1021/bi00182a020; HOUSEMAN ALP, 1994, BIOCHEMISTRY-US, V33, P10000, DOI 10.1021/bi00199a025; Hu CY, 1996, BIOCHEMISTRY-US, V35, P12201, DOI 10.1021/bi961105a; MAURIE AM, 1980, THESIS U ILLINOIS UR; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MERCHANT S, 1983, EUR J BIOCHEM, V137, P373, DOI 10.1111/j.1432-1033.1983.tb07838.x; Nilges M. J., 1979, THESIS U ILLINOIS UR; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; Sambrook J., 2002, MOL CLONING LAB MANU; SELMANREIMER S, 1981, BIOCHEMISTRY-US, V20, P5476, DOI 10.1021/bi00522a020; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBBER AN, 1993, J BIOL CHEM, V268, P12990; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	39	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30481	30486		10.1074/jbc.274.43.30481	http://dx.doi.org/10.1074/jbc.274.43.30481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521428	hybrid			2022-12-25	WOS:000083276700024
J	Nogami, K; Shima, M; Hosokawa, K; Suzuki, T; Koide, T; Saenko, EL; Scandella, D; Shibata, M; Kamisue, S; Tanaka, I; Yoshioka, A				Nogami, K; Shima, M; Hosokawa, K; Suzuki, T; Koide, T; Saenko, EL; Scandella, D; Shibata, M; Kamisue, S; Tanaka, I; Yoshioka, A			Role of factor VIIIC2 domain in factor VIII binding to factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; LIGHT-CHAIN; C2 DOMAIN; VONWILLEBRAND-FACTOR; HEMOPHILIA-A; THROMBIN; ACTIVATION; CLEAVAGE; ANTIBODY; SITE	Factor VIII (FVIII) is activated by proteolytic cleavages with thrombin and factor Xa (FXa) in the intrinsic blood coagulation pathway, The anti-Ca monoclonal antibody ESH8, which recognizes residues 2248-2285 and does not inhibit FVIII binding to von Willebrand factor or phospholipid, inhibited FVIII activation by FXa in a clotting assay. Furthermore, analysis by SDS-polyacrylamide gel electrophoresis showed that ESH8 inhibited FXa cleavage in the presence or absence of phospholipid. The light chain (LCh) fragments (both 80 and 72 kDa) and the recombinant C2 domain dose-dependently bound to immobilized anhydro-FXa, a catalytically inactive derivative of FXa in which dehydroalanine replaces the active-site serine. The affinity (K-d) values for the 80- and 72-kDa LCh fragments and the C2 domain were 55, 51, and 560 nM, respectively. The heavy chain of FVIII did not bind to anhydro-FXa. Similarly, competitive assays using overlapping synthetic peptides corresponding to ESH8 epitopes (residues 2248-2285) demonstrated that a peptide designated EP-2 (residues 2253-2270; TSMYVKEFLISSSQDGHQ) inhibited the binding of the C2 domain or the 72-kDa LCh to anhydro-FXa by more than 95 and 84%, respectively. Our results provide the first evidence for a direct role of the C2 domain in the association between FVIII and FXa.	Nara Med Univ, Dept Pediat, Kashihara, Nara 634, Japan; Fujimori Kogyo Co, Nakahara Ku, Kawasaki, Kanagawa 211, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigori, Hyogo 678, Japan; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Nara Medical University; University of Hyogo; American Red Cross	Shima, M (corresponding author), Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 634, Japan.	mshima@nmu-gw.cc.naramed-u.ac.jp						ALTIERI DC, 1990, J IMMUNOL, V145, P246; ASHTON RW, 1995, BIOCHEMISTRY-US, V34, P6454, DOI 10.1021/bi00019a027; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOYER LW, 1981, BLOOD, V58, P1; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KAMISUE S, 1994, BRIT J HAEMATOL, V86, P106, DOI 10.1111/j.1365-2141.1994.tb03259.x; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; NEUENSCHWANDER PF, 1992, ARCH BIOCHEM BIOPHYS, V296, P426, DOI 10.1016/0003-9861(92)90593-L; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1989, BLOOD, V74, P1612; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; SHIMA M, 1992, BRIT J HAEMATOL, V81, P533, DOI 10.1111/j.1365-2141.1992.tb02988.x; SHIMA M, 1986, J NARA MED ASS, V31, P672; Thompson AR, 1997, BLOOD, V90, P1902, DOI 10.1182/blood.V90.5.1902; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1994, NUCLEIC ACIDS RES, V22, P3511, DOI 10.1093/nar/22.17.3511; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	43	70	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31000	31007		10.1074/jbc.274.43.31000	http://dx.doi.org/10.1074/jbc.274.43.31000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521497	hybrid			2022-12-25	WOS:000083276700093
J	Ridder, IS; Rozeboom, HJ; Kalk, KH; Dijkstra, BW				Ridder, IS; Rozeboom, HJ; Kalk, KH; Dijkstra, BW			Crystal structures of intermediates in the dehalogenation of haloalkanoates by L-2-haloacid dehalogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHOBACTER-AUTOTROPHICUS GJ10; SITE-DIRECTED MUTAGENESIS; HALIDE-BINDING-SITE; PSEUDOMONAS SP. YL; X-RAY STRUCTURE; HALOACID DEHALOGENASE; STRUCTURE REFINEMENT; PROTEIN STRUCTURES; REACTION-MECHANISM; ACTIVE-SITE	The L-2-haloacid dehalogenase from the 1,2-dichloroethane-degrading bacterium Xanthobacter autotrophicus GJ10 catalyzes the hydrolytic dehalogenation of small L-2-haloalkanoates to their corresponding D-2-hydroxyalkanoates, with inversion of the configuration at the C-2 atom. The structure of the apoenzyme at pH 8 was refined at 1.5-Angstrom resolution. By lowering the pH, the catalytic activity of the enzyme was considerably reduced, allowing the crystal structure determination of the complexes with L-2-monochloropropionate and monochloroacetate at 1.7 and 2.1 Angstrom resolution, respectively. Both complexes showed unambiguous electron density extending from the nucleophile Asp(8) to the C-2 atom of the dechlorinated substrates corresponding to a covalent enzyme-ester reaction intermediate. The halide ion that is cleaved off is found in line with the Asp8 O delta 1-C-2 bond in a halide-stabilizing cradle made up of Arg(39), Asn(115) and Phe(175). In both complexes, the Asp(8) 0 delta 2 carbonyl oxygen atom interacts with Thr(12), Ser(171) and Asn(173) which possibly constitute the oxyanion hole in the hydrolysis of the ester bond. The carboxyl moiety of the substrate is held in position by interactions with Ser(114), Lys(147) and main chain NR groups. The L-2-monochloropropionate CH3 group is located in a small pocket formed by side chain atoms of Ly(147), Asn(173), Phe(175), and Asp(176). The size and position of the pocket explain the stereospecificity and the limited substrate specificity of the enzyme. These crystallographic results demonstrate that the reaction of the enzyme proceeds via the formation of a covalent enzyme-ester intermediate at the nucleophile Asp(8).	Univ Groningen, Dept Chem, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Chem, BIOSAN Res Inst, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Dept Chem, Biophys Chem Lab, Nijanborgh 4, NL-9747 AG Groningen, Netherlands.	b.w.dijkstra@chem.rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Ridder, Ivo Steven/0000-0002-1669-4161; Rozeboom, Henriette/0000-0002-1656-6477				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; DAHMS AS, 1973, J BIOL CHEM, V248, P6592; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fersht A., 1985, ENZYME STRUCTURE MEC; Fetzner S, 1998, APPL MICROBIOL BIOT, V50, P633, DOI 10.1007/s002530051346; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; Krooshof GH, 1998, BIOCHEMISTRY-US, V37, P15013, DOI 10.1021/bi9815187; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YF, 1998, J BIOCHEM-TOKYO, V124, P20, DOI 10.1093/oxfordjournals.jbchem.a022080; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MacArthur MW, 1996, J MOL BIOL, V264, P1180, DOI 10.1006/jmbi.1996.0705; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Ridder IS, 1999, ACTA CRYSTALLOGR D, V55, P1273, DOI 10.1107/S090744499900534X; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; RIDDER IS, 1995, PROTEIN SCI, V4, P2619, DOI 10.1002/pro.5560041220; STUCKI G, 1995, ENVIRON SCI TECHNOL, V29, P2339, DOI 10.1021/es00009a028; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; VERSCHUEREN KHG, 1993, BIOCHEMISTRY-US, V32, P9031, DOI 10.1021/bi00086a008; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	46	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30672	30678		10.1074/jbc.274.43.30672	http://dx.doi.org/10.1074/jbc.274.43.30672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521454	hybrid, Green Published			2022-12-25	WOS:000083276700050
J	Aman, MJ; Migone, TS; Sasaki, A; Ascherman, DP; Zhu, MH; Soldaini, E; Imada, K; Miyajima, A; Yoshimura, A; Leonard, WJ				Aman, MJ; Migone, TS; Sasaki, A; Ascherman, DP; Zhu, MH; Soldaini, E; Imada, K; Miyajima, A; Yoshimura, A; Leonard, WJ			CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; IL-2 RECEPTOR; ALPHA-CHAIN; CYTOPLASMIC DOMAINS; MULTIPLE CYTOKINES; JAK-STAT5 PATHWAY; SH2 DOMAIN; GENE; PROTEIN; ACTIVATION	CIS is a cytokine-induced SH2-containing protein that was originally cloned as an interleukin (IL)-3-inducible gene. CIS is known to associate with the IL-3 receptor beta chain and erythropoietin receptor and to inhibit signaling mediated by IL-3 and erythropoietin. We now demonstrate that CLS also interacts with the IL-2 receptor beta chain (IL-2R beta), This interaction requires the A region of IL-2R beta (residues 313-382), which also mediates the association of IL-2R beta with Lck and Jak3. Correspondingly, CIS inhibits functions associated with both of these kinases: Lck-mediated phosphorylation of IL-2R beta and IL-2-mediated activation of Stat5. Thus, we demonstrate that CIS can negatively control at least two independent IL-2 signaling pathways. Although a functional SH2 binding domain of CIS was not required for its interaction with IL-2R beta in vitro, its phosphotyrosine binding capability was essential for the inhibitory action of CIS. On this basis, we have generated a mutant form of CIS protein with an altered SH2 domain that acts as a dominant negative and should prove useful in further understanding CIS action.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Tokyo; Kurume University	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022; Yoshimura, Akihiko/K-5515-2013	Imada, Kazunori/0000-0002-0945-0513; Sasaki, Atsuo/0000-0003-2963-4501				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AMAN MJ, 1997, CURR BIOL, V12, pR784; Ascherman DP, 1997, J BIOL CHEM, V272, P8704, DOI 10.1074/jbc.272.13.8704; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OTANI H, 1993, J BIOL CHEM, V268, P22733; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	42	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30266	30272		10.1074/jbc.274.42.30266	http://dx.doi.org/10.1074/jbc.274.42.30266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514520	hybrid			2022-12-25	WOS:000083176400099
J	Campbell, PG; Durham, SK; Hayes, JD; Suwanichkul, A; Powell, DR				Campbell, PG; Durham, SK; Hayes, JD; Suwanichkul, A; Powell, DR			Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; PLASMINOGEN ACTIVATORS; WOUND FLUID; TISSUE-TYPE; CELLS; LOCALIZATION; PROTEOLYSIS; HEPARIN; ANALOGS; COMPLEX	Following tissue injury, a fibrin network formed at the wound site serves as a scaffold supporting the early migration of stromal cells needed for wound hearing. Growth factors such as insulin-like growth factor-I (IGF-I) concentrate in wounds to stimulate stromal cell function and proliferation. The ability of IGF-binding proteins (IGFBPs) such as IGFBP-3 to reduce the rate of IGF-I clearance from wounds suggests that IGFBP-3 might bind directly to fibrinogen/fibrin. Studies presented here show that IGFBP-3 does indeed bind to fibrinogen and fibrin immobilized on immunocapture plates, with K-d values = 0.67 and 0.70 nM, respectively, and competitive binding studies suggest that the IGFBP-3 heparin binding domain may participate in this binding. IGF-I does not compete for IGFBP-3 binding; instead, IGF-I binds immobilized IGFBP-3 fibrinogen and IGFBP-3 fibrin complexes with affinity similar to that of IGF-I for the type I IGF receptor. In the presence of plasminogen, most IGFBP-3 binds directly to fibrinogen, although 35-40% of the IGFBP-3 binds to fibrinogen-bound plasminogen, IGFBP-3 also binds specifically to native fibrin clots, and addition of exogenous IGFBP-3 increases IGF-I binding. These studies suggest that IGF-I can concentrate at wound sites by binding to fibrin-immobilized IGFBP-3, and that the lower IGF affinity of fibrin-bound IGFBP-3 allows IGF-I release to type I IGF receptors of stromal cells migrating into the fibrin clot.	Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15212 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Carnegie Mellon University; Baylor College of Medicine	Powell, DR (corresponding author), Texas Childrens Hosp, Feigin Ctr, MC 3-2482,6621 Fannin, Houston, TX 77030 USA.	dpowell@bcm.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN B, 1989, THROMB HAEMOSTASIS, V62, P1078; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; ARAI T, 1994, J BIOL CHEM, V269, P20388; BALLARD FJ, 1993, GROWTH REGULAT, V3, P40; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Campbell PG, 1998, AM J PHYSIOL-ENDOC M, V275, pE321, DOI 10.1152/ajpendo.1998.275.2.E321; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE1005, DOI 10.1152/ajpendo.1997.273.5.E1005; Chan K, 1998, ENDOCRINOLOGY, V139, P559, DOI 10.1210/en.139.2.559; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; DOOLITTLE RF, 1987, ANNU REV BIOCHEM, V53, P195; Durham SK, 1997, PEDIATR RES, V42, P335, DOI 10.1203/00006450-199709000-00014; Durham SK, 1999, HORM METAB RES, V31, P216, DOI 10.1055/s-2007-978722; FROST VJ, 1993, J ENDOCRINOL, V138, P545, DOI 10.1677/joe.0.1380545; GREENBERG CS, 1985, BLOOD, V66, P1028; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; ICHINOSE A, 1986, J CLIN INVEST, V78, P163, DOI 10.1172/JCI112546; IINO M, 1995, EUR J BIOCHEM, V232, P90, DOI 10.1111/j.1432-1033.1995.tb20785.x; JOBE MI, 1992, CLIN HEMATOLOGY PRIN, P579; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Jones John I., 1995, Progress in Growth Factor Research, V6, P319, DOI 10.1016/0955-2235(95)00015-1; KEIJER J, 1991, BLOOD, V78, P401; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; LALOU C, 1994, ENDOCRINOLOGY, V135, P2318, DOI 10.1210/en.135.6.2318; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; LIU CY, 1979, J BIOL CHEM, V254, P421; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; Robertson JG, 1996, ENDOCRINOLOGY, V137, P2774, DOI 10.1210/en.137.7.2774; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROSTAGNO A, 1994, J BIOL CHEM, V269, P31938; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; Sahni A, 1998, J BIOL CHEM, V273, P7554, DOI 10.1074/jbc.273.13.7554; SKOTTNER A, 1990, ACTA PAEDIATR SCAND, P63; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; TUSZYNSKI GP, 1985, J BIOL CHEM, V260, P2240; Vogt PM, 1998, PLAST RECONSTR SURG, V102, P117, DOI 10.1097/00006534-199807000-00018; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40	45	82	97	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30215	30221		10.1074/jbc.274.42.30215	http://dx.doi.org/10.1074/jbc.274.42.30215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514513	hybrid			2022-12-25	WOS:000083176400092
J	Sanchez, MA; Ullman, B; Landfear, SM; Carter, NS				Sanchez, MA; Ullman, B; Landfear, SM; Carter, NS			Cloning and functional expression of a gene encoding a P1 type nucleoside transporter from Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; UNUSUAL ADENOSINE TRANSPORTER; BLOOD-STREAM FORMS; S-ADENOSYLMETHIONINE; AFRICAN TRYPANOSOMES; MOLECULAR-CLONING; MESSENGER-RNAS; ANALOGS; EI; RHODESIENSE	Nucleoside transporters are Likely to play a central role in the biochemistry of the parasite Trypanosoma brucei, since these protozoa are unable to synthesize purines de novo and must salvage them from their hosts. Furthermore, nucleoside transporters have been implicated in the uptake of antiparasitic and experimental drugs in these and other parasites. We have cloned the gene fora T. brucei nucleoside transporter, TbNT2, and shown that this permease is related in sequence to mammalian equilibrative nucleoside transporters, Expression of the TbNT2 gene in Xenopus oocytes reveals that the permease transports adenosine, inosine, and guanosine and hence has the substrate specificity of the P1 type nucleoside transporters that have been previously characterized by uptake assays in intact parasites. TbNT2 mRNA is expressed in bloodstream form (mammalian host stage) parasites but not in procyclic form (insect stage) parasites, indicating that the gene is developmentally regulated during the parasite life cycle. Genomic Southern blots suggest that there are multiple genes related in sequence to TbNT2, implying the existence of a family of nucleoside transporter genes in these parasites.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Sanchez, MA (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	sanchezm@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R01AI025920, R37AI023682, R01AI044138] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25920, AI 23682, AI44138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BACCHI CJ, 1993, BIOCHEM PHARMACOL, V46, P471, DOI 10.1016/0006-2952(93)90524-Z; Bacchi CJ, 1997, ANTIMICROB AGENTS CH, V41, P2108, DOI 10.1128/AAC.41.10.2108; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BRUN R, 1979, ACTA TROP, V36, P289; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; deKoning HP, 1997, MOL BIOCHEM PARASIT, V89, P245, DOI 10.1016/S0166-6851(97)00129-1; Goldberg B, 1997, FASEB J, V11, P256, DOI 10.1096/fasebj.11.4.9068614; Goldberg B, 1998, BIOCHEM PHARMACOL, V56, P95, DOI 10.1016/S0006-2952(98)00118-X; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; THISSEN JA, 1991, EXP PARASITOL, V72, P243, DOI 10.1016/0014-4894(91)90143-K; Tye CK, 1998, BIOORG MED CHEM LETT, V8, P811, DOI 10.1016/S0960-894X(98)00095-X; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	38	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30244	30249		10.1074/jbc.274.42.30244	http://dx.doi.org/10.1074/jbc.274.42.30244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514517	hybrid			2022-12-25	WOS:000083176400096
J	Yoon, KS; Hille, R; Hemann, C; Tabita, FR				Yoon, KS; Hille, R; Hemann, C; Tabita, FR			Rubredoxin from the green sulfur bacterium Chlorobium tepidum functions as an electron acceptor for pyruvate ferredoxin oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HYDROGENOBACTER-THERMOPHILUS TK-6; OPEN READING FRAMES; 2 4FE-4S CLUSTERS; PYROCOCCUS-FURIOSUS; PHOTOSYNTHETIC BACTERIUM; AZOTOBACTER-VINELANDII; PSEUDOMONAS-OLEOVORANS; REDUCTION POTENTIALS; GENE-CLUSTER	Rubredoxin (Rd) from the moderately thermophilic green sulfur bacterium Chlorobium tepidum was found to function as an electron acceptor for pyruvate ferredoxin oxidoreductase (PFOR), This enzyme, which catalyzes the conversion of pyruvate to acetyl-CoA and CO2, exhibited an absolute dependence upon the presence of Rd, However, Rd was incapable of participating in the pyruvate, synthase or CO2 fixation reaction of C. tepidum PFOR, for which two different reduced ferredoxins are employed as electron donors, These results suggest a specific functional role for Rd in pyruvate oxidation and provide the initial indication that the two important physiological reactions catalyzed by PFOR/pyruvate synthase are dependent on different electron carriers in the cell, The W-visible spectrum of oxidized Rd, with a monomer molecular weight of 6500, gave a molar absorption coefficient at 492 nm of 6.89 mM(-1) cm(-1) with an A(492)/A(280) ratio of 0.343 and contained one iron atom/molecule. Further spectroscopic studies indicated that the CD spectrum of oxidized C. tepidum Rd exhibited a unique absorption maximum at 385 nm and a shoulder at 420 nm, The EPR spectrum of oxidized Rd also exhibited unusual anisotropic resonances at g = 9.675 and g = 4.322, which is composed of a narrow central feature with broader shoulders to high and low field, The midpoint reduction potential of C. tepidum Rd was determined to be -87 mV, which is the most electronegative value reported for Rd from any source.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.			Hemann, Craig/0000-0002-7380-4072	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052322] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; BUCHANAN BB, 1969, METHOD ENZYMOL, V28, P170; CAVAGNERO S, 1995, BIOCHEMISTRY-US, V34, P9865, DOI 10.1021/bi00031a007; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P122, DOI 10.1016/0167-4781(92)90111-C; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; Eaton W. A., 1973, IRON SULFUR PROTEINS, V2, P131; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; EVANS MCW, 1965, P NATL ACAD SCI USA, V53, P1420, DOI 10.1073/pnas.53.6.1420; FU CL, 1994, GENE, V145, P91, DOI 10.1016/0378-1119(94)90328-X; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GEHRING U, 1972, J BIOL CHEM, V247, P6963; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; HALL DO, 1969, NATURE, V223, P1342, DOI 10.1038/2231342a0; HORMEL S, 1986, FEBS LETT, V201, P147, DOI 10.1016/0014-5793(86)80588-9; Hughes NJ, 1998, J BACTERIOL, V180, P1119, DOI 10.1128/JB.180.5.1119-1128.1998; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; Lee HJ, 1998, BIOCHEMISTRY-US, V37, P15513, DOI 10.1021/bi981853v; LEE WY, 1995, ARCH BIOCHEM BIOPHYS, V318, P80, DOI 10.1006/abbi.1995.1207; LeGall J, 1998, FEBS LETT, V429, P295, DOI 10.1016/S0014-5793(98)00610-3; LeJohn H B, 1975, Methods Enzymol, V41, P293; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma K, 1997, P NATL ACAD SCI USA, V94, P9608, DOI 10.1073/pnas.94.18.9608; MCKENNA EJ, 1970, J BIOL CHEM, V245, P3882; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; MEYER TE, 1971, BIOCHIM BIOPHYS ACTA, V234, P266, DOI 10.1016/0005-2728(71)90081-8; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; OHOKA H, 1995, FEBS LETT, V365, P30, DOI 10.1016/0014-5793(95)00433-A; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PEARSON DJ, 1965, METHOD ENZYMOL, V13, P545; PEISACH J, 1971, J BIOL CHEM, V246, P5877; RAGSDALE SW, 1983, J BACTERIOL, V155, P1224, DOI 10.1128/JB.155.3.1224-1237.1983; RAO KK, 1972, BIOCHEM J, V129, P1063, DOI 10.1042/bj1291063; REED LJ, 1990, J BIOL CHEM, V265, P8971; REY L, 1992, J MOL BIOL, V228, P998, DOI 10.1016/0022-2836(92)90886-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEKI S, 1988, J BIOCHEM-TOKYO, V103, P583, DOI 10.1093/oxfordjournals.jbchem.a122310; SHIMIZU F, 1989, BIOCHIMIE, V71, P1171, DOI 10.1016/0300-9084(89)90020-5; SIEKER LC, 1994, METHOD ENZYMOL, V243, P203; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; Swartz PD, 1996, BIOCHEMISTRY-US, V35, P13772, DOI 10.1021/bi960611x; UYEDA K, 1971, J BIOL CHEM, V246, P3111; WAHL RC, 1987, J BIOL CHEM, V262, P10489; WAHLUND TM, 1995, J BACTERIOL, V177, P2583, DOI 10.1128/jb.177.9.2583-2588.1995; WAHLUND TM, 1991, ARCH MICROBIOL, V156, P81, DOI 10.1007/BF00290978; WOOLLEY KJ, 1987, EUR J BIOCHEM, V163, P161, DOI 10.1111/j.1432-1033.1987.tb10750.x; YANG SS, 1980, BIOCHIM BIOPHYS ACTA, V590, P24, DOI 10.1016/0005-2728(80)90143-7; Yoon KS, 1997, BIOSCI BIOTECH BIOCH, V61, P510, DOI 10.1271/bbb.61.510; Yoon KS, 1997, ARCH MICROBIOL, V167, P275, DOI 10.1007/s002030050443; Yoon KS, 1996, J BACTERIOL, V178, P3365, DOI 10.1128/jb.178.11.3365-3368.1996	53	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29772	29778		10.1074/jbc.274.42.29772	http://dx.doi.org/10.1074/jbc.274.42.29772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514453	hybrid			2022-12-25	WOS:000083176400032
J	Brancaccio, M; Guazzone, S; Menini, N; Sibona, E; Hirsch, E; De Andrea, M; Rocchi, M; Altruda, F; Tarone, G; Silengo, L				Brancaccio, M; Guazzone, S; Menini, N; Sibona, E; Hirsch, E; De Andrea, M; Rocchi, M; Altruda, F; Tarone, G; Silengo, L			Melusin is a new muscle-specific interactor for beta(1) integrin cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CARDIAC-MUSCLE; SEQUENCE; PROTEIN; IDENTIFICATION; LOCALIZATION; EXPRESSION; ABSENCE; CELLS; BINDING	Here we describe the isolation and partial characterization of a new muscle-specific protein (Melusin) which interacts with the integrin cytoplasmic domain. The cDNA encoding Melusin was isolated in a two-hybrid screening of a rat neonatal heart library using beta(1)A and beta(1)D integrin cytoplasmic regions as baits. Melusin is a cysteine-rich cytoplasmic protein of 38 kDa, with a stretch of acidic amino acid residues at the extreme carboxyl-terminal end. In addition, putative binding sites for SH3 and SH2 domains are present in the aminoterminal half of the molecule. Chromosomic analysis showed that melusin gene maps at Xq12.1/13 in man and in the synthenic region X band D in mouse. Melusin is expressed in skeletal and cardiac muscles but not in smooth muscles or other tissues. Immunofluorescence analysis showed that Melusin is present in a costamere-like pattern consisting of two rows flanking alpha-actinin at Z line, Its expression is up-regulated during in vitro differentiation of the C2C12 murine myogenic cell line, and it is regulated during in vivo skeletal muscle development. A fragment corresponding to the tail region of Melusin interacted strongly and specifically with beta(1) integrin cytoplasmic domain in a two-hybrid test, but the full-length protein did not. Because the tail region of Melusin contains an acidic amino acid stretch resembling high capacity and low affinity calcium binding domains, we tested the possibility that Ca2+ regulates Melusin-integrin association. In vitro binding experiments demonstrated that interaction of full-length Melusin with detergent-solubilized integrin heterodimers occurred only in absence of cations, suggesting that it can be regulated by intracellular signals affecting Ca2+ concentration.	Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; Univ Bari, Inst Genet, I-70122 Bari, Italy; Univ Turin, Immunogenet & Expt Oncol Ctr, I-10126 Turin, Italy	University of Turin; Universita degli Studi di Bari Aldo Moro; University of Turin	Brancaccio, M (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Via Santena 5 Bis, I-10126 Turin, Italy.	brancacc@molinette.unito.it	Hirsch, Emilio/F-4848-2013; De Andrea, Marco/J-5253-2012	Hirsch, Emilio/0000-0002-9073-6024; De Andrea, Marco/0000-0002-3188-5783; Tarone, Guido/0000-0003-4805-086X	Telethon [E.0672] Funding Source: Medline	Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; Brancaccio M, 1998, CELL ADHES COMMUN, V5, P193, DOI 10.3109/15419069809040291; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fassler R, 1996, J CELL SCI, V109, P2989; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HEGYI H, 1993, COMPUT APPL BIOSCI, V9, P371; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hirsch E, 1998, J CELL SCI, V111, P2397; KOTELIANSKY VE, 1983, FEBS LETT, V159, P158, DOI 10.1016/0014-5793(83)80437-2; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MartinBermudo MD, 1996, J CELL BIOL, V134, P217, DOI 10.1083/jcb.134.1.217; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MCDONALD KA, 1995, J CELL SCI, V108, P2573; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SWASDISON S, 1989, CELL TISSUE RES, V257, P537, DOI 10.1007/BF00221463; TOYOTA N, 1984, CELL TISSUE RES, V236, P549; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZORNIG M, 1995, CYTOGENET CELL GENET, V71, P37, DOI 10.1159/000134057	38	94	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29282	29288		10.1074/jbc.274.41.29282	http://dx.doi.org/10.1074/jbc.274.41.29282			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506186	hybrid			2022-12-25	WOS:000083017800065
J	Jaenicke, E; Decker, H; Gebauer, WA; Markl, J; Burmester, T				Jaenicke, E; Decker, H; Gebauer, WA; Markl, J; Burmester, T			Identification, structure, and properties of hemocyanins from diplopod myriapoda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROPOD HEMOCYANINS; EVOLUTION; PHYLOGENY; HEXAMERINS; PROTEINS; INSECTS	Hemocyanins are copper-containing, respiratory proteins that occur in the hemolymph of many arthropod species. Here we report for the first time the presence of hemocyanins in the diplopod Myriapoda, demonstrating that these proteins are more widespread among the Arthropoda than previously thought. The hemocyanin of Spirostreptus sp, (Diplopoda: Spirostreptidae) is composed of two immunologically distinct subunits in the 75-kDa range that are most likely arranged in a 36-mer (6 x 6) native molecule. It has a high oxygen affinity (P-50 = 4.7 torr) but low cooperativity (h 1.3 +/- 0,2). Spirostreptus hemocyanin is structurally similar to the single known hemocyanin from the myriapod taxon, Scutigera coleoptrata (Chilopoda), indicating a rather conservative architecture of the myriapod hemocyanins. Western blotting demonstrates shared epitopes of Spirostreptus hemocyanin with both chelicerate and crustacean hemocyanins, confirming its identity as an arthropod hemocyanin.	Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Univ Mainz, Inst Mol Biophys, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Burmester, T (corresponding author), Univ Mainz, Inst Zool, D-55099 Mainz, Germany.		Burmester, Thorsten/I-7225-2013; Jaenicke, Elmar/A-5317-2010	Burmester, Thorsten/0000-0002-5772-7863; Jaenicke, Elmar/0000-0002-5157-7219				BEGAUER W, 1999, IN PRESS NATURWISSEN, V86; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; BOISST N, 1990, BIOL CELL, V86, P73; Boore JL, 1998, NATURE, V392, P667, DOI 10.1038/33577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brusca R.C., 1990, INVERTEBRATES; Burmester T, 1998, J MOL EVOL, V47, P93, DOI 10.1007/PL00006366; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; Burmester T, 1999, J BIOL CHEM, V274, P13217, DOI 10.1074/jbc.274.19.13217; BURMESTER T, 1999, IN PRESS EUR J ENTOM, V96; FRIEDRICH M, 1995, NATURE, V376, P165, DOI 10.1038/376165a0; HARRIS JR, 1970, J ULTRA MOL STRUCT R, V33, P219, DOI 10.1016/S0022-5320(70)90017-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; LOEWE R, 1978, J COMP PHYSIOL, V128, P161, DOI 10.1007/BF00689480; MANGUM CP, 1985, P NATL ACAD SCI USA, V82, P3721, DOI 10.1073/pnas.82.11.3721; Mangum CP, 1986, INVERTEBRATE OXYGEN, P276; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; MARKL J, 1986, BIOL BULL, V171, P90, DOI 10.2307/1541909; SHEAR WA, 1997, SYSTEMATIC ASS SPECI, V55, P211; Terwilliger NB, 1999, P NATL ACAD SCI USA, V96, P2013, DOI 10.1073/pnas.96.5.2013; TURBEVILLE JM, 1991, MOL BIOL EVOL, V8, P669; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x	24	42	42	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29071	29074		10.1074/jbc.274.41.29071	http://dx.doi.org/10.1074/jbc.274.41.29071			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506159	hybrid			2022-12-25	WOS:000083017800038
J	Xu, HJ; Storch, T; Yu, M; Elliott, SP; Haslam, DB				Xu, HJ; Storch, T; Yu, M; Elliott, SP; Haslam, DB			Characterization of the human Forssman synthetase gene - An evolving association between glycolipid synthesis and host-microbial interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPLANTATION MOUSE EMBRYO; THIN-LAYER CHROMATOGRAMS; EXPRESSION CLONING; ESCHERICHIA-COLI; SHIGA TOXIN; ANTIGEN; RECEPTORS; BINDING; ALPHA-1,3-GALACTOSYLTRANSFERASE; GLYCOSPHINGOLIPIDS	Differences in glycolipid expression between species contribute to the tropism of many infectious pathogens for their hosts. For example, we demonstrate that cultured human and monkey urinary epithelial cells fail to bind a canine Escherichia coli uropathogenic isolate; however, transfection of these cells with the canine Forssman synthetase (FS) cDNA enables abundant adherence by the same pathogen, indicating that addition of a single sugar residue to a glycolipid receptor has marked effects on microbial attachment. Given the contribution of glycolipids to host-microbial interactions, we sought to determine why human tissues do not express Forssman glycolipid. Query of the GenBank(TM) data base yielded a human sequence with high identity to the canine FS cDNA. Reverse transcription polymerase chain reaction and Northern blotting demonstrated the presence of FS mRNA in all tissues examined. A human FS cDNA was characterized, revealing identities with the canine FS gene of 86 and 83% at the nucleotide and predicted amino acid sequences, respectively, In contrast to the canine FS cDNA, transfection of COS-1 cells with the human FS cDNA resulted in no detectable FS enzyme activity. These results suggest that variability in glycolipid synthesis between species is an important determinant of microbial tropism. Evolutionary pressure from pathogenic organisms may have contributed to diversity in glycolipid expression among species.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Haslam, DB (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.	haslam@kids.wustl.edu	Haslam, David/G-3825-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD033688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042817] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI042817, AI42817] Funding Source: Medline; NICHD NIH HHS [HD33688] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASU M, 1987, METHOD ENZYMOL, V138, P575; BEACHEY EH, 1988, AM REV RESPIR DIS, V138, pS45, DOI 10.1164/ajrccm/138.6_Pt_2.S45; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; COOLING LLW, 1995, J INFECT DIS, V172, P1198, DOI 10.1093/infdis/172.5.1198; FREDMAN P, 1993, ADV LIPID RES, V25, P213; GALILI U, 1988, J BIOL CHEM, V263, P17755; HAKOMORI S, 1977, P NATL ACAD SCI USA, V74, P3023, DOI 10.1073/pnas.74.7.3023; Hakomori S, 1980, Prog Clin Biol Res, V41, P873; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; HANSSON GC, 1984, FEBS LETT, V170, P15, DOI 10.1016/0014-5793(84)81359-9; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HASLAM DB, 1994, MOL MICROBIOL, V14, P399, DOI 10.1111/j.1365-2958.1994.tb02175.x; JACEWICZ MS, 1994, J INFECT DIS, V169, P538, DOI 10.1093/infdis/169.3.538; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KALLENIUS G, 1981, LANCET, V2, P1369; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1992, APMIS, V100, P71; KEUSCH GT, 1991, REV INFECT DIS, V13, pS304; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEFFLER H, 1983, P 7 INT S GLYC, P643; LINGWOOD CA, 1993, ADV LIPID RES, V25, P189; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; LINGWOOD CA, 1992, BIOCHEM J, V283, P25, DOI 10.1042/bj2830025; MELDGAARD P, 1994, CANCER RES, V54, P2440; MONNER DA, 1993, IMMUNOBIOLOGY, V188, P82, DOI 10.1016/S0171-2985(11)80489-4; ONO K, 1994, J HISTOCHEM CYTOCHEM, V42, P659, DOI 10.1177/42.5.7512587; SADAHIRA Y, 1991, IMMUNOLOGY, V73, P498; SAKAKIBARA N, 1991, CANCER LETT, V57, P187, DOI 10.1016/0304-3835(91)90155-B; SANDHOFF K, 1993, ADV LIPID RES, V26, P119; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SHAPER NL, 1992, GENOMICS, V12, P613, DOI 10.1016/0888-7543(92)90458-5; STINNAKRE MG, 1981, J EMBRYOL EXP MORPH, V61, P117; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1988, P NATL ACAD SCI USA, V85, P4902, DOI 10.1073/pnas.85.13.4902; STROMBERG N, 1988, FEBS LETT, V232, P193, DOI 10.1016/0014-5793(88)80415-0; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; VONKLEIST R, 1990, IMMUNOBIOLOGY, V180, P405; WILLISON KR, 1978, CELL, V14, P785, DOI 10.1016/0092-8674(78)90334-3; YAMAZAKI M, 1995, BLOOD COAGUL FIBRIN, V6, P5, DOI 10.1097/00001721-199502000-00001; YOKOTA M, 1981, CANCER RES, V41, P4185; YOUNG WW, 1979, J IMMUNOL METHODS, V28, P59, DOI 10.1016/0022-1759(79)90328-4	44	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29390	29398		10.1074/jbc.274.41.29390	http://dx.doi.org/10.1074/jbc.274.41.29390			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506200	hybrid			2022-12-25	WOS:000083017800079
J	Walzog, B; Weinmann, P; Jeblonski, F; Scharffetter-Kochanek, K; Bommert, K; Gaehtgens, P				Walzog, B; Weinmann, P; Jeblonski, F; Scharffetter-Kochanek, K; Bommert, K; Gaehtgens, P			A role for beta(2) integrins (CD11/CD18) in the regulation of cytokine gene expression of polymorphonuclear neutrophils during the inflammatory response	FASEB JOURNAL			English	Article						inflammation; adhesion; host defense; interleukin 8; interleukin 1	PROTEIN-TYROSINE PHOSPHORYLATION; SURFACE-ADHERENT PLATELETS; MONOCLONAL-ANTIBODIES; ADHESION MOLECULES; PERIPHERAL-BLOOD; COUNTER-RECEPTOR; CELL FUNCTION; L-SELECTIN; ACTIVATION; CD11B/CD18	Growing evidence supports the idea that adhesion via beta(2) integrins not only allows cellular targeting, but also induces intracellular signaling, which in turn activates functional responses of adherent cells. This study investigates whether beta(2) integrin-mediated adhesion of human polymorphonuclear neutrophils (PMN) has a functional impact on cytokine production. Aggregation of the b(2) integrin Mac-1 (CD11b/CD18) by antibody cross-linking was found to induce substantial de novo synthesis of IL-8 mRNA as measured by semiquantitative RT-PCR and Northern blotting technique, respectively. Induction of IL-8 mRNA was also observed upon adhesion of PMN to immobilized fibrinogen, a functional equivalent of its clotting product fibrin that serves as a native ligand of Mac-1. Results were confirmed using PMN derived from CD18-deficient mice, which were unable to produce MIP-2 mRNA, a homologue of human IL-8, in the presence of immobilized fibrinogen, In contrast, a substantial increase of MIP-2 mRNA was observed when wild-type PMN were incubated on immobilized fibrinogen, In human PMN, ELISA technique showed that the gene activation that required tyrosine kinase activity resulted in a substantial production and secretion of biologically active IL-8 and IL-1 beta. In contrast, no TNF-alpha or IL-6 production was found, revealing that beta(2), integrins mediate differential expression of proinflammatory cytokines, The biological relevance of the present findings was confirmed in an in vivo model of acute inflammation. Altogether, the present findings provide evidence for a functional link between clotting and inflammatory responses that may contribute to the recruitment and/or activation of PMN and other cells at sites of lesion.	Free Univ Berlin, Dept Physiol, D-14195 Berlin, Germany; Univ Cologne, Dept Dermatol, D-5000 Cologne, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; University of Cologne; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Walzog, B (corresponding author), Free Univ Berlin, Dept Physiol, Arnimallee 22, D-14195 Berlin, Germany.		Bommert, Kurt/G-9247-2011					ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; CASSATELLA MA, 1992, J IMMUNOL, V148, P3216; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835, DOI 10.1002/jlb.59.6.835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DANILENKO DM, 1995, J IMMUNOL, V155, P35; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Diacovo TG, 1996, BLOOD, V88, P146; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DOSQUET C, 1995, J CARDIOVASC PHAR S2, V25, P13; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; HAWKINS HK, 1992, PEDIATR PATHOL, V12, P119, DOI 10.3109/15513819209023288; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kuijper PHM, 1997, BLOOD, V89, P2131, DOI 10.1182/blood.V89.6.2131; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; Lub M, 1996, J LEUKOCYTE BIOL, V59, P648, DOI 10.1002/jlb.59.5.648; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARCUS AJ, 1994, SEMIN HEMATOL, V31, P261; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nakagawa M, 1998, CIRCULATION, V98, P2307, DOI 10.1161/01.CIR.98.21.2307; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; PAYNE CM, 1994, MICROSC RES TECHNIQ, V28, P327, DOI 10.1002/jemt.1070280408; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; SCHWAGER I, 1994, BLOOD, V83, P152, DOI 10.1182/blood.V83.1.152.bloodjournal831152; STRIETER RM, 1995, J BIOL CHEM, V270, P27248; TECAMPOLSON P, 1990, J EXP MED, V172, P911; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Walzog B, 1996, J LEUKOCYTE BIOL, V59, P747, DOI 10.1002/jlb.59.5.747; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; Walzog B, 1997, FASEB J, V11, P1177, DOI 10.1096/fasebj.11.13.9367353; WALZOG B, 1999, AM J PHYSIOL, V276, pC1125; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; Weinmann P, 1999, BLOOD, V93, P3106; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	50	86	92	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1855	1865		10.1096/fasebj.13.13.1855	http://dx.doi.org/10.1096/fasebj.13.13.1855			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506590				2022-12-25	WOS:000083063400022
J	Ouzzine, M; Magdalou, J; Burchell, B; Fournel-Gigleux, S				Ouzzine, M; Magdalou, J; Burchell, B; Fournel-Gigleux, S			An internal signal sequence mediates the targeting and retention of the human UDP-glucuronosyltransferase 1A6 to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; TRANSMEMBRANE PROTEINS; ESCHERICHIA-COLI; STOP TRANSFER; MEMBRANE; EXPRESSION; GLUCURONIDATION; TRANSLOCATION; BILIRUBIN; DOMAIN	The human UDP-glucuronosyltransferase isoform UGT1A6 is predicted to be a type I transmembrane protein anchored in the endoplasmic reticulum by a single C-terminal transmembrane domain, followed by a short cytoplasmic tail. This topology is thought to be! established through the sequential action of a cleavable N-terminal signal peptide and of a C-terminal stop transfer/anchor sequence, We found that the deletion of the signal peptide did not prevent membrane targeting and insertion of this protein expressed in an in vitro transcription/translation system or in yeast Pichia pastoris, Interestingly, the same results were obtained when the protein was depleted of both the signal peptide and the C-terminal transmembrane domain/cytoplasmic tail sequences, suggesting the presence of an internal topogenic element able to translocate and retain UGT1A6 in the endoplasmic reticulum membrane in vitro and in yeast cells. To identify such a sequence, the insertion of several N-terminal deletion mutants of UGT1A6 into microsomal membranes was investigated in vitro. The data clearly showed that the deletion of the N-terminal end did not affect endoplasmic reticulum targeting and retention until residues 140-240 were deleted, The signal-like activity of the 140-240 region was demonstrated by the ability of this segment to confer endoplasmic reticulum residency to the cytosolic green fluorescent protein expressed in mammalian cells. Finally, we show that this novel topogenic sequence can posttranslationally mediate the translocation of UGT1A6. This study provides the first evidence that the membrane assembly of the human UGT1A6 involves an internal signal retention sequence.	Univ Nancy 1, UMR CNRS 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Universite de Lorraine; University of Dundee	Ouzzine, M (corresponding author), Univ Nancy 1, UMR CNRS 7561, Fac Med, BP 184, F-54505 Vandoeuvre Les Nancy, France.	ouzzine@pharmaco-med.u-nancy.fr	Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950				BLACHLYDYSON E, 1987, J CELL BIOL, V104, P1183, DOI 10.1083/jcb.104.5.1183; BLOBEL G, 1980, P NATL ACAD SCI USA, V79, P3111; BOCK KW, 1993, BIOCHEM PHARMACOL, V45, P1809, DOI 10.1016/0006-2952(93)90437-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO CCK, 1987, MOL CELL BIOL, V7, P3842, DOI 10.1128/MCB.7.10.3842; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Ciotti M, 1998, BIOCHEMISTRY-US, V37, P11018, DOI 10.1021/bi980747q; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; Dutton G.F., 1980, GLUCURONIDATION DRUG; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; Herber R, 1995, DRUG METAB DISPOS, V23, P1305; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; Meech R, 1998, ARCH BIOCHEM BIOPHYS, V356, P77, DOI 10.1006/abbi.1998.0750; Meech R, 1997, J BIOL CHEM, V272, P26913, DOI 10.1074/jbc.272.43.26913; MIZE NK, 1986, CELL, V47, P711, DOI 10.1016/0092-8674(86)90514-3; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; OUZZINE M, 1994, FEBS LETT, V339, P195, DOI 10.1016/0014-5793(94)80414-1; OUZZINE M, 1994, ARCH BIOCHEM BIOPHYS, V310, P196, DOI 10.1006/abbi.1994.1157; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PILLOT T, 1993, J BIOL CHEM, V268, P25636; RADOMINSKA A, 1993, J BIOL CHEM, V268, P15127; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPHERD SRP, 1989, BIOCHEM J, V259, P617, DOI 10.1042/bj2590617; SILVE S, 1987, MOL CELL BIOL, V7, P3306, DOI 10.1128/MCB.7.9.3306; TAM LY, 1994, J BIOL CHEM, V269, P32542; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; YOKOTA H, 1992, J BIOCHEM, V112, P192, DOI 10.1093/oxfordjournals.jbchem.a123876; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471; ZUCKER SD, 1994, J BIOL CHEM, V269, P19262	51	88	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31401	31409		10.1074/jbc.274.44.31401	http://dx.doi.org/10.1074/jbc.274.44.31401			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531341	hybrid			2022-12-25	WOS:000083379400045
J	Qadri, I; Siddiqui, A				Qadri, I; Siddiqui, A			Expression of hepatitis B virus polymerase in Ty1-his3AI retroelement of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA SYNTHESIS; REVERSE-TRANSCRIPTASE; RNA INTERMEDIATE; PROTEIN; REPLICATION; ELEMENT; YEAST	Hepatitis B virus (HBV), although a DNA virus, replicates using reverse transcriptase encoded by the HBV polymerase (pol) gene, The biochemical dissection of HBV pol has been hampered by failure to liberate enzymatically active protein from nucleocapsids. Here, we have employed a yeast-based genetic approach to express the HBV reverse transcriptase. In this strategy, the reverse transcriptase of yeast retrotransposon Ty1 element is replaced with the HBV pol gene to produce the hybrid Ty1/HBV element. Additionally, the indicator gene his3AI is combined in an antisense orientation to the transcripts of the hybrid Ty1/HBVRT element. The splicing of his3AI; cDNA synthesis of the Ty1/HBVRT RNA and subsequent integration relies on the reverse transcriptase activity. The production of histidine prototrophs results from the successful reverse transcription of Ty1/HBVRThis3AI transcripts followed by either homologous recombination or integrase-mediated insertion and subsequent expression of HIS3 gene. Using this approach we successfully detected the reverse transcriptase activity of HBV in yeast strains defective in endogenous Ty1 expression. Consistent with the unique priming activity associated with HBV pol, the minus strand DNA synthesis was protein-primed. Deletion of HBV reverse transcriptase (RT) or RNase H domains resulted in a dramatic drop in histidine prototrophs, The addition of HBV encoded HBx protein in virus-like particles during in vitro RT reaction stimulated the RT reaction by severalfold. Furthermore, in the presence of 3TC, a known inhibitor of HBV reverse transcriptase, yeast His(+) growth of His protrophs was not observed. Thus, this approach, which is based on genetic selection in yeast, is safe, economic, and a reliable strategy with a potential for large scale screening of cofactors and inhibitors of HBV polymerase functions.	Univ Colorado, Hlth Sci Ctr, Dept Microbiol B172, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Siddiqui, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol B172, 4200 E 9th Ave, Denver, CO 80262 USA.		Qadri, Ishtiaq/I-6889-2013	Qadri, Ishtiaq/0000-0003-4334-0585				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BEASLEY RP, 1981, LANCET, V2, P1129; Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; FOUREL I, 1994, J VIROL, V68, P1059, DOI 10.1128/JVI.68.2.1059-1065.1994; GERLICH WH, 1980, CELL, V21, P801, DOI 10.1016/0092-8674(80)90443-2; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Lanford RE, 1997, J VIROL, V71, P2996, DOI 10.1128/JVI.71.4.2996-3004.1997; Levin HL, 1997, CELL, V88, P5, DOI 10.1016/S0092-8674(00)81851-6; LOEB DD, 1993, REVERSE TRANSCRIPTAS, P329; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; NASAL M, 1996, J VIROL, V67, P3254; NASSAL M, 1993, TRENDS MICROBIOL, V1, P222; Nissley DV, 1996, NATURE, V380, P30, DOI 10.1038/380030a0; Nissley DV, 1998, P NATL ACAD SCI USA, V95, P13905, DOI 10.1073/pnas.95.23.13905; Qadri I, 1996, J BIOL CHEM, V271, P15443, DOI 10.1074/jbc.271.26.15443; SEEGER C, 1986, SCIENCE, V232, P477, DOI 10.1126/science.3961490; SEEGER C, 1991, CURR TOP MICROBIOL, V168, P41; SEIFER M, 1993, J VIROL, V67, P4513, DOI 10.1128/JVI.67.8.4513-4520.1993; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TAVIS JE, 1993, P NATL ACAD SCI USA, V90, P4107, DOI 10.1073/pnas.90.9.4107; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8	25	4	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31359	31365		10.1074/jbc.274.44.31359	http://dx.doi.org/10.1074/jbc.274.44.31359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531336	hybrid			2022-12-25	WOS:000083379400040
J	Ro, HS; Miles, EW				Ro, HS; Miles, EW			Catalytic mechanism of the tryptophan synthase alpha(2)beta(2) complex - Effects of pH, isotopic substitution, and allosteric ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; INDUCED CONFORMATIONAL-CHANGES; O-ACETYLSERINE SULFHYDRYLASE; CARBON CARBON LYASES; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; BETA-SUBUNIT; L-SERINE; PYRIDOXAL-PHOSPHATE; INTERSUBUNIT COMMUNICATION	The mechanism of the tryptophan synthase alpha(2)beta(2) complex from Salmonella typhimurium is explored by determining the effects of pH, of temperature, and of isotopic substitution on the pyridoxal phosphate-dependent reaction of L-serine with indole to form L-tryptophan, The pH dependence of the kinetic parameters indicates that three ionizing groups are involved in substrate binding and catalysis with pK(a)1 = 6.5, pK(a)2 = 7.3, and pK(a)3 = 8.2-9. A significant primary isotope effect (similar to 3.5) on V and V/K is observed at low pH (pH 7), but not at high pH (pH 9), indicating that the base that accepts the alpha-proton (beta Lys-87) is protonated at low pH, slowing the abstraction of the alpha-proton and making this step at least partially rate- limiting. pK(a)2 is assigned to beta Lys-87 on the basis of the kinetic isotope effect results and of the observation that the competitive inhibitors glycine and oxindolyl-L-alanine display single pK(i) values of 7.3. The residue with this pK(a) (beta Lys-87) must be unprotonated for binding glycine or oxindolyl-L-alanine and, by inference, L-serine. Investigations of the temperature dependence of the pK(a) values support the assignment of pK(a)2 to beta Lys-87 and suggest that the ionizing residue with pK(a)1 could be a carboxylate, possibly beta Asp-305, and that the residue associated with a conformational change at pK(a)3 may be beta Lys-167. The occurrence of a closed to open conformational conversion at high pH is supported by investigations of the effects of pH on reaction specificity and on the equilibrium distribution of enzyme-substrate intermediates.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Miles, EW (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,8 Ctr Dr,MSC 0830, Bethesda, MD 20892 USA.	EdithM@intra.niddk.nih.gov	Ro, Hyeon-Su/V-7023-2019					AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; Ahmed SA, 1996, J BIOL CHEM, V271, P29100, DOI 10.1074/jbc.271.46.29100; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Cleland W W, 1979, Methods Enzymol, V63, P500; Davis L, 1972, ENZYMES, P33; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; Fan YX, 1999, BIOCHEMISTRY-US, V38, P7881, DOI 10.1021/bi990307e; FERSHT A, 1985, ENZYME STRUCTURE MEC, P163; GRIMSHAW CE, 1981, BIOCHEMISTRY-US, V20, P5655, DOI 10.1021/bi00523a003; HEILMANN HD, 1978, BIOCHIM BIOPHYS ACTA, V522, P614, DOI 10.1016/0005-2744(78)90092-X; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JENCKS WP, 1959, J AM CHEM SOC, V81, P475, DOI 10.1021/ja01511a053; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7333, DOI 10.1021/bi00419a023; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7339, DOI 10.1021/bi00419a024; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; PHILLIPS RS, 1985, J BIOL CHEM, V260, P4665; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rowlett R, 1998, BIOCHEMISTRY-US, V37, P2961, DOI 10.1021/bi972286z; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; SAVIGE WE, 1980, INT J PEPT PROT RES, V15, P285; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Tipton K F, 1979, Methods Enzymol, V63, P183; TURNER PD, 1985, BIOCHIM BIOPHYS ACTA, V832, P280, DOI 10.1016/0167-4838(85)90261-4; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7118, DOI 10.1021/bi982918x; Yang LH, 1997, J BIOL CHEM, V272, P7859, DOI 10.1074/jbc.272.12.7859; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1993, J BIOL CHEM, V268, P22269	51	12	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31189	31194		10.1074/jbc.274.44.31189	http://dx.doi.org/10.1074/jbc.274.44.31189			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531312	hybrid			2022-12-25	WOS:000083379400016
J	Edwards, HM; Kam, CM; Powers, JC; Trapani, JA				Edwards, HM; Kam, CM; Powers, JC; Trapani, JA			The human cytotoxic T cell granule serine protease granzyme H has chymotrypsin-like (chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET-CELLS; MEDIATED APOPTOSIS; DNA FRAGMENTATION; LYMPHOCYTES; PURIFICATION; SUBSTRATE; PERFORIN; SPECIFICITY; ACTIVATION; RECEPTOR	Serine proteases (granzymes) contained within the cytoplasmic granules of cytotoxic T cells and natural killer cells play a variety of roles including the induction of target cell apoptosis, breakdown of extracellular matrix proteins and induction of cytokine secretion by bystander leukocytes, Different granzymes display proteolytic specificities that mimic the activities of trypsin or chymotrypsin, or may cleave substrates at acidic ("Asp-ase") or at long unbranched amino acids such as Met ("Met-ase"). Here, we report that recombinant granzyme H has chymotrypsin-like (chymase) activity, the first report of a human granzyme with this proteolytic specificity. Recombinant 32-kDa granzyme H expressed in the baculovirus vector pBacPAK8 was secreted from Sf21 cells and recovered by Ni-affinity chromatography, using a poly-His tag encoded at the predicted carboxyl terminus of fall-length granzyme H cDNA. The granzyme H efficiently cleaved Suc-Phe-Leu-Phe-SBzI (v = 185 nM/s at [S] = 0.217 mM) and also hydrolyzed Boc-Ala-Ala-X-SBzI (X = Phe, Tyr, Met, Me, or Nva) with slower rates but had little tryptase or Asp-ase activity. Enzymatic activity was inhibited completely by 0.1 mM 3,4-dichloroisocoumarin and 84% by 1.0 mM phenylmethylsulfonyl fluoride. Fluoresceinated granzyme H was internalized in a temperature-dependent manner by Jurkat cells into endosome-like vesicles, suggesting that it can bind to cell surface receptors similar to those that bind granzyme B. This suggests a hitherto unsuspected intracellular function for granzyme H.	Austin Res Inst, John Connell Lab, Heidelberg, Vic 3084, Australia; Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	Austin Research Institute; University System of Georgia; Georgia Institute of Technology	Trapani, JA (corresponding author), Austin Res Inst, John Connell Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	j.trapani@ari.unimelb.edu.au		Trapani, Joseph/0000-0003-0983-1532	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054401] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54401] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jackson DS, 1998, J MED CHEM, V41, P2289, DOI 10.1021/jm970543s; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1999, J BIOL CHEM, V274, P3953, DOI 10.1074/jbc.274.7.3953; KLEIN JL, 1990, TISSUE ANTIGENS, V35, P220, DOI 10.1111/j.1399-0039.1990.tb01787.x; Maclvor DM, 1999, BLOOD, V93, P963, DOI 10.1182/blood.V93.3.963.403k18_963_973; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PEITSCH MC, 1994, METHOD ENZYMOL, V244, P80; Pham CTN, 1998, J BIOL CHEM, V273, P1629, DOI 10.1074/jbc.273.3.1629; Pinkoski MJ, 1998, BLOOD, V92, P1044; POE M, 1991, J BIOL CHEM, V266, P98; POWERS JC, 1995, METHOD ENZYMOL, V248, P3; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Smyth MJ, 1996, J IMMUNOL, V156, P4174; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Sower LE, 1996, J IMMUNOL, V156, P2585; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Sutton VR, 1997, J IMMUNOL, V158, P5783; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1999, IMMUNOL TODAY, V20, P351, DOI 10.1016/S0167-5699(99)01488-7; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Woodard SL, 1998, J IMMUNOL, V160, P4988	34	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30468	30473		10.1074/jbc.274.43.30468	http://dx.doi.org/10.1074/jbc.274.43.30468			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521426	hybrid			2022-12-25	WOS:000083276700022
J	Fleischmann, MM; Ravanel, S; Delosme, R; Olive, J; Zito, F; Wollman, FA; Rochaix, JD				Fleischmann, MM; Ravanel, S; Delosme, R; Olive, J; Zito, F; Wollman, FA; Rochaix, JD			Isolation and characterization of photoautotrophic mutants of Chlamydomonas reinhardtii deficient in state transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; PROTEIN-PHOSPHORYLATION; PHOTOSYSTEM-II; NUCLEAR TRANSFORMATION; PHOTOSYNTHETIC SYSTEMS; POLYPHENOL OXIDASE; EXCITATION-ENERGY; LHCII KINASE; WILD-TYPE; IN-VIVO	In photosynthetic cells of higher plants and algae, the distribution of light energy between photosystem I and photosystem II is controlled by light quality through a process called state transition. It involves a reorganization of the light-harvesting complex of photosystem II (LHCII) within the thylakoid membrane whereby light energy captured preferentially by photosystem II is redirected toward photosystem I or vice versa. State transition is correlated with the reversible phosphorylation of several LHCII proteins and requires the presence of functional cytochrome b(6)f complex. Most factors controlling state transition are still not identified. Here we describe the isolation of photoautotrophic mutants of the unicellular alga Chlamydomonas reinhardtii, which are deficient in state transition. Mutant stt7 is unable to undergo state transition and remains blocked in state I as assayed by fluorescence and photoacoustic measurements. Immunocytochemical studies indicate that the distribution of LHCII and of the cytochrome b(6)f complex between appressed and nonappressed thylakoid membranes does not change significantly during state transition in stt7, in contrast to the wild type. This mutant displays the same deficiency in LHCII phosphorylation as observed for mutants deficient in cytochrome b(6)f complex that are known to be unable to undergo state transition. The stt7 mutant grows photoautotrophically, although at a slower rate than wild type, and does not appear to be more sensitive to photoinactivation than the wild-type strain. Mutant stt3-4b is partially deficient in state transition but is still able to phosphorylate LHCII. Potential factors affected in these mutant strains and the function of state transition in C. reinhardtii are discussed.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva, Switzerland; Inst Biol Phys Chim, F-75005 Paris, France; Univ Denis Diderot, CNRS, Inst Jacques Monod, F-75251 Paris, France	University of Geneva; University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Rochaix, JD (corresponding author), Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland.		Rochaix, Jean-David/ABC-5243-2020	Zito, Francesca/0000-0003-1783-5090; Ravanel, Stephane/0000-0001-9475-4222				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BASSI R, 1991, PLANTA, V183, P423, DOI 10.1007/BF00197742; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DELEPELAIRE P, 1985, BIOCHIM BIOPHYS ACTA, V809, P277, DOI 10.1016/0005-2728(85)90071-4; DELOSME R, 1994, BBA-BIOENERGETICS, V1185, P56, DOI 10.1016/0005-2728(94)90193-7; Delosme R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3; Delphin E, 1995, BBA-BIOENERGETICS, V1232, P91, DOI 10.1016/0005-2728(95)00133-6; FENTON JM, 1990, PHOTOSYNTH RES, V26, P59, DOI 10.1007/BF00048977; GAL A, 1990, J BIOL CHEM, V265, P19742; GAL A, 1992, FEBS LETT, V298, P33, DOI 10.1016/0014-5793(92)80016-A; GILLHAM NW, 1965, GENETICS, V52, P529; GODDE D, 1982, ARCH MICROBIOL, V131, P197, DOI 10.1007/BF00405878; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; Gumpel Nicola J., 1994, Trends in Cell Biology, V4, P299, DOI 10.1016/0962-8924(94)90222-4; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HIND G, 1995, BIOCHEMISTRY-US, V34, P8157, DOI 10.1021/bi00025a022; HORTON P, 1990, BIOCHIM BIOPHYS ACTA, V1017, P160, DOI 10.1016/0005-2728(90)90147-V; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; MICHEL H, 1991, J BIOL CHEM, V266, P17584; OHAD I, 1990, J BIOL CHEM, V265, P1972; OWENS GC, 1982, J CELL BIOL, V93, P712, DOI 10.1083/jcb.93.3.712; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUSTER G, 1986, J CELL BIOL, V103, P71, DOI 10.1083/jcb.103.1.71; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; SOKOLENKO A, 1995, FEBS LETT, V371, P176, DOI 10.1016/0014-5793(95)00892-D; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; TURPIN DH, 1990, FEBS LETT, V263, P99, DOI 10.1016/0014-5793(90)80714-T; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; VERNOTTE C, 1979, BIOCHIM BIOPHYS ACTA, V545, P519, DOI 10.1016/0005-2728(79)90160-9; VITRY CD, 1988, BIOCHIM BIOPHYS ACTA, V933, P444; WILLEBRAND KO, 1989, PLANT PHYSIOL, V190, P1084; Wollman F.-A., 1988, PHOTOCATALYTIC PRODU, P210; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V1017, P235; WOLLMAN FA, 1983, J CELL BIOL, V97, P1; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	50	89	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30987	30994		10.1074/jbc.274.43.30987	http://dx.doi.org/10.1074/jbc.274.43.30987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521495	Green Published, hybrid			2022-12-25	WOS:000083276700091
J	Posner, BA; Gilman, AG; Harris, BA				Posner, BA; Gilman, AG; Harris, BA			Regulators of g protein signaling 6 and 7 - Purification of complexes with G beta 5 and assessment of their effects on G protein-mediated signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; MAMMALIAN ADENYLYL CYCLASES; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C ISOZYMES; RGS PROTEINS; ALPHA-SUBUNITS; TRANSITION-STATE; SF9 CELLS; EXPRESSION	Regulators of G protein signaling (RGS) proteins that contain DEP (disheveled, (E) under bar GL-10, (p) under bar leckstrin) and GGL ((G) under bar protein <(gamma)under bar> subunit-(l) under bar ike) domains form a subfamily that includes the mammalian RGS proteins RGS6, RGS7, RGS9, and RGS11. We describe the cloning of RGS6 cDNA, the specificity of interaction of RGS6 and RGS7 with G protein beta subunits, and certain biochemical properties of RGS6/beta 5 and RGS7/beta 5 complexes. After expression in Sf9 cells, complexes of both RGS6 and RGS7 with the G beta 5 subunit (but not G beta s 1-4) are found in the cytosol. When purified, these complexes are similar to RGS11/beta 5 in that they act as GTPase-activating proteins specifically toward G alpha(o). Unlike conventional G(beta gamma) complexes, RGS6/beta 5 and RGS7/beta 5 do not form heterotrimeric complexes with either G alpha(o)-GDP or G alpha(q)-GDP. Neither RGS6/beta 5 nor RGS7/beta 5 altered the activity of adenylyl cyclases types I, II, or V, nor were they able to activate either phospholipase C-beta 1 or -beta 2. However, the RGS/beta 5 complexes inhibited beta(1)gamma(2)-mediated activation of phospholipase C-beta 2. RGS/beta 5 complexes may contribute to the selectivity of signal transduction initiated by receptors coupled to G(i) and G(o) by binding to phospholipase C and stimulating the GTPase activity of G alpha(o).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Hoechst Marion Roussel Inc, Bridgewater, NJ 08807 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Elmore T, 1998, DNA CELL BIOL, V17, P983, DOI 10.1089/dna.1998.17.983; Gold SJ, 1997, J NEUROSCI, V17, P8024; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Ingi T, 1998, J NEUROSCI, V18, P7178; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LEE E, 1994, METHOD ENZYMOL, V237, P146; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P4573; Pepperl DJ, 1998, BIOCHEM BIOPH RES CO, V243, P52, DOI 10.1006/bbrc.1997.8056; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	39	115	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31087	31093		10.1074/jbc.274.43.31087	http://dx.doi.org/10.1074/jbc.274.43.31087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521509	hybrid			2022-12-25	WOS:000083276700105
J	Rudolph, MG; Weise, C; Mirold, S; Hillenbrand, B; Bader, B; Wittinghofer, A; Hardt, WD				Rudolph, MG; Weise, C; Mirold, S; Hillenbrand, B; Bader, B; Wittinghofer, A; Hardt, WD			Biochemical analysis of SopE from Salmonella typhimurium, a highly efficient guanosine nucleotide exchange factor for RhoGTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; SEC7 DOMAIN; 3-DIMENSIONAL STRUCTURES; SECONDARY-STRUCTURE; PROTEIN; RAS; RHO; MECHANISM; BINDING; GTPASES	RhoGTPases are key regulators of eukaryotic cell physiology, The bacterial enteropathogen Salmonella typhimurium modulates host cell physiology by translocating specific toxins into the cytoplasm of host cells that induce responses such as apoptotic cell death in macrophages, the production of proinflammatory cytokines, the rearrangement of the host cell actin cytoskeleton (membrane ruffling), and bacterial entry into host cells. One of the translocated toxins is SopE, which has been shown to bind to RhoGTPases of the host cell and to activate RhoGTPase signaling. SopE is sufficient to induce profuse membrane ruffling in Cos cells and to facilitate efficient bacterial internalization. We show here that SopE belongs to a novel class of bacterial toxins that modulate RhoGTPase function by transient interaction, Surface plasmon resonance measurements revealed that the kinetics of formation and dissociation of the SopE.CDC42 complex are in the same order of magnitude as those described for complex formation of GTPases of the Ras superfamily with their cognate guanine nucleotide exchange factors (GEFs), In the presence of excess GDP, dissociation of the SopE.CDC42 complex was accelerated more than 1000-fold. SopE-mediated guanine nucleotide exchange was very efficient (e.g. exchange rates almost 10(5)-fold above the level of the uncatalyzed reaction; substrate affinity), and the kinetic constants were similar to those described for guanine nucleotide exchange mediated by CDC25 or RCC1, Far-UV CD spectroscopy revealed that SopE has a high content of alpha-helical structure, a feature also found in Dbl homology domains, Sec7-like domains, and the Ras-GEF domain of Sos. Despite the lack of any obvious sequence similarity, our data suggest that SopE may closely mimic eukaryotic GEFs.	Univ Munich, Max Von Pettenkofer Inst, D-80336 Munich, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	University of Munich; Max Planck Society; Free University of Berlin	Hardt, WD (corresponding author), Univ Munich, Max Von Pettenkofer Inst, Pettenkoferstr 9A, D-80336 Munich, Germany.			Hardt, Wolf-Dietrich/0000-0002-9892-6420; Bader, Benjamin/0000-0002-5299-396X; Rudolph, Markus/0000-0003-0447-1101				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOUME HR, 1991, NATURE, V349, P117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Groisman EA, 1997, TRENDS MICROBIOL, V5, P343, DOI 10.1016/S0966-842X(97)01099-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; HART M, 1995, METHOD ENZYMOL, V255, P129; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1988, J BIOL CHEM, V263, P11792; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MIKI T, 1995, METHOD ENZYMOL, V256, P90; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Rudolph MG, 1999, PROTEIN SCI, V8, P778; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Watson PR, 1998, INFECT IMMUN, V66, P1432, DOI 10.1128/IAI.66.4.1432-1438.1998; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; YANG JT, 1986, CALCULATION PROTEIN, P208	49	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30501	30509		10.1074/jbc.274.43.30501	http://dx.doi.org/10.1074/jbc.274.43.30501			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521431	hybrid			2022-12-25	WOS:000083276700027
J	Suh, WC; Lu, CZ; Gross, CA				Suh, WC; Lu, CZ; Gross, CA			Structural features required for the interaction of the Hsp70 molecular chaperone DnaK with its cochaperone DnaJ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; SHOCK COGNATE PROTEIN; ESCHERICHIA-COLI DNAJ; ATPASE ACTIVITY; SUBSTRATE-BINDING; MOTIF; SITE; ACTIVATION; STIMULATE; FRAGMENT	Hsp70 family members together with their Hsp40 co-chaperones function as molecular chaperones, using an ATP-controlled cycle of polypeptide binding and release to mediate protein folding. Hsp40 plays a key role in the chaperone reaction by stimulating the ATPase activity and activating the substrate binding of Hsp70. We have explored the interaction between the Escherichia coli Hsp70 family member, DnaK, and its cochaperone partner DnaJ. Our data show that the binding of ATP, subsequent conformational changes in DnaK, and DnaJ-stimulated ATP hydrolysis are all required for the formation of a DnaK-DnaJ complex as monitored by Biacore analysis. In addition, our data imply that the interaction of the J-domain with DnaK depends on the substrate binding stale of DnaK.	Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gross, CA (corresponding author), Univ Calif San Francisco, Dept Microbiol, 513 Parnassus,Box 0512, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036278, R37GM036278] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36278-13] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auger I, 1997, J CLIN INVEST, V99, P1818, DOI 10.1172/JCI119348; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BUKAU B, 1999, MOL CHAPERONES FOLDI; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; FEILFEL B, 1996, EUR J BIOCHEM, V237, P318; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300	30	117	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30534	30539		10.1074/jbc.274.43.30534	http://dx.doi.org/10.1074/jbc.274.43.30534			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521435	hybrid			2022-12-25	WOS:000083276700031
J	Barmina, OY; Walling, HW; Fiacco, GJ; Freije, JMP; Lopez-Otin, C; Jeffrey, JJ; Partridge, NC				Barmina, OY; Walling, HW; Fiacco, GJ; Freije, JMP; Lopez-Otin, C; Jeffrey, JJ; Partridge, NC			Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; INTERSTITIAL COLLAGENASE; MEDIATED ENDOCYTOSIS; OSTEOBLASTIC CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; SYNTHESIZE COLLAGENASE; RECYCLING RECEPTORS; MOUSE OSTEOBLASTS; TISSUE INHIBITOR	We have previously identified a specific receptor for collagenase-3 that mediates the binding, internalization, and degradation of this ligand in UMR 106-01 rat osteoblastic osteosarcoma cells. In the present study, we show that collagenase-3 binding is calcium-dependent and occurs in a variety of cell types, including osteoblastic and fibroblastic cells. We also present evidence supporting a two-step mechanism of collagenase-3 binding and internalization involving both a specific collagenase-3 receptor and the low density lipoprotein receptor-related protein. Ligand blot analysis shows that I-125-collagenase-3 binds specifically to two proteins (similar to 170 kDa and similar to 600 kDa) present in UMR 106-01 cells. Western blotting identified the 600-kDa protein as the low density lipoprotein receptor-related protein. Our data suggest that the 170-kDa protein is a specific collagenase-3 receptor. Low density lipoprotein receptor-related protein-null mouse embryo fibroblasts bind but fail to internalize collagenase-3, whereas UMR 106-01 and wildtype mouse embryo fibroblasts bind and internalize collagenase-3. Internalization, but not binding, is inhibited by the 39-kDa receptor-associated protein. We conclude that the internalization of collagenase-3 requires the participation of the low density lipoprotein receptor-related protein and propose a model in which the cell surface interaction of this ligand requires a sequential contribution from two receptors, with the collagenase-3 receptor acting as a high affinity primary binding site and the low density lipoprotein receptor-related protein mediating internalization.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Albany Med Coll, Dept Biochem, Albany, NY 12208 USA	Saint Louis University; University of Oviedo; Albany Medical College	Partridge, NC (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.		López-Otín, Carlos/AAB-2106-2020; Freije, José M.P./A-6535-2008	López-Otín, Carlos/0000-0001-6964-1904; Freije, José M.P./0000-0002-4688-8266; Partridge, Nicola/0000-0002-5406-4814	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040661] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40661] Funding Source: Medline; NICHD NIH HHS [HD 05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BU GJ, 1994, J BIOL CHEM, V269, P29874; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KAHN AJ, 1987, AM J OTOLARYNG, V8, P258, DOI 10.1016/S0196-0709(87)80044-3; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LORENZO JA, 1992, MATRIX, V12, P282, DOI 10.1016/S0934-8832(11)80080-6; LUNDGREN S, 1994, EXP CELL RES, V212, P344, DOI 10.1006/excr.1994.1153; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MEIKLE MC, 1992, J CELL SCI, V103, P1093; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; Nagase H, 1992, Matrix Suppl, V1, P421; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RIFAS L, 1989, J CLIN INVEST, V84, P686, DOI 10.1172/JCI114216; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; THOMSON BM, 1987, BIOCHEM BIOPH RES CO, V148, P596, DOI 10.1016/0006-291X(87)90918-1; VARGHESE S, 1994, ENDOCRINOLOGY, V134, P2438, DOI 10.1210/en.134.6.2438; Walling HW, 1998, J CELL PHYSIOL, V177, P563, DOI 10.1002/(SICI)1097-4652(199812)177:4<563::AID-JCP7>3.0.CO;2-B; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	52	107	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30087	30093		10.1074/jbc.274.42.30087	http://dx.doi.org/10.1074/jbc.274.42.30087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514495	hybrid			2022-12-25	WOS:000083176400074
J	Bode, JG; Gatsios, P; Ludwig, S; Rapp, UR; Haussinger, D; Heinrich, PC; Graeve, L				Bode, JG; Gatsios, P; Ludwig, S; Rapp, UR; Haussinger, D; Heinrich, PC; Graeve, L			The mitogen-activated protein (MAP) kinase p38 and its upstream activator MAP kinase kinase 6 are involved in the activation of signal transducer and activator of transcription by hyperosmolarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; INFLAMMATORY CYTOKINES; MAMMALIAN-CELLS; GENE-EXPRESSION; PHOSPHATASE; INTERLEUKIN-6; BINDING; PATHWAY; STRESS; RECEPTOR	Environmental stress (e.g. aniso-osmolarity and UV light), hypoxia/reoxygenation, and reactive oxygen species activate intracellular signaling cascades such as the "stress-responsive" mitogen-activated protein kinases and nuclear factor kappa B. We have recently shown that the Janus tyrosine kinase/signal transducer and activator of transcription (Jak/STAT) pathway is ligand-independently activated by hyperosmotic shock. In the present study, we show that besides STAT1 also the tyrosine phosphatase SNP2 became tyrosine-phosphorylated upon hyperosmolarity. SE 202190 and SE 203580 (specific inhibitors of p38) inhibited both STAT activation and tyrosine phosphorylation of SHP2 induced by hyperosmotic stress. Overexpression of wild-type p38 mitogen-activated protein kinase and its upstream activator mitogen-activated protein kinase kinase 6 (MKK6) resulted in an enhanced STAT1 tyrosine phosphorylation upon osmotic shock. Accordingly, overexpression of dominant negative mutants of p38 and MKK6 largely decreased hyperosmotic STAT1 activation and tyrosine phosphorylation of SHP2. Furthermore, we provide evidence that a genistein-sensitive tyrosine kinase different from Jak1 is involved in stress-activation of STAT1 and tyrosine phosphorylation of SHP2. These results strongly suggest that hyperosmotic shock activates STAT1 and SHP2 via p38 and its upstream activator MKK6.	Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Dusseldorf, Med Klin, D-40255 Dusseldorf, Germany	RWTH Aachen University; University of Wurzburg; Heinrich Heine University Dusseldorf	Heinrich, PC (corresponding author), Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.			Ludwig, Stephan/0000-0003-4490-3052				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Haussinger D, 1996, BIOCHEM J, V313, P697; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sambrook J., 2002, MOL CLONING LAB MANU; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	37	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30222	30227		10.1074/jbc.274.42.30222	http://dx.doi.org/10.1074/jbc.274.42.30222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514514	hybrid			2022-12-25	WOS:000083176400093
J	Dalton, SL; Scharf, E; Davey, G; Assoian, RK				Dalton, SL; Scharf, E; Davey, G; Assoian, RK			Transforming growth factor-beta overrides the adhesion requirement for surface expression of alpha(5)beta(1) integrin in normal rat kidney fibroblasts - A necessary effect for induction of anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR	We have previously shown that the expression of alpha(5)beta(1) integrin on the cell surface is dependent upon cell adhesion to the extracellular matrix, and we report here that transforming growth factor-beta (TGF-beta) overcomes this requirement in normal rat kidney (NRK) fibroblasts. Thus, suspended NRK cells treated with TGF-beta show levels of surface alpha(5)beta(1) integrin that are equivalent to those seen in adherent cells. Moreover, several experiments showed that this effect is necessary for the induction of anchorage-independent growth by TGF-beta. First, a kinetic analysis showed that surface expression of alpha(5)beta(1) integrin was restored in TGF-beta-treated NRK cells prior to the induction of anchorage-independent growth. Second, NRK cell mutants that have lost their TGF-beta requirement for surface expression of alpha(5)beta(1) integrin were anchorage-independent in the absence of TGF-beta, Third, an antisense oligonucleotide to the beta(1) integrin subunit or, fourth, stable expression of an alpha(5)-antisense cDNA blocked the ability of TGF-beta to stimulate anchorage-independent growth. Thus, TGF-beta overrides the adhesion requirement for surface expression of alpha(5)beta(1) integrin in NRK cells, and this effect is necessary for the induction of anchorage-independent growth.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Assoian, RK (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk,167 Johnson Pavill, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048224, R01GM051878] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48224, GM51878] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; DALTON SL, 1992, J BIOL CHEM, V267, P3186; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iavarone A, 1997, NATURE, V387, P417; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHREINER C, 1991, CANCER RES, V51, P1738; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154	26	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30139	30145		10.1074/jbc.274.42.30139	http://dx.doi.org/10.1074/jbc.274.42.30139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514503	hybrid			2022-12-25	WOS:000083176400082
J	DeLong, CJ; Shen, YJ; Thomas, MJ; Cui, Z				DeLong, CJ; Shen, YJ; Thomas, MJ; Cui, Z			Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; N-METHYLTRANSFERASE; N-METHYLTRANSFERASE-2; EXPRESSION; CELLS; PROTEINS; GROWTH; LIVER	In addition to the CDP-choline pathway for phosphatidylcholine (PC) synthesis, the liver has a unique phosphatidylethanolamine (PE) methyltransferase activity for PC synthesis via three methylations of the ethanolamine moiety of PE, Previous studies indicate that the two pathways are functionally different and not interchangeable even though PC is the common product of both pathways. This study was designed to test the hypothesis that these two pathways produce different profiles of PC species. The PC species from these two pathways were labeled with specific stable isotope precursors, DS-choline and D4-ethanolamine, and analyzed by electrospray tandem mass spectrometry. Our studies revealed a profound distinction in PC profiles between the CDP-choline pathway and the PE methylation pathway, PC molecules produced from the CDP-choline pathway were mainly comprised of medium chain, saturated (e.g. 16:0/18:0) species. On the other hand, PC molecules from the PE methylation pathway were much more diverse and were comprised of significantly more long chain, polyunsaturated (e.g. 18:0/20:4) species. PC species from the methylation pathway contained a higher percentage of arachidonate and were more diverse than those from the CDP-choline pathway, This profound distinction of PC profiles may contribute to the different functions of these two pathways in the liver.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Cui, Z (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.			DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [R01-CA85757, CA-09422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNSTROM K, 1991, ANAL BIOCHEM, V198, P203, DOI 10.1016/0003-2697(91)90530-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; BRYANT DK, 1991, ANAL CHEM, V63, P1110, DOI 10.1021/ac00011a010; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Cui Z, 1995, BIOCHEM J, V312, P939, DOI 10.1042/bj3120939; CUI Z, 1993, J BIOL CHEM, V268, P16655; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; KERWIN JL, 1994, J LIPID RES, V35, P1102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RAETZ CRH, 1982, PHOSPHOLIPIDS, P435; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16856; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Tessitore L, 1997, BIOCHEM J, V322, P151, DOI 10.1042/bj3220151; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Vance DE, 1998, CURR OPIN LIPIDOL, V9, P125, DOI 10.1097/00041433-199804000-00008; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172	24	284	289	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29683	29688		10.1074/jbc.274.42.29683	http://dx.doi.org/10.1074/jbc.274.42.29683			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514439	hybrid			2022-12-25	WOS:000083176400018
J	Ekinci, FJ; Malik, KU; Shea, TB				Ekinci, FJ; Malik, KU; Shea, TB			Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid - Map kinase mediates beta-amyloid-induced neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMERS-DISEASE; TAU-PROTEIN; FREE-RADICALS; HIPPOCAMPAL-NEURONS; NEUROBLASTOMA-CELLS; CORTICAL-NEURONS; TISSUE-INJURY; CA2+ CHANNELS; PHOSPHORYLATION	Neuronal degeneration in Alzheimer's disease (AD) has been variously attributed to increases in cytosolic calcium, reactive oxygen species, and phosphorylated forms of the microtubule-assooiated protein tau, beta-Amyloid (beta A), which accumulates extracellularly in AD brain, induces calcium influx in culture via the L voltage-sensitive calcium channel. Since this channel is normally activated by protein kinase A-mediated phosphorylation, we examined kinase activities recruited following beta A treatment of cortical neurons and SH-SY-5Y neuroblastoma, beta A increased channel phosphorylation; this increase was unaffected by the protein kinase A inhibitor H89 but was reduced by the mitogen-activated protein (MAP) kinase inhibitor PD98059, Pharmacological and antisense oligonucleotide-mediated reduction of MAP kinase activity also reduced beta A-induced accumulation of calcium, reactive oxygen species, phospho-tau immunoreactivity, and apoptosis. These findings indicate that MAP kinase mediates multiple aspects of beta A-induced neurotoxicity and indicates that calcium influx initiates neurodegeneration in AD. beta A increased MAP kinase-mediated phosphorylation of membrane-associated proteins and reduced phosphorylation of cytosolic: proteins without increasing overall MAP kinase activity. Increasing MAP kinase activity with epidermal growth factor did not increase channel phosphorylation, These findings indicate that redirection, rather than increased activation, of MAP kinase activity mediates beta A-induced neurotoxicity.	Univ Massachusetts, Ctr Cellular Neurobiol & Neurodegenerat Res, Dept Sci Biol, Lowell, MA 01854 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA	University of Massachusetts System; University of Massachusetts Lowell; University of Tennessee System; University of Tennessee Health Science Center	Shea, TB (corresponding author), Univ Massachusetts, Ctr Cellular Neurobiol & Neurodegenerat Res, Dept Sci Biol, 1 Univ Ave, Lowell, MA 01854 USA.	Thomas_Shea@uml.edu						ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Boyce JJ, 1997, INT J DEV NEUROSCI, V15, P295, DOI 10.1016/S0736-5748(97)00010-5; BOYNE LJ, 1995, J NEUROSCI RES, V40, P439, DOI 10.1002/jnr.490400403; CHAJRY N, 1994, BIOCHEM BIOPH RES CO, V203, P984, DOI 10.1006/bbrc.1994.2279; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; CRESSMAN CM, 1995, J NEUROSCI RES, V42, P648, DOI 10.1002/jnr.490420507; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EKINCI FJ, 1999, IN PRESS MOL BIOL CE; FREEMAN BA, 1982, LAB INVEST, V47, P412; GIFFIN K, 1991, NEURON, V6, P321, DOI 10.1016/0896-6273(91)90242-R; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GRAY CW, 1995, BRAIN RES, V691, P169, DOI 10.1016/0006-8993(95)00669-H; Haas C., 1992, NATURE, V359, P149; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARTMANN H, 1993, BIOCHEM BIOPH RES CO, V194, P1216, DOI 10.1006/bbrc.1993.1952; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; KHODOROV B, 1993, FEBS LETT, V324, P271, DOI 10.1016/0014-5793(93)80132-E; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LATIMER DA, 1995, FEBS LETT, V365, P42, DOI 10.1016/0014-5793(95)00434-B; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LIN LW, 1995, DRUG AGING, V6, P136, DOI 10.2165/00002512-199506020-00006; Lin MC, 1996, GWUMC DEPT, P331; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; LU Q, 1993, J NEUROSCI RES, V35, P439, DOI 10.1002/jnr.490350411; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MORI H, 1992, J BIOL CHEM, V267, P17082; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PEI JJ, 1994, BRAIN RES, V655, P70, DOI 10.1016/0006-8993(94)91598-9; PERRY G, 1999, IN PRESS NEUROREPORT; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; Pundreddy S, 1997, NEUROSCI RES COMMUN, V21, P173, DOI 10.1002/(SICI)1520-6769(199711/12)21:3<173::AID-NRC221>3.0.CO;2-P; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; RAGHUNANDAN R, 1995, BIOCHEM BIOPH RES CO, V215, P1056, DOI 10.1006/bbrc.1995.2571; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEA TB, 1990, J NEUROCHEM, V55, P1784, DOI 10.1111/j.1471-4159.1990.tb04969.x; Shea TB, 1997, J NEUROSCI RES, V49, P759, DOI 10.1002/(SICI)1097-4547(19970915)49:6<759::AID-JNR10>3.0.CO;2-N; Shea TB, 1997, J NEUROSCI RES, V50, P114, DOI 10.1002/(SICI)1097-4547(19971001)50:1<114::AID-JNR12>3.0.CO;2-B; Shea TB, 1996, J NEUROCHEM, V66, P1539; SHEA TB, 1993, J NEUROSCI RES, V35, P507, DOI 10.1002/jnr.490350507; SHEA TB, 1995, NEUROREPORT, V6, P1437, DOI 10.1097/00001756-199507100-00019; Shea TB, 1998, NEUROSCI RES COMMUN, V22, P45, DOI 10.1002/(SICI)1520-6769(199801/02)22:1<45::AID-NRC7>3.0.CO;2-S; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SINGH TJ, 1995, FEBS LETT, V358, P4, DOI 10.1016/0014-5793(94)01383-C; SINGH TJ, 1994, FEBS LETT, V267, P358; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Ueda K, 1997, J NEUROCHEM, V68, P265; You YD, 1997, BIOPHYS J, V72, P175, DOI 10.1016/S0006-3495(97)78656-9; Zhou Y, 1996, J NEUROCHEM, V67, P1419	63	148	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30322	30327		10.1074/jbc.274.42.30322	http://dx.doi.org/10.1074/jbc.274.42.30322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514528	hybrid			2022-12-25	WOS:000083176400107
J	Knodler, LA; Noiva, R; Mehta, K; McCaffery, JM; Aley, SB; Svard, SG; Nystul, TG; Reiner, DS; Silberman, JD; Gillin, FD				Knodler, LA; Noiva, R; Mehta, K; McCaffery, JM; Aley, SB; Svard, SG; Nystul, TG; Reiner, DS; Silberman, JD; Gillin, FD			Novel protein-disulfide isomerases from the early-diverging protist Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CHAPERONE ACTIVITIES; CYST WALL PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SURFACE-ANTIGEN; BOND FORMATION; ENERGY-METABOLISM; PEPTIDE BINDING; IN-VITRO; THIOREDOXIN	Protein-disulfide isomerase is essential for formation and reshuffling of disulfide bonds during nascent protein folding in the endoplasmic reticulum, The two thioredoxin-like active sites catalyze a variety of thiol-disulfide exchange reactions. We have characterized three novel protein-disulfide isomerases from the primitive eukaryote Giardia lamblia, Unlike other protein-disulfide isomerases, the giardial enzymes have only one active site. The active-site sequence motif in the giardial proteins (CGHC) is characteristic of eukaryotic protein-disulfide isomerases, and not other members of the thioredoxin superfamily that have one active site, such as thioredoxin and Dsb proteins from Gram-negative bacteria, The three giardial proteins have very different amino acid sequences and molecular masses (26, 50, and 13 kDa). All three enzymes were capable of rearranging disulfide bonds, and giardial protein-disulfide isomerase-2 also displayed oxidant and reductant activities. Surprisingly, the three giardial proteins also hard Ca2+-dependent transglutaminase activity. This is the first report of protein-disulfide isomerases with a single! active site that have diverse roles in protein cross-linking. This study may provide clues to the evolution of key functions of the endoplasmic reticulum in eukaryotic: cells, protein disulfide formation, and isomerization.	Univ Calif San Diego, Sch Med, Dept Pathol, Div Infect Dis, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, San Diego, CA 92103 USA; Univ S Dakota, Sch Med, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of South Dakota; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego; Marine Biological Laboratory - Woods Hole	Gillin, FD (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, Div Infect Dis, 214 Dickinson St, San Diego, CA 92103 USA.		Reiner, David S./F-6106-2012; Silberman, Jeffrey D/AAK-8220-2020	Reiner, David S./0000-0002-8289-7311; Silberman, Jeffrey D/0000-0002-2965-9197; Knodler, Leigh/0000-0002-3028-2198; Aley, Stephen/0000-0003-1214-4688; Svard, Staffan/0000-0002-7392-1746	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042488, R01AI024285, R21AI024285] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42488, AI24285] Funding Source: Medline; NIGMS NIH HHS [GM53835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Alberts B., 1994, MOL BIOL CELL; ALEY SB, 1993, EXP PARASITOL, V77, P295, DOI 10.1006/expr.1993.1087; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARDWELL JC, 1991, CELL, V67, P582; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BROWN DM, 1993, MOL BIOCHEM PARASIT, V61, P155, DOI 10.1016/0166-6851(93)90169-X; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DAS S, 1991, J BIOL CHEM, V266, P21318; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hetsko ML, 1998, EXP PARASITOL, V88, P172, DOI 10.1006/expr.1998.4246; HILARIO E, 1995, BIOCHIM BIOPHYS ACTA, V128, P94; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jeon S, 1998, P NATL ACAD SCI USA, V95, P687, DOI 10.1073/pnas.95.2.687; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LINDMARK DG, 1980, MOL BIOCHEM PARASIT, V1, P1, DOI 10.1016/0166-6851(80)90037-7; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; Mehta K, 1996, MOL BIOCHEM PARASIT, V76, P105, DOI 10.1016/0166-6851(95)02549-9; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1993, J BIOL CHEM, V268, P19210; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PUIG A, 1994, J BIOL CHEM, V269, P19128; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; Que XC, 1996, MOL BIOCHEM PARASIT, V81, P101, DOI 10.1016/0166-6851(96)02698-9; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Smith MW, 1998, MOL BIOCHEM PARASIT, V95, P267, DOI 10.1016/S0166-6851(98)00113-3; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Svard SG, 1998, MOL MICROBIOL, V30, P979, DOI 10.1046/j.1365-2958.1998.01125.x; Svard SG, 1999, MOL BIOCHEM PARASIT, V98, P253, DOI 10.1016/S0166-6851(98)00174-1; Tachikawa H, 1997, BIOCHEM BIOPH RES CO, V239, P710, DOI 10.1006/bbrc.1997.7426; TACHIKAWA H, 1995, FEBS LETT, V369, P212, DOI 10.1016/0014-5793(95)00750-4; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Westphal V, 1999, J MOL BIOL, V286, P1229, DOI 10.1006/jmbi.1999.2560	61	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29805	29811		10.1074/jbc.274.42.29805	http://dx.doi.org/10.1074/jbc.274.42.29805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514458	hybrid			2022-12-25	WOS:000083176400037
J	Scotti, PA; Valent, QA; Manting, EH; Urbanus, ML; Driessen, AJM; Oudega, B; Luirink, J				Scotti, PA; Valent, QA; Manting, EH; Urbanus, ML; Driessen, AJM; Oudega, B; Luirink, J			SecA is not required for signal recognition particle-mediated targeting and initial membrane insertion of a nascent inner membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SRP; ENDOPLASMIC-RETICULUM; PROTONMOTIVE FORCE; RECEPTOR; BINDING; FTSY; RIBONUCLEOPROTEIN; TRANSLOCATION; PERMEASE; VESICLES	In Escherichia coli, signal recognition particle (SRP)-dependent targeting of inner membrane proteins has been described. In vitro cross-linking studies have demonstrated that short nascent chains exposing a highly hydrophobic targeting signal interact with the SRP. This SRP, assisted by its receptor, FtsY, mediates the transfer to a common translocation site in the inner membrane that contains SecA, SecG, and SecY. Here we describe a further in vitro reconstitution of SRP-mediated membrane insertion in which purified ribosome-nascent chain-SRP complexes are targeted to the purified SecYEG complex contained in proteoliposomes in a process that requires the SRP-receptor FtsY and GTP. We found that in this system SecA and ATP are dispensable for both the transfer of the nascent inner membrane protein FtsQ to SecY and its stable membrane insertion. Release of the SRP from nascent FtsQ also occurred in the absence of SecYEG complex indicating a functional interaction of FtsY with lipids. These data suggest that SRP/FtsY and SecB/SecA constitute distinct targeting routes.	Bioctr Amsterdam, Inst Mol Biol Sci, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Amsterdam; University of Groningen	Luirink, J (corresponding author), Bioctr Amsterdam, Inst Mol Biol Sci, Dept Microbiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	luirink@bio.vu.nl	Driessen, Arnold J.M./D-1876-2012; Luirink, Joen/AAB-8658-2021	SCOTTI, Pier-Arnaldo/0000-0003-4427-3695; Driessen, Arnold J.M./0000-0001-9258-9104; Luirink, J./0000-0001-8431-0804				Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; deLeeuw E, 1997, FEBS LETT, V416, P225, DOI 10.1016/S0014-5793(97)01238-6; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; LUIRINK J, 1994, MOL MICROBIOL, V11, P9, DOI 10.1111/j.1365-2958.1994.tb00284.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	31	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29883	29888		10.1074/jbc.274.42.29883	http://dx.doi.org/10.1074/jbc.274.42.29883			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514469	Green Published, hybrid			2022-12-25	WOS:000083176400048
J	Swarnakar, S; Temel, RE; Connelly, MA; Azhar, S; Williams, DL				Swarnakar, S; Temel, RE; Connelly, MA; Azhar, S; Williams, DL			Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ADRENOCORTICAL-CELLS; SR-BI; APOLIPOPROTEIN-E; TARGETED MUTATION; RAT; HDL; EXPRESSION; PROTEIN; CLA-1; LDL	Scavenger receptor, class B, type I (SR-BI) is a cell-surface glycoprotein that mediates selective uptake of high density lipoprotein cholesteryl ester (CE) without the concomitant uptake and degradation of the particle. We have investigated the endocytic and selective uptake of low density lipoprotein (LDL)-CE by SIR-BI using COS-7 cells transiently transfected with mouse SR-BI. Analysis of lipoprotein uptake data showed a concentration-dependent LDL-CE-selective uptake when doubly labeled LDL particles were incubated with SR-BI-expressing COS-7 cells. In contrast to vector-transfected cells, SR-BI-expressing COS-7 cells showed marked increases in LDL cell association and CE uptake by the selective uptake pathway, but only a modest increase in CE uptake by the endocytic pathway. SR-BI-mediated LDL-CE-selective uptake exceeded LDL endocytic uptake by 50-100-fold. SR-BI-mediated LDL-CE-selective uptake was not inhibited by the proteoglycan synthesis inhibitor, p-nitrophenyl-beta-D-xylopyranoside or by the sulfation inhibitor sodium chlorate, indicating that SR-BI-mediated LDL-CE uptake occurs independently of LDL interaction with cell-surface proteoglycan. Analyses with subclones of Y1 adrenocortical cells showed that LDL-CF-selective uptake was proportional to the level of SR-BI expression. Furthermore; antibody directed to the extracellular domain of ESR-BI blocked LDL-CE-selective uptake in adrenocortical cells. Thus, in cells that normally express SR-BI and in transfected COS-7 cells SR-BI mediates the efficient uptake of LDL-CE via the selective uptake mechanism. These results suggest that SR-BI may influence the metabolism of apoB-containing lipoproteins in vivo by mediating LDL-CE uptake into SR-BI-expressing cells.	SUNY Stony Brook, Dept Pharmacal Sci, Med Ctr, Stony Brook, NY 11794 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Williams, DL (corresponding author), SUNY Stony Brook, Dept Pharmacal Sci, Med Ctr, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [HL 58012, HL 32868] Funding Source: Medline; NIDDK NIH HHS [DK 49705] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868, R01HL058012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049705] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Azhar S, 1998, J LIPID RES, V39, P1616; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Cooper AD, 1997, J LIPID RES, V38, P2173; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; JI ZS, 1994, J BIOL CHEM, V269, P2764; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rothblat GH, 1999, J LIPID RES, V40, P781; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920	37	101	103	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29733	29739		10.1074/jbc.274.42.29733	http://dx.doi.org/10.1074/jbc.274.42.29733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514447	hybrid			2022-12-25	WOS:000083176400026
J	Wieland, K; Ter Laak, AM; Smit, MJ; Kuhne, R; Timmerman, H; Leurs, R				Wieland, K; Ter Laak, AM; Smit, MJ; Kuhne, R; Timmerman, H; Leurs, R			Mutational analysis of the antagonist-binding site of the histamine H-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE DOMAIN; DIRECTED MUTAGENESIS; PHARMACOLOGICAL CHARACTERIZATION; BETA(2)-ADRENERGIC RECEPTOR; GENOMIC CLONING; AGONIST BINDING; FUNCTIONAL-ROLE; EXPRESSION; GENE	We combined in a previously derived three-dimensional model of the histamine H-1 receptor (Ter Laak, A. M., Timmerman, H., Leurs, a, Nederkoorn, P. H. J., Snail, M. J,, and Donne-Op den Kelder, G. M. (1995) J. Comp. Aid. Mol; Design. 9, 319-330) a pharmacophore for the H-1 antagonist binding site (Ter Laak, A. M., Venhorst, J,, Timmerman, H., and Donne-Op de Kelder, G.M. (1994) J. Med Chem, 38, 3351-3360) with the known interacting amino acid residue Asp(116) (in transmembrane domain III) of the H-1 receptor and verified the predicted receptor- ligand interactions by site-directed mutagenesis. This resulted in the identification of the aromatic amino acids Trp(167), Phe(433), and Phe(436) in transmembrane domains IV and VI of the H-1 receptor as probable interaction points for the trans-aromatic ring of the H-1 antagonists, Subsequently, a specific interaction of carboxylate moieties of two therapeutically important, zwitterionic H-1 antagonists with Lys(200) in transmembrane domain V was predicted. A Lys(200) --> Ala mutation results in a 50- (acrivastine) to 8-fold (d-cetirizine) loss of affinity of these zwitterionic antagonists, In contrast, the affinities of structural analogs of acrivastine and cetirizine lacking the carboxylate group, triprolidine and meclozine, respectively, are unaffected by the Lys(200) --> Ala mutation. These data strongly suggest that Lys(200), unique for the H-1 receptor, acts as a specific anchor point for these "second generation" H-1 antagonists.	Free Univ Amsterdam, Dept Pharmacochem, Leiden Amsterdam Ctr Drug Res, Div Med Chem,Fac Chem, NL-1081 HV Amsterdam, Netherlands; Inst Mol Pharmacol, Biocomp Mol Modelling Grp, D-10315 Berlin, Germany	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Leurs, R (corresponding author), Free Univ Amsterdam, Dept Pharmacochem, Leiden Amsterdam Ctr Drug Res, Div Med Chem,Fac Chem, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.		Leurs, Rob/ABB-4299-2021; Leurs, Rob/AAC-8508-2022	Leurs, Rob/0000-0003-1354-2848; Smit, Martine/0000-0003-2713-0238; ter Laak, Antonius/0000-0003-1820-002X				BLUML K, 1994, J BIOL CHEM, V269, P18870; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO W, 1995, J NEUROCHEM, V65, P2105, DOI 10.1046/j.1471-4159.1995.65052105.x; CHOUDHARY MS, 1995, MOL PHARMACOL, V47, P450; COHEN AF, 1985, CLIN PHARMACOL THER, V38, P381, DOI 10.1038/clpt.1985.191; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DEBACKER MD, 1993, BIOCHEM BIOPH RES CO, V197, P1601, DOI 10.1006/bbrc.1993.2662; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DUBUSKE LM, 1996, J ALLERG CLIN IMMU S, V98, P307; Fourneau E, 1933, ARCH INT PHARMACOD T, V46, P178; FUJIMOTO K, 1993, BIOCHEM BIOPH RES CO, V190, P294, DOI 10.1006/bbrc.1993.1045; FUKUI H, 1994, BIOCHEM BIOPH RES CO, V201, P894, DOI 10.1006/bbrc.1994.1786; GODFREY PP, 1992, SIGNAL TRANSDUCTION, P105; GREEN SA, 1993, J BIOL CHEM, V268, P23116; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; Inoue I, 1996, GENOMICS, V36, P178, DOI 10.1006/geno.1996.0441; JANSSENS MML, 1994, KIRK OTHMER ENCY CHE, V13, P290; Kristiansen K, 1996, PROTEINS, V26, P81, DOI 10.1002/(SICI)1097-0134(199609)26:1<81::AID-PROT8>3.0.CO;2-J; Kuipers W, 1997, MOL PHARMACOL, V51, P889, DOI 10.1124/mol.51.5.889; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; LEURS R, 1994, BIOCHEM BIOPH RES CO, V201, P295, DOI 10.1006/bbrc.1994.1701; LEURS R, 1995, BIOCHEM BIOPH RES CO, V214, P110, DOI 10.1006/bbrc.1995.2263; MOGUILEVSKY N, 1995, J RECEPT SIGNAL TR R, V15, P91, DOI 10.3109/10799899509045210; MOGUILEVSKY N, 1994, EUR J BIOCHEM, V224, P489, DOI 10.1111/j.1432-1033.1994.00489.x; NAUTA WT, 1968, PHYSICO CHEM ASPECTS, P305; OHTA K, 1994, BIOCHEM BIOPH RES CO, V203, P1096, DOI 10.1006/bbrc.1994.2295; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; RIHOUX JP, 1993, CLIN REV ALLERG, V11, P65; SMIT MJ, 1995, BIOCHEM BIOPH RES CO, V214, P1138, DOI 10.1006/bbrc.1995.2404; TERLAAK AM, 1995, J COMPUT AID MOL DES, V9, P319, DOI 10.1007/BF00125173; TERLAAK AM, 1995, J MED CHEM, V38, P3351, DOI 10.1021/jm00017a019; TRAIFFORT E, 1994, J NEUROCHEM, V62, P507; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; WOODWARD R, 1994, J NEUROCHEM, V62, P1664; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; ZHANG MQ, 1997, BURGERS MEDICINAL CH; ZHANG MQ, 1997, CURR MED CHEM, V4, P187; Zhao MM, 1996, MOL PHARMACOL, V50, P1118	43	99	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29994	30000		10.1074/jbc.274.42.29994	http://dx.doi.org/10.1074/jbc.274.42.29994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514483	Green Published, hybrid			2022-12-25	WOS:000083176400062
J	Cook, T; Gebelein, B; Belal, M; Mesa, K; Urrutia, P				Cook, T; Gebelein, B; Belal, M; Mesa, K; Urrutia, P			Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily of Sp1-like zinc finger proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; BOX-BINDING PROTEIN; GROWTH-FACTOR-BETA; ACTIVATION DOMAINS; MOLECULAR-CLONING; HUMAN OSTEOBLASTS; MULTIGENE FAMILY; GENE; CELLS; IDENTIFICATION	Sp1-like transcription factors are characterized by three highly homologous C-terminal zinc finger motifs that bind CC-rich sequences. These proteins behave as either activators or repressors and have begun to be classified into different subfamilies based upon the presence of conserved motifs outside the zinc finger domain. This classification predicts that different Sp1-like subfamilies share certain functional properties. TIEG1 and TIEG2 constitute a new subfamily of transforming growth factor-beta-inducible Sp1-like proteins whose zinc finger motifs also bind GC-rich sequences. However, regions outside of the DNA-binding domain that differ in structure from other Sp1-like family members remain poorly characterized. Here, we have used extensive mutagenesis and GAL4-based transcriptional assays to identify three repression domains within TIEG1 and TIEG2 that we call R1, R2, and R3. R1 is 10 amino acids, R2 is 12 amino acids, and R3 is approximately 80 amino acids long None of these domains share homology with previously described transcriptional regulatory motifs, but they share strong sequence homology and are functionally conserved between TIEG1 and TIEG2. Together, these data demonstrate that TIEG proteins are capable of repressing transcription, define domains critical for this function, and further support the idea that different subfamilies of Sp1-like proteins have evolved to mediate distinct transcriptional functions.	Mayo Clin, Gastroenterol Res Unit, Rochester, MN 55901 USA; Mayo Clin, Dept Mol Neurosci, Rochester, MN 55901 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Urrutia, P (corresponding author), Mayo Clin & Mayo Fdn, St Marys Hosp, GI Res Unit, 200 1st St SW, Rochester, MN 55905 USA.		Nakafuku, Masato/J-3068-2013	Cook, Tiffany/0000-0002-3100-5248	NIDDK NIH HHS [DK52913, DK07198, R01 DK052913, R01 DK052913-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R56DK052913, T32DK007198] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ElRouby S, 1996, ONCOGENE, V13, P2623; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Imhof A, 1999, MOL CELL BIOL, V19, P194; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOBAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P91, DOI 10.1093/oxfordjournals.jbchem.a124727; Kojima S, 1997, J BIOCHEM, V121, P389; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Yajima S, 1997, J NEUROSCI, V17, P8657; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	46	104	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29500	29504		10.1074/jbc.274.41.29500	http://dx.doi.org/10.1074/jbc.274.41.29500			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506214	hybrid			2022-12-25	WOS:000083017800093
J	Galvan, DL; Borrego-Diaz, E; Perez, PJ; Mignery, GA				Galvan, DL; Borrego-Diaz, E; Perez, PJ; Mignery, GA			Subunit oligomerization, and topology of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; STRUCTURAL ORGANIZATION; SKELETAL-MUSCLE; COILED COILS; ION-CHANNEL; CALCIUM; PROTEIN; DOMAIN; PHOSPHOLAMBAN; TRISPHOSPHATE	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is a tetrameric assembly of highly conserved subunits that contain multiple membrane-spanning sequences in the C-terminal region of the protein. In studies aimed at investigating the oligomerization and transmembrane topology of the type-1 InsP(3)R, a series of membrane-spanning region truncation and deletion plasmids were constructed. These plasmids were transiently transfected in COS-1 cells, and the resulting expression products were analyzed for the ability to assemble into tetrameric structures. The topology of the membrane-spanning region truncations and the full-length receptor was determined by immunocytochemical analysis of transfected COS-1 cells using complete or selective permeabilization strategies, Our results are the first to experimentally define the presence of six membrane-spanning regions. These results are consistent with the current model for the organization of the InsP(3)R in the endoplasmic reticulum and show that the truncation mutants are properly targeted and oriented in the endoplasmic reticulum membrane, thus making them amenable reagents to study receptor subunit oligomerization. Fractionation of soluble and membrane protein components revealed that the first two membrane-spanning regions were necessary for membrane targeting of the receptor, Sedimentation and immunoprecipitation experiments show that assembly of the receptor subunits was an additive process as the number of membrane-spanning regions increased. Immunoprecipitations from cells co-expressing the full-length receptor and carboxyl-terminal truncations reveal that constructs expressing the first two or more membrane-spanning domains were capable of co-assembling with the full-length receptor. Inclusion of the fifth membrane-spanning segment significantly enhanced the degree of oligomerization, Furthermore, a deletion construct containing only membrane-spanning regions 5 and 6 oligomerized to a similar extent as that of the wild type protein. Membrane-spanning region deletion constructions that terminate with the receptor's 145 carboxyl-terminal amino acids were found to have enhanced assembly characteristics and implicate the carboxyl terminus as a determinant in oligomerization. Our results reveal a process of receptor assembly involving several distinct yet additive components and define the fifth and sixth membrane spanning regions as the key determinants in receptor oligomerization.	Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Mignery, GA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.		Galvan, Daniel L./L-2768-2019	Galvan, Daniel L./0000-0001-7541-6252	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053367] Funding Source: NIH RePORTER; NIMH NIH HHS [R29 MH53367] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAK DOD, 1999, BIOPHYS J, V76, P375; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; SANKARARAMAKRISHNAN R, 1995, BBA-BIOMEMBRANES, V1239, P122, DOI 10.1016/0005-2736(95)00165-Y; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5	31	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29483	29492		10.1074/jbc.274.41.29483	http://dx.doi.org/10.1074/jbc.274.41.29483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506212	hybrid			2022-12-25	WOS:000083017800091
J	Pomies, P; Macalma, T; Beckerle, MC				Pomies, P; Macalma, T; Beckerle, MC			Purification and characterization of an alpha-actinin-binding PDZ-LIM protein that is up-regulated during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PROTEIN; BEE FLIGHT-MUSCLE; SMOOTH-MUSCLE; CAENORHABDITIS-ELEGANS; DOMAIN PROTEIN; MESSENGER-RNA; Z-DISK; IDENTIFICATION; CYTOSKELETON; LOCALIZATION	alpha-Actinin is required for the organization and function of the contractile machinery of muscle. In order to understand more precisely the molecular mechanisms by which alpha-actinin might contribute to the formation and maintenance of the contractile apparatus within muscle cells, we performed a screen to identify novel alpha-actinin binding partners present in chicken smooth muscle cells. In this paper, we report the identification, purification, and characterization of a 36-kDa smooth muscle protein (p36) that interacts with alpha-actinin. Using a variety of in vitro binding assays, we demonstrate that the association between alpha-actinin and p36 is direct, specific, and saturable and exhibits a moderate affinity. Furthermore, native co-immunoprecipitation reveals that the two proteins are complexed in vice. p36 is expressed in cardiac muscle and tissues enriched in smooth muscle. Interestingly, in skeletal muscle, a closely related protein of 40 kDa (p40) is detected. The expression of p36 and p40 is dramatically up-regulated during smooth and skeletal muscle differentiation, respectively, and p40 colocalizes with alpha-actinin at the Z-lines of differentiated myotubes. me have established the relationship between p36 and p40 by molecular cloning of cDNAs that encode both proteins and have determined that they are the products of a single gene. Both proteins display an identical N-terminal PDZ domain and an identical C-terminal LIM domain; an internal 63-amino acid sequence present in p36 is replaced by a unique 111-amino acid sequence in p40. Analysis of the sequences of p36 and p40 suggest that they are the avian forms of the actinin-associated LIM proteins (ALPs) recently described in rat (Xia, H., Winokur, S. T., Kuo, W.-L., Altherr, M. R., and Bredt, D. S. (1997) J. Cell Biol. 139, 507-515). The expression of the human ALP gene has been postulated to be affected by mutations that cause facioscapulohumeral muscular dystrophy; thus, the characterization of ALP function may ultimately provide insight into the mechanism of this disease.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Beckerle, MC (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	beckerle@bioscience.utah.edu	Pomiès, Pascal/AAC-8037-2020	Pomiès, Pascal/0000-0002-5301-6087	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060591] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NHLBI NIH HHS [HL60591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTHERR MR, 1995, MUSCLE NERVE, pS32; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CHENG NQ, 1989, J CELL BIOL, V108, P1761, DOI 10.1083/jcb.108.5.1761; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DEATHERAGE JF, 1989, J CELL BIOL, V108, P1775, DOI 10.1083/jcb.108.5.1775; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FRANCIS GR, 1985, J CELL BIOL, V101, P1532, DOI 10.1083/jcb.101.4.1532; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; GEIGER B, 1981, J CELL BIOL, V91, P614, DOI 10.1083/jcb.91.3.614; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; NOZAKI Y, 1976, BIOCHEMISTRY-US, V15, P3884, DOI 10.1021/bi00662a036; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROULIER EM, 1992, J CELL BIOL, V116, P911, DOI 10.1083/jcb.116.4.911; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; VANDEUTEKOM JCT, 1993, HUM MOL GENET, V2, P2037; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507	37	54	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29242	29250		10.1074/jbc.274.41.29242	http://dx.doi.org/10.1074/jbc.274.41.29242			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506181	hybrid			2022-12-25	WOS:000083017800060
J	Prabhakar, R; Boivin, GP; Hoit, B; Wieczorek, DF				Prabhakar, R; Boivin, GP; Hoit, B; Wieczorek, DF			Rescue of high expression beta-tropomyosin transgenic mice by 5-propyl-2-thiouracil - Regulating the alpha-myosin heavy chain promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE PROTEINS; THYROID-HORMONE; GENE-EXPRESSION; CARDIAC MYOSIN; HEART; HETEROGENEITY; ELEMENTS; MUSCLE; RATS	Tropomyosin is an essential component of the sarcomeric thin filament in striated muscle that participates in the regulation of muscle contraction through Ca2+- mediated activation. The two predominant tropomyosin isoforms expressed in striated muscle are alpha- and beta-tropomyosin, which exhibit an 86% amino acid identity between themselves. Previous studies by our laboratory utilized a transgenic mouse system to overexpress beta-tropomyosin in the heart to address the functional differences between these two tropomyosin isoforms, Interestingly, when a high percentage of beta-tropomyosin replaces alpha-tropomyosin in the hearts of transgenic mice, the mice die due to severe cardiac abnormalities. In this study, we have rescued these high expression beta-tropomyosin mice by turning off the alpha-myosin heavy chain promoter, which is driving the beta-tropomyosin transgene. This down-regulation of the ru-myosin heavy chain promoter was accomplished by the administration of 5-propyl-2-thiouracil, which disrupts thyroid hormone synthesis and inhibits promoter activity through thyroid regulatory elements located in the 5'-flanking region of the promoter. Results show that as beta-tropomyosin expression is down-regulated, alpha-tropomyosin expression is increased, Also, alpha- and beta-myosin heavy chain expression is modified in response to the changes in thyroid hormone expression. Morphological analysis of these rescued mice show a moderate pathological phenotype, characterized by atrial myocytolysis; echocardiographic analyses demonstrate altered ventricular functions, such as peak filling rates and left ventricular fractional shortening. This is the first report demonstrating that transcriptional regulatory elements located within the alpha-myosin heavy chain promoter can be manipulated to rescue potentially lethal phenotypes, such as high expression beta-tropomyosin transgenic mice.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Div Cardiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Wieczorek, DF (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054912] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54912] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRONSON DD, 1982, J BIOL CHEM, V257, P3937; FLINK IL, 1990, J BIOL CHEM, V265, P11233; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KATZEFF HL, 1994, AM J PHYSIOL, V267, pE63, DOI 10.1152/ajpendo.1994.267.1.E63; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MATTILA J, 1990, AM J PHYSIOL, V258, pR1464; MORLEY JE, 1981, HORM RES, V14, P18, DOI 10.1159/000179353; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1999, CIRC RES, V85, P47; Muthuchamy M, 1997, TRENDS CARDIOVAS MED, V7, P124, DOI 10.1016/S1050-1738(97)00004-2; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Ojamaa K, 1996, ENDOCRINOLOGY, V137, P802, DOI 10.1210/en.137.3.802; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; Rethinasamy P, 1998, CIRC RES, V82, P116; Robbins J, 1998, CIRC RES, V82, P134; SCHACHAT F, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P279; SCHACHAT FH, 1985, J BIOL CHEM, V260, P1108; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167	22	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29558	29563		10.1074/jbc.274.41.29558	http://dx.doi.org/10.1074/jbc.274.41.29558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506222	hybrid			2022-12-25	WOS:000083017800101
J	Rajan, DP; Kekuda, R; Huang, W; Wang, HP; Devoe, LD; Leibach, FH; Prasad, PD; Ganapathy, V				Rajan, DP; Kekuda, R; Huang, W; Wang, HP; Devoe, LD; Leibach, FH; Prasad, PD; Ganapathy, V			Cloning and expression of a b(0,+)-like amino acid transporter functioning as a heterodimer with 4F2hc instead of rBAT - A new candidate gene for cystinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; HEAVY-CHAIN; RAT-KIDNEY; SURFACE-ANTIGEN; SYSTEM; CDNA; CELLS; Y(+)L	We have cloned a transporter protein from rabbit small intestine, which, when coexpressed with the 4F2 heavy chain (4F2hc) in mammalian cells, induces a b(0,+) like amino acid transport activity, This protein (4F2-lc6 for the sixth member of the 4F2 light chain family) consists of 487 amino acids and has 12 putative transmembrane domains, At the level of amino acid sequence, 4F2-1c6 shows significant homology (44% identity) to the other five known members of the 4F2 light chain family, namely LAT1 (4F2-1c1), y(+)LATI (4F2-1c2), y(+)LAT2 (4F2-1c3), xCT (4F2-1c4), and LAT2 (4F2-1c5), The 4F2hc/4F2-1c6 complex-mediated transport process is Na+-independent and exhibits high affinity for neutral and cationic amino acids and cystine. These characteristics are similar to those of the b(0,+)-like amino acid transport activity previously shown to be associated with rBAT (protein related to b(0,+) amino acid transport system). However, the newly cloned 4F2-lc6 does not interact with rBAT, This is the first report of the existence of a b(0'+)-like amino acid transport process that is independent of rBAT, 4F2-lc6 is expressed predominantly in the small intestine and kidney. Based on the characteristics of the transport process mediated by the 4F2hc/4F2-1c6 complex and the expression pattern of 4F2-lc6 in mammalian tissues, we suggest that 4F2-lc6 is a new candidate gene for cystinuria.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 33347] Funding Source: Medline; NIDA NIH HHS [DA 10045] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Bruno M, 1997, CONTRIB NEPHROL, V122, P173; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; Gitomer WL, 1996, J UROLOGY, V156, P1907, DOI 10.1016/S0022-5347(01)65389-8; Huang W, 1997, INVEST OPHTH VIS SCI, V38, P1578; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kekuda R, 1997, AM J PHYSIOL-GASTR L, V272, pG1463, DOI 10.1152/ajpgi.1997.272.6.G1463; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Palacin M, 1996, AMINO ACIDS, V11, P225, DOI 10.1007/BF00813862; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; Pierides AM, 1997, CONTRIB NEPHROL, V122, P167; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; RAMAMOORTHY S, 1994, CURR EYE RES, V13, P523, DOI 10.3109/02713689408999884; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SEGAL S, 1995, METABOLIC MOL BASES, P3581; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	32	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29005	29010		10.1074/jbc.274.41.29005	http://dx.doi.org/10.1074/jbc.274.41.29005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506149	hybrid			2022-12-25	WOS:000083017800028
J	Bulavin, DV; Tararova, ND; Aksenov, ND; Pospelov, VA; Pospelova, TV				Bulavin, DV; Tararova, ND; Aksenov, ND; Pospelov, VA; Pospelova, TV			Deregulation of p53/p21(Cip1/Waf1) pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation	ONCOGENE			English	Article						transformation; E1A; cHa-ras; p53/Rb-pathway; G1/S and G2/M checkpoints	ANTICANCER AGENTS; DNA-REPLICATION; E7 ONCOPROTEIN; E1A PROTEINS; ADENOVIRUS; P21; P53; TRANSCRIPTION; ARREST; P21(CIP1/WAF1)	The p53/p21(CiP1/Waf1)-dependent checkpoint control of G1/S and G2/M phases of the cell cycle in response to DNA damage is an important mechanism of genome stability maintenance in normal cells. In many tumor cells, due to frequent point mutations and deletions of p53, the stringent control of the cell cycle and apoptosis is compromised. We have examined the cell cycle control and cell death of the rat embryo fibroblast cells (REF) transformed by E1A + cHa-ras oncogenes and expressing wild type p53, Gamma-irradiation at a dosage of 6 Gy has been used to analyse the p53-dependent transactivation of the target p21(cip1/waf1) gene and the levels of activity of cyclin-dependent kinases, Our results show that the cell cycle inhibitors p21(Cip1/Waf1) and p27(KIP) accumulate in response to irradiation both in REF and E1A+cHa-ras cells. In contrast to normal REF cells, the accumulation of p21(Cip1\Waf1) and p27(KIP) inhibitors, however, does not lead to inhibition of Cdk2 and cyclins E, A-associated kinase activities and to a G1/S block in E1A+cHa-ras cells. It is unlikely that the lack of inhibitory function of p21(Cip1/Waf1) can be explained by its inability to bind Cdk2 and Cdk4 kinases or PCNA, Moreover, the p21(Cip1/Waf1)-associated kinase activity is increased upon gamma-irradiation of E1A + cHa-ras cells. We suggest that inactivation of p21(Cip1/Waf1) may be accounted for by its interaction with E1A oncoproducts as the inhibitor is detected in immunoprecipitates using E1A-specific antibodies. During a temporary G2/M delay induced by gamma-irradiation, E1A+cHa-ras transformants continue DNA replication, which leads to accumulation of polyploid cells with lobulated nuclei and micronuclei, Thus, DNA damage of E1A + cHa-ras transformed cells, with a combination of functionally active wild type p53 and inactive p21(Cip1/Waf1), contributes to formation of polyploid cells which then die due to apoptosis.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelova, TV (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.		Aksenov, Nikolay D/F-1679-2017					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOU T, 1993, ONCOGENE, V8, P1765; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kranenburg O, 1996, J VIROL, V70, P7804, DOI 10.1128/JVI.70.11.7804-7810.1996; Kurash YK, 1998, MOL BIOL+, V32, P308; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUDBERG AS, 1993, MOL CELL BIOL, V18, P753; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; NEVINS JR, 1992, SCIENCE, V258, P424; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Orlovskaya EI, 1997, MOL BIOL+, V31, P184; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKIYA T, 1985, JPN J CANCER RES, V76, P851; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPITOVSKY D, 1994, J VIROL, V72, P975; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996	38	49	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5611	5619		10.1038/sj.onc.1202945	http://dx.doi.org/10.1038/sj.onc.1202945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523840				2022-12-25	WOS:000083016500001
J	De Medina, SGD; Popov, Z; Chopin, DK; Southgate, J; Tucker, GC; Delouvee, A; Thiery, JP; Radvanyi, F				De Medina, SGD; Popov, Z; Chopin, DK; Southgate, J; Tucker, GC; Delouvee, A; Thiery, JP; Radvanyi, F			Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas	ONCOGENE			English	Article						bladder; E-cadherin; fibroblast growth factor receptor; human, transitional cell carcinoma	CELL CELL-ADHESION; GENE-MUTATIONS; TUMOR-CELLS; IN-VITRO; INVASION; CANCERS; BREAST; LINES	E-cadherin is a cell-cell adhesion molecule expressed predominantly by epithelial cells. Reduction or loss of E-cadherin immunoreactivity has been associated with tumour progression in many epithelial cancers, including bladder carcinomas. The fibroblast growth factor receptor 2b (FGFR2b) recognized specifically by FGF7 is expressed only by epithelial cells. Recently, decreased expression of FGFR2b protein and mRNA,vas found to be associated with tumour progression in bladder carcinomas. The purpose of this investigation was to look for a possible relationship between E-cadherin and FGFR2b expression in bladder carcinomas, As decreased E-cadherin immunoreactivity was found to correlate directly with decreased expression at the mRNA level, the possible relationship between E-cadherin and FGFR2b was investigated at the mRNA le, el using semi-quantitative RT-PCR in 92 transitional cell carcinomas (TCCs) and four lymph node metastases, All tumours with low E-cadherin expression had low expression of FGFR2b, whereas tumours with low FGFR2b mRNA could express any level of E-cadherin mRNA, The same observation was equally valid for bladder and colon cancer cell lines suggesting that, besides bladder tumours, this relationship could apply to other carcinomas types. These results suggest that a relationship exists between the transcription of the E-cadherin and FGFR2b genes preventing high expression of FGFR2b where expression of E-cadherin is lon. We suggest that reduced expression of FGFR2b in conjunction with decreased expression of E-cadherin mag contribute to the aggressive behaviour attributable to high grade TCCs.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; CHU Henri Mondor, Grp Etud Tumeurs Urol, CRCHM, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France; Univ St Cyril & Methudius, Fac Med, Urol Clin, Skopje 9100, Macedonia; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Saints Cyril & Methodius University of Skopje; Saint James's University Hospital; Servier; Institut de Recherches Internationales Servier	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Southgate, Jennifer/AAJ-9089-2021; Popov, Zivko/AAG-1481-2021; Thiery, Jean Paul/M-9387-2019; Popov, Zivko/Q-9497-2017; Thiery, Jean Paul/H-1550-2011	Southgate, Jennifer/0000-0002-0135-480X; Popov, Zivko/0000-0002-7178-0927; Popov, Zivko/0000-0002-7178-0927; Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1996, ONCOGENE, V13, P1919; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRINGUIER PP, 1993, CANCER RES, V53, P3241; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GIROLDI LA, 1994, INVAS METAST, V14, P71; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HENNIG G, 1995, ONCOGENE, V11, P475; Matsubara A, 1998, CANCER RES, V58, P1509; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OTTO T, 1994, CANCER RES, V54, P3120; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Rubin J. S., 1995, V74, P191; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	22	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5722	5726		10.1038/sj.onc.1202958	http://dx.doi.org/10.1038/sj.onc.1202958			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523852				2022-12-25	WOS:000083016500014
J	Hatcher, HC; Wright, NM; Chao, J; Chao, L; Ma, JX				Hatcher, HC; Wright, NM; Chao, J; Chao, L; Ma, JX			Kallikrein-binding protein is induced by growth hormone in the dwarf rat	FASEB JOURNAL			English	Article						growth hormone deficiency; serpins; tissue kallikrein	HUMAN TISSUE KALLIKREIN; HUMAN OCULAR-TISSUES; MESSENGER-RNA; CELLULAR-LOCALIZATION; DIABETES-MELLITUS; TRANSGENIC MICE; FACTOR-I; GENE; KALLISTATIN; EXPRESSION	Rat kallikrein-binding protein (KBP), a member of the serpin family, is a tissue kallikrein inhibitor, It has been shown to be a potential pathogenic factor of diabetic retinopathy and may play a role in animal development and growth. To determine whether reduced KBP expression is involved in retarded animal growth, we examined the in vivo effect of growth hormone (GH) deficiency on the expression of KBP in the Lewis dwarf (dw/dw), We found that serum levels of functionally active KBP were reduced in the dwarf rat (P<0.05) as determined by complex formation assay between serum KBP and I-125-labeled rat tissue kallikrein. Enzyme-linked immunosorbent assay showed that KBP levels were significantly reduced in the serum of the dwarf rat compared to the Lewis rat (213.8 ng/ml vs. 413.8 ng/ml, n=4, P<0.01), The decreased KBP levels were confirmed by Western blot analysis, Moreover, treatment of the dwarf rat with recombinant human GH for 4 wk resulted in a significant increase in KBP activity (P<0.01) and serum KBP levels compared with the untreated dwarf rat (549.8 ng/ml, n=5, vs. 213.8 ng/ml, n=4, P<0.02), Northern blot analysis and densitometry showed that liver KBP mRNA levels were reduced by fivefold in the dwarf rat compared to the Lewis rat and the decrease was reversed by the GH treatment. These results indicate that the KBP levels are regulated at the RNA level. Furthermore, in vitro studies using cultured rat hepatocytes showed that GH may have a direct regulatory effect on KBP expression since KBP levels increased in the conditioned media of cells treated with GH. These results demonstrated that KBP is reduced in the genetic dwarf rat and is restored to normal by GH; therefore, KBP is a GH-dependent protein and may be a new target for studying the mechanism of pathological animal growth.	Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Div Endocrinol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Ma, JX (corresponding author), Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL EYE INSTITUTE [R01EY012600] Funding Source: NIH RePORTER; NEI NIH HHS [EY12600] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERRY SA, 1984, ENDOCRINOLOGY, V115, P1164, DOI 10.1210/endo-115-3-1164; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BLUETPAJOT MT, 1983, NEUROENDOCRINOLOGY, V36, P307, DOI 10.1159/000123472; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; Chao J, 1995, BIOL CHEM H-S, V376, P705; CHAO S, 1989, BIOTECHNIQUES, V7, P68; CHARLTON HM, 1988, J ENDOCRINOL, V119, P51, DOI 10.1677/joe.0.1190051; CHATTERJEE B, 1983, J BIOL CHEM, V258, P688; CHEN LM, 1995, KIDNEY INT, V48, P690, DOI 10.1038/ki.1995.339; Chen LM, 1996, J BIOL CHEM, V271, P27590, DOI 10.1074/jbc.271.44.27590; DERCOLE AJ, 1987, SER S BAS CLIN ASP G, P259; DONAHUE LR, 1993, J ENDOCRINOL, V136, P91, DOI 10.1677/joe.0.1360091; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Handa H, 1989, Adv Exp Med Biol, V247B, P443; HARVEY JN, 1992, DIABETOLOGIA, V35, P857, DOI 10.1007/BF00399932; Hatcher HC, 1997, INVEST OPHTH VIS SCI, V38, P658; JAFFA AA, 1992, KIDNEY INT, V41, P789, DOI 10.1038/ki.1992.122; KURTZ DT, 1977, P NATL ACAD SCI USA, V74, P4791, DOI 10.1073/pnas.74.11.4791; LAPERCHE Y, 1983, CELL, V32, P453, DOI 10.1016/0092-8674(83)90465-8; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087; Ma JX, 1996, CURR EYE RES, V15, P1117, DOI 10.3109/02713689608995143; Ma JX, 1996, BBA-GENE STRUCT EXPR, V1307, P285, DOI 10.1016/0167-4781(96)81374-1; MAES M, 1983, DIABETES, V32, P1060, DOI 10.2337/diabetes.32.11.1060; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MAYFIELD RK, 1985, DIABETES, V34, P22, DOI 10.2337/diabetes.34.1.22; ROY AK, 1982, SERONO S, V51, P35; RUSSELLJONES DL, 1993, ACTA ENDOCRINOL-COP, V128, P44; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1102, DOI 10.1210/endo-116-3-1102; SINHA YN, 1979, P SOC EXP BIOL MED, V161, P78, DOI 10.3181/00379727-161-40494; TANNENBAUM GS, 1981, ENDOCRINOLOGY, V108, P76, DOI 10.1210/endo-108-1-76; TECCE MF, 1986, BIOCHEMISTRY-US, V25, P5831, DOI 10.1021/bi00367a073; WRIGHT NM, 1995, J BONE MINER RES, V10, P127; XIONG W, 1992, TOHOKU J EXP MED, V171, P135; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	40	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1839	1844		10.1096/fasebj.13.13.1839	http://dx.doi.org/10.1096/fasebj.13.13.1839			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506588				2022-12-25	WOS:000083063400020
J	Su, L; Rickert, RC; David, M				Su, L; Rickert, RC; David, M			Rapid STAT phosphorylation via the B cell receptor - Modulatory role of CD19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; LYMPHOCYTES-B; ACTIVATION; KINASE; EXPRESSION; PROTEINS	Engagement of the B cell receptor (BCR) initiates multiple signaling cascades which mediate different biological responses, depending on the stage of B cell differentiation, antigen binding affinity, and duration of stimulation. Aggregation of co-receptors such as CD19 with the antigen receptor has been suggested to modulate the signals necessary for the development and functioning of the humoral immune system. In this study, we demonstrate that engagement of the antigen receptor on peripheral blood B cells, but not naive splenic B lymphocytes, leads to rapid phosphorylation of signal transducers and activators of transcription 1 (STAT1) on Tyr-701 and Ser-727, Interestingly, phosphorylation on tyrosine diminished with increased stimulation, whereas serine phosphorylation correlated directly with the level of BCR cross linking. In contrast, phosphorylation of STAT3 occurs exclusively on serine and is sensitive to inhibitors of the PI3-kinase and the ERK1/2 pathways. Finally, we show that co ligation of CD19 with the BCR results in increased tyrosine phosphorylation of STAT1 relative to BCR cross-linking alone, establishing CD19 as a positive modulator of BCR-mediated STAT activation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,Bonner Hall 3138, La Jolla, CA 92093 USA.			Su, Leon/0000-0001-7654-9997	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA080105-03, R01 CA080105-01, R01 CA080105-02, R01 CA080105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GOLD MR, 1992, J IMMUNOL, V148, P2012; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; Karras JG, 1996, J IMMUNOL, V157, P2299; LAMER AC, 1993, SCIENCE, V261, P1730; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	28	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31770	31774		10.1074/jbc.274.45.31770	http://dx.doi.org/10.1074/jbc.274.45.31770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542198	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:000083532100006
J	Pentikainen, O; Hoffren, AM; Ivaska, J; Kapyla, J; Nyronen, T; Heino, J; Johnson, MS				Pentikainen, O; Hoffren, AM; Ivaska, J; Kapyla, J; Nyronen, T; Heino, J; Johnson, MS			"RKKH" peptides from the snake venom metalloproteinase of Bothrops jararaca bind near the metal ion-dependent adhesion site of the human integrin alpha(2) I-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; ECHOVIRUS-1 INTERACTION; COLLAGEN RECEPTOR; DIVALENT-CATION; LIGAND-BINDING; CROTALUS-ATROX; NUCLEIC-ACIDS; ADAMALYSIN-II; FORCE-FIELD	Integrin alpha(1)beta(1) and alpha(2)beta(1) are the major cellular receptors for collagen, and collagens bind to these integrins at the inserted I-domain in their cw subunit. We have previously shown that a cyclic peptide derived from the metalloproteinase domain of the snake venom protein jararhagin blocks the collagen-binding function of the alpha(2) I-domain. Here, we have optimized the structure of the peptide and identified the site where the peptide binds to the alpha(2) I-domain. The peptide sequence Arg-Lys-Lys-His is critical for recognition by the I-domain, and five negatively charged residues surrounding the "metal ion-dependent adhesion site" (MIDAS) of the I-domain, when mutated, show significantly impaired binding of the peptide. Removal of helix alpha C, located along one side of the MIDAS and suggested to be involved in collagen-binding in these I-domains, does not affect peptide binding. This study supports the notion that the metalloproteinase initially binds to the alpha(2) I-domain at a location distant from the active site of the protease, thus blocking collagen binding to the adhesion molecule in the vicinity of the MIDAS, while at the same time leaving the active site free to degrade nearby proteins, the closest being the beta(1) subunit of the alpha(2)beta(1) cell-surface integrin itself.	Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm & Sci, FIN-40351 Jyvaskyla, Finland; Ctr Comp Sci, FIN-02120 Espoo, Finland	Abo Akademi University; University of Turku; University of Turku; University of Jyvaskyla	Johnson, MS (corresponding author), Abo Akad Univ, Dept Biochem & Pharm, Tykistokatu 6 A,POB 66, FIN-20521 Turku, Finland.		Nyrönen, Tommi H./A-3612-2010; Pentikäinen, Olli T/E-1980-2012	Pentikäinen, Olli T/0000-0001-7188-4016; Kapyla, Jarmo/0000-0003-3036-713X; Nyronen, Tommi/0000-0002-5569-5183; Ivaska, Johanna/0000-0002-6295-6556				Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; Bergman DL, 1997, J MOL GRAPH MODEL, V15, P301, DOI 10.1016/S1093-3263(98)00003-5; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; *CAMBR CRYST DAT C, 1992, CSD SYST DOC; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Gomis-Ruth FX, 1998, PROTEIN SCI, V7, P283; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HITE LA, 1992, BIOCHEMISTRY-US, V31, P6203, DOI 10.1021/bi00142a005; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUGHES AL, 1992, MOL BIOL EVOL, V9, P216; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JOHNSON MS, 1994, CRIT REV BIOCHEM MOL, V29, P1, DOI 10.3109/10409239409086797; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P959; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAAKSONEN L, 1992, J MOL GRAPHICS, V10, P33, DOI 10.1016/0263-7855(92)80007-Z; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; MERRIT EA, 1997, METHOD ENZYMOL, V177, P505; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PISCHEL KD, 1987, J IMMUNOL, V138, P226; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; STUCLIFFE MJ, 1987, PROTEIN ENG, V5, P377; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKEYA H, 1990, J BIOCHEM-TOKYO, V108, P711, DOI 10.1093/oxfordjournals.jbchem.a123270; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; ZHANG DC, 1994, P NATL ACAD SCI USA, V91, P8447, DOI 10.1073/pnas.91.18.8447	59	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31493	31505		10.1074/jbc.274.44.31493	http://dx.doi.org/10.1074/jbc.274.44.31493			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531352	hybrid			2022-12-25	WOS:000083379400056
J	Marino, M; Friedlander, JA; McCluskey, RT; Andrews, D				Marino, M; Friedlander, JA; McCluskey, RT; Andrews, D			Identification of a heparin-binding region of rat thyroglobulin involved in megalin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; LDL RECEPTOR; LOW-DENSITY; SULFATE PROTEOGLYCANS; LIPOPROTEIN-LIPASE; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; HEYMANN NEPHRITIS; AFFINITY-BINDING; APOLIPOPROTEIN-E	We recently showed that thyroglobulin (Tg) is a heparin-binding protein and that heparin inhibits binding of Tg to its endocytic receptor megalin (gp330), Here we have identified a heparin-binding region in the carboxyl-terminal portion of rat Tg and have studied its involvement in megalin binding. Rat thyroid extracts, obtained by ammonium sulfate precipitation, were separated by column fractionation into four Tg polypeptides, with apparent masses of 660, 330, 210, and 50 kDa. As assessed by enzyme-linked immunoadsorbent assays and ligand blot binding assays, megalin bound to intact Tg (660 and 330 kDa) and, to a even greater extent, to the 210-kDa Tg polypeptide, Furthermore, the 210-kDa Tg polypeptide inhibited megalin binding to intact Tg by similar to 70%, Solid phase assays showed binding of biotin-labeled heparin to intact Tg and to the 210-kDa Tg polypeptide, We characterized the 810-kDa Tg polypeptide by matrix-assisted laser desorption/ionization mass spectrometry analysis and found that it corresponds to the carboxyl-terminal portion of rat Tg, We developed a synthetic peptide corresponding to a 15-amino acid sequence in the carboxyl-terminal portion of rat Tg (Arg(689)-Lys(703)), containing a heparin-binding consensus sequence (SRRLKRP) and demonstrated heparin binding to this peptide. A rabbit antibody raised against the peptide recognized intact Tg in its native conformation and under denaturing conditions. This antibody markedly reduced heparin-binding to intact Tg, indicating that the region of native Tg corresponding to the peptide is involved in heparin binding. Furthermore, the anti-Tg peptide antibody almost completely inhibited binding of megalin to Tg, suggesting that the Tg region containing the peptide sequence is required for megalin binding. Physiologically, Tg binding to megalin on thyroid cells may be facilitated by Tg interaction with heparin-libe molecules (heparan sulfate proteoglycans) via adjacent binding sites.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Res Lab, Charlestown, MA 02129 USA; Univ Pisa, Dept Endocrinol, I-56100 Pisa, Italy	Harvard University; Massachusetts General Hospital; University of Pisa	Marino, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Res Lab, 149 13th St, Charlestown, MA 02129 USA.				NIDDK NIH HHS [DK 46301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNIERVALENTIN F, 1990, J BIOL CHEM, V265, P17373; BERNIERVALENTIN F, 1991, ENDOCRINOLOGY, V129, P2194, DOI 10.1210/endo-129-4-2194; Berzofsky Jay A., 1993, P235; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Caturegli P, 1997, CLIN IMMUNOL IMMUNOP, V85, P221, DOI 10.1006/clin.1997.4428; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; CONRAD HE, 1998, HEPARIN BINDING PROT, P367; CONRAD HE, 1998, HEPARIN BINDING PROT, P413; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; CONSIGLIO E, 1979, J BIOL CHEM, V254, P5065; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; DUNN A, 1996, WERNER INGBARS THYRO, P81; Dunn John T., 1996, P85; Ehring H, 1997, RAPID COMMUN MASS SP, V11, P1867; Emoto N, 1995, THYROID, V5, P455, DOI 10.1089/thy.1995.5.455; EMOTO N, 1994, ENDOCRINOL METAB, V1, P123; ESQUIVEL PS, 1977, J EXP MED, V145, P1250, DOI 10.1084/jem.145.5.1250; Fenselau C, 1997, ANAL CHEM, V69, pA661, DOI 10.1021/ac971831z; Giraud A, 1997, ENDOCRINOLOGY, V138, P2325, DOI 10.1210/en.138.6.2325; GRAVES PN, 1990, MOL ENDOCRINOL, V4, P155, DOI 10.1210/mend-4-1-155; GUTMANN EJ, 1989, AM J PHYSIOL, V257, pC397, DOI 10.1152/ajpcell.1989.257.2.C397; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; JI ZS, 1993, J BIOL CHEM, V268, P10160; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KOSTROUCH Z, 1993, ENDOCRINOLOGY, V132, P2645, DOI 10.1210/en.132.6.2645; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEMANSKY P, 1992, EUR J BIOCHEM, V209, P111, DOI 10.1111/j.1432-1033.1992.tb17267.x; Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Marino M, 1999, J BIOL CHEM, V274, P12898, DOI 10.1074/jbc.274.18.12898; MEDEIROSNETO G, 1993, ENDOCR REV, V14, P165, DOI 10.1210/er.14.2.165; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MORTZ E, 1994, BIOL MASS SPECTROM, V23, P249, DOI 10.1002/bms.1200230503; MULDER M, 1993, J BIOL CHEM, V268, P9369; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Patterson SD, 1996, ELECTROPHORESIS, V17, P877, DOI 10.1002/elps.1150170509; Perlmutter DH, 1999, LAB INVEST, V79, P623; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Raychowdhury R, 1996, AM J PATHOL, V148, P1613; ROUSSET B, 1991, MOL CELL ENDOCRINOL, V78, P89; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Weaver AM, 1997, J LIPID RES, V38, P1841; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462; ZHENG G, 1994, ANN NY ACAD SCI, V737, P154, DOI 10.1111/j.1749-6632.1994.tb44309.x; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	52	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30377	30386		10.1074/jbc.274.43.30377	http://dx.doi.org/10.1074/jbc.274.43.30377			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521414	hybrid			2022-12-25	WOS:000083276700010
J	Mineo, C; Gill, GN; Anderson, GW				Mineo, C; Gill, GN; Anderson, GW			Regulated migration of epidermal growth factor receptor from caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; EGF RECEPTOR; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; MEDIATED ENDOCYTOSIS; PROTEIN-KINASE; MAP KINASE; PHOSPHORYLATION; SRC; BINDING	In quiescent fibroblasts, epidermal growth factor (EGF) receptors (EGFR) are initially concentrated in caveolae but rapidly move out of this membrane domain in response to EGF. To better understand the dynamic localization of EGFR to caveolae, we have studied the behavior of wild-type and mutant receptors expressed in cells lacking endogenous EGFR, AU of the receptors we examined, including those missing the first 274 amino acids or most of the cytoplasmic tail, were constitutively concentrated in caveolae. By contrast, migration from caveolae required EGF binding, an active receptor kinase domain, and at least one of the five tyrosine residues present in the regulatory domain of the receptor. Movement appears to be modulated by Src kinase, is blocked by activators of protein kinase C, and occurs independently of internalization by clathrin-coated pits. Two mutant receptors previously shown to induce an oncogenic phenotype lack the ability to move from caveolae in response to EGF, suggesting that a prolonged residence in this domain may contribute to abnormal cell behavior.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Anderson, GW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.				NCI NIH HHS [CA58689] Funding Source: Medline; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Baulida J, 1996, J BIOL CHEM, V271, P5251; BILDER GE, 1991, AM J PHYSIOL, V260, P721; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUND KA, 1990, J BIOL CHEM, V265, P20517; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MASUI H, 1991, CANCER RES, V51, P6170; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; vanderHeyden MAG, 1997, EXP CELL RES, V234, P521, DOI 10.1006/excr.1997.3661; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	47	248	257	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30636	30643		10.1074/jbc.274.43.30636	http://dx.doi.org/10.1074/jbc.274.43.30636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521449	hybrid			2022-12-25	WOS:000083276700045
J	Hussain, MA; Habener, JF				Hussain, MA; Habener, JF			Glucagon gene transcription activation mediated by synergistic interactions of pax-6 and cdx-2 with the p300 co-activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PROGLUCAGON GENE; BINDING-PROTEINS; ISLET CELLS; DOMAIN; CBP; DIFFERENTIATION; COACTIVATORS; PANCREAS; REVEALS	In the endocrine pancreas, alpha-cell-specific expression of the glucagon gene is mediated by DNA-binding proteins that interact with the proximal GL promoter element, which contains several AT-rich domains. The homeodomain transcription factors brain-4, pax-6, and cdx-2 have been shown to bind to these sites and to transactivate glucagon gene expression. In the present study, we investigated the interaction of cdx-2 and pax-6 with p300, a co-activator coupled to the basal transcription machinery. In transient transfection-expression experiments, we found that the transactivating effects of cdx-2 and pax-6 on the glucagon gene were greatly enhanced by the additional expression of p300. This enhancement was due to direct protein-protein interactions of both pax-6 and cdx-2 with the N-terminal C/H1 domain of p300. pax-6 and cdx-2 also directly interacted with one another at the protein level. pax-6, bound to its DNA recognition site in the glucagon G1 promoter element, tethered cdx-2 to the molecular complex of pax-g and p300. Further, we found that the presence of cdx-2 enhanced the interaction of pax-g with p300, thus establishing a molecular complex of transcription factors implicated in tissue-specific glucagon gene expression with the basal transcriptional machinery.	Howard Hughes Med Inst, Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Habener, JF (corresponding author), Howard Hughes Med Inst, Massachusetts Gen Hosp, Mol Endocrinol Lab, 55 Fruit St,WEL320, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030834] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK30834] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HABENER JF, 1996, INSULINOTROPIC GUT H, V13; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; HUSSAIN MM, UNPUB; JIN T, 1995, MOL ENDOCRINOL, V9, P1306, DOI 10.1210/me.9.10.1306; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270	24	96	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28950	28957		10.1074/jbc.274.41.28950	http://dx.doi.org/10.1074/jbc.274.41.28950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506141	hybrid			2022-12-25	WOS:000083017800020
J	Matsuura, H; Sakaue, M; Subbaramaiah, K; Kamitani, H; Eling, TE; Dannenberg, AJ; Tanabe, T; Inoue, H; Arata, J; Jetten, AM				Matsuura, H; Sakaue, M; Subbaramaiah, K; Kamitani, H; Eling, TE; Dannenberg, AJ; Tanabe, T; Inoue, H; Arata, J; Jetten, AM			Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells - Role of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; NECROSIS-FACTOR-ALPHA; CULTURED HUMAN KERATINOCYTES; VASCULAR ENDOTHELIAL-CELLS; FACTOR RECEPTOR ACTIVATION; MAMMARY EPITHELIAL-CELLS; COLON-CANCER CELLS; NF-KAPPA-B; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION	Treatment of normal human epidermal keratinocytes (NHEK) with interferon-gamma (IFN-gamma) causes a 9-fold increase in the level of cyclooxggenase-2 (COX-2) mRNA expression. Nuclear run-off assays indicate that this induction is at least partly due to increased transcription. Activation of the epidermal growth factor receptor (EGFR) signaling pathway due to the enhanced transforming growth factor alpha (TGF alpha) expression plays an important role in the induction of COX-2 by IFN-gamma. This is supported by the ability of TGF alpha to rapidly induce COX-2 and the inhibition of the IFN-gamma-mediated COX-2 mRNA induction by an EGFR antibody and EGFR-selective kinase inhibitors. Deletion and mutation analysis indicates the importance of the proximal cAMP-response element/ATF site in the transcriptional control of this gene by TGF alpha. The increase in COX-2 mRNA by TGF alpha requires activation of both the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways. Inhibition of p38 MAPK decreases the stability of COX-2 mRNA, while inhibition of MAPK/ERK kinase (MEK) does not. These results suggest that the p38 MAPK signaling pathway controls COX-2 at the level of mRNA stability, while the ERK signaling pathway regulates COX-2 at the level of transcription. In contrast to NHEK IFN-gamma and TGF alpha are not very effective in inducing TGF alpha or COX-2 expression in several squamous carcinoma cell lines, indicating alterations in both IFN-gamma and TGF alpha response pathways.	NIEHS, Cell Biol Sect, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; New York Presbyterian Hosp, Strang Canc Prevent Ctr, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Digest Dis, New York, NY 10021 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 5658565, Japan; Okayama Univ, Sch Med, Dept Dermatol, Okayama 700, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); NewYork-Presbyterian Hospital; Cornell University; National Cerebral & Cardiovascular Center - Japan; Okayama University	Jetten, AM (corresponding author), NIEHS, Cell Biol Sect, Pulm Pathobiol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Asano K, 1997, J CLIN INVEST, V99, P1057, DOI 10.1172/JCI119233; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BATES EJ, 1995, PROSTAG LEUKOTR ESS, V53, P75, DOI 10.1016/0952-3278(95)90133-7; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; Elias P M, 1996, Exp Dermatol, V5, P191, DOI 10.1111/j.1600-0625.1996.tb00117.x; EVANS CB, 1993, PROSTAG LEUKOTR ESS, V49, P777, DOI 10.1016/0952-3278(93)90025-R; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; Fransson J, 1996, ARCH DERMATOL RES, V289, P14, DOI 10.1007/s004030050146; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FURSTENBERGER G, 1990, CELL BIOL REV, V24, P1; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GOMI T, 1991, ARCH DERMATOL, V127, P827, DOI 10.1001/archderm.127.6.827; GREWE M, 1995, J INVEST DERMATOL, V104, P3, DOI 10.1111/1523-1747.ep12613446; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; HENKE DC, 1984, ANAL BIOCHEM, V162, P156; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Holbrook K., 1994, KERATINOCYTE HDB, P3; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jetten Anton M., 1997, Journal of Dermatology (Tokyo), V24, P711; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Komuves LG, 1998, J INVEST DERMATOL, V111, P429, DOI 10.1046/j.1523-1747.1998.00296.x; Konger RL, 1998, BBA-MOL CELL RES, V1401, P221, DOI 10.1016/S0167-4889(97)00114-6; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Leong J, 1996, EXP CELL RES, V224, P79, DOI 10.1006/excr.1996.0113; Loftin CD, 1996, ARCH BIOCHEM BIOPHYS, V330, P419, DOI 10.1006/abbi.1996.0271; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Maldve RE, 1996, MOL CARCINOGEN, V17, P207, DOI 10.1002/(SICI)1098-2744(199612)17:4<207::AID-MC4>3.0.CO;2-A; MARKS F, 1993, ENVIRON HEALTH PERSP, V101, P95, DOI 10.2307/3431849; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Matsuura H, 1999, MOL CELL ENDOCRINOL, V147, P85, DOI 10.1016/S0303-7207(98)00214-7; MATUE H, 1992, J INVEST DERMATOL, V99, pS42; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Mestre JR, 1997, CANCER RES, V57, P2890; MILLER CC, 1994, J BIOL CHEM, V269, P3529; Minghetti L, 1996, J NEUROCHEM, V66, P1963; Muller-Decker K, 1998, MOL CARCINOGEN, V23, P36, DOI 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; Naik SM, 1997, J BIOL CHEM, V272, P1283, DOI 10.1074/jbc.272.2.1283; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; NICKOLOFF BJ, 1991, ARCH DERMATOL, V127, P871, DOI 10.1001/archderm.127.6.871; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Sorensen HN, 1998, VITAM HORM, V54, P121, DOI 10.1016/S0083-6729(08)60924-3; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TAMAI K, 1995, J BIOL CHEM, V270, P392, DOI 10.1074/jbc.270.1.392; Tennenbaum T, 1996, CELL GROWTH DIFFER, V7, P615; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1983, CANCER RES, V43, P5707; Zakar T, 1998, BBA-LIPID LIPID MET, V1391, P37, DOI 10.1016/S0005-2760(97)00195-1; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	83	172	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29138	29148		10.1074/jbc.274.41.29138	http://dx.doi.org/10.1074/jbc.274.41.29138			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506169	hybrid			2022-12-25	WOS:000083017800048
J	Hua, YJ; Tanaka, Y; Nakamura, K; Sakakibara, M; Nagata, S; Kataoka, H				Hua, YJ; Tanaka, Y; Nakamura, K; Sakakibara, M; Nagata, S; Kataoka, H			Identification of a prothoracicostatic peptide in the larval brain of the silkworm, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRYLLUS-BIMACULATUS ENSIFERA; ECDYSONE BIOSYNTHESIS; MOLECULAR-CLONING; OOSTATIC HORMONE; JUVENILE-HORMONE; MANDUCA-SEXTA; GALANIN; NEUROPEPTIDES; GRYLLIDAE; SEQUENCE	Prothoracicotropic hormone (PTTH) stimulates ecdysteroid biosynthesis in the prothoracic gland (PG) of insects. A peptide inhibiting ecdysteroid biosynthesis in the PG was isolated from the extracts of 2,000 larval brains of the silkworm, Bombyx mori, using a protocol that included four reversed-phase high performance liquid chromatography procedures. The primary structure of this prothoracicostatic peptide (Bom-PTSP) was determined to be H-Ala-Trp-Gln-Asp-Leu-Asn-Ser-Ala-Trp-NH2. This neuropeptide has the same sequence as Mas-MIP-I, a myoinhibitory peptide previously isolated from the ventral nerve cord of the tobacco hornworm, Manduca sexta, and is highly homologous with the N-terminal portion of vertebrate peptides of the galanin family. This peptide inhibited PTTH-stimulated ecdysteroidogenesis in the PG at both the spinning and feeding stages, which indicates that Bom-PTSP interferes with PTTH-stimulated ecdysteroidogenesis.	Natl Inst Sericultural & Entomol Sci, Lab Bioact Subst, Tsukuba, Ibaraki 3058634, Japan; Osaka City Univ, Dept Biol, Sumiyoshi Ku, Osaka 558, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1130032, Japan	National Institute of Agrobiological Sciences - Japan; Osaka Metropolitan University; University of Tokyo	Tanaka, Y (corresponding author), Natl Inst Sericultural & Entomol Sci, Lab Bioact Subst, Ohwashi 1-2, Tsukuba, Ibaraki 3058634, Japan.							BERSANI M, 1991, FEBS LETT, V283, P189, DOI 10.1016/0014-5793(91)80585-Q; BLACKBURN MB, 1995, REGUL PEPTIDES, V57, P213, DOI 10.1016/0167-0115(95)00034-9; Bollenbacher W.E., 1985, P109; BYLEMANS D, 1994, REGUL PEPTIDES, V50, P61, DOI 10.1016/0167-0115(94)90192-9; CARLISLE DB, 1968, NATURE, V220, P706, DOI 10.1038/220706a0; Chung JS, 1996, NEUROPEPTIDES, V30, P95, DOI 10.1016/S0143-4179(96)90061-X; DONLY BC, 1993, P NATL ACAD SCI USA, V90, P8807, DOI 10.1073/pnas.90.19.8807; HUA YJ, 1995, REGUL PEPTIDES, V57, P263, DOI 10.1016/0167-0115(95)00040-I; HUA YJ, 1994, MOL CELL ENDOCRINOL, V104, pR1; Hua YJ, 1997, ARCH INSECT BIOCHEM, V35, P125, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<125::AID-ARCH11>3.3.CO;2-A; ISHIBASHI J, 1994, BIOCHEMISTRY-US, V33, P5912, DOI 10.1021/bi00185a031; KATAOKA H, 1989, SCIENCE, V243, P1481, DOI 10.1126/science.243.4897.1481; KAWAKAMI A, 1990, SCIENCE, V247, P1333, DOI 10.1126/science.2315701; KELLY TJ, 1986, INSECT BIOCHEM, V16, P273, DOI 10.1016/0020-1790(86)90106-X; KELLY TJ, 1984, J EXP ZOOL, V229, P491, DOI 10.1002/jez.1402290318; Kopec S, 1922, BIOL BULL-US, V42, P323, DOI 10.2307/1536759; LOPEZ FJ, 1991, P NATL ACAD SCI USA, V88, P4508, DOI 10.1073/pnas.88.10.4508; Lorenz JI, 1997, EUR J ENTOMOL, V94, P369; LORENZ MW, 1995, J BIOL CHEM, V270, P21103, DOI 10.1074/jbc.270.36.21103; Lorenz MW, 1998, ARCH INSECT BIOCHEM, V38, P32, DOI 10.1002/(SICI)1520-6327(1998)38:1&lt;32::AID-ARCH4&gt;3.0.CO;2-X; Redfern C.P.F., 1989, P182; SCHOOFS L, 1991, REGUL PEPTIDES, V36, P111, DOI 10.1016/0167-0115(91)90199-Q; TAKEDA S, 1986, Bulletin of the Sericultural Experiment Station (Tokyo), V30, P361; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; TEMPEL DL, 1990, BRAIN RES, V536, P353, DOI 10.1016/0006-8993(90)90050-L	25	108	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31169	31173		10.1074/jbc.274.44.31169	http://dx.doi.org/10.1074/jbc.274.44.31169			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531308	hybrid			2022-12-25	WOS:000083379400012
J	Nagarajan, RP; Liu, J; Chen, Y				Nagarajan, RP; Liu, J; Chen, Y			Smad3 inhibits transforming growth factor-beta and activin signaling by competing with Smad4 for FAST-2 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; TGF-BETA; TUMOR-SUPPRESSOR; INDUCED TRANSCRIPTION; MESODERM FORMATION; DNA-BINDING; RECEPTOR; GENE; IDENTIFICATION; ACTIVATION	Transcriptional regulation by transforming growth factor-p and activin is mediated by interaction of Smad2 and Smad3 with specific transcription factors and/or DNA elements. However, Smad3 behaves differently from Smad2 in regulating transcription by a winged-helix transcription factor, FAST-S, on an activin-responsive element (ARE) in the Xenopus Mix.2 promoter. Smad3 alone was able to stimulate the ARE through FAST-S, but inhibited the ARE transactivation mediated by Smad2/Smad4 following receptor activation. We characterized the functional domains that are involved in these two activities of Smad3, Deletion of the MH1 domain as well as mutations of four lysine residues in the MH1 domain abrogated the inhibitory activity of Smad3, but did not compromise the self-stimulatory function. In contrast, deletion of the MH2 domain or a point mutation of glycine 379 within this domain obliterated the self-stimulatory activity of Smad3, but not the inhibitory activity. In an electrophoretic mobility shift assay, we found that Smad3 was able to associate with the FAST-2.ARE complex and that this association was dependent on FAST-2. In addition, Smad3 was not able to directly bind the ARE in a DNase I protection assay, in which FAST-2 binds the ARE around a motif (TGTG-TATT) previously characterized to associate with the human FAST-1 protein. Interestingly, Smad4 was also able to directly associate with the FAST-2.ARE complex through binding with FAST-2. In a gel shift assay, the association of FAST-2 with Smad4 was mutually exclusive from the association with Smad3. Taken together, these data indicate that Smad3 exerts the inhibitory activity by competitive association with FAST-2.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB130, Indianapolis, IN 46202 USA.	ychen3@iupui.edu	N, Rajendra Prasad/X-1743-2019	N, Rajendra Prasad/0000-0002-3937-8735				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maxam A M, 1980, Methods Enzymol, V65, P499; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; VALE W, 1988, RECENT PROG HORM RES, V44, P1; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	52	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31229	31235		10.1074/jbc.274.44.31229	http://dx.doi.org/10.1074/jbc.274.44.31229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531318	hybrid			2022-12-25	WOS:000083379400022
J	Taylor, SC; Batten, TFC; Peers, C				Taylor, SC; Batten, TFC; Peers, C			Hypoxic enhancement of quantal catecholamine secretion - Evidence for the involvement of amyloid beta-peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ION CHANNELS; RAT PC12 CELLS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CALCIUM CHANNELS; CHROMAFFIN CELLS; GENE-EXPRESSION; CAROTID-BODY; INHIBITION; ISCHEMIA	Prolonged exposure to hypoxia (16% O-2) enhanced quantal catecholamine release evoked from O-2-sensing pheochromocytoma (PC12) cells, as monitored using single-cell amperometric recordings. The enhancement of exocytosis was apparent after 12 h of hypoxia and was maximal at 24 h. Elevated levels of secretion were due to the emergence of a Ca2+ influx pathway that persisted during complete blockade of known voltage-gated Ca2+ channels. Secretion triggered by this Ca2+ influx was severely reduced by known inhibitors of Alzheimer's amyloid beta-peptides (A beta Ps), including an N terminus-directed monoclonal antibody. The enhancing effect on secretion of chronic hypoxia was mimicked closely by direct application of A beta P to cells under normoxic conditions, although the effects of A beta P were more rapid at onset, being maximal after only 6 h. The present results suggest that prolonged hypoxia can induce formation of Ca2+-permeable A beta P channels and that such induction can lead directly to excessive neurosecretion. This is a potential contributory factor to A beta P pathophysiology following cerebral ischemia.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.			Batten, Trevor/0000-0003-3988-5603; Peers, Chris/0000-0002-8354-346X				ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Chow Robert H., 1995, P245; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kobayashi S, 1998, J PHYSIOL-LONDON, V512, P351, DOI 10.1111/j.1469-7793.1998.351be.x; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592, DOI 10.1152/ajpcell.1998.274.6.C1592; Liu HY, 1996, J NEUROSCI, V16, P7557; LOPEZBARNEO J, 1994, TRENDS NEUROSCI, V17, P133, DOI 10.1016/0166-2236(94)90084-1; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; PELZER D, 1989, ANN NY ACAD SCI, V560, P138, DOI 10.1111/j.1749-6632.1989.tb24091.x; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Taylor SC, 1998, BIOCHEM BIOPH RES CO, V248, P13, DOI 10.1006/bbrc.1998.8905; Taylor SC, 1999, J PHYSIOL-LONDON, V514, P483, DOI 10.1111/j.1469-7793.1999.483ae.x; TISCHLER AS, 1983, J NEUROCHEM, V40, P364, DOI 10.1111/j.1471-4159.1983.tb11291.x; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WU JQ, 1995, EUR J PHARMACOL, V284, pR1, DOI 10.1016/0014-2999(95)00539-W; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	44	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31217	31222		10.1074/jbc.274.44.31217	http://dx.doi.org/10.1074/jbc.274.44.31217			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531316	hybrid			2022-12-25	WOS:000083379400020
J	Hu, WH; Johnson, H; Shu, HB				Hu, WH; Johnson, H; Shu, HB			Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappa B and JNK activation and apoptosis through distinct pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-ASSOCIATED PROTEIN TRADD; FADD-DEPENDENT APOPTOSIS; DEATH DOMAIN; CELL-DEATH; KINASE COMPLEX; MEK KINASE-1; TRAIL; TNF; FAMILY; ALPHA	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that interacts with several receptors, including TRAIL-RI, TRAIL-R2, and TRAIL-R4. TRAIL-R1 and TRAIL-R2 can induce apoptosis of cancer cells and activate the transcription factor NF-kappa B. TRAIL-R4 can activate NF-kappa B and protect cells from TRAIL-induced apoptosis. Here we show that TRAIL-R1-, TRAIL-R2-, and TRAIL-R4-induced NF-kappa B activation are mediated by a TRAF2-NIK-I kappa B kinase alpha/beta signaling cascade but is MEKK1 independent. TRAIL receptors also activate the protein kinase JNK. JNK activation by TRAIL-R1 is mediated by a TRAF2-MEKK1-MKK4 but not the TRAF2-NIL-I kappa B kinase alpha/beta Signaling pathway. We also show that activation of NF-kappa B or overexpression of TRAIL-R4 does not protect TRAIL-R1-induced apoptosis. Moreover, inhibition of NF-kappa B by I kappa B alpha sensitizes cells to tumor necrosis factor- but not TRAIL-induced apoptosis. These findings suggest that TRAIL receptors induce apoptosis, NF-kappa B and JNK activation through distinct signaling pathways, and activation of NF-kappa B is not sufficient for protecting cells from TRAIL-induced apoptosis.	Natl Jewish Med & Res Ctr, Div Basic Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Shu, HB (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MONGKOLSAPAYA J, 1988, J IMMUNOL, V160, P3; NATAGA DS, 1997, CELL, V88, P355; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SHU HB, 1995, J CELL SCI, V108, P2955; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	200	209	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30603	30610		10.1074/jbc.274.43.30603	http://dx.doi.org/10.1074/jbc.274.43.30603			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521444	hybrid			2022-12-25	WOS:000083276700040
J	McFerran, BW; Weiss, JL; Burgoyne, RD				McFerran, BW; Weiss, JL; Burgoyne, RD			Neuronal Ca2+ sensor 1 - Characterization of the myristoylated protein, its cellular effects in permeabilized adrenal chromaffin cells, Ca2+-independent membrane association, and interaction with binding proteins, suggesting a role in rapid Ca2+ signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EXOCYTOSIS; REGULATED EXOCYTOSIS; NERVOUS-SYSTEM; CA2+-BINDING PROTEIN; MOLECULAR-CLONING; RHODOPSIN KINASE; ESCHERICHIA-COLI; CYCLIC-AMP; PC12 CELLS; RECOVERIN	Overexpression of frequenin and its orthologue neuronal Ca2+ sensor 1 (NCS-1) has been shown to increase evoked exocytosis in neurons and neuroendocrine cells. The site of action of NCS-1 and its biochemical targets that affect exocytosis are unknown. To allow further investigation of NCS-1 function, we have demonstrated that NCS-1 is a substrate for N-myristoyltransferase and generated recombinant myristoylated NCS-1, The bacterially expressed NCS-1 shows Ca2+-induced conformational changes. The possibility that NCS-1 directly interacts with the exocytotic machinery to enhance exocytosis was tested using digitonin-permeabilized chromaffin cells. Exogenous NCS-1 was retained in permeabilized cells but had no effect on Ca2+-dependent release of catecholamine. In addition, exogenous NCS-1 did not regulate cyclic nucleotide levels in this system. These data suggest that the effects of NCS-1 seen in intact cells are likely to be due to an action on the early steps of stimulus-secretion coupling or on Ca2+ homeostasis. Myristoylated NCS-1 bound to membranes in the absence of Ca2+ and endogenous NCS-1 was tightly membrane-associated. Using biotinylated NCS-1, a series of specific binding proteins were detected in cytosol, chromaffin granule membrane, and microsome fractions of adrenal medulla. These included proteins distinct from those detected by biotinylated calmodulin, demonstrating the presence of multiple specific Ca2+-independent and Ca2+-dependent binding proteins as putative targets for NCS-1 action. A model for NCS-1 function, from these data, indicates a constitutive membrane association independent of Ca2+. This differs from the Ca2+ myristoyl switch model for the closely related recoverin and suggests a possible action in rapid Ca2+ signal transduction in response to local Ca2+ signals.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Weiss, Jamie/HHS-2536-2022; Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Burgoyne RD, 1997, FEBS LETT, V414, P349, DOI 10.1016/S0014-5793(97)01031-4; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COX JA, 1994, J BIOL CHEM, V269, P32807; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Faurobert E, 1996, J BIOL CHEM, V271, P10256, DOI 10.1074/jbc.271.17.10256; Glenn DE, 1998, J NEUROCHEM, V71, P2023; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LADANT D, 1995, J BIOL CHEM, V270, P3179; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POULAIN C, 1994, PFLUG ARCH EUR J PHY, V427, P71, DOI 10.1007/BF00585944; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VONEULER US, 1955, ACTA PHYSIOL SCAND, V33, P45; ZOZULYA S, 1995, METHOD ENZYMOL, V250, P383; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	41	90	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30258	30265		10.1074/jbc.274.42.30258	http://dx.doi.org/10.1074/jbc.274.42.30258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514519	hybrid			2022-12-25	WOS:000083176400098
J	de Moissac, D; Zheng, H; Kirshenbaum, LA				de Moissac, D; Zheng, H; Kirshenbaum, LA			Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappa B signaling pathway for suppression of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; VENTRICULAR MYOCYTES; X-L; ALPHA; PROTEIN; INHIBITION; GENE; ACTIVATION	Nuclear factor (NF) kappa B is a ubiquitously expressed transcription factor whose function is regulated by the cytoplasmic inhibitor protein, I kappa B alpha. We have previously shown that I kappa B alpha activity is diminished in ventricular myocytes expressing Bcl-2, (de Moissac, D., Mustapha, S., Greenberg, A. H., and Kirshenbaum, L. A. (1998) J. Biol. Chem. 273, 23946-23951). In view of the growing evidence that the conserved N-terminal BH4 domain of Bcl-2 plays a critical role in suppressing apoptosis, we ascertained whether this region accounts for the underlying effects of Bcl-2 on I kappa B alpha activity. Transfection of human embryonic 293 cells with full length Bcl-2 resulted in a significant 1.9-fold reduction in I kappa B alpha activity (p < 0.006) with a concomitant increase in DNA binding and 3.4-fold increase in NF kappa B-dependent gene transcription (p < 0.022) compared with vector transfected control cells. In contrast, no significant change in I kappa B alpha activity was detected with either a BH4 domain deletion mutant (residues 10-30) or BH4 domain point substitution mutants, I14G, V15G, Y18G, K22G, and L23G (p = 2.77). However, a small 0.60-fold decrease (p < 0.04) in I kappa B alpha activity was noted with the BH4 mutant I19G, suggesting that this residue may not be critical for I kappa B alpha regulation. Furthermore, adenovirus-mediated delivery of an I kappa B alpha mutant to prevent NF kappa B activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNF alpha plus cycloheximide in ventricular myocytes, The data provide the first evidence for the regulation of I kappa B alpha by Bcl-2 through a mechanism that requires the conserved BH4 domain that links Bcl-2 to the NF kappa B signaling pathway for suppression of apoptosis.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Kirshenbaum, LA (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Rm 3016,351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.		Kirshenbaum, Lorrie A./F-5742-2014	Ryplanski, Kairee/0000-0002-3737-7181				BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1984, J BIOL CHEM, V259, P3492; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, SEMIN HEMATOL, V34, P9; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; URBAN MB, 1991, NEW BIOL, V3, P279; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WARTERS RL, 1992, CANCER RES, V52, P883; WILLIAMS RS, 1993, AM J MED SCI, V306, P129, DOI 10.1097/00000441-199308000-00013; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	41	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29505	29509		10.1074/jbc.274.41.29505	http://dx.doi.org/10.1074/jbc.274.41.29505			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506215	hybrid			2022-12-25	WOS:000083017800094
J	Kuusinen, A; Abele, R; Madden, DR; Keinanen, K				Kuusinen, A; Abele, R; Madden, DR; Keinanen, K			Oligomerization and ligand-binding properties of the ectodomain of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunit GluRD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; TETRAMERIC STRUCTURE; ESCHERICHIA-COLI; PROTEINS; DOMAINS; CHANNEL; SITE; STOICHIOMETRY	The extracellular part of ionotropic glutamate receptor (iGluR) subunits can be divided into a conserved two-lobed ligand-binding domain ("S1S2") and an N-terminal similar to 400-residue segment of unknown function ("X domain") which shows high sequence variation among subunits. To investigate the structure and properties of the N-terminal domain, we have now produced affinity-tagged recombinant fragments which represent the X domain of the GluRD subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-selective glutamate receptors either alone or covalently linked to the ligand-binding domain ("XS1S2"). These fragments were expressed in insect cells as secreted soluble proteins and were recognized by a conformation-specific anti-GluRD monoclonal antibody. A hydrodynamic analysis of the purified fragments revealed them to be dimers, in contrast to the S1S2 ligand-binding domain which is monomeric. The X domain did not bind radiolabeled AMPA or glutamate nor did its presence affect the ligand binding properties of the S1S2 domain. Our findings demonstrate that the N-terminal domain of AMPA receptor can be expressed as a soluble polypeptide and suggest that subunit interactions in iGluR may involve the extracellular domains.	Univ Helsinki, Dept Biosci, Div Biochem, Viikki Bioctr, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; VTT, Biotechnol & Food Res, FIN-02044 Espoo, Finland; Max Planck Inst Med Res, Ion Channel Struct Res Grp, D-69120 Heidelberg, Germany	University of Helsinki; University of Helsinki; VTT Technical Research Center Finland; Max Planck Society	Keinanen, K (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikki Bioctr, POB 56,Viikinkaari 5D, FIN-00014 Helsinki, Finland.		Tampé, Robert/H-2953-2015; Keinanen, Kari/E-9122-2010	Tampé, Robert/0000-0002-0403-2160; 				Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; Green WN, 1998, J NEUROSCI, V18, P5555; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Ivanovic A, 1998, J BIOL CHEM, V273, P19933, DOI 10.1074/jbc.273.32.19933; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; KUUSINEN A, 1995, EUR J BIOCHEM, V233, P720, DOI 10.1111/j.1432-1033.1995.720_3.x; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Villarroel A, 1998, NEURON, V20, P329, DOI 10.1016/S0896-6273(00)80460-2; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; Wells GB, 1998, J BIOL CHEM, V273, P964, DOI 10.1074/jbc.273.2.964; WO ZGL, 1995, J BIOL CHEM, V270, P2000, DOI 10.1074/jbc.270.5.2000	32	78	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28937	28943		10.1074/jbc.274.41.28937	http://dx.doi.org/10.1074/jbc.274.41.28937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506139	hybrid			2022-12-25	WOS:000083017800018
J	Liu, CWY; Wang, RH; Dohadwala, M; Schonthal, AH; Villa-Moruzzi, E; Berndt, N				Liu, CWY; Wang, RH; Dohadwala, M; Schonthal, AH; Villa-Moruzzi, E; Berndt, N			Inhibitory phosphorylation of PP1 alpha catalytic subunit during the G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TYPE-1 PROTEIN PHOSPHATASE; RETINOBLASTOMA PROTEIN; S-PHASE; AFFINITY-CHROMATOGRAPHY; FUNCTIONAL INACTIVATION; CELL-PROLIFERATION; RESTRICTION POINT; GENE; RB	We have shown earlier that, in cells expressing the retinoblastoma protein (pRB), a protein phosphatase (PP) 1 alpha mutant (T320A) resistant to inhibitory phosphorylation by cyclin-dependent kinases (Cdks) causes G(1) arrest. In this study, we examined the cell cycle-dependent phosphorylation of PP1 alpha in, vivo using three different antibodies. PP1 alpha was phosphorylated at Thr-320 during M-phase and again in late G(1)- through early S-phase. Inhibition of Cdk2 led to a small increase in PP1 activity and also prevented PP1 alpha phosphorylation. In vitro, PP1 alpha was a substrate for Cdk2 but not Cdk4. In pRB-deficient cells, phosphorylation of PP1 alpha occurred in RI-phase but not at G(1)/S G(1)/S phosphorylation was at least partially restored after reintroduction of pRB into these cells. Consistent with this result, PP1 alpha phosphorylated at Thr-320 co-precipitated with pRB during G(1)/S but was found in extracts immunodepleted of pRB in M-phase. In conjunction with earlier studies, these results indicate that PP1 alpha may control PRE function throughout the cell cycle. In addition, our new results suggest that different subpopulations of PP1 alpha regulate the G(1)/S and G(2)/M transitions and that PP1 alpha complexed to pRB requires inhibitory phosphorylation by G(1)-specific Cdks in order to prevent untimely reactivation of PRE and permit transition from G(1)- to S-phase and/or complete S-phase.	Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ Pisa, Dipartimento Patol Sperimentale, I-56126 Pisa, Italy	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Pisa	Berndt, N (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Schonthal, Axel/ABH-3846-2020		NATIONAL CANCER INSTITUTE [R01CA054167] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54167] Funding Source: Medline; Telethon [1112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon)		ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; BERNDT N, 1995, ADV PROTEIN PHOSPHAT, V9, P63; Berndt Norbert, 1999, Frontiers in Bioscience, V4, pD22, DOI 10.2741/Berndt; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAUTIGAN DL, 1995, SEMIN CANCER BIOL, V6, P211, DOI 10.1006/scbi.1995.0028; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dohadwala M, 1998, METH MOL B, V93, P191; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FUNG YKT, 1993, ONCOGENE, V8, P2659; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lundberg AS, 1999, EUR J CANCER, V35, P531; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Mueller Daniel, 1997, Oncogene, V15, P2561; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Oliver Carey J., 1998, Frontiers in Bioscience, V3, pD961; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; Puntoni F, 1997, ARCH BIOCHEM BIOPHYS, V340, P177, DOI 10.1006/abbi.1997.9889; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RUNNEGAR M, 1995, BIOCHEM BIOPH RES CO, V216, P162, DOI 10.1006/bbrc.1995.2605; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; VILLAMORUZZI E, 1991, FEBS LETT, V293, P67, DOI 10.1016/0014-5793(91)81154-Z; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Zhao SM, 1996, ARCH BIOCHEM BIOPHYS, V325, P82, DOI 10.1006/abbi.1996.0010	51	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29470	29475		10.1074/jbc.274.41.29470	http://dx.doi.org/10.1074/jbc.274.41.29470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506210	hybrid			2022-12-25	WOS:000083017800089
J	Petukhova, G; Van Komen, S; Vergano, S; Klein, H; Sung, P				Petukhova, G; Van Komen, S; Vergano, S; Klein, H; Sung, P			Yeast Rad54 promotes Rad51-dependent homologous DNA pairing via ATP hydrolysis-driven change in DNA double helix conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MEIOTIC RECOMBINATION; COMPLEX-FORMATION; DEPENDENT ATPASE; BINDING-PROTEIN; REPAIR PROTEIN; RECA PROTEIN	Saccharomyces cerevisiae RAD54 gene functions in the formation of heteroduplex DNA, a key intermediate in recombination processes. Rad54 is monomeric in solution, but forms a dimer/oligomer on DNA. Rad54 dimer/oligomer alters the conformation of the DNA double helix in an ATP-dependent manner, as revealed by a change in the DNA linking number in a topoisomerase I-linked reaction. DNA conformational alteration does not occur in the presence of non-hydrolyzable ATP analogues, nor when mutant rad54 proteins defective in ATP hydrolysis replace Rad54. Accordingly the Rad54 ATPase activity is shown to be required for biological function in vivo and for promoting Rad51-mediated homologous DNA pairing in vitro, Taken together, the results are consistent with a model in which a Rad54 dimer/oligomer promotes nascent heteroduplex joint formation via a specific interaction with Rad51 protein and an ability to transiently unwind duplex DNA.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	University of Texas System; University of Texas Health San Antonio; New York University; New York University	Klein, H (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.	kleinh01@mcrcr.med.nyu.edu; sung@uthscsa.edu		Klein, Hannah/0000-0003-4228-8535	NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM57814, GM53738] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM053738] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Dresser ME, 1997, GENETICS, V147, P533; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Klein HL, 1997, GENETICS, V147, P1533; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Moreau S, 1999, MOL CELL BIOL, V19, P556; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara M, 1997, GENETICS, V147, P1545; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wong I, 1995, METHOD ENZYMOL, V259, P95; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	55	156	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29453	29462		10.1074/jbc.274.41.29453	http://dx.doi.org/10.1074/jbc.274.41.29453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506208	hybrid			2022-12-25	WOS:000083017800087
J	Roberts, CM; Tani, PH; Bridges, LC; Laszik, Z; Bowditch, RD				Roberts, CM; Tani, PH; Bridges, LC; Laszik, Z; Bowditch, RD			MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; ADAM-12 MELTRIN-ALPHA; NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; VENOM DISINTEGRINS; MEMBRANE-PROTEINS; MESSENGER-RNAS; TNF-ALPHA; DOMAIN; CELLS	The metalloprotease disintegrin cysteine-rich (MDC) proteins are a recently identified family of transmembrane proteins that function in proteolytic processing of cell surface molecules and in cell adhesion, Since lymphocytes must interact with a constantly changing environment, we hypothesized that lymphocytes would express unique MDC proteins. To identify MDC proteins expressed in human lymph node, a polymerase chain reaction-based strategy combined with degenerate oligonucleotide primers was employed, We report here the identification of MDC-L (ADAM 23), a novel member of the MDC protein family, The results obtained from cDNA cloning and Northern blot analysis of mRNA isolated from various lymphoid tissues indicate that a 2.8-kilobase mRNA encoding a transmembrane form, MDC-Lm, and a 2.2-kilobase mRNA encoding a secreted form, MDC-Ls, are expressed in a tissue-specific manner. MDC-L mRNA was shown to be predominantly expressed in secondary lymphoid tissues, such as lymph node, spleen, small intestine, stomach, colon, appendix, and trachea. Furthermore, immunohistochemical staining with an anti-MDC-L antibody demonstrated that cells with typical lymphocyte morphology are responsible for expression of the MDC-L antigen in these lymphoid tissues. MDC-Lm was found to be expressed on the surface of human peripheral blood lymphocytes and transformed B- and T-lymphocyte cell lines as an 87-kDa protein, Thus, we have identified a novel lymphocyte-expressed MDC protein family member.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Bowditch, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, BRC 417,POB 26901, Oklahoma City, OK 73190 USA.	ron-bowditch@ouhsc.edu			NIGMS NIH HHS [GM51616] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FREEHAN C, 1996, J BIOL CHEM, V271, P7019; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARLOW E, 1988, ANTIBODIES; HERRMANN J, 1990, BIOTECHNIQUES, V8, P376; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KAMIGUTI AS, 1994, THROMB HAEMOSTASIS, V72, P244; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mueller CGF, 1997, J EXP MED, V186, P655, DOI 10.1084/jem.186.5.655; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Patel IR, 1998, J IMMUNOL, V160, P4570; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RETZIOS AD, 1988, THROMB RES, V52, P541, DOI 10.1016/0049-3848(88)90127-2; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; van Huijsduijnen RH, 1998, GENE, V206, P273, DOI 10.1016/S0378-1119(97)00597-0; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	49	56	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29251	29259		10.1074/jbc.274.41.29251	http://dx.doi.org/10.1074/jbc.274.41.29251			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506182	hybrid			2022-12-25	WOS:000083017800061
J	Vogt, TCB; Bechinger, B				Vogt, TCB; Bechinger, B			The interactions of histidine-containing amphipathic helical peptide antibiotics with lipid bilayers - The effects of charges and pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE; ION CHANNELS; PHOSPHOLIPID-BILAYERS; PORE FORMATION; TRITON X-100; XENOPUS SKIN; CELL-LINES; MEMBRANES; MAGAININ-2; MELITTIN	The alpha-helix of the designed amphipathic peptide antibiotic LAH(4) (KHALLALALHHLAHLALHLALALKKANH(2)) strongly interacts with phospholipid membranes. The peptide is oriented parallel to the membrane surface under acidic conditions, but transmembrane at physiological pH (Bechinger, B, (1996) J. Mol. Biol. 263, 768-775). LAH(4) exhibits antibiotic activities against Escherichia coli and Bacillus subtilis; the peptide does not, however, lyse human red blood cells at bacteriocidal concentrations. The antibiotic activities of LAH(4) are 2 orders of magnitude more pronounced at pH 5 when compared with pH 7,5. Although peptide association at low pH is reduced when compared with pH 7,5, the release of the fluorophore calcein from large unilamellar 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol vesicles is more pronounced at pH values where LAH(4) adopts an orientation along the membrane surface. The calcein release experiments thereby parallel the results obtained in antibiotic assays, Despite a much higher degree of association, calcein release activity of LAH(4) is significantly decreased for negatively charged membranes. Pronounced differences in the interactions of LAH(4) with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol or 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine membranes also become apparent when the mechanisms of dye release are investigated. The results presented in this paper support models in which antibiotic activity is caused by detergent-like membrane destabilization, rather than pore formation by helical peptides in transmembrane alignments.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Bechinger, B (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.							AKIYO I, 1998, BIOL PHARM BULL, V20, P267; ALDER GM, 1991, BIOCHIM BIOPHYS ACTA, V1061, P111, DOI 10.1016/0005-2736(91)90275-D; ANTONOV VF, 1980, NATURE, V283, P585, DOI 10.1038/283585a0; Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BECHINGER B, 1999, IN PRESS BIOPOLYMERS, V51; BELLO J, 1982, BIOCHEMISTRY-US, V21, P461, DOI 10.1021/bi00532a007; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BOHEIM G, 1974, J MEMBRANE BIOL, V19, P277, DOI 10.1007/BF01869983; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; DeGeyter C, 1997, FEBS LETT, V400, P149, DOI 10.1016/S0014-5793(96)01379-8; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; Haimovich B, 1995, BBA-BIOMEMBRANES, V1240, P149, DOI 10.1016/0005-2736(95)00204-9; HE K, 1995, BIOCHEMISTRY-US, V34, P15614, DOI 10.1021/bi00048a002; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; JACOB L, 1994, CIBA F SYMP, V186, P197; JONES RV, 1990, MEMBRANE BIOCHEM, V9, P171, DOI 10.3109/09687689009025838; JURETIC D, 1994, BIOCHEMISTRY-US, V33, P4562, DOI 10.1021/bi00181a017; KAUFMANN K, 1983, BIOPHYS CHEM, V18, P89, DOI 10.1016/0301-4622(83)85002-9; Kinder R, 1999, BIOPHYS J, V76, pA443; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Ludtke S, 1995, BIOCHEMISTRY-US, V34, P16764, DOI 10.1021/bi00051a026; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P12553, DOI 10.1021/bi00039a009; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; OHSAKI Y, 1992, CANCER RES, V52, P3534; Polozov IV, 1998, BBA-BIOMEMBRANES, V1368, P343, DOI 10.1016/S0005-2736(97)00210-1; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; SANSOM MSP, 1993, EUR BIOPHYS J BIOPHY, V22, P105, DOI 10.1007/BF00196915; SCHLIEPER P, 1977, ARCH BIOCHEM BIOPHYS, V184, P204, DOI 10.1016/0003-9861(77)90343-5; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SOBALLE PW, 1995, INT J CANCER, V60, P280; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Vunnam S, 1998, J PEPT RES, V51, P38; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WADE D, 1992, INT J PEPT PROT RES, V40, P429; Wenk MR, 1998, BIOCHEMISTRY-US, V37, P3909, DOI 10.1021/bi972615n; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; Wieprecht T, 1996, BIOCHEMISTRY-US, V35, P10844, DOI 10.1021/bi960362c; WOODBURY DJ, 1989, J MEMBRANE BIOL, V109, P145, DOI 10.1007/BF01870853; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YOSHIKAWA K, 1988, BIOPHYS CHEM, V29, P293, DOI 10.1016/0301-4622(88)85051-8; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	59	150	155	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29115	29121		10.1074/jbc.274.41.29115	http://dx.doi.org/10.1074/jbc.274.41.29115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506166	hybrid			2022-12-25	WOS:000083017800045
J	Wang, YX; Kaguni, LS				Wang, YX; Kaguni, LS			Baculovirus expression reconstitutes Drosophila mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CLONING; EMBRYOS; REPAIR; GENE; IDENTIFICATION; REPLICATION; PROTEIN; GAMMA	Drosophila mitochondrial DNA polymerase has been reconstituted and purified from baculovirus-infected insect cells. Baculoviruses encoding full-length and mature forms of the catalytic and accessory subunits were generated and used in single and co-infection studies. Recombinant heterodimeric holoenzyme was reconstituted in both the mitochondria and cytoplasm of Sf9 cells and required the mitochondrial presequences in both subunits. The recombinant holoenzyme contains DNA polymerase and 3'-5' exonuclease that are stimulated substantially by both salt and mitochondrial single-stranded DNA-binding protein. Thus, the recombinant enzyme exhibits biochemical properties indistinguishable from those of the native enzyme from Drosophila embryos. Production of the catalytic subunit alone yielded soluble protein with the chromatographic properties of the heterodimeric holoenzyme. However, the purified catalytic core has a 50-fold lower specific activity. This provides evidence of a critical role for the accessory subunit in the catalytic efficiency of Drosophila mitochondrial DNA polymerase.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	lskauni@pilot.msu.edu			NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; FOURY F, 1989, J BIOL CHEM, V264, P20552; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Harris PV, 1996, MOL CELL BIOL, V16, P5764; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; SINGH G, 1992, PHARMACOL THERAPEUT, V54, P217, DOI 10.1016/0163-7258(92)90033-V; TABOR S, 1987, J BIOL CHEM, V262, P16212; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WEISSBACH A, 1979, ARCH BIOCHEM BIOPHYS, V198, P386, DOI 10.1016/0003-9861(79)90511-3; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764	21	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28972	28977		10.1074/jbc.274.41.28972	http://dx.doi.org/10.1074/jbc.274.41.28972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506144	hybrid			2022-12-25	WOS:000083017800023
J	Meplan, C; Mann, K; Hainaut, P				Meplan, C; Mann, K; Hainaut, P			Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC DNA; RAT L6 MYOBLASTS; TUMOR-SUPPRESSOR; OXIDATIVE STRESS; MAMMALIAN-CELLS; IN-VITRO; METALLOTHIONEIN GENE; TRANSITION-METALS; BINDING ACTIVITY; MCF-7 CELLS	The p53 tumor suppressor protein is a transcription factor that binds DNA in a sequence-specific manner through a protein domain stabilized by the coordination of zinc within a tetrahedral cluster of three cysteine residues and one histidine residue. We show that cadmium, a metal that binds thiols with high affinity and substitutes for zinc in the cysteinyl clusters of many proteins, inhibits the binding of recombinant, purified murine p53 to DNA. In human breast cancer MCF7 cells (expressing wild-type p53), exposure to cadmium (5-40 mu M) disrupts native (wild-type) p53 conformation, inhibits DNA binding, and down-regulates transcriptional activation of a reporter gene. Cadmium at 10-30 mu M impairs the p53 induction in response to DNA-damaging agents such as actinomycin D, methylmethane sulfonate, and hydrogen peroxide. Exposure to cadmium at 20 mu M also suppresses the p53-dependent cell cycle arrest in G(1) and G(2)/M phases induced by gamma-irradiation. These observations indicate that cadmium at subtoxic levels impairs p53 function by inducing conformational changes in the wild-type protein. There is evidence that cadmium is carcinogenic to humans, in particular for lung and prostate, and cadmium is known to accumulate in several organs. This inhibition of p53 function could play a role in cadmium carcinogenicity.	Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, F-69372 Lyon 08, France; Univ Alaska Anchorage, Anchorage, AK 99508 USA	World Health Organization; International Agency for Research on Cancer (IARC); University of Alaska System; University of Alaska Anchorage	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mechanisms Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Abshire MK, 1996, J TOXICOL ENV HEALTH, V48, P359, DOI 10.1080/009841096161258; Abshire MK, 1996, CARCINOGENESIS, V17, P1349, DOI 10.1093/carcin/17.6.1349; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Bacus SS, 1996, ONCOGENE, V12, P2535; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Calmels S, 1997, CANCER RES, V57, P3365; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COFFER AI, 1994, BBA-PROTEIN STRUCT M, V1209, P279, DOI 10.1016/0167-4838(94)90197-X; COOGAN TP, 1992, TOXICOL APPL PHARM, V113, P227, DOI 10.1016/0041-008X(92)90118-C; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; Ellis K J, 1980, Am J Ind Med, V1, P339, DOI 10.1002/ajim.4700010310; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Maki CG, 1996, CANCER RES, V56, P2649; MARCOVECCHIO JE, 1993, ENVIRON MONIT ASSESS, V25, P119, DOI 10.1007/BF00549133; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; NOCENTINI S, 1987, NUCLEIC ACIDS RES, V15, P4211, DOI 10.1093/nar/15.10.4211; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; PRISE KM, 1995, INT J RADIAT BIOL, V67, P393, DOI 10.1080/09553009514550451; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; REID TM, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3431764; ROELS HA, 1981, ENVIRON RES, V26, P217, DOI 10.1016/0013-9351(81)90199-7; Rossman T G, 1992, IARC Sci Publ, P367; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shimada H, 1998, J TOXICOL ENV HEAL A, V54, P159; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SRINIVASAN R, 1993, CANCER RES, V53, P5361; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TSUZUKI K, 1994, ENVIRON HEALTH PERSP, V102, P341, DOI 10.2307/3431817; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Waalkes MP, 1999, CARCINOGENESIS, V20, P65, DOI 10.1093/carcin/20.1.65; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zheng H, 1996, TOXICOL APPL PHARM, V136, P229, DOI 10.1006/taap.1996.0029	64	153	155	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31663	31670		10.1074/jbc.274.44.31663	http://dx.doi.org/10.1074/jbc.274.44.31663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531375	hybrid			2022-12-25	WOS:000083379400079
J	Michelson, RJ; Collard, MW; Ziemba, AJ; Persinger, J; Bartholomew, B; Huggenvik, JI				Michelson, RJ; Collard, MW; Ziemba, AJ; Persinger, J; Bartholomew, B; Huggenvik, JI			Nuclear DEAF-1-related (NUDR) protein contains a novel DNA binding domain and represses transcription of the heterogeneous nuclear ribonucleoprotein A2/B1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; LUNG-CANCER; C-MYC; DROSOPHILA-MELANOGASTER; FUNCTIONAL-ANALYSIS; FUSION PARTNER; TARGET GENES; LIM DOMAINS; RNA; EXPRESSION	Nuclear DEAF-1-related (NUDR) protein is a novel transcriptional regulator with sequence similarity to developmental and oncogenic proteins. NUDR protein deletions were used to localize the DNA binding domain between amino acids 167 and 368, and site-specific DNA photocross-linking indicated at least two sites of protein-DNA contact within this domain. The DNA binding domain contains a proline-rich region and a region with similarity to a Myc-type helix-loop-helix domain but does not include the zinc finger motif at the C terminus, Deoxyribonuclease I protection assays confirmed the presence of multiple NUDR binding motifs (TTC(C/G)G) in the heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) promoter and also in the 5'-untranslated region (UTR) of hNUDR cDNA. NUDR produced a 65-70% repression of the hnRNP A2/B1 promoter activity, and NUDE binding motifs in the 5'-UTR were found to mediate this repression NUDR-dependent repression was also observed when the 5'-UTR of NUDR was placed onto a heterologous thymidine kinase promoter in an analogous 5'-UTR position but not when placed upstream of transcription initiation. These results suggest that NUDE may regulate the in vivo expression of hnRNP A2/B1 and NUDE genes and imply that inactivation of NUDE could contribute to the overexpression of hnRNP A2/B1 observed in some human cancers.	So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Med Biochem, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University	Huggenvik, JI (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.	jhuggenvik@som.siu.edu			NICHD NIH HHS [HD31613, HD32484] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD031613, R29HD032484] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KUIPER GGJM, 1993, BIOCHEM J, V296, P161, DOI 10.1042/bj2960161; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Liu CT, 1998, CANCER GENE THER, V5, P3; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Montuenga LM, 1998, AM J RESP CELL MOL, V19, P554, DOI 10.1165/ajrcmb.19.4.3185; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Ogbourne S, 1998, BIOCHEM J, V331, P1; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; PLET A, 1995, ONCOGENE, V10, P319; Qiao YL, 1997, CANCER EPIDEM BIOMAR, V6, P893; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; TOCKMANMS, 1996, J CELL BIOCHEM, V25, P177; Valge-Archer V, 1998, ONCOGENE, V17, P3199, DOI 10.1038/sj.onc.1202353; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WOLF DA, 1995, NUCLEIC ACIDS RES, V23, P3373, DOI 10.1093/nar/23.17.3373; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760; Zhou J, 1998, CLIN CANCER RES, V4, P1631	59	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30510	30519		10.1074/jbc.274.43.30510	http://dx.doi.org/10.1074/jbc.274.43.30510			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521432	hybrid			2022-12-25	WOS:000083276700028
J	Moser, J; Lorenz, S; Hubschwerlen, C; Rompf, A; Jahn, D				Moser, J; Lorenz, S; Hubschwerlen, C; Rompf, A; Jahn, D			Methanopyrus kandleri glutamyl-tRNA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA REDUCTASE; ESCHERICHIA-COLI; CHLOROPHYLL BIOSYNTHESIS; TRNA(GLU) REDUCTASE; BACILLUS-SUBTILIS; PURIFICATION; INHIBITION; SYNTHETASE; HEME; DEHYDROGENASE	The initial reaction of tetrapyrrole formation in archaea is catalyzed by a NADPH-dependent glutamyl-tRNA reductase (GluTR). The hemA gene encoding GluTR was cloned from the extremely thermophilic archaeon Methanopyrus kandleri and overexpressed in Escherichia coli, Purified recombinant GluTR is a tetrameric enzyme with a native M-r = 190,000 +/- 10,000. Using a newly established enzyme assay, a specific activity of 0.75 nmol h(-1) mg(-1) at 56 degrees C with E. coli glutamyl-tRNA as substrate was measured. A temperature optimum of 90 degrees C and a pH optimum of 8.1 were determined. Neither heme cofactor, nor flavin, nor metal ions were required for GluTR catalysis, Heavy metal compounds, Zn2+, and heme inhibited the enzyme. GluTR inhibition by the newly synthesized inhibitor glutamycin, whose structure is similar to the 3' end of the glutamyl-tRNA substrate, revealed the importance of an intact chemical bond between glutamate and tRNA(Glu) for substrate recognition. The absolute requirement for NADPH in the reaction of GluTR was demonstrated using four NADPH analogues. Chemical modification and site-directed mutagenesis studies indicated that a single cysteinyl residue and a single histidinyl residue were important for catalysis, It was concluded that during GluTR catalysis the highly reactive sulfhydryl group of Cys-48 acts as a nucleophile attacking the alpha-carbonyl group of tRNA-bound glutamate with the formation of an enzyme-localized thioester intermediate and the concomitant release of tRNA(Glu). In the presence of NADPH, direct hydride transfer to enzyme-bound glutamate, possibly facilitated by His-84, leads to glutamate-1-semialdehyde formation. In the absence of NADPH, a newly discovered esterase activity of GluTR hydrolyzes the highly reactive thioester of tRNA(Glu) to release glutamate.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; F Hoffmann La Roche & Co Ltd, Preclin Res, CH-4070 Basel, Switzerland	University of Freiburg; Roche Holding	Jahn, D (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albert Str 21, D-79104 Freiburg, Germany.			Jahn, Dieter/0000-0002-4064-9205				Boschi-Muller S, 1999, ARCH BIOCHEM BIOPHYS, V363, P259, DOI 10.1006/abbi.1998.1080; CHAPMAN KT, 1993, J MED CHEM, V36, P4293, DOI 10.1021/jm00078a019; CHEN MW, 1990, J BIOL CHEM, V265, P4054; CHEN MW, 1990, J BIOL CHEM, V265, P4058; FRANKENBERG N, 1999, IN PRESS BIOCHEMISTR; Habenicht A, 1997, BIOL CHEM, V378, P1413; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Hungerer C, 1996, BIOORGAN MED CHEM, V4, P1089, DOI 10.1016/0968-0896(96)00098-3; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JAHN D, 1991, J BIOL CHEM, V266, P2542; JORDAN PM, NEW COMPREHENSIVE BI, V19, P1; KANNANGARA CG, 1994, CIBA F SYMP, V180, P3; MAU YH, 1987, ARCH BIOCHEM BIOPHYS, V255, P75, DOI 10.1016/0003-9861(87)90295-5; Nagradova NK, 1998, BIOCHEMISTRY-MOSCOW+, V63, P504; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; PONTOPPIDAN B, 1994, EUR J BIOCHEM, V225, P529, DOI 10.1111/j.1432-1033.1994.00529.x; PROULX M, 1985, METHOD ENZYMOL, V113, P50; RIEBLE S, 1991, J BIOL CHEM, V266, P9740; SCHRODER I, 1992, BIOCHEM J, V281, P843, DOI 10.1042/bj2810843; Talfournier F, 1998, EUR J BIOCHEM, V252, P447, DOI 10.1046/j.1432-1327.1998.2520447.x; VERKAMP E, 1992, J BIOL CHEM, V267, P8275; Vothknecht UC, 1996, P NATL ACAD SCI USA, V93, P9287, DOI 10.1073/pnas.93.17.9287; Vothknecht UC, 1998, PHYTOCHEMISTRY, V47, P513, DOI 10.1016/S0031-9422(97)00538-4	25	60	65	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30679	30685		10.1074/jbc.274.43.30679	http://dx.doi.org/10.1074/jbc.274.43.30679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521455	hybrid			2022-12-25	WOS:000083276700051
J	Rawadi, G; Zugaza, JL; Lemercier, B; Marvaud, JC; Popoff, M; Bertoglio, J; Roman-Roman, S				Rawadi, G; Zugaza, JL; Lemercier, B; Marvaud, JC; Popoff, M; Bertoglio, J; Roman-Roman, S			Involvement of small GTPases in Mycoplasma fermentans membrane lipoproteins-mediated activation of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALDRICH-SYNDROME PROTEIN; SIGNALING PATHWAY; RHO-PROTEINS; KINASE; BINDING; CDC42; CASCADES	Mycoplasma fermentans lipoproteins (LAMPf) are capable of activating macrophages and inducing the secretion of proinflammatory cytokines. We have recently reported that mitogen-activated protein kinase (MAPK) pathways and NF-kappa B and activated protein 1 (AP-1) play a crucial role in the activation induced by this bacterial compound. To further elucidate the mechanisms by which LAMPf mediate the activation of macrophages, we assessed the effects of inhibiting small G proteins Rac, Cdc42, and Rho, The Rho-specific inhibitor C3 enzyme completely abolished the secretion of tumor necrosis factor alpha by macrophages stimulated with LAMPf and also inhibited the activation of extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 kinase. In addition, we have shown that LAMPf stimulate Cdc42 and that inhibition of Cdc42 or Rac by dominant negative mutants abrogates LAMPf-mediated activation of JNK and transactivation of NF-kappa B and AP-1 in the murine macrophage cell line RAW 264.7, These results indicate that small G: proteins Rho, Cdc42, and Rac are involved in the cascade of events leading to the macrophage activation by mycoplasma lipoproteins.	Inst Pasteur, Lab Mycoplasmes, F-75724 Paris 15, France; Inst Pasteur, Lab Toxine Microbienne, F-75724 Paris, France; Univ Paris 11, Fac Pharm, INSERM, U461, F-92296 Chatenay Malabry, France; Hoechst Marion Roussel, Ctr Rech Romainville, F-93230 Romainville, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France	Rawadi, G (corresponding author), Hoechst Marion Roussel, Infect Dis Grp, 102 Route Noisy, F-93230 Romainville, France.		Roman-Roman, Sergio/K-9993-2014; Bustelo, Xose R./A-9526-2010	Roman-Roman, Sergio/0000-0001-6459-2613; Bustelo, Xose R./0000-0001-9398-6072; Rawadi, Georges/0000-0003-4735-2188; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRASIER AR, 1994, CURRENT PROTOCOLS MO; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Garcia J, 1998, J BIOL CHEM, V273, P34391, DOI 10.1074/jbc.273.51.34391; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Henderson B, 1996, IMMUNOPHARMACOLOGY, V35, P1, DOI 10.1016/0162-3109(96)00144-0; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Marvaud J. C., 1998, Zentralblatt fuer Bakteriologie Supplement, V29, P72; Rawadi G, 1996, INFECT IMMUN, V64, P637, DOI 10.1128/IAI.64.2.637-643.1996; Rawadi G, 1999, J IMMUNOL, V162, P2193; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; RAZIN S, 1985, MYCOPLASMAS, V4; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TaylorRobinson D, 1996, CLIN INFECT DIS, V23, P671, DOI 10.1093/clinids/23.4.671; TaylorRobinson D, 1996, J CLIN PATHOL, V49, P781, DOI 10.1136/jcp.49.10.781; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Weber KSC, 1998, EUR J IMMUNOL, V28, P2245, DOI 10.1002/(SICI)1521-4141(199807)28:07<2245::AID-IMMU2245>3.0.CO;2-V; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	28	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30794	30798		10.1074/jbc.274.43.30794	http://dx.doi.org/10.1074/jbc.274.43.30794			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521470	hybrid			2022-12-25	WOS:000083276700066
J	Acosta-Serrano, A; Cole, RN; Mehlert, A; Lee, MGS; Ferguson, MAJ; Englund, PT				Acosta-Serrano, A; Cole, RN; Mehlert, A; Lee, MGS; Ferguson, MAJ; Englund, PT			The procyclin repertoire of Trypanosoma brucei - Identification and structural characterization of the Glu-Pro-rich polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC REPETITIVE PROTEIN; AMANITIN-RESISTANT TRANSCRIPTION; 3'-UNTRANSLATED REGION; AFRICAN TRYPANOSOMES; TRANS-SIALIDASE; SURFACE-ANTIGEN; CULTURE FORMS; EXPRESSION; INSECT; GENES	The surface of the insect stages of the protozoan parasite Trypanosoma brucei is covered by abundant glycosyl phosphatidylinositol (GPI)-anchored glycoproteins known as procyclins. One type of procyclin, the EP isoform, is predicted to have 22-30 Glu-Pro (EP) repeats in its C-terminal domain and is encoded by multiple genes. Because of the similarity of the EP isoform sequences and the heterogeneity of their GPI anchors, it has been impossible to separate and characterize these polypeptides by standard protein fractionation techniques. To facilitate their structural and functional characterization, we used a combination of matrix-assisted laser desorption ionization and electrospray mass spectrometry to analyze the entire procyclin repertoire expressed on the trypanosome cell. This analysis, which required removal of the GPI anchors by aqueous hydrofluoric acid treatment and cleavage at aspartate-proline bonds by mild acid hydrolysis, provided precise information about the glycosylation state and the number of Glu-Pro repeats in these proteins. Using this methodology we detected in a T. brucei clone the glycosylated products of the EP3 gene and two different products of the EP1 gene (EP1-1 and EP1-2). Furthermore, only low amounts of the nonglycosylated products of the GREET and EP2 genes were detected. Because all procyclin genes are transcribed polycistronically, the latter finding indicates that the expression of the GREET and ER2 genes is post-transcriptionaly regulated. This is the first time that the whole procyclin repertoire from procyclic trypanosomes has been characterized at the protein level.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	Johns Hopkins University; University of Dundee; New York University	Acosta-Serrano, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	aacostas@welchlink.welch.jhu.edu	Acosta-Serrano, Alvaro/L-5503-2015; Ferguson, Michael A. J./F-7829-2010	Acosta-Serrano, Alvaro/0000-0002-2576-7959; Ferguson, Michael A. J./0000-0003-1321-8714	NIAID NIH HHS [AI28953, AI21334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028953, R01AI028953, R21AI028953, R01AI021334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUN R, 1979, ACTA TROP, V36, P289; Butikofer P, 1997, BIOCHEM J, V326, P415; Butikofer P, 1999, J CELL SCI, V112, P1785; BUTIKOFER P, 1995, ANAL BIOCHEM, V229, P125, DOI 10.1006/abio.1995.1388; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; ENGSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1, DOI 10.1016/0166-6851(93)90153-O; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; Hwa KY, 1999, GLYCOBIOLOGY, V9, P181, DOI 10.1093/glycob/9.2.181; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; JACKSON DG, 1993, J BIOL CHEM, V268, P1894; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; Mehlert A, 1999, MOL BIOCHEM PARASIT, V98, P291, DOI 10.1016/S0166-6851(98)00168-6; MOWATT MR, 1989, MOL CELL BIOL, V9, P1332, DOI 10.1128/MCB.9.3.1332; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; MOWATT MR, 1988, MOL CELL BIOL, V8, P4055, DOI 10.1128/MCB.8.10.4055; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; RODITI I, 1999, IN PRESS MOL BIOCH P; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Schurch N, 1997, MOL BIOCHEM PARASIT, V89, P109, DOI 10.1016/S0166-6851(97)00107-2; STEBECK CE, 1995, MOL BIOCHEM PARASIT, V71, P1, DOI 10.1016/0166-6851(95)00022-S; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; VICKERMAN K, 1969, J CELL SCI, V5, P163; Wilson K, 1999, EXP PARASITOL, V91, P222, DOI 10.1006/expr.1998.4366	36	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29763	29771		10.1074/jbc.274.42.29763	http://dx.doi.org/10.1074/jbc.274.42.29763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514452	hybrid			2022-12-25	WOS:000083176400031
J	Ai, LS; Chau, LY				Ai, LS; Chau, LY			Post-transcriptional regulation of H-ferritin mRNA - Identification of a pyrimidine-rich sequence in the 3 '-untranslated region associated with message stability in human monocytic THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; BINDING-PROTEIN; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; HEAVY-CHAIN; POLYPYRIMIDINE TRACT; MOLECULAR-CLONING; MUSCLE-CELLS	We have previously demonstrated that phorbol myristate acetate (PMA) up-regulates H-ferritin gene expression in myeloid cells by stabilization of its message. In the present report, we showed that insertion of the 3'-untranslated region (3'-UTR) of H-ferritin mRNA at the 3'-end of luciferase coding sequence significantly reduced the stability of luciferase mRNA in human monocytic THP-1 cells. However, the half-life of the chimeric transcript was markedly prolonged after PMA treatment. A cytosolic protein factor from THP-1 cells was found to specifically bind to H-ferritin 3'-UTR. PMA treatment of THP-1 cells resulted in the reduction of the RNA binding activity in a time-dependent manner. Deletion analysis and RNase T1 mapping revealed a pyrimidine-rich sequence within the 3'-UTR which interacts with the protein factor. Competition experiments with homoribopolymers further demonstrated the importance of uridines for the binding activity. Point mutations in uridines of the pyrimidine-rich sequence reduced the protein binding to 3'-UTR, while increasing the stability of the chimeric luciferase transcript. Together, these results demonstrate that the pyrimidine-rich sequence in the 3'-UTR is involved in post-transcriptional regulation of H-ferritin gene expression in myeloid cells.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan.		Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328				AMARA FM, 1994, J BIOL CHEM, V269, P6709; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COLUCCIDAMATO LG, 1989, BIOCHEM BIOPH RES CO, V165, P506, DOI 10.1016/0006-291X(89)91098-X; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P6910; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Haynes SR, 1997, MOL CELL BIOL, V17, P2708, DOI 10.1128/MCB.17.5.2708; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIAU G, 1991, J BIOL CHEM, V266, P18819; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCARY GA, 1990, J BIOL CHEM, V265, P7539; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; Pang JHS, 1996, BIOCHEM J, V319, P185, DOI 10.1042/bj3190185; Pang JHS, 1996, J CLIN INVEST, V97, P2204, DOI 10.1172/JCI118661; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; Tsai KC, 1997, J NEUROSCI, V17, P1950; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30209	30214		10.1074/jbc.274.42.30209	http://dx.doi.org/10.1074/jbc.274.42.30209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514512	hybrid			2022-12-25	WOS:000083176400091
J	Janssen, GMC; Maassen, JA; van den Ouweland, JMW				Janssen, GMC; Maassen, JA; van den Ouweland, JMW			The diabetes-associated 3243 mutation in the mitochondrial tRNA(Leu(UUR)) gene causes severe mitochondrial dysfunction without a strong decrease in protein synthesis rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; DNA; AMINOACYLATION; DEFECTS; DISEASE; MTDNA; CELLS; TRANSCRIPTION; TERMINATION; RESPIRATION	Cells harboring patient-derived mitochondria with an A-to-G; transition at nucleotide position 3243 of their mitochondrial DNA display severe loss of respiration when compared with cells containing the wild-type adenine but otherwise identical mitochondrial DNA sequence. The amount and degree of leucylation of tRNA(Leu(UUR)) were both found to be highly reduced in mutant cells. Despite the low level of leucyl-tRNA(Leu(UUR)), the rate of mitochondrial translation was not seriously affected by this mutation. Therefore, decrease of mitochondrial protein synthesis as such does not appear to be a necessary prerequisite for loss of respiration Rather, the mitochondrially encoded proteins seem subject to elevated degradation, leading to a severe reduction in their steady state levels. Our results favor a scheme in which the 3243 mutation causes loss of respiration through accelerated protein degradation, leading to a disequilibrium between the levels of mitochondrial and nuclear encoded respiratory chain subunits and thereby a reduction of functional respiratory chain complexes. The possible mechanisms underlying the pathogenesis of mitochondrial diabetes is discussed.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Janssen, GMC (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.							CHAMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; El Meziane A, 1998, NAT GENET, V18, P350; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Grossman LI, 1996, BIOESSAYS, V18, P983, DOI 10.1002/bies.950181208; Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118; JANSSEN GMC, 1990, RIBOSOMES PROTEIN SY, P51; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; Kessler S W, 1981, Methods Enzymol, V73, P442; KING MP, 1993, J BIOL CHEM, V268, P10228; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Maassen JA, 1996, DIABETOLOGIA, V39, P375; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; OGILVIE A, 1979, BIOCHIM BIOPHYS ACTA, V565, P293, DOI 10.1016/0005-2787(79)90206-5; Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1994, THESIS LEIDEN U; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523	32	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29744	29748		10.1074/jbc.274.42.29744	http://dx.doi.org/10.1074/jbc.274.42.29744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514449	hybrid			2022-12-25	WOS:000083176400028
J	Chew, LJ; Huang, F; Boutin, JM; Gallo, V				Chew, LJ; Huang, F; Boutin, JM; Gallo, V			Identification of nuclear orphan receptors as regulators of expression of a neurotransmitter receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR COUP; RETINOIC ACID RECEPTORS; CENTRAL-NERVOUS-SYSTEM; COREPRESSOR N-COR; THYROID-HORMONE; RESPONSE ELEMENTS; FACTOR-I; NGFI-B; AMPA/KAINATE RECEPTORS; MULTIPLE MECHANISMS	Nuclear orphan receptors are known to be important mediators of neurogenesis, but the target genes of these transcription factors in the vertebrate nervous system remain largely undefined, We have previously shown that a 500-base pair fragment in the first intron of the GRIK5 gene, which encodes the kainate-preferring glutamate receptor subunit KA2, down-regulates gene expression. In our present studies, mutation of an Ii-base pair element within this fragment resulted in a loss of nuclear protein binding and reverses negative regulation by the intron. Using yeast one-hybrid screening, we have identified intron-binding proteins from rat brain as COUP-TFI, EAR2, and NURR1. Gel shift studies with postnatal day 2 rat brain extract indicate the presence of COUP-TFs, EAR2, and NURR1 in the DNA-protein complex. Competition assays with GRIK5-binding site mutations show that the recombinant clones exhibit differential binding characteristics and suggest that the DNA-protein complex from postnatal day 2 rat brain may consist primarily of EAR2. The DNA binding activity was also observed to be enriched in rat neural tissue and developmentally regulated. Co-transfection assays showed that recombinant nuclear orphan receptors function as transcriptional repressors in both CV1 cells and rat CG4 oligodendrocyte cells. Direct interaction of the orphan receptors with and relief of repression by TFIIB indicate likely role(s) in active and/or transrepression. Our findings are thus consistent with the notion that multiple nuclear orphan receptors can regulate the transcription of a widely expressed neurotransmitter receptor gene by binding a common element in an intron and directly modulating the activity of the transcription machinery.	NICHHD, Lab Cellular & Mol Neurophysiol, NIH, Bethesda, MD 20892 USA; Univ Montreal, Ctr Hosp, Dept Med, Montreal, PQ H2W 1T8, Canada; Univ Montreal, Ctr Hosp, Div Endocrinol, Montreal, PQ H2W 1T8, Canada	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universite de Montreal; Universite de Montreal	Gallo, V (corresponding author), NICHHD, Lab Cellular & Mol Neurophysiol, NIH, 49 Convent Dr,Bldg 49,Rm 5A78, Bethesda, MD 20892 USA.							Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Anderson GW, 1998, J BIOL CHEM, V273, P16391, DOI 10.1074/jbc.273.26.16391; BAHN S, 1994, J NEUROSCI, V14, P5525; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; Bandoh S, 1997, J NEUROENDOCRINOL, V9, P3, DOI 10.1046/j.1365-2826.1997.00571.x; Bardoul M, 1997, INT J DEV NEUROSCI, V15, P695, DOI 10.1016/S0736-5748(97)00033-6; Bardoul M, 1998, J CHEM NEUROANAT, V14, P79, DOI 10.1016/S0891-0618(97)10016-3; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Castillo SO, 1998, GENE EXPRESSION, V7, P1; Cauley K, 1997, J NEUROSCI RES, V47, P311, DOI 10.1002/(SICI)1097-4547(19970201)47:3<311::AID-JNR9>3.0.CO;2-L; Chan RM, 1997, MOL BRAIN RES, V45, P50, DOI 10.1016/S0169-328X(96)00236-7; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; Chu K, 1997, J MOL ENDOCRINOL, V19, P163, DOI 10.1677/jme.0.0190163; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; CONNOR H, 1995, J BIOL CHEM, V270, P15066, DOI 10.1074/jbc.270.25.15066; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DASILVA SL, 1995, TRENDS NEUROSCI, V18, P542, DOI 10.1016/0166-2236(95)98376-A; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dingledine R, 1999, PHARMACOL REV, V51, P7; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Goodman RH, 1998, CURR OPIN NEUROBIOL, V8, P413, DOI 10.1016/S0959-4388(98)80069-X; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HEUTTNER JE, 1990, NEURON, V5, P255; Huang F, 1997, J BIOL CHEM, V272, P8618, DOI 10.1074/jbc.272.13.8618; ING NH, 1992, J BIOL CHEM, V267, P17617; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Leichter M, 1999, EUR J NEUROSCI, V11, P1937, DOI 10.1046/j.1460-9568.1999.00617.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leng X, 1996, MOL CELL BIOL, V16, P2332; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Myers SJ, 1998, J NEUROSCI, V18, P6723; NEUMAN K, 1995, J NEUROSCI RES, V41, P39, DOI 10.1002/jnr.490410106; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Paulsen RE, 1995, J MOL NEUROSCI, V6, P249, DOI 10.1007/BF02736784; PEREIRA FA, 1995, J STEROID BIOCHEM, V53, P503, DOI 10.1016/0960-0760(95)00097-J; PIZZI M, 1994, NEUROSCI LETT, V166, P77, DOI 10.1016/0304-3940(94)90844-3; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; Sahara Y, 1997, J NEUROSCI, V17, P6611; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; Scherer SE, 1998, J NEUROSCI RES, V52, P356, DOI 10.1002/(SICI)1097-4547(19980501)52:3<356::AID-JNR12>3.0.CO;2-4; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; SUN ZM, 1995, J BIOL CHEM, V270, P20962, DOI 10.1074/jbc.270.36.20962; Thiel G, 1999, NATURWISSENSCHAFTEN, V86, P1, DOI 10.1007/s001140050561; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Xing GQ, 1997, MOL BRAIN RES, V47, P251, DOI 10.1016/S0169-328X(97)00056-9; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	74	15	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29366	29375		10.1074/jbc.274.41.29366	http://dx.doi.org/10.1074/jbc.274.41.29366			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506197	hybrid			2022-12-25	WOS:000083017800076
J	Giusti, AF; Carroll, DJ; Abassi, YA; Terasaki, M; Foltz, KR; Jaffe, LA				Giusti, AF; Carroll, DJ; Abassi, YA; Terasaki, M; Foltz, KR; Jaffe, LA			Requirement of a Src family kinase for initiating calcium release at fertilization in starfish eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA; MEDIATED ACTIVATION; SH2 DOMAIN; SPERM; CA2+; PHOSPHORYLATION; PLC-GAMMA-1; MECHANISM	Signal transduction leading to calcium release in echinoderm eggs at fertilization requires phospholipase C gamma-mediated production of inositol trisphosphate (IP3), indicating that a tyrosine kinase is a likely upstream regulator. Because previous work has shown a fertilization-dependent association between the Src homology 2 (SH2) domains of phospholipase C gamma and a Src family kinase, we examined whether a Src family kinase was required for Ca2+ release at fertilization. To inhibit the function of kinases in this family. we injected starfish eggs with the SH2 domains of Src and Fyn kinases. This inhibited Ca2+ release in response to fertilization but not in response to injection of IP3. We further established the specificity of the inhibition by showing that the SH2 domains of several other tyrosine kinases (Abl, Syk, and ZAP-70), and the SH3 domain of Src, were not inhibitory. Also, a point-mutated Src SH2 domain, which has reduced affinity for phosphotyrosine, was a correspondingly less effective inhibitor of fertilization-induced Ca2+ release. These results indicate that a Src family kinase, by way of its SH2 domain, links sperm-egg interaction to IP3-mediated Ca2+ release at fertilization in starfish eggs.	Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06032 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Calif Santa Barbara, Dept Mol & Cellular Biol, Santa Barbara, CA 93106 USA	University of Connecticut; Marine Biological Laboratory - Woods Hole; University of California System; University of California Santa Barbara	Jaffe, LA (corresponding author), Univ Connecticut, Sch Med, Dept Physiol, MC3505, Farmington, CT 06032 USA.			Carroll, David/0000-0002-1334-3518				Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CIAPA B, 1991, FEBS LETT, V295, P167, DOI 10.1016/0014-5793(91)81410-A; DALE B, 1985, EXPERIENTIA, V41, P1068, DOI 10.1007/BF01952148; DHAR A, 1994, J BIOL CHEM, V269, P9123; Dupont G, 1996, BIOCHEM J, V316, P583, DOI 10.1042/bj3160583; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Giusti AF, 1999, DEV BIOL, V208, P189, DOI 10.1006/dbio.1998.9187; Glahn D, 1999, DEV BIOL, V205, P171, DOI 10.1006/dbio.1998.9042; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KIEHART DP, 1982, METHOD CELL BIOL, V25, P13, DOI 10.1016/S0091-679X(08)61418-1; Kinsey WH, 1996, DEV BIOL, V174, P281, DOI 10.1006/dbio.1996.0073; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Kyozuka K, 1998, DEVELOPMENT, V125, P4099; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MCCULLOH DH, 1992, J GEN PHYSIOL, V99, P137, DOI 10.1085/jgp.99.2.137; Mehlmann LM, 1998, DEV BIOL, V203, P221, DOI 10.1006/dbio.1998.9051; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; Onodera H, 1999, DEV GROWTH DIFFER, V41, P19; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Shearer J, 1999, DEVELOPMENT, V126, P2273; Shen SS, 1999, DEV GROWTH DIFFER, V41, P345; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STEINHAR.RA, 1974, P NATL ACAD SCI USA, V71, P1915, DOI 10.1073/pnas.71.5.1915; Tian MX, 1996, ONCOGENE, V12, P727; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0	38	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29318	29322		10.1074/jbc.274.41.29318	http://dx.doi.org/10.1074/jbc.274.41.29318			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506191	hybrid			2022-12-25	WOS:000083017800070
J	Lee, BS; Gluck, SL; Holliday, LS				Lee, BS; Gluck, SL; Holliday, LS			Interaction between vacuolar H+-ATPase and microfilaments during osteoclast activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; SURFACE-RECEPTORS; RESORPTION CYCLE; BOVINE KIDNEY; CATHEPSIN-K; PROTON PUMP; MYOSIN-II; F-ACTIN; PROTEIN; PURIFICATION	Vacuolar H+-ATPases (V-ATPases) are multisubunit enzymes that acidify compartments of the vacuolar system of all eukaryotic cells. In osteoclasts, the cells that degrade bone, V-ATPases, are recruited from intracellular membrane compartments to the ruffled membrane, a specialized domain of the plasma membrane, where they are maintained at high densities, serving to acidify the resorption bay at the osteoclast attachment site on bone (Blair, H. C,, Teitelbaum, S. L,, Ghiselli, R., and Gluck, S. L. (1989) Science 249, 855-857). Here, we describe a new mechanism involved in controlling the activity of the bone-resorptive cell. V-ATPase in osteoclasts cultured in vitro was found to form a detergent-insoluble complex with actin and myosin II through direct binding of V-ATPase to actin filaments. Plating bone marrow cells onto dentine slices, a physiologic stimulus that activates osteoclast resorption, produced a profound change in the association of the V-ATPase with actin, assayed by coimmunoprecipitation and immunocytochemical colocalization of actin filaments and V-ATPase in osteoclasts. Mouse marrow and bovine kidney V-ATPase bound rabbit muscle F-actin directly with a maximum stoichiometry of 1 mol of V-ATPase per 8 mol of F-actin and an apparent affinity of 0.05 mu M. Electron microscopy of negatively stained samples confirmed the binding interaction. These findings link transport of V-ATPase to reorganization of the actin cytoskeleton during osteoclast activation.	Univ Florida, Coll Med, Dept Med, Div Nephrol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Washington University (WUSTL)	Holliday, LS (corresponding author), Univ Florida, Coll Med, Dept Med, Div Nephrol, Campus Box 100224,1500 SW Archer Rd,Room CG-98, Gainesville, FL 32610 USA.		Holliday, Lexie/GYQ-4972-2022; Lee, Beth S/E-9578-2010	Lee, Beth S/0000-0002-1468-6387; Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [P01 AR32087] Funding Source: Medline; NIDDK NIH HHS [R01 DK38848, R01 DK52131] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, R01DK052131] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BROWN D, 1987, J CELL BIOL, V105, P1636; BROWN D, 1991, KIDNEY INT S, V33, P79; DANCKER P, 1975, BIOCHIM BIOPHYS ACTA, V400, P407, DOI 10.1016/0005-2795(75)90196-8; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GLUCK S, 1984, J CLIN INVEST, V73, P1704, DOI 10.1172/JCI111378; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HEATH JP, 1983, NATURE, V302, P532, DOI 10.1038/302532a0; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; HOLLIDAY LS, 1995, BIOCHEM BIOPH RES CO, V208, P1073, DOI 10.1006/bbrc.1995.1444; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lee BS, 1996, AM J PHYSIOL-CELL PH, V270, pC382, DOI 10.1152/ajpcell.1996.270.1.C382; Lehenkari PP, 1997, BIOCHEM BIOPH RES CO, V235, P838, DOI 10.1006/bbrc.1997.6894; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MANNHERZ HG, 1975, FEBS LETT, V60, P34, DOI 10.1016/0014-5793(75)80412-1; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Sambrook J., 2002, MOL CLONING LAB MANU; SATO M, 1990, CELL MOTIL CYTOSKEL, V17, P250, DOI 10.1002/cm.970170311; SCHWARTZ MA, 1986, J CELL BIOL, V102, P2067, DOI 10.1083/jcb.102.6.2067; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470; ZIMOLO Z, 1995, J CLIN INVEST, V96, P2277, DOI 10.1172/JCI118283	37	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29164	29171		10.1074/jbc.274.41.29164	http://dx.doi.org/10.1074/jbc.274.41.29164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506172	hybrid			2022-12-25	WOS:000083017800051
J	Maier, U; Babich, A; Nurnberg, B				Maier, U; Babich, A; Nurnberg, B			Roles of non-catalytic subunits in G beta gamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; LIPID KINASE; PI 3-KINASE; PATHWAY; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; IDENTIFICATION; NEUTROPHILS	By using purified preparations we show that nanomolar concentrations of G beta gamma significantly stimulated lipid kinase activity of phosphatidylinositol 3-kinase (PI3K) beta and PI3K gamma in the presence as well as in the absence of non-catalytic subunits such as p85 alpha or p101. Concomitantly, G beta gamma stimulated autophosphorylation of the catalytic subunit of PI3K gamma (EC50, 30 nm; stoichiometry greater than or equal to 0.6 mol of P-i/mol of p110 gamma), which also occurred in the absence of p101. Surprisingly, we found that p101 affected the lipid substrate preference of PI3R gamma in its G beta gamma-stimulated state. With phosphatidylinositol as substrate, p110 gamma but not p101/p110 gamma was significantly stimulated by G beta gamma to form PI-3-phosphate (EC50, 20 nM). The opposite situation was found when PI-4,5-bisphosphate served as substrate. G beta gamma efficiently and potently (EC50, 5 nM) activated the p101/p110 gamma heterodimer but negligibly stimulated the p110 gamma monomer to form PI-3,4,5-trisphosphate. However, this weak stimulatory effect on p110 gamma was overcome by excess concentrations of G beta gamma (EC50, 100 nM). This finding is in accordance with the in vivo situation, where activated PI3K catalyzes the formation of PI-3,4,5-trisphosphate but not PI-3-phosphate. We conclude that p101 is responsible for PI-4,5-bisphosphate substrate selectivity of PI3K gamma by sensitizing p110 gamma toward G beta gamma in the presence of PI-4,5 P-2.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Nurnberg, B (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.			Nurnberg, Bernd/0000-0002-5995-6555				Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Downes CP, 1998, CURR BIOL, V8, pR865, DOI 10.1016/S0960-9822(07)00546-5; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Hu ZW, 1999, MOL ENDOCRINOL, V13, P3, DOI 10.1210/me.13.1.3; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kodama T, 1999, BIOCHEM J, V337, P201, DOI 10.1042/0264-6021:3370201; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	56	183	192	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29311	29317		10.1074/jbc.274.41.29311	http://dx.doi.org/10.1074/jbc.274.41.29311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506190	hybrid			2022-12-25	WOS:000083017800069
J	Premont, RT; Macrae, AD; Aparicio, SAJR; Kendall, HE; Welch, JE; Lefkowitz, RJ				Premont, RT; Macrae, AD; Aparicio, SAJR; Kendall, HE; Welch, JE; Lefkowitz, RJ			The GRK4 subfamily of G protein-coupled receptor kinases - Alternative splicing, gene organization, and sequence conservation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; CHROMOSOMAL LOCALIZATION; IDENTIFICATION; PALMITOYLATION; EXPRESSION; FAMILY; MOUSE; AUTOPHOSPHORYLATION; PURIFICATION; SUBUNITS	G protein-coupled receptor kinases (GRKs) desensitize G protein-coupled receptors by phosphorylating activated receptors. The six known GRKs have been classified into three subfamilies based on sequence and functional similarities. Examination of the mouse GRK4 subfamily (GRKs 4, 5, and 6) suggests that mouse GRK4 is not alternatively spliced in a manner analogous to human or rat GRK4, whereas GRK6 undergoes extensive alternative splicing to generate three variants with distinct carboxyl termini. Characterization of the mouse GRK 5 and 6 genes reveals that all members of the GRK4 subfamily share an identical gene structure, in which 15 introns interrupt the coding sequence at equivalent positions in all three genes. Surprisingly, none of the three GRK subgroups (GRK1, GRK2/3, and GRK4/5/6) shares even a single intron in common, indicating that these three subfamilies are distinct gene lineages that have been maintained since their divergence over 1 billion years ago. Comparison of the amino acid sequences of GRKs from various mammalian species indicates that GRK2, GRK5, and GRK6 exhibit a remarkably high degree of sequence conservation, whereas GRK1 and particularly GRK4 have accumulated amino acid changes at extremely rapid rates over the past 100 million years. The divergence of individual GRKs at vastly different rates reveals that strikingly different evolutionary pressures apply to the function of the individual GRKs.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Wellcome CRC Inst, Cambridge CB2 1QR, England; US EPA, Reprod Toxicol Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; United States Environmental Protection Agency	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Aparicio, Samuel/0000-0002-0487-9599; Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; BULLRICH F, 1995, CYTOGENET CELL GENET, V70, P250, DOI 10.1159/000134045; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Firsov D, 1997, AM J PHYSIOL-CELL PH, V273, pC953, DOI 10.1152/ajpcell.1997.273.3.C953; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gagnon AW, 1997, GENE, V184, P13, DOI 10.1016/S0378-1119(96)00567-7; GROSSON CLS, 1994, MAMM GENOME, V5, P424, DOI 10.1007/BF00357002; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Khani SC, 1996, GENOMICS, V35, P571, DOI 10.1006/geno.1996.0399; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PENN RB, 1994, J BIOL CHEM, V269, P14924; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sallese M, 1997, J BIOL CHEM, V272, P10188; Sambrook J., 2002, MOL CLONING LAB MANU; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; Stoffel RH, 1998, BIOCHEMISTRY-US, V37, P16053, DOI 10.1021/bi981432d; Virlon B, 1998, ENDOCRINOLOGY, V139, P2784, DOI 10.1210/en.139.6.2784; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568	40	66	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29381	29389		10.1074/jbc.274.41.29381	http://dx.doi.org/10.1074/jbc.274.41.29381			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506199	hybrid			2022-12-25	WOS:000083017800078
J	Teubl, M; Groschner, K; Kohlwein, SD; Mayer, B; Schmidt, K				Teubl, M; Groschner, K; Kohlwein, SD; Mayer, B; Schmidt, K			Na+/Ca2+ exchange facilitates Ca2+-dependent activation of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; NA-CA EXCHANGE; CARDIAC MYOCYTES; CELLS; CAVEOLAE; INHIBITION; CURRENTS; PROTEIN; RELEASE; STORE	Recent evidence suggests the expression of a Na+/ Ca2+ exchanger (NCX) in vascular endothelial cells, To elucidate the functional role of endothelial NCX, we studied Ca2+ signaling and Ca2+-dependent activation of endothelial nitric-oxide synthase (eNOS) at normal, physiological Na+ gradients and after loading of endothelial cells with Na+ ions using the ionophore monensin. Monensin-induced Na+ loading markedly reduced Ca2+ entry and, thus, steady-state levels of intracellular free Ca2+ ([Ca2+](i)) in thapsigargin-stimulated endothelial cells due to membrane depolarization. Despite this reduction of overall [Ca2+](i), Ca2+-dependent activation of eNOS was facilitated as indicated by a pronounced leftward shift of the Ca2+ concentration response curve in monensin-treated cells. This facilitation of Ca2+-dependent activation of eNOS was strictly dependent on the presence of Na+ ions during treatment of the cells with monensin, Na+-induced facilitation of eNOS activation was not due to a direct effect of Na+ ions on the Ca2+ sensitivity of the enzyme. Moreover, the effect of Na+ was not related to Na+ entry-induced membrane depolarization or suppression of Ca2+ entry, since neither elevation of extracellular K+ nor the Ca2+ entry blocker 1-(beta-[3-(4-methoxyphenyl)-propoxy]-4-methoxyphenethyl)-1H-imidazole hydrochloride (SK&F 96365) mimicked the effects of Na+ loading. The effects of monensin were completely blocked by 3',4'-dichlorobenzamil, a potent and selective inhibitor of NCX, whereas the structural analog amiloride, which barely affects Na+/Ca2+ exchange, was ineffective. Consistent with a pivotal role of Na+/Ca2+ exchange in Ca2+-dependent activation of eNOS, an NCX protein was detected in caveolin-rich membrane fractions containing both eNOS and caveolin-1. These results demonstrate for the first time a crucial role of cellular Na+ gradients in regulation of eNOS activity and suggest that a tight functional interaction between endothelial NCX and eNOS may take place in caveolae.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Graz Univ Technol, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria	University of Graz; Graz University of Technology	Schmidt, K (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	kurt.schmidt@kfunigraz.ac.at	Groschner, Klaus/A-2550-2010; Mayer, Bernd/B-9391-2008	Groschner, Klaus/0000-0002-8659-377X; Mayer, Bernd/0000-0002-2921-3494; Kohlwein, Sepp Dieter/0000-0002-1030-0598				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CANNELL MB, 1991, ANN NY ACAD SCI, V639, P428, DOI 10.1111/j.1749-6632.1991.tb17330.x; CANNELL MB, 1989, J PHYSIOL-LONDON, V419, P555, DOI 10.1113/jphysiol.1989.sp017886; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; ELLIOTT SJ, 1995, FREE RADICAL BIO MED, V19, P649, DOI 10.1016/0891-5849(95)00080-H; Encabo A, 1996, BRIT J PHARMACOL, V119, P702, DOI 10.1111/j.1476-5381.1996.tb15729.x; Fujimoto T, 1998, J ELECTRON MICROSC, V47, P451, DOI 10.1093/oxfordjournals.jmicro.a023616; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GROSCHNER K, 1992, BIOCHIM BIOPHYS ACTA, V1137, P162, DOI 10.1016/0167-4889(92)90198-K; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; GROSCHNER K, 1994, CIRC RES, V75, P304, DOI 10.1161/01.RES.75.2.304; HARLOW E, 1988, ANTIBODIES LAB MANUA, P386; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; JUHASZOVA M, 1994, AM J PHYSIOL, V266, pC234, DOI 10.1152/ajpcell.1994.266.1.C234; KLATT P, 1992, J BIOL CHEM, V267, P11374; LASKEY RE, 1990, J BIOL CHEM, V265, P2613; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEVI AJ, 1993, CARDIOVASC RES, V27, P1677, DOI 10.1093/cvr/27.9.1677; LI L, 1995, CIRC RES, V76, P396, DOI 10.1161/01.RES.76.3.396; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Paltauf-Doburzynska J, 1998, J PHYSIOL-LONDON, V513, P369, DOI 10.1111/j.1469-7793.1998.369bb.x; Pfeiffer S, 1998, MOL PHARMACOL, V53, P795, DOI 10.1124/mol.53.4.795; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REUTER H, 1968, J PHYSIOL-LONDON, V195, P451, DOI 10.1113/jphysiol.1968.sp008467; SAGE SO, 1991, J PHYSIOL-LONDON, V440, P569, DOI 10.1113/jphysiol.1991.sp018725; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; Schmidt K, 1999, EUR J BIOCHEM, V259, P25, DOI 10.1046/j.1432-1327.1999.00003.x; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; SCHOEFFTER P, 1986, MOL PHARMACOL, V30, P53; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIEGL PKS, 1984, P NATL ACAD SCI-BIOL, V81, P3238, DOI 10.1073/pnas.81.10.3238; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Venema VJ, 1997, BIOCHEM BIOPH RES CO, V236, P155, DOI 10.1006/bbrc.1997.6921; WINQUIST RJ, 1985, J PHARMACOL EXP THER, V235, P644	48	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29529	29535		10.1074/jbc.274.41.29529	http://dx.doi.org/10.1074/jbc.274.41.29529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506218	hybrid			2022-12-25	WOS:000083017800097
J	Miosge, N; Sasaki, T; Timpl, R				Miosge, N; Sasaki, T; Timpl, R			Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls	FASEB JOURNAL			English	Article						binding assays; extracellular matrix; immunogold staining	HEPARAN-SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE ZONES; GLOBULAR DOMAIN; COLLAGEN-XVIII; MOUSE KIDNEY; FIBULIN-2; PROTEIN; GROWTH; TROPOELASTIN; EXPRESSION	The endothelial cell inhibitor endostatin (22 kDa) is part of the carboxyl-terminal globular domain of collagen XVIII and shows a widespread tissue distribution. Immunohistology of adult mouse tissues demonstrated a preferred localization in many vessel walls and some other basement membrane zones. A strong immunogold staining was observed across elastic fibers in the multiple elastic membranes of aorta and other large arteries. Staining was less strong along sparse elastic fibers of veins and almost none was observed in the walls of arterioles and capillaries. Strong evidence was also obtained for some intracellular and basement membrane associations. Immunogold double staining of elastic fibers showed a close colocalization of endostatin with fibulin-2, fibulin-1, and nidogen-2, but not with perlecan. Reasonable amounts of endostatin could be extracted from aorta and skin by EDTA, followed by detergents, with aorta being the richest source of the inhibitor identified so far. Solubilizations with collagenase and elastase were similar to fivefold less efficient. Immunoblots of aortic extracts detected major endostatin components of 22-25 kDa whereas skin extracts also contained some larger components. Solid-phase assays demonstrated distinct binding of recombinant mouse endostatin to the fibulins and nidogen-2, consistent with their tissue colocalization. Together, the data indicate several different ways for endostatin to be associated with the extracellular matrix, and its release may determine biological activation. This also defines a novel function for some elastic tissues. -Miosge, N., Sasaki, T., Timpl, R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Gottingen, Abt Histol, Zentrum Anat, D-37075 Gottingen, Germany	Max Planck Society; University of Gottingen	Timpl, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	TIMPL@biochem.mpg.de	Miosge, Nicolai/E-3244-2010					Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HERKEN R, 1987, HISTOCHEMISTRY, V87, P59, DOI 10.1007/BF00518725; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MIOSGE N, 1995, J HISTOCHEM CYTOCHEM, V43, P675, DOI 10.1177/43.7.7608521; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Musso O, 1998, HEPATOLOGY, V28, P98, DOI 10.1002/hep.510280115; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PasqualiRonchetti I, 1995, CIBA F SYMP, V192, P31; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RAGHUNATH M, 1999, IN PRESS J INVEST DE, V112; REHN M, 1994, J BIOL CHEM, V269, P13929; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; SLOT JW, 1981, J CELL BIOL, V90, P533, DOI 10.1083/jcb.90.2.533; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x	44	112	119	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1743	1750		10.1096/fasebj.13.13.1743	http://dx.doi.org/10.1096/fasebj.13.13.1743			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506577				2022-12-25	WOS:000083063400009
J	Thevenod, F; Friedmann, JM				Thevenod, F; Friedmann, JM			Cadmium-mediated oxidative stress in kidney proximal tubule cells induces degradation of Na+/K+-ATPase through proteasomal and endo-/lysosomal proteolytic pathways	FASEB JOURNAL			English	Article						nephrotoxicity; heavy metals; oxygen radicals; Fanconi syndrome; ubiquitin	DIFFERENT SENSITIVITIES; HYDROGEN-PEROXIDE; PROTEIN OXIDATION; MAMMALIAN-CELLS; AMINO-ACID; MECHANISMS; SUBUNIT; RATS; UBIQUITINATION; COTRANSPORT	The mechanisms of cadmium (Cd) -dependent nephrotoxicity were studied in a rat proximal tubule (PT) cell line. CdCl2 (5 mu M) increased the production of reactive oxygen species (ROS), as determined by oxidation of dihydrorhodamine 123 to fluorescent rhodamine 123. The levels of ubiquitin-conjugated cellular proteins were increased by Cd in a time-dependent fashion (maximum at 24-48 h). This was prevented by coincubation with the thiol antioxidant N-acetylcysteine (NAC, 15 mM). Cd also increased apoptosis (controls: 2.4+/-1.6%; Cd: 8.1+/-1.9%), but not necrosis (controls: 0.5 +/- 0.3%; Cd: 1.4+/- 2,5%). Exposure of PT cells with Cd decreased protein levels of the catalytic subunit (alpha 1) of Na+/ K+-ATPase, a long-lived membrane protein (t(1/2) >48 h) that drives reabsorption of ions and nutrients through Na+-dependent transporters in PT, Incubation of PT cells for 48 h with Cd decreased Na+/ K+-ATPase alpha 1-subunit, as determined by immunoblotting, by approximate to 50%, and NAC largely prevented this effect, Inhibitors of the proteasome such as MG-132 (20 mu M) or lactacystin (10 mu M), as well as lysosomotropic weak bases such as chloroquine (0.2 mM) or NH4Cl (30 mM), significantly reduced the decrease of Na+/K+-ATPase alpha 1-subunit induced by Cd, and in combination abolished the effect of Cd on Na+/ K+-ATPase. Immunofluorescence labeling of Na+/ K+-ATPase showed a reduced expression of the protein in the plasma membrane of Cd-exposed cells. After addition of lactacystin and chloroquine to Cd-exposed PT cells, immunoreactive material accumulated into intracellular vesicles. The data indicate that micromolar concentrations of Cd can increase ROS production and exert a toxic effect on PT cells. Oxidative damage increases the degradation of Na+/K+-ATPase through both the proteasomal and endo-/lysosomal proteolytic pathways. Degradation of oxidatively damaged Na+/K+-ATPase may contribute to the 'Fanconi syndrome'-like Nat-dependent transport defects associated with Cd-nephrotoxicity. -Thevenod, F., Friedmann, J. M. Cadmium-mediated oxidative stress in kidney proximal tubule cells induces degradation of Na+/K+-ATPase through proteasomal and endo-/lysosomal proteolytic pathways.	Univ Saarlandes, Inst Physiol 2, Fak Med, Dept Physiol 2, D-66421 Homburg, Germany	Saarland University	Thevenod, F (corresponding author), Univ Saarlandes, Inst Physiol 2, Fak Med, Dept Physiol 2, D-66421 Homburg, Germany.							ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CHAMBERS SK, 1992, BLOOD, V80, P1559; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coppi MV, 1997, FEBS LETT, V405, P281, DOI 10.1016/S0014-5793(97)00182-8; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GonzalezFlecha B, 1996, BBA-GEN SUBJECTS, V1290, P46, DOI 10.1016/0304-4165(95)00186-7; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HAMADA T, 1994, NEPHRON, V68, P104, DOI 10.1159/000188227; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; Hauser IA, 1998, KIDNEY INT, V54, P1139, DOI 10.1046/j.1523-1755.1998.00095.x; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KIM YK, 1988, PHARMACOL TOXICOL, V63, P342, DOI 10.1111/j.1600-0773.1988.tb00966.x; Kinne RKH, 1995, TOXICOL APPL PHARM, V135, P216, DOI 10.1006/taap.1995.1226; Klaassen CD, 1997, DRUG METAB REV, V29, P79, DOI 10.3109/03602539709037574; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Liu J, 1998, TOXICOL APPL PHARM, V153, P48, DOI 10.1006/taap.1998.8506; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Messler P, 1996, J NEUROSCI METH, V69, P137, DOI 10.1016/S0165-0270(96)00032-5; O'Brien P, 1998, ARCH TOXICOL, V72, P690, DOI 10.1007/s002040050562; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PISCATOR M, 1986, CADMIUM HDB EXPT PHA, V80, P194; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIMADA H, 1991, J PHARMACOBIO-DYNAM, V14, P555, DOI 10.1248/bpb1978.14.555; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SUN XM, 1992, ANAL BIOCHEM, V204, P351, DOI 10.1016/0003-2697(92)90251-2; TANAKA M, 1995, VET HUM TOXICOL, V37, P203; Thevenod F, 1996, J BIOL CHEM, V271, P3300, DOI 10.1074/jbc.271.6.3300; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; Wagner CA, 1996, AM J PHYSIOL-RENAL, V271, pF926, DOI 10.1152/ajprenal.1996.271.4.F926; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; ZOLOTARJOVA N, 1994, BBA-BIOMEMBRANES, V1192, P125, DOI 10.1016/0005-2736(94)90152-X	52	182	187	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1751	1761		10.1096/fasebj.13.13.1751	http://dx.doi.org/10.1096/fasebj.13.13.1751			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506578				2022-12-25	WOS:000083063400010
J	Howard, L; Nelson, KK; Maciewicz, RA; Blobel, CP				Howard, L; Nelson, KK; Maciewicz, RA; Blobel, CP			Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; BINDING PARTNERS; MEMBRANE-FUSION; CELL-ADHESION; SORTING NEXIN; GENE FAMILY; IDENTIFICATION; RECEPTORS; SYNAPTOJANIN	Metalloprotease disintegrins (a disintegrin and metalloprotease (ADAM) and metalloprotease, disintegrin, cysteine-rich proteins (MDC)) are a family of membrane-anchored glycoproteins that function in diverse biological processes, including fertilization, neurogenesis, myogenesis, and ectodomain processing of cytokines and other proteins. The cytoplasmic domains of ADAMs often include putative signaling motifs, such as proline-rich SH3 ligand domains, suggesting that interactions with cytoplasmic proteins may affect metalloprotease disintegrin function. Here we report that two SH3 domain-containing proteins, endophilin I (SH3GL2, SH3p4) and a novel SH3 domain- and phox homology (PX) domain-containing protein, termed SH3PX1, can interact with the cytoplasmic domains of the metalloprotease disintegrins MDC9 and MDC15. These interactions were initially identified in a yeast two-hybrid screen and then confirmed using bacterial fusion proteins and co-immunoprecipitations from eukaryotic cells expressing both binding partners. SHSPX1 and endophilin I both preferentially bind the precursor but not the processed form of MDC9 and MDC15 in COS-7 cells. Since rat endophilin I is thought to play a role in synaptic vesicle endocytosis and SH3PX1 has sequence similarity to sorting nexins in yeast, we propose that endophilin I and SH3PX1 may have a role in regulating the function of MDC9 and MDC15 by influencing their intracellular processing, transport, or final subcellular localization.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; AstraZeueca Pharmaceut, Resp & Inflammat Res, Macclesfield SK10 4TG, Cheshire, England	Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Howard, Linda/B-2463-2009	HOWARD, LINDA/0000-0003-4760-7996	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018585, R55GM051988] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [F32GM18585-02, R55GM51988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; EVANS JP, 1995, J CELL SCI, V108, P3267; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUANG TF, 1987, J BIOL CHEM, V262, P16157; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nath D, 1999, J CELL SCI, V112, P579; NELSON KK, 1999, IN PRESS BIOCH J; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sotillos S, 1997, DEVELOPMENT, V124, P4769; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhu GZ, 1999, GENE, V234, P227, DOI 10.1016/S0378-1119(99)00208-5	63	147	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31693	31699		10.1074/jbc.274.44.31693	http://dx.doi.org/10.1074/jbc.274.44.31693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531379	hybrid			2022-12-25	WOS:000083379400083
J	Morris, DP; Phatnani, HP; Greenleaf, AL				Morris, DP; Phatnani, HP; Greenleaf, AL			Phospho-carboxyl-terminal domain binding and the role of a prolyl isomerase in pre-mRNA 3 '-end formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; REPEAT DOMAIN; WW DOMAINS; IN-VIVO; PHOSPHORYLATION; TRANSCRIPTION; GENE; CTD	A phospho-carboxyl-terminal domain (CTD) affinity column created with yeast CTD kinase I and the CTD of RNA polymerase II was used to identify Ess1/Pin1 as a phospho-CTD-binding protein. Ess1/Pin1 is a peptidyl prolyl isomerase involved in both mitotic regulation and pre-mRNA 3'-end formation. Like native Ess1, a GST-Ess1 fusion protein associates specifically with the phosphorylated but not with the unphosphorylated CTD. Further, hyperphosphorylated RNA polymerase II appears to be the dominant Ess1 binding protein in total yeast extracts. We demonstrate that phospho-CTD binding is mediated by the small WW domain of Ess1 rather than the isomerase domain. These findings suggest a mechanism in which the WW domain binds the phosphorylated CTD of elongating RNA polymerase II and the isomerase domain reconfigures the CTD though isomerization of proline residues perhaps by a processive mechanism. This process may be linked to a variety of pre-mRNA maturation events that use the phosphorylated CTD, including the coupled processes of pre-mRNA S'-end formation and transcription termination.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Greenleaf, AL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							Albert A, 1999, J CELL SCI, V112, P2493; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P388; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wang GL, 1999, MOL CELL BIOL, V19, P342; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329	36	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31583	31587		10.1074/jbc.274.44.31583	http://dx.doi.org/10.1074/jbc.274.44.31583			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531363	hybrid			2022-12-25	WOS:000083379400067
J	Tamarit, J; Mulliez, E; Meier, C; Trautwein, A; Fontecave, M				Tamarit, J; Mulliez, E; Meier, C; Trautwein, A; Fontecave, M			The anaerobic ribonucleotide reductase from Escherichia coli - The small protein is an activating enzyme containing a [4Fe-4S](2+) center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; MOLECULAR-PROPERTIES; CLUSTER; QUANTITATION; CONVERSION; 2FE-2S; 4FE-4S; SITE; DNA	For deoxyribonucleotide synthesis during anaerobic growth, Escherichia coli cells depend on an oxygen-sensitive class III ribonucleotide reductase, The enzyme system consists of two proteins: protein alpha, on which ribonucleotides bind and are reduced, and protein beta, of which the function is to introduce a catalytically essential glycyl radical on protein alpha, Protein beta can assemble one [4Fe-4S] center per polypeptide enjoying both the [4Fe-4S](2+) and [4Fe-4S](1+) redox state, as shown by iron and sulfide analysis, Mossbauer spectroscopy (delta = 0.43 mm.s(-1), Delta E-Q = 1.0 mm.s(-1), [4Fe-4S](2+)), and EPR spectroscopy (g = 2.03 and 1.93, [4Fe-4S](1+)). This iron center is sensitive to oxygen and can decompose into stable [2Fe-2S](2+) centers during exposure to air. This degraded form is nevertheless active, albeit to a lesser extent because of the conversion of the cluster into [4Fe-4S] forms during the strongly reductive conditions of the assay. Furthermore, protein beta has the potential to activate several molecules of protein alpha, suggesting that protein beta is an activating enzyme rather than a component of an alpha(2)beta(2) complex as previously claimed.	Univ Grenoble 1, Lab Chim & Biochim, Dept Biol Mol & Struct Chim & Biochim, CEA,1087 CNRS,Ctr Redox Biol, F-38054 Grenoble 9, France; Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Lubeck	Fontecave, M (corresponding author), Univ Grenoble 1, Lab Chim & Biochim, Dept Biol Mol & Struct Chim & Biochim, CEA,1087 CNRS,Ctr Redox Biol, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Tamarit, Jordi/C-6316-2008	Tamarit, Jordi/0000-0003-3227-6928				BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FREY M, 1994, J BIOL CHEM, V269, P12432; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; MULLIEZ E, 1999, IN PRESS J BIOL INOR; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCHULZ C, 1976, J PHYS-PARIS, V37, pC6153; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005	29	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31291	31296		10.1074/jbc.274.44.31291	http://dx.doi.org/10.1074/jbc.274.44.31291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531327	Green Published, hybrid			2022-12-25	WOS:000083379400031
J	Tominaga, K; Morisaki, H; Kaneko, Y; Fujimoto, A; Tanaka, T; Ohtsubo, M; Hirai, M; Okayama, H; Ikeda, K; Nakanishi, M				Tominaga, K; Morisaki, H; Kaneko, Y; Fujimoto, A; Tanaka, T; Ohtsubo, M; Hirai, M; Okayama, H; Ikeda, K; Nakanishi, M			Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; LARGE-T-ANTIGEN; ATAXIA-TELANGIECTASIA CELLS; FISSION YEAST; PROTEIN-KINASE; S-PHASE; GENE; ATM; PATHWAY; MUTATIONS	In response to DNA damage, mammalian cells adopt checkpoint regulation, by phosphorylation and stabilization of p53, to delay cell cycle progression. However, most cancer cells that lack functional p53 retain an unknown checkpoint mechanism(s) by which cells are arrested at the G(2)/M phase. Here we demonstrate that a human homolog of Cds1/Rad53 kinase (hCds1) is rapidly phosphorylated and activated in response to DNA damage not only in normal cells but in cancer cells lacking functional p53. A survey of various cancer cell lines revealed that the expression level of hCds1 mRNA is inversely related to the presence of functional p53. In addition, transfection of normal human fibroblasts with SV40 T antigen or human papilloma viruses E6 or E7 causes a marked induction of hCds1 mRNA, and the introduction of functional p53 into SV40 T antigen- and E6-, but not E7-, transfected cells decreases the hCds1 level, suggesting that p53 negatively regulates the expression of hCds1. In cells without functional ataxia telangiectasia mutated (ATM) protein, phosphorylation and activation of hCds1 were observed in response to DNA damage induced by UV but not by ionizing irradiation. These results suggest that hCds1 is activated through an ATM-dependent as well as -independent pathway and that it may complement the function of p53 in DNA damage checkpoints in mammalian cells.	Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Kurume Univ, Inst Life Sci, Div Mol Genet, Kurume, Fukuoka 8390861, Japan; Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 113, Japan	Nagoya City University; Kurume University; University of Tokyo	Nakanishi, M (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, 1 Kawasumi,Mizuhocho, Nagoya, Aichi 4678601, Japan.		Tominaga, Kaoru/AAL-4250-2020	Tominaga, Kaoru/0000-0001-8799-528X; ohtsubo, motoaki/0000-0002-2479-3178				Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; DUTHU A, 1992, ONCOGENE, V7, P2161; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Fuse T, 1996, BIOCHEM BIOPH RES CO, V225, P759, DOI 10.1006/bbrc.1996.1247; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KANEKO Y, 1999, IN PRESS ONCOGENE; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4532; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SASAKI MS, 1994, MUTAT RES, V307, P107, DOI 10.1016/0027-5107(94)90282-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEGAWA K, 1993, ONCOGENE, V8, P543; Tanikawa M, 1998, J BIOL CHEM, V273, P18522, DOI 10.1074/jbc.273.29.18522; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	47	77	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31463	31467		10.1074/jbc.274.44.31463	http://dx.doi.org/10.1074/jbc.274.44.31463			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531348	hybrid			2022-12-25	WOS:000083379400052
J	Mao, ZX; Wiedmann, M				Mao, ZX; Wiedmann, M			Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2C; GROWTH-FACTOR-I; CYCLOSPORINE-A; MUSCLE DIFFERENTIATION; INDUCED APOPTOSIS; NERVOUS-SYSTEM; FAMILY MEMBER; T-CELL; ACTIVATION; EXPRESSION	Myocyte enhancer factor 2 (MEF2) has been shown recently to be necessary for mediating activity-dependent neuronal survival. In this study, we show that calcium signals regulate MEF2 activity through a serine/threonine phosphatase calcineurin. In cultured primary cerebellar granule neurons, the electrophoretic mobility of MEF2A protein was sensitive to the level of extracellular potassium chloride (KCI) and depolarizing concentrations of KCl led to hypophosphorylation of the protein. The specific inhibitors of calcineurin cyclosporin A (CsA) and FK506 could overcome KCl-dependent MEF2A hypophosphorylation, The effects of CsA and FK506 were KCl specific as they had little effect on MEF2A phosphorylation when granule neurons were cultured in the presence of full media. Hyperphosphorylation of MEF2A led to the loss of its DNA binding activity as determined by DNA mobility shift assay. Consistent with this, CsA/FK506 also inhibited MEF2-dependent reporter gene expression. These findings demonstrate that regulation of MEF2A by calcium signals requires the action of protein phosphatase calcineurin. By maintaining MEF2A in a hypophosphorylated state, calcineurin enhances the DNA binding activity of MEF2A and therefore maximizes its transactivation capability. The identification of MEF2 as a novel target of calcineurin may provide in part a biochemical explanation for the therapeutic and toxic effects of immunosuppressants CsA and FK506.	Rhode Isl Hosp, Dept Med, Liver Res Ctr, Providence, RI 02903 USA; Brown Univ, Sch Med, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Mao, ZX (corresponding author), Rhode Isl Hosp, Dept Med, Liver Res Ctr, Providence, RI 02903 USA.							Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Rao S, 1998, J BIOL CHEM, V273, P26123, DOI 10.1074/jbc.273.40.26123; Satyaraj E, 1998, J IMMUNOL, V161, P4795; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schulz JB, 1996, J NEUROSCI, V16, P4696; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	35	125	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31102	31107		10.1074/jbc.274.43.31102	http://dx.doi.org/10.1074/jbc.274.43.31102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521511	hybrid			2022-12-25	WOS:000083276700107
J	Beier, F; Taylor, AC; LuValle, P				Beier, F; Taylor, AC; LuValle, P			The Raf-1/MEK/ERK pathway regulates the expression of the p21(Cip1/Waf1) gene in chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; MAP KINASE CASCADES; VITAMIN-D-RECEPTOR; CELL-CYCLE ARREST; MICE LACKING; SKELETAL DEVELOPMENT; HERITABLE DISEASES; MOLECULAR INSIGHTS; TRANSGENIC MICE; BONE-FORMATION	The gene encoding the cyclin-dependent kinase inhibitor p21(Cip2/Waf1) is up-regulated in many differentiating cells, including maturing chondrocytes. Since strict control of chondrocyte proliferation is essential for proper bone formation and since p21 is likely involved in this control, we initiated analyses of the mechanisms regulating expression of p21 in chondrocytes. p21 expression and promoter activity was strongly increased during the differentiation of chondrogenic MCT cells. We have identified a 68-base pair fragment conferring transcriptional up-regulation of the p21 gene in chondrocytes. The activity of this fragment required active Raf-1 in MCT cells as well as in primary mouse chondrocytes. Inhibition of downstream factors of Raf-1 (MEK1/2, ERK1/2, and Ets2) also repressed the activity off the 68-base pair fragment in MCT cells. The chemical MEK1/2 inhibitor PD98059 reduced protein levels of p21 in MCTs and primary mouse chondrocytes. These data suggest that signaling through the Raf-1 pathway is necessary for the optimal expression of p21 in chondrocytes and may play an important role in the control of bone formation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	LuValle, P (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	vpalu@acs.ucalgary.ca	Beier, Frank/G-4595-2013; Beier, Frank/T-4734-2019	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Aigner T, 1997, HISTOCHEM CELL BIOL, V107, P435, DOI 10.1007/s004180050130; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Beier F, 1999, J CELL BIOCHEM, V72, P549, DOI 10.1002/(SICI)1097-4644(19990315)72:4<549::AID-JCB10>3.0.CO;2-1; Beier F, 1999, MATRIX BIOL, V18, P109, DOI 10.1016/S0945-053X(99)00009-8; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097-0177(199711)210:3<249::AID-AJA6>3.0.CO;2-G; HUPPI K, 1994, ONCOGENE, V9, P3017; KANEKO Y, 1994, CALCIFIED TISSUE INT, V54, P426, DOI 10.1007/BF00305531; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; LEFEBVRE V, 1995, J CELL BIOL, V128, P239, DOI 10.1083/jcb.128.1.239; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stewart MC, 1997, CALCIFIED TISSUE INT, V61, P199, DOI 10.1007/s002239900323; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	55	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30273	30279		10.1074/jbc.274.42.30273	http://dx.doi.org/10.1074/jbc.274.42.30273			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514521	hybrid			2022-12-25	WOS:000083176400100
J	Kuhn, DM; Geddes, TJ				Kuhn, DM; Geddes, TJ			Peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation - Coincident nitration of enzyme tyrosyl residues has minimal impact on catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; CARBON-DIOXIDE; DOPAMINERGIC NEUROTOXICITY; SEROTONIN NEURONS; MDMA ECSTASY; BRAIN; METHAMPHETAMINE; ACID; PROTEINS	Tryptophan hydroxylase, the initial and rate-limiting enzyme in serotonin biosynthesis, is inactivated by peroxynitrite in a concentration-dependent manner. This effect is prevented by molecules that react directly with peroxynitrite such as dithiothreitol, cysteine, glutathione, methionine tryptophan, and uric acid but not by scavengers of superoxide (superoxide dismutase), hydroxyl radical (Me2SO, mannitol), and hydrogen peroxide (catalase), Assuming simple competition kinetics between peroxynitrite scavengers and the enzyme, a second-order rate constant of 3.4 x 10(4) M-1 s(-1) at 25 degrees C and pH 7.4 was estimated. The peroxynitrite-induced loss of enzyme activity was accompanied by a concentration-dependent oxidation of protein sulfhydryl groups, Peroxynitrite-modified tryptophan hydroxylase was resistant to reduction by arsenite, borohydride, and dithiothreitol, suggesting that sulfhydryls were oxidized beyond sulfenic acid. Peroxynitrite also caused the nitration of tyrosyl residues in tryptophan hydroxylase, with a maximal modification of 3.8 tyrosines/monomer, Sodium bicarbonate protected tryptophan hydroxylase from peroxynitrite-induced inactivation and lessened the extent of sulfhydryl oxidation while causing a 2-fold increase in tyrosine nitration, Tetranitromethane, which oxidizes sulfhydryls at pH 6 or 8, but which nitrates tyrosyl residues at pH 8 only, inhibited tryptophan hydroxylase equally at either pH, Acetylation of tyrosyl residues with N-acetylimidazole did not alter tryptophan hydroxylase activity, These data suggest that peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation, Modification of tyrosyl residues by peroxynitrite plays a relatively minor role in the inhibition of tryptophan hydroxylase catalytic activity.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Kuhn, DM (corresponding author), 2125 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.				NIDA NIH HHS [DA10756] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010756] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Acikgoz O, 1998, BRAIN RES, V813, P200, DOI 10.1016/S0006-8993(98)01020-8; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRO L, 1994, J BIOL CHEM, V269, P29409; COHEN LA, 1968, ANNU REV BIOCHEM, V37, P695, DOI 10.1146/annurev.bi.37.070168.003403; Crow JP, 1996, METHOD ENZYMOL, V269, P185; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; DSa CM, 1996, J NEUROCHEM, V67, P917; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GARTSIDE SE, 1992, PSYCHOPHARMACOLOGY, V109, P251, DOI 10.1007/BF02245511; Gibb J W, 1997, NIDA Res Monogr, V173, P128; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Itzhak Y, 1998, J PHARMACOL EXP THER, V284, P1040; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kuhn DM, 1997, J NEUROCHEM, V68, P1495; Kuhn DM, 1997, J NEUROCHEM, V68, P2220; Kuhn DM, 1998, J NEUROSCI, V18, P7111; KUHN DM, 1980, J BIOL CHEM, V255, P4137; Kuhn DM, 1997, J NEUROSCI, V17, P7245; KUHN DM, 1996, J NEUROCHEM, V67, P1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MATSUBARA C, 1983, ANAL BIOCHEM, V130, P128, DOI 10.1016/0003-2697(83)90659-0; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCCANN UD, 1994, NEUROPSYCHOPHARMACOL, V10, P129, DOI 10.1038/npp.1994.15; McCann UD, 1998, J NEUROSCI, V18, P8417; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; PAUL SM, 1990, J CLIN PSYCHIAT S, V51, P1; Persichini T, 1998, BIOCHEM BIOPH RES CO, V250, P575, DOI 10.1006/bbrc.1998.9350; Pryor WA, 1997, FREE RADICAL BIO MED, V23, P331, DOI 10.1016/S0891-5849(97)00121-4; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, METHOD ENZYMOL, V269, P354; Radi R, 1999, METHOD ENZYMOL, V301, P353; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Reist M, 1998, J NEUROCHEM, V71, P2431; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Riordan J F, 1972, Methods Enzymol, V25, P500, DOI 10.1016/S0076-6879(72)25046-7; Smith MA, 1997, J NEUROSCI, V17, P2653; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; STEELE TD, 1994, ADDICTION, V89, P539, DOI 10.1111/j.1360-0443.1994.tb03330.x; Whitaker-Azmitia PM, 1990, ANN NY ACAD SCI, V600, P1; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863; Zheng YW, 1998, BRAIN RES, V795, P257, DOI 10.1016/S0006-8993(98)00313-8	60	60	61	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29726	29732		10.1074/jbc.274.42.29726	http://dx.doi.org/10.1074/jbc.274.42.29726			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514446	hybrid			2022-12-25	WOS:000083176400025
J	Wang, XT; Gorospe, M; Holbrook, NJ				Wang, XT; Gorospe, M; Holbrook, NJ			gadd45 is not required for activation of c-Jun N-terminal kinase or p38 during acute stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; RESPONSES; PATHWAYS; CASCADES	Cells respond to environmental stress with activation of c-Jun N-terminal kinase (JNK) and p38. Recent studies have implicated Gadd45 and two related proteins, MyD118/Gadd45 beta and CR6/Gadd45 gamma, as initiators of JNK/p38 signaling via their interaction with an upstream kinase MTK1. It was proposed that stress-induced expression of the Gadd45-related proteins leads to MTK1 activation and subsequent JNK/p38 activation. Using embryo fibroblasts from gadd45-null mice, we have addressed the requirement for Gadd45 in mediating JNK/p38 activation during acute stress. Comparison of JNH/p38 activities in response to methyl methanesulfonate, hydrogen peroxide, WC irradiation, sorbitol, and anisomycin treatment of gadd45(+/+) and gadd45(-/-) fibroblasts revealed no deficiency in JNK/p38 activation in gadd45(-/-) fibroblasts. In addition, in wild type cells, JNK and p38 activation significantly preceded gadd45 induction with all stresses. Examination of myd118/ gadd45 beta and cr6/gadd45 gamma expression in gadd45(+/+) and gadd45(-/-) fibroblasts revealed similar induction patterns in the two cell types, which, like gadd45 expression, was delayed relative to JNK/p38 activation. We conclude that gadd45 expression is not required for activation of JNK/p38 by environmental stresses, nor are stress-induced increases in myd118/gadd45 beta and cr6/ gadd45 gamma expression necessary for kinase activation in response to such insults.	NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Biol Chem Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	nikki-holbrook@nih.gov						ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; YAN MH, 1994, NATURE, V372, P798; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	22	47	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29599	29602		10.1074/jbc.274.42.29599	http://dx.doi.org/10.1074/jbc.274.42.29599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514426	hybrid			2022-12-25	WOS:000083176400005
J	Willars, GB; Heding, A; Vrecl, M; Sellar, R; Blomenrohr, M; Nahorski, SR; Eidne, KA				Willars, GB; Heding, A; Vrecl, M; Sellar, R; Blomenrohr, M; Nahorski, SR; Eidne, KA			Lack of a C-terminal tail in the mammalian gonadotropin-releasing hormone receptor confers resistance to agonist-dependent phosphorylation and rapid desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; INTERNALIZATION KINETICS; SIGNAL-TRANSDUCTION; NEUROBLASTOMA-CELLS; ALPHA-T3-1 CELLS; BETA-ARRESTIN; KINASE-C; SITES	The mammalian gonadotropin-releasing hormone receptor (GnRH-R) is, at present, the only G-protein-coupled receptor that activates phospholipase C and lacks a C-terminal tail, We have previously demonstrated that this unique structural feature is associated with resistance to rapid desensitization of phosphoinositide signaling in COS-7 and HEK-293 cells (Heding, A., Vrecl, M., Bogerd, J., McGregor, A., Sellar, R., Taylor, P. L., and Eidne, K. A. (1998) J. Biol Chem. 273, 11472-11477). Using receptors tagged with a nonapeptide of the influenza hemagglutinin protein to enable immunoprecipitation, we now demonstrate that the mammalian GnRH-R is not phosphorylated in an agonist-dependent manner. In contrast, the mammalian thyrotropin-releasing hormone receptor and the African catfish GnRH-R, both of which have a C-terminal tail, are phosphorylated in response to agonist challenge. Furthermore, chimeras of the mammalian GnRH-R with the C-terminal tail of either the mammalian thyrotropin-releasing hormone receptor or the catfish GnRH-R are also phosphorylated in an agonist-dependent manner. Only those receptors having C-terminal tails showed desensitization of phosphoinositide responses within 5-10 min of agonist challenge, We also show that the internalization of all these receptors when expressed transiently in COS-7 cells is similar. This dissociates receptor internalization from rapid desensitization and demonstrates that the lack of a C-terminal tail in the mammalian GnRH-R results in an inability of the receptor to undergo agonist-dependent phosphorylation and that this results directly in a resistance to rapid desensitization.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; MRC, Ctr Reprod Biol, Reprod Biol Unit, Edinburgh EH3 9EW, Midlothian, Scotland; Univ Utrecht, Dept Expt Zool, NL-3584 CH Utrecht, Netherlands	University of Leicester; Utrecht University	Willars, GB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Maurice Shock Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Vrecl, Milka/A-6127-2008					ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ANDERSON L, 1995, ENDOCRINOLOGY, V136, P5228, DOI 10.1210/en.136.11.5228; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Balmforth AJ, 1997, BRIT J PHARMACOL, V122, P1469, DOI 10.1038/sj.bjp.0701522; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Garland AM, 1996, MOL PHARMACOL, V49, P438; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; ISHII K, 1994, J BIOL CHEM, V269, P1125; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; McArdle CA, 1996, J BIOL CHEM, V271, P23711, DOI 10.1074/jbc.271.39.23711; MCARDLE CA, 1995, ENDOCRINOLOGY, V136, P4864, DOI 10.1210/en.136.11.4864; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MOENTER SM, 1992, ENDOCRINOLOGY, V130, P503, DOI 10.1210/en.130.1.503; MOENTER SM, 1991, ENDOCRINOLOGY, V129, P1175, DOI 10.1210/endo-129-3-1175; Neill JD, 1997, MOL CELL ENDOCRINOL, V127, P143, DOI 10.1016/S0303-7207(96)04003-8; NEMETH K, 1995, J BIOL CHEM, V270, P27601, DOI 10.1074/jbc.270.46.27601; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; TAKANO T, 1994, J BIOL CHEM, V269, P22453; Tensen C, 1997, EUR J BIOCHEM, V243, P134, DOI 10.1111/j.1432-1033.1997.0134a.x; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Willars GB, 1996, BIOCHEM J, V316, P905, DOI 10.1042/bj3160905; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737	42	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30146	30153		10.1074/jbc.274.42.30146	http://dx.doi.org/10.1074/jbc.274.42.30146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514504	hybrid			2022-12-25	WOS:000083176400083
J	Raab-Graham, KF; Cirilo, LJ; Boettcher, AA; Radeke, CM; Vandenberg, CA				Raab-Graham, KF; Cirilo, LJ; Boettcher, AA; Radeke, CM; Vandenberg, CA			Membrane topology of the amino-terminal region of the sulfonylurea receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; MULTIDRUG-RESISTANCE PROTEIN; TRANSMEMBRANE PROTEINS; STRUCTURE PREDICTION; INSULIN-SECRETION; EPITOPE INSERTION; P-GLYCOPROTEIN; GLYCOSYLATION; SUBUNIT; REGULATOR	The sulfonylurea receptor (SUR) is a member of the ATP-binding cassette family that is associated with Kir 6.x to form ATP-sensitive potassium channels. SUR is involved in nucleotide regulation of the channel and is the site of pharmacological interaction with sulfonylurea drugs and potassium channel openers. SUR contains three hydrophobic domains, TM0, TM1, and TM2, with nucleotide binding folds following TM1, and TM2,. Two topological models of SUR have been proposed containing either 13 transmembrane segments (in a 4+5+4 arrangement) or 17 transmembrane segments (in a 5+6+6 arrangement) (Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W, Clement, J. P. t., Boyd, A E., III, Gonzalez, G., Herrera-Sosa, H., Nguy, K., Bryan, J., and Nelson, D. A (1995) Science 268, 423-426; Tusnady, G. E., Bakes, E., Varadi, A, and Sarkadi, B. (1997) FEES Left. 402, 1-3; Aguilar-Bryan, L., Clement, J. P., IV, Gonzalez, G., Kunjilwar, K, Babenko, A, and Bryan, J. (1998) Physiol. Rev. 78, 227-245). We analyzed the topology of the aminoterminal TM0 region of SUR1 using glycosylation and protease protection studies. Deglycosylation using peptide-N-glycosidase F and site-directed mutagenesis established that Asn(10), near the amino terminus, and Asn(1050) are the only sites of N-linked glycosylation, thus placing these sites on the extracellular side of the membrane. To study in detail the topology of SUR1, we constructed and expressed in vitro fusion proteins containing 1-5 hydrophobic segments of the TM0 region fused to the reporter prolactin. The fusion proteins were subjected to a protease protection assay that reported the accessibility of the prolactin epitope. Our results indicate that the TM0 region is comprised of 5 transmembrane segments. These data support the 5+6+6 model of SUR1 topology.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	vandenbe@lifesci.ucsb.edu		Raab-Graham, Kimberly/0000-0001-6502-057X	NHLBI NIH HHS [HL41656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041656, R01HL041656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levy D, 1996, Essays Biochem, V31, P49; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; PARKS GD, 1993, J BIOL CHEM, V268, P19101; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SKACH WR, 1993, MECH INTRACELLULAR T, P19; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stride BD, 1996, MOL PHARMACOL, V49, P962; STRUHL K, 1991, CURRENT PROTOCOLS MO; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709	46	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29122	29129		10.1074/jbc.274.41.29122	http://dx.doi.org/10.1074/jbc.274.41.29122			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506167	hybrid			2022-12-25	WOS:000083017800046
J	Wu, J; Zhou, L; Tonissen, K; Tee, R; Artzt, K				Wu, J; Zhou, L; Tonissen, K; Tee, R; Artzt, K			The quaking I-5 protein (QKI-5) has a novel nuclear localization signal and shuttles between the nucleus and the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; KH DOMAIN; GENE; EXPRESSION; SAM68; TRANSCRIPTION; SEQUENCE; SRC; IDENTIFICATION; TRANSDUCTION	The mouse quaking (qk) gene is essential in both myelination and early embryogenesis. Its product, QKI is an RNA-binding protein belonging to a growing protein family called STAR (signal transduction and activator of RNA). All members have an similar to 200-amino acid STAR domain, which contains a single extended heteronuclear ribonucleoprotein K homologue domain flanked by two domains called QUA1 and QUA2. We found that QKI isoforms could associate with each other, while one of the lethal mutations qkI(kt4) with a single amino acid change in QUA1 domain, leads to a loss of QKI self-interaction. This suggests that the QUA1 domain is responsible for QKI dimerization. Three QKI isoforms have different carboxyl termini and different subcellular localization. Here, using GFP fusion protein, we identified a 7-amino acid novel nuclear localization sequence in the carboxyl terminus of QKI-5, which is conserved in a subclass of STAR proteins containing SAM68 and ETLE/T-STAR. Thus, we name this motif STAR-NLS. In addition, the effects of active transcription, RNA-binding and self-interaction on QKI-5 localization were analyzed. Furthermore, using an interspecies heterokaryon assay, we found that QKI-5, but not another STAR protein ETLE, shuttles between the nucleus and the cytoplasm, which suggests that QKI-5 functions in both cell compartments.	Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Artzt, K (corresponding author), Univ Texas, Inst Cellular & Mol Biol, 2500 Speedway, Austin, TX 78712 USA.		Tonissen, Kathryn F/E-9424-2010	Tonissen, Kathryn F/0000-0002-1018-2798	NICHD NIH HHS [HD10668, HD30658] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010668, R01HD030658] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arning S, 1996, RNA, V2, P794; Baehrecke EH, 1997, DEVELOPMENT, V124, P1323; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; CAMPAGNONI AT, 1991, ANN NY ACAD SCI, V633, P178; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; FRYBERG C, 1997, GENE, V197, P315; FUJITA N, 1990, J NEUROCHEM, V55, P1056, DOI 10.1111/j.1471-4159.1990.tb04596.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fung ET, 1998, FEBS LETT, V437, P29, DOI 10.1016/S0014-5793(98)01151-X; Fyrberg C, 1998, BIOCHEM GENET, V36, P51, DOI 10.1023/A:1018700202971; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hardy RJ, 1998, J NEUROSCI RES, V51, P417, DOI 10.1002/(SICI)1097-4547(19980215)51:4<417::AID-JNR1>3.0.CO;2-F; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Hardy RJ, 1998, J NEUROSCI RES, V54, P46, DOI 10.1002/(SICI)1097-4547(19981001)54:1<46::AID-JNR6>3.0.CO;2-H; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; JUSTICE MJ, 1988, GENET RES, V51, P95, DOI 10.1017/S0016672300024101; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kondo T, 1999, MAMM GENOME, V10, P662; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Magoulas C, 1996, DNA CELL BIOL, V15, P305, DOI 10.1089/dna.1996.15.305; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Mezquita J, 1998, MOL REPROD DEV, V50, P70, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;70::AID-MRD9&gt;3.0.CO;2-U; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SACCOMANNO L, 1999, IN PRESS P NATL ACAD; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; Tanaka H, 1997, MECH DEVELOP, V69, P209, DOI 10.1016/S0925-4773(97)00164-0; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zaffran S, 1997, DEVELOPMENT, V124, P2087; Zhang D, 1998, J BIOL CHEM, V273, P6868, DOI 10.1074/jbc.273.12.6868; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176; Zorn AM, 1997, GENE, V188, P199, DOI 10.1016/S0378-1119(96)00795-0	52	112	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29202	29210		10.1074/jbc.274.41.29202	http://dx.doi.org/10.1074/jbc.274.41.29202			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506177	hybrid			2022-12-25	WOS:000083017800056
J	DiScipio, RG; Linton, SM; Rushmere, NK				DiScipio, RG; Linton, SM; Rushmere, NK			Function of the factor I modules (FIMS) of human complement component C6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; HUMAN PLASMA-PROTEINS; AFFINITY-CHROMATOGRAPHY; COVALENT-BINDING; C5B-7 COMPLEX; HUMAN C5; C7; DEFICIENCY; FRACTIONATION; PURIFICATION	In order to elucidate the function of complement component C6, truncated C6 molecules were expressed recombinantly, These were either deleted of the factor I modules (FIMs) (C6des-748-913) or both complement control protein (CCP) modules and FIMs (C6des-611-913), C6des-748-913 exhibited approximately 60-70% of the hemolytic activity of full-length C6 when assayed for Alternative Pathway activity, but when measured for the Classical Pathway, C6des-748-914 was only 4-6% as effective as C6, The activity difference between C6 and C6des-748-913 for the two complement pathways can be explained by a greater stability of newly formed metastable C5b* when produced by the Alternative Pathway compared with that made by the Classical Pathway. The half-lives of metastable C5b* and the decay of I-125-C5b measured from cells used to activate the Alternative Pathway were found to be about 5-12-fold longer than those same parameters derived from cells that had activated the Classical Pathway. I-125-C5 binds reversibly to C6 in an ionic strength-dependent fashion, but I-125-C5 binds only weakly to C6des-FIMs and not at all to C6des-CCP/FIMs, Therefore, although the FIMs are not required absolutely for C6 activity, these modules promote interaction of C6 with C5 enabling a more efficient bimolecular coupling ultimately leading to the formation of the C5b-6 complex.	La Jolla Inst Expt Med, La Jolla, CA 92037 USA; Univ Wales Coll Cardiff, Coll Med, Dept Biochem Med, Cardiff CF4 4XX, S Glam, Wales	Cardiff University	DiScipio, RG (corresponding author), La Jolla Inst Expt Med, 505 Coast Blvd S, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022415] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 22415] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARROYAVE CM, 1973, J IMMUNOL, V111, P536; CAMPBELL ID, 1991, PHILOS T R SOC B, V332, P165, DOI 10.1098/rstb.1991.0045; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DiScipio R. G, 1998, COMPLEMENT SYSTEM, P50; DISCIPIO RG, 1994, PROTEIN EXPRES PURIF, V5, P178, DOI 10.1006/prep.1994.1028; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1982, MOL IMMUNOL, V19, P1425, DOI 10.1016/0161-5890(82)90189-4; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1992, J BIOL CHEM, V267, P17087; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DISCIPIO RG, 1989, J BIOL CHEM, V264, P16197; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; DISCIPIO RG, 1994, PROTEIN EXPRES PURIF, V5, P170, DOI 10.1006/prep.1994.1027; EGGERTSEN G, 1981, MOL IMMUNOL, V18, P125, DOI 10.1016/0161-5890(81)90078-X; FARRIES TC, 1988, BIOCHEM J, V252, P47, DOI 10.1042/bj2520047; FEARON DT, 1977, J EXP MED, V146, P22, DOI 10.1084/jem.146.1.22; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GOLDBERGER G, 1987, J BIOL CHEM, V262, P10065; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HOBART MJ, 1993, BIOCHEMISTRY-US, V32, P6198, DOI 10.1021/bi00075a012; HOFFMANN LG, 1977, METHODS IMMUNOLOGY I, V4, P137; Kemeny D. M., 1997, IMMUNOCHEMISTRY, V1, P147; KOLB WP, 1973, J EXP MED, V138, P428, DOI 10.1084/jem.138.2.428; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; Lengweiler S, 1997, BBA-PROTEIN STRUCT M, V1342, P13, DOI 10.1016/S0167-4838(97)00072-1; MARDINEY MR, 1968, AM J PATHOL, V53, P253; MORGAN BP, 1989, CLIN EXP IMMUNOL, V75, P396; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8; ORREN A, 1992, IMMUNOLOGY, V75, P10; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PODACK ER, 1980, J EXP MED, V151, P301, DOI 10.1084/jem.151.2.301; PODACK ER, 1984, J BIOL CHEM, V259, P8641; PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0; Rushmere NK, 1997, IMMUNOLOGY, V90, P640, DOI 10.1046/j.1365-2567.1997.00200.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIN ML, 1986, J IMMUNOL, V136, P1777; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; TRAUT TW, 1986, MOL CELL BIOCHEM, V70, P3; Ullman CG, 1997, BIOCHEM J, V326, P939, DOI 10.1042/bj3260929v; Whaley K., 1997, COMPLEMENT PRACTICAL, V1, P19; WURZNER R, 1995, J CLIN INVEST, V95, P1877, DOI 10.1172/JCI117868; WURZNER R, 1991, CLIN EXP IMMUNOL, V83, P430; WURZNER R, 1995, IMMUNOLOGY, V85, P214	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31811	31818		10.1074/jbc.274.45.31811	http://dx.doi.org/10.1074/jbc.274.45.31811			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542204	hybrid			2022-12-25	WOS:000083532100012
J	Levin, MK; Patel, SS				Levin, MK; Patel, SS			The helicase from hepatitis C virus is active as an oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA HELICASE; ESCHERICHIA-COLI; DNA HELICASE; NONSTRUCTURAL PROTEIN-3; CRYSTAL-STRUCTURE; NS3 PROTEIN; DUPLEX DNA; DOMAIN; MUTANT	The helicase from hepatitis C virus (HCV NS3h) residing on the C terminal domain of nonstructural protein 3 was considered to be monomeric by several researchers. Here we demonstrate, based on biochemical kinetic data, that the HCV helicase acts as an oligomer. The increase in the ATPase k(cat) of the NS3h protein with increasing protein concentration provided evidence for oligomerization. A sharp decrease in the unwinding rate was observed when the wild type NS3h was mixed with the ATPase deficient mutants of NS3h protein. This provided strong support for both mixed oligomer formation and subunit interactions for the HCV helicase, Chemical cross-linking of NS3h protein was an inefficient process, but yielded cross-linked protein oligomers of various sizes. The information currently available for HCV helicase is consistent with the hypothesis that oligomers of NS3h are not stable and the helicase subunits exchange during unwinding. Nevertheless, oligomerization of HCV helicase stimulates the ATPase activity, and it is required for the helicase activity.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Patel, SS (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1998, PROTEIN SCI, V7, P605, DOI 10.1002/pro.5560070309; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Moussalli J, 1998, J VIRAL HEPATITIS, V5, P73, DOI 10.1046/j.1365-2893.1998.00086.x; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Vishnuvardhan D, 1997, FEBS LETT, V402, P209, DOI 10.1016/S0014-5793(96)01532-3; WONG I, 1992, J BIOL CHEM, V267, P7596; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	31	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31839	31846		10.1074/jbc.274.45.31839	http://dx.doi.org/10.1074/jbc.274.45.31839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542208	hybrid			2022-12-25	WOS:000083532100016
J	Xia, ZC; Zhang, W; Nguyen, BD; La Mar, GN; Kloek, AP; Goldberg, DE				Xia, ZC; Zhang, W; Nguyen, BD; La Mar, GN; Kloek, AP; Goldberg, DE			H-1 NMR investigation of the distal hydrogen bonding network and ligand tilt in the cyanomet complex of oxygen-avid Ascaris suum hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPERM WHALE MYOGLOBIN; HEME ELECTRONIC-STRUCTURE; SPIN FERRIHEME SYSTEMS; RAY CRYSTAL-STRUCTURE; AXIAL LIGANDS; PARAMAGNETIC PROTEIN; 2-DIMENSIONAL NMR; CYANIDE COMPLEXES; H-1-NMR STRUCTURE	The O-2-avid hemoglobin from the parasitic nematode Ascaris suum exhibits one of the slowest known O-2 off rates. Solution H-1 NMR has been used to investigate the electronic and molecular structural properties of the active site for the cyano-met derivative of the recombinant first domain of this protein. Assignment of the heme, axial His, and majority of the residues in contact with the heme reveals a molecular structure that is the same as reported in the A. suum HbO(2) crystal structure (Yang, J., Kloek, A., Goldberg, D. E., and Mathews, F. S. (1995) Proc. Natl, Acad, Sci. U. S. A. 92, 4224-4228) with the exception that the heme in solution is rotated by 180 degrees about the alpha,gamma-meso axis relative to that in the crystal, The observed dipolar shifts, together with the crystal coordinates of HbO(2), provide the orientation of the magnetic axes in the molecular framework. The major magnetic axis, which correlates with the Fe CN vector, is found oriented similar to 30 degrees away from the heme normal and indicates significant steric tilt because of interaction with Tyr(30)(B10). Th, three side chain labile protons for the distal residues Tyr(30)(B10) and Gln(64)(E7) were identified, and their relaxation, dipolar shifts, and nuclear Overhauser effects to adjacent residues used to place them in the distal pocket. It is shown that these two distal residues exhibit the same orientations ideal for H bonding to the ligand and to each other, as found in the A. suum HbO(2) crystal. It is concluded that the ligated cyanide participates in the same distal H bonding network as ligated O-2. The combination of the strong steric tilt of the bound cyanide and slow ring reorientation of the Tyr(30)(B10) side chain supports a crowded and constrained distal pocket.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	University of California System; University of California Davis; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.	lamar@indigo.ucdavis.edu			NHLBI NIH HHS [HL16087] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; BISIG DA, 1995, J BIOL CHEM, V270, P20754, DOI 10.1074/jbc.270.35.20754; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BRANCACCIO A, 1994, J BIOL CHEM, V269, P13843; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brennan L, 1997, BBA-PROTEIN STRUCT M, V1342, P1, DOI 10.1016/S0167-4838(97)00071-X; BYRN MP, 1983, J AM CHEM SOC, V105, P4916, DOI 10.1021/ja00353a013; CONTI E, 1993, J MOL BIOL, V233, P498, DOI 10.1006/jmbi.1993.1527; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P3925, DOI 10.1021/bi952625t; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P65; Dou Y, 1996, BIOCHEMISTRY-US, V35, P7107, DOI 10.1021/bi9600299; EMERSON SD, 1988, J AM CHEM SOC, V110, P4176, DOI 10.1021/ja00221a013; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEWSBURY P, 1995, J PHYS CHEM-US, V99, P12677, DOI 10.1021/j100033a047; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Kolczak U, 1997, J AM CHEM SOC, V119, P12643, DOI 10.1021/ja9722133; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; MABBUTT BC, 1985, BIOCHIM BIOPHYS ACTA, V832, P175, DOI 10.1016/0167-4838(85)90329-2; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; Nguyen BD, 1999, J AM CHEM SOC, V121, P208, DOI 10.1021/ja982555o; Nguyen BD, 1998, J BIOL CHEM, V273, P9517, DOI 10.1074/jbc.273.16.9517; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; OOSTERHUIS WT, 1969, PHYS REV, V178, P439, DOI 10.1103/PhysRev.178.439; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; Press W., 1986, NUMERICAL RECIPES; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; QIN J, 1993, J MOL BIOL, V231, P1009, DOI 10.1006/jmbi.1993.1348; Raitsimring AM, 1998, J AM CHEM SOC, V120, P991, DOI 10.1021/ja9722640; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P5493, DOI 10.1021/bi00184a018; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; ROYER WE, 1995, J MOL BIOL, V253, P168, DOI 10.1006/jmbi.1995.0543; SANDSTROM J, 1982, DYNAMIC NMR SPECTROS, P12; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; Shokhirev NV, 1998, J AM CHEM SOC, V120, P981, DOI 10.1021/ja972265s; SHRAGER RL, 1970, J ACM, V17, P446, DOI 10.1145/321592.321597; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; Slebodnick C, 1997, J BIOL INORG CHEM, V2, P521, DOI 10.1007/s007750050165; Spiro TG, 1997, J BIOL INORG CHEM, V2, P516, DOI 10.1007/s007750050164; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TRAYLOR TG, 1980, J AM CHEM SOC, V102, P2844, DOI 10.1021/ja00528a058; TURNER DL, 1993, EUR J BIOCHEM, V211, P563, DOI 10.1111/j.1432-1033.1993.tb17583.x; TURNER DL, 1995, EUR J BIOCHEM, V227, P829, DOI 10.1111/j.1432-1033.1995.tb20208.x; Vangberg T, 1997, J BIOL INORG CHEM, V2, P526, DOI 10.1007/s007750050166; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wu YY, 1996, BBA-PROTEIN STRUCT M, V1298, P261, DOI 10.1016/S0167-4838(96)00137-9; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P131; Yamamoto Y, 1998, ANNU REP NMR SPECTRO, V36, P1, DOI 10.1016/S0066-4103(08)60005-8; YAMAMOTO Y, 1992, J MOL BIOL, V228, P343, DOI 10.1016/0022-2836(92)90823-3; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Zhang W, 1997, BIOPHYS J, V73, P1019, DOI 10.1016/S0006-3495(97)78135-9; Zhang W, 1996, EUR J BIOCHEM, V237, P841, DOI 10.1111/j.1432-1033.1996.0841p.x; Zhang W, 1997, J BIOL CHEM, V272, P3000, DOI 10.1074/jbc.272.5.3000; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	73	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31819	31826		10.1074/jbc.274.45.31819	http://dx.doi.org/10.1074/jbc.274.45.31819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542205	hybrid			2022-12-25	WOS:000083532100013
J	Maemura, K; Hsieh, CM; Jain, MK; Fukumoto, S; Layne, MD; Liu, YX; Kourembanas, S; Yet, SF; Perrella, MA; Lee, ME				Maemura, K; Hsieh, CM; Jain, MK; Fukumoto, S; Layne, MD; Liu, YX; Kourembanas, S; Yet, SF; Perrella, MA; Lee, ME			Generation of a dominant-negative mutant of endothelial PAS domain protein 1 by deletion of a potent C-terminal transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; GROWTH-FACTOR GENE; TRANSCRIPTION FACTOR; DIOXIN RECEPTOR; FACTOR 1-ALPHA; CLOCK GENE; CELLS; EXPRESSION; ACTIVATION; DROSOPHILA	Endothelial PAS domain protein 1 (EPAS1) is a basic helix-loop-helix/PAS domain transcription factor that is preferentially expressed in vascular endothelial cells, EPAS1 shares high homology with hypoxia-inducible factor-1 alpha (HIF-1 alpha) and, like HIF-1 alpha, has been shown to bind to the HIF-1-binding site and to activate its downstream genes such as vascular endothelial growth factor (VEGF) and erythropoietin. In this report, we show that EPAS1 increased VEGF gene expression through the DIP-I-binding site. This transactivation was enhanced further by cotransfection of an aryl hydrocarbon receptor nuclear translocator expression plasmid. Deletion analysis of EPAS1 revealed a potent activation domain (amino acids 486-639) essential for EPAS1 to transactivate the VEGF promoter. We confirmed the ability of this domain to activate transcription using a Ga14 fusion protein system. Because a truncated EPAS1 protein lacking the transactivation domain at amino acids 486-639 eliminated induction of the VEGF promoter by wildtype EPAS1, the truncated protein functions as a dominant-negative mutant. Most important, infection of the cells with an adenoviral construct expressing this mutant inhibited the induction of VEGF mRNA under conditions that mimic hypoxia. Our results suggest that EPAS1 is an important regulator of VEGF gene expression. Since VEGF plays a crucial role in angiogenesis, the ability of dominant-negative EPAS1 ito inhibit VEGF promoter activity raises the possibility of a novel approach to inhibiting pathological angiogenesis.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Joint Program Neonatol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Lee, ME (corresponding author), Brigham & Womens Hosp, Dept Med, Program Dev Cardiovasc Biol, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.		Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010113, R01HL055454, F32HL009008] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55454, HL 09008, HL 10113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LI H, 1994, J BIOL CHEM, V269, P28098; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG GL, 1998, BLOOD, V82, P8610; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	38	53	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31565	31570		10.1074/jbc.274.44.31565	http://dx.doi.org/10.1074/jbc.274.44.31565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531360	hybrid			2022-12-25	WOS:000083379400064
J	Juszczak, LJ; Friedman, JM				Juszczak, LJ; Friedman, JM			UV resonance Raman spectra of ligand binding intermediates of sol-gel encapsulated hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY STRUCTURE; CONFORMATIONAL-CHANGES; T-STATE; INOSITOL HEXAPHOSPHATE; SPECTROSCOPY; PROTEINS; DYNAMICS; COMMUNICATION; RESOLUTION; TRANSITION	We report for the first time specific conformational changes for a homogeneous population of ligand-bound adult deoxy human hemoglobin A (HbA) generated by introducing CO into a sample of deoxy-HbA with the effector, inositol hexaphosphate, encapsulated in a porous sol-gel. The preparation of ligand-bound deoxy-HbA results from the speed of ligand diffusion relative to globin conformational dynamics within the sol-gel (1). The ultraviolet resonance Raman (UVRR) difference spectra obtained reveal that E helix motion is initiated upon ligand binding, as signaled by the appearance of an alpha 14 beta 15 Trp W3 band difference at 1559 cm(-1). The subsequent appearance of Tyr (Y8a and Y9a) and W3 (1549 cm(-1)) UVRR difference bands suggest conformational shifts for the penultimate Tyr alpha 140 on the F helix, the "switch" region Tyr alpha 42, and the "hinge" region Trp beta 37. The UVRR results expose a sequence of conformational steps leading up to the ligation-induced T to R quaternary structure transition as opposed to a single, concerted switch. More generally, this report demonstrates that sol-gel encapsulation of proteins can be used to study a sequence of specific conformational events triggered by substrate binding because the traditional limitation of substrate diffusion times is overcome.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu			NHLBI NIH HHS [R01 HL58247, P01 HL51084] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058247, P01HL051084] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER SA, 1993, ANAL CHEM, V65, pA59, DOI 10.1021/ac00052a715; AUSTIN JC, 1993, BIOMOLECULAR SPECT A, V20, P55; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; DAS TK, 1999, IN PRESS BIOSPECTROS; DAVE BC, 1994, ANAL CHEM, V66, pA1120, DOI 10.1021/ac00094a001; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; Henry ER, 1997, BIOCHEMISTRY-US, V36, P6511, DOI 10.1021/bi9619177; Hirsch RE, 1996, J BIOL CHEM, V271, P372, DOI 10.1074/jbc.271.1.372; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; Hu XH, 1997, BIOCHEMISTRY-US, V36, P15701, DOI 10.1021/bi971136l; Huang SC, 1997, BIOCHEMISTRY-US, V36, P6197, DOI 10.1021/bi970018v; JAYARAMAN V, 1995, SCIENCE, V269, P1843, DOI 10.1126/science.7569921; JAYARAMAN V, 1993, BIOCHEMISTRY-US, V32, P4547, DOI 10.1021/bi00068a009; Juszczak LJ, 1998, J RAMAN SPECTROSC, V29, P963, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<963::AID-JRS332>3.0.CO;2-4; Kavanaugh JS, 1998, BIOCHEMISTRY-US, V37, P4358, DOI 10.1021/bi9708702; KITAGAWA T, 1992, PROG BIOPHYS MOL BIO, V58, P1, DOI 10.1016/0079-6107(92)90009-U; Kwiatkowski LD, 1998, BIOCHEMISTRY-US, V37, P4325, DOI 10.1021/bi970866q; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; NAGAI M, 1995, J BIOL CHEM, V270, P1636, DOI 10.1074/jbc.270.4.1636; Nagai M, 1999, BIOCHEMISTRY-US, V38, P1243, DOI 10.1021/bi982269p; Nagai M, 1996, J MOL STRUCT, V379, P65, DOI 10.1016/0022-2860(95)09177-7; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SASSAROLI M, 1987, BIOCHEMISTRY-US, V26, P3092, DOI 10.1021/bi00385a022; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; Shibayama N, 1999, J MOL BIOL, V285, P1383, DOI 10.1006/jmbi.1998.2407; Shibayama N, 1999, J AM CHEM SOC, V121, P444, DOI 10.1021/ja983652k; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Sokolov L, 1998, J PHYS CHEM B, V102, P8314, DOI 10.1021/jp982099q; SU C, 1989, J AM CHEM SOC, V111, P3457, DOI 10.1021/ja00191a068; Wang DJ, 1998, BIOCHEMISTRY-US, V37, P9940, DOI 10.1021/bi980295h	37	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30357	30360		10.1074/jbc.274.43.30357	http://dx.doi.org/10.1074/jbc.274.43.30357			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521410	hybrid			2022-12-25	WOS:000083276700006
J	McEwen, DG; Green, RP; Naski, MC; Towler, DA; Ornitz, DM				McEwen, DG; Green, RP; Naski, MC; Towler, DA; Ornitz, DM			Fibroblast growth factor receptor 3 gene transcription is suppressed by cyclic adenosine 3 ',5 '-monophosphate - Identification of a chondrocytic regulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; BOVINE CYP17 GENE; CAMP-DEPENDENT TRANSCRIPTION; ORPHAN NUCLEAR RECEPTOR; PARATHYROID-HORMONE; THANATOPHORIC DYSPLASIA; RETINOIC ACID; BONE-GROWTH; METAPHYSEAL CHONDRODYSPLASIA; CONSTITUTIVE ACTIVATION	Signaling through fibroblast growth factor receptors (FGFRs) is critical for the development and patterning of the vertebrate skeleton. Gain-of-function alleles of fgfr2 and fgfr3 have been linked to several dominant skeletal disorders in humans, while null mutations in fgfr3 result in the overgrowth of long bones in a mouse model system. interestingly, the expression pattern of fgfr3 in growth plate chondrocytes overlaps that of the parathyroid hormone (PTH)-related peptide (PTHrP) receptor, a signaling molecule that also regulates endochondral ossification. The coincident expression of these two receptors suggests that their signaling pathways may also interact. To gain insight into the regulatory mechanism(s) that govern the expression of the fgfr3 gene in chondrocytes, we have identified a cell-specific transcriptional regulatory element (CSRh) by measuring the activity of various promoter fragments in FGFR3-expressing (CFK2) and nonexpressing (RCJ) chondrocyte-like cell lines. Furthermore, we demonstrate that activation of PTH/PTHrP receptors, either by stimulation with PTH or through the introduction of activating mutations, represses CSRh-mediated transcriptional activity. Finally, the transcriptional repression of the CSRh element was mimicked by treatment with forskolin, 8-bromo-cAMP, and 3-isobutyl-1-methylxanthine or by overexpression of the catalytic subunit of protein kinase A. Together, these data suggest that protein kinase A activity is a critical factor that regulates fgfr3 gene expression in the proliferative or prehypertrophic compartment of the epiphyseal growth plate, Furthermore, these results provide a possible link between PTHrP signaling and fgfr3 gene expression during the process of endochondral ossification.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Ornitz, DM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629; Towler, Dwight/0000-0003-2107-7923	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035692] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35692] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Alini M, 1996, J BONE MINER RES, V11, P105; Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKKE M, 1995, ENDOCR RES, V21, P509, DOI 10.3109/07435809509030468; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; BARON J, 1994, ENDOCRINOLOGY, V135, P2790, DOI 10.1210/en.135.6.2790; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BERNIER SM, 1990, J CELL PHYSIOL, V145, P274, DOI 10.1002/jcp.1041450212; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EdwallArvidsson C, 1996, ANAT EMBRYOL, V193, P453; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; IWAMOTO M, 1993, EXP CELL RES, V205, P213, DOI 10.1006/excr.1993.1079; IWAMOTO M, 1994, MICROSC RES TECHNIQ, V28, P483, DOI 10.1002/jemt.1070280604; IWAMOTO M, 1993, EXP CELL RES, V207, P413, DOI 10.1006/excr.1993.1209; Karaplis Andrew C., 1998, Frontiers in Bioscience, V3, pD795; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lund J, 1997, STEROIDS, V62, P43, DOI 10.1016/S0039-128X(96)00157-2; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McEwen DG, 1997, BIOTECHNIQUES, V22, P1068, DOI 10.2144/97226bm12; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Naski M C, 1998, Front Biosci, V3, pd781; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Quarto R, 1997, ENDOCRINOLOGY, V138, P4966, DOI 10.1210/en.138.11.4966; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Skaer H, 1997, CURR BIOL, V7, pR238, DOI 10.1016/S0960-9822(06)00110-2; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; ZANGER UM, 1992, FASEB J, V6, P719, DOI 10.1096/fasebj.6.2.1311271; ZUSCIK MJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P352, DOI 10.1006/abbi.1994.1511	66	20	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30934	30942		10.1074/jbc.274.43.30934	http://dx.doi.org/10.1074/jbc.274.43.30934			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521488	hybrid			2022-12-25	WOS:000083276700084
J	Orsini, MJ; Parent, JL; Mundell, SJ; Benovic, JL				Orsini, MJ; Parent, JL; Mundell, SJ; Benovic, JL			Trafficking of the HIV coreceptor CXCR4 - Role of arrestins and identification of residues in the C-terminal tail that mediate receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; IMMUNODEFICIENCY-VIRUS TYPE-1; DOMINANT-NEGATIVE MUTANT; SMALL-MOLECULE INHIBITOR; T-CELL RECEPTOR; CHEMOKINE RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; DOWN-REGULATION; SIGNAL-TRANSDUCTION	The G protein-coupled chemokine receptor CXCR4 serves as the primary coreceptor for entry of T-cell tropic human immunodeficiency virus. CXCR4 undergoes tonic internalization as well as internalization in response to stimulation with phorbol esters and ligand (SDF-1 alpha). We investigated the trafficking of this receptor, and we attempted to define the residues of CXCR4 that were critical for receptor internalization. In both COS-1 and HEK-293 cells transiently overexpressing CXCR4, SDF-1 alpha and phorbol esters (PMA) promoted rapid internalization of cell surface receptors as assessed by both enzyme-linked immunosorbent assay and immunoflouorescence analysis. Expression of GRK2 and/or arrestins promoted modest additional CXCR4 internalization in response to both PMA and SDF, Both PMA- and SDF-mediated CXCR4 internalization was inhibited by coexpression of dominant negative mutants of dynamin-1 and arrestin-3. Arrestin was also recruited to the plasma membrane and appeared to colocalize with internalized receptors in response to SDF but not PMA. We then evaluated the ability of CXCR4 receptors containing mutations of serines and threonines, as well as a dileucine motif, within the C-terminal tail to be internalized and phosphorylated in response to either PMA or SDF-1 alpha: This analysis showed that multiple residues within the CXCR4 C-terminal tail appear to mediate both PMA- and SDF-1 alpha-mediated receptor internalization. The ability of coexpressed GRK2 and arrestins to promote internalization of the CXCR4 mutants revealed distinct differences between respective mutants and suggested that the integrity of the dileucine motif (IIe-328 and Leu-329) and serines 324, 325, 338, and 339 are critical for receptor internalization.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovie@lac.jci.tju.edu			NIDDK NIH HHS [5-T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM47419] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arakaki R, 1999, J VIROL, V73, P1719, DOI 10.1128/JVI.73.2.1719-1723.1999; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Cole SW, 1999, J IMMUNOL, V162, P1392; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1998, J BIOL CHEM, V273, P24232, DOI 10.1074/jbc.273.37.24232; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Marechal V, 1999, J VIROL, V73, P3608; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Peacock JW, 1999, J IMMUNOL, V162, P215; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451; Rucker J, 1998, AIDS RES HUM RETROV, V14, pS241; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; Secchiero P, 1999, J IMMUNOL, V162, P2427; Secchiero P, 1998, BLOOD, V92, P4521, DOI 10.1182/blood.V92.12.4521.424k38_4521_4528; Signoret N, 1998, J CELL SCI, V111, P2819; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Ugolini S, 1997, J IMMUNOL, V159, P3000; Wang JB, 1998, J LEUKOCYTE BIOL, V64, P642, DOI 10.1002/jlb.64.5.642; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yang AG, 1997, P NATL ACAD SCI USA, V94, P11567, DOI 10.1073/pnas.94.21.11567; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang YJ, 1999, J VIROL, V73, P3443, DOI 10.1128/JVI.73.4.3443-3448.1999; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	84	204	210	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31076	31086		10.1074/jbc.274.43.31076	http://dx.doi.org/10.1074/jbc.274.43.31076			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521508	hybrid			2022-12-25	WOS:000083276700104
J	Yuan, HD; Mao, JH; Li, L; Wu, DQ				Yuan, HD; Mao, JH; Li, L; Wu, DQ			Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; DROSOPHILA; APC; PHOSPHORYLATION; COMPLEX; FAMILY; AXIN; PROTOONCOGENE	Glycogen synthase kinase-3 (GSK) can be regulated by different signaling pathways including those mediated by protein kinase Akt and Wnt proteins. Wnt proteins are believed to activate a transcription factor leukemia enhancer factor-1 (LEF-1) by inhibiting GSK, and Akt was shown to phosphorylate GSK and inhibit its kinase activity. We investigated the effect of an activated Akt on the accumulation of cytosolic beta-catenin and LEF-1-dependent transcription. Although the activated Akt, mAkt, clearly inhibited the kinase activity of GSK, mAkt alone did not induce accumulation of cytosolic beta-catenin or activate LEF-1-dependent transcription. On the contrary, coexpressed Wnt-1 and Frat activated LEF-1 but did not show significant inhibition of GSK-mediated phosphorylation of a peptide substrate. However, mAkt could act synergistically with Wnt-1 or Frat to activate LEF-1. In addition, the interaction of GSK for Axin appeared to decrease in the presence of mAkt, whereas the interaction for Frat remained unchanged. Consistently, a GSK mutant with substitution of a Phe residue for residue Tyr-216, which showed one-fifth of kinase activity of the wild-type GSK, exhibited a reduced association for Axin than the wild-type GSK. These results suggest that inhibition of GSK kinase activity is not sufficient for activation of LEF-1 but may facilitate the activation by reducing the interaction of GSK for Axin, The additional mechanism for LEF-1 activation may require dissociation of GSK from Axin as Frat facilitates the dissociation of GSK from Axin.	Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem, Shanghai, Peoples R China	University of Rochester; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	wud@pharmacol.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54167, GM53162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dale TC, 1998, BIOCHEM J, V329, P209; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1997, BIOCHEM SOC T, V25, P710; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; WANG QM, 1994, J BIOL CHEM, V269, P14566; Wang YS, 1996, J BIOL CHEM, V271, P4468; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	37	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30419	30423		10.1074/jbc.274.43.30419	http://dx.doi.org/10.1074/jbc.274.43.30419			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521419	hybrid			2022-12-25	WOS:000083276700015
J	Basora, N; Herring-Gillam, FE; Boudreau, F; Perreault, N; Pageot, LP; Simoneau, M; Bouatrouss, Y; Beaulieu, JF				Basora, N; Herring-Gillam, FE; Boudreau, F; Perreault, N; Pageot, LP; Simoneau, M; Bouatrouss, Y; Beaulieu, JF			Expression of functionally distinct variants of the beta(4)A integrin subunit in relation to the differentiation state in human intestinal cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE EXPRESSION; TRANSIENT MOSAIC PATTERNS; CRYPT-VILLUS AXIS; A-CHAIN ISOFORMS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; BETA-4 INTEGRIN; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; SIGNAL-TRANSDUCTION	Integrins are important mediators of cell-laminin interactions. In the small intestinal epithelium, which consists of spatially separated proliferative and differentiated cell populations located, respectively, in the crypt and on the villus, laminins and laminin-binding; integrins are differentially expressed along the cryptvillus axis. One exception to this is the integrin alpha(6)beta(4), which is thought to be ubiquitously expressed by intestinal cells. However, in this study, a re-evaluation of the beta(4) subunit expression with different antibodies revealed that two forms of beta(4) exist in the human intestinal epithelium. Furthermore, we show that differentiated enterocytes express a full-length 205-kDa beta(4)A subunit, whereas undifferentiated crypt cells express a novel beta(4)A subunit that does not contain the COOH-terminal segment of the cytoplasmic domain (beta(4)A(ctd-)). This new form was not found to arise from alternative beta(4) mRNA splicing. Moreover, we found that these two beta(4)A forms can associate into alpha(6)beta(4)A complexes; however, the beta 4A(ctd-) integrin expressed by the undifferentiated crypt cells is not functional for adhesion to laminin-5. Hence, these studies identify a novel alpha(6)beta(4)A(ctd-) integrin expressed in undifferentiated intestinal crypt cells that is functionally distinct.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, CUSE,Ctr Rech Clin,Ctr Rech Biol Dev Epitheliums, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Beaulieu, JF (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, CUSE,Ctr Rech Clin,Ctr Rech Biol Dev Epitheliums, Sherbrooke, PQ J1H 5N4, Canada.		Beaulieu, Jean-Francois/D-2054-2010					AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Basora N, 1997, GASTROENTEROLOGY, V113, P1510, DOI 10.1053/gast.1997.v113.pm9352853; Beaulieu Jean-Francois, 1999, Frontiers in Bioscience, V4, pD310, DOI 10.2741/Beaulieu; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1994, GASTROENTEROLOGY, V106, P829, DOI 10.1016/0016-5085(94)90740-4; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1994, GASTROENTEROLOGY, V107, P957, DOI 10.1016/0016-5085(94)90219-4; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BOYLE WJ, 1995, CURR OPIN GASTROEN, V11, P121, DOI 10.1097/00001574-199503000-00006; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKE AS, 1994, CELL ADHES COMMUN, V2, P1, DOI 10.3109/15419069409014197; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FALCIONI R, 1989, MOL CARCINOGEN, V2, P361, DOI 10.1002/mc.2940020611; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1996, J CELL SCI, V109, P1165; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; LEBLOND CP, 1981, AM J ANAT, V160, P114; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Leivo I, 1996, J HISTOCHEM CYTOCHEM, V44, P1267, DOI 10.1177/44.11.8918902; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Niessen CM, 1997, J CELL SCI, V110, P1705; Niessen CM, 1997, MOL BIOL CELL, V8, P555, DOI 10.1091/mbc.8.4.555; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Nievers MG, 1998, J CELL SCI, V111, P1659; OrianRousseau V, 1996, DEV DYNAM, V206, P12, DOI 10.1002/(SICI)1097-0177(199605)206:1<12::AID-AJA2>3.0.CO;2-3; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; PERREAULT N, 1995, ANAT REC, V242, P242, DOI 10.1002/ar.1092420214; PINTO M, 1983, BIOL CELL, V47, P323; PODOLSKY DK, 1995, TXB GASTROENTEROLOGY, P546; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; RODIRGUEZBOULAN E, 1989, SCIENCE, V245, P718; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; SIMONASSMANN P, 1994, DEV DYNAM, V201, P71, DOI 10.1002/aja.1002010108; SONNENBERG A, 1992, PATHOL BIOL, V40, P773; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL PHYSIOL, V166, P198, DOI 10.1002/(SICI)1097-4652(199601)166:1<198::AID-JCP21>3.0.CO;2-A; VACHON PH, 1995, AM J PHYSIOL, V268, P857; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; vanLeusden MR, 1997, BIOCHEM BIOPH RES CO, V235, P826, DOI 10.1006/bbrc.1997.6892; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEWER UM, 1994, METHOD ENZYMOL, V245, P85; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727	78	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29819	29825		10.1074/jbc.274.42.29819	http://dx.doi.org/10.1074/jbc.274.42.29819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514460	hybrid			2022-12-25	WOS:000083176400039
J	Fay, PJ; Scandella, D				Fay, PJ; Scandella, D			Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; HEMOPHILIA-A; BINDING-SITE; A1/A3-C1-C2 DIMER; MOLECULAR-BASIS; LIGHT-CHAIN; FACTOR-X; A2-SUBUNIT; IDENTIFICATION	Factor VIIIa, a heterotrimer of the A1, A2, and A3-C1-C2 subunits, increases the catalytic efficiency for factor IXa-catalyzed activation of factor X. A significant fraction of naturally occurring, anti-factor VIII inhibitor antibodies reacts with the A2 domain. Utilizing the capacity for isolated A2 subunit to stimulate factor IXa activity, we show that a panel of these inhibitors block this activity, inhibition of activity parallels the antibody potency as measured in the Bethesda assay. These antibodies also block the A2-dependent increases in fluorescence anisotropy of fluorescein-Phe-Phe-Arg factor IXa. Similar to the IgG fractions, a peptide representing the sequence of the inhibitor epitope (A2 residues 484-509) blocked the A2-dependent stimulation of factor IXa. These results indicate that antibodies possessing this specificity directly inhibit the interaction of A2 subunit with factor IXa, thus abrogating the contribution of this subunit to cofactor activity. Furthermore, these results also suggest that factor VIII residues 484-509 contribute to a factor IXa-interactive site.	Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med,Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med,Dept Med, Rochester, NY 14642 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA	University of Rochester; University of Rochester; American Red Cross	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med,Dept Biochem & Biophys, 601 Elmwood Ave,POB 610, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NHLBI NIH HHS [HL 30616, HL 38199, HL 55273] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL055273, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, BLOOD, V91, P538, DOI 10.1182/blood.V91.2.538.538_538_548; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Feinstein D I, 1972, Prog Hemost Thromb, V1, P75; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KemballCook G, 1997, NUCLEIC ACIDS RES, V25, P128, DOI 10.1093/nar/25.1.128; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LAZARCHICK J, 1978, J CLIN INVEST, V62, P1048, DOI 10.1172/JCI109209; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Lollar P, 1995, ADV EXP MED BIOL, V386, P3; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; TUDDENHAM EGD, 1994, NUCLEIC ACIDS RES, V22, P3511, DOI 10.1093/nar/22.17.3511; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; Zhong DG, 1998, BLOOD, V92, P136, DOI 10.1182/blood.V92.1.136.413k35_136_142	36	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29826	29830		10.1074/jbc.274.42.29826	http://dx.doi.org/10.1074/jbc.274.42.29826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514461	hybrid			2022-12-25	WOS:000083176400040
J	Knarr, G; Modrow, S; Todd, A; Gething, MJ; Buchner, J				Knarr, G; Modrow, S; Todd, A; Gething, MJ; Buchner, J			BiP-binding sequences in HIV gp160 - Implications for the binding specificity of BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNOGLOBULIN LIGHT-CHAINS; HSP70 MOLECULAR CHAPERONES; ENVELOPE GLYCOPROTEIN; PEPTIDE-BINDING; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; CONFORMATIONAL CHANGE; MEMBRANE-FUSION	BiP, a resident endoplasmic reticulum member of the HSP70 family of molecular chaperones, associates transiently with a wide variety of newly synthesized exocytotic proteins. In addition to immunoglobulin heavy and light chains, the first natural substrates identified for BiP, a number of viral polypeptides including the human immunodeficiency virus type 1 envelope glycoprotein gp160 interact with BiP during their passage through the endoplasmic reticulum. We have used a computer algorithm developed to predict BiP-binding sites within protein primary sequences to identify sites within gp160 that might mediate its association with BiP. Analysis of the ability of 22 synthetic heptapeptides corresponding to predicted binding sites to stimulate the ATPase activity of BiP or to compete with an unfolded polypeptide for binding to BiP indicated that about half of them are indeed recognized by the chaperone. All of the confirmed binding sites are localized within conserved regions of gp160, suggesting a conserved role for BiP in the folding of gp160. Information on the characteristics of confirmed BiP-binding peptides gained in this and previous studies has been utilized to improve the predictive power of the BiP Score algorithm and to investigate the differences in peptide binding specificities of HSP70 family members.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93042 Regensburg, Germany; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	University of Regensburg; University of Regensburg; University of Melbourne	Buchner, J (corresponding author), Tech Univ Munich, Inst Org Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010	Corlett, Alicia/0000-0003-1146-2465; Buchner, Johannes/0000-0003-1282-7737				ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Brewer J. W., 1997, MOL CHAPERONE PROTEI, P415; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEDERA D, 1992, J VIROL, V66, P1207, DOI 10.1128/JVI.66.2.1207-1209.1992; DONCH J, 1968, J BACTERIOL, V95, P1555, DOI 10.1128/JB.95.5.1555-1559.1968; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Gething MJ, 1995, COLD SPRING HARB SYM, V60, P417, DOI 10.1101/SQB.1995.060.01.046; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GETHING MJ, 1997, MOL CHAPERONES PROTE, P59; GNANN JW, 1987, J VIROL, V61, P2639, DOI 10.1128/JVI.61.8.2639-2641.1987; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAAS IG, 1988, P NATL ACAD SCI USA, V85, P2250, DOI 10.1073/pnas.85.7.2250; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOZUTSUMI Y, 1999, J CELL SCI S, V11, P115; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MIAO B, 1997, MOL CHAPERONES PROTE, P3; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; Otteken A, 1996, J VIROL, V70, P3407, DOI 10.1128/JVI.70.6.3407-3415.1996; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	56	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29850	29857		10.1074/jbc.274.42.29850	http://dx.doi.org/10.1074/jbc.274.42.29850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514465	hybrid			2022-12-25	WOS:000083176400044
J	Liu, T; Pemberton, PA; Robertson, AD				Liu, T; Pemberton, PA; Robertson, AD			Three-estate unfolding and self-association of maspin, a tumor-suppressing serpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYOEPITHELIAL CELL; PLASMINOGEN-ACTIVATOR; BREAST-CARCINOMA; MOLECULAR-BASIS; CANCER CELLS; PROTEIN; OVALBUMIN; COOPERATIVITY; RECOMBINANT; RESOLUTION	Maspin is a tumor suppressor protein expressed by normal human mammary epithelium but not by many breast tumor cell lines, Recombinant human maspin (rMaspin) inhibits tumor cell motility, invasion, and metastasis and thus has potential value as an anti-cancer therapeutic, Maspin is a member of the serpin family and, although the molecular mechanism by which maspin acts is unknown, recent work suggests that tissue plasminogen activator is a potential target. A puzzling observation in previous cell culture studies was loss of rMaspin activity at higher protein concentrations, One hypothesis to explain these results is self-association of rMaspin at the higher concentrations, which would be consistent with the tendency of serpins to form noncovalent polymers, This hypothesis is addressed by examining the relationship between rMaspin stability and self-association. Urea denaturation of rMaspin at pH 7 and 25 degrees C and at protein concentrations ranging from 0.01 to 0.2 mg/ml has been monitored by circular dichroism and intrinsic tryptophan fluorescence, Denaturation profiles show a protein concentration dependence and indicate the presence of at least one unfolding intermediate. The results suggest that destabilization of native monomeric rMaspin leads to partial unfolding and formation of an intermediate which can self-associate.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Canc, Iowa City, IA 52242 USA; LXR Biotechnol, Richmond, CA 94804 USA	University of Iowa; University of Iowa	Robertson, AD (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.		Liu, Ting/GRS-6266-2022		NCRR NIH HHS [S10 RR10409] Funding Source: Medline; NIGMS NIH HHS [GM46869] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046869] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEWELL NM, 1993, TRENDS BIOCHEM SCI, V18, P1, DOI 10.1016/0968-0004(93)90077-Z; BRUCH M, 1988, J BIOL CHEM, V263, P16623; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Eftink MR, 1995, METHOD ENZYMOL, V259, P487; Fitzpatrick PA, 1996, PROTEIN ENG, V9, P585, DOI 10.1093/protein/9.7.585; FREIRE E, 1991, J MOL BIOL, V222, P687, DOI 10.1016/0022-2836(91)90505-Z; FREIRE E, 1992, BIOCHEMISTRY-US, V31, P250, DOI 10.1021/bi00116a034; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, P91; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Mikus P, 1996, J BIOL CHEM, V271, P10048, DOI 10.1074/jbc.271.17.10048; Onda M, 1997, J BIOL CHEM, V272, P3973, DOI 10.1074/jbc.272.7.3973; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; Raschke TM, 1998, CURR OPIN BIOTECH, V9, P80, DOI 10.1016/S0958-1669(98)80088-8; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Seftor REB, 1998, CANCER RES, V58, P5681; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Umekita Y, 1997, CANCER LETT, V113, P87, DOI 10.1016/S0304-3835(97)04600-4; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29628	29632		10.1074/jbc.274.42.29628	http://dx.doi.org/10.1074/jbc.274.42.29628			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514431	hybrid			2022-12-25	WOS:000083176400010
J	Schroter, S; Derr, P; Conrad, HS; Nimtz, M; Hale, G; Kirchhoff, C				Schroter, S; Derr, P; Conrad, HS; Nimtz, M; Hale, G; Kirchhoff, C			Male-specific modification of human CD52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED GLYCOPROTEIN; BETA-TRACE PROTEIN; SEMINAL PLASMA; SPERM SURFACE; EPIDIDYMAL MATURATION; MONOCLONAL-ANTIBODIES; CAMPATH-1 ANTIGEN; PEPTIDE BACKBONE; RAT SPERMATOZOA; MESSENGER-RNA	CD52 is an unusually short, bipolar glycopeptide bearing a highly charged N-Linked carbohydrate moiety and a glycosylphosphatidylinositol membrane anchor. It is exclusively expressed on lymphocytes and in the male genital tract where it is shed into the seminal plasma and inserts into the sperm membrane. The sperm surface molecule has potential significance as a target for antibodies that inhibit sperm function and gamete interaction. Western blot analyses suggested cell type-specific modifications of the antigen. It was purified from seminal plasma and a detailed structural analysis performed. The majority of anchor structures in male genital tract CD52 showed 2-inositol palmitoylation, rendering molecules insensitive toward phospholipase C, and a sn-1-alkyl-2-lyso-glycerol structure in place of the diacylated anchor described by Treumann st al. (Treumann, A., Lifely, M. R., Schneider, P,, and Ferguson, M, A. (1995) J. Biol. Chem. 270, 6088-6099). N-Glycans of the male genital tract product were based on bi-, tri-, and tetraan-tennary structures of highly charged (up to -7), terminally sialylated complex-type sugars. A substantial proportion carried varying numbers of lactosamine repeats of which nearly 30% were branched. Different from lymphocytes, 10-15% of all N-glycans of the male genital tract antigen also contained peripheral fucose, These data confirm that male genital tract CD52 is distinct from the lymphocyte form by both N-linked glycans and COOH-terminal attached lipid anchor.	Univ Hamburg, Inst Hormon & Fortpflanzungsforsch, D-22529 Hamburg, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Hamburg; Gesellschaft fur Biotechnologische Forschung mbH; University of Oxford	Kirchhoff, C (corresponding author), Univ Hamburg, Inst Hormon & Fortpflanzungsforsch, Grandweg 64, D-22529 Hamburg, Germany.	kirchhoff@ihf.de		Hale, Geoff/0000-0001-9473-423X				ANUMULA KR, 1992, ANAL BIOCHEM, V203, P101, DOI 10.1016/0003-2697(92)90048-C; BEDFORD JM, 1963, NATURE, V200, P1178, DOI 10.1038/2001178a0; Benoff S, 1997, MOL HUM REPROD, V3, P599, DOI 10.1093/molehr/3.7.599; BOLDT J, 1989, BIOL REPROD, V40, P887, DOI 10.1095/biolreprod40.4.887; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COOPER GW, 1971, ANAT REC, V169, P300; Diekman AB, 1997, BIOL REPROD, V57, P1136, DOI 10.1095/biolreprod57.5.1136; DIEKMAN AB, 1995, IMMUNOLOGY HUMAN REP, P1; ECCLESTON ED, 1994, MOL REPROD DEV, V37, P110, DOI 10.1002/mrd.1080370115; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; Hale G, 1995, IMMUNOTECHNOLOGY, V1, P175, DOI 10.1016/1380-2933(95)00017-8; Hale G, 1998, ENCY IMMUNOLOGY, P402; HAMILTON DW, 1986, BIOL REPROD, V34, P925, DOI 10.1095/biolreprod34.5.925; HOFFMANN A, 1994, J NEUROCHEM, V63, P2185; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; ILG T, 1992, J BIOL CHEM, V267, P6834; ISOJIMA S, 1989, REPROD FERT DEVELOP, V1, P193, DOI 10.1071/RD9890193; JONES R, 1989, OXFORD REV REPROD B, V11, P285; Kallajoki M, 1998, PROSTATE, V35, P263, DOI 10.1002/(SICI)1097-0045(19980601)35:4<263::AID-PROS5>3.0.CO;2-H; KAMEDA K, 1992, BIOL REPROD, V46, P349, DOI 10.1095/biolreprod46.3.349; KIRCHHOFF C, 1993, MOL REPROD DEV, V34, P8, DOI 10.1002/mrd.1080340103; Kirchhoff C, 1996, MOL HUM REPROD, V2, P9, DOI 10.1093/molehr/2.1.9; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; KRULL N, 1993, MOL REPROD DEV, V34, P16, DOI 10.1002/mrd.1080340104; KURPISZ M, 1995, FERTIL STERIL, V63, P158, DOI 10.1016/S0015-0282(16)57312-9; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P269, DOI 10.1016/0165-0378(91)90040-W; MANJUNATH P, 1994, BIOCHEM J, V303, P121, DOI 10.1042/bj3030121; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; MOORE A, 1989, BIOCHEM BIOPH RES CO, V160, P460, DOI 10.1016/0006-291X(89)92455-8; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; Pera I, 1997, MOL REPROD DEV, V48, P433, DOI 10.1002/(SICI)1098-2795(199712)48:4<433::AID-MRD3>3.0.CO;2-R; Rooney IA, 1996, J CLIN INVEST, V97, P1675, DOI 10.1172/JCI118594; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Soubeyrand S, 1998, BBA-LIPID LIPID MET, V1392, P176, DOI 10.1016/S0005-2760(98)00037-X; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Tsuji Y, 1995, IMMUNOLOGY HUMAN REP, P23; TULSIANI DRP, 1999, J REPROD FERTIL S, V53, P85; VALENTIN H, 1992, TRANSPLANTATION, V54, P97, DOI 10.1097/00007890-199207000-00018; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; WALTER EI, 1992, J BIOL CHEM, V267, P1245; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; *WHO, 1992, WHO LAB MAN EX HUM S, P8; XIA MQ, 1991, EUR J IMMUNOL, V21, P1677, DOI 10.1002/eji.1830210714; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; YANAGIMACHI R, 1994, PHYSL REPROD, V0002, P00189; Yeung CH, 1997, MOL REPROD DEV, V48, P267, DOI 10.1002/(SICI)1098-2795(199710)48:2<267::AID-MRD15>3.0.CO;2-V; ZEHEB R, 1984, J BIOL CHEM, V259, P839	54	95	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29862	29873		10.1074/jbc.274.42.29862	http://dx.doi.org/10.1074/jbc.274.42.29862			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514467	hybrid			2022-12-25	WOS:000083176400046
J	Thomas, CJ; Surolia, N; Surolia, A				Thomas, CJ; Surolia, N; Surolia, A			Surface plasmon resonance studies resolve the enigmatic endotoxin neutralizing activity of polymyxin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; PERMEABILITY-INCREASING PROTEIN; LIPID-A; HOST-DEFENSE; LIPOPOLYSACCHARIDE; BINDING; SPECIFICITY	Polymyxin B (PMB), a cyclic cationic peptide antibiotic, despite its severe side effects continues to occupy a premiere position for treating endotoxicosis. Its mode of neutralization of endotoxin has remained elusive for the last three decades. Several synthetic peptide mimics of PMB, capable of binding endotoxin, have been made. However, the binding ability alone appears to be a deceptive indicator of endotoxin neutralizing activity as molecules with similar binding propensities could either sequester or opsonize the toxin. Hence identification of additional physical parameters which describe adequately the outcome of PMB-endotoxin interaction become imperative. Surface plasmon resonance (SPR) studies reported here show that several mimics of PMB despite exhibiting lipopolysaccharide binding affinities comparable with it but, unlike it, do not sequester the endotoxin. These studies thus provide a striking illustration of the difference in the behavior of PMB, vis a vis its mimics toward the endotoxin lamellae, and define further, in chemical terms, mechanism of the action of PMB and allow us to posit that the design of molecules as effective antidotes for sepsis should incorporate the ability to sequester endotoxin specifically.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@mbu.iisc.ernet.in	SUROLIA, AVADESHA/C-5442-2009					CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; COOPER MA, 1997, CHEM COMMUN, V1625; CROSS AS, 1994, J ENDOTOXIN RES, V1, P57; David SA, 1996, J ENDOTOXIN RES, V3, P369, DOI 10.1177/096805199600300501; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; FINK PF, 1990, HDB CRITICAL CARE, P619; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; LIEVE L, 1974, ANN NY ACAD SCI, V235, P109; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; RIFKIND D, 1967, J BACTERIOL, V93, P1463, DOI 10.1128/JB.93.4.1463-1464.1967; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SHIHYI L, 1995, BIOCHIM BIOPHYS ACTA, V1252, P312; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; Thomas CJ, 1998, J AM CHEM SOC, V120, P12428, DOI 10.1021/ja981777j; Thomas CJ, 1999, FEBS LETT, V445, P420, DOI 10.1016/S0014-5793(99)00150-7; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; VAARA M, 1983, NATURE, V303, P526, DOI 10.1038/303526a0; YIN ET, 1972, BIOCHIM BIOPHYS ACTA, V261, P284	21	54	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29624	29627		10.1074/jbc.274.42.29624	http://dx.doi.org/10.1074/jbc.274.42.29624			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514430	hybrid			2022-12-25	WOS:000083176400009
J	Witteveen, CFB; Giovanelli, J; Kaufman, S				Witteveen, CFB; Giovanelli, J; Kaufman, S			Reactivity of tetrahydrobiopterin bound to nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE-HYDROXYLASE; L-ARGININE; REDUCTIVE ACTIVATION; FLAVIN SEMIQUINONE; HYDROGEN-PEROXIDE; NO SYNTHASE; HEME IRON; BRAIN; GENERATION; SUPEROXIDE	Levels of tetrahydrobiopterin (BH4) bound to nitric-oxide synthase (NOS) were examined during multiple turnovers of the enzyme in the presence of an NADPH-regenerating system. Our findings show that NOS-bound BH4 does not remain in a static state but undergoes redox reactions. Under these experimental conditions, the redox state of BH4 was determined by the balance between calcium/calmodulin (Ca2+/CaM)dependent oxidation of BH4 mediated by the uncoupled formation of superoxide/hydrogen peroxide on the one hand and by reductive regeneration of BH4 on the other hand. BH4 oxidation was appreciably increased in the presence of arginine. Levels of NOS-bound BH4 were also examined under single turnover conditions in the absence of an NADPH-regenerating system and in the presence of added superoxide dismutase and catalase to suppress the accumulation of superoxide and hydrogen peroxide. BH4 oxidation was again dependent on Ca2+/CaM. The insensitivity to superoxide dismutase and catalase suggested that the single turnover oxidation of BH4 did not proceed through superoxide/peroxide, although the involvement of these oxidants could not be definitively excluded. The amount of BH4 oxidized was highest in the presence of arginine, and this oxidation significantly exceeded that in the presence of N-G-hydroxy-L-arginine, The findings that single turnover oxidation of BH4 is stimulated by arginine in the presence of Ca2+/CaM and that BH4 is regenerated are consistent with a role for the pterin as an electron donor in product formation; this role remains to be defined.	NIMH, Neurochem Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Giovanelli, J (corresponding author), NIMH, Neurochem Lab, Bldg 36,Rm 3D30,36 Convent Dr,MSC 4096, Bethesda, MD 20892 USA.							AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32218; [Anonymous], 1980, ENZYMATIC BASIS DETO; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUBLITZ C, 1977, BIOCHEM MED METAB B, V17, P13, DOI 10.1016/0006-2944(77)90004-7; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CAMPOS KL, 1992, BIOL NITRIC OXIDE, V2, P47; CITRON BA, 1992, PROTEIN EXPRES PURIF, V3, P93, DOI 10.1016/S1046-5928(05)80024-5; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; EBERLEIN G, 1984, J AM CHEM SOC, V106, P7916, DOI 10.1021/ja00337a047; Fee J.A., 1977, SUPEROXIDE SUPEROXID, P19; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; FURFINE ES, 1993, BIOCHEMISTRY-US, V32, P8512, DOI 10.1021/bi00084a017; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Gorren ACF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P734; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Halliwell B, 1995, ACTIVE OXYGEN BIOCH, P313; HASSAN HM, 1980, ENZYMATIC BASIS DETO, V1, P311; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; KATOH S, 1970, CHEM BIOL PTERIDINES, P225; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KAUFMAN S, 1961, J BIOL CHEM, V236, P804; KAUFMAN S, 1964, J BIOL CHEM, V239, P332; KAUFMAN S, 1987, ENZYMES B, V18, P217; Kim S, 1998, EXP MOL MED, V30, P221, DOI 10.1038/emm.1998.32; KLATT P, 1994, J BIOL CHEM, V269, P13861; KOMORI Y, 1995, J BIOCHEM-TOKYO, V117, P923, DOI 10.1093/oxfordjournals.jbchem.a124797; KOWLESSUR D, 1995, P NATL ACAD SCI USA, V92, P4743, DOI 10.1073/pnas.92.11.4743; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P752; LEWIS DFV, 1996, CYTOCHROMES P450 STR, P79; MANITZ B, 1992, BIOL NITRIC OXIDE, V2, P116; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MITTAL CK, 1993, BIOCHEM BIOPH RES CO, V193, P126, DOI 10.1006/bbrc.1993.1599; PEARSON AJ, 1974, CHEM IND-LONDON, P233; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RENGASAMY A, 1994, BIOCHEM PHARMACOL, V48, P423, DOI 10.1016/0006-2952(94)90116-3; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; STUEHR DJ, 1990, BIOCHEM BIOPH RES CO, V168, P558, DOI 10.1016/0006-291X(90)92357-6; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; Witteveen CFB, 1998, BIOCHEM BIOPH RES CO, V250, P36, DOI 10.1006/bbrc.1998.8807; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	68	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29755	29762		10.1074/jbc.274.42.29755	http://dx.doi.org/10.1074/jbc.274.42.29755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514451	hybrid			2022-12-25	WOS:000083176400030
J	Thangaraju, M; Sharma, K; Leber, B; Andrews, DW; Shen, SH; Srikant, CB				Thangaraju, M; Sharma, K; Leber, B; Andrews, DW; Shen, SH; Srikant, CB			Regulation of acidification and apoptosis by SHP-1 and Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FAS-MEDIATED APOPTOSIS; BREAST-CANCER CELLS; SOMATOSTATIN ANALOG SMS-201-995; SIGNALING COMPLEX DISC; GROWTH-FACTOR RECEPTOR; HUMAN TUMOR-CELLS; GENE BAX-ALPHA; WILD-TYPE P53; INTRACELLULAR ACIDIFICATION	Recruitment of the SH2 domain containing cytoplasmic protein-tyrosine phosphatase SHP-1 to the membrane by somatostatin (SST) is an early event in its antiproliferative signaling that induces intracellular acidification-dependent apoptosis in breast cancer cells. Fas ligation also induces acidification-dependent apoptosis in a manner requiring the presence of SHP-1 at the membrane. Moreover, we have recently reported that SRP-I is required not only for acidification, but also for apoptotic events that follow acidification (Thangaraju, M., Sharma, K., Liu, D., Shen, S. H., and Srikant, C. B. (1999) Cancer Res. 59, 1649-1654). Here we show that ectopically expressed SHP-1 was predominantly membrane-associated and amplified the cytotoxic signaling initiated upon SST receptor activation and Fas ligation. The catalytically inactive mutant of SHP-1 (SHP-1C455S) abolished the ability of the SST agonists to signal apoptosis by preventing the recruitment of wild type SHP-1 to the membrane. Overexpression of the anti-apoptotic protein Bcl-2 in MCF-7 cells inhibited SST-induced apoptosis upstream of acidification by inhibiting p53-dependent induction of Bax as well as by raising the resting pH(i) and attenuating SST-induced decrease in pH. By contrast, Bcl-2 failed to prevent apoptosis triggered by direct acidification. These data demonstrate that (i) membrane-associated SHP-1 is required for receptor-mediated cytotoxic signaling that causes intracellular acidification and apo ptosis, and (ii) Bcl-2 acts distal to SHP-1 and p53 to prevent SST-induced acidification but cannot inhibit the apoptotic events that ensue intracellular acidification.	Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 325, Canada; McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON L8N 325, Canada; Natl Res Council Canada, Biotechnol Res Inst, Pharmacol Sector, Montreal, PQ H4P 2R2, Canada	McGill University; Royal Victoria Hospital; McGill University; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; National Research Council Canada	Srikant, CB (corresponding author), Royal Victoria Hosp, M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARRY MA, 1993, CANCER RES, V53, P2349; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; BIERY M, 1998, P NATL ACAD SCI USA, V95, P2446; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CANDI E, 1995, CANCER LETT, V96, P141, DOI 10.1016/0304-3835(95)03924-L; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; FLORIO T, 1992, J BIOL CHEM, V267, P24169; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Furlong IJ, 1997, J CELL SCI, V110, P653; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kim CN, 1997, CANCER RES, V57, P3115; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; Sakakura C, 1997, SURG TODAY, V27, P676, DOI 10.1007/BF02388231; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Sakakura C, 1997, SURG TODAY, V27, P90, DOI 10.1007/BF01366949; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sharma K, 1998, INT J CANCER, V76, P259, DOI 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7; Sharma K, 1998, BIOCHEM BIOPH RES CO, V242, P134, DOI 10.1006/bbrc.1997.7933; Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688; SHEARD MA, 1997, INT J CANCER, V737, P57; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SRIKANT CB, 1995, BIOCHEM BIOPH RES CO, V209, P400, DOI 10.1006/bbrc.1995.1517; Srikant CB, 1996, ENDOCRINOLOGY, V137, P3461, DOI 10.1210/en.137.8.3461; Su X, 1996, J IMMUNOL, V156, P4198; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Takayama H, 1996, J IMMUNOL, V157, P3943; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Thangaraju M, 1999, CANCER RES, V59, P1649; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG J, 1997, SCIENCE, V275, P1126; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zanke BW, 1998, CANCER RES, V58, P2801; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	80	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29549	29557		10.1074/jbc.274.41.29549	http://dx.doi.org/10.1074/jbc.274.41.29549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506221	hybrid			2022-12-25	WOS:000083017800100
J	Turko, IV; Francis, SH; Corbin, JD				Turko, IV; Francis, SH; Corbin, JD			Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; LIGAND-BINDING; CATALYTIC DOMAIN; PROTEIN-KINASE; AMINO-ACIDS; ANALOGS; SUBSTRATE; LIVER	The regulatory domain of the cGMP-binding cGMP-specific 3':5'-cyclic nucleotide phosphodiesterase (PDE5) contains two homologous segments of amino acid sequence that encode alllosteric cyclic nucleotide-binding sites, referred to as site a and site b, which are highly selective for cGMP over cAMP. The possibility that the state of protonation in these sites contributes to cyclic nucleotide selectivity was investigated. The binding of cGMP or cAMP was determined using saturation and competition kinetics at pH values between 5.2 and 9.5. The total cGMP binding by PDES was unchanged by variation in pH, but the relative affinity for cGMP versus cAMP progressively decreased as the pH was lowered. Using site-directed mutagenesis, a conserved residue, Asp-289, in site a of PDE5 has been identified as being important for cyclic nucleotide discrimination in this site. It is proposed that deprotonation of Asp-289 enhances the number and strength of bonds formed with cGMP, while concomitantly decreasing the interactions with cAMP.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	jackie.corbin@mcmail.vanderbilt.edu						ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DSOUZA UM, 1995, BIOCHEMISTRY-US, V34, P13635, DOI 10.1021/bi00041a044; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ERNEUX C, 1985, J CYCLIC NUCL PROT, V10, P463; Gordon SE, 1996, BIOCHEMISTRY-US, V35, P3994, DOI 10.1021/bi952607b; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HASCHENMEYER RH, 1974, PROTEINS GUIDE STUDY, P266; Hebert MC, 1998, J BIOL CHEM, V273, P5557, DOI 10.1074/jbc.273.10.5557; LLEWELLYN LE, 1994, BIOCHEMISTRY-US, V33, P12312, DOI 10.1021/bi00206a039; LOUGHNEY K, 1999, GENE, V216, P139; MANGANIELLO VC, 1990, MOL PHARM CELL REGUL, V2, P61; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MOSS J, 1977, J BIOL CHEM, V252, P5211; PETTIGREW DW, 1979, J BIOL CHEM, V254, P1887; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEM J, V329, P505; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526	26	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29038	29041		10.1074/jbc.274.41.29038	http://dx.doi.org/10.1074/jbc.274.41.29038			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506154	hybrid			2022-12-25	WOS:000083017800033
J	Zumbihl, R; Aepfelbacher, M; Andor, A; Jacobi, CA; Ruckdeschel, H; Rouot, B; Heesemann, J				Zumbihl, R; Aepfelbacher, M; Andor, A; Jacobi, CA; Ruckdeschel, H; Rouot, B; Heesemann, J			The cytotoxin YopT of Yersinia enterocolitica induces modification and cellular redistribution of the small GTP-binding protein RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLATION; EFFECTOR PROTEIN; FOCAL ADHESIONS; CELLS; VIRULENCE; KINASE; RAS; PHOSPHORYLATION; IDENTIFICATION; GLUCOSYLATION	Pathogenic Yersinia enterocolitica produces two virulence plasmid-encoded cytotoxins, YopE and YopT, that are translocated into target cells where they disrupt the actin cytoskeleton. Here we show that infection of cells with wild type Y. enterocolitica and a yopE mutant, but not with a yopT mutant, induces an increase in the electrophoretic mobility of the small. GTPase RhoA As tested by isoelectric focusing, YopT-dependent modification resulted in an acidic shift of RhoA. Furthermore, RhoA modification induced by YopT was accompanied by redistribution of membrane-bound RhoA toward the cytosol, Finally, a yopE mutant of Y, enterocolitica expressing the cytotoxic activity of YopT specifically disrupted RhoA-controlled actin stress fibers. These findings provide evidence for inactivation of RhoA by the translocated Y. enterocolitica cytotoxin YopT and suggest a novel inhibitory modification of RhoA by a bacterial virulence factor.	Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; Univ Montpellier 2, INSERM, U431, F-34095 Montpellier, France	University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Zumbihl, R (corresponding author), Max Von Pettenkofer Inst Hyg & Med Microbiol, Pettenkoferstr 9A, D-80336 Munich, Germany.	aepfelbacher@m3401.mpk.med.uni-muenchen.de						Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Anderson DM, 1999, CURR OPIN MICROBIOL, V2, P18, DOI 10.1016/S1369-5274(99)80003-4; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Gorg A, 1994, CELL BIOL LABORATORY, P231; HAAS R, 1993, GENE, V130, P23, DOI 10.1016/0378-1119(93)90342-Z; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V48, P229, DOI 10.1016/0378-1097(87)90167-4; HEESEMANN J, 1986, INFECT IMMUN, V54, P561, DOI 10.1128/IAI.54.2.561-567.1986; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; Immler D, 1998, ELECTROPHORESIS, V19, P1015, DOI 10.1002/elps.1150190617; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Pederson KJ, 1999, MOL MICROBIOL, V32, P393, DOI 10.1046/j.1365-2958.1999.01359.x; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173	35	124	128	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29289	29293		10.1074/jbc.274.41.29289	http://dx.doi.org/10.1074/jbc.274.41.29289			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506187	hybrid			2022-12-25	WOS:000083017800066
J	Duncan, MR; Frazier, KS; Abramson, S; Williams, S; Klapper, H; Huang, XF; Grotendorst, GR				Duncan, MR; Frazier, KS; Abramson, S; Williams, S; Klapper, H; Huang, XF; Grotendorst, GR			Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: downregulation by cAMP	FASEB JOURNAL			English	Article						fibrosis; wound repair; granulation tissue; cholera toxin; transgenic	FACTOR GENE-EXPRESSION; ANCHORAGE-INDEPENDENT GROWTH; HUMAN DERMAL FIBROBLASTS; NECROSIS FACTOR-ALPHA; STEADY-STATE LEVELS; NUCLEAR FACTOR-I; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; SYSTEMIC-SCLEROSIS; WOUND REPAIR	Connective tissue growth factor (CTGF) is a cysteine-rich peptide synthesized and secreted by fibroblastic cells after activation with transforming growth factor beta (TGF-beta) that acts as a downstream mediator of TGF-beta-induced fibroblast proliferation. We performed in vitro and in vivo studies to determine whether CTGF is also essential for TGF-beta-induced fibroblast collagen synthesis. lit vitro studies with normal rat kidney (NRK) fibroblasts demonstrated CTGF potently induces collagen synthesis and transfection with an antisense CTGF gene blocked TGF-beta stimulated collagen synthesis. Moreover, TGF-beta-induced collagen synthesis in both NRK and human foreskin fibroblasts was effectively blocked with specific anti-CTGF antibodies and by suppressing TGF-beta-induced CTGF gene expression by elevating: intracellular cAMP levels with either membrane-permeable 8-Br-cAMP or an adenylyl cyclase activator, cholera toxin (CTX). cAMP also inhibited collagen synthesis induced by CTGF itself, in contrast to its previously reported lack of effect on CTGF-induced DNA synthesis. In animal assays, CTX injected intradermally in transgenic mice suppressed TGF-beta activation of a human CTGF promoter/lacZ reporter transgene. Both 8-Br-cAMP and CTX blocked TGF-beta-induced collagen deposition in a wound chamber model of fibrosis in rats. CTX also reduced dermal granulation tissue fibroblast population increases induced by TGF-beta in neonatal mice, but not increases induced by CTGF or TGF-beta com bined with CTGF. Our data indicate that CTGF mediates TGF-beta-induced fibroblast collagen synthesis and that in vivo blockade of CTGF synthesis or action reduces TGF-beta-induced granulation tissue formation by inhibiting both collagen synthesis and fibroblast accumulation.	Univ Miami, Sch Med R124, Dept Anat & Cell Biol, Miami, FL 33136 USA; Cleveland Clin, Ft Lauderdale, FL 33309 USA; FibroGen Inc, S San Francisco, CA 94080 USA	University of Miami; Cleveland Clinic Foundation; FibroGen	Grotendorst, GR (corresponding author), Univ Miami, Sch Med R124, Dept Anat & Cell Biol, 1600 NW 10th Ave, Miami, FL 33136 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037223] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07057-01A1] Funding Source: Medline; NIGMS NIH HHS [GM37223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; BERMAN B, 1992, J INVEST DERMATOL, V98, P706, DOI 10.1111/1523-1747.ep12499916; BERMAN B, 1989, J INVEST DERMATOL, V92, P605, DOI 10.1111/1523-1747.ep12712140; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; CLARK RAF, 1993, J DERMATOL SURG ONC, V19, P693, DOI 10.1111/j.1524-4725.1993.tb00413.x; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P282, DOI 10.1111/1523-1747.ep12612819; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GORDON J, 1992, ILAR NEWS, V34, P45; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; GROTENDORST GR, 1985, J CLIN INVEST, V76, P2323, DOI 10.1172/JCI112243; GROTENDORST GR, 1996, CELL GROWTH DIFFER, V7, P1; HANRAHAN D, 1989, MANIPULATING MOUSE E, P174; HUNT TK, 1967, AM J SURG, V114, P302, DOI 10.1016/0002-9610(67)90388-1; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; KELLY D, 1989, DIFFERENTIATION, V41, P34, DOI 10.1111/j.1432-0436.1989.tb00729.x; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; NAGY P, 1991, HEPATOLOGY, V14, P269, DOI 10.1002/hep.1840140211; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Oemar BS, 1997, CIRCULATION, V95, P831; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Peterson TC, 1996, IMMUNOPHARMACOLOGY, V31, P183, DOI 10.1016/0162-3109(95)00048-8; Preaux AM, 1997, HEPATOLOGY, V26, P315, DOI 10.1002/hep.510260210; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SCHILLING JA, 1959, SURGERY, V46, P702; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SMITH EA, 1990, J INVEST DERMATOL, V95, pS125, DOI 10.1111/1523-1747.ep12874998; SPORN MB, 1983, SCIENCE, V219, P1329, DOI 10.1126/science.6572416; THALACKER FW, 1992, BIOCHEM J, V287, P855, DOI 10.1042/bj2870855; VADJY M, 1992, IMMUNOLOGY, V75, P488; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WASSARMAN PM, 1992, METHOD ENZYMOL, V225, P459; WEBSTER DF, 1979, ANAL BIOCHEM, V96, P220, DOI 10.1016/0003-2697(79)90576-1	54	521	590	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1774	1786		10.1096/fasebj.13.13.1774	http://dx.doi.org/10.1096/fasebj.13.13.1774			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506580				2022-12-25	WOS:000083063400012
J	Gardiol, D; Kuhne, C; Glaunsinger, B; Lee, SS; Javier, R; Banks, L				Gardiol, D; Kuhne, C; Glaunsinger, B; Lee, SS; Javier, R; Banks, L			Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation	ONCOGENE			English	Article						HPV E6; DLG; proteasome; transformation	CERVICAL-CANCER; PDZ DOMAINS; HPV-18 E6; GUANYLATE KINASES; HUMAN HOMOLOG; GENE-PRODUCT; IN-VIVO; BINDING; P53; INHIBITION	Previous studies have shown that the oncogenic HPV E6 proteins form a complex with the human homologue of the Drosophila tumour suppressor protein, discs large (Dlg), This is mediated by the carboxy terminus of the E6 proteins and involves recognition of at least one PDZ domain of Dig, This region of E6 is not conserved amongst E6 proteins from the low risk papillomavirus types and, hence, binding of HPV E6 proteins to Dig correlates with the oncogenic potential of these viruses. We have performed studies to investigate the consequences of the interaction between E6 and Dig, Mutational analysis of both the HPV18 E6 and Dig proteins has further defined the regions of E6 and Dig necessary for complex formation. Strikingly, co-expression of wild type HPV18 E6 with Dig in vitro or in vivo results in a dramatic decrease in the amount of Dig protein, whereas mutants of E6 which fail to complex with Dig have minimal effect on Dig protein levels. The oncogenic HPV16 E6 also decreased the Dig levels, but this was not observed with the low risk HPV11 E6 protein. Moreover, a region within the first 544 amino acids of Dig containing the three PDZ domains confers susceptibility to E6 mediated degradation. Finally, treatment of cells with a proteasome inhibitor overrides the capacity of E6 to degrade Dig, These results demonstrate that Dig is targeted by high risk HPV E6 proteins for proteasome mediated degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58541, R01 CA058541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCO EL, 1992, CANCER EPIDEM BIOMAR, V1, P499; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PIM D, 1994, ONCOGENE, V9, P1869; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	40	239	250	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5487	5496		10.1038/sj.onc.1202920	http://dx.doi.org/10.1038/sj.onc.1202920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523825				2022-12-25	WOS:000082894700001
J	El Nemer, W; Colin, Y; Bauvy, C; Codogno, P; Fraser, RH; Cartron, JP; Le van Kim, C				El Nemer, W; Colin, Y; Bauvy, C; Codogno, P; Fraser, RH; Cartron, JP; Le van Kim, C			Isoforms of the lutheran/basal cell adhesion molecule glycoprotein are differentially delivered in polarized epithelial cells - Mapping of the basolateral sorting signal to a cytoplasmic di-leucine motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; POLYMERIC IMMUNOGLOBULIN RECEPTOR; BLOOD-GROUP GLYCOPROTEIN; LU-A/LU-B; MDCK CELLS; SURFACE GLYCOPROTEIN; CLATHRIN ADAPTERS; GROUP ANTIGENS; TYROSINE; BINDING	Lu and Lu(v13) are two glycoprotein (gp) isoforms that belong to the immunoglobulin superfamily and carry both the Lutheran (Lu) blood group antigens and the basal cell adhesion molecule epithelial cancer antigen. Lu (85 kDa) and Lu(v13) (78 kDa) gps, which differ only in the length of their cytoplasmic domain, are adhesion molecules that bind laminin. In nonerythroid tissues, the Lu/basal cell adhesion molecule antigens are predominantly expressed in the endothelium of blood vessel walls and in the basement membrane region of normal epithelial cells, whereas they exhibit a nonpolarized expression in some epithelial cancers. Here, we analyzed the polarization of Lu and Lu(v13) gps in epithelial cells by confocal microscopy and domain-selective biotinylation assays. Differentiated human colon carcinoma Caco-2 cells exhibited a polarized expression of endogenous Lu antigens associated with a predominant expression of the Lu isoform at the basolateral domain of the plasma membrane and a very low expression of the Lu(v13) isoform at both the apical and basolateral domains, Analysis of transfected Madin-Darby canine kidney cells revealed a basolateral expression of Lu gp and a nonpolarized expression of Lu(v13) gp, Delivery of Lu(v13) to both apical and basolateral surfaces showed similar kinetics, indicating that this isoform is directly transported to each surface domain. A dileucine motif at position 608-609, specific to the Lu isoform, was characterized as a dominant basolateral sorting signal that prevents Lu gp from taking the apical delivery pathway.	Inst Natl Transfus Sanguine, INSERM U76, F-75015 Paris, France; Hop Paul Brousse, INSERM U504, Villejuif, France; Scottish Natl Blood Transfus Serv, Glasgow G2 5UA, Lanark, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Le van Kim, C (corresponding author), Inst Natl Transfus Sanguine, INSERM U76, 6 Alexandre Cabanel, F-75015 Paris, France.		Nemer, Wassim El/N-4247-2017; Codogno, Patrice/G-1384-2013; colin, yves/O-1910-2017; le van kim, caroline/O-7030-2017	Nemer, Wassim El/0000-0001-8184-427X; Codogno, Patrice/0000-0002-5492-3180; colin, yves/0000-0001-5196-4254; le van kim, caroline/0000-0002-3251-1310				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BUTOR C, 1992, EXP CELL RES, V203, P115, DOI 10.1016/0014-4827(92)90046-B; CAMPBELL IG, 1994, CANCER RES, V54, P5761; CHESAGARIN P, 1994, INT J ONCOL, V5, P1261; DANIELS G, 1989, VOX SANG, V57, P137, DOI 10.1111/j.1423-0410.1989.tb01151.x; El Nemer W, 1998, J BIOL CHEM, V273, P16686; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; Gut A, 1998, J BIOL CHEM, V273, P29381, DOI 10.1074/jbc.273.45.29381; HANZEL D, 1991, CELL BIOL, V2, P341; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; INGLIS G, 1993, TRANSFUS MED S, V3, P94; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Parsons SF, 1997, BLOOD, V89, P4219, DOI 10.1182/blood.V89.11.4219; PARSONS SF, 1987, TRANSFUSION, V27, P61, DOI 10.1046/j.1537-2995.1987.27187121477.x; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PINTO M, 1983, BIOL CELL, V47, P323; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Rahuel C, 1996, BLOOD, V88, P1865; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Reich V, 1996, J CELL SCI, V109, P2133; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YURCHENKO PD, 1993, MOL CELLULAR ASPECTS, P121; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728	46	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31903	31908		10.1074/jbc.274.45.31903	http://dx.doi.org/10.1074/jbc.274.45.31903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542217	hybrid			2022-12-25	WOS:000083532100025
J	Cote, F; Do, TH; Laflamme, L; Gallo, JM; Gallo-Payet, N				Cote, F; Do, TH; Laflamme, L; Gallo, JM; Gallo-Payet, N			Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; BETA-TUBULIN ISOTYPE; ADULT-RAT BRAIN; TYPE-2 RECEPTOR; GRANULE CELLS; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; CONVERTING ENZYME; BLOOD-PRESSURE; PC12W CELLS	Microexplant cultures from three-day-old rats were used to investigate whether angiotensin II (Ang II), through its AT(1) and AT(2) receptors, could be involved in the morphological differentiation of cerebellar cells. Specific activation of the AT(2) receptor during 4-day treatment induced two major morphological changes. The first was characterized by increased elongation of neurites. The second change was cell migration from the edge of the microexplant toward the periphery. Western blot analyses and indirect immuno fluorescence studies revealed an increase in the expression of neuron-specific beta III-tubulin, as well as an increase in expression of the microtubule-associated proteins tau and MAP2. These effects were demonstrated by co-incubation of Ang II with 1 mu M DUP 753 (AT(1) receptor antagonist) or with 10 nM CGP 42112 (AT(2) receptor agonist) but abolished when Ang II was co-incubated with 1 mu M PD 123319 (AT(2) receptor antagonist), indicating that differentiation occurs through AT(2) receptor activation and that the AT(1) receptor inhibits the AT(2) effect. Taken together, these results demonstrate that Ang II is involved in cerebellum development for both neurite outgrowth and cell migration, two important processes in the organization of the various layers of the cerebellum.	Univ Sherbrooke, Fac Med, Serv Endocrinol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Neurosurg, Sherbrooke, PQ J1H 5N4, Canada; Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London SE5 8AF, England	University of Sherbrooke; University of Sherbrooke; University of London; King's College London	Gallo-Payet, N (corresponding author), Univ Sherbrooke, Fac Med, Serv Endocrinol, Sherbrooke, PQ J1H 5N4, Canada.	ngallo01@courrier.ushorb.ca		Gallo, Jean-Marc/0000-0003-0214-4545				AVILA J, 1994, INT J DEV BIOL, V38, P13; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; Breault L, 1996, J CLIN ENDOCR METAB, V81, P3914, DOI 10.1210/jc.81.11.3914; BRILLA CG, 1994, J MOL CELL CARDIOL, V26, P809, DOI 10.1006/jmcc.1994.1098; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; BURGOYNE RD, 1984, NEUROSCIENCE, V11, P157, DOI 10.1016/0306-4522(84)90220-3; BURGOYNE RD, 1988, EMBO J, V7, P2311, DOI 10.1002/j.1460-2075.1988.tb03074.x; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CAMBRAYDEAKIN MA, 1987, DEV BRAIN RES, V37, P197, DOI 10.1016/0165-3806(87)90241-0; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CHAI SY, 1987, NEUROSCIENCE, V20, P615; CONNOR JA, 1987, J NEUROSCI, V7, P1384; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; Erdmann B, 1996, HYPERTENSION, V28, P818, DOI 10.1161/01.HYP.28.5.818; Ferguson AV, 1998, PROG NEUROBIOL, V54, P169, DOI 10.1016/S0301-0082(97)00065-8; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; FUXE K, 1980, NEUROSCI LETT, V18, P245, DOI 10.1016/0304-3940(80)90292-X; Gallinat S, 1997, NEUROSCI LETT, V227, P29, DOI 10.1016/S0304-3940(97)00291-7; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; Gendron L, 1998, ENDOCR RES, V24, P409, DOI 10.3109/07435809809032623; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; JIANG YQ, 1992, J CELL SCI, V103, P643; JOHNSON JE, 1995, METHOD CELL BIOL, V46, P243; Johren O, 1996, NEUROREPORT, V7, P1349; Johren O, 1998, BRAIN RES, V793, P176, DOI 10.1016/S0006-8993(98)00170-X; Johren O, 1995, NEUROREPORT, V6, P2549; KANG J, 1992, BRAIN RES, V580, P317, DOI 10.1016/0006-8993(92)90960-H; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; Komuro H, 1998, J NEUROSCI, V18, P1478; Komuro H, 1996, NEURON, V17, P275, DOI 10.1016/S0896-6273(00)80159-2; Laferriere NB, 1997, BIOCHEM CELL BIOL, V75, P103, DOI 10.1139/bcb-75-2-103; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lenkei Z, 1996, J COMP NEUROL, V373, P322, DOI 10.1002/(SICI)1096-9861(19960923)373:3<322::AID-CNE2>3.0.CO;2-4; Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MOONEN G, 1982, DEV BRAIN RES, V5, P59, DOI 10.1016/0165-3806(82)90113-4; Munzenmaier DH, 1996, HYPERTENSION, V27, P760, DOI 10.1161/01.HYP.27.3.760; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; PRZYBORSKI SA, 1995, DEV BRAIN RES, V89, P187, DOI 10.1016/0165-3806(95)00117-V; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; ROCAMORA N, 1993, MOL BRAIN RES, V17, P1, DOI 10.1016/0169-328X(93)90065-W; Schutz S, 1996, AM J PATHOL, V149, P2067; SEGAL RA, 1995, J NEUROSCI, V15, P4970; Shenoy UV, 1999, ENDOCRINOLOGY, V140, P500, DOI 10.1210/en.140.1.500; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TANAKA M, 1995, BIOCHEM BIOPH RES CO, V207, P593, DOI 10.1006/bbrc.1995.1229; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; Tsuzuki S, 1996, BIOCHEM BIOPH RES CO, V228, P825, DOI 10.1006/bbrc.1996.1739; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Yoshimura Y, 1996, ENDOCRINOLOGY, V137, P1204, DOI 10.1210/en.137.4.1204; Yu K, 1996, ENDOCRINOLOGY, V137, P2503, DOI 10.1210/en.137.6.2503	62	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31686	31692		10.1074/jbc.274.44.31686	http://dx.doi.org/10.1074/jbc.274.44.31686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531378	hybrid			2022-12-25	WOS:000083379400082
J	Lauvau, G; Gubler, B; Cohen, H; Daniel, S; Caillat-Zucman, S; van Endert, PM				Lauvau, G; Gubler, B; Cohen, H; Daniel, S; Caillat-Zucman, S; van Endert, PM			Tapasin enhances assembly of transporters associated with antigen processing-dependent and -independent peptides with HLA-A2 and HLA-B27 expressed in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HISTOCOMPATIBILITY COMPLEX ANTIGENS; ENDOPLASMIC-RETICULUM; REVEALS POLYMORPHISM; MOLECULAR CHAPERONES; SURFACE EXPRESSION; TAP TRANSPORTERS; HEAVY-CHAIN; LINE .220; T-CELL	Assembly of HLA class I-peptide complexes is assisted by multiple proteins that associate with HLA molecules in loading complexes. These include the housekeeping chaperones calnexin and calreticulin and two essential proteins, the transporters associated with antigen processing (TAP) for peptide supply, and the protein tapasin which is thought to act as a specialized chaperone. We dissected functional effects of processing cofactors by co-expressing in insect cells various combinations of the human proteins HLA-A2, HLA-B27, beta(2)-microglobulin, TAP, calnexin, calreticulin, and tapasin, Stability at 37 degrees C and surface expression of class I dimers correlated closely in baculovirus-infected Sf9 cells, suggesting that these cells retain empty dimers in the endoplasmic reticulum, Both HLA molecules form substantial quantities of stable complexes with insect cell-produced peptide pools. These pools are TAP-selected cytosolic peptides for HLA-B27 but endoplasmic reticulum-derived, i.e. TAP-independent peptides for HLA-A2. This discrepancy may be due to peptide selection by human TAP which is much better adapted to the HLA-B27 than to the HLA-A2 ligand preferences. HLA class I assembly with peptides from TAP-dependent and -independent pools was enhanced strongly by tapasin, Thus, tapasin acts as a chaperone and/or peptide editor that facilitates assembly of peptides with HLA class I molecules independently of mediating their interaction with TAP and/or retention in the endoplasmic reticulum.	Hop Necker Enfants Malad, INSERM U25, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	van Endert, PM (corresponding author), Hop Necker Enfants Malad, INSERM U25, 161 Rue Sevres, F-75743 Paris 15, France.		Gubler, Brigitte/D-9479-2018; van Endert, Peter/R-4606-2017	van Endert, Peter/0000-0003-3782-0750; Caillat-Zucman, Sophie/0000-0002-4535-3550				ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; Bach JM, 1997, J AUTOIMMUN, V10, P375, DOI 10.1006/jaut.1997.0143; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Benham AM, 1998, J IMMUNOL, V161, P83; CARRENO BM, 1995, J IMMUNOL, V155, P4726; Copeman J, 1998, EUR J IMMUNOL, V28, P3783, DOI 10.1002/(SICI)1521-4141(199811)28:11<3783::AID-IMMU3783>3.0.CO;2-9; Daniel S, 1997, J IMMUNOL, V159, P2350; Daniel S, 1998, J IMMUNOL, V161, P617; Deng YP, 1998, J IMMUNOL, V161, P1677; GODEAU F, 1992, INT IMMUNOL, V4, P265, DOI 10.1093/intimm/4.2.265; Grandea AG, 1998, IMMUNOGENETICS, V48, P260, DOI 10.1007/s002510050430; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; Harris MR, 1998, J IMMUNOL, V160, P5404; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; LEVY F, 1990, INT IMMUNOL, V2, P995, DOI 10.1093/intimm/2.10.995; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 1999, J BIOL CHEM, V274, P8649, DOI 10.1074/jbc.274.13.8649; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Marusina K, 1997, BIOCHEMISTRY-US, V36, P856, DOI 10.1021/bi9619738; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; Neisig A, 1996, J IMMUNOL, V156, P3196; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; SCOTT JE, 1995, J IMMUNOL, V155, P143; SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1; Simmons WA, 1997, IMMUNITY, V7, P641, DOI 10.1016/S1074-7613(00)80385-4; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Solheim JC, 1997, J IMMUNOL, V158, P2236; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WANG J, 1994, J IMMUNOL, V152, P1197; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YellenShaw AJ, 1997, J EXP MED, V186, P1655, DOI 10.1084/jem.186.10.1655; Zhang Q, 1998, J IMMUNOL, V160, P831	68	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31349	31358		10.1074/jbc.274.44.31349	http://dx.doi.org/10.1074/jbc.274.44.31349			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531335	hybrid			2022-12-25	WOS:000083379400039
J	Sebastian, S; White, JA; Wilson, JE				Sebastian, S; White, JA; Wilson, JE			Characterization of the rat type III hexokinase gene promoter - A functional Octamer 1 motif is critical for basal promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN TRANSCRIPTION FACTORS; POU-DOMAIN; BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; EXPRESSION; ISOZYMES; PURIFICATION; MITOCHONDRIA; LOCALIZATION; ELEMENTS	A 1532-base pair 5'-flanking region of the gene encoding rat type Ill hexokinase has been cloned and sequenced. The total sequence includes positions -1548 to -17 (A of the translational start ATG; as position +1). Using luciferase reporter constructs transfected into PC12 (rat pheochromocytoma) and L2 (rat lung) cells, basal promoter activity has been associated with sequence between -182 and -89. This includes a single transcriptional start site, an adenine at position -134 identified by primer extension. Together with previously cloned cDNA sequence, this accounts for an mRNA of approximately 3.9 kilobases, found by Northern blotting of RNA from rat lung and kidney. Sequence upstream of the transcriptional start site was devoid of canonical TATA and CAAT elements, An octamer 1 (Oct-1) binding site, located between positions -166 and -159 was shown by deletion analysis and site-directed mutation to be critical for promoter activity. Nuclear extracts from PC12 cells contained a protein (or proteins) specifically binding the octamer sequence, and supershift experiments with anti-Oct-1 indicated involvement of this ubiquitously expressed transcription factor in the complex. Sequence including the Oct-1 site and immediately adjacent regions was protected from DNase I digestion in footprinting experiments with nuclear extracts from PC12 cells. Reverse transcription polymerase chain reaction indicated that levels of type IPI hexokinase mRNA in rat tissues increased in the order brain < liver < lung approximate to kidney; immunoblotting indicated that type III hexokinase protein in these tissues increased in a similar manner.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Wilson, JE (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	WILSONJ@PILOT.MSU.EDU			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009910] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 09910] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL320, DOI 10.1152/ajplung.1998.274.3.L320; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAS G, 1993, J BIOL CHEM, V268, P25026; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; ICHIHARA J, 1995, BBA-GENE STRUCT EXPR, V1260, P365, DOI 10.1016/0167-4781(94)00226-S; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; JAFFE J, 1995, BBA-GENE STRUCT EXPR, V1261, P201, DOI 10.1016/0167-4781(94)00246-Y; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZENELLENBOGE.WM, 1959, CLIN CHIM ACTA, V4, P515; KUROKAWA M, 1982, MOL CELL BIOCHEM, V45, P151; LEWIN B, 1997, GENES, V6, P823; Liu WJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P142, DOI 10.1006/abbi.1997.0295; Malkki M, 1997, DIABETOLOGIA, V40, P1461, DOI 10.1007/s001250050850; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sui DX, 1997, ARCH BIOCHEM BIOPHYS, V345, P111, DOI 10.1006/abbi.1997.0241; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Tsai HJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P183, DOI 10.1006/abbi.1996.9850; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WHALLON JH, 1994, SCANNING, V16, P111; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093	36	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31700	31706		10.1074/jbc.274.44.31700	http://dx.doi.org/10.1074/jbc.274.44.31700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531380	hybrid			2022-12-25	WOS:000083379400084
J	Suzuki, T; Ichiyama, A; Saitoh, H; Kawakami, T; Omata, M; Chung, CH; Kimura, M; Shimbara, N; Tanaka, K				Suzuki, T; Ichiyama, A; Saitoh, H; Kawakami, T; Omata, M; Chung, CH; Kimura, M; Shimbara, N; Tanaka, K			A new 30-kDa ubiquitin-related SUMO-1 hydrolase from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; PROTEINS; CONJUGATION; RANGAP1; MODIFIER; RANBP2	SUMO-1 is a ubiquitin-like protein functioning as an important reversible protein modifier. To date there is no report on a SUMO-1 hydrolase/isopeptidase catalyzing the release of SUMO-1 from its precursor or SUMO-1-ligated proteins in mammalian tissues. Here we found multiple activities that cleave the SUMO-1 moiety from two model substrates, I-125-SUMO-1-alpha NH-HSTVG-SMHISPPEPESEEEEEHYC and/or GST-SUMO-1-S-35-RanGAP1 conjugate, in bovine brain extracts. Of them, a major SUMO-1 C-terminal hydrolase had been partially purified by successive chromatographic operations. The enzyme had the ability to cleave SUMO-1 not only from its precursor but also from a SUMO-1-ligated RanGAP1 but did not exhibit any significant cleavage of the ubiquitin- and NEDD8-precursor, The activity of SUMO-1 hydrolase was almost completely inhibited by N-ethylmaleimide, but not by phenylmethanesulfonyl fluoride, EDTA, and ubiquitin-aldehyde known as a potent inhibitor of deubiquitinylating enzymes. Intriguingly, the apparent molecular mass of the isolated SUMO-1 hydrolase was approximately 30 kDa, which is significantly smaller than the recently identified yeast Smt3/SUMO-1 specific protease Ulp1. These results indicate that there are multiple SUMO-1 hydrolase/isopeptidases in mammalian cells and that the 30-kDa small SUMO-1 hydrolase plays a central role in processing of the SUMO-1-precursor.	Tokyo Metropolitian Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan; Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka 4313192, Japan; Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Seoul Natl Univ, Coll Nat Sci, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Coll Nat Sci, Res Ctr Cell Differentiat, Seoul 151742, South Korea; Sumitomo Elect Ind Ltd, Biomed Res & Dev Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	Hamamatsu University School of Medicine; University of Tokyo; Seoul National University (SNU); Seoul National University (SNU); Sumitomo Electric Industries; Northwell Health	Tanaka, K (corresponding author), Tokyo Metropolitian Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1130021, Japan.	tanakak@rinshoken.or.jp		Suzuki, Toshiaki/0000-0002-0650-6251				Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAWAKAMI T, 1999, IN PRESS J BIOCH; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanaka K, 1998, MOL CELLS, V8, P503; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766	21	64	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31131	31134		10.1074/jbc.274.44.31131	http://dx.doi.org/10.1074/jbc.274.44.31131			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531301	Green Submitted, hybrid			2022-12-25	WOS:000083379400005
J	Almeida, PC; Nantes, IL; Rizzi, CCA; Judice, WAS; Chagas, JR; Juliano, L; Nader, HB; Tersariol, ILS				Almeida, PC; Nantes, IL; Rizzi, CCA; Judice, WAS; Chagas, JR; Juliano, L; Nader, HB; Tersariol, ILS			Cysteine proteinase activity regulation - A possible role of heparin and heparin-like glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-B; SULFATE PROTEOGLYCANS; BINDING-SITE; PAPAIN; INHIBITION; RESOLUTION; CONSTANT; MEMBRANE; PEPTIDE; PH	Papain is considered to be the archetype of cysteine proteinases. The interaction of heparin and other glycosaminoglycans with papain may be representative of many mammalian cysteine proteinase-glycosaminoglycan interactions that can regulate the function of this class of proteinases in vivo. The conformational changes in papain structure due to glycosaminoglycan interaction were studied by circular dichroism spectroscopy, and the changes in enzyme behavior were studied by kinetic analysis, monitored with fluorogenic substrate. The presence of heparin significantly increases the a-helix content of papain. Heparin binding to papain was demonstrated by affinity chromatography and shown to be mediated by electrostatic interactions. The incubation of papain with heparin promoted a powerful increase in the affinity of the enzyme for the substrate. In order to probe the glycosaminoglycan structure requirements for the papain interaction, the effects of two other glycosaminoglycans were tested. Like heparin, heparan sulfate, to a lesser degree, was able to decrease the papain substrate affinity, and it simultaneously induced a-helix structure in papain. On the other hand, dermatan sulfate was not able to decrease the substrate affinity and did not induce a-helix structure in papain. Heparin stabilizes the papain structure and thereby its activity at alkaline pH.	Univ Mogi Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Biomed, BR-08780911 Mogi Das Cruzes, SP, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Inst Nacl Farmacol, Dept Biofis, BR-04044020 Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Inst Nacl Farmacol, Disciplina Biol Mol, BR-04044020 Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Tersariol, ILS (corresponding author), Univ Mogi Cruzes, Ctr Interdisciplinar Invest Bioquim, Ctr Ciencias Biomed, Predoio 2,Sala 22-09,Av Dr Candido X Almeida So, BR-08780911 Mogi Das Cruzes, SP, Brazil.		Dos Santos Tersariol, Ivarne Luis/G-4042-2012; de Almeida, Paulo C/D-8285-2014; Nader, Helena Bonciani/D-9253-2012; Nantes, Iseli Lourenço/B-9517-2012; DE SOUZ A S JUDICE, WAGNER ALVES/O-1050-2013; Juliano, Luiz/D-7204-2012; de Almeida, Paulo/D-4794-2012; DE SOUZA JUDICE, WAGNER ALVES/AAG-3225-2020; Chagas, Jair R/A-1701-2012; Chagas, Jair Ribeiro/AFV-6501-2022	Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; de Almeida, Paulo C/0000-0002-5136-5152; Nantes, Iseli Lourenço/0000-0003-1434-3154; DE SOUZ A S JUDICE, WAGNER ALVES/0000-0002-1608-9105; Juliano, Luiz/0000-0002-5589-2822; Chagas, Jair R/0000-0002-0357-8276; Chagas, Jair Ribeiro/0000-0002-0357-8276; NADER, HELENA/0000-0002-7569-2166				BAKER EN, 1987, BIOL MACROMOLECULES; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Conrad H. E., 1998, HEPARIN BINDING PROT; Dalet-Fumeron V, 1998, ARCH BIOCHEM BIOPHYS, V358, P283, DOI 10.1006/abbi.1998.0868; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; DUFOUR E, 1988, BIOCHIM BIOPHYS ACTA, V995, P58; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; FERRAN DS, 1992, BIOCHEMISTRY-US, V31, P5010, DOI 10.1021/bi00136a014; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GINEC N, 1992, FEBS LETT, V24, P305; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KATUNUMA N, 1989, INTRACELLULAR PROTEO; Lalmanach G, 1998, J BIOL CHEM, V273, P25112, DOI 10.1074/jbc.273.39.25112; LELLOUCH AC, 1992, BIOCHEMISTRY-US, V31, P2279, DOI 10.1021/bi00123a010; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; Moin K, 1998, BIOL CHEM, V379, P1093, DOI 10.1515/bchm.1998.379.8-9.1093; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; NADER HB, 1998, HEPARIN CHEM BIOL PR; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; POLGAR L, 1989, MECH PROTEASE ACTION; SHEAHAN K, 1989, CANCER RES, V49, P3809; Sloane B F, 1988, Adv Exp Med Biol, V233, P259; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; SOLISMENDIOLA S, 1992, BIOCHIM BIOPHYS ACTA, V1118, P288, DOI 10.1016/0167-4838(92)90286-M; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TURK B, 1994, BIOCHEMISTRY-US, V33, P14800, DOI 10.1021/bi00253a019; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk B, 1997, BIOL CHEM, V378, P141; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; YAMAMOTO D, 1991, J BIOL CHEM, V266, P14771; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	43	51	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30433	30438		10.1074/jbc.274.43.30433	http://dx.doi.org/10.1074/jbc.274.43.30433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521421	hybrid			2022-12-25	WOS:000083276700017
J	Bartkiewicz, M; Houghton, A; Baron, R				Bartkiewicz, M; Houghton, A; Baron, R			Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl - A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; PROTOONCOGENE PRODUCT P120(CBL); CELL ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELLS; SIGNALING PATHWAYS; EGF RECEPTOR; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; 2-HYBRID SYSTEM	The 120-kDa proto-oncogenic protein c-Cbl is a multidomain adaptor protein that is phosphorylated in response to the stimulation of a broad range of cell surface receptors and participates in the assembly of signaling complexes that are formed as a result of the activation of various signal transduction pathways. Several structural features of c-Cbl, including the phosphotyrosine-binding domain, proline-rich domain, and motifs containing phosphotyrosine and phosphoserine residues, mediate the association of c-Cbl with other components of these complexes. In addition to those domains that have been demonstrated to play a role in the binding of c-Cbl to other signaling molecules, c-Cbl also contains a RING finger motif and a putative leucine zipper. In this study, we demonstrate that the previously identified putative leucine zipper mediates the formation of Cbl homodimers. Using the yeast two-hybrid system, we show that deletion of the leucine zipper domain is sufficient to abolish Cbl homodimerization, while Cbl mutants carrying extensive N-terminal truncations retain the ability to dimerize with the full-length Cbl, The requirement of the leucine zipper for the homodimerization of Cbl was confirmed by in vitro binding assays, using deletion variants of the C-terminal half of Cbl with and without the leucine zipper domain, and in cells using Myc and green fluorescent protein (GFP) N-terminal-tagged Cbl variants. In cells, the deletion of the leucine zipper caused a decrease in both the tyrosine phosphorylation of Cbl and its association with the epidermal growth factor receptor following stimulation with epidermal growth factor, thus demonstrating a role for the leucine zipper in c-Cbl's signaling functions. Thus, the leucine zipper domain enables c-Cbl to homodimerize, and homodimerization influences Cbl's signaling function, modulating the activity of Cbl itself and/or affecting Cbl's associations with other signaling proteins in the cell.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06510 USA	Yale University; Yale University	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42927] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BLAKE TJ, 1991, ONCOGENE, V6, P653; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MAEKAWA T, 1993, J CELL SCI, V105, P589; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Marengere LEM, 1997, J IMMUNOL, V159, P70; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sattler M, 1996, ONCOGENE, V12, P839; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Tong Q, 1997, J BIOL CHEM, V272, P9043; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Ueno N, 1997, BIOCHEM BIOPH RES CO, V232, P126, DOI 10.1006/bbrc.1997.6229; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	59	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30887	30895		10.1074/jbc.274.43.30887	http://dx.doi.org/10.1074/jbc.274.43.30887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521482	hybrid			2022-12-25	WOS:000083276700078
J	Daff, S; Sagami, I; Shimizu, T				Daff, S; Sagami, I; Shimizu, T			The 42-amino acid insert in the FMN domain of neuronal nitric-oxide synthase exerts control over Ca2+/calmodulin-dependent electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINDING DOMAIN; REDUCTASE DOMAIN; CALMODULIN; HEME; ACTIVATION; MECHANISM; SUBSTRATE; CAVEOLIN; ISOFORMS	The neuronal and endothelial nitric-oxide synthases (nNOS and eNOS) differ from inducible NOS in their dependence on the intracellular Ca2+ concentration. Both nNOS and eNOS are activated by the reversible binding of calmodulin (CaM) in the presence of Ca2+, whereas inducible NOS binds CaM irreversibly. One major divergence in the close sequence similarity between the NOS isoforms is a 40-50-amino acid insert in the middle of the FMN-binding domains of nNOS and eNOS. It has previously been proposed that this insert forms an autoinhibitory domain designed to destabilize CaM binding and increase its Ca2+ dependence. To examine the importance of the insert we constructed two deletion mutants designed to remove the bulk of it from nNOS. Both mutants (Delta 40 and Delta 42) retained maximal NO synthesis activity at lower concentrations of free Ca2+ than the wild type enzyme. They were also found to retain 30% of their activity in the absence of Ca2+/CaM, indicating that the insert plays an important role in disabling the enzyme when the physiological Ca2+ concentration is low. Reduction of nNOS heme by NADPH under rigorous anaerobic conditions was found to occur in the wild type enzyme only in the presence of Ca2+/CaM. However, reduction of heme in the Delta 40 mutant occurred spontaneously on addition of NADPH in the absence of Ca2+/CaM. This suggests that the insert regulates activity by inhibiting electron transfer from FMN to heme in the absence of Ca2+/CaM and by destabilizing CaM binding at low Ca2+ concentrations, consistent with its role as an autoinhibitory domain.	Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	Tohoku University	Daff, S (corresponding author), Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan.			Shimizu, Toru/0000-0002-3950-5554				ABOUSOUD HM, 1995, J BIOL CHEM, V270, P22997; ABOUSOUD HM, 1997, J BIOL CHEM, V272, P17349; ABOUSOUD HM, 1997, BIOCHEMISTRY-US, V36, P10811; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; Louerat-Oriou B, 1998, EUR J BIOCHEM, V258, P1040, DOI 10.1046/j.1432-1327.1998.2581040.x; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Picciotto M R, 1996, Adv Pharmacol, V36, P251, DOI 10.1016/S1054-3589(08)60585-2; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; SAGAMI I, 1998, BIOL NITRIC OXIDE, V6; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHIMIZU T, 1994, J BIOL CHEM, V269, P13296; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	40	113	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30589	30595		10.1074/jbc.274.43.30589	http://dx.doi.org/10.1074/jbc.274.43.30589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521442	hybrid			2022-12-25	WOS:000083276700038
J	Moriguchi, T; Kawachi, K; Kamakura, S; Masuyama, N; Yamanaka, H; Matsumoto, K; Kikuchi, A; Nishida, E				Moriguchi, T; Kawachi, K; Kamakura, S; Masuyama, N; Yamanaka, H; Matsumoto, K; Kikuchi, A; Nishida, E			Distinct domains of mouse dishevelled are responsible for the c-Jun N-terminal kinase/stress-activated protein kinase activation and the axis formation in vertebrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; XENOPUS-EMBRYOS; PLASMA-MEMBRANE; BETA-CATENIN; MAP KINASES; PATHWAYS; POLARITY; STRESS; JNK; IDENTIFICATION	Recent studies have shown that Drosophila Dishevelled (Dsh), an essential component of the wingless signal transduction, is also involved in planar polarity signaling through the c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) pathway in Drosophila. Here, we show that expression of a mouse homolog of Dsh (mDvl-1) in NIH3T3 cells activates JNK/SAPK, and its activator MKK7. A C-terminal half of mDvl-1 which contains the DEP domain was sufficient for the activation of JNK/SAPK, whereas an N-terminal half of mDvl-1 as well as the DEP domain is required for stimulation of the TCF/LEF-1-dependent transcriptional activation, a beta-catenin-dependent process. A single amino acid substitution (Met for Lys) within the DEP domain (mDvl-1 (KM)) abolished the JNK/SAPK-activating activity of mDvl-1, but did not affect the activity to activate the LEF-1-dependent transcription. Ectopic expression of mDvl-1 (KM) or an N-terminal half of mDvl-1, but not the C-terminal, was able to induce secondary axis in Xenopus embryos. Because the secondary axis formation is dependent on the Wnt/beta-catenin signaling pathway, these results suggest that distinct domains of mDvl-1 are responsible for the two downstream signaling pathways, the beta-catenin pathway and the JNK/SAPK pathway in vertebrates.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	Kyoto University; Nagoya University; Japan Science & Technology Agency (JST); Hiroshima University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	35	119	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30957	30962		10.1074/jbc.274.43.30957	http://dx.doi.org/10.1074/jbc.274.43.30957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521491	hybrid			2022-12-25	WOS:000083276700087
J	Tozawa, R; Ishibashi, S; Osuga, J; Yagyu, H; Oka, T; Chen, Z; Ohashi, K; Perrey, S; Shionoiri, F; Yahagi, N; Harada, K; Gotoda, T; Yazaki, Y; Yamada, N				Tozawa, R; Ishibashi, S; Osuga, J; Yagyu, H; Oka, T; Chen, Z; Ohashi, K; Perrey, S; Shionoiri, F; Yahagi, N; Harada, K; Gotoda, T; Yazaki, Y; Yamada, N			Embryonic lethality and defective neural tube closure in mice lacking squalene synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LEMLI-OPITZ-SYNDROME; MOLECULAR-CLONING; APOLIPOPROTEIN-B; CHOLESTEROL-BIOSYNTHESIS; KNOCKOUT MICE; LDL RECEPTOR; YOLK-SAC; IN-VIVO; GENE	Squalene synthase (SS) catalyzes the reductive head-to-head condensation of two molecules of farnesyl diphosphate to form squalene, the first specific intermediate in the cholesterol biosynthetic pathway. We used gene targeting to knock out the mouse SS gene. The mice heterozygous for the mutation (SS+/-) were apparently normal. SS+/- mice showed 60% reduction in the hepatic mRNA levels of SS compared with SS+/+ mice. Consistently, the SS enzymatic activities were reduced by 50% in the liver and testis, Nevertheless, the hepatic cholesterol synthesis was not different between SS+/- and SS+/+ mice, and plasma lipoprotein profiles were not different irrespective of the presence of the low density lipoprotein receptor, indicating that SS is not a rate-limiting enzyme in the cholesterol biosynthetic pathway. The mice homozygous for the disrupted SS gene (SS-/-) were embryonic lethal around midgestation. E9.5-10.5 SS-/- embryos exhibited severe growth retardation and defective neural tube closure. The lethal phenotype was not rescued by supplementing the dams either with dietary squalene or cholesterol. We speculate that cholesterol is required for the development, particularly of the nervous system, and that the chorioallantoic circulatory system is not mature enough to supply the rapidly growing embryos with maternal cholesterol at this developmental stage.	Univ Tokyo, Dept Metab Dis, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Cardiol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Dept Pathol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Ishibashi, S (corresponding author), Univ Tokyo, Dept Metab Dis, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Yahagi, Naoya/D-2360-2014	Yahagi, Naoya/0000-0002-1823-1865				ABE I, 1994, NAT PROD REP, V11, P279, DOI 10.1039/np9941100279; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Amin D, 1997, J PHARMACOL EXP THER, V281, P746; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BELKNAP WM, 1988, J CLIN INVEST, V82, P2077, DOI 10.1172/JCI113829; Bostedor RG, 1997, J BIOL CHEM, V272, P9197; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; COHEN LH, 1986, BIOCHEM BIOPH RES CO, V138, P335, DOI 10.1016/0006-291X(86)90285-8; Eisele B, 1997, J LIPID RES, V38, P564; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; INOUE T, 1995, BBA-GENE STRUCT EXPR, V1260, P49, DOI 10.1016/0167-4781(94)00178-6; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; Jurevics HA, 1997, J LIPID RES, V38, P723; LIU GCK, 1976, J LIPID RES, V17, P38; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; MINSKER DH, 1983, TERATOLOGY, V28, P449, DOI 10.1002/tera.1420280316; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V311, P277, DOI 10.1006/abbi.1994.1238; OSUGA J, 1995, BIOCHEM BIOPH RES CO, V214, P653, DOI 10.1006/bbrc.1995.2336; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PRATT HPM, 1982, DEV BIOL, V89, P101, DOI 10.1016/0012-1606(82)90298-6; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; REPETTO M, 1990, TERATOLOGY, V42, P611, DOI 10.1002/tera.1420420605; Roullet JB, 1997, J BIOL CHEM, V272, P32240, DOI 10.1074/jbc.272.51.32240; Roullet JB, 1996, J CLIN INVEST, V97, P2384, DOI 10.1172/JCI118682; Salen G, 1996, J LIPID RES, V37, P1169; SCALLEN T, 1974, FED PROC, V38, P1733; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; STORM HM, 1993, LIPIDS, V28, P555, DOI 10.1007/BF02536088; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Wyne KL, 1998, J LIPID RES, V39, P518; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007	52	99	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30843	30848		10.1074/jbc.274.43.30843	http://dx.doi.org/10.1074/jbc.274.43.30843			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521476	hybrid, Green Published			2022-12-25	WOS:000083276700072
J	Wolf, BB; Schuler, M; Echeverri, F; Green, DR				Wolf, BB; Schuler, M; Echeverri, F; Green, DR			Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; CLEAVAGE; PROTEASE; INHIBITOR; CPP32; CALPAIN; TARGET	Caspase-3 initiates apoptotic DNA fragmentation by proteolytically inactivating DFF45 (DNA fragmentation factor-45)/ICAD (inhibitor of caspase-activated DNase), which releases active DFF40/CAD (caspase-activated DNase), the inhibitor's associated endonuclease. Here, we examined whether other apoptotic proteinases initiated DNA fragmentation via DFF45/ICAD inactivation. In a cell-free assay, caspases-3, -6, -7, -8, and granzyme B initiated benzoyloxycarbonyl-Asp-Glu-Val-Asp (DEVD) cleaving caspase activity, DFF45/ICAD inactivation, and DNA fragmentation, but calpain and cathepsin D failed to initiate these events. Strikingly, only the DEVD cleaving caspases, caspase-3 and caspase-7, inactivated DFF45/ICAD and promoted DNA fragmentation in an in vitro DFF40/CAD assay, suggesting that granzyme B, caspase-6, and caspase-8 promote DFF45/ICAD inactivation and DNA fragmentation indirectly by activating caspase-3 and/or caspase-7. In vitro, however, caspase-3 inactivated DFF45/ICAD and promoted DNA fragmentation more effectively than caspase-7 and endogenous levels of caspase-7 failed to inactivate DFF45/ICAD in caspase-3 null MCF7 cells and extracts. Together, these data suggest that caspase-3 is the primary inactivator of DFF45/ICAD and therefore the primary activator of apoptotic DNA fragmentation.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USA	La Jolla Institute for Immunology; University of California System; University of California San Diego	Wolf, BB (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [K08CA075268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER; NCI NIH HHS [CA69831, CA75268-01] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G; Roberg K, 1998, AM J PATHOL, V152, P1151; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	29	410	431	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30651	30656		10.1074/jbc.274.43.30651	http://dx.doi.org/10.1074/jbc.274.43.30651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521451	hybrid			2022-12-25	WOS:000083276700047
J	Chakraborty, TR; Vancura, A; Balija, VS; Haldar, D				Chakraborty, TR; Vancura, A; Balija, VS; Haldar, D			Phosphatidic acid synthesis in mitochondria - Topography of formation and transmembrane migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SN-GLYCEROL 3-PHOSPHATE; GLYCEROPHOSPHATE ACYLTRANSFERASE; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; TRANSVERSE-PLANE; OUTER-MEMBRANE; PURIFICATION; ENZYMES; CELLS; ACYLATION	The topography of formation and migration of phosphatidic acid (PA) in the transverse plane of rat liver mitochondrial outer membrane (MOM) were investigated. Isolated mitochondria and microsomes, incubated with sn-glycerol 3-phosphate and an immobilized substrate palmitoyl-CoA-agarose, synthesized both lyse-PA and PA. The mitochondrial and microsomal acylation of glycerophosphate with palmitoyl-CoA-agarose was 80-100% of the values obtained in the presence of free palmitoyl-CoA, In another series of experiments, both free polymyxin B and polymyxin B-agarose stimulated mitochondrial glycerophosphate acyltransferase activity approximately a-fold. When PA loaded mitochondria were treated with Liver fatty acid binding protein, a fifth of the phospholipid left the mitochondria. The amount of expel-table PA reduced with the increase in the time of incubation, In another approach, PA-loaded mitochondria were treated with phospholipase A(2). The amount of phospholipase A(2)-sensitive PA reduced when the incubation time was increased. Taken together, the results suggest that lysophosphatidic acid (LPA) and PA are synthesized on the outer surface of the MOM and that PA moves to the inner membrane presumably for cardiolipin formation.	St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	Saint John's University	Haldar, D (corresponding author), St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA.			Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM-57643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P17, DOI 10.1016/0003-9861(82)90003-0; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DAS SK, 1987, LIPIDS, V22, P757, DOI 10.1007/BF02533977; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DRICKS LK, 1997, BIOCHIM BIOPHYS ACTA, V1348, P17; FITZPATRICK SM, 1982, J NEUROCHEM, V39, P286, DOI 10.1111/j.1471-4159.1982.tb04738.x; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HALDAR D, 1990, J BIOL CHEM, V265, P11014; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HESLER CB, 1990, J BIOL CHEM, V265, P6600; HOSTETLER KY, 1982, PHOSPHOLIPIDS, P481; KENNEDY EP, 1953, J BIOL CHEM, V201, P399; KENNEDY EP, 1961, FED PROC, V20, P934; KORNBERG A, 1953, J BIOL CHEM, V204, P345; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; NACHBAURT J, 1986, BIOCHEM BIOPH RES CO, V33, P315; Nikonov A., 1996, FASEB Journal, V10, pA1110; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; SALEM L, 1962, J CHEM PHYS, V37, P2100, DOI 10.1063/1.1733431; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SMITH ME, 1967, EUR J BIOCHEM, V3, P70, DOI 10.1111/j.1432-1033.1967.tb19499.x; STERN W, 1978, J BIOL CHEM, V253, P8047; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VANCURA A, 1994, J BIOL CHEM, V269, P27209; VANDEENEN LLM, 1965, PROGRESS CHEMISTRY 1, V8, P1; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WOJTCZAK L, 1990, BIOCHIM BIOPHYS ACTA, V1044, P284, DOI 10.1016/0005-2760(90)90315-O; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	37	25	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29786	29790		10.1074/jbc.274.42.29786	http://dx.doi.org/10.1074/jbc.274.42.29786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514455	hybrid			2022-12-25	WOS:000083176400034
J	Fathy, DB; Leeb, T; Mathis, SA; Leeb-Lundberg, LMF				Fathy, DB; Leeb, T; Mathis, SA; Leeb-Lundberg, LMF			Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists - Effect of basal desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; KININ RECEPTORS; CELLS; ANTAGONIST; ACTIVATION; HOE-140; BINDING; STATE; B1	In this report, we show that desensitization regulates ligand-independent, spontaneous activity of the human B2 bradykinin (BK) receptor, and the level of spontaneous receptor activity determines the action of the BK antagonists and partial receptor agonists NPC17731 and HOE140 as agonists or inverse agonists, Spontaneous receptor activity was monitored by measuring basal cellular phosphoinositide (PI) hydrolysis as a function of the density of the receptor in transiently transfected HEK293 cells, Minimal spontaneous activity of the wildtype B2 receptor was detected in these cells. Mutating a cluster of serines and threonines within the fourth intracellular domain of the receptor, which is critical for agonist-promoted desensitization, significantly increased the spontaneous receptor activity. BK, the natural B2 receptor ligand and, consequently, a full agonist, stimulated PI hydrolysis at high and low levels of spontaneous receptor activity. On the other hand, the partial agonists NPC17731 and HOE140 were stimulatory, or agonists, at the lower level of receptor activity but inhibitory, or inverse agonists, at the higher level of activity. These results show that receptors are desensitized in response to their spontaneous activity. Furthermore, these results, which refute traditional theories, show that the capacity of a drug to modulate a receptor response is not intrinsic to the drug but is also dependent on the cellular environment in which the drug acts.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Leeb-Lundberg, LMF (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880	NIGMS NIH HHS [GM41659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Chidiac P, 1996, MOL PHARMACOL, V50, P662; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Fathy DB, 1998, J BIOL CHEM, V273, P12210, DOI 10.1074/jbc.273.20.12210; FELETOU M, 1994, BRIT J PHARMACOL, V112, P683, DOI 10.1111/j.1476-5381.1994.tb13130.x; Furchgott RF., 1966, ADV DRUG RES, V3, P21; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; Kenakin T, 1996, PHARMACOL REV, V48, P413; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Marie J, 1999, MOL PHARMACOL, V55, P92, DOI 10.1124/mol.55.1.92; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5113; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Soskic V, 1999, J BIOL CHEM, V274, P8539, DOI 10.1074/jbc.274.13.8539; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191	28	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29603	29606		10.1074/jbc.274.42.29603	http://dx.doi.org/10.1074/jbc.274.42.29603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514427	hybrid			2022-12-25	WOS:000083176400006
J	Song, L; De Sarno, P; Jope, RS				Song, L; De Sarno, P; Jope, RS			Muscarinic receptor stimulation increases regulators of G-protein signaling 2 mRNA levels through a protein kinase C-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA SH-SY5Y CELLS; PHOSPHOINOSITIDE HYDROLYSIS; TYROSINE PHOSPHORYLATION; CHOLINERGIC STIMULATION; OXIDATIVE STRESS; RGS PROTEINS; ACTIVATION; AP-1; EXPRESSION; RGS2/G0S8	RGS2, a member of the Regulators of:G-protein Signaling family, modulates the activity of G-proteins coupled to the phosphoinositide signal transduction system, but little is known about what regulates RGS2, In human neuroblastoma SH-SY5Y cells stimulation of muscarinic receptors by carbachol activates phosphoinositide signaling and also caused a rapid, large, and long lasting increase in RGS2 mRNA levels. Direct activation, of protein kinase C also rapidly increased RGS2 mRNA levels, Inhibition of protein kinase C with Ro318220, GF109203x, or Go6976 or down-regulation of protein kinase C inhibited increases in RGS2 mRNA levels induced by carbachol or by the activation of protein kinase C, Blockade of calcium signaling did not alter carbachol-induced increases in RGS2 mRNA levels. Neither activation of epidermal growth factor receptors nor stimulation of cyclic AMP production with forskolin increased RGS2 mRNA levels, Pretreatment with actinomycin D blocked increases in RGS2 mRNA levels but caused a surprisingly small, although statistically significant, partial blockade of protein kinase C-mediated feedback inhibition of carbachol-induced phosphoinositide hydrolysis. Thus, RGS2 mRNA levels are increased by activation of muscarinic receptors coupled to the phosphoinositide signal transduction system through a protein kinase C-dependent mechanism. This action may contribute to negative feedback control of this signaling cascade, but because the small contribution to negative feedback contrasts with the large and prolonged elevations in RGS2 mRNA levels, we speculate that its primary role may be in modulating other signaling components.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama, Sparks Ctr 1057, Dept Psychiat, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752, R56MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [AG06569] Funding Source: Medline; NIMH NIH HHS [MH38752] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Beadling C, 1999, J IMMUNOL, V162, P2677; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Burchett SA, 1999, J NEUROCHEM, V72, P1529, DOI 10.1046/j.1471-4159.1999.721529.x; Burchett SA, 1998, J NEUROCHEM, V70, P2216; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Ingi T, 1998, J NEUROSCI, V18, P7178; Jope RS, 1999, J NEUROSCI RES, V55, P329, DOI 10.1002/(SICI)1097-4547(19990201)55:3<329::AID-JNR8>3.0.CO;2-K; Jope RS, 1997, MOL BRAIN RES, V50, P171, DOI 10.1016/S0169-328X(97)00183-6; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; LARSSON C, 1994, EUR J PHARM-MOLEC PH, V268, P19; Li XH, 1998, BIOCHEM J, V331, P599, DOI 10.1042/bj3310599; Li XH, 1996, J NEUROSCI, V16, P5914; Li XH, 1998, MOL BRAIN RES, V53, P196, DOI 10.1016/S0169-328X(97)00290-8; Pacheco MA, 1996, PROG NEUROBIOL, V50, P255, DOI 10.1016/S0301-0082(96)00035-4; Pepperl DJ, 1998, BIOCHEM BIOPH RES CO, V243, P52, DOI 10.1006/bbrc.1997.8056; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; Standaert ML, 1999, ENDOCRINOLOGY, V140, P2145, DOI 10.1210/en.140.5.2145; TREJO J, 1991, J BIOL CHEM, V266, P7876; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2	26	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29689	29693		10.1074/jbc.274.42.29689	http://dx.doi.org/10.1074/jbc.274.42.29689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514440	hybrid			2022-12-25	WOS:000083176400019
J	Viswanathan, M; Lovett, ST				Viswanathan, M; Lovett, ST			Exonuclease X of Escherichia coli - A novel 3 '-5 ' DNase and DnaQ superfamily member involved in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; DIRECTED MISMATCH REPAIR; SINGLE-STRANDED-DNA; POLYMERASE-I; 3'->5' EXONUCLEASE; KLENOW FRAGMENT; SYNDROME GENE; RECF PATHWAY; TRANSFER-RNA; RECOMBINATION	DNA exonucleases are critical for DNA replication, repair, and recombination. In the bacterium Escherichia coli there are 14 DNA exonucleases including exonucleases I-IX (including the two DNA polymerase I exonucleases), RecJ exonuclease, SbcCD exonuclease, RNase T, and the exonuclease domains of DNA polymerase II and III. Here we report the discovery and characterization of a new E. coli exonuclease, exonuclease X Exonuclease X is a member of a superfamily of proteins that have homology to the 3'-5' exonuclease proofreading subunit (DnaQ) of E. coli DNA polymerase III. We have engineered and purified a (His)(6)-exonuclease X fusion protein and characterized its activity. Exonuclease X is a potent distributive exonuclease, capable of degrading both single-stranded and duplex DNA with 3'-5' polarity. Its high affinity for single-strand DNA and its rapid catalytic rate are similar to the processive exonucleases RecJ and exonuclease I. Deletion of the exoX gene exacerbated the UV sensitivity of a strain lacking RecJ, exonuclease I, and exonuclease VII. When overexpressed, exonuclease X is capable of substituting for exonuclease I in UV repair. As we have proposed for the other single-strand DNA exonucleases, exonuclease X may facilitate recombinational repair by pre-synaptic and/or post-synaptic DNA degradation.	Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Lovett, ST (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.		Lovett, Susan/AAC-1810-2021	Lovett, Susan/0000-0003-2792-1857	NIGMS NIH HHS [R01 GM43889, GM07122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007122, R01GM043889] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, SHORT PROTOCOLS MOL; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COOPER DL, 1993, J BIOL CHEM, V268, P11823; CORRETTEBENNETT SE, 1995, J BIOL CHEM, V270, P6881, DOI 10.1074/jbc.270.12.6881; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Haggerty TJ, 1997, J BACTERIOL, V179, P6705, DOI 10.1128/jb.179.21.6705-6713.1997; Harris RS, 1998, J BACTERIOL, V180, P989, DOI 10.1128/JB.180.4.989-993.1998; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KOONIN EV, 1997, CURR BIOL, V7, P604; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRISTENSEN CS, 1995, J BACTERIOL, V177, P52, DOI 10.1128/jb.177.1.52-58.1995; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Miesel L, 1996, J BACTERIOL, V178, P3146, DOI 10.1128/jb.178.11.3146-3155.1996; MILLER JH, 1992, SHORT COURSE BACTERI, P268; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; THOMAS KR, 1978, J BIOL CHEM, V253, P424; Viswanathan M, 1999, GENETICS, V151, P929; Viswanathan M, 1998, GENETICS, V149, P7; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang XL, 1998, J BACTERIOL, V180, P2779, DOI 10.1128/JB.180.10.2779-2781.1998	42	57	59	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30094	30100		10.1074/jbc.274.42.30094	http://dx.doi.org/10.1074/jbc.274.42.30094			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514496	hybrid			2022-12-25	WOS:000083176400075
J	Akashi, T; Matsumura, T; Ideguchi, T; Iwakiri, K; Kawakatsu, T; Taniguchi, I; Hase, T				Akashi, T; Matsumura, T; Ideguchi, T; Iwakiri, K; Kawakatsu, T; Taniguchi, I; Hase, T			Comparison of the electrostatic binding sites on the surface of ferredoxin for two ferredoxin-dependent enzymes, ferredoxin-NADP(+) reductase and sulfite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; AMINO-ACID-RESIDUES; NADP+ REDUCTASE; 2FE-2S FERREDOXIN; ANGSTROM RESOLUTION; GLUTAMATE SYNTHASE; ANABAENA PCC-7119; MAIZE FERREDOXIN; DIFFERENTIAL EXPRESSION; NITRITE OXIDOREDUCTASE	Plant-type ferredoxin (Fd), a [2Fe-2S] iron-sulfur protein, functions as an one-electron donor to Fd-NADP(+) reductase (FNR) or sulfite reductase (SiR), interacting electrostatically with them. In order to understand the protein-protein interaction between Fd and these two different enzymes, 10 acidic surface residues in maize Fd (isoform III), Asp-27, Glu-30, Asp-58, Asp-61, Asp-66/ Asp-67, Glu-71/Glu-72, Asp-85, and Glu-93, were substituted with the corresponding amide residues by site-directed mutagenesis. The redox potentials of the mutated Fds were not markedly changed, except for E93Q, the redox potential of which was more positive by 67 mV than that of the wild type. Kinetic experiments showed that the mutations at Asp-66/Asp-67 and Glu-93 significantly affected electron transfer to the two enzymes. Interestingly, D66N/D67N was less efficient in the reaction with FNR than E93Q, whereas this relationship was reversed in the reaction with SiR. The static interaction of the mutant Fds with each the two enzymes was analyzed by gel filtration of a mixture of Fd and each enzyme, and by affinity chromatography on Fd-immobilized resins. The contributions of Asp-66/ Asp-67 and Glu-93 were found to be most important for the binding to FNR and SiR, respectively, in accordance with the kinetic data. These results allowed us to map the acidic regions of Fd required for electron transfer and for binding to FNR and SiR and demonstrate that the interaction sites for the two enzymes are at least partly distinct.	Osaka Univ, Inst Prot Res, Div Enzymol, Osaka 5650871, Japan; Kumamoto Univ, Fac Engn, Dept Appl Chem & Biochem, Kumamoto 8600862, Japan	Osaka University; Kumamoto University	Akashi, T (corresponding author), Osaka Univ, Inst Prot Res, Div Enzymol, Osaka 5650871, Japan.		Hase, Toshiharu/H-9271-2013					Aliverti A, 1997, BBA-PROTEIN STRUCT M, V1342, P45, DOI 10.1016/S0167-4838(97)00079-4; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; CAMMACK R, 1977, BIOCHEM J, V168, P205, DOI 10.1042/bj1680205; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; Dose MM, 1997, PLANT PHYSIOL, V114, P1047, DOI 10.1104/pp.114.3.1047; FUKUYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1017, DOI 10.1093/oxfordjournals.jbchem.a124800; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; HASE T, 1991, PLANT PHYSIOL, V96, P77, DOI 10.1104/pp.96.1.77; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRASAWA M, 1993, BIOCHIM BIOPHYS ACTA, V1140, P304, DOI 10.1016/0005-2728(93)90070-V; HIRASAWA M, 1993, BIOCHIM BIOPHYS ACTA, V1144, P85, DOI 10.1016/0005-2728(93)90034-D; HIRASAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P171, DOI 10.1016/0003-9861(91)90024-D; HOLDEN HM, 1994, J BIOENERG BIOMEMBR, V26, P67, DOI 10.1007/BF00763220; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; IKEMIZU S, 1994, ACTA CRYSTALLOGR D, V50, P167, DOI 10.1107/S0907444993009588; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; Jacquot JP, 1997, FEBS LETT, V400, P293, DOI 10.1016/S0014-5793(96)01407-X; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIMATA Y, 1989, PLANT PHYSIOL, V89, P1193, DOI 10.1104/pp.89.4.1193; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Matsumura T, 1997, PLANT PHYSIOL, V114, P653, DOI 10.1104/pp.114.2.653; Matsumura T, 1999, PLANT PHYSIOL, V119, P481, DOI 10.1104/pp.119.2.481; MEDINA M, 1992, EUR J BIOCHEM, V210, P577, DOI 10.1111/j.1432-1033.1992.tb17457.x; MEDINA M, 1992, EUR J BIOCHEM, V203, P373, DOI 10.1111/j.1432-1033.1992.tb16560.x; Piubelli L, 1996, EUR J BIOCHEM, V236, P465, DOI 10.1111/j.1432-1033.1996.00465.x; PUEYO JJ, 1991, PREP BIOCHEM, V21, P191, DOI 10.1080/10826069108018571; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; Schmitz S, 1996, BBA-BIOENERGETICS, V1277, P135, DOI 10.1016/S0005-2728(96)00095-3; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; Taniguchi I, 1997, CHEM LETT, P929, DOI 10.1246/cl.1997.929; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; Yonekura-Sakakibara K, 1998, J BIOCHEM, V124, P615, DOI 10.1093/oxfordjournals.jbchem.a022156; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035	39	71	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29399	29405		10.1074/jbc.274.41.29399	http://dx.doi.org/10.1074/jbc.274.41.29399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506201	hybrid			2022-12-25	WOS:000083017800080
J	Kolkman, JA; Christophe, OD; Lenting, PJ; Mertens, K				Kolkman, JA; Christophe, OD; Lenting, PJ; Mertens, K			Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED FACTOR-IX; VIII LIGHT-CHAIN; FACTOR-X; TISSUE-FACTOR; PLASMINOGEN-ACTIVATOR; BINDING ENZYME; EGF DOMAIN; PROTEIN-C; THROMBIN; COMPLEX	In factor IX residues 199-204 encompass one of six surface loops bordering its substrate-binding groove, To investigate the contribution of this loop to human factor IX function, a series of chimeric factor IX variants was constructed, in which residues 199-204 were replaced by the corresponding sequence of factor VII, factor X, or prothrombin. The immunopurified and activated chimeras were indistinguishable from normal factor Ma in hydrolyzing a small synthetic substrate, indicating that this region is not involved in the interaction with substrate residues on the N-terminal side of the scissile bond. In contrast, replacement of loop 199-204 resulted in a 5-25-fold reduction in reactivity toward the macromolecular substrate factor X This reduction was due to a combination of increased K-m and reduced k(cat). In the presence of factor VIIIa the impaired reactivity toward factor X was largely restored for all factor Ma variants, resulting in a more pronounced stimulation by factor VIIIa compared with normal factor Ma (3 to 5 x 10(4)-fold versus 5 x 10(3)-fold). Inhibition by antithrombin was only slightly affected for the factor Ma variant with the prothrombin loop sequence, whereas factor Ma variants containing the analogous residues of factor VII or factor X were virtually insensitive to antithrombin inhibition. In the presence of heparin, however, all chimeric factor Ma variants formed complexes with antithrombin, Thus the cofactors heparin and factor VIIIa have in common that they both alleviate the deleterious effects of mutations in the factor IX loop 199-204. Collectively, our data demonstrate that loop 199-204 plays an important role in the interaction of factor Ma with macromolecular substrates.	CLB, Dept Plasma Prot Technol, NL-1066 CX Amsterdam, Netherlands		Mertens, K (corresponding author), CLB, Dept Plasma Prot Technol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		christophe, olivier/W-4268-2017; Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	christophe, olivier/0000-0002-9080-6336; Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BJORK I, 1997, CHEM BIOL SERPINS; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; CASTILLO MJ, 1983, BIOCHEMISTRY-US, V22, P1021, DOI 10.1021/bi00274a004; Chang JL, 1998, J BIOL CHEM, V273, P12089, DOI 10.1074/jbc.273.20.12089; Chang JL, 1998, BLOOD, V92, p184A; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; Gerlitz B, 1996, J BIOL CHEM, V271, P22285, DOI 10.1074/jbc.271.37.22285; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HUGHES PE, 1994, PROTEIN ENG, V7, P1121, DOI 10.1093/protein/7.9.1121; JORDAN RE, 1980, J BIOL CHEM, V255, P81; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; Kurth T, 1997, BIOCHEMISTRY-US, V36, P10098, DOI 10.1021/bi970937l; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MANN KG, 1990, BLOOD, V76, P1; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; Mathur A, 1998, BLOOD, V92, p352A; MERTENS K, 1984, BIOCHEM J, V223, P607, DOI 10.1042/bj2230607; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; STENFLO J, 1991, BLOOD, V78, P1637; Tachias K, 1997, J BIOL CHEM, V272, P14580, DOI 10.1074/jbc.272.23.14580; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874	46	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29087	29093		10.1074/jbc.274.41.29087	http://dx.doi.org/10.1074/jbc.274.41.29087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506162	hybrid			2022-12-25	WOS:000083017800041
J	Costa, C; Zhao, L; Burton, WV; Bondioli, KR; Williams, BL; Hoagland, TA; Ditullio, PA; Ebert, KM; Fodor, WL				Costa, C; Zhao, L; Burton, WV; Bondioli, KR; Williams, BL; Hoagland, TA; Ditullio, PA; Ebert, KM; Fodor, WL			Expression of the human alpha 1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis	FASEB JOURNAL			English	Article						alpha 1; 2; H-transferase; hyperacute rejection; delayed xenograft rejection; xenotransplantation	PRIMATE CARDIAC XENOGRAFTS; COMPLEMENT REGULATORY PROTEINS; DECAY-ACCELERATING FACTOR; HUMAN CD59; HYPERACUTE REJECTION; XENOGENEIC TRANSPLANTATION; NATURAL ANTIBODIES; VASCULAR REJECTION; IN-VIVO; SURVIVAL	Hyperacute rejection (HAR) is the first critical immunological hurdle that must be addressed in order to develop xenogeneic organs for human transplantation. In the area of cell-based xenotransplant therapies, natural antibodies (XNA) and complement have also been considered barriers to successful engraftment. Transgenic expression of human complement inhibitors in donor cells and organs has significantly prolonged the survival of xenografts. However, expression of complement inhibitors without eliminating xenogeneic natural antibody (XNA) reactivity may provide insufficient protection for clinical application. An approach designed to prevent XNA reactivity during HAR is the expression of human alpha 1,2-fucosyltransferase (H-transferase, HT). H-transferase expression modifies the cell surface carbohydrate phenotype of the xenogeneic cell, resulting in the expression of the universal donor O antigen and a concomitant reduction in the expression of the antigenic Gal alpha 1,3-Gal epitope. We have engineered various transgenic pig lines that express HI in different cells and tissues, including the vascular endothelium. We demonstrate that in two different HT transgenic lines containing two different HT promoter constructs, expression can be differentially regulated in a constitutive and cytokine-inducible manner. The transgenic expression of HT results in a significant reduction in the expression of the Gal alpha 1,3-Gal epitope, reduced XNA reactivity, and an increased resistance to human serum-mediated cytolysis. Transgenic pigs that express H-transferase promise to become key components for the development of xenogeneic cells and organs for human traosplantation.-Costa, C., Zhao, L., Burton, W. V., Bondioli, K. R., Williams, B. L., Hoagland, T. A, DiTullio, P. A., Ebert, K. M., Fodor, W. L. Expression of the human alpha 1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype human serum-mediated cytolysis.	Alex Pharmaceut Inc, Dept Mol Sci, New Haven, CT 06511 USA; US Surg Corp, N Haven, CT 06473 USA; Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA; TranXenoGen, Shrewsbury, MA 01545 USA	University of Connecticut	Fodor, WL (corresponding author), Alex Pharmaceut Inc, Dept Mol Sci, 25 Sci Pk, New Haven, CT 06511 USA.	fodorw@alxn.com	Costa, Cristina/AAP-4005-2020	Costa, Cristina/0000-0002-1837-4268	NICHD NIH HHS [R44 HD095784] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; BACH FH, 1991, TRANSPL P, V23, P205; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; Chen CG, 1998, TRANSPLANTATION, V65, P832, DOI 10.1097/00007890-199803270-00011; Chen CG, 1996, XENOTRANSPLANTATION, V3, P69, DOI 10.1111/j.1399-3089.1996.tb00121.x; Chen SC, 1997, ANN NY ACAD SCI, V831, P350; Cohney S, 1997, TRANSPLANTATION, V64, P495, DOI 10.1097/00007890-199708150-00020; Costa C, 1999, XENOTRANSPLANTATION, V6, P6, DOI 10.1034/j.1399-3089.1999.00004.x; Cowan PJ, 1998, TRANSPLANTATION, V65, P1599, DOI 10.1097/00007890-199806270-00010; Cozzi E., 1997, XENOTRANSPLANTATION, P665; Cramer Donald V., 1996, P473; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; Davis EA, 1996, TRANSPLANTATION, V62, P1018, DOI 10.1097/00007890-199610150-00022; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Diamond LE, 1996, TRANSPLANTATION, V61, P1241, DOI 10.1097/00007890-199604270-00021; Edge ASB, 1998, CELL TRANSPLANT, V7, P525, DOI 10.1016/S0963-6897(98)00043-8; FLEISCHMAN RA, 1991, AM J MED SCI, V301, P353, DOI 10.1097/00000441-199105000-00011; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; GALLILI U, 1997, XENOTRANSPLANTATION, P95; GOODMAN DJ, 1997, XENOTRANSPLANTATION, P95; HAYES CE, 1974, J BIOL CHEM, V249, P1904; Honmou O, 1996, J NEUROSCI, V16, P3199; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; KENNEDY SP, 1994, TRANSPLANTATION, V57, P1494; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; Kroshus TJ, 1996, TRANSPLANTATION, V61, P1513, DOI 10.1097/00007890-199605270-00018; KRUEGER GG, 1994, J INVEST DERMATOL, V103, pS76, DOI 10.1111/1523-1747.ep12399100; Kwiatkowski P, 1999, TRANSPLANTATION, V67, P219, DOI 10.1097/00007890-199901270-00006; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LEVENTHAL JR, 1994, TRANSPLANTATION, V57, P974; LEVENTHAL JR, 1995, TRANSPLANTATION, V59, P294, DOI 10.1097/00007890-199501270-00024; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; Lin SS, 1998, J CLIN INVEST, V101, P1745, DOI 10.1172/JCI2134; LU CY, 1994, FASEB J, V8, P1122, DOI 10.1096/fasebj.8.14.7958617; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; OHAIR DP, 1994, ANN THORAC SURG, V58, P1311, DOI 10.1016/0003-4975(94)91902-X; Pascher A, 1998, TRANSPLANTATION, V65, P737, DOI 10.1097/00007890-199803150-00023; PLATT JL, 1991, CURR OPIN IMMUNOL, V3, P735, DOI 10.1016/0952-7915(91)90105-A; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SAADI S, 1995, J EXP MED, V181, P21, DOI 10.1084/jem.181.1.21; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SCHAAPHERDER AFM, 1994, TRANSPLANTATION, V57, P1376, DOI 10.1097/00007890-199405150-00016; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; SOMERVILLE CA, 1993, KIDNEY INT, V44, pS112; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Taniguchi S, 1996, TRANSPLANTATION, V62, P1379, DOI 10.1097/00007890-199611270-00001; Vanhove Bernard, 1994, Xenotransplantation, V1, P17, DOI 10.1111/j.1399-3089.1994.tb00046.x; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6	57	68	81	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1762	1773		10.1096/fasebj.13.13.1762	http://dx.doi.org/10.1096/fasebj.13.13.1762			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506579				2022-12-25	WOS:000083063400011
J	Ho, E; Chen, GM; Bray, TM				Ho, E; Chen, GM; Bray, TM			Supplementation of N-acetylcysteine inhibits NF kappa B activation and protects against alloxan-induced diabetes in CD-1 mice	FASEB JOURNAL			English	Article						free radicals; antioxidants; GSH; transcription factor; IDDM	NITRIC-OXIDE SYNTHASE; ENZYME GENE-EXPRESSION; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; FREE-RADICALS; REDOX REGULATION; BETA-CELLS; RAT ISLETS; ANTIOXIDANT; DESTRUCTION	Reactive oxygen species (ROS) are involved in the destruction of pancreatic beta cells and the development of insulin-dependent diabetes mellitus (IDDM), However, the cellular mechanism responsible for beta cell death is still unclear. We hypothesize that activation of NF kappa B by ROS is the key cellular signal in initiating a cascade of events leading to beta cell death. Thus, enhancement of pancreatic GSH, a known antioxidant and key regulator of NF-KB, should protect against IDDM, Weanling CD1 mice (n=5) were injected with alloxan (50 mg/kg i.v.) to induce IDDM, Using EPR spin trapping techniques, we demonstrated that alloxan generated ROS in the pancreas 15 min after administration. Activation of NF kappa B in pancreatic nuclear extracts was observed 30 min after alloxan injection, as assessed by an electrophoretic mobility shift assay. Fasting blood glucose levels were monitored for 14 days. Supplementation with N-acetylcysteine (NAC, 500 mg/kg), a GSH precursor, inhibited alloxan-induced NF kappa B activation and reduced hyperglycemia, Thus, NF kappa B activation by ROS may initiate a sequence of events leading to IDDM, Inhibition of NF-kappa B activation by NAC attenuated the severity of IDDM, This research will contribute to the understanding of the etiology of IDDM and may lead to the development of better strategies for disease prevention.	Ohio State Univ, Dept Human Nutr, Columbus, OH 43210 USA; Univ Guelph, Dept Clin Studies, Guelph, ON N1G 2W1, Canada	University System of Ohio; Ohio State University; University of Guelph	Bray, TM (corresponding author), Ohio State Univ, Dept Human Nutr, 347 Campbell Hall,1787 Neil Ave, Columbus, OH 43210 USA.							ADAMS DD, 1984, LANCET, V1, P420; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOITARD C, 1994, DIABETOLOGIA, V37, pS90, DOI 10.1007/BF00400831; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Fehsel K, 1995, RES IMMUNOL, V146, P711, DOI 10.1016/0923-2494(96)84924-8; Fox ES, 1997, J IMMUNOL, V158, P5418; Gilston Vanessa, 1997, Biochemical Society Transactions, V25, p518S; GORUS FK, 1982, BIOCHEM J, V208, P513, DOI 10.1042/bj2080513; HEIKKILA RE, 1976, BIOCHEM PHARMACOL, V25, P1085, DOI 10.1016/0006-2952(76)90502-5; Heller B, 1997, Adv Pharmacol, V38, P629; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Holstad M, 1997, GEN PHARMACOL-VASC S, V29, P697, DOI 10.1016/S0306-3623(97)00012-8; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; McDaniel ML, 1997, ADV EXP MED BIOL, V426, P313; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MORISZE ZJ, 1997, J CLIN GASTROENTE S1, V25, pS61; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; RABINOVITCH A, 1992, DIABETOLOGIA, V35, P409, DOI 10.1007/BF02342435; Rabinovitch A, 1996, J CLIN ENDOCR METAB, V81, P3197, DOI 10.1210/jc.81.9.3197; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCOTT FW, 1991, CAN J PHYSIOL PHARM, V69, P311, DOI 10.1139/y91-048; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Stoian I, 1996, BIOCHEM MOL MED, V59, P93, DOI 10.1006/bmme.1996.0072; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WU GY, 1995, DIABETES, V44, P360, DOI 10.2337/diabetes.44.3.360; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZONANA J, 1976, NEW ENGL J MED, V295, P603, DOI 10.1056/NEJM197609092951106	52	121	126	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1845	1854		10.1096/fasebj.13.13.1845	http://dx.doi.org/10.1096/fasebj.13.13.1845			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506589				2022-12-25	WOS:000083063400021
J	Schmidt, G; Goehring, UM; Schirmer, J; Lerm, M; Aktories, K				Schmidt, G; Goehring, UM; Schirmer, J; Lerm, M; Aktories, K			Identification of the C-terminal part of Bordetella dermonecrotic toxin as a transglutaminase for rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; CYTOTOXIC NECROTIZING FACTOR-1; BINDING PROTEIN-RHO; ESCHERICHIA-COLI; GENE-PRODUCT; FACTOR-XIIIA; DEAMIDATION; GLN-63; CELLS; SITE	Bordetella dermonecrotic toxin (DNT) causes the deamidation of glutamine 63 of Rho. Here we identified the region of DNT harboring the enzyme activity and compared the toxin with the cytotoxic necrotizing factor 1, which also deamidates Rho. The DNT fragment (Delta DNT) covering amino acid residues 1136-1451 caused deamidation of RhoA at glutamine 63 as determined by mass spectrometric analysis and by the release of ammonia. In the presence of dansylcadaverine or ethylenediamine, Delta DNT caused transglutamination of Rho. Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of Delta DNT. Deamidation and transglutamination induced by Delta DNT blocked intrinsic and Rho-GTPase-activating protein-stimulated GTPase activity of RhoA. Delta DNT deamidated and transglutaminated Rac and Cdc42 in the absence and presence of ethylenediamine, respectively. Modification of Rho proteins by Delta DNT was nucleotide-dependent and did not occur with GTP gamma S-loaded GTPases, In contrast to cytotoxic necrotizing factor, which caused the same kinetics of ammonia release in the absence and presence of ethylenediamine, ammonia release by Delta DNT was largely increased in the presence of ethylenediamine, indicating that Delta DNT acts primarily as a transglutaminase.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Aktories, Klaus/CAJ-5682-2022; Lerm, Maria/AAA-1780-2020; Lerm, Maria/AAM-8705-2020	Aktories, Klaus/0000-0002-5397-0436; Lerm, Maria/0000-0002-5092-9892; 				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KANAJI T, 1993, J BIOL CHEM, V268, P11565; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; Pullinger GD, 1996, INFECT IMMUN, V64, P4163, DOI 10.1128/IAI.64.10.4163-4171.1996; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1998, NATURWISSENSCHAFTEN, V85, P253, DOI 10.1007/s001140050495; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAGI J, 1995, EUR J BIOCHEM, V232, P773, DOI 10.1111/j.1432-1033.1995.773zz.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094	23	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31875	31881		10.1074/jbc.274.45.31875	http://dx.doi.org/10.1074/jbc.274.45.31875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542213	hybrid			2022-12-25	WOS:000083532100021
J	Wright, DJ; Jack, WE; Modrich, P				Wright, DJ; Jack, WE; Modrich, P			The kinetic mechanism of EcoRI endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; RESTRICTION-ENDONUCLEASE; RI ENDONUCLEASE; LINEAR DIFFUSION; MODIFICATION ENZYMES; CRYSTAL-STRUCTURE; CLEAVAGE CENTER; PLASMID DNA; RECOGNITION; SEQUENCES	Steady-state parameters governing cleavage of pBR322 DNA by EcoRI endonuclease are highly sensitive to ionic environment, with K-m and k(cat) increasing 1,000-fold and 15-fold, respectively, when ionic strength is increased from 0.059 to 0.23 M. By contrast, pre-steady-state analysis has shown that recognition, as well as first and second strand cleavage events that occur once the enzyme has arrived at the EcoRI site, are essentially insensitive to ionic strength, and has demonstrated that the rate-limiting step for endonuclease turnover occurs after double-strand cleavage under all conditions tested. Furthermore, processive cleavage of a pBR322 variant bearing two closely spaced EcoRI sites is governed by the same turnover number as hydrolysis of parental pBR322, which contains only a single EcoRI sequence, ruling out slow release of the enzyme from the cleaved site or a slow conformational change subsequent to double-strand cleavage. We attribute the effects of ionic strength on steady-state parameters to nonspecific endonuclease DNA interactions, reflecting facilitated diffusion processes, that occur prior to EcoRI sequence recognition and subsequent to DNA cleavage.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023719, R37GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHENG SC, 1984, J BIOL CHEM, V259, P1571; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; Erskine SG, 1997, BIOCHEMISTRY-US, V36, P7567, DOI 10.1021/bi970155s; FERSHT AR, 1985, EMZYME STRUCTURE MEC; HALFORD SE, 1980, BIOCHEM J, V191, P593, DOI 10.1042/bj1910593; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HEDGPETH J, 1972, P NATL ACAD SCI USA, V80, P31; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JACK WE, 1983, PARTICIPATION OUTSID; JELTSCH A, 1994, BIOCHEMISTRY-US, V33, P10215, DOI 10.1021/bi00200a001; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; Jeltsch A, 1996, EMBO J, V15, P5104, DOI 10.1002/j.1460-2075.1996.tb00891.x; Jeltsch A, 1998, BIOCHEMISTRY-US, V37, P2160, DOI 10.1021/bi9719206; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KIRSCH JF, 1964, J AM CHEM SOC, V86, P837, DOI 10.1021/ja01059a019; LANGOWSKI J, 1981, NUCLEIC ACIDS RES, V9, P3483, DOI 10.1093/nar/9.14.3483; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LU AL, 1981, J BIOL CHEM, V256, P3200; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MODRICH P, 1976, J BIOL CHEM, V251, P5866; MODRICH P, 1979, Q REV BIOPHYS, V12, P315, DOI 10.1017/S0033583500005461; Modrich P., 1982, NUCLEASES, P109; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBERT Y, 1993, CURR OPIN OPHTHALMOL, V4, P35; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; RUBEN G, 1977, NUCLEIC ACIDS RES, V4, P1803, DOI 10.1093/nar/4.6.1803; RUBIN RA, 1978, NUCLEIC ACIDS RES, V5, P2991, DOI 10.1093/nar/5.8.2991; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	41	63	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31896	31902		10.1074/jbc.274.45.31896	http://dx.doi.org/10.1074/jbc.274.45.31896			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542216	hybrid			2022-12-25	WOS:000083532100024
J	Choi, CY; Lee, YM; Kim, YH; Park, T; Jeon, BH; Schulz, RA; Kim, Y				Choi, CY; Lee, YM; Kim, YH; Park, T; Jeon, BH; Schulz, RA; Kim, Y			The homeodomain transcription factor NK-4 acts as either a transcriptional activator or repressor and interacts with the p300 coactivator and the Groucho corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; GERM-CELL MIGRATION; GENE-EXPRESSION; HOMEOBOX GENES; COOPERATIVE INTERACTIONS; PROTEIN-INTERACTION; GONADAL MESODERM; DROSOPHILA CBP; HEART; TINMAN	NK-4 (tinman) encodes an NK-2 class homeodomain transcription factor that is required for development of the Drosophila dorsal mesoderm, including heart. Genetic evidence suggests its important role in mesoderm subdivision, yet the properties of NK-4 as a transcriptional regulator and the mechanism of gene transcription by NK-4 are not completely understood. Here, we describe its properties as a transcription factor and its interaction with the p300 coactivator and the Groucho corepressor. We demonstrate that NK-4 can activate or repress target genes in cultured cells, depending on functional domains that are conserved between Drosophila melanogaster and Drosophila virilis NK-4 genes. Using GAL4-NK-4 fusion constructs, we have mapped a transcriptional activation domain (amino acids 1-110) and repression domains (amino acids 111-188 and time homeodomain) and found an inhibitory function for the homeodomain in transactivation by NK-4. Furthermore, we demonstrate that NK-4-dependent transactivation is augmented by the p300 coactivator and show that NK-4 physically interacts with p300 via the activation domain. In addition, cotransfection experiments indicate that the repressor activity of NK-4 is strongly enhanced by the Groucho corepressor. Using immunoprecipitation and in vitro pull-down assays, we show that NK-4 directly interacts with the Groucho corepressor, for which the homeodomain is required. Together, our results indicate that NK-4 can act as either a transcriptional activator or repressor and provide the first evidence of NK-4 interactions with the p300 coactivator and the Groucho corepressor.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; Konkuk Univ, Dept Mol Biol, Chungju, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Konkuk University; University of Texas System; UTMD Anderson Cancer Center	Kim, Y (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10 Rm 8N228,10 Ctr Dr MSC1762, Bethesda, MD 20892 USA.	yongsok@helix.nih.gov						Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Biggin MD, 1997, DEVELOPMENT, V124, P4425; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; Broihier HT, 1998, DEVELOPMENT, V125, P655; BURGLIN T, 1994, GUIDEBOOK HOMEOBOX G, P26; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; Gajewski K, 1998, DEV GENES EVOL, V208, P382, DOI 10.1007/s004270050194; GAJEWSKI K, 1997, EMBO J, V16, P516; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Haun C, 1998, P NATL ACAD SCI USA, V95, P5072, DOI 10.1073/pnas.95.9.5072; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moore LA, 1998, DEVELOPMENT, V125, P667; NIRENBERG M, 1995, ANN NY ACAD SCI, V758, P224, DOI 10.1111/j.1749-6632.1995.tb24830.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; Riechmann V, 1998, DEVELOPMENT, V125, P713; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	71	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31543	31552		10.1074/jbc.274.44.31543	http://dx.doi.org/10.1074/jbc.274.44.31543			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531357	hybrid, Green Published			2022-12-25	WOS:000083379400061
J	Ilg, T; Montgomery, J; Stierhof, YD; Handman, E				Ilg, T; Montgomery, J; Stierhof, YD; Handman, E			Molecular cloning and characterization of a novel repeat-containing Leishmania major gene, ppg1, that encodes a membrane-associated form of proteophosphoglycan with a putative glycosylphosphatidylinositol anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; SURFACE-ANTIGEN; GLYCOSYLATED PHOSPHATIDYLINOSITOLS; STRUCTURAL CHARACTERIZATION; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; MEXICANA AMASTIGOTES; TRYPANOSOMA-BRUCEI; LIPOPHOSPHOGLYCAN; PROMASTIGOTES	Leishmania parasites secrete a variety of proteins that are modified by phosphoglycan chains structurally similar to those of the cell surface glycolipid lipophosphoglycan. These proteins are collectively called proteophosphoglycans. We report here the cloning and sequencing of a novel Leishmania major proteophosphoglycan gene, ppg1. It encodes a large polypeptide of approximately 2300 amino acids. The N-terminal domain of approximately 70 kDa exhibits 11 imperfect amino acid repeats that show some homology to promastigote surface glycoproteins of the psa2/gp46 complex. The large central domain apparently consists exclusively of approximately 100 repetitive peptides of the sequence APSASSSSA(P/S)SSSSS(+/-S). Gene fusion experiments demonstrate that these peptide repeats are the targets of phosphoglycosylation in Leishmania and that they form extended filamentous structures reminiscent of mammalian mucins. The C-terminal domain contains a functional glycosylphosphatidylinositol anchor addition signal sequence, which confers cell surface localization to a normally secreted Leishmania acid phosphatase when fused to its C terminus. Antibody binding studies show that the ppg1 gene product is phosphoglycosylated by phosphoglycan repeats and cap oligosaccharides. In contrast to previously characterized proteophosphoglycans, the ppg1 gene product is predominantly membrane-associated and it is expressed on the promastigote cell surface. Therefore this membrane-bound proteophosphoglycan may be important for direct host-parasite interactions.	Max Planck Inst Biol, Abt Membranbiochem, D-72076 Tubingen, Germany; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Max Planck Society; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Ilg, T (corresponding author), Max Planck Inst Biol, Abt Membranbiochem, Corrensstr 38, D-72076 Tubingen, Germany.	thomas.ilg@tuebingen.mpg.de						Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BRUN R, 1979, ACTA TROP, V36, P289; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESCOTEAUX A, 1993, PARASITOL TODAY, V9, P468, DOI 10.1016/0169-4758(93)90105-O; Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HOMANS SW, 1992, BIOCHEMISTRY-US, V31, P654, DOI 10.1021/bi00118a004; Ilg T, 1999, BIOCHEM SOC T, V27, P518; Ilg T, 1999, TRENDS GLYCOSCI GLYC, V11, P53, DOI 10.4052/tigg.11.53; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1995, EUR J CELL BIOL, V66, P205; Ilg T, 1998, J BIOL CHEM, V273, P13509, DOI 10.1074/jbc.273.22.13509; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1992, J BIOL CHEM, V267, P6834; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KILLICKKENDRICK R, 1988, PARASITOL RES, V74, P586, DOI 10.1007/BF00531639; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P873, DOI 10.1093/glycob/7.7.873-c; MENZ B, 1991, MOL BIOCHEM PARASIT, V47, P101, DOI 10.1016/0166-6851(91)90152-V; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MORAN LS, 1990, GENE, V93, P163, DOI 10.1016/0378-1119(90)90153-I; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; Piedrafita D, 1999, EUR J IMMUNOL, V29, P235, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;235::AID-IMMU235&gt;3.0.CO;2-S; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; PUENTES SM, 1990, J IMMUNOL, V145, P4311; SACKS DL, 1994, PARASITOLOGY, V108, pS55, DOI 10.1017/S0031182000075727; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stierhof YD, 1998, J MOL BIOL, V282, P137, DOI 10.1006/jmbi.1998.2012; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; Stierhof YD, 1999, EUR J CELL BIOL, V78, P675, DOI 10.1016/S0171-9335(99)80036-3; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wiese M, 1996, MOL BIOCHEM PARASIT, V82, P153, DOI 10.1016/0166-6851(96)02729-6; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; Wolfram M, 1996, EUR J IMMUNOL, V26, P3153, DOI 10.1002/eji.1830261248	61	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31410	31420		10.1074/jbc.274.44.31410	http://dx.doi.org/10.1074/jbc.274.44.31410			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531342	hybrid			2022-12-25	WOS:000083379400046
J	Neels, JG; van den Berg, BMM; Lookene, A; Olivecrona, G; Pannekoek, H; van Zonneveld, AJ				Neels, JG; van den Berg, BMM; Lookene, A; Olivecrona, G; Pannekoek, H; van Zonneveld, AJ			The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; COMPLEMENT-TYPE REPEATS; ALPHA-2-MACROGLOBULIN RECEPTOR; TISSUE-TYPE; ALPHA(2)-MACROGLOBULIN RECEPTOR; SPECIALIZED CHAPERONE; MOLECULAR CHAPERONE; INTERACTION SITES; 39-KDA PROTEIN; HIGH-AFFINITY	The low density lipoprotein receptor-related protein (LRP) is a multifunctional endocytic cell-surface receptor that binds and internalizes a diverse array of ligands. The receptor contains four putative ligand-binding domains, generally referred to as clusters I, II, III, and IV. In this study, soluble recombinant receptor fragments, representing each of the four individual clusters, were used to map the binding sites of a set of structurally and functionally distinct ligands. Using surface plasmon resonance, we studied the binding of these fragments to methylamine-activated alpha(2)-macroglobulin, pro-urokinase-type plasminogen activator, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1, t-PA plasminogen activator inhibitor-1 complexes, lipoprotein lipase, apolipoprotein E, tissue factor pathway inhibitor, lactoferrin, the light chain of blood coagulation factor MII, and the intracellular chaperone receptor-associated protein (EAF). No binding of the cluster I fragment to any of the tested ligands was observed. The cluster III fragment only bound to the anti-LRP monoclonal antibody alpha(2)MR alpha 3 and weakly to RAP. Except for t-PA, we found that each of the ligands tested binds both to cluster II and to cluster IV. The affinity rate constants of ligand binding to clusters II and IV and to LRP were measured, showing that clusters II and IV display only minor differences in ligand-binding kinetics, Furthermore, we demonstrate that the subdomains C3-C7 of cluster II are essential for binding of ligands and that this segment partially overlaps with a RAP-binding site on cluster II. Finally, we show that one RAP molecule can bind to different clusters simultaneously, supporting a model in which RAP binding to LRP induces a conformational change in the receptor that is incompatible with ligand binding.	Univ Amsterdam, Dept Biochem, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	University of Amsterdam; Academic Medical Center Amsterdam; Umea University	Neels, JG (corresponding author), Univ Amsterdam, Dept Biochem, Acad Med Ctr, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	j.g.neels@amc.uva.nl	Neels, Jaap G/F-5534-2010; van Zonneveld, Anton Jan/D-8060-2018	Neels, Jaap G/0000-0002-5900-8395; van Zonneveld, Anton Jan/0000-0002-1676-7738				BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DELAIN E, 1994, ANN NY ACAD SCI, V737, P202, DOI 10.1111/j.1749-6632.1994.tb44313.x; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Gliemann J, 1998, BIOL CHEM, V379, P951; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HORN IR, 1995, J BIOL CHEM, V270, P11770, DOI 10.1074/jbc.270.20.11770; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KEIJER J, 1991, BLOOD, V78, P401; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; Martinho RG, 1996, MOL BIOL CELL, V7, P1771, DOI 10.1091/mbc.7.11.1771; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	40	128	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31305	31311		10.1074/jbc.274.44.31305	http://dx.doi.org/10.1074/jbc.274.44.31305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531329	hybrid			2022-12-25	WOS:000083379400033
J	Alberici, A; Moratto, D; Benussi, L; Gasparini, L; Ghidoni, R; Gatta, LB; Finazzi, D; Frison, GB; Trabucchi, M; Growdon, JH; Nitsch, RM; Binetti, G				Alberici, A; Moratto, D; Benussi, L; Gasparini, L; Ghidoni, R; Gatta, LB; Finazzi, D; Frison, GB; Trabucchi, M; Growdon, JH; Nitsch, RM; Binetti, G			Presenilin 1 protein directly interacts with Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; SPINAL MUSCULAR-ATROPHY; PROGRAMMED CELL-DEATH; IN-VIVO; ENDOPLASMIC-RETICULUM; INCREASED SENSITIVITY; MISSENSE MUTATIONS; CYTOCHROME-C; BETA-CATENIN	Presenilin proteins are involved in familial Alzheimer's disease, a neurodegenerative disorder characterized by massive death of neurons. We describe a direct interaction between presenilin 1 (PS1) and Bcl-2, a key factor in the regulation of apoptosis, by yeast two-hybrid interaction system, by co-immunoprecipitation, and by cross-linking experiments. Our data show that PS1 and Bcl-2 assemble into a macromolecular complex, and that they are released from this complex in response to an apoptotic: stimulus induced by staurosporine. The results support the idea of cross-talk between these two proteins during apoptosis.	Ist Ricovero & Cura Carattere Sci, Ctr S Giovanni Dio, Neurobiol Lab, Alzheimers Dis Unit, I-25123 Brescia, Italy; Univ Brescia, Sch Med, Inst Chem, I-25123 Brescia, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00154 Rome, Italy; Univ Zurich, Dept Psychiat Res, CH-8091 Zurich, Switzerland; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA	University of Brescia; University of Rome Tor Vergata; University of Zurich; Harvard University; Harvard Medical School	Binetti, G (corresponding author), Ist Ricovero & Cura Carattere Sci, Ctr S Giovanni Dio, Neurobiol Lab, Alzheimers Dis Unit, Via Pilastroni 4, I-25123 Brescia, Italy.		Binetti, Giuliano/K-4519-2016; Frisoni, Giovanni B./K-1360-2016; Ghidoni, Roberta/K-4507-2016; BENUSSI, LUISA/K-4409-2016; finazzi, dario/GYV-1567-2022; Gasparini, Laura/G-7711-2011; Frisoni, Giovanni/K-1360-2016	Binetti, Giuliano/0000-0003-2759-5844; Frisoni, Giovanni B./0000-0002-6419-1753; Ghidoni, Roberta/0000-0002-7691-1957; BENUSSI, LUISA/0000-0003-2836-8141; Gasparini, Laura/0000-0003-3894-9898; Frisoni, Giovanni/0000-0001-7075-7082; Finazzi, Dario/0000-0001-5176-2839				BAFFY G, 1993, J BIOL CHEM, V268, P6511; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Gasparini L, 1997, NEUROSCI LETT, V231, P113, DOI 10.1016/S0304-3940(97)00536-3; GASPARINI L, 1998, SOC NEUROSCI, V24, P8; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Keller JN, 1998, J NEUROSCI, V18, P4439; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shinozaki K, 1998, INT J MOL MED, V1, P797; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Waragai M, 1997, BIOCHEM BIOPH RES CO, V239, P480, DOI 10.1006/bbrc.1997.7488; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang WJ, 1998, J NEUROSCI, V18, P914; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	50	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30764	30769		10.1074/jbc.274.43.30764	http://dx.doi.org/10.1074/jbc.274.43.30764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521466	hybrid			2022-12-25	WOS:000083276700062
J	Alberta, JA; Auger, KR; Batt, D; Iannarelli, P; Hwang, G; Elliott, HL; Duke, R; Roberts, TM; Stiles, CD				Alberta, JA; Auger, KR; Batt, D; Iannarelli, P; Hwang, G; Elliott, HL; Duke, R; Roberts, TM; Stiles, CD			Platelet-derived growth factor stimulation of monocyte chemoattractant protein-1 gene expression is mediated by transient activation of the phosphoinositide 3-kinase signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; MULTIPLE SEQUENCE ELEMENTS; SERUM RESPONSE ELEMENTS; KINASE IN-VITRO; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; FACTOR INDUCTION; BINDING SITE; 3T3 CELLS	Platelet-derived growth factor (PDGF) stimulates transcription of an immediate-early gene set in Balb/c 3T3 cells. One cohort of these genes, typified by c-fos, is induced within minutes following activation of PDGF receptors. A second cohort responds to PDGF only after a significant time delay, although induction is still a primary response to receptor activation as shown by "superindnction" in the presence of the protein synthesis inhibitor cycloheximide. PDGF-receptor activated signaling pathways for the "slow" immediate-early genes are poorly resolved. Using gain-of-function mutations together with small molecule inhibitors of kinase activity, we show that activation of PI 3-kinase is both necessary and sufficient for the induction of the prototype slow immediate-early gene, monocyte chemoattractant-1 (MCP-1), Following activation of PDGF receptors, MCP-1 mRNA does not begin to accumulate for at least 90 min. However, only a brief (10 min) interval of PI 3-kinase activity is required to trigger this delayed response. The serine/threonine protein kinase, Akt/PKB, likely functions as a downstream affector of PI 3-kinase for this induction.	Dana Farber Canc Inst, Dept Microbiol & Mol Genet, Div Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Stiles, CD (corresponding author), Dana Farber Canc Inst, Dept Microbiol & Mol Genet, Div Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NICHD NIH HHS [P01 HD24826] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Coffer PJ, 1998, BIOCHEM J, V335, P1; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1989, ONCOGENE RES, V4, P177; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY K, 1988, J BIOL CHEM, V263, P4828; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POWIS G, 1994, CANCER RES, V54, P2419; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; Shamah SM, 1997, CANCER RES, V57, P4141; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sridhar P, 1999, MOL CELL BIOL, V19, P4219; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagle A, 1998, J BIOL CHEM, V273, P14968, DOI 10.1074/jbc.273.24.14968; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513	62	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31062	31067		10.1074/jbc.274.43.31062	http://dx.doi.org/10.1074/jbc.274.43.31062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521506	hybrid			2022-12-25	WOS:000083276700102
J	de la Motte, CA; Hascall, VC; Calabro, A; Yen-Lieberman, B; Strong, SA				de la Motte, CA; Hascall, VC; Calabro, A; Yen-Lieberman, B; Strong, SA			Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with Poly(I center dot C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; ADHESION MOLECULE-1 VCAM-1; INTER-ALPHA-INHIBITOR; DOUBLE-STRANDED-RNA; ENDOTHELIAL-CELLS; CROHNS-DISEASE; ULCERATIVE-COLITIS; MUSCULARIS MUCOSAE; MESENCHYMAL CELLS; MEASLES-VIRUS	Pathological changes in inflammatory bowel disease include an increase in intestinal mucosal mononuclear leukocytes and hyperplasia of the muscularis mucosae smooth muscle cells (M-SMCs), Because virus infections have correlated with disease flare, we tested the response of cultured M-SMCs to respiratory syncytial virus, measles virus, and the viral analogue, poly(I.C). Adhesion of U937 cells and peripheral blood mononuclear cells was used to measure the leukocyte-interactive potential of M-SMCs. Untreated M-SMCs, only minimally adhesive for leukocytes, bound U937 cells after treatment with respiratory syncytial virus or measles virus. Mononuclear leukocytes also bound to poly(I.C)-treated M-SMCs, Although both vascular cell adhesion molecule-1 mRNA and protein increased 3-4-fold in poly(I.C)-treated M-SMC cultures, U937 cell adhesion was not blocked by an anti-vascular cell adhesion molecule-1 monoclonal antibody. However, hyaluronidase digestion of poly(I.C)- or virus-treated M-SMCs dramatically reduced leukocyte adhesion (similar to 75%), Fluorophore-assisted carbohydrate electrophoresis demonstrated a similar to 3-fold increase in surface-bound hyaluronan on poly(I.C)treated M-SMCs compared with untreated controls. In addition, pretreatment of mononuclear cells with a blocking anti-CD44 antibody, greatly decreased adhesion to poly(I.C)-treated M-SMCs. Recognition of this virus-induced hyaluronan/CD44 mechanism of mesenchymal cell/leukocyte interaction introduces a new avenue in the research of gut inflammation.	Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Strong, SA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, NB3,9500 Euclid Ave, Cleveland, OH 44195 USA.							ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Cho JH, 1998, P NATL ACAD SCI USA, V95, P7502, DOI 10.1073/pnas.95.13.7502; COUFFINHAL T, 1993, ARTERIOSCLER THROMB, V13, P407, DOI 10.1161/01.ATV.13.3.407; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; delaMotte CA, 1997, GASTROENTEROLOGY, V112, pA956; DENNING SM, 1990, J IMMUNOL, V144, P7; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; DOUKAS J, 1994, AM J PATHOL, V145, P137; Epstein SE, 1996, LANCET, V348, pS13, DOI 10.1016/S0140-6736(96)98005-8; FARMER GW, 1973, GASTROENTEROLOGY, V65, P8; Fiocchi C, 1997, INFLAMM BOWEL DIS, V3, P133, DOI 10.1002/ibd.3780030209; FIOCCHI C, 1993, CAN J GASTROENTEROL, V7, P110, DOI 10.1155/1993/172735; Fuss IJ, 1996, J IMMUNOL, V157, P1261; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; Haller H, 1997, J IMMUNOL, V158, P1061; Heinegard D, 1998, WENN GR INT, V72, P113; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Johnston SL, 1997, PEDIATR PULM, P88; KANGRO HO, 1990, GASTROENTEROLOGY, V98, P549, DOI 10.1016/0016-5085(90)90272-3; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LEE EY, 1991, MODERN PATHOL, V4, P87; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LI HM, 1993, AM J PATHOL, V143, P1551; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCGUIRE PG, 1987, J CELL PHYSIOL, V133, P267, DOI 10.1002/jcp.1041330210; MIYAMOTO H, 1995, J GASTROENTEROL, V30, P28, DOI 10.1007/BF01211371; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MONTGOMERY SM, 1999, J MED VIROL, V116, P796; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; Roberts AI, 1997, GASTROENTEROLOGY, V113, P144, DOI 10.1016/S0016-5085(97)70089-1; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; ROSAI J, 1996, ACKERMANS SURG PATHO, V1, P729; Salmi M, 1998, INFLAMM BOWEL DIS, V4, P149; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; Strong SA, 1998, GASTROENTEROLOGY, V114, P1244, DOI 10.1016/S0016-5085(98)70431-7; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WAKEFIELD AJ, 1992, J MED VIROL, V38, P183, DOI 10.1002/jmv.1890380306; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; YANG J, 1994, J IMMUNOL, V152, P361	58	167	171	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30747	30755		10.1074/jbc.274.43.30747	http://dx.doi.org/10.1074/jbc.274.43.30747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521464	hybrid			2022-12-25	WOS:000083276700060
J	Giudici-Orticoni, MT; Guerlesquin, F; Bruschi, M; Nitschke, W				Giudici-Orticoni, MT; Guerlesquin, F; Bruschi, M; Nitschke, W			Interaction-induced redox switch in the electron transfer complex rusticyanin-cytochrome c(4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; EXTREME ACID STABILITY; BLUE-COPPER PROTEIN; THIOBACILLUS-FERROOXIDANS; METHYLAMINE DEHYDROGENASE; CRYSTAL-STRUCTURE; BINDING-DYNAMICS; AMICYANIN; OXIDATION; PLASTOCYANIN	The blue copper protein rusticyanin isolated from the acidophilic proteobacterium Thiobacillus ferrooxidans displays a pH-dependent redox midpoint potential with a pK value of 7 on the oxidized form of the protein. The nature of the alterations of optical and EPR spectra observed above the pK value indicated that the redox-linked deprotonation occurs on the epsilon-nitrogen of the histidine ligands to the copper ion. Complex formation between rusticyanin and its probable electron transfer partner, cytochrome c(4), induced a decrease of rusticyanin's redox midpoint potential by more than 100 mV together with spectral changes similar to those observed above the pK value of the free form. Complex formation thus substantially modifies the pK value of the surface-exposed histidine ligand to the copper ion and thereby tunes the redox midpoint potential of the copper site. Comparisons with reports on other blue copper proteins suggest that the surface-exposed histidine ligand is employed as a redox tuning device by many members of this group of soluble electron carriers.	Inst Biol Struct & Mikrobiol, CNRS, UPR 9036, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Nitschke, W (corresponding author), Inst Biol Struct & Microbiol, CNRS, UPR 9036, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Nitschke, Wolfgang/C-4812-2012	Nitschke, Wolfgang/0000-0003-2084-3032				Appia-Ayme C, 1998, FEMS MICROBIOL LETT, V167, P171, DOI 10.1111/j.1574-6968.1998.tb13224.x; BLAKE RC, 1994, BIOCHEMISTRY-US, V33, P9220, DOI 10.1021/bi00197a025; Botuyan MV, 1996, J MOL BIOL, V263, P752, DOI 10.1006/jmbi.1996.0613; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; CAVAZZA C, 1995, FEMS MICROBIOL LETT, V130, P193; Cavazza C, 1996, EUR J BIOCHEM, V242, P308, DOI 10.1111/j.1432-1033.1996.0308r.x; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; COX JC, 1978, BIOCHEM J, V174, P497, DOI 10.1042/bj1740497; COX JC, 1978, FEBS LETT, V93, P157, DOI 10.1016/0014-5793(78)80826-6; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; Drepper F, 1997, BIOCHEMISTRY-US, V36, P1418, DOI 10.1021/bi961350u; DUTTON PL, 1970, BIOCHEMISTRY-US, V9, P5077, DOI 10.1021/bi00828a006; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; Elbehti A, 1999, J BIOL CHEM, V274, P16760, DOI 10.1074/jbc.274.24.16760; GIUDICIORTICONI MT, 1997, BIOMINE, V97; GRAY KA, 1988, J BIOL CHEM, V263, P13987; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HALADJIAN J, 1993, J ELECTROANAL CHEM, V352, P329, DOI 10.1016/0022-0728(93)80276-N; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; INGLEDEW WJ, 1977, FEMS MICROBIOL LETT, V2, P193; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LOMMEN A, 1990, J BIOL CHEM, V265, P2768; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MOSER CC, 1988, BIOCHEMISTRY-US, V27, P2450, DOI 10.1021/bi00407a031; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NG TCN, 1995, BBA-BIOENERGETICS, V1230, P119, DOI 10.1016/0005-2728(95)00043-I; NUNZI F, 1993, BIOCHIM BIOPHYS ACTA, V1162, P28, DOI 10.1016/0167-4838(93)90123-9; NUNZI F, 1994, BIOCHEM BIOPH RES CO, V203, P1655, DOI 10.1006/bbrc.1994.2376; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P340; PETTIGREW GW, 1988, BIOCHEM J, V252, P427, DOI 10.1042/bj2520427; Schoepp B, 1999, ADV INORG CHEM, V47, P335, DOI 10.1016/S0898-8838(08)60082-3; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; VANDERKOOI J, 1974, ARCH BIOCHEM BIOPHYS, V162, P385, DOI 10.1016/0003-9861(74)90196-9; Walter RL, 1996, J MOL BIOL, V263, P730, DOI 10.1006/jmbi.1996.0612; YAMANAKA T, 1991, DEV GEOCHEM, V6, P267; Zhu ZY, 1998, BIOCHEMISTRY-US, V37, P17128, DOI 10.1021/bi9817919	36	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30365	30369		10.1074/jbc.274.43.30365	http://dx.doi.org/10.1074/jbc.274.43.30365			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521412	hybrid			2022-12-25	WOS:000083276700008
J	Roujeinikova, A; Sedelnikova, S; de Boer, GJ; Stuitje, AR; Slabas, AR; Rafferty, JB; Rice, DW				Roujeinikova, A; Sedelnikova, S; de Boer, GJ; Stuitje, AR; Slabas, AR; Rafferty, JB; Rice, DW			Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN REDUCTASE; ESCHERICHIA-COLI; REFINEMENT; SYSTEM; MODELS; ERRORS; ENVM; MAPS	Enoyl acyl carrier protein reductase (ENR) is involved in fatty acid biosynthesis. In Escherichia coli this enzyme is the target for the experimental family of antibacterial agents, the diazaborines, and for triclosan, a broad spectrum antimicrobial agent. Biochemical studies have suggested that the mechanism of diazaborine inhibition is dependent on NAD(+) and not NADH, and resistance of Brassica napus ENR to diazaborines is thought to be due to the replacement of a glycine in the active site of the E. coli enzyme by an alanine at position 138 in the plant homologue, We present here an x-ray analysis of crystals of B. napus ENR A138G grown in the presence of either NAD(+) or NADH and the structures of the corresponding ternary complexes with thienodiazaborine obtained either by soaking the drug into the crystals or by co-crystallization of the mutant with NAD(+) and diazaborine. Analysis of the ENR A138G complex with diazaborine and NAD(+) shows that the site of diazaborine binding is remarkably close to that reported for E. coli ENR. However, the structure of the ternary ENR A138G-NAD(+)-diazaborine complex obtained using cocrystallization reveals a previously unobserved conformational change affecting 11 residues that flank the active site and move closer to the nicotinamide moiety making extensive van der Waals contacts with diazaborine, Considerations of the mode of substrate binding suggest that this conformational change may reflect a structure of ENR that is important in catalysis.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Vrije Univ Amsterdam, Inst Mol Biol Studies, Dept Genet, NL-1081 HV Amsterdam, Netherlands; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England	University of Sheffield; Vrije Universiteit Amsterdam; Durham University	Rice, DW (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Liu, Shih/Q-1672-2019; Heterocycles, BoronNitrogen/Q-1699-2019	Roujeinikova, Anna/0000-0001-8478-4751; Rafferty, John/0000-0003-1183-7474				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baldock C, 1998, J MOL BIOL, V284, P1529, DOI 10.1006/jmbi.1998.2271; Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BURGI HB, 1983, ACCOUNTS CHEM RES, V16, P153, DOI 10.1021/ar00089a002; de Boer GJ, 1999, MOL MICROBIOL, V31, P443, DOI 10.1046/j.1365-2958.1999.01182.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MOEWS PC, 1975, J MOL BIOL, V91, P201, DOI 10.1016/0022-2836(75)90160-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WILKIE J, 1995, J CHEM SOC PERK T 2, P1559, DOI 10.1039/p29950001559	26	48	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30811	30817		10.1074/jbc.274.43.30811	http://dx.doi.org/10.1074/jbc.274.43.30811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521472	hybrid, Green Published			2022-12-25	WOS:000083276700068
J	D'Angelo, G; Graceffa, P; Wang, CLA; Wrangle, J; Adam, LP				D'Angelo, G; Graceffa, P; Wang, CLA; Wrangle, J; Adam, LP			Mammal-specific, ERK-dependent, caldesmon phosphorylation in smooth muscle - Quantitation using novel anti-phosphopeptide antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NONMUSCLE CALDESMON; MYOSIN PHOSPHATASE; P34CDC2 KINASE; CROSS-LINKING; H-CALDESMON; MAP KINASE; IDENTIFICATION; PURIFICATION; EXPRESSION	Extracellular signal-regulated kinases (ERKs) phosphorylate the high molecular mass isoform of the actin-binding protein caldesmon (h-CaD) at two sites (Ser(759) and Ser(789)) during smooth muscle stimulation. To investigate the role of phosphorylation at these sites, antibodies were generated against phosphopeptides analogous to the sequences around Ser(759) and Ser(789). Affinity-purified antibodies were phosho- and sequence-specific. The major site of phosphorylation in h-CaD in porcine carotid arterial muscle strips was at Ser(789); however, the amount of phosphate did not vary appreciably with either KCl or phorbol ester stimulation. Phosphorylation at Ser(759) of h-CaD was almost undetectable (<0.005 mol of phosphate/mol of protein). Moreover, phosphorylation of the low molecular mass isoform of the protein (l-CaD) at the site analogous to Ser(789) was greater in serum-stimulated cultured smooth muscle cells than in serum-starved cells. Serum-stimulated l-Call phosphorylation was attenuated by the protein kinase inhibitor PD98059. These data 1) identify Ser(789) of h-CaD as the major site of ERK-dependent phosphorylation in carotid arteries; 2) show that the level of phosphorylation at Ser(789) is relatively constant following carotid arterial muscle stimulation, despite an increase in total protein phosphate content; and 3) suggest a functional role for ERK-dependent l-CaD phosphorylation in cell division.	Boston Biomed Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Adam, LP (corresponding author), Bristol Myers Squibb Co, Cardiovasc Drug Discovery, F14-07,POB 4000, Princeton, NJ 08543 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030917, P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56035] Funding Source: Medline; NIAMS NIH HHS [AR41637, AR30917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BARANY K, 1992, BIOCHIM BIOPHYS ACTA, V1134, P233, DOI 10.1016/0167-4889(92)90181-A; BARANY M, 1992, ARCH BIOCHEM BIOPHYS, V294, P571, DOI 10.1016/0003-9861(92)90727-E; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; Franklin MT, 1997, AM J PHYSIOL-CELL PH, V273, pC1819, DOI 10.1152/ajpcell.1997.273.6.C1819; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Gerthoffer WT, 1997, AM J PHYSIOL-LUNG C, V272, pL244, DOI 10.1152/ajplung.1997.272.2.L244; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; MAK AS, 1991, J BIOL CHEM, V266, P19971; MARSTON SB, 1991, BIOCHEM J, V279, P1; NIXON GF, 1995, J PHYSIOL-LONDON, V487, P283, DOI 10.1113/jphysiol.1995.sp020879; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOBUE K, 1991, J BIOL CHEM, V266, P12115; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; WATSON MH, 1993, CIRC RES, V73, P109, DOI 10.1161/01.RES.73.1.109; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	27	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30115	30121		10.1074/jbc.274.42.30115	http://dx.doi.org/10.1074/jbc.274.42.30115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514499	hybrid			2022-12-25	WOS:000083176400078
J	Kholodenko, BN; Demin, OV; Moehren, G; Hoek, JB				Kholodenko, BN; Demin, OV; Moehren, G; Hoek, JB			Quantification of short term signaling by the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; TYROSINE-PHOSPHORYLATED PEPTIDES; ACTIVATED PROTEIN-KINASE; SH2 DOMAIN SPECIFICITY; CELL-CYCLE ARREST; EGF RECEPTOR; LATERAL DIFFUSION; PHOSPHOLIPASE-C; INSULIN-RECEPTOR; RAT HEPATOCYTES	During the past decade, our knowledge of molecular mechanisms involved in growth factor signaling has proliferated almost explosively. However, the kinetics and control of information transfer through signaling networks remain poorly understood. This paper combines experimental kinetic analysis and computational modeling of the short term pattern of cellular responses to epidermal growth factor (EGF) in isolated hepatocytes. The experimental data show transient tyrosine phosphorylation of the EGF receptor (EGFR) and transient or sustained response patterns in multiple signaling proteins targeted by EGFR. Transient responses exhibit pronounced maxima, reached within 15-30 s of EGF stimulation and followed by a decline to relatively low (quasi-steady-state) levels. In contrast to earlier suggestions, we demonstrate that the experimentally observed transients can be accounted for without requiring receptor-mediated activation of specific tyrosine phosphatases, following EGF stimulation. The kinetic model predicts how the cellular response is controlled by the relative levels and activity states of signaling proteins and under what conditions activation patterns are transient or sustained. EGFR. signaling patterns appear to be robust with respect to variations in many elemental rate constants within the range of experimentally measured values. On the other hand, we specify which changes in the kinetic scheme, rate constants, and total amounts of molecular factors involved are incompatible with the experimentally observed kinetics of signal transfer. Quantitation of signaling network responses to growth factors allows us to assess how cells process information controlling their growth and differentiation.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Moscow State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	Jefferson University; Lomonosov Moscow State University	Kholodenko, BN (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Admin, SBI/HGB-2738-2022	Hoek, Jan/0000-0001-7127-4218; Kholodenko, Boris/0000-0002-9483-4975	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, R01AA008714] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215, AA07186, AA08714] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ARGETSINGER LS, 1992, J BIOL CHEM, V267, P22095; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Carver RS, 1997, ENDOCRINOLOGY, V138, P5195, DOI 10.1210/en.138.12.5195; CHAIDARUN SS, 1994, J ENDOCRINOL, V143, P489, DOI 10.1677/joe.0.1430489; CHERRY RJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P289, DOI 10.1016/0304-4157(79)90009-1; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; Dahmane A, 1996, EUR J CELL BIOL, V69, P335; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELTIS LD, 1991, BIOCHEMISTRY-US, V30, P3663, DOI 10.1021/bi00229a011; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FOSTER WR, 1993, J NEUROPHYSIOL, V70, P2502, DOI 10.1152/jn.1993.70.6.2502; GLADHAUG IP, 1992, DIGEST DIS SCI, V37, P233, DOI 10.1007/BF01308177; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; GUPTA BD, 1990, J PHYSIOL-LONDON, V430, P483, DOI 10.1113/jphysiol.1990.sp018303; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; Haugh JM, 1997, BIOPHYS J, V72, P2014, DOI 10.1016/S0006-3495(97)78846-5; HEARON JOHN Z., 1953, BULL MATH BIOPHYS, V15, P121, DOI 10.1007/BF02476377; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; HOEK JB, 1987, J BIOL CHEM, V262, P682; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUBLER L, 1989, J BIOL CHEM, V264, P1558; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KHOLODENKO BN, 1995, TRENDS BIOCHEM SCI, V20, P52, DOI 10.1016/S0968-0004(00)88955-0; Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1; Kholodenko BN, 1998, BBA-GEN SUBJECTS, V1379, P337, DOI 10.1016/S0304-4165(97)00114-1; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; LITWIN CME, 1992, FEBS LETT, V309, P275, DOI 10.1016/0014-5793(92)80788-I; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAYO KH, 1989, J BIOL CHEM, V264, P17838; MYERS AC, 1987, J BIOL CHEM, V262, P6494; NAQVI KR, 1974, CHEM PHYS LETT, V28, P280; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; ORourke MF, 1997, BIOCHEM PHARMACOL, V53, P1445, DOI 10.1016/S0006-2952(97)00085-3; PAN MG, 1995, ONCOGENE, V11, P2005; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pei ZD, 1996, BIOCHEM BIOPH RES CO, V228, P802, DOI 10.1006/bbrc.1996.1735; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; POSNER I, 1992, J BIOL CHEM, V267, P20638; POSNER I, 1994, FEBS LETT, V353, P155, DOI 10.1016/0014-5793(94)00989-9; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; Saso K, 1997, GASTROENTEROLOGY, V112, P2073, DOI 10.1053/gast.1997.v112.pm9178701; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Shymko RM, 1997, BIOCHEM J, V326, P463, DOI 10.1042/bj3260463; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Thoresen GH, 1998, J CELL PHYSIOL, V175, P10, DOI 10.1002/(SICI)1097-4652(199804)175:1<10::AID-JCP2>3.3.CO;2-6; TORNEY DC, 1983, PROC R SOC LON SER-A, V387, P147, DOI 10.1098/rspa.1983.0055; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WOFSY C, 1992, BIOPHYS J, V63, P98, DOI 10.1016/S0006-3495(92)81572-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YANG LJ, 1994, J BIOL CHEM, V269, P7156; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	95	447	458	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30169	30181		10.1074/jbc.274.42.30169	http://dx.doi.org/10.1074/jbc.274.42.30169			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514507	hybrid			2022-12-25	WOS:000083176400086
J	Rani, PG; Bachhawat, K; Misquith, S; Surolia, A				Rani, PG; Bachhawat, K; Misquith, S; Surolia, A			Thermodynamic studies of saccharide binding to artocarpin, a B-cell mitogen, reveals the extended nature of its interaction with mannotriose [3,6-di-O-(alpha-D-mannopyranosyl)-D-mannose]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN-CARBOHYDRATE INTERACTIONS; LENS-CULINARIS LECTIN; PISUM-SATIVUM LECTIN; CONCANAVALIN-A; TITRATION MICROCALORIMETRY; CORE TRIMANNOSIDE; GLYCOPEPTIDES; SPECIFICITIES; OLIGOMANNOSE; RECOGNITION	The thermodynamics of binding of various saccharides to artocarpin, from Artocarpus integrifolia seeds, a homotetrameric lectin (M-r 65,000) with one binding site per subunit, was determined by isothermal titration calorimetry measurements at 280 and 293 K, The binding enthalpies, Delta H-b, are the same at both temperatures, and the values range from -10.94 to -47.11 kJ mol(-1). The affinities of artocarpin as obtained from isothermal titration calorimetry are in reasonable agreement with the results obtained by enzyme-linked lectin absorbent essay, which is based on the minimum amount of ligand required to inhibit horseradish peroxidase binding to artocarpin in enzyme-linked lectin absorbent essay (Misquith, S,, Rani, P. G., and Surolia, A. (1994) J. Biol. Chem. 269, 30393-30401). The interactions are mainly enthalpically driven and exhibit enthalpy-entropy compensation. The order of binding affinity of artocarpin is as follows: mannotriose >Man alpha 3Man > GlcNAc(2)Man(3)> Me alpha Man >Man >Man alpha 6Man >Man alpha 2Man >Me alpha Glc >Glc, i.e. 7>4>2>1.4>1>0.4>0.3>0.24>0.11. The Delta H for the interaction of Man alpha 3Man, Man alpha 6Man, and Me alpha Man are similar and 20 kJ mol(-1) lower than that of mannotriose, This indicates that, while Man alpha 3Man and Man alpha 6Man interact with the lectin exclusively through their non-reducing end monosaccharide with the subsites specific for the alpha 1,3 and alpha 1,6 arms, the mannotriose interacts with the lectin simultaneously through all three of its mannopyranosyl residues. This study thus underscores the distinction in the recognition of this common oligosaccharide motif in comparison with that displayed by other lectins with related specificity.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560012, Karnataka, India; St Josephs Coll, Dept Chem, Bangalore 560025, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); St. Josephs College	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BUNNMORENO MM, 1981, J IMMUNOL, V127, P427; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; Dam TK, 1998, J BIOL CHEM, V273, P32826, DOI 10.1074/jbc.273.49.32826; Dam TK, 1998, J BIOL CHEM, V273, P12082, DOI 10.1074/jbc.273.20.12082; de Miranda-Santos I K, 1991, J Immunol Methods, V140, P197; Dong HD, 1996, IMMUNOL INVEST, V25, P65, DOI 10.3109/08820139609059291; GarciaHernandez E, 1997, PROTEINS, V29, P467, DOI 10.1002/(SICI)1097-0134(199712)29:4<467::AID-PROT7>3.0.CO;2-5; Goldstein I.I., 2012, LECTINS PROPERTIES F, P233; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; MANDAL DK, 1993, BIOCHEMISTRY-US, V32, P5116, DOI 10.1021/bi00070a020; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Schwarz FP, 1996, BIOCHEM J, V316, P123, DOI 10.1042/bj3160123; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHARON N, 1989, LECTINS; SHARON N, 1990, CHEM BRITAIN ROYAL S; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66	27	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29694	29698		10.1074/jbc.274.42.29694	http://dx.doi.org/10.1074/jbc.274.42.29694			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514441	hybrid			2022-12-25	WOS:000083176400020
J	Franchi-Gazzola, R; Visigalli, R; Bussolati, O; Dall'Asta, V; Gazzola, GC				Franchi-Gazzola, R; Visigalli, R; Bussolati, O; Dall'Asta, V; Gazzola, GC			Adaptive increase of amino acid transport system A requires ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; PROTEIN-KINASE CASCADES; CANINE KIDNEY-CELLS; HYPERTONIC STRESS; PLASMA-MEMBRANE; MAP KINASE; S6 KINASE; INSULIN; INDUCTION; MECHANISM	Amino acid starvation markedly stimulates the activity of system A, a widely distributed transport route for neutral amino acids. The involvement of MAPK (mitogen-activated protein kinase) pathways in this adaptive increase of transport activity was studied in cultured human fibroblasts. In these cells, a 3-fold stimulation of system A transport activity required a 6-h amino acid-free incubation. However, a rapid tyrosine phosphorylation of ERK (extracellular regulated kinase) 1 and 2, and JNK (Jun N-terminal kinase) 1, but not of p38, was observed after the substitution of complete medium with amino acid-free saline solution. ERK1/2 activity was 4-fold enhanced after a 15-min amino acid-free incubation and maintained at stimulated values thereafter. A transient, less evident stimulation of JNK1 activity was also detected, while the activity of p38 was not affected by amino acid deprivation. PD98059, an inhibitor of ERK1/2 activation, completely suppressed the adaptive increase of system A transport activity that, conversely, was unaffected by inhibitors of other transduction pathways, such as rapamycin and wortmannin, as well as by chronic treatment with phorbol esters. In the presence of either L-proline or 2-(methylaminoisobutyric) acid, two substrates of system A, the transport increase was prevented and no sustained stimulation of ERK1/2 was observed. To identify the stimulus that maintains MAPK activation, cell volume was monitored during amino acid-free incubation. It was found that amino acid deprivation caused a progressive cell shrinkage (30% after a 6-h starvation). If proline was added to amino acid-starved, shrunken cells, normal values of cell volume were rapidly restored. However, proline-dependent volume rescue was hampered if cells were pretreated with PD98059. It is concluded that (a) the triggering of adaptive increase of system A activity requires a prolonged activation of ERK1 and 2 and that (b) cell volume changes, caused by the depletion of intracellular amino acid pool, may underlie the activation of MAPKs.	Univ Parma, Ist Patol Gen, I-43100 Parma, Italy	University of Parma	Gazzola, GC (corresponding author), Univ Parma, Ist Patol Gen, Via Volturno 39, I-43100 Parma, Italy.		Dall'Asta, Valeria/M-6698-2015; Bussolati, Ovidio/B-7589-2013	Dall'Asta, Valeria/0000-0001-8540-0916; Bussolati, Ovidio/0000-0002-4301-2939				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BARBER EF, 1983, J BIOL CHEM, V258, P1851; Bianchini L, 1997, J BIOL CHEM, V272, P271; BONADONNA RC, 1993, J CLIN INVEST, V91, P514, DOI 10.1172/JCI116230; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Bussolati O, 1996, FASEB J, V10, P920, DOI 10.1096/fasebj.10.8.8666170; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; DalL'Asta V, 1999, AM J PHYSIOL-CELL PH, V276, pC865, DOI 10.1152/ajpcell.1999.276.4.C865; DALLASTA V, 1991, J BIOL CHEM, V266, P1591; DALLASTA V, 1994, J BIOL CHEM, V269, P10485; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; FranchiGazzola R, 1996, J BIOL CHEM, V271, P26124, DOI 10.1074/jbc.271.42.26124; GAZZOLA G, 1991, Cellular Physiology and Biochemistry, V1, P131, DOI 10.1159/000154601; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; GAZZOLA GC, 1981, J BIOL CHEM, V256, P3191; GAZZOLA GC, 1972, BIOCHIM BIOPHYS ACTA, V266, P407, DOI 10.1016/0005-2736(72)90097-1; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Horio M, 1997, AM J PHYSIOL-CELL PH, V272, pC804, DOI 10.1152/ajpcell.1997.272.3.C804; HUANG SX, 1995, BIOCHEM J, V310, P881, DOI 10.1042/bj3100881; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KLIP A, 1986, J CELL PHYSIOL, V127, P244, DOI 10.1002/jcp.1041270209; Kultz D, 1998, J EXP BIOL, V201, P3015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LONGO N, 1985, BIOCHIM BIOPHYS ACTA, V844, P216, DOI 10.1016/0167-4889(85)90093-X; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; McDowell HE, 1998, FEBS LETT, V441, P15, DOI 10.1016/S0014-5793(98)01508-7; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TRAMACERE M, 1984, EXP CELL RES, V151, P70, DOI 10.1016/0014-4827(84)90356-2; YAMAUCHI A, 1994, AM J PHYSIOL-CELL PH, V267, pC1493, DOI 10.1152/ajpcell.1994.267.5.C1493	44	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28922	28928		10.1074/jbc.274.41.28922	http://dx.doi.org/10.1074/jbc.274.41.28922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506137	hybrid			2022-12-25	WOS:000083017800016
J	Nissim, I; Brosnan, ME; Yudkoff, M; Nissim, I; Brosnan, JT				Nissim, I; Brosnan, ME; Yudkoff, M; Nissim, I; Brosnan, JT			Studies of hepatic glutamine metabolism in the perfused rat liver with N-15-labeled glutamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS ISOTOPOMER ANALYSIS; UREA SYNTHESIS; NITROGEN-METABOLISM; HEPATOCYTES; UREAGENESIS; GLUCOSE; DEHYDROGENASE; SYNTHETASE; INSULIN; AMMONIA	This study examines the role of glucagon and insulin in the incorporation of N-15 derived from N-15-labeIed gin tamine into aspartate, citrulline and, thereby, [N-15]urea isotopomers. Rat livers were perfused, in the nonrecirculating mode, with 0.3 mM NH4Cl and either 2-N-15- or 5-N-15-labeled glutamine (1 mM). The isotopic enrichment of the two nitrogenous precursor pools (ammonia and aspartate) involved in urea synthesis as well as the production of [N-15]urea isotopomers were determined using gas chromatography-mass spectrometry. This information was used to examine the hypothesis that 5-N of glutamine is directly channeled to carbamyl phosphate (CP) synthesis. The results indicate that the predominant metabolic fate of [2-N-15] and [5-N-15]glutamine is incorporation into urea. Glucagon significantly stimulated the uptake of N-15-labeled glutamine and its metabolism via phosphate dependent glutaminase (PDG) to form Um+1 and Um+2 (urea containing one or two atoms of N-15). However, insulin had little effect compared with control. The [5-N-15]glutamine primarily entered into urea via ammonia incorporation into CP, whereas the [2-N-15]glutamine was predominantly incorporated via aspartate. This is evident hom the relative enrichments of aspartate and of citrulline generated from each substrate. Furthermore, the data indicate that the (NH3)-N-15 that was generated in the mitochondria by either PDG (from 5-N-15) or glutamate dehydrogenase (from 2-N-15) enjoys the same partition between incorporation into CP or exit hom the mitochondria Thus, there is no evidence for preferential access for ammonia that arises by the action of PDG to carbamyl-phosphate synthetase. To the contrary, we provide strong evidence that such ammonia is metabolized without any such metabolic channeling. The glucagon-induced increase in [N-15]urea synthesis was associated with a significant elevation in hepatic N-acetylglutamate concentration. Therefore, the hormonal regulation of [N-15]urea isotopomer production depends upon the coordinate action of the mitochondrial PDG pathway and the synthesis of N-acetylglutamate (an obligatory activator of CP). The current study may provide the theoretical and methodological foundations for in vivo investigations of the relationship between the hepatic urea cycle enzyme activities, the flux of N-15-labeled glutamine into the urea cycle, and the production of urea isotopomers.	Univ Penn, Sch Med, Dept Pediat, Div Child Dev & Rehabil, Philadelphia, PA 19104 USA; Mem Univ Newfoundland, Dept Biochem, St Johns, NF A1B 3X9, Canada	University of Pennsylvania; Memorial University Newfoundland	Nissim, I (corresponding author), Abramson Pediat Res Ctr, Div Child Dev, Rm 510C,34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.				NICHD NIH HHS [HD-34900] Funding Source: Medline; NIDDK NIH HHS [DK-53761] Funding Source: Medline; NINDS NIH HHS [NS-37915] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053761, R01DK053761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKMORE PF, 1979, J BIOL CHEM, V254, P2828; BROSNAN JT, 1970, BIOCHEM J, V117, P91, DOI 10.1042/bj1170091; Brosnan JT, 1996, J BIOL CHEM, V271, P16199, DOI 10.1074/jbc.271.27.16199; BROSNAN JT, 1995, ADV ENZYME REGUL, V35, P131, DOI 10.1016/0065-2571(94)00003-L; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; CASTILLO L, 1993, P NATL ACAD SCI USA, V90, P7749, DOI 10.1073/pnas.90.16.7749; CHARLES AS, 1998, NEW ENGL J MED, V338, P1352; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; FAHIEN LA, 1964, J BIOL CHEM, V239, P1935; GEYER JW, 1971, ANAL BIOCHEM, V39, P412, DOI 10.1016/0003-2697(71)90431-3; HALL LM, 1958, J BIOL CHEM, V230, P1013; HAMBERG O, 1994, J HEPATOL, V21, P381, DOI 10.1016/S0168-8278(05)80317-4; HAUSSINGER D, 1983, BIOCHIM BIOPHYS ACTA, V755, P272, DOI 10.1016/0304-4165(83)90214-3; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KASHIWAGURA T, 1985, J BIOL CHEM, V260, P407; KIRSTEN E, 1963, BIOCHEM Z, V337, P312; LUND P, 1984, BIOCHEM J, V218, P991, DOI 10.1042/bj2180991; MAGNUSSON I, 1995, DIABETES, V44, P185, DOI 10.2337/diabetes.44.2.185; MCGIVAN JD, 1975, FEBS LETT, V52, P1, DOI 10.1016/0014-5793(75)80624-7; MEIJER AJ, 1985, FEBS LETT, V191, P249, DOI 10.1016/0014-5793(85)80018-1; NISSIM I, 1981, ANAL BIOCHEM, V114, P125, DOI 10.1016/0003-2697(81)90462-0; NISSIM I, 1993, J AM SOC NEPHROL, V3, P1416; Nissim I, 1996, J BIOL CHEM, V271, P31234, DOI 10.1074/jbc.271.49.31234; NISSIM I, 1992, ARCH BIOCHEM BIOPHYS, V292, P393, DOI 10.1016/0003-9861(92)90008-K; PACITTI AJ, 1992, J SURG RES, V53, P298, DOI 10.1016/0022-4804(92)90051-Z; Reeds PJ, 1997, EUR J PEDIATR, V156, pS50, DOI 10.1007/PL00014272; Sies H, 1978, Methods Enzymol, V52, P48; STEWART PM, 1980, J BIOL CHEM, V255, P5270; VINNARS E, 1975, ANN SURG, V182, P665, DOI 10.1097/00000658-197512000-00001; Yudkoff M, 1996, J CLIN INVEST, V98, P2167, DOI 10.1172/JCI119023	32	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28958	28965		10.1074/jbc.274.41.28958	http://dx.doi.org/10.1074/jbc.274.41.28958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506142	hybrid			2022-12-25	WOS:000083017800021
J	Fetrow, JS; Siew, N; Skolnick, J				Fetrow, JS; Siew, N; Skolnick, J			Structure-based functional motif identifies a potential disulfide oxidoreductase active site in the serine/threonine protein phosphatase-1 subfamily	FASEB JOURNAL			English	Article						functional genomics; function prediction; structural genomics; structure-based function annotation; fuzzy functional form	INTERLEUKIN-1 SIGNAL-TRANSDUCTION; TUMOR-NECROSIS-FACTOR; TO-FUNCTION PARADIGM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REDOX REGULATION; THIOREDOXIN; INACTIVATION; THIOLTRANSFERASE; RESOLUTION	In previous work, 3-dimensional descriptors of protein function ('fuzzy functional forms') were used to identify disulfide oxidoreductase active sites in high-resolution protein structures. During this analysis, a potential disulfide oxidoreductase active site in the serine/threonine protein phosphatase-1 (PP1) crystal structure was discovered. In PP1, the potential redox active site is located in close proximity to the phosphatase active site. This result is interesting in view of literature suggesting that serine/threonine phosphatases could be subject to redox control mechanisms within the cell; however, the actual source of this control is unknown. Additional analysis presented here shows that the putative oxidoreductase active site is highly conserved in the serine/threonine phosphatase-l subfamily, but not in the serine/threonine phosphatase-2A or -2B subfamilies. These results demonstrate the significant advantages of using structure-based motifs for protein functional site identification. First, a putative disulfide oxidoreductase active site has been identified in serine-threonine phosphatases using a descriptor built from the glutaredoxin/thioredoxin family, proteins that have no apparent evolutionary relationship whatsoever to the PPI proteins. Second, the proximity of the putative disulfide oxidoreductase active site to the phosphatase active site provides evidence toward a regulatory control mechanism. No sequence-based method could provide either piece of information.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Scripps Research Institute	Fetrow, JS (corresponding author), GeneFormat Inc, 5830 Oberlin Dr,Ste 200, San Diego, CA 92121 USA.	jacque@geneformatics.com	Kishore, Gade/C-6943-2011	Kishore, Gade/0000-0003-0911-4381; Fetrow, Jacquelyn/0000-0002-0528-2049				ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; CHAOHONG S, 1997, PROTEIN SCI, V6, P383; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Fetrow JS, 1998, J MOL BIOL, V281, P949, DOI 10.1006/jmbi.1998.1993; Fetrow JS, 1998, J MOL BIOL, V282, P703, DOI 10.1006/jmbi.1998.2061; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; GUY GR, 1993, J BIOL CHEM, V268, P2141; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Jia ZC, 1997, BIOCHEM CELL BIOL, V75, P17, DOI 10.1139/bcb-75-1-17; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEMANI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P24, DOI 10.1006/abbi.1993.1004; REY A, 1993, PROTEINS, V16, P8, DOI 10.1002/prot.340160103; SHENKIN PS, 1991, PROTEINS, V11, P297, DOI 10.1002/prot.340110408; SOULIE JM, 1985, EUR J BIOCHEM, V152, P565, DOI 10.1111/j.1432-1033.1985.tb09232.x; YANG YF, 1991, J BIOL CHEM, V266, P12766; YANG YF, 1991, J BIOL CHEM, V266, P12759; Zhang L, 1998, FOLD DES, V3, P535, DOI 10.1016/S1359-0278(98)00069-8	29	68	70	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1866	1874		10.1096/fasebj.13.13.1866	http://dx.doi.org/10.1096/fasebj.13.13.1866			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506591				2022-12-25	WOS:000083063400023
J	Patel, HJ; Belvisi, MG; Donnelly, LE; Yacoub, MH; Chung, KF; Mitchell, JA				Patel, HJ; Belvisi, MG; Donnelly, LE; Yacoub, MH; Chung, KF; Mitchell, JA			Constitutive expressions of type INOS in human airway smooth muscle cells: evidence for an antiproliferative role	FASEB JOURNAL			English	Article						hyperplasia; human respiratory tract; nitric oxide	NITRIC-OXIDE SYNTHASE; RELAXING FACTOR; HUMAN-NEUTROPHILS; L-ARGININE; RELEASE; RAT; CYCLO-OXYGENASE-2; NEUROTRANSMITTER; INHIBITORS; MESSENGER	In airway diseases, smooth muscle cells can proliferate at exaggerated rates; thus, the identification of endogenous pathways that limit proliferative responses is important. Here we show that human airway smooth muscle express type I nitric oxide synthase (NOS), which results in inhibition of DNA synthesis and cell proliferation. In addition, superoxide dismutase (SOD), a cell-permeable mimetic that increases the biological half-life and therefore enhances the biological activity of endogenously released nitric oxide (NO), or NO-releasing drugs also greatly reduce DNA synthesis and cell proliferation. Observations in this study have important clinical implications: 1) NOS inhibition may exacerbate airway disease and 2) inhaled SOD/mimetics or NO/nitrovasodilators may be therapies for the treatment of asthma or chronic obliterative pulmonary disease.	Royal Brompton & Natl Heart Hosp, Unit Crit Care Med, Imperial Coll, Sch Med, London SW3 6NP, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Thorac Med, London SW3 6LY, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Cardiothorac Surg, London SW3 6LY, England; Rhone Poulenc Rorer, Dept Pharmacol, Dagenham Res Ctr R&D, Dagenham RM10 7XS, Essex, England	Imperial College London; Imperial College London; Imperial College London; Sanofi-Aventis	Mitchell, JA (corresponding author), Royal Brompton & Natl Heart Hosp, Unit Crit Care Med, Imperial Coll, Sch Med, Sydney St, London SW3 6NP, England.		Belvisi, Maria G/A-3055-2009; Mitchell, Jane A/A-1991-2009; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Donnelly, Louise/0000-0002-0753-5425	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNAL JF, 1994, AM J PHYSIOL, V36, pC1381; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; Belvisi MG, 1998, BRIT J PHARMACOL, V125, P1102, DOI 10.1038/sj.bjp.0702104; BELVISI MG, 1995, ARCH INT PHARMACOD T, V329, P97; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; Curzen NP, 1996, INTENS CARE MED, V22, P596, DOI 10.1007/BF01708105; FLOWER MA, 1995, AM J PHYSIOL, V269, P11198; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574, DOI 10.1165/ajrcmb/7.6.574; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kallio EA, 1997, J CLIN INVEST, V100, P2984, DOI 10.1172/JCI119852; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MITCHELL JA, 1993, BRIT J PHARMACOL, V109, P265, DOI 10.1111/j.1476-5381.1993.tb13563.x; MULSCH A, 1990, N-S ARCH PHARMACOL, V341, P143; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Sarkar R, 1998, J VASC RES, V35, P135, DOI 10.1159/000025576; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; WARD JK, 1995, J PHYSIOL-LONDON, V483, P525, DOI 10.1113/jphysiol.1995.sp020603; WHITTLE BJR, 1995, HISTOCHEM J, V27, P727; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	32	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1810	1816		10.1096/fasebj.13.13.1810	http://dx.doi.org/10.1096/fasebj.13.13.1810			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506584	Bronze			2022-12-25	WOS:000083063400016
J	Hoober, KL; Glynn, NM; Burnside, J; Coppock, DL; Thorpe, C				Hoober, KL; Glynn, NM; Burnside, J; Coppock, DL; Thorpe, C			Homology between egg white sulfhydryl oxidase and quiescin Q6 defines a new class of flavin-linked sulfhydryl oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EXPRESSION; GENE	The flavin-dependent sulfhydryl oxidase from chicken egg white catalyzes the oxidation of sulfhydryl groups to disulfides with the reduction of oxygen to hydrogen peroxide. Reduced proteins are the preferred thiol substrates of this secreted enzyme. The egg white oxidase shows an average 64% identity (from randomly distributed peptides comprising more than 30% of the protein sequence) to a human protein, Quiescin Q6, involved in growth regulation. Q6 is strongly expressed when fibroblasts enter reversible quiescence (Coppock, D. L., Cina-Poppe, D., Gilleran, S, (1998) Genomics 54, 460-468). A peptide antibody against Q6 cross-reacts with both the egg white enzyme and a flavin-linked sulfhydryl oxidase isolated from bovine semen. Sequence analyses show that the egg white oxidase joins human Q6, bone-derived growth factor, GEC-3 from guinea pig, and homologs found in a range of multicellular organisms as a member of a new protein family. These proteins are formed from the fusion of thioredoxin and ERV motifs, In contrast, the flavin-linked sulfhydryl oxidase from Aspergillus niger is related to the pyridine nucleotide-dependent disulfide oxidoreductases, and shows no detectable sequence similarity to this newly recognized protein family.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Delaware, Dept Anim & Food Sci, Newark, DE 19716 USA; Winthrop Univ Hosp, Oncol Res Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Med Ctr, Dept Med, Stony Brook, NY 11790 USA	University of Delaware; University of Delaware; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Thorpe, C (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	cthorpe@udel.edu	Crozier, Laura B/C-5891-2011; Nolen, Danielle/A-5250-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; CLARE DA, 1988, ARCH BIOCHEM BIOPHYS, V265, P351, DOI 10.1016/0003-9861(88)90138-5; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DELAMOTTE RS, 1987, BIOCHEMISTRY-US, V26, P7363, DOI 10.1021/bi00397a025; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gandhi CR, 1999, HEPATOLOGY, V29, P1435, DOI 10.1002/hep.510290522; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GOLDSMITH LA, 1987, METHOD ENZYMOL, V143, P510; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; Hu LQ, 1997, PROTEIN SCI, V6, P43; JANOLINO VG, 1992, MILCHWISSENSCHAFT, V47, P143; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; KUSAKABE H, 1982, AGR BIOL CHEM TOKYO, V46, P2057, DOI 10.1080/00021369.1982.10865382; LASH LH, 1984, BIOCHIM BIOPHYS ACTA, V779, P191, DOI 10.1016/0304-4157(84)90008-X; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; OSTROWSKI MC, 1979, BIOCHEM BIOPH RES CO, V87, P171, DOI 10.1016/0006-291X(79)91662-0; SCHMELZER CH, 1982, BIOCHEM BIOPH RES CO, V107, P196, DOI 10.1016/0006-291X(82)91688-6; Stein G, 1998, YEAST, V14, P171, DOI 10.1002/(SICI)1097-0061(19980130)14:2<171::AID-YEA209>3.0.CO;2-U; Verbakel JM, 1996, US patent, Patent No. [5529926, US5529926]; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	33	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31759	31762		10.1074/jbc.274.45.31759	http://dx.doi.org/10.1074/jbc.274.45.31759			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542195	hybrid			2022-12-25	WOS:000083532100003
J	Iwasiow, RM; Nantel, MF; Tiberi, M				Iwasiow, RM; Nantel, MF; Tiberi, M			Delineation of the structural basis for the activation properties of the dopamine D1 receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; LIGAND-BINDING SPECIFICITY; POLAR AMINO-ACIDS; ALPHA(1B)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; TRANSMEMBRANE DOMAINS; ADRENERGIC-RECEPTOR; AGONIST; MUTATION; IDENTIFICATION	To delineate the structural determinants involved in the constitutive activation of the D1 receptor subtypes, we have constructed chimeras between the D1A and D1B receptors, These chimeras harbored a cognate domain corresponding to transmembrane regions 6 and 7 as well as the third extracellular loop (EL3) and cytoplasmic tail, a domain referred herein to as the terminal receptor locus (TRL), A chimeric D1A receptor harboring the D1B-TRL (chimera 1) displays an increased affinity for dopamine that is indistinguishable from the wild-type D1B receptor. Likewise, a chimeric D1B receptor containing the D1A-TRL cassette (chimera 2) binds dopamine with a reduced affinity that is highly reminiscent of the dopamine affinity for the wild-type D1A receptor. Furthermore, we show that the agonist independent activity of chimera I is identical to the wild-type D1B receptor whereas the chimera 2 displays a low agonist independent activity that is indistinguishable from the wild-type D1A receptor. Dopamine potencies for the wild-type DIA and D1B receptor were recapitulated in cells expressing the chimera 2 or chimera 1, respectively. However, the differences observed in agonist-mediated maximal activation of adenylyl cyclase elicited by the DIA and D1B receptors remain unchanged in cells expressing the chimeric receptors, To gain further mechanistic insights into the structural determinants of the TRL involved in the activation properties of the D1 receptor subtypes, we have engineered two additional chimeric D1 receptors that contain the EL3 region of their respective cognate wild-type counterparts (hD1A-EL3B and hD1B-EL3A), In marked contrast to chimera 1 and 2, dopamine affinity and constitutive activation were partially modulated by the exchange of the EL3, Meanwhile, hD1A-EL3B and hD1B-EL3A mutant receptors display a full switch in the agonist-mediated maximal activation, which is reminiscent of their cognate wild-type counterparts. Overall, our studies suggest a fundamental role for the TRL in shaping the intramolecular interactions implicated in the constitutive activation and coupling properties of the dopamine D1 receptor subtypes.	Ottawa Hosp, Loeb Hlth Res Inst, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Med Cellular, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Mol Med, Ottawa, ON K1Y 4K9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Tiberi, M (corresponding author), Ottawa Hosp, Loeb Hlth Res Inst, Civ Campus,725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.	mtiberi@lri.ca						Alberts GL, 1998, MOL PHARMACOL, V54, P379, DOI 10.1124/mol.54.2.379; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; Cardinaud B, 1997, J BIOL CHEM, V272, P2778, DOI 10.1074/jbc.272.5.2778; CATTERALL WA, 1989, SCIENCE, V243, P236, DOI 10.1126/science.2536189; Charpentier S, 1996, J BIOL CHEM, V271, P28071, DOI 10.1074/jbc.271.45.28071; Cleator JH, 1999, FEBS LETT, V443, P205, DOI 10.1016/S0014-5793(98)01704-9; COLLINS P, 1991, PSYCHOPHARMACOLOGY, V103, P503, DOI 10.1007/BF02244250; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; JARVIE KR, 1993, ADV NEUROL, V60, P325; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kozell LB, 1997, MOL PHARMACOL, V52, P1137, DOI 10.1124/mol.52.6.1137; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; Leeb T, 1997, J BIOL CHEM, V272, P311; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MACKENZIE RG, 1993, FEBS LETT, V32, P59; Martin M. W., 1995, Society for Neuroscience Abstracts, V21, P1118; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Motulsky H., 1995, INTUITIVE BIOSTATIST; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NIZNIK HB, 1987, MOL CELL ENDOCRINOL, V54, P1, DOI 10.1016/0303-7207(87)90134-1; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Sokal R. R, 1981, BIOMETRY; Sugamori KS, 1998, J NEUROCHEM, V71, P1685; Sugamori KS, 1998, J NEUROCHEM, V71, P2593; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TOMIC M, 1993, BIOCHEM BIOPH RES CO, V191, P1020, DOI 10.1006/bbrc.1993.1319; Vassart G, 1997, HORM RES, V48, P47, DOI 10.1159/000191313; WADDINGTON JL, 1994, DOPAMINE RECEPTORS T; Warner DR, 1999, P NATL ACAD SCI USA, V96, P4268, DOI 10.1073/pnas.96.8.4268; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Zhao MM, 1998, MOL PHARMACOL, V53, P524, DOI 10.1124/mol.53.3.524	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31882	31890		10.1074/jbc.274.45.31882	http://dx.doi.org/10.1074/jbc.274.45.31882			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542214	hybrid			2022-12-25	WOS:000083532100022
J	Munshi, N; Ganju, RK; Avraham, S; Mesri, EA; Groopman, JE				Munshi, N; Ganju, RK; Avraham, S; Mesri, EA; Groopman, JE			Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; DNA-SEQUENCES; AIDS; RAFTK; PYK2; PHOSPHORYLATION; CYTOKINES	The Kaposi's sarcoma-associated herpesvirus (KSHV) (also known as human herpesvirus 8) has been implicated in the pathogenesis of Kaposi's sarcoma and B cell primary effusion lymphomas, KSHV encodes a Gr protein-coupled receptor (GPCR) that acts as an oncogene and constitutively activates two protein kinases, c-Jun amino-terminal kinase (JNK)/stress-activated protein kinase (SAPK) and p38 mitogen-activated protein kinase, It also induces the production of vascular endothelial growth factor. These processes are believed to be important in KSHV-GPCR-related oncogenesis. We have characterized the signaling pathways mediated by KSHV-GPCR in a reconstituted 293T cell model in which the related adhesion focal tyrosine kinase (RAFTK) was ectopically expressed. RAFTK has been shown to play an important role in growth factor signaling in endothelium and in B cell antigen receptor signaling in B lymphocytes. KSHV-GPCR induced the tyrosine phosphorylation of RAFTK, Expression of wild-type RAFTK enhanced GPCR-mediated JNK/SAPK activation, whereas dominant negative mutant constructs of RAFTK, such as K457A (which lacks kinase activity) and Y402F (a Src-binding mutant), inhibited KSHV-GPCR-mediated activation of JNK/SAPK. RAFTK also mediated the KSHV-GPCR-induced activation of Lyn, a Src family kinase. However, RAFTK did not mediate the activation of p38 mitogen-activated protein kinase induced by KSHV-GPCR, Human interferon gamma-inducible protein-10, which is known to inhibit KSHV-GPCR activity, was found to reduce RAFTK phosphorylation and JNK/SAPK activation. These results suggest that in cells expressing RAFTK/proline-rich tyrosine kinase 2, such as endothelial and B cells, RAFTK can act to enhance KSHV-GPCR-mediated downstream signaling to transcriptional regulators such as JNK/SAPK.	Harvard Univ, Harvard Inst Med, Div Expt Med & Hematol Oncol, Sch Med,Harvard Inst Med,Robert Mapplethorpe Lab, Boston, MA 02115 USA; Cornell Univ, Coll Med, Div Hematol Oncol, Lab Viral Oncogenesis, New York, NY 10021 USA	Harvard University; Harvard Medical School; Cornell University	Groopman, JE (corresponding author), Harvard Univ, Harvard Inst Med, Div Expt Med & Hematol Oncol, Sch Med,Harvard Inst Med,Robert Mapplethorpe Lab, 4 Blackfan Circle, Boston, MA 02115 USA.							Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; GANEM D, 1995, CURR BIOL, V5, P469, DOI 10.1016/S0960-9822(95)00093-5; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Karp JE, 1996, HEMATOL ONCOL CLIN N, V10, P1031, DOI 10.1016/S0889-8588(05)70383-X; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; MASOOD R, 1993, AIDS RES HUM RETROV, V9, P741, DOI 10.1089/aid.1993.9.741; Mesri EA, 1999, BLOOD, V93, P4031, DOI 10.1182/blood.V93.12.4031.412a37_4031_4033; Miles Steven A., 1994, Current Opinion in Oncology, V6, P497, DOI 10.1097/00001622-199409000-00009; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Reed JA, 1998, BLOOD, V91, P3825, DOI 10.1182/blood.V91.10.3825.3825_3825_3832; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360	47	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31863	31867		10.1074/jbc.274.45.31863	http://dx.doi.org/10.1074/jbc.274.45.31863			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542211	hybrid			2022-12-25	WOS:000083532100019
J	Cross, JV; Deak, JC; Rich, EA; Qian, YY; Lewis, M; Parrott, LA; Mochida, K; Gustafson, D; Vande Pol, S; Templeton, DJ				Cross, JV; Deak, JC; Rich, EA; Qian, YY; Lewis, M; Parrott, LA; Mochida, K; Gustafson, D; Vande Pol, S; Templeton, DJ			Quinone reductase inhibitors block SAPK/JNK and NF kappa B pathways and potentiate apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DT-DIAPHORASE; SIGNALING CASCADE; JNK ACTIVATION; CELL-DEATH; JUN KINASE; STRESS; MEKK1	A variety of environmental stresses stimulate the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEKK) > stress-activated protein kinase (SAPK)-ERK kinase (SEK) > SAPK/c-Jun NH2-terminal kinase (JNK) stress-activated protein kinase cascade and coordinately activate the transcription factor NF kappa B, Mechanisms of stress activation upstream of MEKK1 have not been precisely determined, Redox mechanisms involving sulfhydryls are likely because N-acetyl-cysteine at millimolar concentrations blocks stress signals. Because intracellular sulfhydryl concentrations can be regulated through redox cycling involving reactive quinones (1), we tested the ability of quinone reductase inhibitors to alter stress signaling, Several quinone reductases are inhibited by dicoumarol, a coumarin derivative, Dicoumarol prevented SAPK activation in vivo by chemical cell stressors and also prevented SAPK activation induced by expression of the tumor necrosis factor alpha (TNF alpha) receptor-associated protein TRAF2 but not by expression of truncated active MEKK1, Other coumarin derivatives failed to block. SAPK activation, but other inhibitors of quinone reductases, particularly menadione, similarly blocked SAPK. activation. Cells deficient in a major quinone reductase, NQO1, displayed hypersensitivity to dicoumarol stress inhibition, whereas SAPK in cells reconstituted with the NQO1 gene displayed relative dicoumarol resistance. Consistent with the proposed role of overlapping upstream signaling cascades in activation of NF kappa B, dicoumarol also blocked NF kappa B activation in primary macrophages stimulated with either lipopolysaccharide or TNF alpha In addition, dicoumarol strongly potentiated TNF alpha-induced apoptosis in HeLa cells, probably by blocking the anti-apoptotic effect of NF kappa B, The ability of dicoumarol to simultaneously inhibit SAPK and NF kappa B activation and to potentiate apoptotic cell death suggests that SAPK is not an obligate participant in apoptosis, Dicoumarol, currently in clinical use as an oral anticoagulant, represents a potential therapeutic inhibitor of the SAPK and NF kappa B response.	Case Western Reserve Univ, Inst Pathol, Dept Med, Cleveland, OH 44106 USA; Colorado State Univ, Ctr Environm Toxicol & Technol, Dept Environm Hlth, Ft Collins, CO 80523 USA	Case Western Reserve University; Colorado State University	Templeton, DJ (corresponding author), Case Western Reserve Univ, Inst Pathol, Dept Med, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	djt2@po.cwru.edu	Pol, Scott Vande/AAO-1068-2020; Templeton, Dennis J/F-7695-2011; Cross, Janet V/F-8276-2011	Pol, Scott Vande/0000-0002-0587-4802; 	NATIONAL CANCER INSTITUTE [R01CA066134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009249, R01HL057940] Funding Source: NIH RePORTER; NCI NIH HHS [CA-66134] Funding Source: Medline; NHLBI NIH HHS [HL-57940, HL-09249-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Coso OA, 1996, J BIOL CHEM, V271, P3963; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Gustafson DL, 1996, MOL PHARMACOL, V50, P728; HOSODA S, 1974, J BIOL CHEM, V249, P6416; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIND C, 1990, METHOD ENZYMOL, V186, P287; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; YAN MH, 1994, NATURE, V372, P798; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	25	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31150	31154		10.1074/jbc.274.44.31150	http://dx.doi.org/10.1074/jbc.274.44.31150			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531305	hybrid			2022-12-25	WOS:000083379400009
J	Aulak, KS; Mishra, R; Zhou, LY; Hyatt, SL; de Jonge, W; Lamers, W; Snider, M; Hatzoglou, M				Aulak, KS; Mishra, R; Zhou, LY; Hyatt, SL; de Jonge, W; Lamers, W; Snider, M; Hatzoglou, M			Post-transcriptional regulation of the arginine transporter Cat-1 by amino acid availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; ECOTROPIC RETROVIRUS RECEPTOR; SYNTHETASE GENE-EXPRESSION; 3' UNTRANSLATED REGION; ASPARAGINE SYNTHETASE; C-MYC; PROTEIN-SYNTHESIS; CELL-LINE; ADAPTIVE REGULATION; HEPATOMA-CELLS	The regulation of the high affinity cationic amino acid transporter (Cat-1) by amino acid availability has been studied. In C6 glioma and NRK kidney cells, cat-1 mRNA levels increased 3.8-18-fold following 2 h of amino acid starvation. The transcription rate of the cat-1 gene remained unchanged during amino acid starvation, suggesting a post-transcriptional mechanism of regulation, This mechanism was investigated by expressing a cat-1 mRNA from a tetracycline-regulated promoter. The cat-1 mRNA contained 1.9 kilobase pairs (kb) of coding sequence, 4.5 kb of 3'-untranslated region, and 80 base pairs of 5'-untranslated region. The full-length (7.9 kb) mRNA increased 5-fold in amino acid-depleted cells. However, a 3.4-kb species that results from the usage of an alternative polyadenylation site was not induced, suggesting that the cat-1 mRNA was stabilized by cis-acting RNA sequences within the 3'-UTR, Transcription and protein synthesis were required for the increase in full-length cat-1 mRNA level. Because omission of amino acids from the cell culture medium leads to a substantial decrease in protein synthesis, the translation of the increased cat-1 mRNA was assessed in amino acid-depleted cells. Western blot analysis demonstrated that cat-1 mRNA and protein levels changed in parallel. The increase in protein level was significantly lower than the increase in mRNA level, supporting the conclusion that cat-2 mRNA is inefficiently translated when the supply of amino acids is limited, relative to amino acid-fed cells. Finally, y(+)-mediated transport of arginine in amino acid-fed and -starved cells paralleled Cat-1 protein levels, We conclude that the cat-1 gene is subject to adaptive regulation by amino acid availability, Amino acid depletion initiates molecular events that lead to increased cat-1 mRNA stability. This causes an increase in Cat-1 protein, and y(+) transport once amino acids become available.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Amsterdam, Lab Anat & Embryol, Amsterdam, Netherlands	Case Western Reserve University; Case Western Reserve University; University of Amsterdam	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	Lamers, Wouter H./D-2965-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053307] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53307-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; GAURAV L, 1999, SCIENCE, V284, P499; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Ito K, 1997, J BIOL CHEM, V272, P26780, DOI 10.1074/jbc.272.42.26780; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V739, P258, DOI 10.1016/0167-4781(83)90099-4; KILBERG MS, 1985, J CELL PHYSIOL, V122, P290, DOI 10.1002/jcp.1041220219; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAINE RO, 1994, J BIOL CHEM, V269, P9693; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lenk SE, 1999, J CELL PHYSIOL, V178, P17, DOI 10.1002/(SICI)1097-4652(199901)178:1<17::AID-JCP3>3.0.CO;2-R; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Maniatis T., 1982, MOL CLONING LAB MANU; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Merrick WC., 1996, TRANSLATION CONTROL, P31; MORELLO D, 1990, ONCOGENE, V5, P1511; OGAWA H, 1991, J BIOL CHEM, V266, P20412; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; PONJANPELTO P, 1990, MOL CELL BIOL, V10, P5814; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PUPPI M, 1995, P SOC EXP BIOL MED, V209, P38, DOI 10.3181/00379727-209-43875; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG SJ, 1992, PROTEIN EXPRES PURIF, V3, P337, DOI 10.1016/1046-5928(92)90010-T; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994	46	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30424	30432		10.1074/jbc.274.43.30424	http://dx.doi.org/10.1074/jbc.274.43.30424			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521420	hybrid			2022-12-25	WOS:000083276700016
J	Feranchak, AP; Roman, RM; Doctor, RB; Salter, KD; Toker, A; Fitz, JG				Feranchak, AP; Roman, RM; Doctor, RB; Salter, KD; Toker, A; Fitz, JG			The lipid products of phosphoinositide 3-kinase contribute to regulation of cholangiocyte ATP and chloride transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCT EPITHELIAL-CELLS; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; CYSTIC-FIBROSIS; VOLUME REGULATION; HEPATOMA-CELLS; BILE SECRETION; LIVER-DISEASE; ACTIVATION; CHANNELS	ATP stimulates Cl- secretion and bile formation by activation of purinergic receptors in the apical membrane of cholangiocytes. The purpose of these studies was to determine the cellular origin of biliary ATP and to assess the regulatory pathways involved in its release. In Mz-Cha-1 human cholangiocarcinoma cells, increases in cell volume were followed by increases in phophoinositide (PI) S-kinase activity, ATP release, and membrane Cl- permeability. PI 3-kinase signaling appears to play a regulatory role because ATP release was inhibited by wortmannin or LY294002 and because volume-sensitive current activation was inhibited by intracellular dialysis with antibodies to the 110 kDa-subunit of PI 3-kinase, Similarly, in intact normal rat cholangiocyte monolayers, increases in cell volume stimulated luminal Cl- secretion through a wortmannin-sensitive pathway. To assess the role of PI 3-kinase more directly, cells were dialyzed with the synthetic lipid products of PI 3-kinase, Intracellular delivery of phosphatidylinositol 3,4-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate activated Cl- currents analogous to those observed following cell swelling. Taken together, these findings indicate that volume-sensitive activation of PI 3-kinase and the generation of lipid messengers modulate cholangiocyte ATP release, Cl- secretion, and, hence, bile formation.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Childrens Hosp, Dept Pediat, Denver, CO USA; Childrens Hosp, Dept Med, Denver, CO USA; Boston Biomed Res Grp, Signal Transduct Grp, Boston, MA 02114 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; Children's Hospital Colorado; Boston Biomedical Research Institute	Feranchak, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, 4200 E 9th Ave,Campus Box B-158,Rm 6412, Denver, CO 80262 USA.				NIDDK NIH HHS [DK-46082, DK-43278] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046082, R37DK046082, R01DK043278] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASAVAPPA S, 1993, GASTROENTEROLOGY, V104, P1796, DOI 10.1016/0016-5085(93)90661-U; Bodily K, 1997, HEPATOLOGY, V25, P403; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; Chari RS, 1996, AM J PHYSIOL-GASTR L, V270, pG246; Coffer PJ, 1998, BIOCHEM J, V335, P1; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FITZ JG, 1993, J CLIN INVEST, V91, P319, DOI 10.1172/JCI116188; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GASKIN KJ, 1988, NEW ENGL J MED, V318, P340, DOI 10.1056/NEJM198802113180602; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LANG F, 1993, RENAL PHYSIOL BIOCH, V16, P48; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; MCGILL J, 1992, HEPATOLOGY, V16, P125; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; MCGILL JM, 1994, AM J PHYSIOL, V266, pG731, DOI 10.1152/ajpgi.1994.266.4.G731; NAGEL RA, 1989, LANCET, V2, P1422; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; OBRIEN S, 1992, GUT, V33, P387, DOI 10.1136/gut.33.3.387; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Schlenker T, 1997, AM J PHYSIOL-GASTR L, V273, pG1108, DOI 10.1152/ajpgi.1997.273.5.G1108; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Shimoke K, 1998, FEBS LETT, V437, P221, DOI 10.1016/S0014-5793(98)01235-6; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; Vroman B, 1996, LAB INVEST, V74, P303; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020	45	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30979	30986		10.1074/jbc.274.43.30979	http://dx.doi.org/10.1074/jbc.274.43.30979			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521494	hybrid			2022-12-25	WOS:000083276700090
J	Lim, CP; Cao, XM				Lim, CP; Cao, XM			Serine phosphorylation and negative regulation of Stat3 by JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASES; EPIDERMAL GROWTH-FACTOR; MAP KINASE; C-JUN; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; DNA-BINDING; CELLULAR STRESSES; GENE-EXPRESSION	STATs are activated by various cytokines and growth factors via tyrosine phosphorylation, which leads to sequential dimer formation, nuclear translocation, binding to specific DNA sequences, and regulation of gene expression. Recently, serine phosphorylation of Stat3 on Ser-727 by ERK has been identified in response to epidermal growth factor (EGF). Here, we report that Ser727 phosphorylation of Stat3 can also be induced by JNK and activated either by stress or by its upstream kinase and that various stress treatments induce serine phosphorylation of Stat3 in the absence of tyrosine phosphorylation. Inhibitors of ERK and p38 did not inhibit UV-induced Stat3 serine phosphorylation, suggesting that neither of them is involved. We further demonstrate that JNK1, activated by its upstream kinase MKK7, negatively regulated the tyrosine phosphorylation and DNA binding and transcriptional activities of Stat3 stimulated by EGF. Correspondingly, pretreatment of cells with UV reduced the EGF-stimulated tyrosine phosphorylation and phosphotyrosine-dependent activities of Stat3. The inhibitory effect was not observed for Stat1, Our results suggest that Stat3 is a target of JNK that may regulate Stat3 activity via both Ser-727 phosphorylation-dependent and -independent mechanisms.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gotoh A, 1996, BLOOD, V88, P138; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	52	188	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31055	31061		10.1074/jbc.274.43.31055	http://dx.doi.org/10.1074/jbc.274.43.31055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521505	hybrid			2022-12-25	WOS:000083276700101
J	Lutsenko, E; Bhagwat, AS				Lutsenko, E; Bhagwat, AS			The role of the Escherichia coli mug protein in the removal of uracil and 3,N-4-ethenocytosine from DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE METHYLATION; GLYCOSYLASE; SUBSTRATE; CELLS; GENE	The human thymine-DNA glycosylase has a sequence homolog in Escherichia coli that is described to excise uracils from U.G mismatches (Gallinari, P,, and Jiricny, J. (1996) Nature 383, 735-738) and is named mismatched uracil glycosylase (Mug), It has also been described to remove 3,N-4-ethenocytosine (EC) from epsilon C.G mismatches (Saparbaev, M,, and Laval, J, (1998) Proc, Natl. Acad, Sci. U.S.A. 95, 8508-8513). We used a mug mutant to clarify the role of this protein in DNA repair and mutation avoidance. We find that inactivation of mug has no effect on C to T or 5-methylcytosine to T mutations in E. coli and that this contrasts with the effect of ung defect on C to T mutations and of usr defect on 5-methylcytosine to T mutations. Even under conditions where it is overproduced in cells, Mug has little effect on the frequency of C to T mutations, Because uracil-DNA glycosylase (Ung) and Ver are known to repair U.G and T.G mismatches, respectively, we conclude that Mug does not repair U.G: or T.G mismatches in vivo, A defect in mug also has little effect on forward mutations, suggesting that Muff does not play a role in avoiding mutations due to endogenous damage to DNA in growing E, coli, Cell-free extracts from mug(+) ung cells show very little ability to remove uracil from DNA, but can excise epsilon C, The latter activity is missing in extracts from mug cells, suggesting that Mug may be the only enzyme in E, coli that can remove this mutagenic adduct, Thus, the principal role of Mug in E, coli may be to help repair damage to DNA caused by exogenous chemical agents such as chloroacetaldehyde.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Bhagwat, AS (corresponding author), Wayne State Univ, Dept Chem, 463 Chem, Detroit, MI 48202 USA.	axb@chem.wayne.edu	Bhagwat, Ashok/ABA-3861-2020; Bhagwat, Ashok/AAU-4186-2021	Bhagwat, Ashok/0000-0003-1188-0579	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARU B, 1995, J BACTERIOL, V177, P2950, DOI 10.1128/jb.177.10.2950-2952.1995; BARTSCH H, 1994, DRUG METAB REV, V26, P349, DOI 10.3109/03602539409029802; BURGERS PMJ, 1986, J BACTERIOL, V166, P905, DOI 10.1128/jb.166.3.905-913.1986; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GUENGERICH FP, 1994, DRUG METAB REV, V26, P47, DOI 10.3109/03602539409029784; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; LEBLANC JP, 1982, J BIOL CHEM, V257, P3477; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; Luria SE, 1943, GENETICS, V28, P491; Lutsenko E, 1999, MUTAT RES-REV MUTAT, V437, P11, DOI 10.1016/S1383-5742(99)00065-4; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; WANG Z, 1989, J BIOL CHEM, V264, P1163; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Wiebauer K, 1993, EXS, V64, P510; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574	20	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					31034	31038		10.1074/jbc.274.43.31034	http://dx.doi.org/10.1074/jbc.274.43.31034			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521502	hybrid			2022-12-25	WOS:000083276700098
J	Moynihan, TP; Ardley, HC; Nuber, U; Rose, SA; Jones, PF; Markham, AF; Scheffner, M; Robinson, PA				Moynihan, TP; Ardley, HC; Nuber, U; Rose, SA; Jones, PF; Markham, AF; Scheffner, M; Robinson, PA			The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; ANGELMAN-SYNDROME; CARRIER PROTEIN; F-BOX; COMPLEX; P53; DEGRADATION; PATHWAY; FAMILY; E6-AP	Ubiquitinylation of proteins appears to be mediated by the specific interplay between ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s). However, cognate E3s and/or substrate proteins have been identified for only a few E2s, To identify proteins that can interact with the human E2 UbcH7, a yeast two-hybrid screen was performed. Two proteins were identified and termed human homologue of Drosophila ariadne (HHARI) and UbcH7-associated protein (H7-AP1). Both proteins, which are widely expressed, are characterized by the presence of RING finger and in between RING fingers (IBR) domains. No other overt structural similarity was observed between the two proteins. In vitro binding studies revealed that an N-terminal RING finger motif (HHARI) and the IBR domain (HHARI and H7-AP1) are involved in the interaction of these proteins with UbcH7. Furthermore, binding of these two proteins to UbcH7 is specific insofar that both HHARI and H7-AP1 can bind to the closely related E2, UbcH8, but not to the unrelated E2s UbcH5 and UbcH1. Although it is not clear at present whether HHARI and H7-AP1 serve, for instance, as substrates for UbcH7 or represent proteins with E3 activity, our data suggests that a subset of RING finger/IBR proteins are functionally linked to the ubiquitin/proteasome pathway.	Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, St Jamess Univ Hosp, Leeds Dent Inst, Leeds LS9 7TF, W Yorkshire, England; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Helmholtz Association; German Cancer Research Center (DKFZ)	Robinson, PA (corresponding author), Univ Leeds, St Jamess Univ Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.	des6par@leeds.ac.uk	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				AGUILERA M, 1998, A CONF DROS RES, V39, pA522; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; Burger J, 1997, AM J HUM GENET, V61, P88, DOI 10.1086/513900; CHIEN CT, 1991, P NATL ACAD SCI USA, V74, P5463; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mitchell SJ, 1998, AM J HUM GENET, V62, P1070, DOI 10.1086/301821; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1998, GENOMICS, V51, P124, DOI 10.1006/geno.1998.5257; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Potuschak T, 1998, P NATL ACAD SCI USA, V95, P7904, DOI 10.1073/pnas.95.14.7904; ROBINSON PA, 1995, MAMM GENOME, V6, P725, DOI 10.1007/BF00354295; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Scheffner M., 1998, UBIQUITIN BIOL CELL, P65; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SU LK, 1995, CANCER RES, V55, P2972; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Varshavsky A., 1998, UBIQUITIN BIOL CELL, P223; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	43	103	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30963	30968		10.1074/jbc.274.43.30963	http://dx.doi.org/10.1074/jbc.274.43.30963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521492	hybrid			2022-12-25	WOS:000083276700088
J	Olson, LJ; Zhang, J; Lee, YC; Dahms, NM; Kim, JJP				Olson, LJ; Zhang, J; Lee, YC; Dahms, NM; Kim, JJP			Structural basis for recognition of phosphorylated high mannose oligosaccharides by the cation-dependent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SPECIFICITY; ANGSTROM RESOLUTION; ARGININE RESIDUES; LYSOSOMAL-ENZYMES; LIGAND-BINDING; CONCANAVALIN-A; LEGUME LECTIN; PROTEIN; COMPLEX; PURIFICATION	Mannose 6-phosphate receptors (MPRs) play an important role in the targeting of newly synthesized soluble acid hydrolases to the lysosome in higher eukaryotic cells. These acid hydrolases carry mannose 6-phosphate recognition markers on their N-linked oligosaccharides that are recognized by two distinct MPRs: the cation-dependent mannose 6-phosphate receptor and the insulin-like growth factor II/cation-independent mannose 6-phosphate receptor. Although much has been learned about the MPRs, it is unclear how these receptors interact with the highly diverse population of lysosomal enzymes. It is known that the terminal mannose 6-phosphate is essential for receptor binding. However, the results from several studies using synthetic oligosaccharides indicate that the binding site encompasses at least two sugars of the oligosaccharide. We now report the structure of the soluble extracytoplasmic domain of a glycosylation-deficient form of the bovine cation-dependent mannose 6-phosphate receptor complexed to pentamannosyl phosphate, This construct consists of the amino-terminal 154 amino acids (excluding the signal sequence) with glutamine substituted for asparagine at positions 31, 57, 68, and 87. The binding site of the receptor encompasses the phosphate group plus three of the five mannose rings of pentamannosyl phosphate. Receptor specificity for mannose arises from protein contacts with the 2-hydroxyl on the terminal mannose ring adjacent to the phosphate group. Glycosidic linkage preference originates from the minimization of unfavorable interactions between the ligand and receptor.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Medical College of Wisconsin; Johns Hopkins University	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R29DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*BIOS MOL SIM, 1995, INS, V2; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BRETTHAU.RK, 1973, BIOCHEMISTRY-US, V12, P1251, DOI 10.1021/bi00731a002; BRUNGER AT, 1992, X PLOR V 3 1 INSTRUC; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MA ZM, 1992, J BIOL CHEM, V267, P19017; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NATOWICZ M, 1983, J CELL BIOL, V96, P915, DOI 10.1083/jcb.96.3.915; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; RINI JM, 1993, J BIOL CHEM, V268, P10126; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROUSSEL, 1994, TURBO VERSION 4 2; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TOMODA H, 1991, CARBOHYD RES, V213, P37, DOI 10.1016/S0008-6215(00)90596-2; TONG PY, 1989, J BIOL CHEM, V264, P7970; VARKI A, 1980, J BIOL CHEM, V255, P847; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	43	46	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29889	29896		10.1074/jbc.274.42.29889	http://dx.doi.org/10.1074/jbc.274.42.29889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514470	hybrid			2022-12-25	WOS:000083176400049
J	Ratovitski, EA; Bao, C; Quick, RA; McMillan, A; Kozlovsky, C; Lowenstein, CJ				Ratovitski, EA; Bao, C; Quick, RA; McMillan, A; Kozlovsky, C; Lowenstein, CJ			An inducible nitric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; SKELETAL-MUSCLE; BACTERIAL LIPOPOLYSACCHARIDE; SUBUNIT DIMERIZATION; DIMERIC ENZYME; SMOOTH-MUSCLE; CELL-LINE; TETRAHYDROBIOPTERIN; DOMAIN; INDUCTION	A variety of transcriptional and post-transcriptional mechanisms regulate the expression of the inducible nitric-oxide synthase (iNOS, or NOS2). Although neurons and endothelial cells express proteins that interact with and inhibit neuronal NOS and endothelial NOS, macrophage proteins that inhibit NOS2 have not been identified. We show that murine macrophages express a 110-kDa protein that interacts with NOS2, which we call NOS-associated protein-110 kDa (NAP110). NAP110 directly interacts with the amino terminus of NOS2, and inhibits NOS catalytic activity by preventing formation of NOS2 homodimers. Expression of NAP110 may be a mechanism by which macrophages expressing NOS2 protect themselves from cytotoxic levels of nitric oxide.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, 950 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.			Lowenstein, Charles/0000-0003-0485-7514	NHLBI NIH HHS [R01 HL5361, P50 HL52315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; GROSS SS, 1993, ADV EXP MED BIOL, V338, P295; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KWON NS, 1989, J BIOL CHEM, V264, P20496; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; SHIMADA S, 1994, CANCER RES, V54, P3831; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	58	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30250	30257		10.1074/jbc.274.42.30250	http://dx.doi.org/10.1074/jbc.274.42.30250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514518	hybrid			2022-12-25	WOS:000083176400097
J	Zhou, YC; Waxman, DJ				Zhou, YC; Waxman, DJ			STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; 9-CIS RETINOIC ACID; GROWTH-HORMONE; CLOFIBRATE-INDUCTION; RAT HEPATOCYTES; FATTY-ACIDS; SH2 DOMAIN; LIVER; GENE; PROTEIN	Growth hormone-activated STAT5b inhibits by up to 80% the transcriptional activity of peroxisome proliferator-activated receptor (PPAR) alpha, a nuclear receptor activated by diverse environmental chemicals and hypolipidemic drugs classified as peroxisome proliferators. This inhibitory cross-talk between STAT5b and PPAR is now reported for PPAR forms gamma and delta and for thyroid hormone receptor, indicating a more general potential for inhibitory cross-talk between JAK/STAT and nuclear receptor signaling pathways. Further investigations revealed that SOCS-3, a growth hormone-inducible negative regulator of cytokine signaling to STAT5b, abolished the STAT5b inhibitory response. A constitutively active STAT5b mutant failed to inhibit PPAR alpha activity, indicating that STAT5b does not induce synthesis of a more proximal PPARa inhibitor. STAT5b inhibition was not reversed by overexpression of the heterodimerization partner of PPAR (retinoid X receptor) or the nuclear receptor coactivators P300 and SRC-1, suggesting that STAT5b does not inhibit PPAR alpha by competing for these limiting cellular cofactors. STAT5b did not inhibit a chimeric receptor comprised of yeast GAL4 DNA-binding domain linked to the ligand binding/AF-2 trans-activation domain of PPAR alpha indicating that the COOH-terminal AF-2 domain of PPAR is not the target of STAT5b inhibition. Rather, STAT5b inhibited transcription driven by the NH2-terminal ligand-independent AF-1 trans-activation domain of PPAR alpha in a GAL4-linked chimera by similar to 80%. The conservation of this AF-1 trans-activation function in many nuclear receptors suggests that AF-1 may serve as an important target for inhibitory cross-talk between STAT transcription factors and nuclear receptors in a variety of signaling pathways.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bio.bu.edu		Waxman, David/0000-0001-7982-9206	NIEHS NIH HHS [ES07381] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Auwerx J, 1999, CELL, V97, P161; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVEY HW, 1999, IN PRESS AM J HUMAN; Desvergne B, 1998, J STEROID BIOCHEM, V65, P65, DOI 10.1016/S0960-0760(97)00182-9; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; Johnson TE, 1997, J STEROID BIOCHEM, V63, P1, DOI 10.1016/S0960-0760(97)00064-2; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RAM PA, 1999, ENDO 1999 SAN DIEGO, V81, P386; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SATO T, 1995, BBA-LIPID LIPID MET, V1256, P327, DOI 10.1016/0005-2760(95)00040-J; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; SUGIYAMA H, 1994, BIOCHEM PHARMACOL, V47, P918, DOI 10.1016/0006-2952(94)90494-4; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V315, P555, DOI 10.1006/abbi.1994.1536; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	57	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29874	29882		10.1074/jbc.274.42.29874	http://dx.doi.org/10.1074/jbc.274.42.29874			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514468	hybrid			2022-12-25	WOS:000083176400047
J	Garcia, B; Olivera, ER; Minambres, B; Fernandez-Valverde, M; Canedo, LM; Prieto, MA; Garcia, JL; Martinez, M; Luengo, JM				Garcia, B; Olivera, ER; Minambres, B; Fernandez-Valverde, M; Canedo, LM; Prieto, MA; Garcia, JL; Martinez, M; Luengo, JM			Novel biodegradable aromatic plastics from a bacterial source - Genetic and biochemical studies on a route of the phenylacetyl-CoA catabolon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII UWD; PSEUDOMONAS-PUTIDA U; CHAIN FATTY-ACIDS; POLY-BETA-HYDROXYBUTYRATE; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; INTRACELLULAR DEPOLYMERASE; POLYHYDROXYALKANOIC ACIDS; PENICILLIUM-CHRYSOGENUM; SUBSTRATE SPECIFICITIES	Novel biodegradable bacterial plastics, made up of units of 3-hydroxy-n-phenylalkanoic acids, are accumulated intracellularly by Pseudomonas putida U due to the existence in this bacterium of (i) an acyl-CoA synthetase (encoded by the fadD gene) that activates the aryl-precursors; (ii) a beta-oxidation pathway that affords 3-OH-aryl-CoAs, and (iii) a polymerization-depolymerization system (encoded in the pha locus) integrated by two polymerases (PhaC1 and PhaC2) and a depolymerase (PhaZ). The complete assimilation of these compounds requires two additional routes that specifically catabolize the phenylacetyl-CoA or the benzoyl-CoA generated from these polyesters through beta-oxidation. Genetic studies have allowed the cloning sequencing, and disruption of the genes included in the pha locus (phaC1, phaC2, and phaZ) as well as those related to the biosynthesis of precursors (fadD) or to the catabolism of their derivatives (acuA, fadA, and paa genes). Additional experiments showed that the blockade of either fadD or phaC1 hindered the synthesis and accumulation of plastic polymers, Disruption of phaC2 reduced the quantity of stored polymers by two-thirds. The blockade of phaZ hampered the mobilization of the polymer and decreased its production. Mutations in the paa genes, encoding the phenylacetic acid catabolic enzymes, did not affect the synthesis or catabolism of polymers containing either 3-hydroxyaliphatic acids or 3-hydroxy-n-phenylalkanoic acids with an odd number of carbon atoms as monomers, whereas the production of polyesters containing units of 3-hydroxy-n-phenylalkanoic acids with an even number of carbon atoms was greatly reduced in these bacteria. Yield-improving studies revealed that mutants defective in the glyoxylic acid cycle (isocitrate lyase(-)) or in the beta-oxidation pathway (fadA), stored a higher amount of plastic polymers (1.4- and 2-fold, respectively), suggesting that genetic manipulation of these pathways could be useful for isolating overproducer strains. The analysis of the organization and function of the pha locus and its relationship with the core of the phenylacetyl-CoA catabolon is reported and discussed.	Univ Leon, Dept Bioquim & Biol Mol, Fac Biol & Vet, E-24007 Leon, Spain; Inst Biomar, Leon 24231, Spain; CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Universidad de Leon; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Luengo, JM (corresponding author), Univ Leon, Dept Bioquim & Biol Mol, Fac Biol & Vet, Campus Vegazana, E-24007 Leon, Spain.	dbbjlr@unileon.es	Prieto, María Auxiliadora/I-8092-2015; OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Olivera, Elias Rodriguez/Q-1166-2019; Luengo, Jose M./E-1935-2016; Garcia Lopez, Jose Luis/G-9139-2015	OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Olivera, Elias Rodriguez/0000-0003-2315-8524; Minambres Rodriguez, Baltasar/0000-0003-4590-4911; Prieto Jimenez, M. Auxiliadora/0000-0002-8038-1223; Luengo, Jose M./0000-0002-4984-6256; Garcia Lopez, Jose Luis/0000-0002-9238-2485				AKIYAMA M, 1992, APPL MICROBIOL BIOT, V37, P698; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BRANDL H, 1990, BIOSEPARATION, V2, P155; Breitmaier E., 1993, STRUCTURE ELUCIDATIO; BYROM D, 1987, TRENDS BIOTECHNOL, V5, P246, DOI 10.1016/0167-7799(87)90100-4; Byrom D., 1994, PLASTICS MICROBES MI, P5; Carnicero D, 1997, FEMS MICROBIOL LETT, V149, P51, DOI 10.1016/S0378-1097(97)00053-0; Cox M. K., 1994, P 3 INT SCI WORKSH B, P120; DELORENZO V, 1993, GENE, V130, P41, DOI 10.1016/0378-1119(93)90344-3; DESMET MJ, 1983, J BACTERIOL, V154, P870, DOI 10.1128/JB.154.2.870-878.1983; DEWAARD P, 1993, J BIOL CHEM, V268, P315; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; DIXON GH, 1959, BIOCHEM J, V72, pP3; DOI Y, 1992, FEMS MICROBIOL LETT, V103, P103, DOI 10.1111/j.1574-6968.1992.tb05827.x; EGGINK G, 1995, CAN J MICROBIOL, V41, P14, DOI 10.1139/m95-163; FERNANDEZCANON JM, 1989, J ANTIBIOT, V42, P1410, DOI 10.7164/antibiotics.42.1410; FERNANDEZVALVERDE M, 1993, APPL ENVIRON MICROB, V59, P1149; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; Ferrandez A, 1997, J BACTERIOL, V179, P2573, DOI 10.1128/jb.179.8.2573-2581.1997; Foster LJR, 1996, INT J BIOL MACROMOL, V19, P177, DOI 10.1016/0141-8130(96)01125-7; FRITZSCHE K, 1990, MAKROMOL CHEM, V191, P1957; Fukui T, 1998, J BACTERIOL, V180, P667, DOI 10.1128/JB.180.3.667-673.1998; Fukui T, 1997, J BACTERIOL, V179, P4821, DOI 10.1128/jb.179.15.4821-4830.1997; HAYWOOD GW, 1991, INT J BIOL MACROMOL, V13, P83, DOI 10.1016/0141-8130(91)90053-W; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Huang RP, 1996, J BIOL CHEM, V271, P22196, DOI 10.1074/jbc.271.36.22196; HUISMAN GW, 1991, J BIOL CHEM, V266, P2191; HUISMAN GW, 1989, APPL ENVIRON MICROB, V55, P1949, DOI 10.1128/AEM.55.8.1949-1954.1989; HUISMAN GW, 1992, APPL MICROBIOL BIOT, V38, P1, DOI 10.1007/BF00169409; JAEGER KE, 1995, APPL ENVIRON MICROB, V61, P3113, DOI 10.1128/AEM.61.8.3113-3118.1995; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMEDA K, 1986, BIOCHEM INT, V13, P343; KIM OY, 1995, CAN J MICROBIOL, V41, P32, DOI 10.1139/m95-165; Kim YB, 1996, MACROMOLECULES, V29, P3432; Kranz RG, 1997, APPL ENVIRON MICROB, V63, P3003, DOI 10.1128/AEM.63.8.3003-3009.1997; LAGEVEEN RG, 1988, APPL ENVIRON MICROB, V54, P2924, DOI 10.1128/AEM.54.12.2924-2932.1988; Langenbach S, 1997, FEMS MICROBIOL LETT, V150, P303, DOI 10.1016/S0378-1097(97)00142-0; Lee SY, 1996, BIOTECHNOL BIOENG, V49, P1; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P511; Lemoigne M., 1926, B SOC CHIM BIOL, V8, P770; LENZ RW, 1992, FEMS MICROBIOL LETT, V103, P207, DOI 10.1111/j.1574-6968.1992.tb05839.x; LUENGO JM, 1987, ANAL BIOCHEM, V164, P559, DOI 10.1016/0003-2697(87)90533-1; Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21, DOI 10.1128/MMBR.63.1.21-53.1999; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; MARTINEZBLANCO H, 1990, FEMS MICROBIOL LETT, V72, P113; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MARTINEZBLANCO H, 1992, J BIOL CHEM, V267, P5474; Minambres B, 1996, J BIOL CHEM, V271, P33531, DOI 10.1074/jbc.271.52.33531; NUNN WD, 1978, P NATL ACAD SCI USA, V75, P3377, DOI 10.1073/pnas.75.7.3377; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PAGE WJ, 1992, FEMS MICROBIOL LETT, V103, P149, DOI 10.1111/j.1574-6968.1992.tb05832.x; PAGE WJ, 1995, CAN J MICROBIOL, V41, P1, DOI 10.1139/m95-161; PAGE WJ, 1995, CAN J MICROBIOL, V41, P106, DOI 10.1139/m95-176; PAGE WJ, 1992, APPL MICROBIOL BIOT, V38, P117, DOI 10.1007/BF00169430; Prieto MA, 1999, APPL ENVIRON MICROB, V65, P3265; Prieto MA, 1999, J BACTERIOL, V181, P858, DOI 10.1128/JB.181.3.858-868.1999; Qi QS, 1998, FEMS MICROBIOL LETT, V167, P89, DOI 10.1111/j.1574-6968.1998.tb13212.x; Qi QS, 1997, FEMS MICROBIOL LETT, V157, P155, DOI 10.1111/j.1574-6968.1997.tb12767.x; RAMSAY BA, 1992, APPL ENVIRON MICROB, V58, P744, DOI 10.1128/AEM.58.2.744-746.1992; REN Q, 1997, THESIS ETH ZURICH; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; RHIE HG, 1995, APPL ENVIRON MICROB, V61, P2487, DOI 10.1128/AEM.61.7.2487-2492.1995; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SCHIRMER A, 1993, APPL ENVIRON MICROB, V59, P1220, DOI 10.1128/AEM.59.4.1220-1227.1993; SCHIRMER A, 1995, CAN J MICROBIOL, V41, P170, DOI 10.1139/m95-184; Sim SJ, 1997, NAT BIOTECHNOL, V15, P63, DOI 10.1038/nbt0197-63; Slater S, 1998, J BACTERIOL, V180, P1979, DOI 10.1128/JB.180.8.1979-1987.1998; Song JJ, 1996, APPL ENVIRON MICROB, V62, P536, DOI 10.1128/AEM.62.2.536-544.1996; STEINBUCHEL A, 1992, FEMS MICROBIOL LETT, V103, P217, DOI 10.1016/0378-1097(92)90313-D; STEINBUCHEL A, 1992, APPL MICROBIOL BIOT, V37, P691; STEINBUCHEL A, 1995, FEMS MICROBIOL LETT, V128, P219, DOI 10.1016/0378-1097(95)00125-O; Steinbuchel A., 1991, BIOMATERIALS NOVEL M, P124; STEINBUECHEL A, 1992, Current Opinion in Biotechnology, V3, P291, DOI 10.1016/0958-1669(92)90107-T; Stuart ES, 1996, INT J BIOL MACROMOL, V19, P171, DOI 10.1016/0141-8130(96)01124-5; THIJSSE GJE, 1964, BIOCHIM BIOPHYS ACTA, V84, P195, DOI 10.1016/0926-6542(64)90078-2; TIMM A, 1992, EUR J BIOCHEM, V209, P15, DOI 10.1111/j.1432-1033.1992.tb17256.x; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; VANDERLEIJ FR, 1995, CAN J MICROBIOL, V41, P222, DOI 10.1139/m95-191; VANNI P, 1990, COMP BIOCHEM PHYS B, V95, P431, DOI 10.1016/0305-0491(90)90002-B; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; WIECZOREK R, 1995, J BACTERIOL, V177, P2425, DOI 10.1128/jb.177.9.2425-2435.1995; Wieczorek R, 1996, FEMS MICROBIOL LETT, V135, P23; Williams MD, 1996, APPL ENVIRON MICROB, V62, P2540, DOI 10.1128/AEM.62.7.2540-2546.1996; YASUSHI S, 1992, Patent No. 1992239842	89	97	107	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29228	29241		10.1074/jbc.274.41.29228	http://dx.doi.org/10.1074/jbc.274.41.29228			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506180	hybrid			2022-12-25	WOS:000083017800059
J	Jung, MY; Schmauss, C				Jung, MY; Schmauss, C			Decreased c-fos responses to dopamine D-1 receptor agonist stimulation in mice deficient for D-3 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RAT STRIATUM; MESSENGER-RNA; AUTORECEPTOR FUNCTION; MOLECULAR MECHANISMS; GLOBUS-PALLIDUS; GROWTH-FACTOR; MUTANT MICE; AMPHETAMINE; NEURONS	The acute administration of dopamine D-1 receptor agonists induces the expression of the immediate early gene c-fos. In wild type mice, this induction is completely abolished by pretreatment with the D-1-selective antagonist SCH23390, and pretreatment with the D-2-like receptor antagonist eticlopride reduces the levels of c-fos expressed in response to D-1 receptor stimulation. Mice deficient for the dopamine D-3 receptor express levels of D-1 agonist-stimulated c-fos immunoreactivity that are lower than c-fos levels of their wild type littermates. Moreover, the acute blockade of D-2 receptors in D-3 mutant mice further reduces c-fos expression levels. These data indicate that the basal activity of both D-2 and D-3 receptors contributes to D-1 agonist-stimulated c-fos responses. The findings therefore indicate that not only D-2 but also D-3 receptors play a role in dopamine-regulated gene expression.	Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Dept Neurosci, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Grad Program Neurobiol, New York, NY 10029 USA	Columbia University; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Schmauss, C (corresponding author), Columbia Univ, Dept Psychiat, 1051 Riverside Dr,Unit 42, New York, NY 10032 USA.							Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; BALK JH, 1995, NATURE, V377, P424; BOUTHENET ML, 1991, BRAIN RES, V564, P203, DOI 10.1016/0006-8993(91)91456-B; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; CURRAN T, 1985, CANCER SURV, V4, P655; Fields RD, 1997, J NEUROSCI, V17, P7252; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Jung MY, 1999, NEUROSCIENCE, V91, P911, DOI 10.1016/S0306-4522(98)00705-2; KEEFE KA, 1995, NEUROSCIENCE, V66, P903, DOI 10.1016/0306-4522(95)00024-D; Koeltzow TE, 1998, J NEUROSCI, V18, P2231; KONRADI C, 1994, J NEUROSCI, V14, P5623; LeMoine C, 1997, J NEUROSCI, V17, P8038; Levant B, 1997, PHARMACOL REV, V49, P231; MERCHANT KM, 1994, J PHARMACOL EXP THER, V271, P460; MERCHANT KM, 1993, P NATL ACAD SCI USA, V90, P3447, DOI 10.1073/pnas.90.8.3447; Mercuri NB, 1997, NEUROSCIENCE, V79, P323; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MORATALLA R, 1992, J NEUROSCI, V12, P2609; Moratalla R, 1996, P NATL ACAD SCI USA, V93, P14928, DOI 10.1073/pnas.93.25.14928; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; ROBERTSON GS, 1994, J PHARMACOL EXP THER, V271, P1058; ROBERTSON GS, 1992, NEUROSCIENCE, V46, P315, DOI 10.1016/0306-4522(92)90054-6; Ruskin DN, 1998, J PHARMACOL EXP THER, V286, P272; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; Wang JQ, 1996, NEUROSCIENCE, V72, P601, DOI 10.1016/0306-4522(95)00597-8; WHITE FJ, 1993, D1 D2 DOPAMINE RECEP, P79; Xu M, 1997, NEURON, V19, P837, DOI 10.1016/S0896-6273(00)80965-4; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	38	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29406	29412		10.1074/jbc.274.41.29406	http://dx.doi.org/10.1074/jbc.274.41.29406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506202	hybrid			2022-12-25	WOS:000083017800081
J	Zhu, T; Dahan, D; Evagelidis, A; Zheng, SX; Luo, J; Hanrahan, JW				Zhu, T; Dahan, D; Evagelidis, A; Zheng, SX; Luo, J; Hanrahan, JW			Association of cystic fibrosis transmembrane conductance regulator and protein phosphatase 2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CL CONDUCTANCE; PHOSPHORYLATION; CAMP; ACTIVATION; MEMBRANE; CELLS; DOMAIN	Cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels are rapidly deactivated by a membrane-bound phosphatase activity. The efficiency of this regulation suggests CFTR and protein phosphatases may be associated within a regulatory complex. In this paper we test that possibility using coimmunoprecipitation and cross-linking experiments. A monoclonal anti-CFTR antibody co-precipitated type 2C protein phosphatase (PP2C) from baby hamster kidney cells stably expressing CFTR but did not co-precipitate PP1, PP2A, or PP2B. Conversely, a polyclonal anti-PP2C antibody co-precipitated CFTR from baby hamster kidney membrane extracts. Exposing baby hamster kidney cell lysates to dithiobis (sulfosuccinimidyl propionate) caused the cross-linking of histidine-tagged CFTR (CFTRHis10) and PP2C into high molecular weight complexes that were isolated by chromatography on Ni2+-nitrilotriacetic acid-agarose. Chemical cross-linking was specific for PP2C, because PP1, PP2A, and PP2B did not co-purify with CFTRhis10 after dithiobis (sulfosuccinimidyl propionate) exposure. These results suggest CFTR and PP2C exist, in a stable complex that facilitates regulation of the channel.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Hanrahan, JW (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054075] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54075-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becq F, 1996, BBA-REV BIOMEMBRANES, V1286, P53, DOI 10.1016/0304-4157(96)00002-0; Becq F, 1996, J BIOL CHEM, V271, P16171, DOI 10.1074/jbc.271.27.16171; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kartner N, 1998, METHOD ENZYMOL, V292, P629; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Reddy MM, 1996, AM J PHYSIOL-CELL PH, V270, pC474, DOI 10.1152/ajpcell.1996.270.2.C474; REINHART PH, 1995, J NEUROSCI, V15, P4572; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; ZHU T, 1997, PEDIATR PULM, V14, P221	31	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29102	29107		10.1074/jbc.274.41.29102	http://dx.doi.org/10.1074/jbc.274.41.29102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506164	hybrid			2022-12-25	WOS:000083017800043
J	Kapusta, J; Modelska, A; Figlerowicz, M; Pniewski, T; Letellier, M; Lisowa, O; Yusibov, V; Koprowski, H; Plucienniczak, A; Legocki, AB				Kapusta, J; Modelska, A; Figlerowicz, M; Pniewski, T; Letellier, M; Lisowa, O; Yusibov, V; Koprowski, H; Plucienniczak, A; Legocki, AB			A plant-derived edible vaccine against hepatitis B virus	FASEB JOURNAL			English	Article						oral vaccines; surface antigen (HBsAg); transgenic lupin; lettuce and engineered plants	TRANSGENIC PLANTS; SURFACE-ANTIGEN; IMMUNOGENICITY; EXPRESSION; POTATO; MICE	The infectious hepatitis B virus represents 42 nm spherical double-shelled particles. However, analysis of blood from hepatitis B virus carriers revealed the presence of smaller 22 nm particles consisting of a viral envelope surface protein. These particles are highly immunogenic and have been used in the design of hepatitis B virus vaccine produced in yeast. Upon expression in yeast, these proteins form virus-like particles that are used for parenteral immunization. Therefore, the DNA fragment encoding hepatitis B virus surface antigen was introduced into Agrobacterium tumerifacience LBA4404 and used to obtain transgenic lupin (Lupinus luteus L.) and lettuce (Lactuca sativa L.) cv. Burpee Bibb expressing envelope surface protein. Mice that were fed the transgenic lupin tissue developed significant levels of hepatitis B virus-specific antibodies. Human volunteers, fed with transgenic lettuce plants expressing hepatitis B virus surface antigen, developed specific serum-IgG response to plant produced protein.	Thomas Jefferson Univ, Biotechnol Fdn Labs, Philadelphia, PA 19107 USA; Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland; Marcinkovski Acad Med Sci, Dept Endocrinol, Poznan, Poland; Marcinkovski Acad Med Sci, Dept Pediat, Poznan, Poland; Inst Biotechnol & Antibiot, Warsaw, Poland	Jefferson University; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Institute of Biotechnology & Antibiotics (IBA)	Koprowski, H (corresponding author), Thomas Jefferson Univ, Biotechnol Fdn Labs, Room M85 JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Figlerowicz, Marek/B-9550-2015; Yusibov, Vidadi/AAA-7408-2019					Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MICHELMORE R, 1987, PLANT CELL REP 6, V439, P442; MOZO T, 1991, PLANT MOL BIOL, V16, P917, DOI 10.1007/BF00015085; Sambrook S, 1989, MOL CLONING LAB MANU; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; Yusibov V, 1997, P NATL ACAD SCI USA, V94, P5784, DOI 10.1073/pnas.94.11.5784	12	265	329	0	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1796	1799		10.1096/fasebj.13.13.1796	http://dx.doi.org/10.1096/fasebj.13.13.1796			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506582				2022-12-25	WOS:000083063400014
J	Ismail, PM; Lu, T; Sawadogo, M				Ismail, PM; Lu, T; Sawadogo, M			Loss of USF transcriptional activity in breast cancer cell lines	ONCOGENE			English	Article						USF; breast cancer cell lines; c-Myc; transcription activation	DNA-BINDING; C-MYC; PROTEINS; EXPRESSION; PROMOTER; UPSTREAM; ONCOGENE; FAMILY; MOTIF; FORMS	USF is a family of transcription factors that are structurally related to the Myc oncoproteins and also share with Myc a common DNA-binding specificity. USF overexpression can prevent c-Myc-dependent cellular transformation and also inhibit the proliferation of certain transformed cells, These antiproliferative activities suggest that USF inactivation could be implicated in carcinogenesis. To explore this possibility, we compared the activities of the ubiquitous USF1 and USF2 proteins in several cell lines derived from either normal breast epithelium or breast tumors. The DNA-binding activities of USF1 and USF2 were present at similar levels in all cell lines. In the non-tumorigenic MCF-10A cells, USF in general, and USF2 in particular, exhibited strong transcriptional activities. In contrast, USF1 and USF2 were completely inactive in three out of six transformed breast cell lines investigated, while the other three transformed cell lines exhibited loss of USF2 activity. Analyses in cells cultured from healthy tissue confirmed the transcriptional activity of USF in normal human mammary epithelial cells. These results demonstrate that a partial or complete loss of USF function is a common event in breast cancer cell lines, perhaps because, like Myc overexpression, it favors rapid proliferation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NCI NIH HHS [CA09299, CA79578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079578, T32CA009299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; ESCOT C, 1993, ONCOGENE, V8, P969; FISCHER DE, 1991, GENE DEV, V5, P2342; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KREIPE H, 1993, CANCER RES, V53, P1956; KRIEF P, 1989, INT J CANCER, V43, P658, DOI 10.1002/ijc.2910430420; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; ROUXDOSSETO M, 1992, EUR J CANCER, V28A, P1600, DOI 10.1016/0959-8049(92)90050-C; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SOULE HD, 1990, CANCER RES, V50, P6075; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VARLEY JM, 1987, ONCOGENE, V1, P423; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WOOD WM, 1989, J BIOL CHEM, V264, P14840	31	72	72	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5582	5591		10.1038/sj.onc.1202932	http://dx.doi.org/10.1038/sj.onc.1202932			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523835				2022-12-25	WOS:000082894700011
J	O'Kane, RL; Martinez-Lopez, I; DeJoseph, MR; Vina, JR; Hawkins, RA				O'Kane, RL; Martinez-Lopez, I; DeJoseph, MR; Vina, JR; Hawkins, RA			Na+-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier - A mechanism for glutamate removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; GLIAL-CELLS; RAT-BRAIN; SODIUM; LOCALIZATION; EXPRESSION; MEMBRANE; CARRIER; CULTURE; RELEASE	Na+-dependent transporters for glutamate exist on astrocytes (EAAT1 and EAAT2) and neurons (EAAT3), These transporters presumably assist in keeping the glutamate concentration low in the extracellular fluid of brain, Recently, Na+-dependent glutamate transport was described on the abluminal membrane of the blood-brain barrier. To determine whether the above-mentioned transporters participate in glutamate transport of the blood brain barrier, total RNA was extracted from bovine cerebral capillaries. cDNA for EAAT1, EAAT2, and EAAT3 was observed, indicating that mRNA was present. Western blot analysis demonstrated all three transporters were expressed on abluminal membranes, but none was detectable on luminal membranes of the blood brain barrier. Measurement of transport kinetics demonstrated voltage dependence, K+-dependence, and an apparent K-m of 14 mu M (aggregate of the three transporters) at a transmembrane potential of -61 mV. Inhibition of glutamate transport was observed using inhibitors specific for EAAT2 (kainic acid and dihydrokainic acid) and EAAT3 (cysteine). The relative activity of the three transporters was found to be approximately 1:3:6 for EAAT1, EAAT2, and EAAT3, respectively. These transporters may assist in maintaining low glutamate concentrations in the extracellular fluid.	Finch Univ Hlth Sci Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL 60064 USA; Univ Valencia, Fac Med & Farm, Dept Bioquim & Biol Mol, Valencia 46010, Spain	Chicago Medical School; University of Valencia	Hawkins, RA (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Physiol & Biophys, 3333 Green Bay Rd, N Chicago, IL 60064 USA.		Viña, Juan R/ABE-5698-2021	Viña, Juan R/0000-0002-4035-3615	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031017] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31017] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Benrabh H, 1996, NEUROSCI LETT, V210, P9, DOI 10.1016/0304-3940(96)12635-5; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; DREWES LR, 1977, AM J PHYSIOL, V233, pE320, DOI 10.1152/ajpendo.1977.233.4.E320; Eliasof S, 1998, VISION RES, V38, P1443, DOI 10.1016/S0042-6989(97)00452-5; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; HAWKINS RA, 1995, CELL TISSUE RES, V281, P207, DOI 10.1007/s004410050417; HAWKINS RA, 1983, HDB NEUROCHEMISTRY, V3, P259; HILLE B, 1992, IONIC CHANNELS EXCIT, P11; HUTCHISON HT, 1985, EXP NEUROL, V87, P260, DOI 10.1016/0014-4886(85)90216-X; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P49; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1101, DOI 10.1152/ajpcell.1998.274.4.C1101; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLDENDORF WH, 1976, AM J PHYSIOL, V230, P94, DOI 10.1152/ajplegacy.1976.230.1.94; PARDRIDGE WM, 1979, ADV BIOCH PHYSL, P125; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; VelazFaircloth M, 1996, AM J PHYSIOL-CELL PH, V270, pC67, DOI 10.1152/ajpcell.1996.270.1.C67; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wang GJ, 1998, MOL PHARMACOL, V53, P88, DOI 10.1124/mol.53.1.88; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	44	217	227	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31891	31895		10.1074/jbc.274.45.31891	http://dx.doi.org/10.1074/jbc.274.45.31891			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542215	hybrid			2022-12-25	WOS:000083532100023
J	Yokoyama, T; Kaya, S; Abe, K; Taniguchi, K; Katoh, T; Yazawa, M; Hayashi, Y; Mardh, S				Yokoyama, T; Kaya, S; Abe, K; Taniguchi, K; Katoh, T; Yazawa, M; Hayashi, Y; Mardh, S			Acid-labile ATP and/or ADP/P-i binding to the tetraprotomeric form of Na/K-ATPase accompanying catalytic phosphorylation-dephosphorylation cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE PHOSPHOENZYME; NA+,K+-ATPASE ACTIVITY; CONFORMATIONAL CHANGE; SUBUNIT INTERACTIONS; LIGHT-CHAINS; ALPHA-CHAIN; NA,K-ATPASE; ENZYME; HALF; SITE	The Na/K-ATPase has been shown to bind 1 and 0.5 mol of P-32/mol of alpha-chain in the presence [gamma-P-32]ATP and [alpha-P-32]ATP, respectively, accompanied by a maximum accumulation of 0.5 mol of ADP-sensitive phosphoenzyme (NaE1P) and potassium sensitive phosphoenzyme (E2P), The former accumulation was followed by the slow constant liberation of P-i, but the latter was accompanied with a rapid similar to 0.25 mol of acid-labile P-i burst. The rubidium (potassium congener)-occluded enzyme (similar to 1.7 mol of rubidium/mol of alpha-chain) completely lost rubidium on the addition of sodium + magnesium, Further addition of similar to 100 mu M [gamma-P-32]ATP and [alpha-P-32]ATP, both induced 0.5 mol of P-32-ATP binding to the enzyme and caused accumulation of similar to 1 mol of rubidium/mol of a-chain, accompanied by a rapid similar to 0.5 mol of P-i burst with no detectable phosphoenzyme under steady state conditions. Electron microscopy of rotary-shadowed soluble and membrane-bound Na/K-ATPases and an antibody-Na/K-ATPase complex, indicated the presence of tetraprotomeric structures (cup), These and other data suggest that Na/K-ATP hydrolysis occurs via four parallel paths, the sequential appearance of (NaE1P:E-ATP)(2), (E2P:E.ATP:E2P:E.ADP/P-i), and (KE2:E.ADP/P-i)(2), each of which has been previously referred to as NaE1P, E2P, and KE2, respectively.	Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan; Kyorin Univ, Sch Med, Dept Biochem, Mitaka, Tokyo 1811611, Japan; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, S-58185 Linkoping, Sweden	Hokkaido University; Kyorin University; Linkoping University	Taniguchi, K (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan.	ktan@ccms1.hucc.hokudai.ac.jp	Abe, Kazuhiro/D-7662-2013	Abe, Kazuhiro/0000-0003-2681-5921				ALBERS RW, 1976, ENZYMES BIOLOGICAL M, V3, P283; Antolovic R, 1999, EUR J BIOCHEM, V261, P181, DOI 10.1046/j.1432-1327.1999.00260.x; ASKARI A, 1980, BIOCHEM BIOPH RES CO, V93, P448, DOI 10.1016/0006-291X(80)91098-0; ASKARI A, 1981, FEBS LETT, V126, P215, DOI 10.1016/0014-5793(81)80245-1; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; ESMANN M, 1985, SODIUM PUMP, P17; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2186; Froehlich JP, 1997, ANN NY ACAD SCI, V834, P280, DOI 10.1111/j.1749-6632.1997.tb52259.x; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; HAASE W, 1977, PFLUGERS ARCH, V381, P127; HANSEN O, 1979, NATURE, V280, P410, DOI 10.1038/280410a0; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Katoh T, 1998, J BIOL CHEM, V273, P11436, DOI 10.1074/jbc.273.19.11436; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; Liu GQ, 1996, FEBS LETT, V390, P323, DOI 10.1016/0014-5793(96)00687-4; MATSUI H, 1983, CURR TOP MEMBR TRANS, V19, P145; PETERS WHM, 1981, NATURE, V290, P338, DOI 10.1038/290338a0; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; SCHONER W, 1994, SODIUM PUMP, P332; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; TANIGUCHI K, 1984, J BIOL CHEM, V259, P5228; TANIGUCHI K, 1986, J BIOCHEM-TOKYO, V100, P1231, DOI 10.1093/oxfordjournals.jbchem.a121828; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Tsuda T, 1998, J BIOL CHEM, V273, P24334, DOI 10.1074/jbc.273.38.24334; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VILSEN B, 1987, J BIOL CHEM, V262, P10511; WALLER GS, 1985, J BIOL CHEM, V260, P4368; YAMAGUCHI M, 1979, J BIOCHEM-TOKYO, V86, P509, DOI 10.1093/oxfordjournals.jbchem.a132551; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688	36	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31792	31796		10.1074/jbc.274.45.31792	http://dx.doi.org/10.1074/jbc.274.45.31792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542201	hybrid			2022-12-25	WOS:000083532100009
J	Gardner, RG; Hampton, RY				Gardner, RG; Hampton, RY			A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-ENHANCED DEGRADATION; RETICULUM MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; SQUALENE EPOXIDASE; MOLECULAR-CLONING; BOUND DOMAIN; IN-VIVO	Sterol synthesis by the mevalonate pathway is modulated, in part, through feedback-regulated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR). In both mammals and yeast, a non-sterol isoprenoid signal positively regulates the rate of HMGR degradation. To define more precisely the molecule that serves as the source of this signal, we have conducted both pharmacological and genetic manipulations of the mevalonate pathway in yeast. We now demonstrate that farnesyl diphosphate (FPP) is the source of the positive signal for Hmg2p degradation in yeast. This FPP-derived signal does not act by altering the endoplasmic reticulum degradation machinery in general. Rather, the FPP-derived signal specifically modulates Hmg2p stability. In mammalian cells, an FPP-derived molecule also serves as a positive signal for HMGR degradation. Thus, both yeast and mammalian cells employ the same strategy for regulation of HMGR degradation, perhaps by conserved molecular processes.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hampton, RY (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Gardner, Richard/0000-0003-2162-6275	NIDDK NIH HHS [DK5199601] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051996, R37DK051996] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARONI M, 1986, GENE, V46, P71, DOI 10.1016/0378-1119(86)90168-X; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; CHAMBON C, 1990, CURR GENET, V18, P41, DOI 10.1007/BF00321113; CHEREST H, 1985, GENE, V34, P269; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Cronin SR, 1999, METHOD ENZYMOL, V302, P58, DOI 10.1016/S0076-6879(99)02010-8; DIETSCHY JM, 1974, J LIPID RES, V15, P508; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; FEGUEUR M, 1991, CURR GENET, V20, P365, DOI 10.1007/BF00317063; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GULDENER U, 1996, NUCLEIC ACIDS RES, V24, P25196; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; LECUREUX LW, 1994, J CELL SCI, V107, P2635; Lopez D, 1997, ARCH BIOCHEM BIOPHYS, V343, P118, DOI 10.1006/abbi.1997.0162; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x; RYDER NS, 1989, CLIN EXP DERMATOL, V14, P98, DOI 10.1111/j.1365-2230.1989.tb00900.x; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; SIPERSTEIN MD, 1966, J BIOL CHEM, V241, P602; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	41	122	128	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31671	31678		10.1074/jbc.274.44.31671	http://dx.doi.org/10.1074/jbc.274.44.31671			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531376	hybrid			2022-12-25	WOS:000083379400080
J	Gillespie, PG; Gillespie, SKH; Mercer, JA; Shah, K; Shokat, KM				Gillespie, PG; Gillespie, SKH; Mercer, JA; Shah, K; Shokat, KM			Engineering of the myosin-I beta nucleotide-binding pocket to create selective sensitivity to N-6-modified ADP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; SITE-DIRECTED MUTAGENESIS; HEAVY-CHAIN GENE; X-RAY STRUCTURES; DICTYOSTELIUM-DISCOIDEUM; MOTOR DOMAIN; HAIR-CELLS; UNCONVENTIONAL MYOSINS; KINETIC CHARACTERIZATION; SUBSTRATE-SPECIFICITY	Distinguishing the cellular functions carried out by enzymes of highly similar structure would be simplified by the availability of isozyme-selective inhibitors. To determine roles played by individual members of the large myosin superfamily, we designed a mutation in myosin's nucleotide-binding pocket that permits binding of adenine nucleotides modified with bulky N-6 substituents. Introduction of this mutation, Y61G in rat myosin-I beta, did not alter the enzyme's affinity for ATP or actin and actually increased its ATPase activity and actin-translocation rate. We also synthesized several N-6-modified ADP analogs that should bind to and inhibit mutant, but not wild-type, myosin molecules, Several of these N-6-modified ADP analogs were more than 40-fold more potent at inhibiting ATP hydrolysis by Y61G than wild-type myosin-I beta; in doing so, these analogs locked Y61G myosin-I beta tightly to actin, N-6-(2-methylbutyl) ADP abolished actin filament motility mediated by Y61G, but not wild-type, myosin-I beta. Furthermore, at small fraction of inhibited Y61G molecules was sufficient to block filament motility mediated by mixtures of wild-type and Y61G myosin-I beta. Introduction of Y61G myosin-I beta molecules into a cell should permit selective inhibition by N-6-modified ADP analogs of cellular processes dependent on myosin-I beta.	Johns Hopkins Univ, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; McLaughlin Res Inst, Great Falls, MT 59405 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA	Johns Hopkins University; Johns Hopkins University; McLaughlin Research Institute for Biomedical Sciences, Inc.; Princeton University; Princeton University	Gillespie, PG (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, NRC04,3181 Sam Jackson Pk Rd, Portland, OR 97201 USA.	gillespp@ohsu.edu		Barr-Gillespie, Peter/0000-0002-9787-5860; Mercer, John/0000-0003-0307-4438	NATIONAL CANCER INSTITUTE [R01CA070331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003279] Funding Source: NIH RePORTER; NCI NIH HHS [CA70331] Funding Source: Medline; NIDCD NIH HHS [DC03279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; ASSAD JA, 1992, J NEUROSCI, V12, P3291; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDE WZ, 1986, METHOD ENZYMOL, V134, P473; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHERSTEIN SK, 1993, NATURE, V365, P841; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GILLESPIE PG, 1993, P NATL ACAD SCI USA, V90, P2710, DOI 10.1073/pnas.90.7.2710; Gillespie PG, 1997, NEURON, V19, P955, DOI 10.1016/S0896-6273(00)80387-6; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; KANG C, 1994, J BIOL CHEM, V269, P24046; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; KIKUGAWA K, 1973, J MED CHEM, V16, P358, DOI 10.1021/jm00262a011; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATE E, 1991, BIOPHYS J, V59, P598, DOI 10.1016/S0006-3495(91)82275-5; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Post PL, 1998, J CELL SCI, V111, P941; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; RUPPERT C, 1995, J CELL SCI, V108, P3775; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; TONOMURA Y, 1967, J BIOCHEM-TOKYO, V61, P460, DOI 10.1093/oxfordjournals.jbchem.a128569; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WANG D, 1993, J MUSCLE RES CELL M, V14, P484, DOI 10.1007/BF00297211; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	63	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31373	31381		10.1074/jbc.274.44.31373	http://dx.doi.org/10.1074/jbc.274.44.31373			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531338	hybrid			2022-12-25	WOS:000083379400042
J	Scherer-Oppliger, T; Leimbacher, W; Blau, N; Thony, B				Scherer-Oppliger, T; Leimbacher, W; Blau, N; Thony, B			Serine 19 of human 6-pyruvoyltetrahydropterin synthase is phosphorylated by cGMP protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-CYCLOHYDROLASE-I; 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; RENAL MESANGIAL CELLS; GENE-EXPRESSION; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE; TETRAHYDROBIOPTERIN BIOSYNTHESIS; SEPIAPTERIN REDUCTASE; INTERFERON-GAMMA; MAST-CELLS; ENZYME	6-Pyruvoyltetrahydropterin synthase (PTPS) participates in tetrahydrobiopterin cofactor biosynthesis. We previously identified in a PTPS-deficient patient an inactive PTPS allele with an Arg(16) to Cys codon mutation. Arg(16) is located in the protein surface exposed phosphorylation motif Arg(16)-Arg-Ile-Ser, with Ser(19) as the putative phosphorylation site for serine-threonine protein kinases. Purification of recombinant PTPS-S19A from bacterial cells resulted in an active enzyme (k(cat)/K-m = 6.4 x 10(3) M-1 s(-1)), which was similar to wild-type PTPS (k(cat)/K-m = 4.1 x 10(3) M-1 s(-1)). In assays with purified enzymes, wild-type but not PTPS-S19A was a specific substrate for the cGMP-dependent protein kinase (cGK) type I and II. Upon expression in COS-1 cells, PTPS-S19A was stable but not phosphorylated and had a reduced activity of similar to 33% in comparison to wild-type PTPS. Extracts from several human cell lines, including brain, contained a kinase that bound to and phosphorylated immobilized wild-type, but not mutant PTPS. Addition of cGMP stimulated phosphotransferase activity 2-fold. Extracts from transfected COS-1 cells overexpressing cGKII stimulated Ser(19) phosphorylation more than 100-fold, but only 4-fold from cGKI overexpressing cells. Moreover, fibroblast extracts from mice! lacking cGKII exhibited significantly reduced phosphorylation of PTPS. These results suggest that Ser(19) of human PTPS may be a substrate for cGKII phosphorylation also in vivo, a modification that is essential for normal activity.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	University of Zurich	Thony, B (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	bthony@kispi.unizh.ch		Blau, Nenad/0000-0003-4347-3230				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Blau N, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P719; Blau N, 1996, J INHERIT METAB DIS, V19, P8, DOI 10.1007/BF01799342; Blau N., 1993, PTERIDINES, V4, P1; BURGISSER DM, 1995, J MOL BIOL, V253, P358, DOI 10.1006/jmbi.1995.0558; BURGISSER DM, 1994, EUR J BIOCHEM, V219, P497, DOI 10.1111/j.1432-1033.1994.tb19964.x; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; DSa C, 1996, MOL BRAIN RES, V41, P105, DOI 10.1016/0169-328X(96)00073-3; FUJII M, 1995, FEBS LETT, V375, P263, DOI 10.1016/0014-5793(95)01223-2; HAUER CR, 1992, BIOCHEM BIOPH RES CO, V182, P953, DOI 10.1016/0006-291X(92)91824-A; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; HIRAYAMA K, 1995, NEUROCHEM INT, V27, P157, DOI 10.1016/0197-0186(95)00008-V; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATOH S, 1994, FEBS LETT, V341, P227, DOI 10.1016/0014-5793(94)80462-1; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; Lapize C, 1998, BIOCHEM BIOPH RES CO, V251, P802, DOI 10.1006/bbrc.1998.9552; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; OPPLIGER T, 1995, J BIOL CHEM, V270, P29498, DOI 10.1074/jbc.270.49.29498; Orstavik S, 1996, BIOCHEM BIOPH RES CO, V220, P759, DOI 10.1006/bbrc.1996.0477; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Ploom T, 1999, J MOL BIOL, V286, P851, DOI 10.1006/jmbi.1998.2511; Pluss C, 1996, BIOCHEM J, V318, P665; Ruth P, 1997, J BIOL CHEM, V272, P10522; Scriver C.R., 1995, METABOLIC MOL BASIS, V7th ed, P1015; Stegenga SL, 1996, J NEUROCHEM, V66, P2541; Thony B, 1997, HUM MUTAT, V10, P11; Thony B, 1997, CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, P713; THONY B, 1994, AM J HUM GENET, V54, P782; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; Turri MO, 1998, BIOL CHEM, V379, P1441; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; WERNER ER, 1990, J BIOL CHEM, V265, P3189; ZHU M, 1994, J BIOL CHEM, V269, P11825; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544	38	20	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31341	31348		10.1074/jbc.274.44.31341	http://dx.doi.org/10.1074/jbc.274.44.31341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531334	hybrid			2022-12-25	WOS:000083379400038
J	Swaminathan, CP; Nandi, A; Visweswariah, SS; Surolia, A				Swaminathan, CP; Nandi, A; Visweswariah, SS; Surolia, A			Thermodynamic analyses reveal role of water release in epitope recognition by a monoclonal antibody against the human guanylyl cyclase C receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; ENTHALPY-ENTROPY COMPENSATION; ANTIGEN-BINDING; MOLECULAR-BASIS; INTERMOLECULAR INTERACTIONS; ANTILYSOZYME ANTIBODIES; 3-DIMENSIONAL STRUCTURE; MUTATIONAL ANALYSIS; CROSS-REACTIVITY; FAB FRAGMENTS	The thermodynamics of a monoclonal antibody (mAb)-peptide interaction have been characterized by isothermal titration microcalorimetry, GCC:B10 mAb, generated against; human guanylyl cyclase C, a membrane-associated receptor and a potential marker for metastatic colon cancer, recognizes the cognate peptide epitope HIPPENIFPLE and its two contiguous mimotopes, HIPPEN and ENIFPLE, specifically and reversibly. The exothermic binding reactions between 6.4 and 42 degrees C are driven by dominant favorable enthalpic contributions between 20 and 42 degrees C, with a large negative heat capacity (Delta C-p) of -421 +/- 27 cal mol(-1) K-1. The unfavorable negative value of entropy (Delta S-b(0)) at 25 degrees C, an unusual feature among protein-protein interactions, becomes a positive one below an inversion temperature of 20.5 degrees C, Enthalpy-entropy compensation due to solvent reorganization accounts for an essentially unchanged free energy of interaction (Delta Delta G(b)(0) congruent to 0). The role of water molecules in the recognition process was tested by coupling an osmotic stress technique with isothermal titration microcalorimetry. The results provide direct and compelling evidence that GCC:B10 mAb recognizes the peptides HIPPENIFPLE, HIPPEN, and ENIFPLE differentially, with a concomitant release of variable and nonadditive numbers of water molecules (15, 7, and 3, respectively) hom the vicinity of the binding site.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@mbu.iisc.ernet.in	SUROLIA, AVADESHA/C-5442-2009; Visweswariah, Sandhya/Q-7500-2019	Visweswariah, Sandhya/0000-0003-2786-7344				Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BAUGH RJ, 1972, J BIOL CHEM, V247, P7498; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Braden BC, 1998, IMMUNOL REV, V163, P45, DOI 10.1111/j.1600-065X.1998.tb01187.x; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CORRADIN G, 1984, J IMMUNOL, V133, P2915; Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DONOVAN JW, 1969, J BIOL CHEM, V244, P1961; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Faiman GA, 1997, J BIOL CHEM, V272, P31407, DOI 10.1074/jbc.272.50.31407; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; Forte LR, 1996, NEWS PHYSIOL SCI, V11, P17; FUKADA H, 1985, BIOCHEMISTRY-US, V24, P5109, DOI 10.1021/bi00340a023; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GOLDANSKII VI, 1995, PROTEIN SOLVENT INTE, P289; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Leffler J. E., 1963, RATES EQUILIBRIA ORG, P315; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; Nandi A, 1997, J CELL BIOCHEM, V66, P500, DOI 10.1002/(SICI)1097-4644(19970915)66:4<500::AID-JCB9>3.0.CO;2-P; Nandi A, 1998, PROTEIN SCI, V7, P2175, DOI 10.1002/pro.5560071015; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Priev A, 1996, BIOCHEMISTRY-US, V35, P2061, DOI 10.1021/bi951842r; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; TAKAHASHI K, 1985, BIOCHEMISTRY-US, V24, P297, DOI 10.1021/bi00323a009; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; van Oss CJ, 1997, J MOL RECOGNIT, V10, P203, DOI 10.1002/(SICI)1099-1352(199709/10)10:5<203::AID-JMR366>3.0.CO;2-Z; VANREGENMORTEL MHV, 1994, IMMUNOCHEMISTRY, P277; Weast R. C., 1980, CRC HDB CHEM PHYSICS, pD229; Weber-Bornhauser S, 1998, BIOCHEMISTRY-US, V37, P13011, DOI 10.1021/bi980874m; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; YANG CP, 1990, OMEGA DATA ORIGIN	61	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31272	31278		10.1074/jbc.274.44.31272	http://dx.doi.org/10.1074/jbc.274.44.31272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531324	hybrid			2022-12-25	WOS:000083379400028
J	Dubin, AE; Huvar, R; D'Andrea, MR; Pyati, J; Zhu, JY; Joy, KC; Wilson, SJ; Galindo, JE; Glass, CA; Luo, L; Jackson, MR; Lovenberg, TW; Erlander, MG				Dubin, AE; Huvar, R; D'Andrea, MR; Pyati, J; Zhu, JY; Joy, KC; Wilson, SJ; Galindo, JE; Glass, CA; Luo, L; Jackson, MR; Lovenberg, TW; Erlander, MG			The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-MT3B receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; HUMAN 5-HYDROXYTRYPTAMINE(3) RECEPTOR; XENOPUS-OOCYTES; K+ CHANNEL; SPLICE VARIANTS; ION CHANNELS; AGONIST SENSITIVITY; MOLECULAR-CLONING; SENSORY NEURONS; LIGAND-BINDING	While homomers containing 5-HT3A subunits form functional ligand-gated serotonin (5-HT) receptors in heterologous expression systems (Jackson, M. B., and Yakel, J. L. (1995) Annu. Rev. Physiol. 57, 447-468; Lambert, J. J., Peters, J. A., and Hope, A. G. (1995) in Ligand-Voltage-Gated Ion Channels (North, R., ed) pp. 177-211, CRC Press, Inc., Boca Raton, FL), it has been proposed that native receptors may exist as heteromers (Fletcher, S., and Barnes, N. M. (1998) Trends Pharmacol. Sci. 19, 212-215). We report the cloning of a subunit 5-HT3B with similar to 44% amino acid identity to 5-HT3A that specifically modified 5-HT3A receptor kinetics, voltage dependence, and pharmacology. Go-expression of 5-HT3B with 5-HT3A modified the duration of 5-HT3 receptor agonist-induced responses, linearized the current-voltage relationship, increased agonist and antagonist affinity, and reduced cooperativity between subunits. Reverse transcriptase-polymerase chain reaction in situ hybridization revealed co-localization of both 5-HT3B and 5-HT3A in a population of neurons in the amygdala, telencephalon, and entorhinal cortex. Furthermore, 5-HT3A and 5-HT3B mRNAs were expressed in spleen and intestine. Our data suggest that 5-HT3B might contribute to tissue-specific functional changes in 5-HT3-mediated signaling and/or modulation.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Dubin, AE (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.							ABI-DARGHAM A, 1993, J NEUROCHEM, V60, P730, DOI 10.1111/j.1471-4159.1993.tb03208.x; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARNES JM, 1992, NEUROSCI BIOBEHAV R, V16, P107, DOI 10.1016/S0149-7634(05)80057-0; BARNES JM, 1990, NEUROPHARMACOLOGY, V29, P1037, DOI 10.1016/0028-3908(90)90110-D; Bartrup JT, 1996, J PHYSIOL-LONDON, V490, P679, DOI 10.1113/jphysiol.1996.sp021177; Belelli D, 1995, MOL PHARMACOL, V48, P1054; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; BOESS FG, 1995, J NEUROCHEM, V64, P1401; BONHAUS DW, 1993, J NEUROCHEM, V61, P1927, DOI 10.1111/j.1471-4159.1993.tb09835.x; BONHAUS DW, 1995, J NEUROCHEM, V65, P104; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; CACHELIN AB, 1991, PFLUG ARCH EUR J PHY, V419, P579, DOI 10.1007/BF00370298; CONLEY EC, 1995, ION CHANNEL FACTS BO, V2, P12; Costall B, 1994, 5 HYDROXYTRYPTAMINE, P203; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DOWNIE DL, 1995, BRIT J PHARMACOL, V114, P1641, DOI 10.1111/j.1476-5381.1995.tb14952.x; Dubin AE, 1999, J NEUROSCI, V19, P1371; Eglen RM, 1996, CURR PHARM DESIGN, V2, P367; FAN P, 1994, NEUROSCIENCE, V62, P515, DOI 10.1016/0306-4522(94)90384-0; Ferriere F, 1997, BIOCHEM J, V323, P251, DOI 10.1042/bj3230251; Fletcher S, 1998, NEUROPHARMACOLOGY, V37, P397, DOI 10.1016/S0028-3908(98)00052-5; Fletcher S, 1998, TRENDS PHARMACOL SCI, V19, P212, DOI 10.1016/S0165-6147(98)01210-3; Fletcher S, 1997, BRIT J PHARMACOL, V122, P655, DOI 10.1038/sj.bjp.0701439; FRASER SP, 1993, ELECTROPHYSIOLOGY PR, P65; GEBAUER A, 1993, N-S ARCH PHARMACOL, V347, P137; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; GILON P, 1995, RECEPTOR CHANNEL, V3, P83; GREEN T, 1995, J BIOL CHEM, V270, P6056, DOI 10.1074/jbc.270.11.6056; Greenshaw AJ, 1997, DRUGS, V53, P20, DOI 10.2165/00003495-199753010-00003; GROSS A, 1991, PFLUG ARCH EUR J PHY, V419, P545, DOI 10.1007/BF00370805; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; Haas KF, 1999, J PHYSIOL-LONDON, V514, P27, DOI 10.1111/j.1469-7793.1999.027af.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; HEHL S, 1993, EUR BIOPHYS J BIOPHY, V22, P1, DOI 10.1007/BF00205806; Hermans E, 1999, BRIT J PHARMACOL, V126, P873, DOI 10.1038/sj.bjp.0702359; Hope AG, 1996, BRIT J PHARMACOL, V118, P1237, DOI 10.1111/j.1476-5381.1996.tb15529.x; HOPE AG, 1993, EUR J PHARM-MOLEC PH, V245, P187, DOI 10.1016/0922-4106(93)90128-V; Hoyer D, 1997, NEUROPHARMACOLOGY, V36, P419, DOI 10.1016/S0028-3908(97)00036-1; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; INVERNIZZI R, 1981, Neurochemistry International, V3, P239, DOI 10.1016/0197-0186(81)90006-1; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; JONES KA, 1994, NEUROSCI LETT, V174, P133, DOI 10.1016/0304-3940(94)90004-3; Lankiewicz S, 1998, MOL PHARMACOL, V53, P202, DOI 10.1124/mol.53.2.202; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIU Y, 1993, BIOPHYS J, V64, P26, DOI 10.1016/S0006-3495(93)81337-7; LUETJE CW, 1991, J NEUROSCI, V11, P837; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Mair ID, 1998, BRIT J PHARMACOL, V124, P1667, DOI 10.1038/sj.bjp.0702037; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; Meyniel JP, 1997, IMMUNOL LETT, V55, P151, DOI 10.1016/S0165-2478(97)02697-7; MIYAKE A, 1995, MOL PHARMACOL, V48, P407; Morales M, 1997, J NEUROSCI, V17, P3157; MORAN O, 1992, FEBS LETT, V302, P21, DOI 10.1016/0014-5793(92)80275-L; MUELLER EA, 1985, J CLIN ENDOCR METAB, V61, P1179, DOI 10.1210/jcem-61-6-1179; NEIJT HC, 1986, EUR J PHARMACOL, V127, P271, DOI 10.1016/0014-2999(86)90374-2; Niemeyer MI, 1998, BRIT J PHARMACOL, V123, P661, DOI 10.1038/sj.bjp.0701657; NUOVO GJ, 1997, PCR SITU HYBRIDIZATI, P271; PETERS JA, 1989, TRENDS PHARMACOL SCI, V10, P172, DOI 10.1016/0165-6147(89)90230-7; PETERS JA, 1992, TRENDS PHARMACOL SCI, V13, P391, DOI 10.1016/0165-6147(92)90119-Q; RAYMOND LA, 1998, FRONT NEUROBIOL, V3, P177; RAZANIBOROUJERDI S, 1993, BRAIN RES, V623, P195, DOI 10.1016/0006-8993(93)91427-T; ROBERTSON DW, 1992, LIFE SCI, V50, P599, DOI 10.1016/0024-3205(92)90372-V; Ronde P, 1998, J NEUROCHEM, V70, P1094; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Sambrook J., 2002, MOL CLONING LAB MANU; SATO N, 1992, JPN J PHARMACOL, V59, P443, DOI 10.1254/jjp.59.443; SEPULVEDA MI, 1991, BRIT J PHARMACOL, V104, P536, DOI 10.1111/j.1476-5381.1991.tb12464.x; SHAO XM, 1991, J NEUROPHYSIOL, V65, P630, DOI 10.1152/jn.1991.65.3.630; Stocker M, 1999, J NEUROCHEM, V72, P1725, DOI 10.1046/j.1471-4159.1999.721725.x; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; van Hooft JA, 1998, P NATL ACAD SCI USA, V95, P11456, DOI 10.1073/pnas.95.19.11456; vanHooft JA, 1997, J NEUROCHEM, V69, P1318; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; YAKUSHIJI T, 1992, BRIT J PHARMACOL, V107, P853, DOI 10.1111/j.1476-5381.1992.tb14536.x; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177; Zar J, 1996, BIOSTAT ANAL, P457; Zhong HJ, 1999, BRAIN RES, V816, P544, DOI 10.1016/S0006-8993(98)01232-3	88	222	232	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30799	30810		10.1074/jbc.274.43.30799	http://dx.doi.org/10.1074/jbc.274.43.30799			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521471	hybrid			2022-12-25	WOS:000083276700067
J	Foti, DM; Welihinda, A; Kaufman, RJ; Lee, AS				Foti, DM; Welihinda, A; Kaufman, RJ; Lee, AS			Conservation and divergence of the yeast and mammalian unfolded protein response - Activation of specific mammalian endoplasmic reticulum stress element of the grp78/BiP promoter by yeast Hac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-ACTING FACTORS; TRANSCRIPTION FACTOR; REGULATORY ELEMENT; ADENOVIRUS E1A; CA2+ DEPLETION; GENE; YY1; INDUCTION; BINDING; CELLS	Yeast Had (yHac1), the transcription factor that binds and activates the unfolded protein response element of endoplasmic reticulum (ER)-chaperone gene promoters, only accumulates in stressed cells after an unconventional splicesosome-free mRNA processing step and escape from translation block In determining whether the novel regulatory mechanisms for yHac1 are conserved in mammalian cells, we discovered a unique unfolded protein response element-like sequence within the endoplasmic reticulum stress element 163, one of the three ER stress elements recently identified in the rat grp78 promoter, The unspliced form of yHac1 is stably expressed in nonstressed mammalian cells and is as active as the spliced form in stimulating the promoter activities of grp genes. Further, the yHac1 mRNA is not processed in response to ER stress in mammalian cells. We identified a CCAGC motif as the yHac1 binding site, which is contained within a YY1 binding site previously shown to be important for mammalian UPR, Dissection of the yHac1 and the YY1 binding sites uncovered specific contact points for an activator protein predicted to be the mammalian homolog of yHac1, the activity of which can be stimulated by YY1. A model of the conserved and unique features of the yeast and mammalian unfolded protein response transcription machinery is proposed.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Sch Med, Los Angeles, CA 90089 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Southern California; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Lee, AS (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Sch Med, Los Angeles, CA 90089 USA.			Welihinda, Ajith/0000-0002-0049-0850; Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607] Funding Source: Medline; NHLBI NIH HHS [HV53777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027607, R37CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee TC, 1998, NUCLEIC ACIDS RES, V26, P3215, DOI 10.1093/nar/26.13.3215; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; Marcus N, 1997, DNA CELL BIOL, V16, P1123, DOI 10.1089/dna.1997.16.1123; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; RAMAKRISHNAN M, 1995, DNA CELL BIOL, V14, P373, DOI 10.1089/dna.1995.14.373; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	34	42	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30402	30409		10.1074/jbc.274.43.30402	http://dx.doi.org/10.1074/jbc.274.43.30402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521417	hybrid			2022-12-25	WOS:000083276700013
J	Cladera, J; Martin, I; Ruysschaert, JM; O'Shea, P				Cladera, J; Martin, I; Ruysschaert, JM; O'Shea, P			Characterization of the sequence of interactions of the fusion domain of the simian immunodeficiency virus with membranes - Role of the membrane dipole potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID HEAD GROUPS; ENVELOPE GLYCOPROTEIN; PHOSPHATIDYLCHOLINE MEMBRANES; INFRARED-SPECTROSCOPY; INFLUENZA-VIRUS; LIPID VESICLES; PEPTIDE; BILAYERS; RECEPTOR; HIV-1	The simian immunodeficiency virus fusion peptide constitutes a 12-residue N-terminal segment of the gp32 protein that is involved in the fusion between the viral and cellular membranes, facilitating the penetration of the virus in the host cell. Simian immunodeficiency virus fusion peptide is a hydrophobic peptide that in Me2SO forms aggregates that contain beta-sheet pleated structures. When added to aqueous media the peptide forms large colloidal aggregates. In the presence of lipidic membranes, however, the peptide interacts with the membranes and causes small changes of the membrane electrostatic potential as shown by fluorescein phosphatidylethanolamine fluorescence. Thioflavin T fluorescence and Fourier transformed infrared spectroscopy measurements reveal that the interaction of the peptide with the membrane bilayer results in complete disassembly of the aggregates originating from an Me2SO stock solution. Above a lipid/peptide ratio of about 5, the membrane disaggregation and water precipitation processes become dependent on the absolute peptide concentration rather than on the lipid/peptide ratio. A schematic mechanism is proposed, which sheds light on how peptide-peptide interactions can be favored with respect to peptide-lipid interactions at various lipid/peptide ratios. These studies are augmented by the use of the fluorescent dye 1-(3-sulfonatopropyl)-4-[beta[2-(di-n-octylamino)-6-naphthyl]vinyl] pyridinium betaine that shows the interaction of the peptide with the membranes has a clear effect on the magnitude of the so-called dipole potential that arises :From dipolar groups located on the lipid molecules and oriented water molecules at the membrane-water interface. It is shown that the variation of the membrane dipole potential affects the extent of the membrane fusion caused by the peptide and implicates the dipolar properties of membranes in their fusion.	Univ Nottingham, Sch Biomed Sci, Fac Med & Hlth Sci, Queens Med Ctr, Nottingham NG7 2UH, England; Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	University of Nottingham; Universite Libre de Bruxelles; Vrije Universiteit Brussel	O'Shea, P (corresponding author), Univ Nottingham, Sch Biomed Sci, Fac Med & Hlth Sci, Queens Med Ctr, Nottingham NG7 2UH, England.	paul.oshea@nottingham.ac.uk	Cladera, Josep/E-6737-2010	Cladera, Josep/0000-0002-1724-3477; O'Shea, paul/0000-0001-9313-8313				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BECHINGER B, 1991, BIOCHEMISTRY-US, V30, P3923, DOI 10.1021/bi00230a017; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; Blumenthal R, 1999, MOL MEMBR BIOL, V16, P43, DOI 10.1080/096876899294742; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; BROCKMAN H, 1994, CHEM PHYS LIPIDS, V73, P57, DOI 10.1016/0009-3084(94)90174-0; BULDT G, 1981, J MEMBRANE BIOL, V58, P81, DOI 10.1007/BF01870972; BULDT G, 1978, NATURE, V271, P182, DOI 10.1038/271182a0; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Cladera J, 1998, BIOPHYS J, V74, P2434, DOI 10.1016/S0006-3495(98)77951-2; Clarke RJ, 1997, BBA-BIOMEMBRANES, V1327, P269, DOI 10.1016/S0005-2736(97)00075-8; Clarke RJ, 1997, BBA-BIOMEMBRANES, V1323, P223, DOI 10.1016/S0005-2736(96)00188-5; Colotto A, 1996, BIOCHEMISTRY-US, V35, P980, DOI 10.1021/bi951991+; Colotto A, 1997, BIOCHEMISTRY-US, V36, P7644, DOI 10.1021/bi970382u; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEMPSEY C, 1989, BIOCHEMISTRY-US, V28, P6590, DOI 10.1021/bi00442a009; DEMPSEY CE, 1987, BIOCHEMISTRY-US, V26, P5803, DOI 10.1021/bi00392a033; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; FRANKLIN JC, 1993, BIOPHYS J, V65, P289, DOI 10.1016/S0006-3495(93)81051-8; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; Golding C, 1996, BIOCHEMISTRY-US, V35, P10931, DOI 10.1021/bi960905i; GROSS E, 1994, BIOPHYS J, V67, P208, DOI 10.1016/S0006-3495(94)80471-0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARTIN I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P124, DOI 10.1016/0005-2736(93)90389-H; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Pereira FB, 1997, BIOPHYS J, V73, P1977, DOI 10.1016/S0006-3495(97)78228-6; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; SIMON SA, 1992, BIOPHYS J, V61, P786, DOI 10.1016/S0006-3495(92)81883-0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506; WALL J, 1995, J CELL SCI, V108, P2673; Wolfe C, 1998, MOL MEMBR BIOL, V15, P221, DOI 10.3109/09687689709044324; Wolfe CA, 1999, MOL MEMBR BIOL, V16, P257, DOI 10.1080/096876899294571	53	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29951	29959		10.1074/jbc.274.42.29951	http://dx.doi.org/10.1074/jbc.274.42.29951			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514478	hybrid			2022-12-25	WOS:000083176400057
J	Papi, A; Johnston, SL				Papi, A; Johnston, SL			Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappa B and GATA transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COMMON COLD VIRUS; ASTHMATIC SUBJECTS; GENE-EXPRESSION; IN-VIVO; ULTRASTRUCTURAL-LOCALIZATION; DIFFERENTIAL REGULATION; VCAM-1 EXPRESSION; E-SELECTIN; ICAM-1	Virus infections, the majority of which are rhinovirus infections, are the major cause of asthma exacerbations. Asthma now affects one-fifth of the population, yet treatment of exacerbations is unsatisfactory, and the pathogenesis is unclear. Intraepithelial lymphocyte and eosinophil infiltration and activation are strongly implicated, but the mechanisms regulating these processes are unknown. We hypothesized that lower airway epithelial expression of vascular cell adhesion molecule-1 (VCAM-1) may be important in intraepithelial inflammation and that expression would be induced by pro-inflammatory stimuli and rhinovirus infection. We investigated respiratory epithelial cell VCAM-1 expression and its regulation to identify new targets for treatment of virus-induced asthma exacerbations. We observed constitutive respiratory epithelial cell VCAM-1 expression and that rhinovirus infection, but no other pro-inflammatory stimuli tested increased VCAM-1 cell surface expression in respiratory epithelial cell lines and primary bronchial epithelial cells, We then observed rhinovirus induction of VCAM-1 mRNA expression, promoter activity, and mRNA transcription. Rhinovirus induction of VCAM-1 promoter activity was critically dependent on up-regulation of proteins binding to the -254/-251 and -239/-236 GATA-binding sites and to the -72/-63 and -57/-48 NF-kappa B-binding sites in the VCAM-1 promoter. These studies identify VCAM-1 and the NF-kappa B and GATA transcription factor families as new targets for development of therapeutic interventions for virus-induced asthma exacerbations.	Univ Southampton, Southampton Gen Hosp, Southampton S016 6YD, Hants, England	University of Southampton	Johnston, SL (corresponding author), Univ Southampton, Southampton Gen Hosp, Tremona Rd, Southampton S016 6YD, Hants, England.		Papi, alberto/AAC-1888-2019; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; PAPI, ALBERTO/0000-0002-6924-4500				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Atsuta J, 1997, AM J RESP CELL MOL, V17, P571, DOI 10.1165/ajrcmb.17.5.2685; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Campbell MJ, 1997, BRIT MED J, V315, P1012, DOI 10.1136/bmj.315.7114.1012; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GARNER CM, 1994, CLIN EXP IMMUNOL, V95, P322; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Johnston SL, 1995, DIAGNOSTIC PROCEDURE, P553; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Lechleitner S, 1998, J EXP MED, V187, P2023, DOI 10.1084/jem.187.12.2023; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LHOTTA K, 1991, CLIN SCI, V81, P477, DOI 10.1042/cs0810477; Li XC, 1997, CELL IMMUNOL, V175, P58, DOI 10.1006/cimm.1996.1050; MEAGHER L, 1994, J IMMUNOL METHODS, V175, P237, DOI 10.1016/0022-1759(94)90366-2; Nagata M, 1998, AM J RESP CELL MOL, V19, P158, DOI 10.1165/ajrcmb.19.1.3001; NAGATA M, 1995, J IMMUNOL, V155, P2194; NAKAJIMA S, 1994, AM J PHYSIOL-LUNG C, V267, pL422, DOI 10.1152/ajplung.1994.267.4.L422; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Ogawa T, 1996, VIRCHOWS ARCH, V429, P283; Ogawa T, 1997, NEPHRON, V75, P54, DOI 10.1159/000189500; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; PIPKORN U, 1984, PROGR ALLERGY CLIN I, P237; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; Richards IM, 1996, AM J RESP CELL MOL, V15, P172, DOI 10.1165/ajrcmb.15.2.8703473; RUCO LP, 1995, J PATHOL, V176, P391, DOI 10.1002/path.1711760410; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1068; SERON D, 1991, NEPHROL DIAL TRANSPL, V6, P917, DOI 10.1093/ndt/6.12.917; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; WUTHRICH RP, 1993, TRANSPLANTATION, V55, P172, DOI 10.1097/00007890-199301000-00032; WUTHRICH RP, 1992, KIDNEY INT, V42, P903, DOI 10.1038/ki.1992.367; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	59	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30041	30051		10.1074/jbc.274.42.30041	http://dx.doi.org/10.1074/jbc.274.42.30041			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514490	hybrid			2022-12-25	WOS:000083176400069
J	Wellmer, F; Kircher, S; Rugner, A; Frohnmeyer, R; Schafer, E; Harter, A				Wellmer, F; Kircher, S; Rugner, A; Frohnmeyer, R; Schafer, E; Harter, A			Phosphorylation of the parsley bZIP transcription factor CPRF2 is regulated by light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE PROMOTER; SIGNAL-TRANSDUCTION; G-BOX; DIFFERENT PHYTOCHROMES; FACTOR GBF1; PROTEINS; HETERODIMERIZATION; RESPONSIVENESS; PROTOPLASTS; EXPRESSION	The analysis of the complex network of signal transduction chains has demonstrated the importance of transcription factor activities for the control of gene expression. To understand how transcription factor activities in plants are regulated in response to Light, we analyzed the common plant regulatory factor 2 (CPRF2) from parsley (Petroselinum crispum L.) that interacts with promoter elements of light-regulated genes. Here, we demonstrate that CPRF2 is a phosphoprotein in vitro and that its phosphorylation state is rapidly increased in response to light. Phosphorylation in vitro as well as in vivo occurs primarily within the C-terminal half of the factor, and is caused by a cytosolic 40-kDa protein serine kinase. In contrast to other plant basic leucine-zipper motif factors, phosphorylation of CPRF2 does not alter its DNA binding activity. Therefore, me discuss alternative functions of the light-dependent phosphorylation of CPRF2 including the regulation of its nucleocytoplasmic partitioning.	Univ Freiburg, Inst biol Bot 2, D-79104 Freiburg, Germany	University of Freiburg	Harter, A (corresponding author), Univ Freiburg, Inst biol Bot 2, Schanzlestr 1, D-79104 Freiburg, Germany.			Wellmer, Frank/0000-0002-2095-0981				ARMSTRONG GA, 1992, PLANT CELL, V4, P525, DOI 10.1105/tpc.4.5.525; BLOCK A, 1990, P NATL ACAD SCI USA, V87, P5387, DOI 10.1073/pnas.87.14.5387; BOWLER C, 1994, GENE DEV, V8, P2188, DOI 10.1101/gad.8.18.2188; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; BUCHHOLZ G, 1995, PLANT PHYSIOL, V108, P227, DOI 10.1104/pp.108.1.227; Ciceri P, 1997, PLANT CELL, V9, P97, DOI 10.1105/tpc.9.1.97; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Feldbrugge M, 1996, MOL GEN GENET, V251, P619, DOI 10.1007/s004380050210; FELDBRUGGE M, 1994, PLANT CELL, V6, P1607, DOI 10.1105/tpc.6.11.1607; FROHNMEYER H, 1994, PLANT J, V5, P437, DOI 10.1111/j.1365-313X.1994.00437.x; Furuya M, 1996, TRENDS PLANT SCI, V1, P301; HAHLBROCK K, 1975, PLANTA, V124, P311, DOI 10.1007/BF00388694; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Kircher S, 1998, MOL GEN GENET, V257, P595, DOI 10.1007/s004380050687; Kircher S, 1999, J CELL BIOL, V144, P201, DOI 10.1083/jcb.144.2.201; KLIMCZAK LJ, 1995, PLANT CELL, V7, P105, DOI 10.1105/tpc.7.1.105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; Meshi T, 1995, PLANT CELL PHYSIOL, V36, P1405; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; SCHAFER E, 1978, OPTISCHE STRAHLUNGSQ, P249; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SCHULZE-LEFERT P, 1989, PLANT CELL, V1, P707, DOI 10.1105/tpc.1.7.707; SCHULZE-LEFERT P, 1989, EMBO J, V8, P651, DOI 10.1002/j.1460-2075.1989.tb03422.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x	39	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29476	29482		10.1074/jbc.274.41.29476	http://dx.doi.org/10.1074/jbc.274.41.29476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506211	hybrid			2022-12-25	WOS:000083017800090
J	Zhu, HJ; Sizeland, AM				Zhu, HJ; Sizeland, AM			Extracellular domain of the transforming growth factor-beta receptor negatively regulates ligand-independent receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTORS; HETEROOLIGOMERIC COMPLEXES; CYTOPLASMIC DOMAINS; EXPRESSION; KINASE; PHOSPHORYLATION; CANCER; CELLS; TRANSPHOSPHORYLATION	We have previously proposed that transforming growth factor (TGF)-beta receptor activation occurs via a relative rotation between the receptors. This model suggests that in the absence of the ligand the receptor extracellular domain negatively regulates the activation of the receptor complex To investigate this proposition, four TGF-beta type I and II receptor extracellular/transmembrane-cytoplasmic and extracellular-transmembrane/cytoplasmic chimeras, T beta RII-I-I and T beta RI-II-II as well as T beta RII-II-I and T beta RI-I-II, and two extracellular domain truncated receptors T beta RI-STC and T beta RII-STC were generated. In either mutant mink lung R1B (lacking functional type I receptor) or DR26 (where the type II receptor is nonfunctional) cells, coexpression of two chimeric receptors, which are complementary in extracellular and cytoplasmic domains, transduced TGF-beta induced signaling, as measured by the transcriptional activation of a p3TP-Lux reporter gene. Coexpression of this type of chimeric receptor with a wild-type receptor containing the opposite cytoplasmic domain exhibited a varied level of constitutive activity depending on the particular combination of the extracellular domains. In general, the type I-type I extracellular domain combination gave higher constitutive activity than the type I-type II or type II-type IZ combinations. Furthermore, coexpression of the extracellular domain truncated receptor with any receptor containing the opposite cytoplasmic domain always resulted in ligand independent receptor signaling. Immunoprecipitation studies showed that the formation of the receptor complexes paralleled the ligand independent activation of p3TP-Lux. Our results support the conclusion that the TGF-beta receptor extracellular domain plays a negative regulatory role in receptor activation in the absence of ligand.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Zhu, HJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.			Zhu, Hong-Jian/0000-0002-1478-995X				Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; OKADOME T, 1994, J BIOL CHEM, V269, P30753; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369; Zhu HJ, 1999, J BIOL CHEM, V274, P11773, DOI 10.1074/jbc.274.17.11773	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29220	29227		10.1074/jbc.274.41.29220	http://dx.doi.org/10.1074/jbc.274.41.29220			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506179	hybrid			2022-12-25	WOS:000083017800058
J	Mockett, RJ; Sohal, RS; Orr, WC				Mockett, RJ; Sohal, RS; Orr, WC			Overexpression of glutathione reductase extends survival in transgenic Drosophila melanogaster under hyperoxia but not normoxia	FASEB JOURNAL			English	Article						aging; oxidative stress; reduced glutathione; free radicals; antioxidant defenses	SUPEROXIDE-DISMUTASE; LIFE-SPAN; OXIDATIVE STRESS; OXYGEN-TOXICITY; RESISTANCE; INCREASES; CATALASE; EXTENSION; DAMAGE; GENE	The purpose of this study was to test the hypothesis that overexpression of glutathione reductase in transgenic Drosophila melanogaster increases resistance to oxidative stress and retards the aging process. Transgenic flies were generated by microinjection and subsequent mobilization of a P element construct containing the genomic glutathione reductase gene of Drosophila, with 4 kb upstream and 1.5 kb downstream of the coding region. Transgenic animals stably overexpressed glutathione reductase by up to 100% throughout adult life and under continuous exposure to 100% oxygen or air. Under hyperoxic conditions, overexpressors had increased longevity, decreased accrual of protein carbonyls, and dramatically increased survival rates after recovery from a semi-lethal dose of 100% oxygen, Under normoxic conditions, overexpression of glutathione reductase had no effect on longevity, protein carbonyl content, reduced glutathione, or glutathione disulfide content, although the total consumption of oxygen was slightly decreased, Glutathione reductase activity does not appear to be a rate-limiting factor in anti-aging defenses under normoxic conditions, but it may become a limiting factor when the level of oxidative stress is elevated. -Mockett, R. J., Sohal, R. S., Orr, W. C. Overexpression of glutathione reductase extends survival in transgenic Drosophila melanogaster under hyperoxia but not normoxia.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, 220 Fondren Sci Bldg, Dallas, TX 75275 USA.	borr@mail.smu.edu			NATIONAL INSTITUTE ON AGING [R01AG007657, R01AG015122] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG15122, R01 AG7657] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akerboom T P, 1981, Methods Enzymol, V77, P373; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brack C, 1997, CELL MOL LIFE SCI, V53, P960, DOI 10.1007/PL00013199; Candas M, 1997, ARCH BIOCHEM BIOPHYS, V339, P323, DOI 10.1006/abbi.1996.9872; HOFFMAN DW, 1995, BIOCHEM PHARMACOL, V49, P411, DOI 10.1016/0006-2952(94)00474-Z; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KEHRER JP, 1984, FUND APPL TOXICOL, V4, P760, DOI 10.1016/0272-0590(84)90097-6; Lakritz J, 1997, ANAL BIOCHEM, V247, P63, DOI 10.1006/abio.1997.2032; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MAKINO N, 1995, BBA-GEN SUBJECTS, V1243, P503, DOI 10.1016/0304-4165(94)00177-Y; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; RALL TW, 1952, J BIOL CHEM, V194, P119; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; RICHIE JP, 1987, P SOC EXP BIOL MED, V184, P113; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SMITH IK, 1988, ANAL BIOCHEM, V175, P408, DOI 10.1016/0003-2697(88)90564-7; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Sun JT, 1999, MOL CELL BIOL, V19, P216; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; WEBER CA, 1990, AM J PHYSIOL, V258, pL308, DOI 10.1152/ajplung.1990.258.6.L308; Wigglesworth VB, 1972, PRINCIPLES INSECT PH	35	89	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1733	1742		10.1096/fasebj.13.13.1733	http://dx.doi.org/10.1096/fasebj.13.13.1733			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506576				2022-12-25	WOS:000083063400008
J	de la Vega, LA; Stockert, RJ				de la Vega, LA; Stockert, RJ			The cytoplasmic coatomer protein COPI - A potential translational regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; MESSENGER-RNAS; BINDING-PROTEIN; HEPATIC BINDING; EXPRESSION; MODULATION; SUBUNITS; REGION; LINE; CGMP	Expression of the asialoglycoprotein receptor (ASGR) by the human hepatocellular carcinoma cell lines HepG2 and HuH-7 in response to intracellular cGMP concentrations was previously shown to be regulated at the translational level (1). Stable transfection of COS-7 cells with deletion constructs encoding the asialogyco-protein receptor H2b subunit localized the cGMP-responsive cis-acting element to the mRNA 5'-untranslated region. Resolution by anion exchange chromatography of an S-100 isolated from human liver resulted in the partial purification of an RNA-binding protein specific to this cis-acting element. Northwestern analysis using the 5'-untranslated region as probe indicated that a 140-kDa protein was the potential RNA-binding protein. Sequence of tryptic peptides suggested that the 140-kDa protein was the alpha-COP subunit of coatomer protein COPI, usually associated with trans-Golgi network membrane traffic. Immunoblot analysis confirmed the presence of alpha-COP in the Mono-Q fraction as well as that of a second coatomer subunit, beta-COP. Antibody induced gel retardation supershift confirmed the identification of the RNA-binding proteins as alpha- and beta-COP. Although the RNA recognition motif appears to reside solely in alpha-COP, antibody-induced supershift strongly indicated that the entire coatomer complex was the trans-acting factor. Depletion of S-100 with the antibody to, beta-COP confirmed that the coatomer was the sole protein binding to the ASGR mRNA 5'-untranslated region in liver cytosol and responsible for inhibition of in vitro translation of the asialoglycoprotein receptor.	Albert Einstein Coll Med, Mar Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stockert, RJ (corresponding author), Albert Einstein Coll Med, Mar Bessin Liver Res Ctr, Ullmann 123,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [DK-32972, DK-17702, DK-41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK017702, P01DK041918, R01DK032972] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; PORAT N, 1995, INFECT IMMUN, V63, P1498, DOI 10.1128/IAI.63.4.1498-1506.1995; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; SHEFF D, 1996, J BIOL CHEM, V271, P30725; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; Stockert RJ, 1997, J BIOL CHEM, V272, P9161; STOCKERT RJ, 1992, J BIOL CHEM, V267, P56; STOCKERT RJ, 1980, CANCER RES, V40, P3632; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; TOWIN H, 1979, P NATL ACAD SCI USA, V76, P4350; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WU GY, 1988, J BIOL CHEM, V263, P14621	20	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31135	31138		10.1074/jbc.274.44.31135	http://dx.doi.org/10.1074/jbc.274.44.31135			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531302	hybrid			2022-12-25	WOS:000083379400006
J	Inouye, S; Hsu, MY; Xu, AG; Inouye, M				Inouye, S; Hsu, MY; Xu, AG; Inouye, M			Highly specific recognition of primer RNA structures for 2 '-OH priming reaction by bacterial reverse transcriptases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; MYXOCOCCUS-XANTHUS; BRANCHED RNA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LINKED MSDNA; RETRON; BIOSYNTHESIS; RETROELEMENT	A minor population of Escherichia coli contains retroelements called retrons, which encode reverse-transcriptases (RT) to synthesize peculiar satellite DNAs called multicopy single-stranded DNA (msDNA). These RTs recognize specific RNA structures in their individual primer-template RNAs to initiate cDNA synthesis from the 2'-OH group of a specific internal G residue (branching G residue). The resulting products (msDNA) consist of RNA and single-stranded DNA, sharing hardly any sequence homology. Here, we investigated how RT-Ec86 recognizes the specific RNA structure in its primer-template RNA. On the basis of structural comparison with HIV-1 RT, domain exchanges were carried out between two E. coli RTs, RT-Ec86 and RT-Ec73. RT-Ec86 (320 residues) and RT-Ec78 (316 residues) share only 71 identical residues (22%), From the analysis of 10 such constructs, the C-terminal 91-residue sequence of RT-Ec86 was found to be essential for the recognition of the unique stem-loop structure and the branching G residue in the primer-template RNA for retron-Ec86. Using the SELEX (systematic evolution of ligands by exponential enrichment) method with RT-Ec86 and primer RNAs containing random sequences, the identical stem-loop structure (including the 3-U loop) to that found in the retron-Ec86 primer-template RNA was enriched. In addition, the highly conserved 4-base sequence (UAGC), including the branching G residue, was also enriched, These results indicate that the highly diverse C-terminal region recognizes specific stem-loop structures and the branching G residue located upstream of the stem-loop structure. The present results with seemingly primitive RNA-dependent DNA polymerases provide insight into the mechanisms for specific protein RNA recognition.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Inouye, Sharon/R-7216-2019		NIGMS NIH HHS [GM 44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; INOUYE S, 1993, CURR OPIN GENET DEV, V3, P713, DOI 10.1016/S0959-437X(05)80088-7; INOUYE S, 1990, P NATL ACAD SCI USA, V87, P942, DOI 10.1073/pnas.87.3.942; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; INOUYE S, 1996, VIRUS GENES, V11, P81; INOUYE S, 1993, REVERSE TRANSCRIPTAS, P391; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LIM DB, 1992, MOL MICROBIOL, V6, P3531, DOI 10.1111/j.1365-2958.1992.tb01788.x; Lima TMO, 1997, PLASMID, V38, P25, DOI 10.1006/plas.1997.1298; Mao JR, 1997, J BACTERIOL, V179, P7865, DOI 10.1128/jb.179.24.7865-7868.1997; MAO JR, 1995, J BIOL CHEM, V270, P19684, DOI 10.1074/jbc.270.34.19684; MILLER JG, 1972, SHORT COURSE BACTERI; RICE SA, 1995, J BACTERIOL, V177, P37, DOI 10.1128/jb.177.1.37-45.1995; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMAMOTO T, 1995, J BIOL CHEM, V270, P581, DOI 10.1074/jbc.270.2.581; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	29	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31236	31244		10.1074/jbc.274.44.31236	http://dx.doi.org/10.1074/jbc.274.44.31236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531319	hybrid			2022-12-25	WOS:000083379400023
J	Ermakova-Gerdes, S; Vermaas, W				Ermakova-Gerdes, S; Vermaas, W			Inactivation of the open reading frame slr0399 in Synechocystis sp PCC 6803 functionally complements mutations near the Q(A) niche of photosystem II - A possible role of slr0399 as a chaperone for quinone binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE INFLUENCE; ISOFLAVONE REDUCTASE; D1 PROTEIN; PHYTOALEXIN BIOSYNTHESIS; CHLOROPLAST GENOME; MEMBRANE-PROTEINS; CDNA CLONING; SP PCC-6803; D2 PROTEIN; PSBA GENE	The Synechocystis sp. PCC 6803 triple mutant D2R8 with V247M/A249T/M329I mutations in the D2 subunit of the photosystem II is impaired in Q(A) function, has an apparently mobile Q(A), and is unable to grow photoautotrophically. Several photoautotrophic pseudorevertants of this mutant have been isolated, each of which retained the original psbDI mutations of D2R8 Using a newly developed mapping technique, the site of the secondary mutations has been located in the open reading frame slr0399. Two different nucleotide substitutions and a deletion of about 60% of slr0399 were each shown to restore photoautotrophy in different pseudorevertants of the mutant D2R8, suggesting that inactivation of Slr0399 leads to photoautotrophic growth in D2R8. Indeed, a targeted deletion of slr0399 restores photoautotrophy in D2R8 and in other psbDI mutants impaired in QA function. Slr0399 is similar to the hypothetical protein Ycf39, which is encoded in the cyanelle genome of Cyanophora paradoxa; in the chloroplast genomes of diatoms, dinoflagellates, and red algae; and in the nuclear genome of Arabidopsis thaliana. Slr0399 and Ycf39 have a NAD(P)H binding motif near their N terminus and have some similarity to isoflavone reductase-like proteins and to a subunit of the eukaryotic NADH dehydrogenase complex I. Deletion of slr0399 in wild type Synechocystis sp. PCC 6803 has no significant phenotypic effects other than a decrease in thermotolerance under both photoautotrophic and photomixotrophic conditions. We suggest that Slr0399 is a chaperone-like protein that aids in, but is not essential for, quinone insertion and protein folding around Q(A) in photosystem II. Moreover, as the effects of Slr0399 are not limited to photosystem II, this protein may also be involved in assembly of quinones in other photosynthetic and respiratory complexes.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Ermakova-Gerdes, S (corresponding author), Arizona State Univ, Dept Plant Biol, Box 871601, Tempe, AZ 85287 USA.							BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARR NG, 1967, ARCH BIOCHEM BIOPHYS, V120, P503, DOI 10.1016/0003-9861(67)90509-7; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CRAMER WA, 1991, ENERGY TRNASDUCTION; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DinkovaKostova AT, 1996, J BIOL CHEM, V271, P29473, DOI 10.1074/jbc.271.46.29473; DIXON RA, 1995, PHYSIOL PLANTARUM, V93, P385, DOI 10.1111/j.1399-3054.1995.tb02243.x; DIXON RA, 1983, ADV ENZYMOL RAMB, V55, P1; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ermakova-Gerdes S, 1998, BIOCHEMISTRY-US, V37, P11569, DOI 10.1021/bi9806596; ErmakovaGerdes S, 1996, PLANT MOL BIOL, V30, P243, DOI 10.1007/BF00020111; FEARNLEY IM, 1991, BIOCHEM J, V278, P821, DOI 10.1042/bj2780821; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GRIGORIEVA G, 1982, FEMS MICROBIOL LETT, V13, P367, DOI 10.1111/j.1574-6968.1982.tb08289.x; HAAG E, 1993, BIOCHEMISTRY-US, V32, P4444, DOI 10.1021/bi00067a037; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; KALEN A, 1990, LIPIDS, V25, P93, DOI 10.1007/BF02562211; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KATOH S, 1988, METHOD ENZYMOL, V167, P269; KLESS H, 1995, J BIOL CHEM, V270, P16536, DOI 10.1074/jbc.270.28.16536; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KLESS H, 1995, J MOL BIOL, V246, P120, DOI 10.1006/jmbi.1994.0071; KOIVUNIEMI A, 1993, FEBS LETT, V327, P343, DOI 10.1016/0014-5793(93)81017-T; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHEL C, 1993, PLANT PHYSIOL BIOCH, V31, P81; Lers A, 1998, PLANT MOL BIOL, V36, P847, DOI 10.1023/A:1005996515602; MORTON RA, 1965, BIOCH QUINONES, P23; NIXON PJ, 1991, PLANT CELL, V3, P383, DOI 10.1105/tpc.3.4.383; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROHLEN DA, 1991, FEBS LETT, V278, P75, DOI 10.1016/0014-5793(91)80087-J; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Schnell DJ, 1998, ANNU REV PLANT PHYS, V49, P97, DOI 10.1146/annurev.arplant.49.1.97; SCHROEDER HU, 1986, FEBS LETT, V199, P23; TAKAHASHI Y, 1985, PHOTOSYNTH RES, V6, P183, DOI 10.1007/BF00032792; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; vanEldik GJ, 1997, PLANT MOL BIOL, V33, P923, DOI 10.1023/A:1005749913203; VERMAAS W, 1990, Z NATURFORSCH C, V45, P359; Vermaas WFJ, 1998, METHOD ENZYMOL, V297, P293; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WU HY, 1995, CURR GENET, V27, P263, DOI 10.1007/BF00326159; Yu JP, 1998, METHOD ENZYMOL, V297, P18	57	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30540	30549		10.1074/jbc.274.43.30540	http://dx.doi.org/10.1074/jbc.274.43.30540			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521436	Green Submitted, hybrid			2022-12-25	WOS:000083276700032
J	Okajima, T; Fukumoto, S; Ito, H; Kiso, M; Hirabayashi, Y; Urano, T; Furukawa, K; Furukawa, K				Okajima, T; Fukumoto, S; Ito, H; Kiso, M; Hirabayashi, Y; Urano, T; Furukawa, K; Furukawa, K			Molecular cloning of brain-specific GD1 alpha synthase (ST6GalNAc V) containing CAG/glutamine repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL-BETA-1,3GALNAC-SPECIFIC GALNAC ALPHA-2,6-SIALYLTRANSFERASE; INHERITED NEURODEGENERATIVE DISEASES; NEURONAL INTRANUCLEAR INCLUSIONS; EXPRESSION CLONING; GANGLIOSIDE GD1-ALPHA; GLUTAMINE REPEATS; G(D3) SYNTHASE; CELLS; MOUSE; CDNA	A novel member of the mouse CMP-NeuAc: beta-N-acetylgalactosaminide alpha 2,6-sialyltransferase (ST6GalNAc) subfamily, designated ST6GalNAc V, was identified by BLAST analysis of expressed sequence tags. The sequence of the longest cDNA clone of ST6GalNAc V encoded a type II membrane protein with 8 amino acids comprising the cytoplasmic domain, 21 amino acids comprising the transmembrane region, and 306 amino acids comprising the catalytic domain. The predicted amino acid sequence showed homology to the previously cloned ST6GalNAc III and IV, with common amino acid sequences in sialyl motifs L and S among these three enzymes. Eleven CAG repeats were found in the stem region. A fusion protein with protein A and extracts from L cells transfected with ST6GalNAc V in a expression vector showed enzyme activity of alpha 2,6-sialyltransferase almost exclusively for GM1b, but not toward glycoproteins. Sialidase treatment and thin layer chromatography immunostaining revealed that the product was GD1 alpha. Northern blotting revealed that three transcripts of the gene were expressed specifically in brain tissues. It is concluded that this enzyme is involved in the synthesis of GD1 alpha in the nervous tissues, and the CAG repeats may have implications in neurodegenerative diseases.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528501, Japan; Gifu Univ, Fac Agr, Dept Appl Bioorgan Chem, Gifu 5011193, Japan; Inst Phys & Chem Res, Frontier Res Program, RIKEN, Lab Cellular Glycobiol, Wako, Saitama 3510198, Japan	Nagoya University; Nagasaki University; Gifu University; RIKEN	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X; Hirabayashi, Yoshio/0000-0002-5774-7354; Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ecsedy JA, 1998, J LIPID RES, V39, P2218; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; FURUYA S, 1994, J BIOL CHEM, V269, P32418; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; MOMOEDA M, 1995, BBA-LIPID LIPID MET, V1256, P151, DOI 10.1016/0005-2760(95)00013-3; MURAYAMA K, 1986, CANCER RES, V46, P1395; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TAKI T, 1986, J BIOL CHEM, V261, P3075; Taki T, 1997, CANCER RES, V57, P1882; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; YAMASHIRO S, 1993, CANCER RES, V53, P5395	42	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30557	30562		10.1074/jbc.274.43.30557	http://dx.doi.org/10.1074/jbc.274.43.30557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521438	hybrid			2022-12-25	WOS:000083276700034
J	Saito, S; Yamaji, N; Yasunaga, K; Saito, T; Matsumoto, S; Katoh, M; Kobayashi, S; Masuho, Y				Saito, S; Yamaji, N; Yasunaga, K; Saito, T; Matsumoto, S; Katoh, M; Kobayashi, S; Masuho, Y			The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; RHEUMATOID-ARTHRITIS; ARTICULAR-CARTILAGE; PLASMA FIBRONECTIN; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CELL-SHAPE; ED-A; INDUCTION	The extra domain-A(EDA), present in fibronectin (FN) molecules arising from alternatively spliced transcripts, appears only during specific biological and pathogenic processes. However, its function is poorly understood. To define the physiologic role of this domain in joint connective tissue, the biological effects on rabbit cartilage explants, chondrocytes, and synovial cells were studied. A recombinant EDA protein (rEDA) increased proteoglycan release (3.6-fold) in cartilage explant cultures and markedly induced production of matrix metalloproteinase (MMP)-1 in chondrocytes. In addition, rEDA induced MMP-1, MMP-3, and MMP-9 in synovial cells. These effects were elicited only by rEDA, while its neighboring type III repeats, III11, or III12, scarcely had any such effects. Interestingly, reorganization of F-actin stress fibers accompanied MMP-1 expression in synovial cells treated with rEDA, suggesting alteration of cellular phenotype, Subsequent Northern blotting revealed expression of pro-inflammatory cytokines, including interleukin (IL)-1 alpha and IL-1 beta, was induced by rEDA prior to MMP-1 expression. Delayed MMP-1 expression suggests that rEDA-induced IL-ls promote MMP-1 expression in an autocrine manner. This hypothesis is supported by the reduction of EDA-induced MIMP-1 production by IL-1 receptor antagonist. The effect of EDA on MMP-1 production was reduced by connection with an adjacent type III repeat on either the NH2 or COOH side of EDA and was abolished by connection on both sides of EDA, suggesting that exposure of either the NH2 or COOH terminus of EDA domain by proteolytic cleavage releases the inducing activity. In agreement with these results, full-length cellular FN did not induce MMP-1 production. Furthermore, a 160-kDa EDA-positive FN fragment, which was purified from human placental tissue and corresponds to the region from NH2 terminus through the EDA, induced MMP-1 production. Taken together, these results suggest that the EDA in FN fragments triggers alterations of cell physiology and plays a role in matrix degradation in joint connective tissue.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Saito, S (corresponding author), Yamanouchi Pharmaceut Co Ltd, Prod Planning Dept, 3-17-1 Hasune, Tokyo 1748612, Japan.			Yasunaga, Kunio/0000-0002-6259-4743; Saito, Tetsu/0000-0002-9045-6743				ANDREWS HJ, 1992, AGENTS ACTIONS, V37, P147, DOI 10.1007/BF01987904; AOTA S, 1994, J BIOL CHEM, V269, P24756; ARNER EC, 1995, ARTHRITIS RHEUM, V38, P1304, DOI 10.1002/art.1780380919; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Chevalier X, 1996, J RHEUMATOL, V23, P1022; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FUKUDA M, 1982, J BIOL CHEM, V257, P6856; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KOCH AE, 1994, J IMMUNOL, V152, P4149; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; LAINE RA, 1987, METHOD ENZYMOL, V144, P420; MANISCALCO WM, 1995, AM J RESP CELL MOL, V13, P377, DOI 10.1165/ajrcmb.13.4.7546767; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; Matsumoto S, 1996, BBA-GENE STRUCT EXPR, V1307, P137, DOI 10.1016/0167-4781(96)00050-4; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Saito S, 1997, J BIOCHEM, V122, P49; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMADA KM, 1977, BIOCHEMISTRY-US, V16, P5552, DOI 10.1021/bi00644a025; Zhang YH, 1998, J IMMUNOL, V161, P3071; Zvaifler NJ, 1997, AM J PATHOL, V150, P1125	43	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30756	30763		10.1074/jbc.274.43.30756	http://dx.doi.org/10.1074/jbc.274.43.30756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521465	hybrid			2022-12-25	WOS:000083276700061
J	Sajan, MP; Standaert, ML; Bandyopadhyay, G; Quon, RJ; Burke, TR; Farese, RV				Sajan, MP; Standaert, ML; Bandyopadhyay, G; Quon, RJ; Burke, TR; Farese, RV			Protein kinase C-zeta and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; GROWTH-FACTOR; MAP KINASE; WORTMANNIN; STIMULATION; INVOLVEMENT	The mechanisms used by insulin to activate the multifunctional intracellular effecters, extracellular signal-regulated kinases 1 and 2 (ERK1/2), are only partly understood and appear to vary in different cell types. Presently, in rat adipocytes, we found that insulin-induced activation of ERK was blocked (a) by chemical inhibitors of both phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC)-zeta, and, moreover, (b) by transient expression of both dominant-negative Delta p85 PI3K subunit and kinase-inactive PKC-zeta. Further, insulin effects on ERK were inhibited by kinase-inactive 3-phosphoinositide-dependent protein kinase-1 (PDK-1), and by mutation of Thr-410 in the activation loop of PKC-zeta, which is the target of PDK-1 and is essential for PI3K/PDK-1-dependent activation of PKC-C In addition to requirements for PI3K, PDK-1, and PKC-zeta, we found that a tyrosine kinase (presumably the insulin receptor), the SH2 domain of GRB2, SOS, RAS, RAF, and MEK1 were required for insulin effects on ERK in the rat adipocyte. Our findings therefore suggested that PDK-1 and PKC-zeta serve as a downstream effecters of PI3K, and act in conjunction with GRB2, SOS, RAS, and RAF, to activate MEK and ERK during insulin action in rat adipocytes.	Univ S Florida, James A Haley Vet Hosp, Coll Med, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Farese, RV (corresponding author), Univ S Florida, James A Haley Vet Hosp, Coll Med, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@com1.med.usf.edu	Burke, Terrence R/N-2601-2014; Farese, Robert/B-3605-2015	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707; Burke, Terrence/0000-0001-9925-8586	NIDDK NIH HHS [R01 DK065969] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Band CJ, 1997, J BIOL CHEM, V272, P138; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; BANDYOPADHYAY G, 1999, IN PRESS MOL ENDOCRI; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin YL, 1998, BIOCHEM BIOPH RES CO, V246, P172, DOI 10.1006/bbrc.1998.8488; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; STANDAERT ML, 1995, BIOCHEM BIOPH RES CO, V209, P1082, DOI 10.1006/bbrc.1995.1608; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H; Yao ZJ, 1999, J MED CHEM, V42, P25, DOI 10.1021/jm980388x	32	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30495	30500		10.1074/jbc.274.43.30495	http://dx.doi.org/10.1074/jbc.274.43.30495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521430	hybrid			2022-12-25	WOS:000083276700026
J	Bathori, G; Parolini, I; Tombola, F; Szabo, I; Messina, A; Oliva, M; De Pinto, V; Lisanti, M; Sargiacomo, M; Zoratti, M				Bathori, G; Parolini, I; Tombola, F; Szabo, I; Messina, A; Oliva, M; De Pinto, V; Lisanti, M; Sargiacomo, M; Zoratti, M			Porin is present in the plasma membrane where it is concentrated in caveolae and caveolae-related domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; HUMAN B-LYMPHOCYTES; OUTER MITOCHONDRIAL-MEMBRANE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; NEUROSPORA-CRASSA; 31 HL; PROTEIN; EXPRESSION; PURIFICATION	Mitochondrial porin, or voltage-dependent anion channel, is a pore-forming protein first discovered in the outer mitochondrial membrane. Later investigations have provided indications for its presence also in other cellular membranes, including the plasma membrane, and in caveolae. This extra-mitochondrial localization is debated and no clear-cut conclusion has been reached up to now. In this work, we used biochemical and electrophysiological techniques to detect and characterize porin within isolated caveolae and caveolae-like domains (low density Triton-insoluble fractions). A new procedure was used to isolate porin from plasma membrane. The outer surface of cultured CEM cells was biotinylated by an impermeable reagent. Low density Triton-insoluble fractions were prepared from the labeled cells and used as starting material to purify a biotinylated protein with the same electrophoretic mobility and immunoreactivity of mitochondrial porin. In planar bilayers, the porin from these sources formed slightly anion-selective pores with properties indistinguishable from those of mitochondrial porin. This work thus provides a strong indication of the presence of porin in the plasma membrane, and specifically in caveolae and caveolae-like domains.	CNR, Ctr Studi Biomembrane, Dipartimento Sci Biomed Sperimentali, I-35121 Padua, Italy; Ist Super Sanita, Dipartimento Ematol & Oncol, I-00161 Rome, Italy; Univ Catania, Fac Sci MFN, Dipartimento Sci Chim, Lab Biochim & Biol Mol, I-95125 Catania, Italy; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto Superiore di Sanita (ISS); University of Catania; Yeshiva University; Albert Einstein College of Medicine	De Pinto, V (corresponding author), Semmelweis Univ, Dept Physiol, Puskin U 9, H-1088 Budapest, Hungary.	vdpbiofa@mbox.unict.it	parolini, Isabella/J-9955-2016; Messina, Angela/ABC-9518-2020; Padova, Ildiko/K-5344-2016; Tombola, Francesco/C-7311-2011; De Pinto, Vito/AAC-2634-2019; Szabo, Ildiko/AAW-5972-2021; Tombola, Francesco/ABA-6002-2020	parolini, Isabella/0000-0001-9863-1051; Szabo, Ildiko/0000-0002-3637-3947; Tombola, Francesco/0000-0002-9315-0352; MESSINA, Angela Anna/0000-0002-5745-9846; Sargiacomo, Massimo/0000-0003-4040-706X; De Pinto, Vito/0000-0001-5513-2906	Telethon [A.059] Funding Source: Medline	Telethon(Fondazione Telethon)		BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; Bathori G, 1996, J BIOENERG BIOMEMBR, V28, P191, DOI 10.1007/BF02110650; Bathori G, 1998, BIOCHEM BIOPH RES CO, V243, P258, DOI 10.1006/bbrc.1997.7926; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Cameron PL, 1997, J NEUROSCI, V17, P9520; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; HUIZING M, 1994, LANCET, V344, P762, DOI 10.1016/S0140-6736(94)92257-8; JAKOB C, 1995, FEBS LETT, V368, P5, DOI 10.1016/0014-5793(95)00465-L; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; LEWIS TM, 1994, NEUROSCI LETT, V181, P83, DOI 10.1016/0304-3940(94)90565-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; NOBILE M, 1988, BIOCHEM BIOPH RES CO, V154, P719, DOI 10.1016/0006-291X(88)90199-4; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oliva M, 1998, FEBS LETT, V430, P327, DOI 10.1016/S0014-5793(98)00693-0; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; Reymann S, 1998, PFLUG ARCH EUR J PHY, V436, P478, DOI 10.1007/s004240050659; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Szabo I, 1998, FASEB J, V12, P495, DOI 10.1096/fasebj.12.6.495; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; Thorp KM, 1996, IMMUNOLOGY, V87, P434, DOI 10.1046/j.1365-2567.1996.486567.x; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; WIGMAN JE, 1993, J CELL BIOL, V123, P269; WINKELBACH H, 1994, BIOCHEM MED METAB B, V52, P120, DOI 10.1006/bmmb.1994.1042; YU WH, 1995, J BIOL CHEM, V270, P13998, DOI 10.1074/jbc.270.23.13998	43	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29607	29612		10.1074/jbc.274.42.29607	http://dx.doi.org/10.1074/jbc.274.42.29607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514428	hybrid			2022-12-25	WOS:000083176400007
J	Bjorbaek, C; El-Haschimi, K; Frantz, JD; Flier, JS				Bjorbaek, C; El-Haschimi, K; Frantz, JD; Flier, JS			The role of SOCS-3 in leptin signaling and leptin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; ERYTHROPOIETIN RECEPTOR; DIABETIC MICE; DB/DB MICE; OB/OB MICE; PROTEIN; ACTIVATION; CELLS; IDENTIFICATION; EXPRESSION	We earlier demonstrated that leptin induces expression of SOCS-3 mRNA in the hypothalamus. Furthermore, transfection data suggest that SOCS-3 is an inhibitor of leptin signaling. However, little is known about the regulation of SOCS-3 expression by leptin and the mechanism by which SOCS-3 inhibits leptin action. We here show that in CHO cells stably expressing the long form of the leptin receptor (CHO-OBRl), leptin induces transient expression of endogenous SOCS-3 mRNA but not of CIS, SOCS-1, or SOCS-2 mRNA. SOCS-3 protein levels were maximal after 2-3 h of leptin treatment and remained elevated at 20 h. Furthermore, in leptin-pretreated CHO-OBRl cells, proximal leptin signaling was blocked for more than 20 h after pretreatment, thus correlating with increased SOCS-3 expression. Leptin pretreatment did not affect cell surface expression of leptin receptors as measured by I-125-Peptin binding assays. In transfected COS cells, forced expression of SOCS-3 results in inhibition of leptin-induced tyrosine phosphorylation of JAK2. Finally, JAK2 co-immunoprecipitates with SOCS-3 in lysates from leptin-treated COS cells. These results suggest that SOCS-3 is a leptin-regulated inhibitor of proximal leptin signaling in vivo. Excessive SOCS-3 activity in leptin-responsive cells is therefore a potential mechanism for leptin resistance, a characteristic feature in human obesity.	Harvard Univ, Sch Med, Dept Med, Div Endocrinol,Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Flier, JS (corresponding author), Harvard Univ, Sch Med, Dept Med, Div Endocrinol,Beth Israel Deaconess Med Ctr, 99 Brookline Ave,Res N, Boston, MA 02215 USA.		Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK R37 28082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Elmquist JK, 1998, J COMP NEUROL, V395, P535; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	44	489	528	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30059	30065		10.1074/jbc.274.42.30059	http://dx.doi.org/10.1074/jbc.274.42.30059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514492	hybrid			2022-12-25	WOS:000083176400071
J	Edberg, JC; Yee, AMF; Rakshit, DS; Chang, DJ; Gokhale, JA; Indik, ZK; Schreiber, AD; Kimberly, RP				Edberg, JC; Yee, AMF; Rakshit, DS; Chang, DJ; Gokhale, JA; Indik, ZK; Schreiber, AD; Kimberly, RP			The cytoplasmic domain of human Fc gamma RIa alters the functional properties of the Fc gamma RI center dot gamma-chain receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; PROTEIN-TYROSINE KINASE; IMMUNOGLOBULIN-G; EPSILON-RI; PHAGOCYTIC FUNCTION; DISTINCT REGIONS; IGE RECEPTOR; C-DELTA; IN-VIVO; SUBUNIT	The gamma/zeta-chain family of proteins mediate cell activation for multiple immunoglobulin receptors, However, the recognition that these receptors may have distinct biologic functions suggests that additional signaling elements may contribute to functional diversity. We hypothesized that the cytoplasmic domain (CY) of the ligand binding alpha-chain alters the biological properties of the receptor complex. Using macrophage Fc gamma RIa as a model system, we created stable transfectants expressing a full-length or a CY deletion mutant of human Fc gamma RIa. Both receptors functionally associate with the endogenous murine gamma-chain. However, we have established that the CY of Fc gamma RIa directly contributes to the functional properties of the receptor complex. Deletion of the Fc gamma RIa CY leads to slower kinetics of receptor-specific phagocytosis and endocytosis as well as lower total phagocytosis despite identical levels of receptor expression. Deletion of the CY also converts the phenotype of calcium independent Fc gamma RIa-specific phagocytosis to a calcium-dependent phenotype, Finally, deletion of the CY abrogates Fc gamma RIa-specific secretion of interleukin-6 but does not, affect production of interleukin-1 beta These results demonstrate a functional role for the CY of Fc gamma RIa and provide a general model for understanding how multiple receptors that utilize the gamma-chain can generate diversity in function.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Cornell Univ, Hosp Special Surg, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cornell University; Cornell University; University of Pennsylvania	Edberg, JC (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 433A Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI022193, R01AI022193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033062, R01AR042476] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22193] Funding Source: Medline; NIAMS NIH HHS [R01-AR42476, R01-AR33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; DAERON M, 1994, J IMMUNOL, V152, P783; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; EDBERG JC, 1994, J IMMUNOL, V152, P5826; Edberg JC, 1998, J BIOL CHEM, V273, P8071, DOI 10.1074/jbc.273.14.8071; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GIBSON AW, 1999, LUPUS MOL CELLULAR P, P557; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; INDIK Z, 1992, IMMUNOBIOLOGY, V185, P183, DOI 10.1016/S0171-2985(11)80640-6; INDIK ZK, 1994, EXP HEMATOL, V22, P599; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KRUTMANN J, 1990, J IMMUNOL, V145, P1337; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; McKenzie S E, 1998, Curr Opin Hematol, V5, P16, DOI 10.1097/00062752-199801000-00003; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MITCHELL MA, 1994, BLOOD, V84, P1753; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PARK JG, 1995, P NATL ACAD SCI USA, V92, P7381, DOI 10.1073/pnas.92.16.7381; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; Pricop L, 1997, J IMMUNOL METHODS, V205, P55, DOI 10.1016/S0022-1759(97)00053-7; PRINS JB, 1993, SCIENCE, V260, P695, DOI 10.1126/science.8480181; QUILLIAM AL, 1993, IMMUNOLOGY, V78, P358; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; SIMMS HH, 1991, J IMMUNOL, V147, P265; SOCOLOVSKY M, 1994, EUR J CELL BIOL, V64, P29; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; Sylvestre DL, 1996, IMMUNITY, V5, P387, DOI 10.1016/S1074-7613(00)80264-2; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; vanVugt MJ, 1996, BLOOD, V87, P3593, DOI 10.1182/blood.V87.9.3593.bloodjournal8793593; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Wolf HM, 1996, CLIN EXP IMMUNOL, V105, P537, DOI 10.1046/j.1365-2249.1996.d01-793.x	47	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					30328	30333		10.1074/jbc.274.42.30328	http://dx.doi.org/10.1074/jbc.274.42.30328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514529	hybrid			2022-12-25	WOS:000083176400108
J	Fairbanks, MB; Mildner, AM; Leone, JW; Cavey, GS; Mathews, WR; Drong, RF; Slightom, JL; Bienkowski, MJ; Smith, CW; Bannow, CA; Heinrikson, RL				Fairbanks, MB; Mildner, AM; Leone, JW; Cavey, GS; Mathews, WR; Drong, RF; Slightom, JL; Bienkowski, MJ; Smith, CW; Bannow, CA; Heinrikson, RL			Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; PROTEOGLYCANS; CLEAVAGE; PEPTIDES; CELLS	Human platelet heparanase has been purified to homogeneity and shown to consist of two, non-covalently associated polypeptide chains of molecular masses 50 and 8 kDa. Protein sequencing provided the basis far determination of the full-length cDNA for this novel protein. Based upon this information and results from protein analysis and mass spectrometry, we propose a scheme to define the structural organization of heparanase in relation to its precursor forms, proheparanase and pre-proheparanase. The 8- and 50-kDa chains which make up the active enzyme reside, respectively, at the NH2- and COOH-terminal regions of the inactive: precursor, proheparanase. The heparanase heterodimer is produced by excision and loss of an internal linking segment. This paper is the first to suggest that human heparanase is a two-chain enzyme.	Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49001 USA; Pharmacia & Upjohn Inc, Genom Res, Kalamazoo, MI 49001 USA; Pharmacia & Upjohn Inc, Struct Analyt & Med Chem, Kalamazoo, MI 49001 USA; Pharmacia & Upjohn Inc, Res Operat, Kalamazoo, MI 49001 USA	Pfizer; Pfizer; Pfizer; Pfizer	Heinrikson, RL (corresponding author), Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49001 USA.							ABRAHAMSSON T, 1992, CIRC RES, V70, P264, DOI 10.1161/01.RES.70.2.264; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; Finkel E, 1999, SCIENCE, V285, P33, DOI 10.1126/science.285.5424.33; FREEMAN C, 1998, BIOCHEM J, V330, P1371; Gonzalez-Stawinski GV, 1999, BBA-PROTEIN STRUCT M, V1429, P431, DOI 10.1016/S0167-4838(98)00254-4; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Rechter M, 1999, BIOCHEM BIOPH RES CO, V255, P657, DOI 10.1006/bbrc.1999.0181; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; THUNBERG L, 1982, J BIOL CHEM, V257, P278; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518	24	158	172	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29587	29590		10.1074/jbc.274.42.29587	http://dx.doi.org/10.1074/jbc.274.42.29587			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514423	hybrid			2022-12-25	WOS:000083176400002
J	Huang, CS; Li, JX; Ma, WY; Dong, ZG				Huang, CS; Li, JX; Ma, WY; Dong, ZG			JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAYS; NERVE GROWTH-FACTOR; NIH 3T3 CELLS; C-JUN; PROTEIN-KINASE; MAMMALIAN-CELLS; AP-1 TRANSACTIVATION; SELECTIVE ACTIVATION	Signal transduction via mitogen-activated protein kinase pathways plays a key role in a variety of cellular responses, including cell proliferation, differentiation, tumor promotion, and cell death, c-Jun N-terminal kinases (JNKs) are identified as members of the mitogen-activated protein kinase family and are known to phosphorylate and activate several transcription factors, including c-Jun, ATF, and Elk-1. However, the role of JNK activation in tumor promotion is not yet defined. Because previous studies have indicated that exposure of JB6 Cl 41 cells to either 12-O-tetradecanoylphorbol-13-acetate (TPA) or tumor necrosis factor-alpha (TNF-alpha) results in cell transformation, we investigated the role of JNKs in this biological process by using dominant negative JNK, and the cell transformation model JB6 C1 41 cells. Incubation of Cl 41 cells with TNF-alpha led to cell transformation and activation of JNKs, Introduction of the dominant negative mutant of JNK(1) into JB6 Cl 41 cells specifically inhibited TNF-alpha induced activation of JNKs, but not Erks and p38 kinases. Most importantly, expressing dominant negative mutant JNK(1) inhibited TNF-alpha-induced cell transformation but not TPA-induced cell transformation. Our results directly demonstrated for the first time that JNK activation is required for TNF-alpha- but not TPA-induced cell transformation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [CA74916] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSCO OA, 1995, CELL, V81, P1137; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DHANWADA KR, 1995, ONCOGENE, V11, P1947; ELBAZ O, 1991, J CLIN INVEST, V87, P838, DOI 10.1172/JCI115087; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huang CS, 1999, CANCER RES, V59, P3053; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Rojanasakul Y, 1997, J BIOL CHEM, V272, P3910, DOI 10.1074/jbc.272.7.3910; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SEGER R, 1994, J BIOL CHEM, V269, P25699; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	57	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29672	29676		10.1074/jbc.274.42.29672	http://dx.doi.org/10.1074/jbc.274.42.29672			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514437	hybrid			2022-12-25	WOS:000083176400016
J	Li, R; Debreceni, B; Jia, BQ; Gao, Y; Tigyi, G; Zheng, Y				Li, R; Debreceni, B; Jia, BQ; Gao, Y; Tigyi, G; Zheng, Y			Localization of the PAK1-, WASP-, and IQGAP1-specifying regions of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; CELL-CYCLE PROGRESSION; ACTIN-CYTOSKELETON; GTPASE CDC42; P21-ACTIVATED KINASE; SIGNALING PATHWAY; TARGET PROTEINS; FOCAL COMPLEXES; INSERT REGION; RAC GTPASES	The Rho family small GTPase Cdc42 transmits divergent intracellular signals through multiple effector proteins to elicit cellular responses such as cytoskeletal reorganization, Potential effectors of Cdc42 implicated in mediating its cytoskeletal effect in mammalian cells include PAK1, WASP, and IQGAP1, To investigate the determinants of Cdc42-effector specificity, we utilized recombinant Cdc42 mutants and chimeras made between Cdc42 and RhoA to map the regions of Cdc42 contributing to specific effector pal-binding domain (PBD) interaction, Site-directed mutants of the switch I domain and neighboring regions of Cdc42 demonstrated differential binding patterns toward the PBDs of PAK1, WASP, and IQGAP1, suggesting that switch I provides essential determinants for the effector binding, but recognition of each effector by Cdc42 involves a distinct mechanism. Differing from Rad, the switch I domain and the surrounding region (amino acids 29 to 55) of Cdc42 appeared to be sufficient for specific binding to PAK1, whereas determinants outside the switch I domain, residues 157-191 anal 84-120 in particular, were necessary and sufficient to confer specificity to WASP and IQGAP1, respectively. In addition, IQGAP1, but not PAK1 nor WASP, required the unique "insert region," residues 122-134, of Cdc42 to achieve high affinity binding. Microinjection of the constitutively active Cdc42/ RhoA chimeras into serum-starved Swiss 3T3 cells showed that although preserving PAK1- and WASP- binding activity could retain the peripheral. actin microspike (PAM)-inducing activity of Cdc42, interaction with PAK1 or WASP was not required for this activity. Moreover, IQGAP1-binding alone by Cdc42 was insufficient for PAM-induction, Thus, Cdc42 utilizes multiple distinct structural determinants to specify different effector recognition and to elicit PAM-inducing effect.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Univ Tennessee, Dept Physiol & Biophys, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA.	yzheng@utmem.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943, R01GM060523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dutartre H, 1996, J CELL SCI, V109, P367; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schwartz MA, 1998, ONCOGENE, V17, P625, DOI 10.1038/sj.onc.1201977; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU XM, 1994, J BIOL CHEM, V269, P23569; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	63	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29648	29654		10.1074/jbc.274.42.29648	http://dx.doi.org/10.1074/jbc.274.42.29648			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514434	hybrid			2022-12-25	WOS:000083176400013
J	De Cesaris, P; Starace, D; Starace, G; Filippini, A; Stefanini, M; Ziparo, E				De Cesaris, P; Starace, D; Starace, G; Filippini, A; Stefanini, M; Ziparo, E			Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; CYTOKINE-INDUCED EXPRESSION; TNF RECEPTOR; KAPPA-B; SERTOLI CELLS; TRANSDUCTION PATHWAYS; SIGNAL-TRANSDUCTION; P55 RECEPTOR; P75 RECEPTOR; IN-VIVO	Tumor necrosis factor alpha (TNF-alpha) is a cytokine implicated in the pathogenesis of numerous chronic and acute inflammatory conditions. We have previously shown that mouse Sertoli cells respond to TNF-alpha by increasing interleukin-6 production and intercellular adhesion molecule-1 (ICAM-1) expression (1). In this cell type TNF-alpha activates the mitogen-activated protein kinase (MAPK) pathways p42/p44 MAPK, JNK/SAPK, and p38, the last of which is responsible for interleukin-6 production (2). To determine which MAPK signaling pathway is required for TNF-alpha induction of ICAM-1 expression, we have utilized the protein kinase inhibitor dimethylaminopurine, demonstrating that treatment of Sertoli cells with such compound significantly reduced ICAM-1 expression and JNK/SAPK activation. Moreover, dimethylaminopurine treatment increased the expression of MAPK phosphatase-2, providing a possible mechanism of action of this compound. By using agonist antibodies to p55 and to p75 TNF-alpha receptors and both human and mouse TNF-alpha, we demonstrate that both TNF receptors are expressed and that only the p55 receptor is involved in ICAM-1 expression. The p55 receptor activates all of the three pathways, whereas p75 failed to activate any of the MAPKs. Altogether our results demonstrate that TNF-alpha up-regulates ICAM-1 expression through the activation of the JNK/SAPK transduction pathway mediated by the p55 receptor.	Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; CNR, Inst Expt Med, Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR)	Ziparo, E (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Ist Pasteur Fdn Cenci Bolognetti, Via A Scarpa 16, I-00161 Rome, Italy.	ziparo@uniroma1.it		Ziparo, Elio/0000-0002-8776-3515				BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Benigni F, 1996, J IMMUNOL, V157, P5563; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Curtis TM, 1998, AM J PHYSIOL-LUNG C, V275, pL126, DOI 10.1152/ajplung.1998.275.1.L126; De Cesaris P, 1998, J BIOL CHEM, V273, P7566, DOI 10.1074/jbc.273.13.7566; DE SK, 1993, ENDOCRINOLOGY, V133, P389, DOI 10.1210/en.133.1.389; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALDIERI M, 1981, J ANDROL, V2, P249; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KOHNO S, 1983, J REPROD IMMUNOL, V5, P339, DOI 10.1016/0165-0378(83)90243-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEUWENBERG JFM, 1995, CYTOKINE, V7, P457, DOI 10.1006/cyto.1995.0062; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Marino MW, 1996, J BIOL CHEM, V271, P28624, DOI 10.1074/jbc.271.45.28624; MAUDUIT C, 1993, ENDOCRINOLOGY, V133, P69, DOI 10.1210/en.133.1.69; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; Pai R, 1996, J IMMUNOL, V156, P2571; PALOMBI F, 1988, BIOL REPROD, V39, P1101, DOI 10.1095/biolreprod39.5.1101; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; POBER JS, 1986, J IMMUNOL, V137, P1893; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Schleif M, 1998, EUR PHYS J A, V1, P171, DOI 10.1007/s100500050046; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Weiss T, 1997, J IMMUNOL, V158, P2398; Worrall NK, 1997, AM J PHYSIOL-HEART C, V273, pH2565, DOI 10.1152/ajpheart.1997.273.6.H2565; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	58	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28978	28982		10.1074/jbc.274.41.28978	http://dx.doi.org/10.1074/jbc.274.41.28978			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506145	hybrid			2022-12-25	WOS:000083017800024
J	Carrasco-Marin, E; Petzold, S; Unanue, ER				Carrasco-Marin, E; Petzold, S; Unanue, ER			Two structural states of complexes or peptide and class II major histocompatibility complex revealed by photoaffinity-labeled peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOZYME PEPTIDE; ANTIGEN-BINDING; MOLECULES; PH; I-A(K); DENATURATION; PROTEINS; BARNASE; EPITOPE; HLA-DR1	The complex of the murine class II histocompatibility molecules I-A(k) with high affinity binding peptides were resistant to denaturation when examined by SDS-polyacrylamide gel electrophoresis at various pH levels. In contrast, complexes made with low affinity binding peptides were highly sensitive to denaturation by SDS. This effect was more pronounced at low pH. Placing a photoactivatable probe at the amino terminus of the peptides resulted in their covalent linkage to soluble I-A(k) molecules. We found an inverse relationship between the capacity of peptides to form SDS-stable complexes with I-A(k) and their extent of covalent association with either the alpha or beta chain. The relationship held true for three different peptides in which the main anchor residues were changed so as to affect their binding affinity for I-A(k) molecules. Thus, high affinity peptides generate a complex in which the motion of their amino termini was restricted, whereas complexes of low affinity peptides are more flexible. In agreement with this observation, complexes of I-A(k) with high affinity peptides were highly resistant to proteolysis, in contrast to those formed with weakly binding peptides, which were more likely to be cleaved. Complexes with low affinity peptides generate a structure with enhanced flexibility as compared with complexes with high affinity peptides.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Unanue, ER (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Marin, Eugenio Carrasco/AAG-1578-2021	Marin, Eugenio Carrasco/0000-0002-3556-9227				Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; CAFLISCH A, 1994, P NATL ACAD SCI USA, V91, P1746, DOI 10.1073/pnas.91.5.1746; CarrascoMarin E, 1996, J IMMUNOL, V156, P450; DONNERMEYER DL, 1989, J IMMUNOL, V142, P1063; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LUESCHER IF, 1990, J IMMUNOL METHODS, V135, P233, DOI 10.1016/0022-1759(90)90277-3; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1988, P NATL ACAD SCI USA, V85, P871, DOI 10.1073/pnas.85.3.871; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; Natarajan SK, 1999, J IMMUNOL, V162, P4030; Natarajan SK, 1999, J IMMUNOL, V162, P3463; Nelson CA, 1996, J IMMUNOL, V157, P755; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; Nelson CA, 1996, IMMUNOL REV, V151, P81, DOI 10.1111/j.1600-065X.1996.tb00704.x; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Verreck FAW, 1996, INT IMMUNOL, V8, P397, DOI 10.1093/intimm/8.3.397	27	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31333	31340		10.1074/jbc.274.44.31333	http://dx.doi.org/10.1074/jbc.274.44.31333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531333	hybrid			2022-12-25	WOS:000083379400037
J	Hanai, J; Chen, LF; Kanno, T; Ohtani-Fujita, N; Kim, WY; Guo, WH; Imamura, T; Ishidou, Y; Fukuchi, M; Shi, MJ; Stavnezer, J; Kawabata, M; Miyazono, K; Ito, Y				Hanai, J; Chen, LF; Kanno, T; Ohtani-Fujita, N; Kim, WY; Guo, WH; Imamura, T; Ishidou, Y; Fukuchi, M; Shi, MJ; Stavnezer, J; Kawabata, M; Miyazono, K; Ito, Y			Interaction and functional cooperation of PEBP2/CBF with Smads - Synergistic induction of the immunoglobulin germline C alpha promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; CLEIDOCRANIAL DYSPLASIA; OSTEOBLAST DIFFERENTIATION; IGA PRODUCTION; TRANSCRIPTION; BINDING; GENE; PROTEINS; CLONING	Smads are signal transducers for members of the transforming growth factor-beta (TGF-beta) superfamily. Upon ligand stimulation, receptor-regulated Smads (R-Smads) are phosphorylated by serine/threonine kinase receptors, form complexes with common-partner Smad, and translocate into the nucleus, where they regulate the transcription of target genes together with other transcription factors. Polyomavirus enhancer binding protein 2/core binding factor (PEEP2/CBF) is a transcription factor complex composed of alpha and beta subunits. The alpha subunits of PEEP2/CBF, which contain the highly conserved Hunt domain, play essential roles in hematopoiesis and osteogenesis. Here we show that three mammalian alpha subunits of PEBP2/CEF form complexes with R-Smads that act in TGF-beta/activin pathways as well as those acting in bone morphogenetic protein (BMP) pathways. Among them, PEBP2 alpha C/CBFA3/AML2 forms a complex with Smads and stimulates transcription of the germline Ig C alpha promoter in a cooperative manner, for which binding of both factors to their specific binding sites is essential. PEEPS may thus be a nuclear target of TGF-beta/BMP signaling.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 708455, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Grad Program Immunol & Virol, Worcester, MA 01655 USA	Japanese Foundation for Cancer Research; Kyoto University; University of Massachusetts System; University of Massachusetts Worcester	Ito, Y (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 708455, Japan.	yito@virus.kyoto-u.ac.jp			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023283] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23283] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN YCA, 1992, J IMMUNOL, V149, P2914; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	43	400	412	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31577	31582		10.1074/jbc.274.44.31577	http://dx.doi.org/10.1074/jbc.274.44.31577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531362	hybrid			2022-12-25	WOS:000083379400066
J	Kislinger, T; Fu, CF; Huber, B; Qu, W; Taguchi, A; Yan, SD; Hofmann, M; Yan, SF; Pischetsrieder, M; Stern, D; Schmidt, AM				Kislinger, T; Fu, CF; Huber, B; Qu, W; Taguchi, A; Yan, SD; Hofmann, M; Yan, SF; Pischetsrieder, M; Stern, D; Schmidt, AM			N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIALYSIS-RELATED AMYLOIDOSIS; MACROPHAGE SCAVENGER RECEPTOR; HUMAN ENDOTHELIAL-CELLS; OXIDANT STRESS; MAILLARD REACTION; DIABETIC COMPLICATIONS; BINDING-PROTEINS; PERIODONTAL-DISEASE; POTENTIAL MECHANISM; FUNCTIONAL-ANALYSIS	Recent studies suggested that interruption of the interaction of advanced glycation end products (AGEs), with the signal-transducing receptor receptor for AGE (RAGE), by administration of the soluble, extracellular ligand-binding domain of RAGE, reversed vascular hyperpermeability and suppressed accelerated atherosclerosis in diabetic rodents. Since the precise molecular target of soluble RAGE in those settings was not elucidated, we tested the hypothesis that predominant specific AGEs within the tissues in disorders such as diabetes and renal failure, N-epsilon-(carboxymethyl)lysine (CML) adducts, are ligands of RAGE. We demonstrate here that physiologically relevant CML modifications of proteins engage cellular RAGE, thereby activating key cell signaling pathways such as NF-KB and modulating gene expression. Thus, CML-RAGE interaction triggers processes intimately linked to accelerated vascular and inflammatory complications that typify disorders in which inflammation is an established component.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Erlangen Nurnberg, Abt Lebensmittelchem, Inst Pharm & Lebensmittelchem, D-91052 Erlangen, Germany	Columbia University; University of Erlangen Nuremberg	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St,P&S 17-501, New York, NY 10032 USA.		Kislinger, Thomas/A-5934-2008	Kislinger, Thomas/0000-0003-3525-5540	NHLBI NIH HHS [HL60901, HL56881] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056881, P01HL060901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Berg TJ, 1998, DIABETES CARE, V21, P1997, DOI 10.2337/diacare.21.11.1997; Bierhaus A, 1997, CIRCULATION, V96, P2262; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Degenhardt TP, 1997, KIDNEY INT, V52, P1064, DOI 10.1038/ki.1997.429; Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Hamada Y, 1996, BIOCHEM BIOPH RES CO, V228, P539, DOI 10.1006/bbrc.1996.1695; Hammes HP, 1999, DIABETOLOGIA, V42, P603, DOI 10.1007/s001250051201; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; INOUE N, 1985, INT J TISSUE REACT, V7, P27; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jinnouchi Y, 1998, J BIOCHEM-TOKYO, V123, P1208; Katsuyama K, 1998, ENDOCRINOLOGY, V139, P4506, DOI 10.1210/en.139.11.4506; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; KUME S, 1995, AM J PATHOL, V147, P654; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; LOE H, 1993, DIABETES CARE, V16, P329, DOI 10.2337/diacare.16.1.329; Meng J, 1998, ATHEROSCLEROSIS, V136, P355, DOI 10.1016/S0021-9150(97)00238-4; Miyata T, 1999, FEBS LETT, V445, P202, DOI 10.1016/S0014-5793(99)00122-2; Miyata T, 1995, Curr Opin Nephrol Hypertens, V4, P493, DOI 10.1097/00041552-199511000-00006; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Niwa T, 1996, KIDNEY INT, V50, P1303, DOI 10.1038/ki.1996.442; Niwa T, 1997, KIDNEY INT, V51, P187, DOI 10.1038/ki.1997.23; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; Owen WF, 1998, KIDNEY INT, V53, P1365, DOI 10.1046/j.1523-1755.1998.00882.x; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; RITTHALER U, 1995, AM J PATHOL, V146, P688; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schmidt AM, 1996, J PERIODONTAL RES, V31, P508, DOI 10.1111/j.1600-0765.1996.tb01417.x; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SELL DR, 1989, J BIOL CHEM, V264, P21597; Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725; Takeda A, 1996, NEUROSCI LETT, V221, P17, DOI 10.1016/S0304-3940(96)13275-4; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; VLASSARA H, 1996, DIABETES, V45, P65; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; WOO KL, 1993, J CHROMATOGR, V638, P97, DOI 10.1016/0021-9673(93)85012-V; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	76	753	776	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31740	31749		10.1074/jbc.274.44.31740	http://dx.doi.org/10.1074/jbc.274.44.31740			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531386	hybrid			2022-12-25	WOS:000083379400090
J	Naumann, M; Wessler, S; Bartsch, C; Wieland, B; Covacci, A; Haas, R; Meyer, TF				Naumann, M; Wessler, S; Bartsch, C; Wieland, B; Covacci, A; Haas, R; Meyer, TF			Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAYS; JUN NH2-TERMINAL KINASE; PEPTIC-ULCER DISEASE; C-JUN; TRANSCRIPTION FACTORS; INFLAMMATORY CYTOKINES; VIRULENCE FACTORS; JNK; INFECTION	Helicobacter pylori interacts with the apical membrane of the gastric epithelium and induces a number of proinflammatory cytokines/chemokines. The subsequent infiltration of macrophages and granulocytes into the mucosa leads to gastric inflammation accompanied by epithelial degeneration. Gastric diseases, e.g peptic ulcer or gastric adenocarcinoma, are more common among people infected with H, pylori strains producing VacA (vacuolating cytotoxin A) and possessing a cog (cytotoxin-associated antigen A) pathogenicity island. For the induction of the cytokine/chemokine genes in response to H. pylori, we studied the signaling leading to the nuclear activation of the early response transcription factor activator protein 1 (AP-1), We found that H. pylori strains carrying the pathogenicity island induce activation of AP-1 and nuclear factor KB, In contrast to the wild type or an isogenic strain without the vacA gene, isogenic H. pylori strains with mutations in certain cog genes revealed only weak AP-1 and nuclear factor KB activation. In respect to the molecular components that direct AP-1 activity, our results indicate a cascade of the cellular stress response kinases c-Jun N-terminal kinase, MAP kinase kinase 4, and p21-activated kinase, and small Rho-GTPases including Rad and Cdc42, which contributes to the activation of proinflammatory cytokines/chemokines induced by H. pylori encoding the cag pathogenicity island.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany; Immunol Res Inst, BIOCINE, IRIS, I-53100 Siena, Italy; Max Von Pettenkofer Inst Hyg & Med Microbiol, Abt Bakteriol, D-80336 Munich, Germany; Max Planck Inst Biol, Abt Infekt Biol, D-72076 Tubingen, Germany	Max Planck Society; Novartis; University of Munich; Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Monbijoustr 2, D-10117 Berlin, Germany.		Meyer, Thomas F. F/J-2485-2013; Naumann, Michael/B-5285-2011; Wessler, Silja/C-6309-2015	Meyer, Thomas F. F/0000-0002-6120-8679; Naumann, Michael/0000-0002-8060-2313; Wessler, Silja/0000-0001-7011-6162				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Atherton JC, 1998, BRIT MED BULL, V54, P105; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; Bodger K, 1998, BRIT MED BULL, V54, P139; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Covacci A, 1998, CURR OPIN MICROBIOL, V1, P96, DOI 10.1016/S1369-5274(98)80148-3; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; GOODWIN CS, 1986, J CLIN PATHOL, V39, P353, DOI 10.1136/jcp.39.4.353; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Naumann M, 1998, J EXP MED, V188, P1277, DOI 10.1084/jem.188.7.1277; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sharma SA, 1998, J IMMUNOL, V160, P2401; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	58	143	149	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31655	31662		10.1074/jbc.274.44.31655	http://dx.doi.org/10.1074/jbc.274.44.31655			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531374	Green Published, hybrid			2022-12-25	WOS:000083379400078
J	Zhou, ZF; Gong, QM; January, CT				Zhou, ZF; Gong, QM; January, CT			Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome - Pharmacological and temperature effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; INHERITED CARDIAC-ARRHYTHMIA; CYSTIC-FIBROSIS; INTRACELLULAR-TRANSPORT; CHEMICAL CHAPERONES; KVLQT1 MUTATIONS; MOLECULAR-BASIS; DYSFUNCTION; PHENOTYPE; PATHWAY	The chromosome 7-linked form of congenital long QT syndrome (LQT2) is caused by mutations in the human ether-a-go-go-related gene (HERG) that encodes the rapidly activating delayed rectifier potassium channel. One mechanism for the loss of normal channel function in LQT2 is defective protein trafficking, which results in the failure of the channel protein to reach the plasma membrane. Here we show that the N470D LQT2 mutant protein is trafficking-deficient when expressed at 37 degrees C in HEK293 cells, whereas at 27 degrees C its trafficking to the plasma membrane and channel function are markedly improved. We further show that the antiarrhythmic drug E-4031, which selectively blocks HERO channels, also corrects defective protein trafficking of the N470D mutant and can restore the generation of HERO current. Similar findings were obtained with the drugs astemizole and cisapride, as well as with high concentrations of glycerol. The effect of E-4031 on HERO protein trafficking was concentration-dependent and required low drug concentrations (saturation present at 5 mu M), developed rapidly with drug exposure,and occurred post-translationally. These findings suggest that protein misfolding leading to defective trafficking of some HERO LQT mutations may be corrected by specific pharmacological strategies.	Univ Wisconsin, Dept Med, Cardiol Sect, Madison, WI 53792 USA; Univ Wisconsin, Dept Physiol, Cardiol Sect, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Zhou, ZF (corresponding author), Univ Wisconsin Hosp & Clin, Cardiol Sect, Dept Med, Room H6-354 CSC,600 Highland Ave, Madison, WI 53792 USA.	zhz@medicine.wisc.edu; ctj@medicine.wisc.edu						Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Mohammad S, 1997, AM J PHYSIOL-HEART C, V273, pH2534, DOI 10.1152/ajpheart.1997.273.5.H2534; Priori SG, 1998, CIRCULATION, V98, P457; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Smith DF, 1998, PHARMACOL REV, V50, P493; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; [No title captured]	29	248	274	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	1999	274	44					31123	31126		10.1074/jbc.274.44.31123	http://dx.doi.org/10.1074/jbc.274.44.31123			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	250FY	10531299	hybrid			2022-12-25	WOS:000083379400003
J	Kim, SY; Grant, P; Lee, JH; Pant, HC; Steinert, PM				Kim, SY; Grant, P; Lee, JH; Pant, HC; Steinert, PM			Differential expression of multiple transglutaminases in human brain - Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; CORNIFIED CELL-ENVELOPE; TISSUE TRANSGLUTAMINASE; PROTRANSGLUTAMINASE-E; CDNA CLONES; RAT-BRAIN; PROTEINS; ENZYME; CALPAIN; FORMS	The transglutaminase (TGase) family of enzymes, of which seven different members are known in the human genome, participate in many biological processes involving cross-linking proteins into large macromolecular assemblies. The TGase 2 enzyme is known to be present in neuronal tissues and may play a role in neuronal degenerative diseases such as Alzheimer's disease (AD) by aberrantly cross-linking proteins. In this paper, we demonstrate by reverse transcriptase-polymase chain reaction and immunological methods with specific antibodies that in fact three members, the TGase 1, TGase 2, and TGase 3 enzymes, and are differentially expressed in various regions of normal human brain tissues. Interestingly, the TGase 1 and 3 enzymes and their proteolytically processed forms are involved in terminal differentiation programs of epithelial cell development and barrier function. In addition, we found that the levels of expression and activity of the TGase 1 and 2 enzymes were both increased in the cortex and cerebellum of AD patients. Furthermore, whereas normal brain tissues contain approximate to 1 residue of cross-link/10,000 residues, AD patient cortex and cerebellum tissues contain 30-50 residues of cross-link/10,000 residues. Together, these findings suggest that multiple TGase enzymes are involved in normal neuronal structure and function, but their elevated expression and cross-linking activity may also contribute to neuronal degenerative disease.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Chungnam Natl Univ, Sch Med, Dept Dermatol, Taejon, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Chungnam National University	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; ANDO M, 1993, MOL CHEM NEUROPATHOL, V19, P121, DOI 10.1007/BF03160173; ANDO M, 1991, NEUROSCI RES, V12, P356, DOI 10.1016/0168-0102(91)90003-H; ANDO Y, 1988, ARCH DERMATOL RES, V280, P380, DOI 10.1007/BF00426618; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Bae CD, 1995, KOREAN J BIOCHEM, V27, P239; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; GENTILE V, 1991, J BIOL CHEM, V266, P478; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; JUNG SW, 1995, J DERMATOL SCI, V10, P98; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KORNER G, 1987, J CELL PHYSIOL, V130, P44, DOI 10.1002/jcp.1041300108; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MELINO G, 1999, IN PRESS METHODS ENZ; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; Piredda L, 1997, CELL DEATH DIFFER, V4, P463, DOI 10.1038/sj.cdd.4400267; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; RASMUSSEN LK, 1994, FEBS LETT, V338, P161, DOI 10.1016/0014-5793(94)80356-0; REICHELT KL, 1992, J NEUROCHEM, V59, P500, DOI 10.1111/j.1471-4159.1992.tb09398.x; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SELKOE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6070, DOI 10.1073/pnas.79.19.6070; SIMON M, 1994, KERATINOCYTE HDB, P275; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; VARANNA G, 1977, DEV NEUROSCI, V19, P172; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	52	188	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30715	30721		10.1074/jbc.274.43.30715	http://dx.doi.org/10.1074/jbc.274.43.30715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521460	hybrid			2022-12-25	WOS:000083276700056
J	Sakurai, H; Chiba, H; Miyoshi, H; Sugita, T; Toriumi, W				Sakurai, H; Chiba, H; Miyoshi, H; Sugita, T; Toriumi, W			I kappa B kinases phosphorylate NF-kappa B p65 subunit on serine 536 in the transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA; ACTIVATION; SIGNAL; BETA; TRANSCRIPTION; UBIQUITINATION; DEGRADATION; COMPLEX; EPSILON	Recent investigations have elucidated the cytokine-induced NF-kappa B activation pathway. I kappa B kinase (IKK) phosphorylates inhibitors of NF-kappa B (I kappa Bs), The phosphorylation targets them for rapid degradation through a ubiquitin-proteasome pathway, allowing the nuclear translocation of NF-kappa B. We have examined the possibility that IKK can phosphorylate the p65 NF-kappa B subunit as well as I kappa B in the cytokine-induced NF-kappa B activation. In the cytoplasm of HeLa cells, the p65 subunit was rapidly phosphorylated in response to TNF-alpha in a time dependent manner similar to I kappa B phosphorylation. In vitro phosphorylation with GST-fused p65 showed that a p65 phosphorylating activity was present in the cytoplasmic fraction and the target residue was Ser-536 in the carboxyl-terminal transactivation domain. The endogenous IKK complex, overexpressed IKKs, and recombinant IKK beta efficiently phosphorylated the same Ser residue of p65 in vitro. The major phosphorylation site in vivo was also Ser-536. Furthermore, activation of IKKs by NF-kappa B-inducing kinase induced phosphorylation of p65 in vivo. Our finding, together with previous observations, suggests dual roles for IKK complex in the regulation of NF-kappa B.I kappa B complex.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka, Japan	Mitsubishi Tanabe Pharma Corporation	Sakurai, H (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, 16-89 Kashima 3 Chome, Osaka, Japan.		Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	44	704	716	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30353	30356		10.1074/jbc.274.43.30353	http://dx.doi.org/10.1074/jbc.274.43.30353			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521409	hybrid			2022-12-25	WOS:000083276700005
J	Wojtasek, H; Leal, WS				Wojtasek, H; Leal, WS			Conformational change in the pheromone-binding protein from Bombyx mori induced by pH and by interaction with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARMYWORM MAMESTRA-BRASSICAE; MOTH ANTHERAEA-POLYPHEMUS; PORE-FORMING DOMAIN; MOLTEN-GLOBULE; MOLECULAR-CLONING; APOLIPOPHORIN-III; MANDUCA-SEXTA; BACTERIAL EXPRESSION; COLICIN-A; ANTENNAE	The pheromone-binding protein (PBP) from Bombyx mori was expressed in Escherichia coli periplasm. It specifically bound radiolabeled bombykol, the natural pheromone for this species. It appeared as a single band both in native and SDS-polyacrylamide gel electrophoresis and was also homogeneous in most chromatographic systems. However, in ion-exchange chromatography, multiple forms sometimes appeared. Attempts to separate them revealed that they could be converted into one another. Analysis of the protein by circular dichroism and fluorescence spectroscopy demonstrated that its tertiary structure was sensitive to pH changes and that a dramatic conformational transition occurred between pH 6.0 and 5.0, This high sensitivity to pH contrasted markedly with its thermal stability and resistance to denaturation by urea. There was also no significant change in CD spectra in the presence of the pheromone, The native protein isolated from male antennae displayed the same changes in its spectroscopic properties as the recombinant material, demonstrating that this phenomenon is not an artifact arising from the. expression system. This conformational transition was reproduced by interaction of the protein with anionic (but not neutral) phospholipid vesicles. Unfolding of the PBP structure triggered by membranes suggests a plausible mechanism for ligand release upon interaction of the PBP-pheromone complex with the surface of olfactory neurons. This pH-linked structural flexibility also explains the heterogeneity reported previously for B, mori PBP and other members of this class of proteins.	Natl Inst Sericultural & Entomol Sci, Lab Chem Prospecting, Tsuchiura, Ibaraki 3058634, Japan		Leal, WS (corresponding author), Natl Inst Sericultural & Entomol Sci, Lab Chem Prospecting, 1-2 Ohwashi, Tsuchiura, Ibaraki 3058634, Japan.		Leal, Walter/ABC-6940-2021	Leal, Walter/0000-0002-6800-1240; Leal Filho, Walter/0000-0002-1241-5225; Wojtasek, Hubert/0000-0002-2369-3634				BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BREER H, 1990, INSECT BIOCHEM, V20, P735, DOI 10.1016/0020-1790(90)90088-C; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Davis-Searles PR, 1998, BIOCHEMISTRY-US, V37, P17048, DOI 10.1021/bi981364v; Dyuisekina AE, 1998, MOL BIOL+, V32, P117; Feng L, 1997, INSECT BIOCHEM MOLEC, V27, P405, DOI 10.1016/S0965-1748(97)00012-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; Hildebrand J.G., 1980, RECEPTORS NEUROTRANS, P261; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; Kaissling KE, 1996, CHEM SENSES, V21, P257, DOI 10.1093/chemse/21.2.257; Kaissling KE, 1998, CHEM SENSES, V23, P385, DOI 10.1093/chemse/23.4.385; KASANG G, 1989, EXPERIENTIA, V45, P81, DOI 10.1007/BF01990456; KASANG G, 1988, Z NATURFORSCH C, V43, P275; KRIEGER J, 1991, BIOCHIM BIOPHYS ACTA, V1088, P277, DOI 10.1016/0167-4781(91)90064-S; KRIEGER J, 1993, INSECT BIOCHEM MOLEC, V23, P449, DOI 10.1016/0965-1748(93)90052-T; Krieger J, 1996, INSECT BIOCHEM MOLEC, V26, P297, DOI 10.1016/0965-1748(95)00096-8; KRIEGER J, 1992, EUR J BIOCHEM, V203, P161, DOI 10.1111/j.1432-1033.1992.tb19841.x; Maibeche-Coisne M, 1998, EUR J BIOCHEM, V258, P768, DOI 10.1046/j.1432-1327.1998.2580768.x; Maibeche-Coisne M, 1998, INSECT BIOCHEM MOLEC, V28, P815, DOI 10.1016/S0965-1748(98)00080-0; Maida R, 1997, CHEM SENSES, V22, P503, DOI 10.1093/chemse/22.5.503; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MUGA A, 1993, J BIOL CHEM, V268, P1553; Prestwich GD, 1997, INSECT PHEROMONE RESEARCH, P131; PRESTWICH GD, 1995, CHEM SENSES, V20, P461, DOI 10.1093/chemse/20.4.461; PRESTWICH GD, 1993, PROTEIN SCI, V2, P420; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1993, FEBS LETT, V317, P181, DOI 10.1016/0014-5793(93)81272-2; RAMING K, 1990, J COMP PHYSIOL B, V160, P503, DOI 10.1007/BF00258977; RAMING K, 1989, FEBS LETT, V256, P215, DOI 10.1016/0014-5793(89)81751-X; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; Rosell FI, 1998, J AM CHEM SOC, V120, P11234, DOI 10.1021/ja971756+; RYAN RO, 1993, J BIOL CHEM, V268, P1525; Shin I, 1997, P NATL ACAD SCI USA, V94, P2848, DOI 10.1073/pnas.94.7.2848; Shin I, 1998, BIOCHEMISTRY-US, V37, P4310, DOI 10.1021/bi973005q; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; Tatulian SA, 1996, J MOL BIOL, V260, P312, DOI 10.1006/jmbi.1996.0402; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Vogt R.G., 1987, P385; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1989, J NEUROSCI, V9, P3332; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108; VOGT RG, 1985, P NATL ACAD SCI USA, V82, P8827, DOI 10.1073/pnas.82.24.8827; VOGT RG, 1991, J NEUROSCI, V11, P2972; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; Wojtasek H, 1998, BIOCHEM BIOPH RES CO, V250, P217, DOI 10.1006/bbrc.1998.9278; ZIEGELBERGER G, 1995, EUR J BIOCHEM, V232, P706, DOI 10.1111/j.1432-1033.1995.tb20864.x	52	193	212	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	1999	274	43					30950	30956		10.1074/jbc.274.43.30950	http://dx.doi.org/10.1074/jbc.274.43.30950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	248LT	10521490	hybrid			2022-12-25	WOS:000083276700086
J	Thompson, JP; Debinski, W				Thompson, JP; Debinski, W			Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; SITE-DIRECTED MUTAGENESIS; COMMON GAMMA-CHAIN; HUMAN GLIOMA-CELLS; PSEUDOMONAS EXOTOXIN; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; IL-4 RECEPTOR; COMPONENT; CLONING	Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of II4-independent IL13 receptors is overexpressed on certain transformed cells, including human malignant gliomas. We introduced mutations into human (h) IL13 to determine the site(s) involved in interaction with the shared receptor and/or the glioma-associated receptor. This analysis identified at least three protein regions that are needed for signaling through the shared receptor. These regions were localized to alpha-helices A, C, and D and were mainly separate from the region(s) needed to interact with the glioma-associated receptor. Glutamic acids at positions 13 and 16 in hIL13 alpha-helix A, arginine and serine at positions 66 and 69 in helix C, and arginine at position 109 in helix D were found to be important in inducing biological signaling since their specific mutation resulted in loss and/or gain of function phenomena. We demonstrate that the molecular requirements of hIL13 to interact with its respective receptors are generally distinct and can be controlled by mutagenesis of the cytokine.	Penn State Univ, Coll Med, Neurosurg Sect, Dept Surg, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Debinski, W (corresponding author), Penn State Univ, Coll Med, Neurosurg Sect, Dept Surg, H110,500 Univ Dr, Hershey, PA 17033 USA.	wdebinski@psghs.edu			NATIONAL CANCER INSTITUTE [R01CA074145] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74145] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAMBOROUGH P, 1994, PROTEIN ENG, V7, P1077, DOI 10.1093/protein/7.9.1077; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; EPPINK MHM, 1995, EUR J BIOCHEM, V231, P157, DOI 10.1111/j.1432-1033.1995.0157f.x; Feng NP, 1998, LAB INVEST, V78, P591; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SALVUCCI ME, 1994, ARCH BIOCHEM BIOPHYS, V314, P178, DOI 10.1006/abbi.1994.1427; Schnarr B, 1997, INT IMMUNOL, V9, P861, DOI 10.1093/intimm/9.6.861; Schnyder B, 1996, BLOOD, V87, P4286, DOI 10.1182/blood.V87.10.4286.bloodjournal87104286; SIRONI M, 1994, BLOOD, V84, P1913; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	32	33	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29944	29950		10.1074/jbc.274.42.29944	http://dx.doi.org/10.1074/jbc.274.42.29944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514477	hybrid			2022-12-25	WOS:000083176400056
J	Yun, J; Chae, HD; Choy, HE; Chung, J; Yoo, HS; Han, MH; Shin, DY				Yun, J; Chae, HD; Choy, HE; Chung, J; Yoo, HS; Han, MH; Shin, DY			p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE; TUMOR SUPPRESSION; MAMMALIAN-CELLS; GENE-EXPRESSION; PROTEIN; PROMOTER; REPRESSION; DNA; INDUCTION	The p53 tumor suppressor protein regulates the transcription of regulatory genes involved in cell cycle arrest and apoptosis. We have reported previously that inducible expression of the p53 gene leads to the cell cycle arrest both at G(1) and G(2)/M in association with induction of p21 and reduction of mitotic cyclins (cyclin A and B) and cdc2 mRNA. In this study, we investigated the mechanism by which p53 regulates transcription of the cdc2 gene. Transient transfection analysis showed that wild type p53 represses whereas various dominant negative mutants of p53 increase cdc2 transcription; The cdc2 promoter activity is not repressed in cells transfected with a transactivation mutant, p53(22/23). An adenovirus oncoprotein, E1B-55K inhibits the p53-mediated repression of the cdc2 promoter, while E1B-19K does not. Since the cdc2 promoter does not contain a TATA sequence, we performed deletion and point mutation analyses and identified the inverted CCAAT sequence located at -76 as a cis-acting element for the p53-mediated regulation. We found that a specific DNA-protein complex is formed at the CCAAT sequence and that this complex contains the NF-Y transcription factor. Consistently, a dominant negative mutant of the NF-YA subunit, NF-YAm29, decreases the cdc2 promoter, and p53 does not further decrease! the promoter activity in the presence of NF-YAm29. These results suggest that p53 negatively regulates cdc2 transcription and that the NF-Y transcription factor is required for the p53-mediated regulation.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Taejon 305600, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST)	Shin, DY (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, POB 115, Taejon 305600, South Korea.	dyshin@mail.kribb.re.kr	Chae, Hee-Don/D-2620-2011					AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen HF, 1996, J BIOL CHEM, V271, P13959, DOI 10.1074/jbc.271.24.13959; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harris LC, 1996, CANCER RES, V56, P2029; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KU DH, 1993, J BIOL CHEM, V268, P2255; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIN JY, 1995, ONCOGENE, V10, P2387; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; RICHTER KH, 1991, CANCER RES, V51, P6010; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tanimoto A, 1998, ONCOGENE, V17, P3103, DOI 10.1038/sj.onc.1202236; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Webster NJG, 1996, CANCER RES, V56, P2781; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	61	146	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1999	274	42					29677	29682		10.1074/jbc.274.42.29677	http://dx.doi.org/10.1074/jbc.274.42.29677			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	246QQ	10514438	hybrid			2022-12-25	WOS:000083176400017
J	Evans, RL; Bell, SM; Schultheis, PJ; Shull, GE; Melvin, JE				Evans, RL; Bell, SM; Schultheis, PJ; Shull, GE; Melvin, JE			Targeted disruption of the NHE1 gene prevents muscarinic agonist-induced up-regulation of Na+/H+ exchange in mouse parotid acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDIBULAR SALIVARY-GLAND; PROTEIN-KINASE-C; INDUCED ACTIVATION; INTRACELLULAR PH; FLUID SECRETION; H+ EXCHANGE; TRANSPORT; ACID; PHOSPHORYLATION; STIMULATION	The onset of salivary gland fluid secretion in response to muscarinic stimulation is accompanied by up-regulation of Na+/H+ exchanger (NHE) activity. Although multiple NHE isoforms (NHE1, NHE2, and NHE3) have been identified in salivary glands, little is known about their specific function(s) in resting and secreting acinar cells. Mice with targeted disruptions of the Nhe1, Nhe2, and Nhe3 genes were used to investigate the contribution of these proteins to the stimulation-induced up-regulation of NHE activity in mouse parotid acinar cells. The lack of NHE1, but not NHE2 or NHE3, prevented intracellular pH recovery from an acid load in resting acinar cells, in acini stimulated to secrete with the muscarinic agonist carbachol, and in acini shrunken by hypertonic addition of sucrose, In HCO3--containing solution, the rate of intracellular pH recovery from a muscarinic agonist-stimulated acid load was significantly inhibited in acinar cells from mice lacking NHE1, but not in cells from NHE2- or NHE3-deficient mice. These data demonstrate that NHE1 is the major regulator of intracellular pH in both resting and muscarinic agonist-stimulated acinar cells and suggest that up-regulation of NHE1 activity has an important role in modulating saliva production in vivo.	Univ Rochester, Med Ctr, Rochester Inst Biomed Sci, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Rochester; University of Rochester; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Rochester Inst Biomed Sci, Ctr Oral Biol, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.			Bell, Sheila/0000-0002-1946-0969	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692, R37DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921, DE09692] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARREOLA J, 1995, J MEMBRANE BIOL, V147, P95; Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BRANT SR, 1995, AM J PHYSIOL-CELL PH, V269, pC198, DOI 10.1152/ajpcell.1995.269.1.C198; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V272, pC90, DOI 10.1152/ajpcell.1997.272.1.C90; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; Evans RL, 1998, BIOCHEM BIOPH RES CO, V245, P301, DOI 10.1006/bbrc.1998.8428; Evans RL, 1998, MOL BIOL CELL, V9, p212A; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; LAU KR, 1989, AM J PHYSIOL, V256, pC288, DOI 10.1152/ajpcell.1989.256.2.C288; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MANGANEL M, 1991, J BIOL CHEM, V266, P10182; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MARMARY Y, 1987, COMP BIOCHEM PHYS A, V88, P307, DOI 10.1016/0300-9629(87)90488-9; MARTINEZ JR, 1985, ARCH ORAL BIOL, V30, P797, DOI 10.1016/0003-9969(85)90134-7; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; OKADA M, 1991, PFLUG ARCH EUR J PHY, V419, P338, DOI 10.1007/BF00371116; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; Robertson MA, 1997, J BIOL CHEM, V272, P287; Roos A, 1981, PHYSIOL REV, V61, P297; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; SEO JT, 1995, J PHYSIOL-LONDON, V487, P185, DOI 10.1113/jphysiol.1995.sp020870; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54	42	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29025	29030		10.1074/jbc.274.41.29025	http://dx.doi.org/10.1074/jbc.274.41.29025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506152	hybrid			2022-12-25	WOS:000083017800031
J	Lee, DCY; Aitchison, JD				Lee, DCY; Aitchison, JD			Kap104p-mediated nuclear import - Nuclear localization signals in mRNA-binding proteins and the role of Ran and RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; VIRAL MESSENGER-RNA; EXPORT SIGNALS; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; HNRNP PROTEINS; PATHWAY; RECEPTOR; YEAST	Kap104p is a Saccharomyces cerevisiae nuclear import receptor for two essential mRNA-binding proteins, Nab2p and Nab4p/Hrp1p. We demonstrate direct binding of Kap104p to each of these substrates. We have defined the nuclear localization signals in both Nab2p and Nab4p/Hrp1p by Hap104p binding in vitro and KAP104-dependent nuclear import in vivo. The nuclear localization signals map to similar arginine/glycine-rich RNA-binding domains in both proteins and are thus termed rg-nuclear localization signals to distinguish them from classical nuclear localization signals. We also demonstrate that Kap104p, like other known beta-karyopherins (or importins), interacts directly with the small GTPase Ran/Gsp1. However, unlike other known import factors, Ran binding is not sufficient to mediate release of substrates from Kapl04p; efficient Ran-GTP-mediated substrate release requires RNA. Also, addition of Kap104p to Nab2p and Nab4p/Hrp1p prebound to single-stranded DNA-cellulose stimulated release of both proteins from the resin. We suggest a simple cycle in which Nab2p and Nab4p/Hrp1p, upon import, are released in the nucleus at sites of transcription by the concerted action of Ran-GTP and binding to newly synthesized mRNA. The resulting ribonucleoprotein complexes are exported to the cytoplasm, where Kap104p rebinds to NabBp and Nab4p/Hrp1p, contributing to their release from mRNA.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Aitchison, JD (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg,Rm 5-14, Edmonton, AB T6G 2H7, Canada.							ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fischer U, 1996, TRENDS CELL BIOL, V6, P290, DOI 10.1016/0962-8924(96)20030-3; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Henry M, 1996, GENETICS, V142, P103; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MICHAEL WM, 1995, CELL, V83, P415; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Seki T, 1996, J BIOCHEM, V120, P207; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siomi MC, 1998, MOL CELL BIOL, V18, P4141, DOI 10.1128/MCB.18.7.4141; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3	64	85	87	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29031	29037		10.1074/jbc.274.41.29031	http://dx.doi.org/10.1074/jbc.274.41.29031			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506153	hybrid			2022-12-25	WOS:000083017800032
J	Nomura, K; Imai, H; Koumura, T; Arai, M; Nakagawa, Y				Nomura, K; Imai, H; Koumura, T; Arai, M; Nakagawa, Y			Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-INDUCED APOPTOSIS; CYTOCHROME-C; CELL-DEATH; PERMEABILITY TRANSITION; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; BCL-2 PROTECTS; NECROSIS; ACTIVATION; GENERATION	Phospholipid hydroperoxide glutathione peroxidase (pHGPx) is a key enzyme in the protection of biomembranes exposed to oxidative stress. We investigated the role of mitochondrial PHGPx in apoptosis using RBL2H3 cells that overexpressed mitochondrial PHGPx (M15 cells), cells that overexpressed non-mitochondrial PHGPx (L9 cells), and control cells (S1 cells). The morphological changes and fragmentation of DNA associated with apoptosis occurred within 15 h in S1 and L9 cells upon exposure of cells to 2-deoxyglucose (2DG). The release of cytochrome c from mitochondria was observed in SI cells after 4 h and was followed by the activation of caspase-3 within 6 h. Overexpression of mitochondrial PHGPx prevented the release of cytochrome c, the activation of caspase-3, and apoptosis, but non-mitochondrial PHGPx lacked the ability to prevent the induction of apoptosis by 2DG. An ability to protect cells from 2DG-induced apoptosis was abolished when the PHGPx activity of M15 cells was inhibited by diethylmalate, indicating that the resistance of M15 cells to apoptosis was indeed due to the overexpression of PHGPx in the mitochondria. The expression of members of the Bcl-2 family of proteins, such as Bcl-2, Bcl-xL, Bax, and Bad, was unchanged by the overexpression of PHGPx in cells. The levels of hydroperoxides, including hydrogen and Lipid peroxide, in mitochondria isolated from S1 and L9 cells were significantly increased after the exposure to 2DG for 2 h, while the level of hydroperoxide in mitochondria isolated from M15 cells was lower than that in SI and L9 cells. M15 cells were also resistant to apoptosis induced by etoposide, staurosporine, UV irradiation, cycloheximide, and actinomycin D, but not to apoptosis induced by Fas-specific antibodies, which induces apoptosis via a pathway distinct from the pathway initiated by 2DG. Our results suggest that hydroperoxide, produced in mitochondria, is a major factor in apoptosis and that mitochondrial PHGPx might play a critical role as an anti-apoptotic agent in mitochondrial death pathways.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	Kitasato University; University of Tokyo	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 108, Japan.							ALBINA JE, 1993, J IMMUNOL, V150, P5080; ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; DEMETRAKOPOULOS GE, 1982, CANCER BIOCHEM BIOPH, V6, P65; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Eguchi Y, 1997, CANCER RES, V57, P1835; FANG W, 1995, J IMMUNOL, V155, P66; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUARNIERI C, 1992, FREE RADICALS AGING, P73; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HORTON RW, 1973, J NEUROCHEM, V21, P507, DOI 10.1111/j.1471-4159.1973.tb05996.x; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAPLAN O, 1990, CANCER RES, V50, P544; Keller JN, 1998, J NEUROSCI, V18, P687; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marton A, 1997, EUR J BIOCHEM, V250, P467, DOI 10.1111/j.1432-1033.1997.0467a.x; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MYERS KM, 1995, J NEUROCHEM, V65, P2432; NADERI S, 1990, ANAL BIOCHEM, V190, P304, DOI 10.1016/0003-2697(90)90198-I; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sakamoto H, 1999, J BIOCHEM-TOKYO, V125, P90, DOI 10.1093/oxfordjournals.jbchem.a022274; Shimizu S, 1996, ONCOGENE, V12, P2251; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; THOMAS JP, 1990, J BIOL CHEM, V265, P454; TURRENS JF, 1990, CLIN ISCHEMIC SYNDRO, P203; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; WICK AN, 1957, J BIOL CHEM, V224, P963; YAMAOKA S, 1990, J NUTR, V120, P415, DOI 10.1093/jn/120.5.415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, BIOCHEM BIOPH RES CO, V250, P454, DOI 10.1006/bbrc.1998.9333; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	66	242	251	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					29294	29302		10.1074/jbc.274.41.29294	http://dx.doi.org/10.1074/jbc.274.41.29294			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506188	hybrid			2022-12-25	WOS:000083017800067
